<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of deep vein thrombosis - Wang, X - 2023 | Cochrane Library</title> <meta content="Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of deep vein thrombosis - Wang, X - 2023 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010956.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of deep vein thrombosis - Wang, X - 2023 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010956.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD010956.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of deep vein thrombosis" name="citation_title"/> <meta content="Xiaoqin Wang&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="McMaster University" name="citation_author_institution"/> <meta content="wangx431@mcmaster.ca" name="citation_author_email"/> <meta content="Yanfang Ma&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="Hong Kong Baptist University" name="citation_author_institution"/> <meta content="Xu Hui" name="citation_author"/> <meta content="Meixuan Li" name="citation_author"/> <meta content="Jing Li" name="citation_author"/> <meta content="Jinhui Tian" name="citation_author"/> <meta content="Qi Wang" name="citation_author"/> <meta content="McMaster University" name="citation_author_institution"/> <meta content="Peijing Yan" name="citation_author"/> <meta content="Sichuan University" name="citation_author_institution"/> <meta content="Jianfeng Li" name="citation_author"/> <meta content="Gansu Provincial Hospital" name="citation_author_institution"/> <meta content="Ping Xie" name="citation_author"/> <meta content="Gansu Provincial Hospital" name="citation_author_institution"/> <meta content="Kehu Yang" name="citation_author"/> <meta content="Liang Yao" name="citation_author"/> <meta content="McMaster University" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="4" name="citation_issue"/> <meta content="10.1002/14651858.CD010956.pub3" name="citation_doi"/> <meta content="2023" name="citation_date"/> <meta content="2023/04/14" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010956.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010956.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010956.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Anticoagulants [adverse effects]; Antithrombins [adverse effects]; Dabigatran [adverse effects]; Factor Xa Inhibitors [adverse effects]; Hemorrhage [chemically induced]; Neoplasm Recurrence, Local [drug therapy]; *Pulmonary Embolism [drug therapy, prevention &amp; control]; Rivaroxaban [adverse effects]; *Venous Thromboembolism [prevention &amp; control]; *Venous Thrombosis [complications]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010956.pub3&amp;doi=10.1002/14651858.CD010956.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010956.pub3&amp;doi=10.1002/14651858.CD010956.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010956.pub3&amp;doi=10.1002/14651858.CD010956.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010956.pub3&amp;doi=10.1002/14651858.CD010956.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010956.pub3&amp;doi=10.1002/14651858.CD010956.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010956.pub3&amp;doi=10.1002/14651858.CD010956.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010956.pub3&amp;doi=10.1002/14651858.CD010956.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010956.pub3&amp;doi=10.1002/14651858.CD010956.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010956.pub3&amp;doi=10.1002/14651858.CD010956.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010956.pub3&amp;doi=10.1002/14651858.CD010956.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010956.pub3&amp;doi=10.1002/14651858.CD010956.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010956.pub3&amp;doi=10.1002/14651858.CD010956.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010956.pub3&amp;doi=10.1002/14651858.CD010956.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010956.pub3&amp;doi=10.1002/14651858.CD010956.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010956.pub3&amp;doi=10.1002/14651858.CD010956.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010956.pub3&amp;doi=10.1002/14651858.CD010956.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010956.pub3&amp;doi=10.1002/14651858.CD010956.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010956.pub3&amp;doi=10.1002/14651858.CD010956.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010956.pub3&amp;doi=10.1002/14651858.CD010956.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010956.pub3&amp;doi=10.1002/14651858.CD010956.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010956.pub3&amp;doi=10.1002/14651858.CD010956.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010956.pub3&amp;doi=10.1002/14651858.CD010956.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010956.pub3&amp;doi=10.1002/14651858.CD010956.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="Xx9QLps0";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD010956\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD010956\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010956\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010956\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANT","ru","pt","ms","hr","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD010956.pub3",title:"Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of deep vein thrombosis",firstPublishedDate:"Apr 14, 2023 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Vascular Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Xx9QLps0&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010956.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010956.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD010956.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD010956.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010956.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD010956.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD010956.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD010956.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD010956.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD010956.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>5301 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD010956.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010956.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010956.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010956.pub3/full#CD010956-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010956.pub3/full#CD010956-sec-0096"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010956.pub3/full#CD010956-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010956.pub3/full#CD010956-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010956.pub3/full#CD010956-sec-0022"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010956.pub3/full#CD010956-sec-0023"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010956.pub3/full#CD010956-sec-0047"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010956.pub3/full#CD010956-sec-0082"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010956.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010956.pub3/appendices#CD010956-sec-0101"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010956.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010956.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/supinfo/CD010956StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/supinfo/CD010956StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010956.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010956.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010956.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010956.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010956.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD010956.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2023 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of deep vein thrombosis </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author custom-tooltip" title="These authors contributed equally to this work"><a href="/cdsr/doi/10.1002/14651858.CD010956.pub3/information#CD010956-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Xiaoqin Wang</a><sup>a</sup></li> <li class="author custom-tooltip" title="These authors contributed equally to this work"><a href="/cdsr/doi/10.1002/14651858.CD010956.pub3/information#CD010956-cr-0005">Yanfang Ma</a><sup>a</sup></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010956.pub3/information#CD010956-cr-0006">Xu Hui</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010956.pub3/information#CD010956-cr-0007">Meixuan Li</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010956.pub3/information#CD010956-cr-0008">Jing Li</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010956.pub3/information#CD010956-cr-0009">Jinhui Tian</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010956.pub3/information#CD010956-cr-0010">Qi Wang</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010956.pub3/information#CD010956-cr-0011">Peijing Yan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010956.pub3/information#CD010956-cr-0012">Jianfeng Li</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010956.pub3/information#CD010956-cr-0013">Ping Xie</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010956.pub3/information#CD010956-cr-0014">Kehu Yang</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010956.pub3/information#CD010956-cr-0015">Liang Yao</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/information/en#CD010956-sec-0111">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 14 April 2023 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD010956.pub3">https://doi.org/10.1002/14651858.CD010956.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD010956-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010956-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010956-abs-0013">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010956-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD010956-abs-0011">Français</a> </li> <li class="section-language"> <a class="" href="full/pt#CD010956-abs-0005">Português</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD010956-abs-0001" lang="en"> <section id="CD010956-sec-0001"> <h3 class="title" id="CD010956-sec-0001">Background</h3> <p>Deep vein thrombosis (DVT) is a condition in which a clot forms in the deep veins, most commonly of the leg. It occurs in approximately one in 1000 people. If left untreated, the clot can travel up to the lungs and cause a potentially life‐threatening pulmonary embolism (PE). Previously, a DVT was treated with the anticoagulants heparin and vitamin K antagonists. However, two forms of direct oral anticoagulants (DOACs) have been developed: oral direct thrombin inhibitors (DTIs) and oral factor Xa inhibitors, which have characteristics that may be favourable compared to conventional treatment, including oral administration, a predictable effect, lack of frequent monitoring or dose adjustment and few known drug interactions. DOACs are now commonly being used for treating DVT: recent guidelines recommended DOACs over conventional anticoagulants for both DVT and PE treatment. This Cochrane Review was first published in 2015. It was the first systematic review to measure the effectiveness and safety of these drugs in the treatment of DVT. This is an update of the 2015 review.  </p> </section> <section id="CD010956-sec-0002"> <h3 class="title" id="CD010956-sec-0002">Objectives</h3> <p>To assess the effectiveness and safety of oral DTIs and oral factor Xa inhibitors versus conventional anticoagulants for the long‐term treatment of DVT. </p> </section> <section id="CD010956-sec-0003"> <h3 class="title" id="CD010956-sec-0003">Search methods</h3> <p>The Cochrane Vascular Information Specialist searched the Cochrane Vascular Specialised Register, CENTRAL, MEDLINE, Embase and CINAHL databases and the World Health Organization International Clinical Trials Registry Platform and ClinicalTrials.gov trials registers to 1 March 2022. </p> </section> <section id="CD010956-sec-0004"> <h3 class="title" id="CD010956-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) in which people with a DVT, confirmed by standard imaging techniques, were allocated to receive an oral DTI or an oral factor Xa inhibitor compared with conventional anticoagulation or compared with each other for the treatment of DVT.  </p> </section> <section id="CD010956-sec-0005"> <h3 class="title" id="CD010956-sec-0005">Data collection and analysis</h3> <p>We used standard Cochrane methods. Our primary outcomes were recurrent venous thromboembolism (VTE), recurrent DVT and PE. Secondary outcomes included all‐cause mortality, major bleeding, post‐thrombotic syndrome (PTS) and quality of life (QoL). We used GRADE to assess the certainty of evidence for each outcome. </p> </section> <section id="CD010956-sec-0006"> <h3 class="title" id="CD010956-sec-0006">Main results</h3> <p>We identified 10 new studies with 2950 participants for this update. In total, we included 21 RCTs involving 30,895 participants. Three studies investigated oral DTIs (two dabigatran and one ximelagatran), 17 investigated oral factor Xa inhibitors (eight rivaroxaban, five apixaban and four edoxaban) and one three‐arm trial investigated both a DTI (dabigatran) and factor Xa inhibitor (rivaroxaban). Overall, the studies were of good methodological quality. </p> <p>Meta‐analysis comparing DTIs to conventional anticoagulation showed no clear difference in the rate of recurrent VTE (odds ratio (OR) 1.17, 95% confidence interval (CI) 0.83 to 1.65; 3 studies, 5994 participants; moderate‐certainty evidence), recurrent DVT (OR 1.11, 95% CI 0.74 to 1.66; 3 studies, 5994 participants; moderate‐certainty evidence), fatal PE (OR 1.32, 95% CI 0.29 to 6.02; 3 studies, 5994 participants; moderate‐certainty evidence), non‐fatal PE (OR 1.29, 95% CI 0.64 to 2.59; 3 studies, 5994 participants; moderate‐certainty evidence) or all‐cause mortality (OR 0.66, 95% CI 0.41 to 1.08; 1 study, 2489 participants; moderate‐certainty evidence). DTIs reduced the rate of major bleeding (OR 0.58, 95% CI 0.38 to 0.89; 3 studies, 5994 participants; high‐certainty evidence).   </p> <p>For oral factor Xa inhibitors compared with conventional anticoagulation, meta‐analysis demonstrated no clear difference in recurrent VTE (OR 0.85, 95% CI 0.71 to 1.01; 13 studies, 17,505 participants; moderate‐certainty evidence), recurrent DVT (OR 0.70, 95% CI 0.49 to 1.01; 9 studies, 16,439 participants; moderate‐certainty evidence), fatal PE (OR 1.18, 95% CI 0.69 to 2.02; 6 studies, 15,082 participants; moderate‐certainty evidence), non‐fatal PE (OR 0.93, 95% CI 0.68 to 1.27; 7 studies, 15,166 participants; moderate‐certainty evidence) or all‐cause mortality (OR 0.87, 95% CI 0.67 to 1.14; 9 studies, 10,770 participants; moderate‐certainty evidence). Meta‐analysis showed a reduced rate of major bleeding with oral factor Xa inhibitors compared with conventional anticoagulation (OR 0.63, 95% CI 0.45 to 0.89; 17 studies, 18,066 participants; high‐certainty evidence).  </p> </section> <section id="CD010956-sec-0007"> <h3 class="title" id="CD010956-sec-0007">Authors' conclusions</h3> <p>The current review suggests that DOACs may be superior to conventional therapy in terms of safety (major bleeding), and are probably equivalent in terms of efficacy. There is probably little or no difference between DOACs and conventional anticoagulation in the prevention of recurrent VTE, recurrent DVT, pulmonary embolism and all‐cause mortality. DOACs reduced the rate of major bleeding compared to conventional anticoagulation. The certainty of evidence was moderate or high. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD010956-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010956-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010956-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010956-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD010956-abs-0012">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD010956-abs-0008">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD010956-abs-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pt#CD010956-abs-0006">Português</a> </li> <li class="section-language"> <a class="" href="full/ru#CD010956-abs-0004">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD010956-abs-0003">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD010956-abs-0002" lang="en"> <h3>Are direct oral anticoagulants (a type of 'blood thinner') better than conventional anticoagulation for treating people with a blood clot in a deep vein?  </h3> <p><b>What is deep vein thrombosis?</b> </p> <p>Deep vein thrombosis (DVT) is when a blood clot forms, usually in a deep vein of the leg or pelvis. Approximately 1 in 1000 people will develop a DVT. If it is not treated, the clot can travel in the blood and block the blood vessels in the lungs. This life‐threatening condition is called a pulmonary embolism. It occurs in approximately 3 to 4 people per 10,000 people. The chances of getting a DVT are increased if you have certain risk factors. These include previous clots, prolonged periods of immobility (such as travelling on aeroplanes or taking bed rest), cancer, exposure to oestrogens (pregnancy, oral contraceptives or hormone replacement therapy), trauma and blood disorders such as thrombophilia (abnormal blood clotting). A DVT is diagnosed by determining the risk factors and performing an ultrasound of the leg veins.  </p> <p><b>How is deep vein thrombosis treated? </b> </p> <p>If a DVT is confirmed, people are treated with an anticoagulant: a medicine that either treats or prevents blood clots, often called a 'blood thinner'. Previously, the medicines of choice were heparin, fondaparinux and vitamin K antagonists, known as 'conventional anticoagulants'. However, these medicines can cause side effects and have limitations. </p> <p>Two types of anticoagulant have been developed: direct thrombin inhibitors (DTI) and factor Xa inhibitors. These anticoagulants are given orally (that is, by mouth, in the form of a pill), have a predictable effect, do not require frequent monitoring or re‐dosing (taking multiple doses), and have few known interactions with other medicines. For these reasons, direct oral anticoagulants have become the medicines of choice for treating DVT.  </p> <p><b>What did we want to find out?</b> </p> <p>We wanted to find out if direct oral anticoagulants are useful and safe for treating people with DVT compared with conventional treatments.  </p> <p><b>What did we do?</b> </p> <p>We searched for studies in which people with a confirmed DVT were randomly allocated to one of two treatment groups. These types of studies give the most reliable evidence about treatment effects. People in the experimental groups received an oral direct thrombin inhibitor or an oral factor Xa inhibitor, and their results were compared to the results of people given conventional anticoagulation. All participants were given long‐term treatment of DVT (minimum duration of 3 months).  </p> <p><b>What did we find?</b> </p> <p>After searching for relevant studies, we found 21 studies with 30,895 participants. We combined the data from the studies and found that there was no clear difference in the incidence of: </p> <p>‐ recurrent venous thromboembolism (DVT, pulmonary embolism, or both);<br/>‐ recurrent DVT;<br/>‐ pulmonary embolism (blood clot in the lungs); or<br/>‐ death<br/>between people treated with oral direct thrombin inhibitors or oral factor Xa inhibitor compared to those given conventional anticoagulants. </p> <p>Compared to conventional treatment, both direct thrombin inhibitors and factor Xa inhibitors reduced the major bleeding which happened during the treatment of DVT. </p> <p><b>What are the limitations of the evidence?</b> </p> <p>Our confidence in the evidence is generally moderate because few people overall experienced the outcomes. The evidence answered the question we addressed directly and the results of the studies were consistent. However, further studies are needed to explore how one direct oral anticoagulant compares with another. Future well‐designed studies may also provide important evidence for post‐thrombotic syndrome (a condition that can happen to people who have had a DVT of the leg, causing chronic pain, swelling and other symptoms in the leg) and quality of life. </p> <p><b>How up to date is this evidence?</b> </p> <p>This review updates a previous Cochrane Review. The evidence is up to date to 1 March 2022. </p> <p><b>Key messages</b> </p> <p>When treating people with a DVT, current evidence shows there is probably a similar effect between direct oral anticoagulants and conventional anticoagulants for preventing recurrent venous thromboembolism, recurrent DVT, pulmonary embolism and death. Direct oral anticoagulants reduced major bleeding compared to conventional anticoagulation. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD010956-sec-0096" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD010956-sec-0096"></div> <h3 class="title" id="CD010956-sec-0097">Implications for practice</h3> <section id="CD010956-sec-0097"> <p>The current review suggests that direct oral anticoagulants (DOACs) may be superior to conventional therapy in terms of safety (major bleeding), and are probably equivalent in terms of efficacy (recurrent venous thromboembolism (VTE), recurrent deep vein thrombosis (DVT), fatal and non‐fatal pulmonary embolism (PE) and mortality). The clear practical benefit of DOACs is the ease of use. This may provide clinical and economic benefits in the avoidance of the warfarin‐loading phase of treatment (as shown in some of the studies), with its concomitant use of parenteral anticoagulants and frequent international normalised ratio (INR) testing. However, precautions are required with the use of DOACs. They are all, to some extent, renally excreted, and there is evidence of wide inter‐individual variation in anticoagulant response.  </p> </section> <h3 class="title" id="CD010956-sec-0098">Implications for research</h3> <section id="CD010956-sec-0098"> <p>There is evidence of wide inter‐individual variation in anticoagulant effect from the fixed doses of DOACs currently prescribed. This may be of clinical importance, and further research is needed to investigate dosage adjustment for various subgroups, including people with: malignancy, DVT in unusual sites (e.g. upper limbs), travel‐associated DVT, thrombophilic abnormality (e.g. anti‐phospholipid syndrome), obesity or renal impairment. Further research is also needed to investigate any impact on the decision to use extended phase anticoagulation and interruption of procedures with DOAC use. Furthermore, future studies should directly compare one DOAC to another to determine which is most effective and safe, especially given that research from observational studies has shown that apixaban decreased risk of major bleeding events compared with rivaroxaban in people with VTE. For outcomes, studies rarely analysed quality of life and post‐thrombotic syndrome (PTS). Future studies should consider recording and reporting these important outcomes. Finally, as we noted above, all‐cause mortality has yet to be estimated for DVT treated with dabigatran, so more research is needed in this area. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD010956-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD010956-sec-0008"></div> <div class="table" id="CD010956-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Oral DTIs versus conventional anticoagulation for participants with diagnosed DVT</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Oral DTIs versus conventional anticoagulation for participants with diagnosed DVT</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> participants with diagnosed DVT <br/><b>Setting: </b> hospital<b> </b> <br/><b>Intervention:</b> oral DTIs <br/><b>Comparison:</b> conventional anticoagulation </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with conventional anticoagulation</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with oral DTIs</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Recurrent VTE</b> </p> <p> </p> <p>(7 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 1.17</b> <br/><b>(0.83 to 1.65)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>5994<br/>(3 RCTs<sup>a</sup>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>21 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>25 per 1000<br/>(18 to 35) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Recurrent DVT</b> </p> <p> </p> <p>(7 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 1.11</b> <br/><b>(0.74 to 1.66)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>5994<br/>(3 RCTs<sup>a</sup>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>15 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>17 per 1000<br/>(11 to 25) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Fatal PE</b> </p> <p> </p> <p>(7 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 1.32</b> <br/><b>(0.29 to 6.02)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>5994<br/>(3 RCTs<sup>a</sup>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 per 1000<br/>(0 to 6) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Non‐fatal PE</b> </p> <p> </p> <p>(7 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 1.29</b> <br/><b>(0.64 to 2.59)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>5994<br/>(3 RCTs<sup>a</sup>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 per 1000<br/>(3 to 12) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>All‐cause mortality</b> </p> <p> </p> <p>(7 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 0.66</b> <br/><b>(0.41 to 1.08)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2489<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>34 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>22 per 1000<br/>(14 to 36) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Major bleeding</b> </p> <p> </p> <p>(7 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 0.58</b> <br/><b>(0.38 to 0.89)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>5994<br/>(3 RCTs<sup>a</sup>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>19 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11 per 1000<br/>(7 to 17) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <br/><b>CI:</b> confidence interval; <b>DTIs:</b> direct thrombin inhibitors; <b>DVT</b> : deep vein thrombosis; <b>OR:</b> odds ratio; <b>PE</b> : pulmonary embolism; <b>RCT</b> : randomised controlled trial; <b>VTE</b>: venous thromboembolism </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>The data from <a href="./references#CD010956-bbs2-0018" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00291330. Efficacy and safety of dabigatran compared to warfarin for 6 month treatment of acute symptomatic venous thromboembolism (RE-COVER I). clinicaltrials.gov/ct/show/NCT00291330 (first received 14 February 2006). SchulmanS , ErikssonH , GoldhaberS , KakkarAK , KearonC , KvammeAM , et al. Dabigatran or warfarin for extended maintenance therapy of venous thromboembolism. Journal of Thrombosis and Haemostasis2011;9(Suppl 2):731-2. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-COVER and RE-COVER II. Blood2013;122:2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RECOVER II. Blood2013;122(21):212. SchulmanS , ErikssonH , GoldhaverSZ , KakkarA , KearonC , MismettiP , et al. Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130:A18594. SchulmanS , KearonC , KakkarAK , MismettiP , SchellongS , ErikssonH , et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. New England Journal of Medicine2009;361(24):2342-52. ">RE‐COVER 2009</a> and <a href="./references#CD010956-bbs2-0019" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00680186. Phase III study testing efficacy &amp; safety of oral dabigatran etexilate vs warfarin for 6 m treatment for acute symp venous thromboembolism (VTE) (RE-COVER II). clinicaltrials.gov/ct2/show/NCT00680186 (first received 20 May 2008). SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-COVER and RE-COVER II. Blood2013;122:2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RECOVER II. Blood2013;122(21):212. SchulmanS , ErikssonH , GoldhaverSZ , KakkarA , KearonC , MismettiP , et al. Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130:A18594. SchulmanS , KakkarAK , GoldhaberSZ , SchellongS , ErikssonH , MismettiP , et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation2014;129:764-72. SchulmanS . A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II). Blood2011;118(21):95-6. ">RE‐COVER II 2014</a> were taken from one pooled analysis and are therefore shown as one study in our analyses<br/><sup>b</sup>We downgraded one level for imprecision due to the low number of events and a small sample size; the possibility of publication bias is not excluded but we did not consider it sufficient to downgrade the certainty of evidence. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010956-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Oral factor Xa inhibitors compared to conventional anticoagulation for participants with diagnosed DVT</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Oral factor Xa inhibitors versus conventional anticoagulation for participants with diagnosed DVT</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> participants with diagnosed DVT <br/><b>Setting: </b> hospital<br/><b>Intervention:</b> oral factor Xa inhibitors<br/><b>Comparison:</b> conventional anticoagulation </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with conventional anticoagulation</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with oral factor Xa</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Recurrent VTE</b> </p> <p> </p> <p>(3 to 12 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 0.85</b> <br/><b>(0.71 to 1.01)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>17,505<br/>(13 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>One of the 13 studies reported no events</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>34 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>29 per 1000<br/>(24 to 34) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Recurrent DVT</b> </p> <p> </p> <p>(3 to 12 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 0.70</b> <br/><b>(0.49 to 1.01)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>16,439<br/>(9 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>16 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>12 per 1000<br/>(8 to 17) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Fatal PE</b> </p> <p> </p> <p>(3 to 12 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 1.18</b> <br/><b>(0.69 to 2.02)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>15,082<br/>(6 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 per 1000<br/>(2 to 6) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Non‐fatal PE</b> </p> <p> </p> <p>(3 to 12 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 0.93</b> <br/><b>(0.68 to 1.27)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>15,166<br/>(7 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 per 1000<br/>(8 to 14) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>All‐cause mortality</b> </p> <p> </p> <p>(3 to 6 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 0.87</b> <br/><b>(0.67 to 1.14)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>10,770<br/>(9 RCTs) </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Three of the nine studies reported no events</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>23 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1000<br/>(16 to 27) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Major bleeding</b> </p> <p> </p> <p>(3 to 12 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 0.63</b> <br/><b>(0.45 to 0.89)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>18,066<br/>(17 RCTs) </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Five of 17 studies reported no events</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>17 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11 per 1000<br/>(8 to 15) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).  </p> <p><b>CI:</b> confidence interval; <b>DVT</b> : deep vein thrombosis; <b>OR:</b> odds ratio; <b>PE</b> : pulmonary embolism; <b>RCT</b> : randomised controlled trial; <b>VTE</b>: venous thromboembolism </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>We downgraded one level for imprecision due to the low number of events and a small sample size; the possibility of publication bias is not excluded but we did not consider it sufficient to downgrade the quality of evidence. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD010956-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD010956-sec-0009"></div> <section id="CD010956-sec-0010"> <h3 class="title" id="CD010956-sec-0010">Description of the condition</h3> <p>Deep vein thrombosis (DVT) occurs when a blood clot or thrombus forms in the deep venous system. This is most commonly observed in the veins in the leg or pelvis. DVT and pulmonary embolism (PE) occur with an incidence of approximately one per 1000 annually in adults (<a href="./references#CD010956-bbs2-0068" title="CushmanM . Epidemiology and risk factors for venous thrombosis. Seminars in Hematology2007;44(2):62-9.">Cushman 2007</a>; <a href="./references#CD010956-bbs2-0131" title="WhiteRH . The epidemiology of venous thromboembolism. Circulation2003;107(23 Suppl 1):I4-8.">White 2003</a>); the incidence of DVT in the general population is around five per 10,000 per annum (<a href="./references#CD010956-bbs2-0077" title="FowkesFJ , PriceJF , FowkesFG . Incidence of diagnosed deep vein thrombosis in the general population: systematic review. European Journal of Vascular and Endovascular Surgery2003;25(1):1-5.">Fowkes 2003</a>). If left untreated, the thrombus can dislodge and travel in the blood to the pulmonary arteries, blocking the supply of blood to the lungs. This is termed a pulmonary embolism (PE) and is a life‐threatening condition. The incidence of PE is approximately four to 12 per 10,000 people, but this is likely to be underestimated and the incidence has been increasing steadily (<a href="./references#CD010956-bbs2-0057" title="BarcoS , ValerioL , GalloA , TurattiG , MahmoudpourSH , AgenoW , et al. Global reporting of pulmonary embolism-related deaths in the World Health Organization mortality database: vital registration data from 123 countries. Research and Practice in Thrombosis and Haemostasis2021;5(5):e12520.">Barco 2021</a>; <a href="./references#CD010956-bbs2-0061" title="BĕlohlávekJ , DytrychV , LinhartA . Pulmonary embolism, part I: epidemiology, risk factors and risk stratification, pathophysiology, clinical presentation, diagnosis and nonthrombotic pulmonary embolism. Experimental and Clinical Cardiology2013;18(2):129-38.">Bĕlohlávek 2013</a>; <a href="./references#CD010956-bbs2-0093" title="KellerK , HobohmL , EbnerM , KresojaKP , MünzelT , KonstantinidesSV , et al. Trends in thrombolytic treatment and outcomes of acute pulmonary embolism in Germany. European Heart Journal2020;41(4):522-9.">Keller 2020</a>; <a href="./references#CD010956-bbs2-0094" title="KonstantinidesSV , MeyerG , BecattiniC , BuenoH , GeersingGJ , HarjolaVP , et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). European Heart Journal2020;41(4):543-603.">Konstantinides 2020</a>; <a href="./references#CD010956-bbs2-0130" title="WendelboeAM , RaskobGE . Global burden of thrombosis: epidemiologic aspects. Circulation Research2016;118(9):1340-7.">Wendelboe 2016</a>). The two interrelated conditions, DVT and PE, are different clinical manifestations of venous thromboembolism (VTE). Among VTE, about two‐thirds of cases manifest as DVT only and one‐third as PE with or without DVT (<a href="./references#CD010956-bbs2-0122" title="StoneJ , HanggeP , AlbadawiH , WallaceA , ShamounF , KnuttienMG , et al. Deep vein thrombosis: pathogenesis, diagnosis, and medical management. Cardiovascular Diagnosis and Therapy2017;7(Suppl 3):S276-s284.">Stone 2017</a>). Another complication of DVT is post‐thrombotic syndrome (PTS). PTS is a long‐term condition caused by the reduction in the return of venous blood to the heart. Symptoms include chronic pain, skin discolouration, oedema and, in severe cases, varicose veins and venous ulceration (<a href="./references#CD010956-bbs2-0085" title="KahnSR , GinsbergJS . The post-thrombotic syndrome: current knowledge, controversies and directions for future research. Blood Reviews2002;16(3):155-65.">Kahn 2002</a>). The incidence of PTS after a symptomatic DVT is estimated to be between 12% and 60%; PTS added an additional 75% to the cost of treating DVT (<a href="./references#CD010956-bbs2-0055" title="AshraniAA , HeitJA . Incidence and cost burden of post-thrombotic syndrome. Jouranl of Thrombosis and Thrombolysis2009;28(4):465-76.">Ashrani 2009</a>; <a href="./references#CD010956-bbs2-0086" title="KahnSR , ShapiroS , WellsPS , RodgerMA , KovacsMJ , Anderson DR et al. Compression stockings to prevent post-thrombotic syndrome: a randomised placebo-controlled trial. Lancet2014;383(9920):880-8.">Kahn 2014</a>). </p> <p>There are many risk factors for DVT. When a risk factor is transient (such as major surgery), DVT is termed "provoked". DVT occurring in the absence of transient risk factors is termed "unprovoked" (<a href="./references#CD010956-bbs2-0091" title="KearonC , AklEA , ComerotaAJ , PrandoniP , BounameauxH , GoldhaberSZ , et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines. Chest2012;141(2 Suppl):e419S-94S.">Kearon 2012</a>). Provoked DVT occurs following surgery or by a non‐surgical transient risk factor, such as the history of VTE, venous insufficiency, chronic heart failure, thrombophilia, obesity, immobility (such as prolonged travel, acute medical illness or hospitalisation), cancer, oestrogens (pregnancy, use of oral contraceptives or hormone replacement therapy) and trauma (<a href="./references#CD010956-bbs2-0115" title="Scottish Intercollegiate Guidelines Network. Prevention and management of venous thromboembolism: a national clinical guideline, 2010. Available at: sign.ac.uk/media/1060/sign122.pdf (accessed 16 August 2022).">SIGN 2010</a>). </p> <p>Diagnosis of DVT is made by general assessment of an individual's medical history and physical examination. The UK National Institute for Health and Care Excellence (NICE) recommends that people presenting with a suspected DVT should be assessed for pre‐test probability of DVT using the 2‐level DVT Wells score (<a href="./references#CD010956-bbs2-0104" title="National Institute for Health and Care Excellence. Venous thromboembolic diseases: diagnosis, management and thrombophilia testing. NG158: 26 March 2020. Available at: nice.org.uk/guidance/ng158 (accessed 16 August 2022).">NICE 2020</a>; <a href="./references#CD010956-bbs2-0129" title="WellsPS , AndersonDR , RodgerM , ForgieM , KearonC , DreyerJ , et al. Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. NEJM2003;349(13):1227-35.">Wells 2003</a>). Points are awarded to clinical features present – including active cancer, recent immobilisation or surgery, tenderness or swelling and history of DVT – in order to estimate the clinical probability of a DVT. The American College of Chest Physicians (ACCP) recommends that people with a low pre‐test probability of a first lower extremity DVT should undergo initial testing with D‐dimer or ultrasound of the proximal veins (<a href="./references#CD010956-bbs2-0058" title="BatesSM , JaeschkeR , StevensSM , GoodacreS , WellsP , StevensonMD , et al. Diagnosis of DVT: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines. Chest2012;141(Suppl 2):e351S-418S.">Bates 2012</a>; <a href="./references#CD010956-bbs2-0129" title="WellsPS , AndersonDR , RodgerM , ForgieM , KearonC , DreyerJ , et al. Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. NEJM2003;349(13):1227-35.">Wells 2003</a>). People with moderate pre‐test probability should undergo D‐dimer, proximal compression or whole‐leg ultrasound, while people with a high pre‐test probability should undergo proximal compression or whole‐leg ultrasound (<a href="./references#CD010956-bbs2-0058" title="BatesSM , JaeschkeR , StevensSM , GoodacreS , WellsP , StevensonMD , et al. Diagnosis of DVT: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines. Chest2012;141(Suppl 2):e351S-418S.">Bates 2012</a>; <a href="./references#CD010956-bbs2-0129" title="WellsPS , AndersonDR , RodgerM , ForgieM , KearonC , DreyerJ , et al. Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. NEJM2003;349(13):1227-35.">Wells 2003</a>). </p> <p>A D‐dimer test is based on the principle that the formation of a thrombus is followed by an immediate fibrinolytic response, including the release of fibrin degradation products, predominantly D‐dimer, into the circulation. Therefore, a negative D‐dimer suggests that thrombosis is not occurring, and thus is a useful tool in excluding DVT, along with clinical scores and imaging. It is important to consider that while a positive result can indicate DVT, there are other potential reasons for a positive D‐dimer or a raised D‐dimer level, including cancer, disseminated intravascular coagulation, pregnancy, inflammation and infection (<a href="./references#CD010956-bbs2-0104" title="National Institute for Health and Care Excellence. Venous thromboembolic diseases: diagnosis, management and thrombophilia testing. NG158: 26 March 2020. Available at: nice.org.uk/guidance/ng158 (accessed 16 August 2022).">NICE 2020</a>). Furthermore, D‐dimer assays vary in sensitivity, and the choice of assay used by an institution is based on cost and availability. </p> <p>Ultrasound is a non‐invasive diagnostic imaging technique that uses sound waves to produce images of structures within the body. Compression ultrasound involves using the probe to try to compress the vascular lumen. If the lumen is fully compressible, it indicates that a thrombus has not occurred. Duplex ultrasound is similar but it involves the use of the Doppler signal to determine blood flow properties. In addition, colour imaging can be used to augment the images. Ultrasound is non‐invasive and has high sensitivity and specificity for detecting proximal DVT (<a href="./references#CD010956-bbs2-0104" title="National Institute for Health and Care Excellence. Venous thromboembolic diseases: diagnosis, management and thrombophilia testing. NG158: 26 March 2020. Available at: nice.org.uk/guidance/ng158 (accessed 16 August 2022).">NICE 2020</a>). Guidelines recommend completing either proximal or whole‐leg ultrasound, determined by local practice, access to testing and cost (<a href="./references#CD010956-bbs2-0058" title="BatesSM , JaeschkeR , StevensSM , GoodacreS , WellsP , StevensonMD , et al. Diagnosis of DVT: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines. Chest2012;141(Suppl 2):e351S-418S.">Bates 2012</a>). </p> </section> <section id="CD010956-sec-0011"> <h3 class="title" id="CD010956-sec-0011">Description of the intervention</h3> <p>Anticoagulation is an essential component of therapy for DVT, which can prevent the progression of DVT to PE and the recurrence of thrombosis. The 30‐day mortality rate exceeds 3% in people with DVT who are not anticoagulated; this mortality risk is as high as 31% in people with PE (<a href="./references#CD010956-bbs2-0117" title="SogaardKK , SchmidtM , PedersenL , Horvath-PuhoE , SorensenHT . 30-year mortality after venous thromboembolism: a population-based cohort study. Circulation2014;130(10):829-36.">Sogaard 2014</a>). The conventional treatment of DVT is with an indirect thrombin inhibitor, namely unfractionated heparin (UFH), or low molecular weight heparin (LMWH), followed by vitamin K antagonists (VKAs). These drugs block the action of thrombin either by "activating naturally occurring thrombin inhibitors or by inhibiting specific factors in the coagulation system that subsequently impact on thrombin generation or activity" (<a href="./references#CD010956-bbs2-0128" title="WeitzJI . A novel approach to thrombin inhibition. Thrombosis Research2003;109(Suppl 1):S17-22.">Weitz 2003</a>). Although heparin and VKAs are effective anticoagulants, there are limitations associated with each. Heparin‐induced thrombocytopenia (HIT) is a rare, potentially life‐threatening, reaction to heparin (<a href="./references#CD010956-bbs2-0106" title="OrtelTL , WelsbyIJ . Management of heparin-induced thrombocytopenia (HIT) during cardiac or vascular surgery. www.uptodate.com/contents/management-of-heparin-induced-thrombocytopenia-hit-during-cardiac-or-vascular-surgery (accessed 8 December 2022).">Ortel 2022</a>). Approximately 50% of people with isolated HIT develop further thrombosis (<a href="./references#CD010956-bbs2-0127" title="WarkentinTE , KeltonJG . A 14-year study of heparin-induced thrombocytopenia. American Journal of Medicine1996;101(5):502-7.">Warkentin 1996</a>). Meanwhile, VKAs have a narrow therapeutic window, require frequent monitoring and dosage adjustments, and have multiple interactions with other drugs (<a href="./references#CD010956-bbs2-0050" title="AgenoW , GallusAS , WittkowskyA , CrowtherM , HylekEM , PalaretiG . Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines. Chest2012;141(Suppl 2):e44S-88S.">Ageno 2012</a>). </p> <p>Two further classes of direct oral anticoagulants (DOACs) have been developed: direct thrombin inhibitors (DTIs) and factor Xa inhibitors. Oral DTIs and factor Xa inhibitors have characteristics that may be favourable over heparin and VKAs, including oral administration, a predictable effect, lack of frequent monitoring or dose adjustment, and few known drug interactions (<a href="./references#CD010956-bbs2-0052" title="AlmutairiAR , ZhouL , GelladWF , LeeJK , SlackMK , MartinJR , et al. Effectiveness and safety of non-vitamin K antagonist oral anticoagulants for atrial fibrillation and venous thromboembolism: a systematic review and meta-analyses. Clinical Therapeutics2017;39(7):1456-1478.e36.">Almutairi 2017</a>; <a href="./references#CD010956-bbs2-0078" title="FoxBD , KahnSR , LanglebenD , EisenbergMJ , ShimonyA . Efficacy and safety of novel oral anticoagulants for treatment of acute venous thromboembolism: direct and adjusted indirect meta-analysis of randomised controlled trials. BMJ2012;345:e7498.">Fox 2012</a>).  </p> <p>Anticoagulant therapy for VTE (DVT and PE) can be divided into three stages: initiation phase (five to 21 days) with initial provision of anticoagulants after diagnosis; treatment phase (three months), the period that completes treatment for the acute VTE following initiation; and the extended phase (three months to no planned stop date) for secondary prevention, with anticoagulant use at full or reduced dose (<a href="./references#CD010956-bbs2-0121" title="StevensSM , WollerSC , Baumann KreuzigerL , BounameauxH , DoerschugK , GeersingGJ , et al. Executive summary: antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report. Chest2021;160(6):2247-59.">Stevens 2021</a>). Previous ACCP guidelines recommend initial therapy for DVT with a parenteral anticoagulant (UFH or LMWH or fondaparinux) and initial VKA initiation; recommendations include the use of LMWH or fondaparinux over UFH for initial therapy of DVT (<a href="./references#CD010956-bbs2-0091" title="KearonC , AklEA , ComerotaAJ , PrandoniP , BounameauxH , GoldhaberSZ , et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines. Chest2012;141(2 Suppl):e419S-94S.">Kearon 2012</a>). The latest updates of ACCP guidelines recommended apixaban, dabigatran, edoxaban or rivaroxaban over VKA as treatment‐phase (first three months) anticoagulant therapy for people with VTE (DVT of the leg or PE), and recommended an oral Xa inhibitor (apixaban, edoxaban, rivaroxaban) over LMWH for the initiation and treatment phases of therapy for acute VTE associated with cancer (<a href="./references#CD010956-bbs2-0092" title="KearonC , AklEA , OrnelasJ , BlaivasA , JimenezD , BounameauxH , et al. Antithrombotic therapy for VTE disease: CHEST Guideline and Expert Panel Report. Chest2016;149(2):315-52.">Kearon 2016</a>; <a href="./references#CD010956-bbs2-0121" title="StevensSM , WollerSC , Baumann KreuzigerL , BounameauxH , DoerschugK , GeersingGJ , et al. Executive summary: antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report. Chest2021;160(6):2247-59.">Stevens 2021</a>). Similarly, the 2019 European Society of Cardiology (ESC) guidelines recommended DOACs in preference to VKAs in eligible individuals ready for an oral anticoagulant (<a href="./references#CD010956-bbs2-0094" title="KonstantinidesSV , MeyerG , BecattiniC , BuenoH , GeersingGJ , HarjolaVP , et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). European Heart Journal2020;41(4):543-603.">Konstantinides 2020</a>). The <a href="./references#CD010956-bbs2-0104" title="National Institute for Health and Care Excellence. Venous thromboembolic diseases: diagnosis, management and thrombophilia testing. NG158: 26 March 2020. Available at: nice.org.uk/guidance/ng158 (accessed 16 August 2022).">NICE 2020</a> guidelines recommended offering either apixaban or rivaroxaban as initial choices, and suggested other regimens only for people suitable for neither: consider a DOAC for people with active cancer and confirmed proximal DVT or PE, and consider other strategies when DOAC is unsuitable. </p> <p>According to research by Lutsey and colleagues, the use of DOACs (especially rivaroxaban and apixaban) to treat VTE has increased dramatically in the USA since the US Food and Drug Administration (FDA) approved them for this application (<a href="./references#CD010956-bbs2-0102" title="LutseyPL , WalkerRF , MacLehoseRF , AlonsoA , AdamTJ , ZakaiNA . Direct oral anticoagulants and warfarin for venous thromboembolism treatment: trends from 2012 to 2017. Research and Practice in Thrombosis and Haemostasis2019;3(4):668-73.">Lutsey 2019</a>). Drawing on individual health insurance data for 2012 to 2017, they found that DOACs accounted for less than 2% of the prescriptions for VTE treatment at the beginning of 2012 and increased to more than 80% by the fourth quarter of 2017 (<a href="./references#CD010956-bbs2-0102" title="LutseyPL , WalkerRF , MacLehoseRF , AlonsoA , AdamTJ , ZakaiNA . Direct oral anticoagulants and warfarin for venous thromboembolism treatment: trends from 2012 to 2017. Research and Practice in Thrombosis and Haemostasis2019;3(4):668-73.">Lutsey 2019</a>).  </p> </section> <section id="CD010956-sec-0012"> <h3 class="title" id="CD010956-sec-0012">How the intervention might work</h3> <section id="CD010956-sec-0013"> <h4 class="title">Oral direct thrombin inhibitors</h4> <p>Oral DTIs work by binding directly to the enzyme thrombin without the need for a co‐factor, such as antithrombin. Unlike heparins and VKAs, DTIs can inhibit both soluble thrombin and fibrin‐bound thrombin (<a href="./references#CD010956-bbs2-0089" title="KamPC , KaurN , ThongCL . Direct thrombin inhibitors: pharmacology and clinical relevance. Anaesthesia2005;60(6):565-74.">Kam 2005</a>). Other advantages include a more predictable anticoagulant effect because of their lack of binding to other proteins, an antiplatelet effect and the absence of HIT (<a href="./references#CD010956-bbs2-0095" title="LeeCJ , AnsellJE . Direct thrombin inhibitors. British Journal of Clinical Pharmacology2011;72(4):581-92.">Lee 2011</a>). There are several types of oral DTIs, but only one available for clinical use. </p> <section id="CD010956-sec-0014"> <h5 class="title">Dabigatran</h5> <p>Dabigatran etexilate is a reversible oral DTI that is metabolised to its active ingredient, dabigatran, in the gastrointestinal tract (<a href="./references#CD010956-bbs2-0050" title="AgenoW , GallusAS , WittkowskyA , CrowtherM , HylekEM , PalaretiG . Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines. Chest2012;141(Suppl 2):e44S-88S.">Ageno 2012</a>). It does not require anticoagulation monitoring, is excreted by the kidneys and has a half‐life of 12 to 17 hours. As well as a treatment for venous thrombosis, this drug has been involved in many large randomised studies of stroke prevention in atrial fibrillation (<a href="./references#CD010956-bbs2-0062" title="CalkinsH , WillemsS , GerstenfeldEP , VermaA , SchillingR , HohnloserSH , OkumuraK , et al. Uninterrupted dabigatran versus warfarin for ablation in atrial fibrillation. New England Journal of Medicine2017;376(17):1627-36.">Calkins 2017</a>; <a href="./references#CD010956-bbs2-0063" title="CannonCP , BhattDL , OldgrenJ , LipGY , EllisSG , KimuraT , et al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. New England Journal of Medicine2017;377(16):1513-24.">Cannon 2017</a>; <a href="./references#CD010956-bbs2-0066" title="ConnollySJ , EzekowitzMD , YusufS , EikelboomJ , OldgrenJ , Parekh, et al. Dabigatran versus warfarin in patients with atrial fibrillation. New England Journal of Medicine2009;361(12):1139-51.">Connolly 2009</a>), acute coronary syndromes (<a href="./references#CD010956-bbs2-0105" title="OldgrenJ , BudajA , GrangerCB , KhderY , RobertsJ , SiegbahnA , et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. European Heart Journal2011;32(22):2781-9.">Oldgren 2011</a>), prevention of thrombosis following orthopaedic surgery (<a href="./references#CD010956-bbs2-0074" title="ErikssonBI , DahlOE , RosenecherN , KurthAA , vanDijkCN , FrostickSP , et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. Journal of Thrombosis and Haemostasis2007;5(11):2178-85.">Eriksson 2007</a>; <a href="./references#CD010956-bbs2-0126" title="Van der VeenL , SegersM , Van RaayJJ , Gerritsma-BleekerCL , BrouwerRW , VeegerNJ , et al. Bleeding complications of thromboprophylaxis with dabigatran, nadroparin or rivaroxaban for 6 weeks after total knee arthroplasty surgery: a randomised pilot study. BMJ Open2021;11(1):e040336.">Van der Veen 2021</a>), and in people with mechanical heart valves (<a href="./references#CD010956-bbs2-0073" title="EikelboomJW , ConnollySJ , BrueckmannM , GrangerCB , KappeteinAP , MackMJ , et al. Dabigatran versus warfarin in patients with mechanical heart valves. New England Journal of Medicine2013;369(13):1206-14.">Eikelboom 2013</a>; <a href="./references#CD010956-bbs2-0124" title="Van de WerfF , BrueckmannM , ConnollySJ , FriedmanJ , GrangerCB , HartterS , et al. A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: the randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN). American Heart Journal2012;163(6):931-7.">Van de Werf 2012</a>). In common with the other DOACs, dabigatran was associated with a lower incidence of intracranial haemorrhage (compared with VKAs). However, again compared with VKAs, dabigatran showed a higher incidence of indigestion, heartburn and gastrointestinal bleeding (<a href="./references#CD010956-bbs2-0112" title="SchulmanS , KakkarAK , GoldhaberSZ , SchellongS , ErikssonH , MismettiP , et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation2014;129(7):764-72.">Schulman 2014</a>).  </p> </section> <section id="CD010956-sec-0015"> <h5 class="title">Ximelagatran</h5> <p>Ximelagatran is a prodrug that is metabolised to melagatran, as it is better absorbed from the gastrointestinal tract (<a href="./references#CD010956-bbs2-0089" title="KamPC , KaurN , ThongCL . Direct thrombin inhibitors: pharmacology and clinical relevance. Anaesthesia2005;60(6):565-74.">Kam 2005</a>). It has a plasma half‐life of three hours, has a predictable response after oral administration and does not require coagulation monitoring. Ximelagatran was found to be effective in the treatment of VTE but caused unacceptable liver toxicity (<a href="./references#CD010956-bbs2-0059" title="BoudesPF . The challenges of new drugs benefits and risks analysis: lessons from the ximelagatran FDA Cardiovascular Advisory Committee. Contemporary Clinical Trials2006;27(5):432-40.">Boudes 2006</a>), especially with prolonged use (<a href="./references#CD010956-bbs2-0123" title="TestaL , AndreottiF , Biondi ZoccaiGG , BurzottaF , BellocciF , CreaF . Ximelagatran/melagatran against conventional anticoagulation: a meta- analysis based on 22,639 patients. International Journal of Cardiology2007;122(2):117-24.">Testa 2007</a>), and was never licensed. </p> </section> </section> <section id="CD010956-sec-0016"> <h4 class="title">Oral factor Xa inhibitors</h4> <p>Factor Xa inhibitors bind directly to the active site of factor Xa, thus blocking the activity of this clotting factor. Unlike indirect factor Xa inhibitors, such as fondaparinux, direct factor Xa inhibitors "inactivate free FXa and FXa incorporated with the prothrombinase complex equally well" and do not require interaction with the inhibitor antithrombin (<a href="./references#CD010956-bbs2-0075" title="ErikssonBI , QuinlanDJ , WeitzJI . Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development. Clinical Pharmacokinetics2009;48(1):1-22.">Eriksson 2009</a>). They have been shown to be non‐inferior to VKAs but without the need for regular blood test monitoring. They appear to have fewer drug interactions (compared with VKAs) and no food or alcohol interactions. </p> <section id="CD010956-sec-0017"> <h5 class="title">Rivaroxaban</h5> <p>Rivaroxaban is a reversible oral direct factor Xa inhibitor with a half‐life estimated to be eight to 10 hours (<a href="./references#CD010956-bbs2-0118" title="SpyropoulosAC , DouketisJD . How I treat anticoagulated patients undergoing an elective procedure or surgery. Blood2012;120(15):2954-62.">Spyropoulos 2012</a>). For the initial treatment of acute DVT, the recommended dosage of rivaroxaban is 15 mg twice daily for the first 21 days followed by 20 mg once daily for continued treatment and prevention of recurrence; the dose can be reduced to 10 mg once daily beyond six months (<a href="./references#CD010956-bbs2-0116" title="SkelleyJW , ThomasonAR , NolenJC , CandidateP . Betrixaban (Bevyxxa): a direct-acting oral anticoagulant factor Xa inhibitor. P &amp; T : a Peer-reviewed Journal for Formulary Management2018;43(2):85-120.">Skelley 2018</a>). The absorption of rivaroxaban (the 15 mg and 20 mg dosage) is predicated on giving it with food; therefore, rivaroxaban is recommended to be taken with food (<a href="./references#CD010956-bbs2-0116" title="SkelleyJW , ThomasonAR , NolenJC , CandidateP . Betrixaban (Bevyxxa): a direct-acting oral anticoagulant factor Xa inhibitor. P &amp; T : a Peer-reviewed Journal for Formulary Management2018;43(2):85-120.">Skelley 2018</a>; <a href="./references#CD010956-bbs2-0119" title="StampfussJ , KubitzaD , BeckaM , MueckW . The effect of food on the absorption and pharmacokinetics of rivaroxaban. International Journal of Clinical Pharmacology and Therapeutics2013;51(7):549-61.">Stampfuss 2013</a>). </p> </section> <section id="CD010956-sec-0018"> <h5 class="title">Apixaban</h5> <p>Apixaban is an oral, small molecule, reversible inhibitor of factor Xa with a plasma half‐life of eight to 15 hours (<a href="./references#CD010956-bbs2-0075" title="ErikssonBI , QuinlanDJ , WeitzJI . Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development. Clinical Pharmacokinetics2009;48(1):1-22.">Eriksson 2009</a>). The recommended dosage for apixaban is 10 mg twice daily for one week, then 5 mg twice daily. For people with severe renal impairment (creatinine clearance (CrCL) of 15 mL/min to 29 mL/min), apixaban should be used with caution (<a href="./references#CD010956-bbs2-0097" title="LeungLL . Direct oral anticoagulants (DOACs) and parenteral direct-acting anticoagulants: dosing and adverse effects. www.uptodate.com/contents/direct-oral-anticoagulants-doacs-and-parenteral-direct-acting-anticoagulants-dosing-and-adverse-effects (accessed prior to 22 March 2023).">Leung 2022</a>). </p> </section> <section id="CD010956-sec-0019"> <h5 class="title">Betrixaban</h5> <p>Betrixaban is an orally administered direct factor Xa inhibitor. It has a half‐life of 15 hours, offers the convenience of once daily dosing and may exhibit fewer drug interactions than warfarin (<a href="./references#CD010956-bbs2-0107" title="PalladinoM , MerliG , ThomsonL . Evaluation of the oral direct factor Xa inhibitor - betrixaban. Expert Opinion on Investigational Drugs2013;22(11):1465-72.">Palladino 2013</a>). Betrixaban is only labelled for VTE prophylaxis, not treatment (<a href="./references#CD010956-bbs2-0116" title="SkelleyJW , ThomasonAR , NolenJC , CandidateP . Betrixaban (Bevyxxa): a direct-acting oral anticoagulant factor Xa inhibitor. P &amp; T : a Peer-reviewed Journal for Formulary Management2018;43(2):85-120.">Skelley 2018</a>). For the prophylaxis of VTE, the recommended dose of betrixaban is an initial single dose of 160 mg starting on day 1, followed by 80 mg once daily taken for 35 to 42 days at the same time each day with food. For people with severe renal impairment (CrCL 15 mL/min to 29 mL/min computed by Cockcroft‐Gault using actual body weight), the recommended dose of betrixaban is an initial single dose of 80 mg followed by 40 mg once daily (<a href="./references#CD010956-bbs2-0076" title="FDA. FDA approved betrixaban (BEVYXXA, Portola) for the prophylaxis of venous thromboembolism(VTE) in adult patients; June 2017. www.fda.gov/drugs/resources-information-approved-drugs/fda-approved-betrixaban-bevyxxa-portola-prophylaxis-venous-thromboembolism-vte-adult-patients (accessed prior to 22 March 2023).">FDA 2017</a>). </p> </section> <section id="CD010956-sec-0020"> <h5 class="title">Edoxaban</h5> <p>Edoxaban is an oral direct inhibitor of activated factor X that is rapidly absorbed with a half‐life of nine to 11 hours. Edoxaban has a dual mechanism of elimination with one‐third eliminated via the kidneys and the remainder excreted in the faeces. It also offers the convenience of once‐daily dosing (<a href="./references#CD010956-bbs2-0072" title="EikelboomJW , WeitzJI . Update on antithrombotic therapy: new anticoagulants. Circulation2010;121(13):1523-32.">Eikelboom 2010</a>). The recommended dose is 60 mg once daily after parenteral anticoagulation for five to 10 days (<a href="./references#CD010956-bbs2-0097" title="LeungLL . Direct oral anticoagulants (DOACs) and parenteral direct-acting anticoagulants: dosing and adverse effects. www.uptodate.com/contents/direct-oral-anticoagulants-doacs-and-parenteral-direct-acting-anticoagulants-dosing-and-adverse-effects (accessed prior to 22 March 2023).">Leung 2022</a>). </p> </section> </section> </section> <section id="CD010956-sec-0021"> <h3 class="title" id="CD010956-sec-0021">Why it is important to do this review</h3> <p>Given the relatively high incidence and serious consequence of DVT, and the emergence and adoption of these DOACs, it is important to establish the safety and effectiveness of these treatments. Multiple non‐Cochrane systematic reviews have examined the effectiveness of DTIs and factor Xa inhibitors versus VKAs in the treatment of VTE (<a href="./references#CD010956-bbs2-0052" title="AlmutairiAR , ZhouL , GelladWF , LeeJK , SlackMK , MartinJR , et al. Effectiveness and safety of non-vitamin K antagonist oral anticoagulants for atrial fibrillation and venous thromboembolism: a systematic review and meta-analyses. Clinical Therapeutics2017;39(7):1456-1478.e36.">Almutairi 2017</a>; <a href="./references#CD010956-bbs2-0078" title="FoxBD , KahnSR , LanglebenD , EisenbergMJ , ShimonyA . Efficacy and safety of novel oral anticoagulants for treatment of acute venous thromboembolism: direct and adjusted indirect meta-analysis of randomised controlled trials. BMJ2012;345:e7498.">Fox 2012</a>; <a href="./references#CD010956-bbs2-0103" title="MulderFI , BoschFT , YoungAM , MarshallA , McBaneRD , ZemlaTJ , et al. Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis. Blood2020;136(12):1433-41.">Mulder 2020</a>). However, their primary outcome was VTE and they did not present results for DVT and PE separately.  </p> <p>This review was originally conducted in 2015 and included 11 randomised controlled trials of 27,945 participants. It examined the effectiveness of oral DTIs and oral factor Xa inhibitors in the treatment of DVT alone, and showed that they are potentially effective and safe alternatives to conventional anticoagulation treatment for acute DVT (<a href="./references#CD010956-bbs2-0134" title="RobertsonL , KestevenP , McCaslinJE . Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of deep vein thrombosis. Cochrane Database of Systematic Reviews2015, Issue 6. Art. No: CD010956. [DOI: 10.1002/14651858.CD010956.pub2]">Robertson 2015</a>). However, none of the included studies in the previous version focused on and measured important outcomes, such as PTS or health‐related quality of life, and all‐cause mortality has yet to be estimated for DVT treated with dabigatran (the only FDA‐approved DTI). In addition, data were limited for important subgroups (e.g. people with cancer). Further, no study compared one DOAC with another, a fact highlighted in both NICE and ACCP guidelines (<a href="./references#CD010956-bbs2-0104" title="National Institute for Health and Care Excellence. Venous thromboembolic diseases: diagnosis, management and thrombophilia testing. NG158: 26 March 2020. Available at: nice.org.uk/guidance/ng158 (accessed 16 August 2022).">NICE 2020</a>; <a href="./references#CD010956-bbs2-0121" title="StevensSM , WollerSC , Baumann KreuzigerL , BounameauxH , DoerschugK , GeersingGJ , et al. Executive summary: antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report. Chest2021;160(6):2247-59.">Stevens 2021</a>). </p> <p>Since 2015, many new randomised controlled trials on this topic have been published (<a href="./references#CD010956-bbs2-0002" title="NakamuraM , NishikawaM , KomuroI , KitajimaI , UetsukaY , YamagamiT , et al. Apixaban for the treatment of Japanese subjects with acute venous thromboembolism (AMPLIFY-J Study). Circulation2015;79(6):1230–36. ">AMPLIFY‐J 2015</a>; <a href="./references#CD010956-bbs2-0010" title="FarhanA , BukhariM , UmarJ , RazaMA . Oral rivaroxaban in symptomatic deep vein thrombosis. Journal of the College of Physicians and Surgeons Pakistan2019;29(9):814-8. ">Farhan 2019</a>; <a href="./references#CD010956-bbs2-0016" title="OhmoriH , KadaA , NakamuraM , SaitoAM , SanayamaY , ShinagawaT , et al. Deep vein thrombosis in severe motor and intellectual disabilities patients and its treatment by anticoagulants of warfarin versus edoxaban. Annals of Vascular Diseases2019;12(3):372-8. OhmoriH , NakamuraM , KadaA , SaitoAM , SanayamaY , ShinagawaT , et al. Multicenter, open-label, randomized controlled trial of warfarin and edoxaban tosilate hydrate for the treatment of deep vein thrombosis in persons with severe motor intellectual disabilities. Kurume Medical Journal2018;65(1):11-6. ">Ohmori 2019</a>; <a href="./references#CD010956-bbs2-0017" title="Kang JiM, ParkKH , AhnS , ChoS , MinSK . Rivaroxaban after thrombolysis in acute iliofemoral venous thrombosis: a randomized, open-labeled, multicenter trial. Scientific Reports2019;9(1):20356. MinSK , AhnS , ParkKH , KangJM , KimJY . Prevention of recurrence after thrombolysis in acute iliofemoral venous thrombosis with rivaroxaban (Prais Study): a prospective, randomized, open label, multicenter trial. European Journal of Vascular and Endovascular Surgery2019;58(6):e516. NCT01986192. Prevention of recurrence after thrombolysis in acute iliofemoral venous thrombosis (PRAIS) study. clinicaltrials.gov/show/NCT01986192 (first received 18 November 2013). ">PRAIS 2019</a>; <a href="./references#CD010956-bbs2-0108" title="RaskobGE , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaD , et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. New England Journal of Medicine2018;378(7):615-24.">Raskob 2018</a>), with some reporting on quality of life (<a href="./references#CD010956-bbs2-0020" title="SukovatykhBS , SereditskiĭAV , MuradianVF , BelikovLN , GerasimovaOF . Results of administering oral anticoagulants for treatment of patients with venous thromboembolic complications. Angiologiia i sosudistaia khirurgiia [Angiology and Vascular Surgery]2017;23(2):82. ">Sukovatykh 2017</a>) and PTS (<a href="./references#CD010956-bbs2-0005" title="NCT02704598. Comparison between xarelto versus warfarin in the recanalization rate of deep venous thrombosis in patients legs. (DVT). clinicaltrials.gov/ct2/show/NCT02704598 (first received 10 March 2016). deAthayde SoaresR , MatieloMF , Brochado NetoFC , AlmeidaRD , SacilottoR . LEV 2. Comparison of the recanalization rate and post-thrombotic syndrome in patients with deep venous thrombosis treated with rivaroxaban or warfarin. Journal of Vascular Surgery2019;70(5):e169-e170. deAthayde SoaresR , MatieloMF , Brochado NetoFC , NogueiraMP , AlmeidaRD , SacilottoR . Comparison of the recanalization rate and postthrombotic syndrome in patients with deep venous thrombosis treated with rivaroxaban or warfarin. Surgery2019;166(6):1076-83. ">de Athayde 2019</a>), and more studies focused on cancer‐associated DVT (<a href="./references#CD010956-bbs2-0004" title="AgenoW , VedovatiMC , CohenA , HuismanM , BauersachsR , GussoniG , et al. Bleeding with apixaban and dalteparin in patients with cancer-associated venous thromboembolism: results from the Caravaggio study. Thrombosis and Haemostasis2021;121(5):616-24. AgnelliG , BecattiniC , BauersachsR , BrennerB , CampaniniM , CohenA , et al. Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the Caravaggio study. Thrombosis and Haemostasis2018;118(9):1668-78. AgnelliG , BecattiniC , MeyerG , MuozA , VersoM . Apixaban for the treatment of venous thromboembolism associated with cancer. New England Journal of Medicine2020;382(17):1599-607. AgnelliG , MuozA , FrancoL , MahéI , BrennerB , ConnorsJM , et al. Apixaban and dalteparin for the treatment of venous thromboembolism in patients with different sites of cancer. Thrombosis and Haemostasis2022;122(5):796-807. BecattiniC , BauersachsR , MarazitiG , BertolettiL , CohenA , ConnorsJM , et al. Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial. Haematologica2021;107(7):1567-76. GiustozziM , ConnorsJM , Ruperez BlancoAB , SzmitS , FalvoN , CohenAT , et al. Clinical characteristics and outcomes of incidental venous thromboembolism in cancer patients: insights from the Caravaggio study. Journal of Thrombosis and Haemostasis2021;19(11):2751-9. NCT03045406. Apixaban for the treatment of venous thromboembolism in patients with cancer (CARAVAGGIO). clinicaltrials.gov/ct2/show/NCT03045406 (first received 7 February 2017). VersoM , MunozA , BauersachsR , HuismanMV , AgnelliG . Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism. European Journal of Cancer2021;148(Suppl C):371-81. ">Caravaggio 2020</a>; <a href="./references#CD010956-bbs2-0012" title="AmayaN , UzuiH , HisazakiK , HasegwaK , KasenoK , TadaH . Edoxaban normalizes the elevated D-dimer levels potently and promptly in patients with venous thromboembolisms: a comparison with traditional anticoagulant therapy. European Heart Journal2016;37:278. BoschFT , Van EsN , Di NisioM , CarrierM , SegersA , GrossoMA , et al. The Ottawa score does not predict recurrent venous thromboembolism in cancer patients: results from the Hokusai-VTE cancer study. Research and Practice in Thrombosis and Haemostasis2019;3(S1):717-8. KraaijpoelN , Di NisioM , MulderFI , Van EsN , RaskobGE . Clinical impact of bleeding in cancer-associated venous thromboembolism: results from the Hokusai VTE Cancer randomized trial. Thrombosis Research2018;164(Suppl 1):S223. [DOI: 10.1016/j.thromres.2018.02.094]MulderFI , Di NisioM , AyC , CarrierM , BoschFT , SegersA , et al. Clinical implications of incidental venous thromboembolism in cancer patients. European Respiratory Journal2020;55(2):1901697. [DOI: 10.1183/13993003.01697-2019]MulderFI , Van EsN , KraaijpoelN , Di NisioM , CarrierM , GarciaD , et al. Efficacy and safety of edoxaban in clinically relevant subgroups: results from the Hokusai VTE Cancer randomized trial. Thrombosis Research2018;164:S194. NCT02073682. Cancer venous thromboembolism (VTE). clinicaltrials.gov/ct2/show/NCT02073682 (first received 27 February 2014). RaskobG , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaD , et al. Edoxaban versus dalteparin for treatment of venous thromboembolism (VTE) associated with cancer: Hokusai VTE-cancer randomized trial. Supportive Care in Cancer2018;26(2):S316-S317. RaskobGE , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaD , et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. New England Journal of Medicine2018;378(7):615-24. RaskobGE , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaDA , et al. A randomized, open-label, blinded outcome assessment trial evaluating the efficacy and safety of LMWH/Edoxaban versus dalteparin for venous thromboembolism associated with cancer: Hokusai VTE-cancer study. Blood2017;130(Suppl 1):LBA-6. ">Hokusai VTE Cancer 2018</a>; <a href="./references#CD010956-bbs2-0014" title="MokademME , HassanA , AlgabyAZ . Efficacy and safety of apixaban in patients with active malignancy and acute deep venous thrombosis. Vascular2021;29(5):745-50. NCT04462003. Efficacy of apixaban in malignancy with deep venous thrombosis (DVT). clinicaltrials.gov/ct2/show/NCT04462003 (first received 3 July 2019). ">Mokadem 2021</a>). Further, the previous version included data published only in a conference abstract for the <a href="./references#CD010956-bbs2-0009" title="PiazzaG , ManiV , GoldhaberSZ , GrossoMA , MercuriM , LanzHJ , et al. Magnetic resonance venography to assess thrombus resolution with edoxaban monotherapy versus parenteral anticoagulation/warfarin for symptomatic deep vein thrombosis: a multicenter feasibility study. Vascular Medicine2016;21(4):361-8. PiazzaG , ManiV , GrossoM , MercuriM , LanzH , SchusslerS , et al. A randomized, open-label, multicenter study of the efficacy and safety of edoxaban monotherapy versus low-molecular weight heparin/warfarin in patients with symptomatic deep vein thrombosis-edoxaban thrombus reduction imaging study (etris). Circulation2014;130:A12074. ">eTRIS 2016</a> study. As DOACs are now ubiquitous in the context of primary treatment for VTE, there is a continued need to assess their comparative effectiveness, and to explore and understand how to optimise their management in high‐risk situations. It is important to update the evidence presented in this Cochrane Review to include any newly available data, providing trustworthy evidence synthesis for more informed decision‐making. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD010956-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD010956-sec-0022"></div> <p>To assess the effectiveness and safety of oral DTIs and oral factor Xa inhibitors versus conventional anticoagulants for the long‐term treatment of DVT. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD010956-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD010956-sec-0023"></div> <section id="CD010956-sec-0024"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD010956-sec-0025"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials in which people with a confirmed DVT were allocated to receive an oral DTI or an oral factor Xa inhibitor for the treatment of DVT. We included published studies and studies in progress if preliminary results were available. We also included non‐English studies in the review. There was no restriction on publication status. We excluded DTIs and factor Xa inhibitors that were not given by the oral route. We also excluded studies where treatment lasted less than three months, as a meta‐analysis of DVT treatment strategies has demonstrated an increased rate of recurrence after less than three months of anticoagulation but no significant difference with various longer periods of treatment (<a href="./references#CD010956-bbs2-0060" title="BoutitieF , PinedeL , SchulmanS , AgnelliG , RaskobG , JulianJ , et al. Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants' data from seven trials. BMJ2011;342:d3036.">Boutitie 2011</a>). </p> </section> <section id="CD010956-sec-0026"> <h4 class="title">Types of participants</h4> <p>We included people with a DVT, confirmed by standard imaging techniques (venography, impedance plethysmography, whole‐leg compression ultrasound, proximal compression ultrasound). </p> </section> <section id="CD010956-sec-0027"> <h4 class="title">Types of interventions</h4> <p>We included the following interventions:</p> <p> <ul id="CD010956-list-0001"> <li> <p>oral DTIs (e.g. dabigatran, ximelagatran) (although ximelagatran was withdrawn from the market in 2006 due to safety issues, we included it in the review to make the results as comprehensive as possible); </p> </li> <li> <p>oral factor Xa inhibitors (e.g. rivaroxaban, apixaban, edoxaban);</p> </li> <li> <p>other anticoagulants (e.g. LMWH, UFH or VKAs).</p> </li> </ul> </p> <p>We included the following comparisons:</p> <p> <ul id="CD010956-list-0002"> <li> <p>oral DTI or oral factor Xa inhibitor versus another anticoagulant;</p> </li> <li> <p>one oral DTI versus another oral DTI;</p> </li> <li> <p>one oral factor Xa inhibitor versus another oral factor Xa inhibitor;</p> </li> <li> <p>oral DTI versus oral factor Xa inhibitor.</p> </li> </ul> </p> <p>Treatment had to be for a minimum duration of three months as this is conventional anticoagulation practice for a DVT. </p> </section> <section id="CD010956-sec-0028"> <h4 class="title">Types of outcome measures</h4> <section id="CD010956-sec-0029"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD010956-list-0003"> <li> <p>Recurrent VTE (clinically overt DVT confirmed by standard imaging techniques, including proximal leg vein ultrasound scan or D‐dimer test, or both; or clinically overt PE confirmed by computed tomography pulmonary angiography (CTPA) or ventilation/perfusion (V/Q) scan, or both) </p> </li> <li> <p>Recurrent DVT, confirmed by standard imaging techniques, including proximal leg vein ultrasound scan or D‐dimer test </p> </li> <li> <p>PE (fatal/non‐fatal), confirmed by CTPA or V/Q scan</p> </li> </ul> </p> </section> <section id="CD010956-sec-0030"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD010956-list-0004"> <li> <p>All‐cause mortality</p> </li> <li> <p>Major bleeding (an adverse event; as defined by the International Society on Thrombosis and Haemostasis (ISTH); <a href="./references#CD010956-bbs2-0111" title="SchulmanS , KearonC , Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. Journal of Thrombosis and Haemostasis2005;3(4):692-4.">Schulman 2005</a>): </p> <ul id="CD010956-list-0005"> <li> <p>fatal bleeding;</p> </li> <li> <p>symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intra‐articular or pericardial, or intramuscular with compartment syndrome; </p> </li> <li> <p>bleeding causing a fall in haemoglobin level of 20 g/L (1.24 mmol/L) or more, or leading to transfusion of two or more units of whole blood or red cells; </p> </li> <li> <p>any combination of the above.</p> </li> </ul> </li> <li> <p>PTS as defined by <a href="./references#CD010956-bbs2-0087" title="KahnSR . The post-thrombotic syndrome. Hematology,  the American Society of Hematology Education Program Book2016;2016(1):413-8. [DOI: 10.1182/asheducation-2016.1.413]">Kahn 2016</a> </p> </li> <li> <p>Health‐related quality of life (as reported in studies)</p> </li> </ul> </p> </section> </section> </section> <section id="CD010956-sec-0031"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD010956-sec-0032"> <h4 class="title">Electronic searches</h4> <p>The Cochrane Vascular Information Specialist conducted systematic searches of the following databases, from inception to 1 March 2022, for randomised controlled trials and controlled clinical trials without language, publication year or publication status restrictions: </p> <p> <ul id="CD010956-list-0006"> <li> <p>the Cochrane Vascular Specialised Register via the Cochrane Register of Studies (CRS‐Web);</p> </li> <li> <p>the Cochrane Central Register of Controlled Trials (CENTRAL; 2022) via the Cochrane Register of Studies Online (CRSO); </p> </li> <li> <p>MEDLINE (Ovid MEDLINE Epub Ahead of Print, In‐Process &amp; Other Non‐Indexed Citations, Ovid MEDLINE Daily and Ovid MEDLINE);  </p> </li> <li> <p>Embase Ovid;</p> </li> <li> <p>CINAHL (Cumulative Index to Nursing and Allied Health Literature) EBSCO. </p> </li> </ul> </p> <p>We developed search strategies for other databases from the search strategy designed for MEDLINE. Where appropriate, they were combined with adaptations of the highly sensitive search strategy designed by Cochrane for identifying randomised controlled trials and controlled clinical trials, as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions </i>Chapter 4 (<a href="./references#CD010956-bbs2-0096" title="LefebvreC , GlanvilleJ , BriscoeS , LittlewoodA , MarshallC , MetzendorfMI , et al. Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch V, editors. Cochrane Handbook for Systematic Reviews of Interventions. Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Lefebvre 2021</a>). Search strategies for major databases are provided in <a href="./appendices#CD010956-sec-0102">Appendix 1</a>. </p> <p>We searched the following trials registries:</p> <p> <ul id="CD010956-list-0007"> <li> <p>the World Health Organization International Clinical Trials Registry Platform (<a href="https://who.int/trialsearch" target="_blank">who.int/trialsearch</a>); </p> </li> <li> <p>ClinicalTrials.gov (<a href="https://clinicaltrials.gov" target="_blank">clinicaltrials.gov</a>). </p> </li> </ul> </p> <p>The most recent searches were carried out on 1 March 2022.</p> </section> <section id="CD010956-sec-0033"> <h4 class="title">Searching other resources</h4> <p>We searched the reference lists of relevant articles retrieved by electronic searches for additional citations. </p> </section> </section> <section id="CD010956-sec-0034"> <h3 class="title" id="CD010956-sec-0034">Data collection and analysis</h3> <section id="CD010956-sec-0035"> <h4 class="title">Selection of studies</h4> <p>Pairs of reviewers (XW, YM, ML, JL, XH, QW, LY), independently and in duplicate, used the selection criteria to identify trials for inclusion.  We resolved any disagreements by discussion. </p> </section> <section id="CD010956-sec-0036"> <h4 class="title">Data extraction and management</h4> <p>Two pairs of review authors (ML, YM, JL, XH) independently extracted the data from the included studies. We recorded information about the trial design; exclusions post‐randomisation; losses to follow‐up; duration of study; unit of randomisation; country and setting; number of participants; age and sex of participants; participant inclusion and exclusion criteria; intervention and control group sample sizes, type, dose and duration of intervention; diagnosis of DVT; baseline characteristics of participants; funding source and declarations of interest declared by study authors. We recorded recurrent VTE, recurrent DVT and PE (fatal and non‐fatal) data as the primary outcome measures. We also collected data on all‐cause mortality, major bleeding, PTS and health‐related quality of life in accordance with the secondary outcome measures. We contacted authors of included studies where further information or clarification was required. We resolved any disagreements in data extraction and management by discussions with a third review author (XW) if required. </p> </section> <section id="CD010956-sec-0037"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two pairs of review authors (ML, YM, JL, XH) independently used Cochrane's risk of bias tool to assess risk of bias for each of the included studies (<a href="./references#CD010956-bbs2-0082" title="HigginsJP , AltmanDG , SterneJA , editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.2.0 (updated June 2017). The Cochrane Colllaboration, 2017. Available from training.cochrane.org/handbook/archive/v5.2.">Higgins 2017</a>). The tool provides a protocol for judgements on sequence generation, allocation methods, blinding, incomplete outcome data, selective outcome reporting and any other relevant biases. We judged each of these domains as high, low or unclear risk of bias according to <a href="./references#CD010956-bbs2-0082" title="HigginsJP , AltmanDG , SterneJA , editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.2.0 (updated June 2017). The Cochrane Colllaboration, 2017. Available from training.cochrane.org/handbook/archive/v5.2.">Higgins 2017</a>, and provided support for each judgement. We presented the conclusions in a risk of bias table. We resolved any disagreements by discussion with a third review author (XW) if required. </p> </section> <section id="CD010956-sec-0038"> <h4 class="title">Measures of treatment effect</h4> <p>We based the analysis on intention‐to‐treat data from the individual clinical trials.   </p> <p>For dichotomous outcomes, we used odds ratios (ORs) as the effect measure, with 95% confidence intervals (CIs). For continuous data, we calculated mean differences (MDs) with 95% CIs. If similar outcomes were measured using different scales, we planned to calculate the standardised mean difference (SMD). </p> </section> <section id="CD010956-sec-0039"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis in this review was the individual participant.</p> </section> <section id="CD010956-sec-0040"> <h4 class="title">Dealing with missing data</h4> <p>We sought information about dropouts, withdrawals and other missing data and, if not reported, we contacted study authors for this information. </p> </section> <section id="CD010956-sec-0041"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed heterogeneity between the trials by: visually examining forest plots to check for overlap among CIs; using the Chi<sup>2</sup> test for homogeneity with a 10% level of significance; and using the I<sup>2</sup> statistic to measure the degree of inconsistency between the studies. An I<sup>2</sup> result of greater than 50% may represent moderate to substantial heterogeneity (<a href="./references#CD010956-bbs2-0069" title="DeeksJJ , HigginsJP , AltmanDG . Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch V, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook.">Deeks 2022</a>). </p> </section> <section id="CD010956-sec-0042"> <h4 class="title">Assessment of reporting biases</h4> <p>We investigated publication bias by funnel plots where a sufficient number of studies (10 or more) were available in the meta‐analyses. There are many reasons for funnel plot asymmetry, and we referred to the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> to aid the interpretation of the results (<a href="./references#CD010956-bbs2-0120" title="SterneJA , EggerM , MoherD . Chapter 10: Addressing reporting biases. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Sterne 2011</a>). </p> </section> <section id="CD010956-sec-0043"> <h4 class="title">Data synthesis</h4> <p>One review author (XW) entered the data into RevMan Web (<a href="./references#CD010956-bbs2-0109" title="Review Manager Web (RevMan Web). Version 1.22. The Cochrane Collaboration, 2019. Available at revman.cochrane.org.">RevMan Web 2019</a>), and a second review author (XH) cross‐checked data entry. We resolved any discrepancies by consulting the source publication. </p> <p>We used a random‐effects model to synthesise the data, even when low heterogeneity was indicated by small I² values. This was because we expected that clinical heterogeneity across studies may exist, such as different oral factor Xa inhibitors (e.g. apixaban, rivaroxaban, edoxaban), different indirect thrombin inhibitors in the control group (e.g. warfarin, dalteparin), and different treatment durations (e.g. three, six and 12 months). </p> </section> <section id="CD010956-sec-0044"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to conduct subgroup analysis only when each subgroup was reported by at least two studies. Due to the limited number of included studies in each subgroup, we were not able to perform the following subgroup analyses:  </p> <p> <ul id="CD010956-list-0008"> <li> <p>history of VTE;</p> </li> <li> <p>age;</p> </li> <li> <p>pregnancy;</p> </li> <li> <p>major surgery requiring general or regional anaesthesia in the previous 12 weeks;</p> </li> <li> <p>recent period of immobility (bedridden for three or more days in the previous 12 weeks);</p> </li> <li> <p>thrombophilia (genetic or acquired).</p> </li> </ul> </p> <p>We performed subgroup analysis by duration of treatment to identify treatment effects of three months of treatment and more than three months of treatment. We also conducted subgroup analysis by different oral Xa factor inhibitors since individual drugs may have potential differences in effectiveness and safety. For treatment effects by populations with active cancer versus no cancer, we carried out subgroup analysis when sufficient data were available. </p> </section> <section id="CD010956-sec-0045"> <h4 class="title">Sensitivity analysis</h4> <p>We performed sensitivity analyses by excluding studies that we judged to be at high risk of bias in any domain. We also performed sensitivity analyses by excluding the study that gave participants ximelagatran, as this drug is no longer available. </p> </section> <section id="CD010956-sec-0046"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We developed summary of finding tables using GRADEpro GDT software (<a href="./references#CD010956-bbs2-0081" title="GRADEpro GDT. Version accessed 6 July 2022. Hamilton (ON): McMaster University (developed by Evidence Prime), 2022. Available at gradepro.org.">GRADEpro GDT</a>). We created one table for the comparisons 'Oral DTIs versus conventional anticoagulation for participants with diagnosed DVT' and 'Oral factor Xa inhibitors compared to conventional anticoagulation for participants with diagnosed DVT'. We assessed the certainty of the body of evidence for each outcome as high, moderate, low or very low by considering the risk of bias, inconsistency, indirectness, imprecision and publication bias, according to the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010956-bbs2-0113" title="SchünemannHJ , VistGE , HigginsJP , SantessoN , DeeksJJ , GlasziouP , et al. Chapter 15: Interpreting results and drawing conclusions. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook.">Schünemann 2022</a>). We assessed the certainty of evidence for the following outcomes: recurrent VTE, recurrent DVT, fatal PE, non‐fatal PE, all‐cause mortality and major bleeding. We included footnotes to justify decisions to downgrade the certainty of the evidence. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD010956-sec-0047" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD010956-sec-0047"></div> <section id="CD010956-sec-0048"> <h3 class="title">Description of studies</h3> <section id="CD010956-sec-0049"> <h4 class="title">Results of the search</h4> <p>See <a href="#CD010956-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD010956-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram" data-id="CD010956-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_n/nCD010956-FIG-01.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> </div> <p>For this update, the searches identified 11,673 records, leaving 8962 records after deduplication. We assessed 8786 records as not relevant based on the title and abstract screening. We assessed 176 potentially relevant records by screening full‐text publications. We identified 10 new studies (35 reports) eligible for inclusion in the review, and 47 additional reports for already included studies. The previous version of the review included 11 studies (44 reports); therefore, we ultimately included a total of 21 studies (126 reports) in this review update. See <a href="./references#CD010956-sec-0117" title="">Characteristics of included studies</a>. Five references reported on more than one study and are listed more than once, making the total count of reports of included studies 131. We excluded 16 studies (51 reports) with reasons; we identified 11 ongoing studies (11 reports); and we assessed one study (one report) as awaiting classification. We assessed the remaining thirty‐one records as not relevant. </p> </section> <section id="CD010956-sec-0050"> <h4 class="title">Included studies</h4> <p>The <a href="./references#CD010956-sec-0117" title="">Characteristics of included studies</a> table presents details of the included studies. </p> <p>Twenty‐one studies (30,895 participants) met the criteria and were included in the review (<a href="./references#CD010956-bbs2-0001" title="AgnelliG , BullerH , MasiukiewiczUP . Apixaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism: a randomized, double-blind trial (AMPLIFY). Journal of Thrombosis and Haemostasis2013;11:18. AgnelliG , BullerHR , CohenA , CurtoD , GallusAS , JohnsonM , et al. Oral apixaban for the treatment of acute venous thromboembolism. New England Journal of Medicine2013;369:799-808. AgnelliG , BullerHR , CohenA , CurtoM , GallusAS , PakR , et al. Apixaban for the treatment of venous thromboembolism in cancer patients: data from the AMPLIFY trial. Canadian Journal of Cardiology2014;30(10 Suppl 1):S278. AgnelliG , BullerHR , CohenA , GallusAS , LeeTC , PakR , et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. Journal of Thrombosis and Haemostasis2015;13(12):2187-91. AgnelliG . Apixaban was non-inferior to enoxaparin plus warfarin in patients with acute venous thromboembolism. Annals of Internal Medicine2013;159(8):JC2. BlekerSM , CohenAT , BüllerHR , AgnelliG , GallusAS , RaskobGE , et al. Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Thrombosis and Haemostasis2016;116(6):159-64. BrekelmansM , ScheresL , BlekerS , HuttenB , TimmermansA , BüllerH , et al. Abnormal vaginal bleeding in women with venous thromboembolism treated with apixaban or warfarin. Thrombosis and Haemostasis2017;117(04):809-15. CohenA , AgnelliG , BullerH , GallusA , RaskobG , SandersP , et al. Characteristics and outcomes in patients with venous thromboembolism taking concomitant anti-platelet agents and anticoagulants in the AMPLIFY Trial. Thrombosis and Haemostasis2019;119(3):461-6. CohenA , AgnelliG , BullerHR , ChaudhuriS , GallusAS , RaskobGE , et al. Analysis of the bleeding and thromboembolic risk with concomitant use of antiplatelet treatment in the AMPLIFY trial. Canadian Journal of Cardiology2014;30(10):S272. CohenA , GallusAS , AgnelliG , BullerHR , PakR , PorcariAR , et al. Time in Therapeutic Range (TTR) and relative efficacy and safety of treatment with apixaban or enoxaparin/warfarin for acute symptomatic venous thromboembolism: an analysis of the Amplify trial data. Blood2014;124(21):1543. CohenAT , PanS , ByonW , IlyasBS , LeeTC . Efficacy, safety, and exposure of apixaban in patients with high body weight or obesity and venous thromboembolism: insights from AMPLIFY. Advances in Therapy2021;38(6):3003-18. EUCTR2007-007867-25-PT. A safety and efficacy trial evaluating the use of apixaban in the treatment of symptomatic deep vein thrombosis and pulmonary embolism revised protocol number: 01, incorporates amendment(s) 02 + protocol amendment 01 (version 1.0 dated 21-Apr-08) site-specific - molecular profiling supplement samples for Pfizer’s exploratory research biobank. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2007%E2%80%90007867%E2%80%9025%E2%80%90PT (first received 14 July 2008). GallusAS , AgnelliG , BullerHR , CohenA , LeeTC , PakR , et al. Apixaban for treatment of venous thromboembolism in patients from study centres in Asia: a subgroup analysis of the Amplify trial. Journal of Thrombosis and Haemostasis2015;13:727. LeeT , PanS , ByonW , IlyasBS . Safety and efficacy of apixaban versus enoxaparin/warfarin in patients with extremes of body weight: post-hoc analysis of the AMPLIFY trial. Blood2019;134(Suppl 1):1152. LiuX , JohnsonM , MardekianJ , PhatakH , ThompsonJ , CohenAT . Apixaban reduces hospitalizations in patients with venous thromboembolism: an analysis of the apixaban for the Initial management of pulmonary embolism and deep‐vein thrombosis as first‐line therapy (AMPLIFY) trial. Journal of the American Heart Association2015;4(12):e002340. NCT00633893. Efficacy and safety study of apixaban for extended treatment of deep vein thrombosis or pulmonary embolism. clinicaltrials.gov/ct2/show/NCT00633893?term=ajax&amp;rank=5 (first received 12 March 2008). NCT00643201. Efficacy and safety study of apixaban for the treatment of deep vein thrombosis or pulmonary embolism. clinicaltrials.gov/ct2/show/NCT00643201 (first received 26 March 2008). RaskobGE , GallusAS , SandersP , ThompsonJR , AgnelliG , BullerHR , et al. Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy: a sub-analysis of the AMPLIFY trial. Thrombosis and Haemostasis2016;115(4):809-16. ">AMPLIFY 2013</a>; <a href="./references#CD010956-bbs2-0002" title="NakamuraM , NishikawaM , KomuroI , KitajimaI , UetsukaY , YamagamiT , et al. Apixaban for the treatment of Japanese subjects with acute venous thromboembolism (AMPLIFY-J Study). Circulation2015;79(6):1230–36. ">AMPLIFY‐J 2015</a>; <a href="./references#CD010956-bbs2-0003" title="BarrettYC , WangJ , KnabbR , MohanP . Apixaban decreases coagulation activity in patients with acute deep-vein thrombosis. Thrombosis and Haemostasis2011;105:181-9. Botticelli Investigators Writing Committee, BullerH , DeitchmanD , PrinsM , SegersA . Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. Journal of Thrombosis and Haemostasis2008;6:1313-8. BullerHR . A dose finding study of the oral direct factor Xa inhibitor apixaban in the treatment of patients with acute symptomatic deep vein thrombosis - the Botticelli Investigators. Journal of Thrombosis and Haemostasis2007;5 (Suppl 2):O-S-003. NCT00252005. Oral direct factor Xa-inhibitor apixaban in patients with acute symptomatic deep-vein thrombosis - the Botticelli DVT study. clinicaltrials.gov/ct/show/NCT00252005?order=1 (first received 11 November 2005). ">Botticelli DVT 2008</a>; <a href="./references#CD010956-bbs2-0004" title="AgenoW , VedovatiMC , CohenA , HuismanM , BauersachsR , GussoniG , et al. Bleeding with apixaban and dalteparin in patients with cancer-associated venous thromboembolism: results from the Caravaggio study. Thrombosis and Haemostasis2021;121(5):616-24. AgnelliG , BecattiniC , BauersachsR , BrennerB , CampaniniM , CohenA , et al. Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the Caravaggio study. Thrombosis and Haemostasis2018;118(9):1668-78. AgnelliG , BecattiniC , MeyerG , MuozA , VersoM . Apixaban for the treatment of venous thromboembolism associated with cancer. New England Journal of Medicine2020;382(17):1599-607. AgnelliG , MuozA , FrancoL , MahéI , BrennerB , ConnorsJM , et al. Apixaban and dalteparin for the treatment of venous thromboembolism in patients with different sites of cancer. Thrombosis and Haemostasis2022;122(5):796-807. BecattiniC , BauersachsR , MarazitiG , BertolettiL , CohenA , ConnorsJM , et al. Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial. Haematologica2021;107(7):1567-76. GiustozziM , ConnorsJM , Ruperez BlancoAB , SzmitS , FalvoN , CohenAT , et al. Clinical characteristics and outcomes of incidental venous thromboembolism in cancer patients: insights from the Caravaggio study. Journal of Thrombosis and Haemostasis2021;19(11):2751-9. NCT03045406. Apixaban for the treatment of venous thromboembolism in patients with cancer (CARAVAGGIO). clinicaltrials.gov/ct2/show/NCT03045406 (first received 7 February 2017). VersoM , MunozA , BauersachsR , HuismanMV , AgnelliG . Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism. European Journal of Cancer2021;148(Suppl C):371-81. ">Caravaggio 2020</a>; <a href="./references#CD010956-bbs2-0005" title="NCT02704598. Comparison between xarelto versus warfarin in the recanalization rate of deep venous thrombosis in patients legs. (DVT). clinicaltrials.gov/ct2/show/NCT02704598 (first received 10 March 2016). deAthayde SoaresR , MatieloMF , Brochado NetoFC , AlmeidaRD , SacilottoR . LEV 2. Comparison of the recanalization rate and post-thrombotic syndrome in patients with deep venous thrombosis treated with rivaroxaban or warfarin. Journal of Vascular Surgery2019;70(5):e169-e170. deAthayde SoaresR , MatieloMF , Brochado NetoFC , NogueiraMP , AlmeidaRD , SacilottoR . Comparison of the recanalization rate and postthrombotic syndrome in patients with deep venous thrombosis treated with rivaroxaban or warfarin. Surgery2019;166(6):1076-83. ">de Athayde 2019</a>; <a href="./references#CD010956-bbs2-0007" title="BullerH , DariusH . EINSTEIN DVT: oral rivaroxaban versus standard therapy in the initial treatment of symptomatic deep vein thrombosis and long-term prevention of recurrent venous thromboembolism. escardio.org/The-ESC/Press-Office/Press-releases/EINSTEIN-DVT-Oral-rivaroxaban-versus-standard-therapy-in-the-initial-treatment (accessed 19 October 2022). BullerHR , AgnelliG . Once- or twice-daily rivaroxaban for the treatment of proximal deep vein thrombosis: similar efficacy and safety to standard therapy in dose-ranging studies. Blood2006;108(11 Part 1):172-3. BullerHR , LensingAW , PrinsMH , AgnelliG , CohenA , GallusAS , et al. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT dose-ranging study. Blood2008;112(6):2242-7. NCT00395772. Once-daily oral direct factor Xa inhibitor BAY59-7939 in patients with acute symptomatic deep-vein thrombosis. clinicaltrials.gov/ct2/show/NCT00395772?term=einstein-dvt&amp;rank=2 (first received 3 November 2006). ">EINSTEIN‐DVT dose 2008</a>; <a href="./references#CD010956-bbs2-0006" title="BamberL , WangMY , PrinsMH , CiniglioC , BauersachsR , LensingAW , et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis. Thrombosis and Haemostasis2013;110(4):732-41. BauersachsR , LensingAW , PapA , DecoususH . No need for a rivaroxaban dose reduction in renally impaired patients with symptomatic venous thromboembolism. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):30-1. BistervelsI , GebelM , LensingA , MiddeldorpS , CoppensM . Effect of polypharmacy on bleeding of rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolism. Research and Practice in Thrombosis and Haemostasis2019;3:798‐9. BookhartBK , HaskellL , BamberL , WangM , ScheinJ , ModySH . Length of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial program. Journal of Medical Economics2014;17(10):691-5. BullerHR . Oral rivaroxaban for the acute and continued treatment of symptomatic venous thromboembolism. The Einstein-DVT and Einstein-Extension study. Blood2010;116(21):187. CheungW , MiddeldorpS , PrinsMP , PapAF , LensingAW , Hoek-tenCA , et al. Post thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep vein thrombosis. Journal of Thrombosis and Haemostasis2015;13(S2):219-20. CheungYW , MiddeldorpS , PrinsMH , PapAF , PrandoniP . Post-thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep-vein thrombosis. A post-hoc analysis. Thrombosis and Haemostasis2016;116(4):733-8. EUCTR2004-002171-16-IT. Once-daily oral direct factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis. The EINSTEIN-DVT dose-finding study. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2004%E2%80%90002171%E2%80%9016%E2%80%90IT (first received 15 October 2008). EUCTR2006-004495-13-DK. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep-vein thrombosis or pulmonary embolism. trialsearch.who.int/?TrialID=EUCTR2006-004495-13-DK (first received 29 March 2007). EerenbergES , MiddeldorpS , LeviM , LensingAW , BüllerHR . Clinical impact and course of major bleeding with rivaroxaban and vitamin K antagonists. Journal of Thrombosis and Haemostasis2015;13(9):1590-6. KlineJA , JimenezD , CourtneyDM , IanusJ , CaoL , WellsPS . Use of the Riete 2008 bleeding score to identify patients at low risk for major bleeding in patients treated with rivaroxaban. Academic Emergency Medicine2015;22:S162. NCT00440193. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep vein thrombosis - The EINSTEIN DVT Study. clinicaltrials.gov/ct2/show/NCT00440193 (first received 26 February 2007). PrinsMH , ErkensPG , LensingAW . Incidence of recurrent venous thromboembolism in patients following completion of the EINSTEIN DVT and EINSTEIN PE studies. Journal of Thrombosis and Haemostasis2013;11(Suppl):257. PrinsMH , LensingAW , BauersachsR , Van BellenB , BounameauxH , BrightonTA , et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thrombosis Journal2013;11(1):21. The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. New England Journal of Medicine2010;363(26):2499-510. Van BellenB , PrinsM , BamberL , WangM , LensingAW . Reduction in initial length of stay with rivaroxaban single-drug regimen versus LMWH-VKA standard of care: findings from the EINSTEIN trial program. Blood2012;120(21):3419. Van BellenB , PrinsM , BamberL , WangM , LensingAW . Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism. Current Medical Research and Opinion2014;30(5):829-37. WangY , WangC , ChenZ , ZhangJ , LiuZ , JinB , et al. Rivaroxaban for the treatment of symptomatic deep vein thrombosis and/or pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):694. WangY , WangC , ChenZ , ZhangJ , LiuZ , JinB , et al. Rivaroxaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Thrombosis Journal2013;11(1):25. ">EINSTEIN‐DVT 2010</a>; <a href="./references#CD010956-bbs2-0008" title="BullerHR , PrinsMH , LensinAW , DecoususH , JacobsonBF , MinarE , et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. New England Journal of Medicine2012;366:1287-97. FermannGJ , Erkens Pmg, PrinsMH , WellsPS , Pap ÁF, LensingAW , et al. Treatment of pulmonary embolism with rivaroxaban: outcomes by simplified pulmonary embolism severity index score from a post hoc analysis of the EINSTEIN PE study. Academic Emergency Medicine2015;22(3):299-307. NCT00439777. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic pulmonary embolism with or without symptomatic deep-vein thrombosis: Einstein-PE evaluation, 2008. clinicaltrials.gov/ct2/show/NCT00439777?term=NCT00439777&amp;rank=1 (first received 26 February 2007). PrinsM , BamberL , CanoS , WangM , LensingAW , BauersachsR . Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic pulmonary embolism. Blood2012;120(21):1163. PrinsMH , BamberL , CanoSJ , WangMY , ErkensP , BauersachsR , et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial. Thrombosis Research2015;135(2):281-8. ">EINSTEIN‐PE 2012</a>; <a href="./references#CD010956-bbs2-0009" title="PiazzaG , ManiV , GoldhaberSZ , GrossoMA , MercuriM , LanzHJ , et al. Magnetic resonance venography to assess thrombus resolution with edoxaban monotherapy versus parenteral anticoagulation/warfarin for symptomatic deep vein thrombosis: a multicenter feasibility study. Vascular Medicine2016;21(4):361-8. PiazzaG , ManiV , GrossoM , MercuriM , LanzH , SchusslerS , et al. A randomized, open-label, multicenter study of the efficacy and safety of edoxaban monotherapy versus low-molecular weight heparin/warfarin in patients with symptomatic deep vein thrombosis-edoxaban thrombus reduction imaging study (etris). Circulation2014;130:A12074. ">eTRIS 2016</a>; <a href="./references#CD010956-bbs2-0010" title="FarhanA , BukhariM , UmarJ , RazaMA . Oral rivaroxaban in symptomatic deep vein thrombosis. Journal of the College of Physicians and Surgeons Pakistan2019;29(9):814-8. ">Farhan 2019</a>; <a href="./references#CD010956-bbs2-0011" title="BistervelsI , BavaliaR , BoersmaW , MeijerK , VerhammeP , Ten Cate-HoekAJ , et al. Hokusai Post-DVT Study: a follow-up study on long-term outcomes of deep vein thrombosis in patients treated with edoxaban vs warfarin. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):PB2207. BrekelmansMP , AgenoW , BeenenLF , BrennerB , BullerHR , ChenCZ , et al. Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology2016;3(9):e437-45. BrekelmansMP , BlekerSM , BauersachsR , BodaZ , BüllerHR , ChoiY , et al. Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists. Thrombosis and Haemostasis2016;116(1):155-61. Di NisioM , Van EsN , CarrierM , WangTF , GarciaD , SegersA , et al. Extended treatment with edoxaban in cancer patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE Cancer study. Journal of Thrombosis and Haemostasis2019;17:1866–74. EUCTR2009-014290-40-SE. A phase 3, randomized, double-blind, double-dummy, parallel group, multi-center, multi-national study for evaluation of efficacy and safety of DU-176b versus warfarin in subjects with atrial fibrillation - effective anticoagulation with factor Xa next generation in atrial fibrillation (ENGAGE-AF TIMI-48). trialsearch.who.int/?trialid=EUCTR2009-014290-40-SE (first received 30 November 2009). EichingerS , LinM , KyrlePA , GrossoMA . Recurrent venous thromboembolism during anticoagulation: an investigator-initiated post-hoc analysis of the hokusai-VTE trial. Blood2018;132:2539. KlokFA , BarcoS , KonstantinidesSV . External validation of the VTE-BLEED score for predicting major bleeding in stable anticoagulated patients with venous thromboembolism. Thrombosis and Haemostasis2017;117(6):1164-70. KraaijpoelN , Van EsN , RaskobGE , BüllerHR , CarrierM , ZhangG , et al. Risk scores for occult cancer in patients with venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2018;118(7):1270-8. MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMP , ChenCZ , et al. Outpatient management in patients with venous thromboembolism with edoxaban: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2017;117(12):2406-14. MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMP , ChenCZ , et al. Safety and efficacy of edoxaban compared with warfarin for the treatment of acute symptomatic deep-vein thrombosis in the outpatient setting. Research and Practice in Thrombosis and Haemostasis2017;1:913. MulderFI , Van EsN , KraaijpoelN , Di NisioM , CarrierM , DuggalA , et al. Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: results from the Hokusai VTE Cancer study. Thrombosis Research2020;185:13-9. NCT00986154. Comparative investigation of Low Molecular Weight (LMW) heparin/edoxaban tosylate (DU176b) versus (LMW) heparin/warfarin in the treatment of symptomatic deep-vein blood clots and/or lung blood clots. (The Edoxaban Hokusai-VTE Study). clinicaltrials.gov/ct2/show/NCT00986154 (first received 29 September 2009). NakamuraM , WangYQ , WangC , OhD , YinWH , KimuraT , et al. Efficacy and safety of edoxaban for treatment of venous thromboembolism: a subanalysis of East Asian patients in the Hokusai-VTE trial. Journal of Thrombosis and Haemostasis2015;13(9):1606-14. NybergJ , KarlssonKE , JönssonS , YinO , MillerR , KarlssonMO , et al. Edoxaban exposure-response analysis and clinical utility index assessment in patients with symptomatic deep-vein thrombosis or pulmonary embolism. CPT Pharmacometrics and Systems Pharmacology2016;5(4):222-32. RaskobG , AgenoW , CohenAT , BrekelmansMP , GrossoMA , SegersA , et al. Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology2016;3(5):e228-e236. RaskobG , BullerH , PrinsM , SegersA , ShiM , SchwochoL , et al. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study - methodological implications for clinical trials. Journal of Thrombosis and Haemostasis2013;11(7):1287-94. RaskobGE , BullerH , AngchaisuksiriP , OhD , BodaZ , LyonsRM , et al. Edoxaban for long-term treatment of venous thromboembolism in cancer patients. Blood2013;122(21):211. RaskobGE , Van EsN , SegersA , AngchaisuksiriP , OhD , BodaZ , et al. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematology2016;3(8):e379-87. ScheresLJ , BrekelmansMA , WalterA , CihanA , BüllerHR , SabineE , et al. Abnormal vaginal bleeding in women of reproductive age treated with edoxaban or warfarin for venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. British Journal of Obstetrics and Gynaecology2018;125(12):1581-9. The Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. New England Journal of Medicine2013;369(15):1406-15. VanasscheT , VerhammeP , WellsPS , SegersA , AgenoW , BrekelmansMP , et al. Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: an analysis of the randomized, double-blind Hokusai-VTE trial. Thrombosis Research2018;162:7-14. VerhammeP , WellsPS , SegersA , AgenoW , BrekelmansMP , CohenAT , et al. Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial. Thrombosis and Haemostasis2016;116(4):747-53. ">Hokusai‐VTE 2013</a>;  <a href="./references#CD010956-bbs2-0012" title="AmayaN , UzuiH , HisazakiK , HasegwaK , KasenoK , TadaH . Edoxaban normalizes the elevated D-dimer levels potently and promptly in patients with venous thromboembolisms: a comparison with traditional anticoagulant therapy. European Heart Journal2016;37:278. BoschFT , Van EsN , Di NisioM , CarrierM , SegersA , GrossoMA , et al. The Ottawa score does not predict recurrent venous thromboembolism in cancer patients: results from the Hokusai-VTE cancer study. Research and Practice in Thrombosis and Haemostasis2019;3(S1):717-8. KraaijpoelN , Di NisioM , MulderFI , Van EsN , RaskobGE . Clinical impact of bleeding in cancer-associated venous thromboembolism: results from the Hokusai VTE Cancer randomized trial. Thrombosis Research2018;164(Suppl 1):S223. [DOI: 10.1016/j.thromres.2018.02.094]MulderFI , Di NisioM , AyC , CarrierM , BoschFT , SegersA , et al. Clinical implications of incidental venous thromboembolism in cancer patients. European Respiratory Journal2020;55(2):1901697. [DOI: 10.1183/13993003.01697-2019]MulderFI , Van EsN , KraaijpoelN , Di NisioM , CarrierM , GarciaD , et al. Efficacy and safety of edoxaban in clinically relevant subgroups: results from the Hokusai VTE Cancer randomized trial. Thrombosis Research2018;164:S194. NCT02073682. Cancer venous thromboembolism (VTE). clinicaltrials.gov/ct2/show/NCT02073682 (first received 27 February 2014). RaskobG , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaD , et al. Edoxaban versus dalteparin for treatment of venous thromboembolism (VTE) associated with cancer: Hokusai VTE-cancer randomized trial. Supportive Care in Cancer2018;26(2):S316-S317. RaskobGE , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaD , et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. New England Journal of Medicine2018;378(7):615-24. RaskobGE , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaDA , et al. A randomized, open-label, blinded outcome assessment trial evaluating the efficacy and safety of LMWH/Edoxaban versus dalteparin for venous thromboembolism associated with cancer: Hokusai VTE-cancer study. Blood2017;130(Suppl 1):LBA-6. ">Hokusai VTE Cancer 2018</a>; <a href="./references#CD010956-bbs2-0013" title="MatsuoH , PrinsM , LensingAW , FujinumaEW , MiyamotoY , KajikawaM . Shortened length of hospital stay with rivaroxaban in patients with symptomatic venous thromboembolism in Japan: the J-EINSTEIN pulmonary embolism and deep vein thrombosis program. Current Medical Research and Opinion2015;31(6):1057-61. NCT01516814. Venous thromboembolism (VTE) treatment study in Japanese pulmonary embolism (PE) patients. clinicaltrials.gov/ct2/show/NCT01516814 (first received 25 January 2012). YamadaN , HirayamaA , MaedaH , SakagamiS , ShikataH , PrinsMH , et al. Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism-the J-EINSTEIN DVT and PE program. Thrombosis Journal2015;13:2. ">J‐EINSTEIN DVT and PE 2015</a>; <a href="./references#CD010956-bbs2-0014" title="MokademME , HassanA , AlgabyAZ . Efficacy and safety of apixaban in patients with active malignancy and acute deep venous thrombosis. Vascular2021;29(5):745-50. NCT04462003. Efficacy of apixaban in malignancy with deep venous thrombosis (DVT). clinicaltrials.gov/ct2/show/NCT04462003 (first received 3 July 2019). ">Mokadem 2021</a>; <a href="./references#CD010956-bbs2-0015" title="AgnelliG , GallusA , GoldhaberSZ , HaasS , HuismanMV , HullRD , et al. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAT 59-7939 in patients with acute symptomatic deep-vein thrombosis) study. Circulation2007;116:180-7. ">ODIXa‐DVT 2007</a>; <a href="./references#CD010956-bbs2-0016" title="OhmoriH , KadaA , NakamuraM , SaitoAM , SanayamaY , ShinagawaT , et al. Deep vein thrombosis in severe motor and intellectual disabilities patients and its treatment by anticoagulants of warfarin versus edoxaban. Annals of Vascular Diseases2019;12(3):372-8. OhmoriH , NakamuraM , KadaA , SaitoAM , SanayamaY , ShinagawaT , et al. Multicenter, open-label, randomized controlled trial of warfarin and edoxaban tosilate hydrate for the treatment of deep vein thrombosis in persons with severe motor intellectual disabilities. Kurume Medical Journal2018;65(1):11-6. ">Ohmori 2019</a>; <a href="./references#CD010956-bbs2-0017" title="Kang JiM, ParkKH , AhnS , ChoS , MinSK . Rivaroxaban after thrombolysis in acute iliofemoral venous thrombosis: a randomized, open-labeled, multicenter trial. Scientific Reports2019;9(1):20356. MinSK , AhnS , ParkKH , KangJM , KimJY . Prevention of recurrence after thrombolysis in acute iliofemoral venous thrombosis with rivaroxaban (Prais Study): a prospective, randomized, open label, multicenter trial. European Journal of Vascular and Endovascular Surgery2019;58(6):e516. NCT01986192. Prevention of recurrence after thrombolysis in acute iliofemoral venous thrombosis (PRAIS) study. clinicaltrials.gov/show/NCT01986192 (first received 18 November 2013). ">PRAIS 2019</a>; <a href="./references#CD010956-bbs2-0018" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00291330. Efficacy and safety of dabigatran compared to warfarin for 6 month treatment of acute symptomatic venous thromboembolism (RE-COVER I). clinicaltrials.gov/ct/show/NCT00291330 (first received 14 February 2006). SchulmanS , ErikssonH , GoldhaberS , KakkarAK , KearonC , KvammeAM , et al. Dabigatran or warfarin for extended maintenance therapy of venous thromboembolism. Journal of Thrombosis and Haemostasis2011;9(Suppl 2):731-2. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-COVER and RE-COVER II. Blood2013;122:2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RECOVER II. Blood2013;122(21):212. SchulmanS , ErikssonH , GoldhaverSZ , KakkarA , KearonC , MismettiP , et al. Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130:A18594. SchulmanS , KearonC , KakkarAK , MismettiP , SchellongS , ErikssonH , et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. New England Journal of Medicine2009;361(24):2342-52. ">RE‐COVER 2009</a>; <a href="./references#CD010956-bbs2-0019" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00680186. Phase III study testing efficacy &amp; safety of oral dabigatran etexilate vs warfarin for 6 m treatment for acute symp venous thromboembolism (VTE) (RE-COVER II). clinicaltrials.gov/ct2/show/NCT00680186 (first received 20 May 2008). SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-COVER and RE-COVER II. Blood2013;122:2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RECOVER II. Blood2013;122(21):212. SchulmanS , ErikssonH , GoldhaverSZ , KakkarA , KearonC , MismettiP , et al. Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130:A18594. SchulmanS , KakkarAK , GoldhaberSZ , SchellongS , ErikssonH , MismettiP , et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation2014;129:764-72. SchulmanS . A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II). Blood2011;118(21):95-6. ">RE‐COVER II 2014</a>; <a href="./references#CD010956-bbs2-0020" title="SukovatykhBS , SereditskiĭAV , MuradianVF , BelikovLN , GerasimovaOF . Results of administering oral anticoagulants for treatment of patients with venous thromboembolic complications. Angiologiia i sosudistaia khirurgiia [Angiology and Vascular Surgery]2017;23(2):82. ">Sukovatykh 2017</a>; <a href="./references#CD010956-bbs2-0021" title="FiessingerJN , HuismanMV , DavidsonBL , BounameauxH , FrancisCW , ErikssonH , et al. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomised trial. JAMA2005;293(6):681-9. FrancisCW , GinsbergJS , BerkowitzSD , BounameauxH , DavidsonBL , ErikssonH , et al. Efficacy and safety of the oral direct thrombin inhibitor ximelagatran compared with current therapy for acute, symptomatic deep vein thrombosis, with or without pulmonary embolus: the THRIVE treatment study. Blood2003;102(11):Abstract 7. HarenbergJ , IngridJ , TivadarF . Treatment of venous thromboembolism with the oral thrombin inhibitor, ximelagatran. Israel Medical Association Journal2002;4(11):1003-5. HarenbergJ , JoergI , WeissC . Incidence of recurrent venous thromboembolism of patients after termination of treatment with ximelagatran. European Journal of Clinical Pharmacology2006;62(3):173-7. HarenbergJ , JorgI , WeissC , HarenbergJ , JorgI , WeissC . Observations of alanine aminotransferase and aspartate aminotransferase in THRIVE studies treated orally with ximelagatran. International Journal of Toxicology2006;25(3):165-9. HuismanMV , The THRIVE Treatment Study Investigators. Efficacy and safety of the oral direct thrombin inhibitor ximelagatran compared with current standard therapy for acute symptomatic deep vein thrombosis, with or without pulmonary embolism: a randomized, double-blind, multinational study. Journal of Thrombosis and Haemostasis2003;1(Suppl 1):Abstract OC003. WimperisJ , FiessingerJN , HuismanMV , DavidsonBL , BounameauxH , FrancisCW , et al. Ximelagatran, an oral direct thrombin inhibitor, compared with current standard therapy for acute, symptomatic deep vein thrombosis, with or without pulmonary embolism: the THRIVE treatment study. British Journal of Haematology2004;125(Suppl 1):66. ">THRIVE 2005</a>). All studies were two‐arm trials with the exception of one, the <a href="./references#CD010956-bbs2-0020" title="SukovatykhBS , SereditskiĭAV , MuradianVF , BelikovLN , GerasimovaOF . Results of administering oral anticoagulants for treatment of patients with venous thromboembolic complications. Angiologiia i sosudistaia khirurgiia [Angiology and Vascular Surgery]2017;23(2):82. ">Sukovatykh 2017</a> study, which was a three‐arm trial, comparing both a DTI (dabigatran) and factor Xa inhibitor (rivaroxaban) to conventional anticoagulation. </p> <p>Four studies (7691 participants) compared oral DTIs with conventional anticoagulation (<a href="./references#CD010956-bbs2-0018" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00291330. Efficacy and safety of dabigatran compared to warfarin for 6 month treatment of acute symptomatic venous thromboembolism (RE-COVER I). clinicaltrials.gov/ct/show/NCT00291330 (first received 14 February 2006). SchulmanS , ErikssonH , GoldhaberS , KakkarAK , KearonC , KvammeAM , et al. Dabigatran or warfarin for extended maintenance therapy of venous thromboembolism. Journal of Thrombosis and Haemostasis2011;9(Suppl 2):731-2. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-COVER and RE-COVER II. Blood2013;122:2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RECOVER II. Blood2013;122(21):212. SchulmanS , ErikssonH , GoldhaverSZ , KakkarA , KearonC , MismettiP , et al. Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130:A18594. SchulmanS , KearonC , KakkarAK , MismettiP , SchellongS , ErikssonH , et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. New England Journal of Medicine2009;361(24):2342-52. ">RE‐COVER 2009</a>; <a href="./references#CD010956-bbs2-0019" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00680186. Phase III study testing efficacy &amp; safety of oral dabigatran etexilate vs warfarin for 6 m treatment for acute symp venous thromboembolism (VTE) (RE-COVER II). clinicaltrials.gov/ct2/show/NCT00680186 (first received 20 May 2008). SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-COVER and RE-COVER II. Blood2013;122:2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RECOVER II. Blood2013;122(21):212. SchulmanS , ErikssonH , GoldhaverSZ , KakkarA , KearonC , MismettiP , et al. Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130:A18594. SchulmanS , KakkarAK , GoldhaberSZ , SchellongS , ErikssonH , MismettiP , et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation2014;129:764-72. SchulmanS . A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II). Blood2011;118(21):95-6. ">RE‐COVER II 2014</a>; <a href="./references#CD010956-bbs2-0020" title="SukovatykhBS , SereditskiĭAV , MuradianVF , BelikovLN , GerasimovaOF . Results of administering oral anticoagulants for treatment of patients with venous thromboembolic complications. Angiologiia i sosudistaia khirurgiia [Angiology and Vascular Surgery]2017;23(2):82. ">Sukovatykh 2017</a>; <a href="./references#CD010956-bbs2-0021" title="FiessingerJN , HuismanMV , DavidsonBL , BounameauxH , FrancisCW , ErikssonH , et al. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomised trial. JAMA2005;293(6):681-9. FrancisCW , GinsbergJS , BerkowitzSD , BounameauxH , DavidsonBL , ErikssonH , et al. Efficacy and safety of the oral direct thrombin inhibitor ximelagatran compared with current therapy for acute, symptomatic deep vein thrombosis, with or without pulmonary embolus: the THRIVE treatment study. Blood2003;102(11):Abstract 7. HarenbergJ , IngridJ , TivadarF . Treatment of venous thromboembolism with the oral thrombin inhibitor, ximelagatran. Israel Medical Association Journal2002;4(11):1003-5. HarenbergJ , JoergI , WeissC . Incidence of recurrent venous thromboembolism of patients after termination of treatment with ximelagatran. European Journal of Clinical Pharmacology2006;62(3):173-7. HarenbergJ , JorgI , WeissC , HarenbergJ , JorgI , WeissC . Observations of alanine aminotransferase and aspartate aminotransferase in THRIVE studies treated orally with ximelagatran. International Journal of Toxicology2006;25(3):165-9. HuismanMV , The THRIVE Treatment Study Investigators. Efficacy and safety of the oral direct thrombin inhibitor ximelagatran compared with current standard therapy for acute symptomatic deep vein thrombosis, with or without pulmonary embolism: a randomized, double-blind, multinational study. Journal of Thrombosis and Haemostasis2003;1(Suppl 1):Abstract OC003. WimperisJ , FiessingerJN , HuismanMV , DavidsonBL , BounameauxH , FrancisCW , et al. Ximelagatran, an oral direct thrombin inhibitor, compared with current standard therapy for acute, symptomatic deep vein thrombosis, with or without pulmonary embolism: the THRIVE treatment study. British Journal of Haematology2004;125(Suppl 1):66. ">THRIVE 2005</a>). One study tested ximelagatran (<a href="./references#CD010956-bbs2-0021" title="FiessingerJN , HuismanMV , DavidsonBL , BounameauxH , FrancisCW , ErikssonH , et al. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomised trial. JAMA2005;293(6):681-9. FrancisCW , GinsbergJS , BerkowitzSD , BounameauxH , DavidsonBL , ErikssonH , et al. Efficacy and safety of the oral direct thrombin inhibitor ximelagatran compared with current therapy for acute, symptomatic deep vein thrombosis, with or without pulmonary embolus: the THRIVE treatment study. Blood2003;102(11):Abstract 7. HarenbergJ , IngridJ , TivadarF . Treatment of venous thromboembolism with the oral thrombin inhibitor, ximelagatran. Israel Medical Association Journal2002;4(11):1003-5. HarenbergJ , JoergI , WeissC . Incidence of recurrent venous thromboembolism of patients after termination of treatment with ximelagatran. European Journal of Clinical Pharmacology2006;62(3):173-7. HarenbergJ , JorgI , WeissC , HarenbergJ , JorgI , WeissC . Observations of alanine aminotransferase and aspartate aminotransferase in THRIVE studies treated orally with ximelagatran. International Journal of Toxicology2006;25(3):165-9. HuismanMV , The THRIVE Treatment Study Investigators. Efficacy and safety of the oral direct thrombin inhibitor ximelagatran compared with current standard therapy for acute symptomatic deep vein thrombosis, with or without pulmonary embolism: a randomized, double-blind, multinational study. Journal of Thrombosis and Haemostasis2003;1(Suppl 1):Abstract OC003. WimperisJ , FiessingerJN , HuismanMV , DavidsonBL , BounameauxH , FrancisCW , et al. Ximelagatran, an oral direct thrombin inhibitor, compared with current standard therapy for acute, symptomatic deep vein thrombosis, with or without pulmonary embolism: the THRIVE treatment study. British Journal of Haematology2004;125(Suppl 1):66. ">THRIVE 2005</a>). The <a href="./references#CD010956-bbs2-0021" title="FiessingerJN , HuismanMV , DavidsonBL , BounameauxH , FrancisCW , ErikssonH , et al. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomised trial. JAMA2005;293(6):681-9. FrancisCW , GinsbergJS , BerkowitzSD , BounameauxH , DavidsonBL , ErikssonH , et al. Efficacy and safety of the oral direct thrombin inhibitor ximelagatran compared with current therapy for acute, symptomatic deep vein thrombosis, with or without pulmonary embolus: the THRIVE treatment study. Blood2003;102(11):Abstract 7. HarenbergJ , IngridJ , TivadarF . Treatment of venous thromboembolism with the oral thrombin inhibitor, ximelagatran. Israel Medical Association Journal2002;4(11):1003-5. HarenbergJ , JoergI , WeissC . Incidence of recurrent venous thromboembolism of patients after termination of treatment with ximelagatran. European Journal of Clinical Pharmacology2006;62(3):173-7. HarenbergJ , JorgI , WeissC , HarenbergJ , JorgI , WeissC . Observations of alanine aminotransferase and aspartate aminotransferase in THRIVE studies treated orally with ximelagatran. International Journal of Toxicology2006;25(3):165-9. HuismanMV , The THRIVE Treatment Study Investigators. Efficacy and safety of the oral direct thrombin inhibitor ximelagatran compared with current standard therapy for acute symptomatic deep vein thrombosis, with or without pulmonary embolism: a randomized, double-blind, multinational study. Journal of Thrombosis and Haemostasis2003;1(Suppl 1):Abstract OC003. WimperisJ , FiessingerJN , HuismanMV , DavidsonBL , BounameauxH , FrancisCW , et al. Ximelagatran, an oral direct thrombin inhibitor, compared with current standard therapy for acute, symptomatic deep vein thrombosis, with or without pulmonary embolism: the THRIVE treatment study. British Journal of Haematology2004;125(Suppl 1):66. ">THRIVE 2005</a> study was a phase III, double‐blind, double‐dummy, dose‐guiding study in which 2489 people with a VTE were given ximelagatran 24 mg, 36 mg, 48 mg or 60 mg twice daily for six months. The control treatment was LMWH (enoxaparin or dalteparin) followed by warfarin. Three studies tested dabigatran (<a href="./references#CD010956-bbs2-0018" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00291330. Efficacy and safety of dabigatran compared to warfarin for 6 month treatment of acute symptomatic venous thromboembolism (RE-COVER I). clinicaltrials.gov/ct/show/NCT00291330 (first received 14 February 2006). SchulmanS , ErikssonH , GoldhaberS , KakkarAK , KearonC , KvammeAM , et al. Dabigatran or warfarin for extended maintenance therapy of venous thromboembolism. Journal of Thrombosis and Haemostasis2011;9(Suppl 2):731-2. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-COVER and RE-COVER II. Blood2013;122:2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RECOVER II. Blood2013;122(21):212. SchulmanS , ErikssonH , GoldhaverSZ , KakkarA , KearonC , MismettiP , et al. Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130:A18594. SchulmanS , KearonC , KakkarAK , MismettiP , SchellongS , ErikssonH , et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. New England Journal of Medicine2009;361(24):2342-52. ">RE‐COVER 2009</a>; <a href="./references#CD010956-bbs2-0019" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00680186. Phase III study testing efficacy &amp; safety of oral dabigatran etexilate vs warfarin for 6 m treatment for acute symp venous thromboembolism (VTE) (RE-COVER II). clinicaltrials.gov/ct2/show/NCT00680186 (first received 20 May 2008). SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-COVER and RE-COVER II. Blood2013;122:2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RECOVER II. Blood2013;122(21):212. SchulmanS , ErikssonH , GoldhaverSZ , KakkarA , KearonC , MismettiP , et al. Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130:A18594. SchulmanS , KakkarAK , GoldhaberSZ , SchellongS , ErikssonH , MismettiP , et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation2014;129:764-72. SchulmanS . A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II). Blood2011;118(21):95-6. ">RE‐COVER II 2014</a>; <a href="./references#CD010956-bbs2-0020" title="SukovatykhBS , SereditskiĭAV , MuradianVF , BelikovLN , GerasimovaOF . Results of administering oral anticoagulants for treatment of patients with venous thromboembolic complications. Angiologiia i sosudistaia khirurgiia [Angiology and Vascular Surgery]2017;23(2):82. ">Sukovatykh 2017</a>). <a href="./references#CD010956-bbs2-0018" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00291330. Efficacy and safety of dabigatran compared to warfarin for 6 month treatment of acute symptomatic venous thromboembolism (RE-COVER I). clinicaltrials.gov/ct/show/NCT00291330 (first received 14 February 2006). SchulmanS , ErikssonH , GoldhaberS , KakkarAK , KearonC , KvammeAM , et al. Dabigatran or warfarin for extended maintenance therapy of venous thromboembolism. Journal of Thrombosis and Haemostasis2011;9(Suppl 2):731-2. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-COVER and RE-COVER II. Blood2013;122:2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RECOVER II. Blood2013;122(21):212. SchulmanS , ErikssonH , GoldhaverSZ , KakkarA , KearonC , MismettiP , et al. Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130:A18594. SchulmanS , KearonC , KakkarAK , MismettiP , SchellongS , ErikssonH , et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. New England Journal of Medicine2009;361(24):2342-52. ">RE‐COVER 2009</a> was a phase III, non‐inferiority, double‐blind, double‐dummy trial in which 2539 people with a VTE were given dabigatran 150 mg twice daily or warfarin. Treatment was for six months and included sham monitoring of international normalised ratio (INR) and sham titration of warfarin in the control group. To gain regulatory approval, the study was repeated with an identical design (<a href="./references#CD010956-bbs2-0019" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00680186. Phase III study testing efficacy &amp; safety of oral dabigatran etexilate vs warfarin for 6 m treatment for acute symp venous thromboembolism (VTE) (RE-COVER II). clinicaltrials.gov/ct2/show/NCT00680186 (first received 20 May 2008). SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-COVER and RE-COVER II. Blood2013;122:2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RECOVER II. Blood2013;122(21):212. SchulmanS , ErikssonH , GoldhaverSZ , KakkarA , KearonC , MismettiP , et al. Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130:A18594. SchulmanS , KakkarAK , GoldhaberSZ , SchellongS , ErikssonH , MismettiP , et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation2014;129:764-72. SchulmanS . A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II). Blood2011;118(21):95-6. ">RE‐COVER II 2014</a>). <a href="./references#CD010956-bbs2-0020" title="SukovatykhBS , SereditskiĭAV , MuradianVF , BelikovLN , GerasimovaOF . Results of administering oral anticoagulants for treatment of patients with venous thromboembolic complications. Angiologiia i sosudistaia khirurgiia [Angiology and Vascular Surgery]2017;23(2):82. ">Sukovatykh 2017</a> was a clinical trial in which 95 participants were randomly divided into the dabigatran (150 mg twice daily for six months), rivaroxaban (15 mg twice daily for three weeks, then 20 mg once daily until end of the six‐month course) or warfarin group. All studies measured recurrent VTE; three studies measured recurrent DVT, PE (fatal and non‐fatal), all‐cause mortality and major clinically relevant bleeding (<a href="./references#CD010956-bbs2-0018" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00291330. Efficacy and safety of dabigatran compared to warfarin for 6 month treatment of acute symptomatic venous thromboembolism (RE-COVER I). clinicaltrials.gov/ct/show/NCT00291330 (first received 14 February 2006). SchulmanS , ErikssonH , GoldhaberS , KakkarAK , KearonC , KvammeAM , et al. Dabigatran or warfarin for extended maintenance therapy of venous thromboembolism. Journal of Thrombosis and Haemostasis2011;9(Suppl 2):731-2. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-COVER and RE-COVER II. Blood2013;122:2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RECOVER II. Blood2013;122(21):212. SchulmanS , ErikssonH , GoldhaverSZ , KakkarA , KearonC , MismettiP , et al. Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130:A18594. SchulmanS , KearonC , KakkarAK , MismettiP , SchellongS , ErikssonH , et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. New England Journal of Medicine2009;361(24):2342-52. ">RE‐COVER 2009</a>; <a href="./references#CD010956-bbs2-0019" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00680186. Phase III study testing efficacy &amp; safety of oral dabigatran etexilate vs warfarin for 6 m treatment for acute symp venous thromboembolism (VTE) (RE-COVER II). clinicaltrials.gov/ct2/show/NCT00680186 (first received 20 May 2008). SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-COVER and RE-COVER II. Blood2013;122:2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RECOVER II. Blood2013;122(21):212. SchulmanS , ErikssonH , GoldhaverSZ , KakkarA , KearonC , MismettiP , et al. Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130:A18594. SchulmanS , KakkarAK , GoldhaberSZ , SchellongS , ErikssonH , MismettiP , et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation2014;129:764-72. SchulmanS . A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II). Blood2011;118(21):95-6. ">RE‐COVER II 2014</a>; <a href="./references#CD010956-bbs2-0021" title="FiessingerJN , HuismanMV , DavidsonBL , BounameauxH , FrancisCW , ErikssonH , et al. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomised trial. JAMA2005;293(6):681-9. FrancisCW , GinsbergJS , BerkowitzSD , BounameauxH , DavidsonBL , ErikssonH , et al. Efficacy and safety of the oral direct thrombin inhibitor ximelagatran compared with current therapy for acute, symptomatic deep vein thrombosis, with or without pulmonary embolus: the THRIVE treatment study. Blood2003;102(11):Abstract 7. HarenbergJ , IngridJ , TivadarF . Treatment of venous thromboembolism with the oral thrombin inhibitor, ximelagatran. Israel Medical Association Journal2002;4(11):1003-5. HarenbergJ , JoergI , WeissC . Incidence of recurrent venous thromboembolism of patients after termination of treatment with ximelagatran. European Journal of Clinical Pharmacology2006;62(3):173-7. HarenbergJ , JorgI , WeissC , HarenbergJ , JorgI , WeissC . Observations of alanine aminotransferase and aspartate aminotransferase in THRIVE studies treated orally with ximelagatran. International Journal of Toxicology2006;25(3):165-9. HuismanMV , The THRIVE Treatment Study Investigators. Efficacy and safety of the oral direct thrombin inhibitor ximelagatran compared with current standard therapy for acute symptomatic deep vein thrombosis, with or without pulmonary embolism: a randomized, double-blind, multinational study. Journal of Thrombosis and Haemostasis2003;1(Suppl 1):Abstract OC003. WimperisJ , FiessingerJN , HuismanMV , DavidsonBL , BounameauxH , FrancisCW , et al. Ximelagatran, an oral direct thrombin inhibitor, compared with current standard therapy for acute, symptomatic deep vein thrombosis, with or without pulmonary embolism: the THRIVE treatment study. British Journal of Haematology2004;125(Suppl 1):66. ">THRIVE 2005</a>); one reported quality of life measured by the 36‐item Short Form Health Survey (SF‐36) (<a href="./references#CD010956-bbs2-0020" title="SukovatykhBS , SereditskiĭAV , MuradianVF , BelikovLN , GerasimovaOF . Results of administering oral anticoagulants for treatment of patients with venous thromboembolic complications. Angiologiia i sosudistaia khirurgiia [Angiology and Vascular Surgery]2017;23(2):82. ">Sukovatykh 2017</a>). </p> <p>Eighteen studies (30,895 participants) tested oral factor Xa inhibitors (<a href="./references#CD010956-bbs2-0001" title="AgnelliG , BullerH , MasiukiewiczUP . Apixaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism: a randomized, double-blind trial (AMPLIFY). Journal of Thrombosis and Haemostasis2013;11:18. AgnelliG , BullerHR , CohenA , CurtoD , GallusAS , JohnsonM , et al. Oral apixaban for the treatment of acute venous thromboembolism. New England Journal of Medicine2013;369:799-808. AgnelliG , BullerHR , CohenA , CurtoM , GallusAS , PakR , et al. Apixaban for the treatment of venous thromboembolism in cancer patients: data from the AMPLIFY trial. Canadian Journal of Cardiology2014;30(10 Suppl 1):S278. AgnelliG , BullerHR , CohenA , GallusAS , LeeTC , PakR , et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. Journal of Thrombosis and Haemostasis2015;13(12):2187-91. AgnelliG . Apixaban was non-inferior to enoxaparin plus warfarin in patients with acute venous thromboembolism. Annals of Internal Medicine2013;159(8):JC2. BlekerSM , CohenAT , BüllerHR , AgnelliG , GallusAS , RaskobGE , et al. Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Thrombosis and Haemostasis2016;116(6):159-64. BrekelmansM , ScheresL , BlekerS , HuttenB , TimmermansA , BüllerH , et al. Abnormal vaginal bleeding in women with venous thromboembolism treated with apixaban or warfarin. Thrombosis and Haemostasis2017;117(04):809-15. CohenA , AgnelliG , BullerH , GallusA , RaskobG , SandersP , et al. Characteristics and outcomes in patients with venous thromboembolism taking concomitant anti-platelet agents and anticoagulants in the AMPLIFY Trial. Thrombosis and Haemostasis2019;119(3):461-6. CohenA , AgnelliG , BullerHR , ChaudhuriS , GallusAS , RaskobGE , et al. Analysis of the bleeding and thromboembolic risk with concomitant use of antiplatelet treatment in the AMPLIFY trial. Canadian Journal of Cardiology2014;30(10):S272. CohenA , GallusAS , AgnelliG , BullerHR , PakR , PorcariAR , et al. Time in Therapeutic Range (TTR) and relative efficacy and safety of treatment with apixaban or enoxaparin/warfarin for acute symptomatic venous thromboembolism: an analysis of the Amplify trial data. Blood2014;124(21):1543. CohenAT , PanS , ByonW , IlyasBS , LeeTC . Efficacy, safety, and exposure of apixaban in patients with high body weight or obesity and venous thromboembolism: insights from AMPLIFY. Advances in Therapy2021;38(6):3003-18. EUCTR2007-007867-25-PT. A safety and efficacy trial evaluating the use of apixaban in the treatment of symptomatic deep vein thrombosis and pulmonary embolism revised protocol number: 01, incorporates amendment(s) 02 + protocol amendment 01 (version 1.0 dated 21-Apr-08) site-specific - molecular profiling supplement samples for Pfizer’s exploratory research biobank. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2007%E2%80%90007867%E2%80%9025%E2%80%90PT (first received 14 July 2008). GallusAS , AgnelliG , BullerHR , CohenA , LeeTC , PakR , et al. Apixaban for treatment of venous thromboembolism in patients from study centres in Asia: a subgroup analysis of the Amplify trial. Journal of Thrombosis and Haemostasis2015;13:727. LeeT , PanS , ByonW , IlyasBS . Safety and efficacy of apixaban versus enoxaparin/warfarin in patients with extremes of body weight: post-hoc analysis of the AMPLIFY trial. Blood2019;134(Suppl 1):1152. LiuX , JohnsonM , MardekianJ , PhatakH , ThompsonJ , CohenAT . Apixaban reduces hospitalizations in patients with venous thromboembolism: an analysis of the apixaban for the Initial management of pulmonary embolism and deep‐vein thrombosis as first‐line therapy (AMPLIFY) trial. Journal of the American Heart Association2015;4(12):e002340. NCT00633893. Efficacy and safety study of apixaban for extended treatment of deep vein thrombosis or pulmonary embolism. clinicaltrials.gov/ct2/show/NCT00633893?term=ajax&amp;rank=5 (first received 12 March 2008). NCT00643201. Efficacy and safety study of apixaban for the treatment of deep vein thrombosis or pulmonary embolism. clinicaltrials.gov/ct2/show/NCT00643201 (first received 26 March 2008). RaskobGE , GallusAS , SandersP , ThompsonJR , AgnelliG , BullerHR , et al. Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy: a sub-analysis of the AMPLIFY trial. Thrombosis and Haemostasis2016;115(4):809-16. ">AMPLIFY 2013</a>; <a href="./references#CD010956-bbs2-0002" title="NakamuraM , NishikawaM , KomuroI , KitajimaI , UetsukaY , YamagamiT , et al. Apixaban for the treatment of Japanese subjects with acute venous thromboembolism (AMPLIFY-J Study). Circulation2015;79(6):1230–36. ">AMPLIFY‐J 2015</a>; <a href="./references#CD010956-bbs2-0003" title="BarrettYC , WangJ , KnabbR , MohanP . Apixaban decreases coagulation activity in patients with acute deep-vein thrombosis. Thrombosis and Haemostasis2011;105:181-9. Botticelli Investigators Writing Committee, BullerH , DeitchmanD , PrinsM , SegersA . Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. Journal of Thrombosis and Haemostasis2008;6:1313-8. BullerHR . A dose finding study of the oral direct factor Xa inhibitor apixaban in the treatment of patients with acute symptomatic deep vein thrombosis - the Botticelli Investigators. Journal of Thrombosis and Haemostasis2007;5 (Suppl 2):O-S-003. NCT00252005. Oral direct factor Xa-inhibitor apixaban in patients with acute symptomatic deep-vein thrombosis - the Botticelli DVT study. clinicaltrials.gov/ct/show/NCT00252005?order=1 (first received 11 November 2005). ">Botticelli DVT 2008</a>; <a href="./references#CD010956-bbs2-0004" title="AgenoW , VedovatiMC , CohenA , HuismanM , BauersachsR , GussoniG , et al. Bleeding with apixaban and dalteparin in patients with cancer-associated venous thromboembolism: results from the Caravaggio study. Thrombosis and Haemostasis2021;121(5):616-24. AgnelliG , BecattiniC , BauersachsR , BrennerB , CampaniniM , CohenA , et al. Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the Caravaggio study. Thrombosis and Haemostasis2018;118(9):1668-78. AgnelliG , BecattiniC , MeyerG , MuozA , VersoM . Apixaban for the treatment of venous thromboembolism associated with cancer. New England Journal of Medicine2020;382(17):1599-607. AgnelliG , MuozA , FrancoL , MahéI , BrennerB , ConnorsJM , et al. Apixaban and dalteparin for the treatment of venous thromboembolism in patients with different sites of cancer. Thrombosis and Haemostasis2022;122(5):796-807. BecattiniC , BauersachsR , MarazitiG , BertolettiL , CohenA , ConnorsJM , et al. Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial. Haematologica2021;107(7):1567-76. GiustozziM , ConnorsJM , Ruperez BlancoAB , SzmitS , FalvoN , CohenAT , et al. Clinical characteristics and outcomes of incidental venous thromboembolism in cancer patients: insights from the Caravaggio study. Journal of Thrombosis and Haemostasis2021;19(11):2751-9. NCT03045406. Apixaban for the treatment of venous thromboembolism in patients with cancer (CARAVAGGIO). clinicaltrials.gov/ct2/show/NCT03045406 (first received 7 February 2017). VersoM , MunozA , BauersachsR , HuismanMV , AgnelliG . Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism. European Journal of Cancer2021;148(Suppl C):371-81. ">Caravaggio 2020</a>; <a href="./references#CD010956-bbs2-0005" title="NCT02704598. Comparison between xarelto versus warfarin in the recanalization rate of deep venous thrombosis in patients legs. (DVT). clinicaltrials.gov/ct2/show/NCT02704598 (first received 10 March 2016). deAthayde SoaresR , MatieloMF , Brochado NetoFC , AlmeidaRD , SacilottoR . LEV 2. Comparison of the recanalization rate and post-thrombotic syndrome in patients with deep venous thrombosis treated with rivaroxaban or warfarin. Journal of Vascular Surgery2019;70(5):e169-e170. deAthayde SoaresR , MatieloMF , Brochado NetoFC , NogueiraMP , AlmeidaRD , SacilottoR . Comparison of the recanalization rate and postthrombotic syndrome in patients with deep venous thrombosis treated with rivaroxaban or warfarin. Surgery2019;166(6):1076-83. ">de Athayde 2019</a>; <a href="./references#CD010956-bbs2-0007" title="BullerH , DariusH . EINSTEIN DVT: oral rivaroxaban versus standard therapy in the initial treatment of symptomatic deep vein thrombosis and long-term prevention of recurrent venous thromboembolism. escardio.org/The-ESC/Press-Office/Press-releases/EINSTEIN-DVT-Oral-rivaroxaban-versus-standard-therapy-in-the-initial-treatment (accessed 19 October 2022). BullerHR , AgnelliG . Once- or twice-daily rivaroxaban for the treatment of proximal deep vein thrombosis: similar efficacy and safety to standard therapy in dose-ranging studies. Blood2006;108(11 Part 1):172-3. BullerHR , LensingAW , PrinsMH , AgnelliG , CohenA , GallusAS , et al. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT dose-ranging study. Blood2008;112(6):2242-7. NCT00395772. Once-daily oral direct factor Xa inhibitor BAY59-7939 in patients with acute symptomatic deep-vein thrombosis. clinicaltrials.gov/ct2/show/NCT00395772?term=einstein-dvt&amp;rank=2 (first received 3 November 2006). ">EINSTEIN‐DVT dose 2008</a>; <a href="./references#CD010956-bbs2-0006" title="BamberL , WangMY , PrinsMH , CiniglioC , BauersachsR , LensingAW , et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis. Thrombosis and Haemostasis2013;110(4):732-41. BauersachsR , LensingAW , PapA , DecoususH . No need for a rivaroxaban dose reduction in renally impaired patients with symptomatic venous thromboembolism. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):30-1. BistervelsI , GebelM , LensingA , MiddeldorpS , CoppensM . Effect of polypharmacy on bleeding of rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolism. Research and Practice in Thrombosis and Haemostasis2019;3:798‐9. BookhartBK , HaskellL , BamberL , WangM , ScheinJ , ModySH . Length of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial program. Journal of Medical Economics2014;17(10):691-5. BullerHR . Oral rivaroxaban for the acute and continued treatment of symptomatic venous thromboembolism. The Einstein-DVT and Einstein-Extension study. Blood2010;116(21):187. CheungW , MiddeldorpS , PrinsMP , PapAF , LensingAW , Hoek-tenCA , et al. Post thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep vein thrombosis. Journal of Thrombosis and Haemostasis2015;13(S2):219-20. CheungYW , MiddeldorpS , PrinsMH , PapAF , PrandoniP . Post-thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep-vein thrombosis. A post-hoc analysis. Thrombosis and Haemostasis2016;116(4):733-8. EUCTR2004-002171-16-IT. Once-daily oral direct factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis. The EINSTEIN-DVT dose-finding study. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2004%E2%80%90002171%E2%80%9016%E2%80%90IT (first received 15 October 2008). EUCTR2006-004495-13-DK. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep-vein thrombosis or pulmonary embolism. trialsearch.who.int/?TrialID=EUCTR2006-004495-13-DK (first received 29 March 2007). EerenbergES , MiddeldorpS , LeviM , LensingAW , BüllerHR . Clinical impact and course of major bleeding with rivaroxaban and vitamin K antagonists. Journal of Thrombosis and Haemostasis2015;13(9):1590-6. KlineJA , JimenezD , CourtneyDM , IanusJ , CaoL , WellsPS . Use of the Riete 2008 bleeding score to identify patients at low risk for major bleeding in patients treated with rivaroxaban. Academic Emergency Medicine2015;22:S162. NCT00440193. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep vein thrombosis - The EINSTEIN DVT Study. clinicaltrials.gov/ct2/show/NCT00440193 (first received 26 February 2007). PrinsMH , ErkensPG , LensingAW . Incidence of recurrent venous thromboembolism in patients following completion of the EINSTEIN DVT and EINSTEIN PE studies. Journal of Thrombosis and Haemostasis2013;11(Suppl):257. PrinsMH , LensingAW , BauersachsR , Van BellenB , BounameauxH , BrightonTA , et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thrombosis Journal2013;11(1):21. The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. New England Journal of Medicine2010;363(26):2499-510. Van BellenB , PrinsM , BamberL , WangM , LensingAW . Reduction in initial length of stay with rivaroxaban single-drug regimen versus LMWH-VKA standard of care: findings from the EINSTEIN trial program. Blood2012;120(21):3419. Van BellenB , PrinsM , BamberL , WangM , LensingAW . Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism. Current Medical Research and Opinion2014;30(5):829-37. WangY , WangC , ChenZ , ZhangJ , LiuZ , JinB , et al. Rivaroxaban for the treatment of symptomatic deep vein thrombosis and/or pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):694. WangY , WangC , ChenZ , ZhangJ , LiuZ , JinB , et al. Rivaroxaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Thrombosis Journal2013;11(1):25. ">EINSTEIN‐DVT 2010</a>; <a href="./references#CD010956-bbs2-0008" title="BullerHR , PrinsMH , LensinAW , DecoususH , JacobsonBF , MinarE , et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. New England Journal of Medicine2012;366:1287-97. FermannGJ , Erkens Pmg, PrinsMH , WellsPS , Pap ÁF, LensingAW , et al. Treatment of pulmonary embolism with rivaroxaban: outcomes by simplified pulmonary embolism severity index score from a post hoc analysis of the EINSTEIN PE study. Academic Emergency Medicine2015;22(3):299-307. NCT00439777. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic pulmonary embolism with or without symptomatic deep-vein thrombosis: Einstein-PE evaluation, 2008. clinicaltrials.gov/ct2/show/NCT00439777?term=NCT00439777&amp;rank=1 (first received 26 February 2007). PrinsM , BamberL , CanoS , WangM , LensingAW , BauersachsR . Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic pulmonary embolism. Blood2012;120(21):1163. PrinsMH , BamberL , CanoSJ , WangMY , ErkensP , BauersachsR , et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial. Thrombosis Research2015;135(2):281-8. ">EINSTEIN‐PE 2012</a>; <a href="./references#CD010956-bbs2-0009" title="PiazzaG , ManiV , GoldhaberSZ , GrossoMA , MercuriM , LanzHJ , et al. Magnetic resonance venography to assess thrombus resolution with edoxaban monotherapy versus parenteral anticoagulation/warfarin for symptomatic deep vein thrombosis: a multicenter feasibility study. Vascular Medicine2016;21(4):361-8. PiazzaG , ManiV , GrossoM , MercuriM , LanzH , SchusslerS , et al. A randomized, open-label, multicenter study of the efficacy and safety of edoxaban monotherapy versus low-molecular weight heparin/warfarin in patients with symptomatic deep vein thrombosis-edoxaban thrombus reduction imaging study (etris). Circulation2014;130:A12074. ">eTRIS 2016</a>; <a href="./references#CD010956-bbs2-0010" title="FarhanA , BukhariM , UmarJ , RazaMA . Oral rivaroxaban in symptomatic deep vein thrombosis. Journal of the College of Physicians and Surgeons Pakistan2019;29(9):814-8. ">Farhan 2019</a>; <a href="./references#CD010956-bbs2-0012" title="AmayaN , UzuiH , HisazakiK , HasegwaK , KasenoK , TadaH . Edoxaban normalizes the elevated D-dimer levels potently and promptly in patients with venous thromboembolisms: a comparison with traditional anticoagulant therapy. European Heart Journal2016;37:278. BoschFT , Van EsN , Di NisioM , CarrierM , SegersA , GrossoMA , et al. The Ottawa score does not predict recurrent venous thromboembolism in cancer patients: results from the Hokusai-VTE cancer study. Research and Practice in Thrombosis and Haemostasis2019;3(S1):717-8. KraaijpoelN , Di NisioM , MulderFI , Van EsN , RaskobGE . Clinical impact of bleeding in cancer-associated venous thromboembolism: results from the Hokusai VTE Cancer randomized trial. Thrombosis Research2018;164(Suppl 1):S223. [DOI: 10.1016/j.thromres.2018.02.094]MulderFI , Di NisioM , AyC , CarrierM , BoschFT , SegersA , et al. Clinical implications of incidental venous thromboembolism in cancer patients. European Respiratory Journal2020;55(2):1901697. [DOI: 10.1183/13993003.01697-2019]MulderFI , Van EsN , KraaijpoelN , Di NisioM , CarrierM , GarciaD , et al. Efficacy and safety of edoxaban in clinically relevant subgroups: results from the Hokusai VTE Cancer randomized trial. Thrombosis Research2018;164:S194. NCT02073682. Cancer venous thromboembolism (VTE). clinicaltrials.gov/ct2/show/NCT02073682 (first received 27 February 2014). RaskobG , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaD , et al. Edoxaban versus dalteparin for treatment of venous thromboembolism (VTE) associated with cancer: Hokusai VTE-cancer randomized trial. Supportive Care in Cancer2018;26(2):S316-S317. RaskobGE , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaD , et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. New England Journal of Medicine2018;378(7):615-24. RaskobGE , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaDA , et al. A randomized, open-label, blinded outcome assessment trial evaluating the efficacy and safety of LMWH/Edoxaban versus dalteparin for venous thromboembolism associated with cancer: Hokusai VTE-cancer study. Blood2017;130(Suppl 1):LBA-6. ">Hokusai VTE Cancer 2018</a>; <a href="./references#CD010956-bbs2-0011" title="BistervelsI , BavaliaR , BoersmaW , MeijerK , VerhammeP , Ten Cate-HoekAJ , et al. Hokusai Post-DVT Study: a follow-up study on long-term outcomes of deep vein thrombosis in patients treated with edoxaban vs warfarin. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):PB2207. BrekelmansMP , AgenoW , BeenenLF , BrennerB , BullerHR , ChenCZ , et al. Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology2016;3(9):e437-45. BrekelmansMP , BlekerSM , BauersachsR , BodaZ , BüllerHR , ChoiY , et al. Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists. Thrombosis and Haemostasis2016;116(1):155-61. Di NisioM , Van EsN , CarrierM , WangTF , GarciaD , SegersA , et al. Extended treatment with edoxaban in cancer patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE Cancer study. Journal of Thrombosis and Haemostasis2019;17:1866–74. EUCTR2009-014290-40-SE. A phase 3, randomized, double-blind, double-dummy, parallel group, multi-center, multi-national study for evaluation of efficacy and safety of DU-176b versus warfarin in subjects with atrial fibrillation - effective anticoagulation with factor Xa next generation in atrial fibrillation (ENGAGE-AF TIMI-48). trialsearch.who.int/?trialid=EUCTR2009-014290-40-SE (first received 30 November 2009). EichingerS , LinM , KyrlePA , GrossoMA . Recurrent venous thromboembolism during anticoagulation: an investigator-initiated post-hoc analysis of the hokusai-VTE trial. Blood2018;132:2539. KlokFA , BarcoS , KonstantinidesSV . External validation of the VTE-BLEED score for predicting major bleeding in stable anticoagulated patients with venous thromboembolism. Thrombosis and Haemostasis2017;117(6):1164-70. KraaijpoelN , Van EsN , RaskobGE , BüllerHR , CarrierM , ZhangG , et al. Risk scores for occult cancer in patients with venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2018;118(7):1270-8. MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMP , ChenCZ , et al. Outpatient management in patients with venous thromboembolism with edoxaban: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2017;117(12):2406-14. MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMP , ChenCZ , et al. Safety and efficacy of edoxaban compared with warfarin for the treatment of acute symptomatic deep-vein thrombosis in the outpatient setting. Research and Practice in Thrombosis and Haemostasis2017;1:913. MulderFI , Van EsN , KraaijpoelN , Di NisioM , CarrierM , DuggalA , et al. Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: results from the Hokusai VTE Cancer study. Thrombosis Research2020;185:13-9. NCT00986154. Comparative investigation of Low Molecular Weight (LMW) heparin/edoxaban tosylate (DU176b) versus (LMW) heparin/warfarin in the treatment of symptomatic deep-vein blood clots and/or lung blood clots. (The Edoxaban Hokusai-VTE Study). clinicaltrials.gov/ct2/show/NCT00986154 (first received 29 September 2009). NakamuraM , WangYQ , WangC , OhD , YinWH , KimuraT , et al. Efficacy and safety of edoxaban for treatment of venous thromboembolism: a subanalysis of East Asian patients in the Hokusai-VTE trial. Journal of Thrombosis and Haemostasis2015;13(9):1606-14. NybergJ , KarlssonKE , JönssonS , YinO , MillerR , KarlssonMO , et al. Edoxaban exposure-response analysis and clinical utility index assessment in patients with symptomatic deep-vein thrombosis or pulmonary embolism. CPT Pharmacometrics and Systems Pharmacology2016;5(4):222-32. RaskobG , AgenoW , CohenAT , BrekelmansMP , GrossoMA , SegersA , et al. Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology2016;3(5):e228-e236. RaskobG , BullerH , PrinsM , SegersA , ShiM , SchwochoL , et al. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study - methodological implications for clinical trials. Journal of Thrombosis and Haemostasis2013;11(7):1287-94. RaskobGE , BullerH , AngchaisuksiriP , OhD , BodaZ , LyonsRM , et al. Edoxaban for long-term treatment of venous thromboembolism in cancer patients. Blood2013;122(21):211. RaskobGE , Van EsN , SegersA , AngchaisuksiriP , OhD , BodaZ , et al. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematology2016;3(8):e379-87. ScheresLJ , BrekelmansMA , WalterA , CihanA , BüllerHR , SabineE , et al. Abnormal vaginal bleeding in women of reproductive age treated with edoxaban or warfarin for venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. British Journal of Obstetrics and Gynaecology2018;125(12):1581-9. The Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. New England Journal of Medicine2013;369(15):1406-15. VanasscheT , VerhammeP , WellsPS , SegersA , AgenoW , BrekelmansMP , et al. Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: an analysis of the randomized, double-blind Hokusai-VTE trial. Thrombosis Research2018;162:7-14. VerhammeP , WellsPS , SegersA , AgenoW , BrekelmansMP , CohenAT , et al. Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial. Thrombosis and Haemostasis2016;116(4):747-53. ">Hokusai‐VTE 2013</a>; <a href="./references#CD010956-bbs2-0013" title="MatsuoH , PrinsM , LensingAW , FujinumaEW , MiyamotoY , KajikawaM . Shortened length of hospital stay with rivaroxaban in patients with symptomatic venous thromboembolism in Japan: the J-EINSTEIN pulmonary embolism and deep vein thrombosis program. Current Medical Research and Opinion2015;31(6):1057-61. NCT01516814. Venous thromboembolism (VTE) treatment study in Japanese pulmonary embolism (PE) patients. clinicaltrials.gov/ct2/show/NCT01516814 (first received 25 January 2012). YamadaN , HirayamaA , MaedaH , SakagamiS , ShikataH , PrinsMH , et al. Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism-the J-EINSTEIN DVT and PE program. Thrombosis Journal2015;13:2. ">J‐EINSTEIN DVT and PE 2015</a>; <a href="./references#CD010956-bbs2-0014" title="MokademME , HassanA , AlgabyAZ . Efficacy and safety of apixaban in patients with active malignancy and acute deep venous thrombosis. Vascular2021;29(5):745-50. NCT04462003. Efficacy of apixaban in malignancy with deep venous thrombosis (DVT). clinicaltrials.gov/ct2/show/NCT04462003 (first received 3 July 2019). ">Mokadem 2021</a>; <a href="./references#CD010956-bbs2-0015" title="AgnelliG , GallusA , GoldhaberSZ , HaasS , HuismanMV , HullRD , et al. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAT 59-7939 in patients with acute symptomatic deep-vein thrombosis) study. Circulation2007;116:180-7. ">ODIXa‐DVT 2007</a>; <a href="./references#CD010956-bbs2-0016" title="OhmoriH , KadaA , NakamuraM , SaitoAM , SanayamaY , ShinagawaT , et al. Deep vein thrombosis in severe motor and intellectual disabilities patients and its treatment by anticoagulants of warfarin versus edoxaban. Annals of Vascular Diseases2019;12(3):372-8. OhmoriH , NakamuraM , KadaA , SaitoAM , SanayamaY , ShinagawaT , et al. Multicenter, open-label, randomized controlled trial of warfarin and edoxaban tosilate hydrate for the treatment of deep vein thrombosis in persons with severe motor intellectual disabilities. Kurume Medical Journal2018;65(1):11-6. ">Ohmori 2019</a>; <a href="./references#CD010956-bbs2-0017" title="Kang JiM, ParkKH , AhnS , ChoS , MinSK . Rivaroxaban after thrombolysis in acute iliofemoral venous thrombosis: a randomized, open-labeled, multicenter trial. Scientific Reports2019;9(1):20356. MinSK , AhnS , ParkKH , KangJM , KimJY . Prevention of recurrence after thrombolysis in acute iliofemoral venous thrombosis with rivaroxaban (Prais Study): a prospective, randomized, open label, multicenter trial. European Journal of Vascular and Endovascular Surgery2019;58(6):e516. NCT01986192. Prevention of recurrence after thrombolysis in acute iliofemoral venous thrombosis (PRAIS) study. clinicaltrials.gov/show/NCT01986192 (first received 18 November 2013). ">PRAIS 2019</a>; <a href="./references#CD010956-bbs2-0020" title="SukovatykhBS , SereditskiĭAV , MuradianVF , BelikovLN , GerasimovaOF . Results of administering oral anticoagulants for treatment of patients with venous thromboembolic complications. Angiologiia i sosudistaia khirurgiia [Angiology and Vascular Surgery]2017;23(2):82. ">Sukovatykh 2017</a>). Of these studies, nine investigated rivaroxaban (<a href="./references#CD010956-bbs2-0005" title="NCT02704598. Comparison between xarelto versus warfarin in the recanalization rate of deep venous thrombosis in patients legs. (DVT). clinicaltrials.gov/ct2/show/NCT02704598 (first received 10 March 2016). deAthayde SoaresR , MatieloMF , Brochado NetoFC , AlmeidaRD , SacilottoR . LEV 2. Comparison of the recanalization rate and post-thrombotic syndrome in patients with deep venous thrombosis treated with rivaroxaban or warfarin. Journal of Vascular Surgery2019;70(5):e169-e170. deAthayde SoaresR , MatieloMF , Brochado NetoFC , NogueiraMP , AlmeidaRD , SacilottoR . Comparison of the recanalization rate and postthrombotic syndrome in patients with deep venous thrombosis treated with rivaroxaban or warfarin. Surgery2019;166(6):1076-83. ">de Athayde 2019</a>; <a href="./references#CD010956-bbs2-0007" title="BullerH , DariusH . EINSTEIN DVT: oral rivaroxaban versus standard therapy in the initial treatment of symptomatic deep vein thrombosis and long-term prevention of recurrent venous thromboembolism. escardio.org/The-ESC/Press-Office/Press-releases/EINSTEIN-DVT-Oral-rivaroxaban-versus-standard-therapy-in-the-initial-treatment (accessed 19 October 2022). BullerHR , AgnelliG . Once- or twice-daily rivaroxaban for the treatment of proximal deep vein thrombosis: similar efficacy and safety to standard therapy in dose-ranging studies. Blood2006;108(11 Part 1):172-3. BullerHR , LensingAW , PrinsMH , AgnelliG , CohenA , GallusAS , et al. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT dose-ranging study. Blood2008;112(6):2242-7. NCT00395772. Once-daily oral direct factor Xa inhibitor BAY59-7939 in patients with acute symptomatic deep-vein thrombosis. clinicaltrials.gov/ct2/show/NCT00395772?term=einstein-dvt&amp;rank=2 (first received 3 November 2006). ">EINSTEIN‐DVT dose 2008</a>; <a href="./references#CD010956-bbs2-0006" title="BamberL , WangMY , PrinsMH , CiniglioC , BauersachsR , LensingAW , et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis. Thrombosis and Haemostasis2013;110(4):732-41. BauersachsR , LensingAW , PapA , DecoususH . No need for a rivaroxaban dose reduction in renally impaired patients with symptomatic venous thromboembolism. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):30-1. BistervelsI , GebelM , LensingA , MiddeldorpS , CoppensM . Effect of polypharmacy on bleeding of rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolism. Research and Practice in Thrombosis and Haemostasis2019;3:798‐9. BookhartBK , HaskellL , BamberL , WangM , ScheinJ , ModySH . Length of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial program. Journal of Medical Economics2014;17(10):691-5. BullerHR . Oral rivaroxaban for the acute and continued treatment of symptomatic venous thromboembolism. The Einstein-DVT and Einstein-Extension study. Blood2010;116(21):187. CheungW , MiddeldorpS , PrinsMP , PapAF , LensingAW , Hoek-tenCA , et al. Post thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep vein thrombosis. Journal of Thrombosis and Haemostasis2015;13(S2):219-20. CheungYW , MiddeldorpS , PrinsMH , PapAF , PrandoniP . Post-thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep-vein thrombosis. A post-hoc analysis. Thrombosis and Haemostasis2016;116(4):733-8. EUCTR2004-002171-16-IT. Once-daily oral direct factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis. The EINSTEIN-DVT dose-finding study. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2004%E2%80%90002171%E2%80%9016%E2%80%90IT (first received 15 October 2008). EUCTR2006-004495-13-DK. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep-vein thrombosis or pulmonary embolism. trialsearch.who.int/?TrialID=EUCTR2006-004495-13-DK (first received 29 March 2007). EerenbergES , MiddeldorpS , LeviM , LensingAW , BüllerHR . Clinical impact and course of major bleeding with rivaroxaban and vitamin K antagonists. Journal of Thrombosis and Haemostasis2015;13(9):1590-6. KlineJA , JimenezD , CourtneyDM , IanusJ , CaoL , WellsPS . Use of the Riete 2008 bleeding score to identify patients at low risk for major bleeding in patients treated with rivaroxaban. Academic Emergency Medicine2015;22:S162. NCT00440193. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep vein thrombosis - The EINSTEIN DVT Study. clinicaltrials.gov/ct2/show/NCT00440193 (first received 26 February 2007). PrinsMH , ErkensPG , LensingAW . Incidence of recurrent venous thromboembolism in patients following completion of the EINSTEIN DVT and EINSTEIN PE studies. Journal of Thrombosis and Haemostasis2013;11(Suppl):257. PrinsMH , LensingAW , BauersachsR , Van BellenB , BounameauxH , BrightonTA , et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thrombosis Journal2013;11(1):21. The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. New England Journal of Medicine2010;363(26):2499-510. Van BellenB , PrinsM , BamberL , WangM , LensingAW . Reduction in initial length of stay with rivaroxaban single-drug regimen versus LMWH-VKA standard of care: findings from the EINSTEIN trial program. Blood2012;120(21):3419. Van BellenB , PrinsM , BamberL , WangM , LensingAW . Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism. Current Medical Research and Opinion2014;30(5):829-37. WangY , WangC , ChenZ , ZhangJ , LiuZ , JinB , et al. Rivaroxaban for the treatment of symptomatic deep vein thrombosis and/or pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):694. WangY , WangC , ChenZ , ZhangJ , LiuZ , JinB , et al. Rivaroxaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Thrombosis Journal2013;11(1):25. ">EINSTEIN‐DVT 2010</a>; <a href="./references#CD010956-bbs2-0008" title="BullerHR , PrinsMH , LensinAW , DecoususH , JacobsonBF , MinarE , et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. New England Journal of Medicine2012;366:1287-97. FermannGJ , Erkens Pmg, PrinsMH , WellsPS , Pap ÁF, LensingAW , et al. Treatment of pulmonary embolism with rivaroxaban: outcomes by simplified pulmonary embolism severity index score from a post hoc analysis of the EINSTEIN PE study. Academic Emergency Medicine2015;22(3):299-307. NCT00439777. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic pulmonary embolism with or without symptomatic deep-vein thrombosis: Einstein-PE evaluation, 2008. clinicaltrials.gov/ct2/show/NCT00439777?term=NCT00439777&amp;rank=1 (first received 26 February 2007). PrinsM , BamberL , CanoS , WangM , LensingAW , BauersachsR . Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic pulmonary embolism. Blood2012;120(21):1163. PrinsMH , BamberL , CanoSJ , WangMY , ErkensP , BauersachsR , et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial. Thrombosis Research2015;135(2):281-8. ">EINSTEIN‐PE 2012</a>; <a href="./references#CD010956-bbs2-0010" title="FarhanA , BukhariM , UmarJ , RazaMA . Oral rivaroxaban in symptomatic deep vein thrombosis. Journal of the College of Physicians and Surgeons Pakistan2019;29(9):814-8. ">Farhan 2019</a>; <a href="./references#CD010956-bbs2-0013" title="MatsuoH , PrinsM , LensingAW , FujinumaEW , MiyamotoY , KajikawaM . Shortened length of hospital stay with rivaroxaban in patients with symptomatic venous thromboembolism in Japan: the J-EINSTEIN pulmonary embolism and deep vein thrombosis program. Current Medical Research and Opinion2015;31(6):1057-61. NCT01516814. Venous thromboembolism (VTE) treatment study in Japanese pulmonary embolism (PE) patients. clinicaltrials.gov/ct2/show/NCT01516814 (first received 25 January 2012). YamadaN , HirayamaA , MaedaH , SakagamiS , ShikataH , PrinsMH , et al. Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism-the J-EINSTEIN DVT and PE program. Thrombosis Journal2015;13:2. ">J‐EINSTEIN DVT and PE 2015</a>; <a href="./references#CD010956-bbs2-0015" title="AgnelliG , GallusA , GoldhaberSZ , HaasS , HuismanMV , HullRD , et al. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAT 59-7939 in patients with acute symptomatic deep-vein thrombosis) study. Circulation2007;116:180-7. ">ODIXa‐DVT 2007</a>; <a href="./references#CD010956-bbs2-0017" title="Kang JiM, ParkKH , AhnS , ChoS , MinSK . Rivaroxaban after thrombolysis in acute iliofemoral venous thrombosis: a randomized, open-labeled, multicenter trial. Scientific Reports2019;9(1):20356. MinSK , AhnS , ParkKH , KangJM , KimJY . Prevention of recurrence after thrombolysis in acute iliofemoral venous thrombosis with rivaroxaban (Prais Study): a prospective, randomized, open label, multicenter trial. European Journal of Vascular and Endovascular Surgery2019;58(6):e516. NCT01986192. Prevention of recurrence after thrombolysis in acute iliofemoral venous thrombosis (PRAIS) study. clinicaltrials.gov/show/NCT01986192 (first received 18 November 2013). ">PRAIS 2019</a>; <a href="./references#CD010956-bbs2-0020" title="SukovatykhBS , SereditskiĭAV , MuradianVF , BelikovLN , GerasimovaOF . Results of administering oral anticoagulants for treatment of patients with venous thromboembolic complications. Angiologiia i sosudistaia khirurgiia [Angiology and Vascular Surgery]2017;23(2):82. ">Sukovatykh 2017</a>), five investigated apixaban (<a href="./references#CD010956-bbs2-0001" title="AgnelliG , BullerH , MasiukiewiczUP . Apixaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism: a randomized, double-blind trial (AMPLIFY). Journal of Thrombosis and Haemostasis2013;11:18. AgnelliG , BullerHR , CohenA , CurtoD , GallusAS , JohnsonM , et al. Oral apixaban for the treatment of acute venous thromboembolism. New England Journal of Medicine2013;369:799-808. AgnelliG , BullerHR , CohenA , CurtoM , GallusAS , PakR , et al. Apixaban for the treatment of venous thromboembolism in cancer patients: data from the AMPLIFY trial. Canadian Journal of Cardiology2014;30(10 Suppl 1):S278. AgnelliG , BullerHR , CohenA , GallusAS , LeeTC , PakR , et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. Journal of Thrombosis and Haemostasis2015;13(12):2187-91. AgnelliG . Apixaban was non-inferior to enoxaparin plus warfarin in patients with acute venous thromboembolism. Annals of Internal Medicine2013;159(8):JC2. BlekerSM , CohenAT , BüllerHR , AgnelliG , GallusAS , RaskobGE , et al. Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Thrombosis and Haemostasis2016;116(6):159-64. BrekelmansM , ScheresL , BlekerS , HuttenB , TimmermansA , BüllerH , et al. Abnormal vaginal bleeding in women with venous thromboembolism treated with apixaban or warfarin. Thrombosis and Haemostasis2017;117(04):809-15. CohenA , AgnelliG , BullerH , GallusA , RaskobG , SandersP , et al. Characteristics and outcomes in patients with venous thromboembolism taking concomitant anti-platelet agents and anticoagulants in the AMPLIFY Trial. Thrombosis and Haemostasis2019;119(3):461-6. CohenA , AgnelliG , BullerHR , ChaudhuriS , GallusAS , RaskobGE , et al. Analysis of the bleeding and thromboembolic risk with concomitant use of antiplatelet treatment in the AMPLIFY trial. Canadian Journal of Cardiology2014;30(10):S272. CohenA , GallusAS , AgnelliG , BullerHR , PakR , PorcariAR , et al. Time in Therapeutic Range (TTR) and relative efficacy and safety of treatment with apixaban or enoxaparin/warfarin for acute symptomatic venous thromboembolism: an analysis of the Amplify trial data. Blood2014;124(21):1543. CohenAT , PanS , ByonW , IlyasBS , LeeTC . Efficacy, safety, and exposure of apixaban in patients with high body weight or obesity and venous thromboembolism: insights from AMPLIFY. Advances in Therapy2021;38(6):3003-18. EUCTR2007-007867-25-PT. A safety and efficacy trial evaluating the use of apixaban in the treatment of symptomatic deep vein thrombosis and pulmonary embolism revised protocol number: 01, incorporates amendment(s) 02 + protocol amendment 01 (version 1.0 dated 21-Apr-08) site-specific - molecular profiling supplement samples for Pfizer’s exploratory research biobank. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2007%E2%80%90007867%E2%80%9025%E2%80%90PT (first received 14 July 2008). GallusAS , AgnelliG , BullerHR , CohenA , LeeTC , PakR , et al. Apixaban for treatment of venous thromboembolism in patients from study centres in Asia: a subgroup analysis of the Amplify trial. Journal of Thrombosis and Haemostasis2015;13:727. LeeT , PanS , ByonW , IlyasBS . Safety and efficacy of apixaban versus enoxaparin/warfarin in patients with extremes of body weight: post-hoc analysis of the AMPLIFY trial. Blood2019;134(Suppl 1):1152. LiuX , JohnsonM , MardekianJ , PhatakH , ThompsonJ , CohenAT . Apixaban reduces hospitalizations in patients with venous thromboembolism: an analysis of the apixaban for the Initial management of pulmonary embolism and deep‐vein thrombosis as first‐line therapy (AMPLIFY) trial. Journal of the American Heart Association2015;4(12):e002340. NCT00633893. Efficacy and safety study of apixaban for extended treatment of deep vein thrombosis or pulmonary embolism. clinicaltrials.gov/ct2/show/NCT00633893?term=ajax&amp;rank=5 (first received 12 March 2008). NCT00643201. Efficacy and safety study of apixaban for the treatment of deep vein thrombosis or pulmonary embolism. clinicaltrials.gov/ct2/show/NCT00643201 (first received 26 March 2008). RaskobGE , GallusAS , SandersP , ThompsonJR , AgnelliG , BullerHR , et al. Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy: a sub-analysis of the AMPLIFY trial. Thrombosis and Haemostasis2016;115(4):809-16. ">AMPLIFY 2013</a>; <a href="./references#CD010956-bbs2-0002" title="NakamuraM , NishikawaM , KomuroI , KitajimaI , UetsukaY , YamagamiT , et al. Apixaban for the treatment of Japanese subjects with acute venous thromboembolism (AMPLIFY-J Study). Circulation2015;79(6):1230–36. ">AMPLIFY‐J 2015</a>; <a href="./references#CD010956-bbs2-0003" title="BarrettYC , WangJ , KnabbR , MohanP . Apixaban decreases coagulation activity in patients with acute deep-vein thrombosis. Thrombosis and Haemostasis2011;105:181-9. Botticelli Investigators Writing Committee, BullerH , DeitchmanD , PrinsM , SegersA . Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. Journal of Thrombosis and Haemostasis2008;6:1313-8. BullerHR . A dose finding study of the oral direct factor Xa inhibitor apixaban in the treatment of patients with acute symptomatic deep vein thrombosis - the Botticelli Investigators. Journal of Thrombosis and Haemostasis2007;5 (Suppl 2):O-S-003. NCT00252005. Oral direct factor Xa-inhibitor apixaban in patients with acute symptomatic deep-vein thrombosis - the Botticelli DVT study. clinicaltrials.gov/ct/show/NCT00252005?order=1 (first received 11 November 2005). ">Botticelli DVT 2008</a>; <a href="./references#CD010956-bbs2-0004" title="AgenoW , VedovatiMC , CohenA , HuismanM , BauersachsR , GussoniG , et al. Bleeding with apixaban and dalteparin in patients with cancer-associated venous thromboembolism: results from the Caravaggio study. Thrombosis and Haemostasis2021;121(5):616-24. AgnelliG , BecattiniC , BauersachsR , BrennerB , CampaniniM , CohenA , et al. Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the Caravaggio study. Thrombosis and Haemostasis2018;118(9):1668-78. AgnelliG , BecattiniC , MeyerG , MuozA , VersoM . Apixaban for the treatment of venous thromboembolism associated with cancer. New England Journal of Medicine2020;382(17):1599-607. AgnelliG , MuozA , FrancoL , MahéI , BrennerB , ConnorsJM , et al. Apixaban and dalteparin for the treatment of venous thromboembolism in patients with different sites of cancer. Thrombosis and Haemostasis2022;122(5):796-807. BecattiniC , BauersachsR , MarazitiG , BertolettiL , CohenA , ConnorsJM , et al. Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial. Haematologica2021;107(7):1567-76. GiustozziM , ConnorsJM , Ruperez BlancoAB , SzmitS , FalvoN , CohenAT , et al. Clinical characteristics and outcomes of incidental venous thromboembolism in cancer patients: insights from the Caravaggio study. Journal of Thrombosis and Haemostasis2021;19(11):2751-9. NCT03045406. Apixaban for the treatment of venous thromboembolism in patients with cancer (CARAVAGGIO). clinicaltrials.gov/ct2/show/NCT03045406 (first received 7 February 2017). VersoM , MunozA , BauersachsR , HuismanMV , AgnelliG . Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism. European Journal of Cancer2021;148(Suppl C):371-81. ">Caravaggio 2020</a>; <a href="./references#CD010956-bbs2-0014" title="MokademME , HassanA , AlgabyAZ . Efficacy and safety of apixaban in patients with active malignancy and acute deep venous thrombosis. Vascular2021;29(5):745-50. NCT04462003. Efficacy of apixaban in malignancy with deep venous thrombosis (DVT). clinicaltrials.gov/ct2/show/NCT04462003 (first received 3 July 2019). ">Mokadem 2021</a>), and four investigated edoxaban (<a href="./references#CD010956-bbs2-0009" title="PiazzaG , ManiV , GoldhaberSZ , GrossoMA , MercuriM , LanzHJ , et al. Magnetic resonance venography to assess thrombus resolution with edoxaban monotherapy versus parenteral anticoagulation/warfarin for symptomatic deep vein thrombosis: a multicenter feasibility study. Vascular Medicine2016;21(4):361-8. PiazzaG , ManiV , GrossoM , MercuriM , LanzH , SchusslerS , et al. A randomized, open-label, multicenter study of the efficacy and safety of edoxaban monotherapy versus low-molecular weight heparin/warfarin in patients with symptomatic deep vein thrombosis-edoxaban thrombus reduction imaging study (etris). Circulation2014;130:A12074. ">eTRIS 2016</a>; <a href="./references#CD010956-bbs2-0012" title="AmayaN , UzuiH , HisazakiK , HasegwaK , KasenoK , TadaH . Edoxaban normalizes the elevated D-dimer levels potently and promptly in patients with venous thromboembolisms: a comparison with traditional anticoagulant therapy. European Heart Journal2016;37:278. BoschFT , Van EsN , Di NisioM , CarrierM , SegersA , GrossoMA , et al. The Ottawa score does not predict recurrent venous thromboembolism in cancer patients: results from the Hokusai-VTE cancer study. Research and Practice in Thrombosis and Haemostasis2019;3(S1):717-8. KraaijpoelN , Di NisioM , MulderFI , Van EsN , RaskobGE . Clinical impact of bleeding in cancer-associated venous thromboembolism: results from the Hokusai VTE Cancer randomized trial. Thrombosis Research2018;164(Suppl 1):S223. [DOI: 10.1016/j.thromres.2018.02.094]MulderFI , Di NisioM , AyC , CarrierM , BoschFT , SegersA , et al. Clinical implications of incidental venous thromboembolism in cancer patients. European Respiratory Journal2020;55(2):1901697. [DOI: 10.1183/13993003.01697-2019]MulderFI , Van EsN , KraaijpoelN , Di NisioM , CarrierM , GarciaD , et al. Efficacy and safety of edoxaban in clinically relevant subgroups: results from the Hokusai VTE Cancer randomized trial. Thrombosis Research2018;164:S194. NCT02073682. Cancer venous thromboembolism (VTE). clinicaltrials.gov/ct2/show/NCT02073682 (first received 27 February 2014). RaskobG , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaD , et al. Edoxaban versus dalteparin for treatment of venous thromboembolism (VTE) associated with cancer: Hokusai VTE-cancer randomized trial. Supportive Care in Cancer2018;26(2):S316-S317. RaskobGE , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaD , et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. New England Journal of Medicine2018;378(7):615-24. RaskobGE , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaDA , et al. A randomized, open-label, blinded outcome assessment trial evaluating the efficacy and safety of LMWH/Edoxaban versus dalteparin for venous thromboembolism associated with cancer: Hokusai VTE-cancer study. Blood2017;130(Suppl 1):LBA-6. ">Hokusai VTE Cancer 2018</a>; <a href="./references#CD010956-bbs2-0011" title="BistervelsI , BavaliaR , BoersmaW , MeijerK , VerhammeP , Ten Cate-HoekAJ , et al. Hokusai Post-DVT Study: a follow-up study on long-term outcomes of deep vein thrombosis in patients treated with edoxaban vs warfarin. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):PB2207. BrekelmansMP , AgenoW , BeenenLF , BrennerB , BullerHR , ChenCZ , et al. Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology2016;3(9):e437-45. BrekelmansMP , BlekerSM , BauersachsR , BodaZ , BüllerHR , ChoiY , et al. Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists. Thrombosis and Haemostasis2016;116(1):155-61. Di NisioM , Van EsN , CarrierM , WangTF , GarciaD , SegersA , et al. Extended treatment with edoxaban in cancer patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE Cancer study. Journal of Thrombosis and Haemostasis2019;17:1866–74. EUCTR2009-014290-40-SE. A phase 3, randomized, double-blind, double-dummy, parallel group, multi-center, multi-national study for evaluation of efficacy and safety of DU-176b versus warfarin in subjects with atrial fibrillation - effective anticoagulation with factor Xa next generation in atrial fibrillation (ENGAGE-AF TIMI-48). trialsearch.who.int/?trialid=EUCTR2009-014290-40-SE (first received 30 November 2009). EichingerS , LinM , KyrlePA , GrossoMA . Recurrent venous thromboembolism during anticoagulation: an investigator-initiated post-hoc analysis of the hokusai-VTE trial. Blood2018;132:2539. KlokFA , BarcoS , KonstantinidesSV . External validation of the VTE-BLEED score for predicting major bleeding in stable anticoagulated patients with venous thromboembolism. Thrombosis and Haemostasis2017;117(6):1164-70. KraaijpoelN , Van EsN , RaskobGE , BüllerHR , CarrierM , ZhangG , et al. Risk scores for occult cancer in patients with venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2018;118(7):1270-8. MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMP , ChenCZ , et al. Outpatient management in patients with venous thromboembolism with edoxaban: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2017;117(12):2406-14. MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMP , ChenCZ , et al. Safety and efficacy of edoxaban compared with warfarin for the treatment of acute symptomatic deep-vein thrombosis in the outpatient setting. Research and Practice in Thrombosis and Haemostasis2017;1:913. MulderFI , Van EsN , KraaijpoelN , Di NisioM , CarrierM , DuggalA , et al. Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: results from the Hokusai VTE Cancer study. Thrombosis Research2020;185:13-9. NCT00986154. Comparative investigation of Low Molecular Weight (LMW) heparin/edoxaban tosylate (DU176b) versus (LMW) heparin/warfarin in the treatment of symptomatic deep-vein blood clots and/or lung blood clots. (The Edoxaban Hokusai-VTE Study). clinicaltrials.gov/ct2/show/NCT00986154 (first received 29 September 2009). NakamuraM , WangYQ , WangC , OhD , YinWH , KimuraT , et al. Efficacy and safety of edoxaban for treatment of venous thromboembolism: a subanalysis of East Asian patients in the Hokusai-VTE trial. Journal of Thrombosis and Haemostasis2015;13(9):1606-14. NybergJ , KarlssonKE , JönssonS , YinO , MillerR , KarlssonMO , et al. Edoxaban exposure-response analysis and clinical utility index assessment in patients with symptomatic deep-vein thrombosis or pulmonary embolism. CPT Pharmacometrics and Systems Pharmacology2016;5(4):222-32. RaskobG , AgenoW , CohenAT , BrekelmansMP , GrossoMA , SegersA , et al. Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology2016;3(5):e228-e236. RaskobG , BullerH , PrinsM , SegersA , ShiM , SchwochoL , et al. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study - methodological implications for clinical trials. Journal of Thrombosis and Haemostasis2013;11(7):1287-94. RaskobGE , BullerH , AngchaisuksiriP , OhD , BodaZ , LyonsRM , et al. Edoxaban for long-term treatment of venous thromboembolism in cancer patients. Blood2013;122(21):211. RaskobGE , Van EsN , SegersA , AngchaisuksiriP , OhD , BodaZ , et al. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematology2016;3(8):e379-87. ScheresLJ , BrekelmansMA , WalterA , CihanA , BüllerHR , SabineE , et al. Abnormal vaginal bleeding in women of reproductive age treated with edoxaban or warfarin for venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. British Journal of Obstetrics and Gynaecology2018;125(12):1581-9. The Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. New England Journal of Medicine2013;369(15):1406-15. VanasscheT , VerhammeP , WellsPS , SegersA , AgenoW , BrekelmansMP , et al. Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: an analysis of the randomized, double-blind Hokusai-VTE trial. Thrombosis Research2018;162:7-14. VerhammeP , WellsPS , SegersA , AgenoW , BrekelmansMP , CohenAT , et al. Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial. Thrombosis and Haemostasis2016;116(4):747-53. ">Hokusai‐VTE 2013</a>; <a href="./references#CD010956-bbs2-0016" title="OhmoriH , KadaA , NakamuraM , SaitoAM , SanayamaY , ShinagawaT , et al. Deep vein thrombosis in severe motor and intellectual disabilities patients and its treatment by anticoagulants of warfarin versus edoxaban. Annals of Vascular Diseases2019;12(3):372-8. OhmoriH , NakamuraM , KadaA , SaitoAM , SanayamaY , ShinagawaT , et al. Multicenter, open-label, randomized controlled trial of warfarin and edoxaban tosilate hydrate for the treatment of deep vein thrombosis in persons with severe motor intellectual disabilities. Kurume Medical Journal2018;65(1):11-6. ">Ohmori 2019</a>). Four studies were dose‐ranging (<a href="./references#CD010956-bbs2-0003" title="BarrettYC , WangJ , KnabbR , MohanP . Apixaban decreases coagulation activity in patients with acute deep-vein thrombosis. Thrombosis and Haemostasis2011;105:181-9. Botticelli Investigators Writing Committee, BullerH , DeitchmanD , PrinsM , SegersA . Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. Journal of Thrombosis and Haemostasis2008;6:1313-8. BullerHR . A dose finding study of the oral direct factor Xa inhibitor apixaban in the treatment of patients with acute symptomatic deep vein thrombosis - the Botticelli Investigators. Journal of Thrombosis and Haemostasis2007;5 (Suppl 2):O-S-003. NCT00252005. Oral direct factor Xa-inhibitor apixaban in patients with acute symptomatic deep-vein thrombosis - the Botticelli DVT study. clinicaltrials.gov/ct/show/NCT00252005?order=1 (first received 11 November 2005). ">Botticelli DVT 2008</a>; <a href="./references#CD010956-bbs2-0007" title="BullerH , DariusH . EINSTEIN DVT: oral rivaroxaban versus standard therapy in the initial treatment of symptomatic deep vein thrombosis and long-term prevention of recurrent venous thromboembolism. escardio.org/The-ESC/Press-Office/Press-releases/EINSTEIN-DVT-Oral-rivaroxaban-versus-standard-therapy-in-the-initial-treatment (accessed 19 October 2022). BullerHR , AgnelliG . Once- or twice-daily rivaroxaban for the treatment of proximal deep vein thrombosis: similar efficacy and safety to standard therapy in dose-ranging studies. Blood2006;108(11 Part 1):172-3. BullerHR , LensingAW , PrinsMH , AgnelliG , CohenA , GallusAS , et al. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT dose-ranging study. Blood2008;112(6):2242-7. NCT00395772. Once-daily oral direct factor Xa inhibitor BAY59-7939 in patients with acute symptomatic deep-vein thrombosis. clinicaltrials.gov/ct2/show/NCT00395772?term=einstein-dvt&amp;rank=2 (first received 3 November 2006). ">EINSTEIN‐DVT dose 2008</a>; <a href="./references#CD010956-bbs2-0013" title="MatsuoH , PrinsM , LensingAW , FujinumaEW , MiyamotoY , KajikawaM . Shortened length of hospital stay with rivaroxaban in patients with symptomatic venous thromboembolism in Japan: the J-EINSTEIN pulmonary embolism and deep vein thrombosis program. Current Medical Research and Opinion2015;31(6):1057-61. NCT01516814. Venous thromboembolism (VTE) treatment study in Japanese pulmonary embolism (PE) patients. clinicaltrials.gov/ct2/show/NCT01516814 (first received 25 January 2012). YamadaN , HirayamaA , MaedaH , SakagamiS , ShikataH , PrinsMH , et al. Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism-the J-EINSTEIN DVT and PE program. Thrombosis Journal2015;13:2. ">J‐EINSTEIN DVT and PE 2015</a>; <a href="./references#CD010956-bbs2-0015" title="AgnelliG , GallusA , GoldhaberSZ , HaasS , HuismanMV , HullRD , et al. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAT 59-7939 in patients with acute symptomatic deep-vein thrombosis) study. Circulation2007;116:180-7. ">ODIXa‐DVT 2007</a>), while the remaining 14 studies were fixed dose (<a href="./references#CD010956-bbs2-0001" title="AgnelliG , BullerH , MasiukiewiczUP . Apixaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism: a randomized, double-blind trial (AMPLIFY). Journal of Thrombosis and Haemostasis2013;11:18. AgnelliG , BullerHR , CohenA , CurtoD , GallusAS , JohnsonM , et al. Oral apixaban for the treatment of acute venous thromboembolism. New England Journal of Medicine2013;369:799-808. AgnelliG , BullerHR , CohenA , CurtoM , GallusAS , PakR , et al. Apixaban for the treatment of venous thromboembolism in cancer patients: data from the AMPLIFY trial. Canadian Journal of Cardiology2014;30(10 Suppl 1):S278. AgnelliG , BullerHR , CohenA , GallusAS , LeeTC , PakR , et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. Journal of Thrombosis and Haemostasis2015;13(12):2187-91. AgnelliG . Apixaban was non-inferior to enoxaparin plus warfarin in patients with acute venous thromboembolism. Annals of Internal Medicine2013;159(8):JC2. BlekerSM , CohenAT , BüllerHR , AgnelliG , GallusAS , RaskobGE , et al. Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Thrombosis and Haemostasis2016;116(6):159-64. BrekelmansM , ScheresL , BlekerS , HuttenB , TimmermansA , BüllerH , et al. Abnormal vaginal bleeding in women with venous thromboembolism treated with apixaban or warfarin. Thrombosis and Haemostasis2017;117(04):809-15. CohenA , AgnelliG , BullerH , GallusA , RaskobG , SandersP , et al. Characteristics and outcomes in patients with venous thromboembolism taking concomitant anti-platelet agents and anticoagulants in the AMPLIFY Trial. Thrombosis and Haemostasis2019;119(3):461-6. CohenA , AgnelliG , BullerHR , ChaudhuriS , GallusAS , RaskobGE , et al. Analysis of the bleeding and thromboembolic risk with concomitant use of antiplatelet treatment in the AMPLIFY trial. Canadian Journal of Cardiology2014;30(10):S272. CohenA , GallusAS , AgnelliG , BullerHR , PakR , PorcariAR , et al. Time in Therapeutic Range (TTR) and relative efficacy and safety of treatment with apixaban or enoxaparin/warfarin for acute symptomatic venous thromboembolism: an analysis of the Amplify trial data. Blood2014;124(21):1543. CohenAT , PanS , ByonW , IlyasBS , LeeTC . Efficacy, safety, and exposure of apixaban in patients with high body weight or obesity and venous thromboembolism: insights from AMPLIFY. Advances in Therapy2021;38(6):3003-18. EUCTR2007-007867-25-PT. A safety and efficacy trial evaluating the use of apixaban in the treatment of symptomatic deep vein thrombosis and pulmonary embolism revised protocol number: 01, incorporates amendment(s) 02 + protocol amendment 01 (version 1.0 dated 21-Apr-08) site-specific - molecular profiling supplement samples for Pfizer’s exploratory research biobank. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2007%E2%80%90007867%E2%80%9025%E2%80%90PT (first received 14 July 2008). GallusAS , AgnelliG , BullerHR , CohenA , LeeTC , PakR , et al. Apixaban for treatment of venous thromboembolism in patients from study centres in Asia: a subgroup analysis of the Amplify trial. Journal of Thrombosis and Haemostasis2015;13:727. LeeT , PanS , ByonW , IlyasBS . Safety and efficacy of apixaban versus enoxaparin/warfarin in patients with extremes of body weight: post-hoc analysis of the AMPLIFY trial. Blood2019;134(Suppl 1):1152. LiuX , JohnsonM , MardekianJ , PhatakH , ThompsonJ , CohenAT . Apixaban reduces hospitalizations in patients with venous thromboembolism: an analysis of the apixaban for the Initial management of pulmonary embolism and deep‐vein thrombosis as first‐line therapy (AMPLIFY) trial. Journal of the American Heart Association2015;4(12):e002340. NCT00633893. Efficacy and safety study of apixaban for extended treatment of deep vein thrombosis or pulmonary embolism. clinicaltrials.gov/ct2/show/NCT00633893?term=ajax&amp;rank=5 (first received 12 March 2008). NCT00643201. Efficacy and safety study of apixaban for the treatment of deep vein thrombosis or pulmonary embolism. clinicaltrials.gov/ct2/show/NCT00643201 (first received 26 March 2008). RaskobGE , GallusAS , SandersP , ThompsonJR , AgnelliG , BullerHR , et al. Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy: a sub-analysis of the AMPLIFY trial. Thrombosis and Haemostasis2016;115(4):809-16. ">AMPLIFY 2013</a>; <a href="./references#CD010956-bbs2-0002" title="NakamuraM , NishikawaM , KomuroI , KitajimaI , UetsukaY , YamagamiT , et al. Apixaban for the treatment of Japanese subjects with acute venous thromboembolism (AMPLIFY-J Study). Circulation2015;79(6):1230–36. ">AMPLIFY‐J 2015</a>; <a href="./references#CD010956-bbs2-0003" title="BarrettYC , WangJ , KnabbR , MohanP . Apixaban decreases coagulation activity in patients with acute deep-vein thrombosis. Thrombosis and Haemostasis2011;105:181-9. Botticelli Investigators Writing Committee, BullerH , DeitchmanD , PrinsM , SegersA . Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. Journal of Thrombosis and Haemostasis2008;6:1313-8. BullerHR . A dose finding study of the oral direct factor Xa inhibitor apixaban in the treatment of patients with acute symptomatic deep vein thrombosis - the Botticelli Investigators. Journal of Thrombosis and Haemostasis2007;5 (Suppl 2):O-S-003. NCT00252005. Oral direct factor Xa-inhibitor apixaban in patients with acute symptomatic deep-vein thrombosis - the Botticelli DVT study. clinicaltrials.gov/ct/show/NCT00252005?order=1 (first received 11 November 2005). ">Botticelli DVT 2008</a>; <a href="./references#CD010956-bbs2-0004" title="AgenoW , VedovatiMC , CohenA , HuismanM , BauersachsR , GussoniG , et al. Bleeding with apixaban and dalteparin in patients with cancer-associated venous thromboembolism: results from the Caravaggio study. Thrombosis and Haemostasis2021;121(5):616-24. AgnelliG , BecattiniC , BauersachsR , BrennerB , CampaniniM , CohenA , et al. Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the Caravaggio study. Thrombosis and Haemostasis2018;118(9):1668-78. AgnelliG , BecattiniC , MeyerG , MuozA , VersoM . Apixaban for the treatment of venous thromboembolism associated with cancer. New England Journal of Medicine2020;382(17):1599-607. AgnelliG , MuozA , FrancoL , MahéI , BrennerB , ConnorsJM , et al. Apixaban and dalteparin for the treatment of venous thromboembolism in patients with different sites of cancer. Thrombosis and Haemostasis2022;122(5):796-807. BecattiniC , BauersachsR , MarazitiG , BertolettiL , CohenA , ConnorsJM , et al. Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial. Haematologica2021;107(7):1567-76. GiustozziM , ConnorsJM , Ruperez BlancoAB , SzmitS , FalvoN , CohenAT , et al. Clinical characteristics and outcomes of incidental venous thromboembolism in cancer patients: insights from the Caravaggio study. Journal of Thrombosis and Haemostasis2021;19(11):2751-9. NCT03045406. Apixaban for the treatment of venous thromboembolism in patients with cancer (CARAVAGGIO). clinicaltrials.gov/ct2/show/NCT03045406 (first received 7 February 2017). VersoM , MunozA , BauersachsR , HuismanMV , AgnelliG . Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism. European Journal of Cancer2021;148(Suppl C):371-81. ">Caravaggio 2020</a>; <a href="./references#CD010956-bbs2-0005" title="NCT02704598. Comparison between xarelto versus warfarin in the recanalization rate of deep venous thrombosis in patients legs. (DVT). clinicaltrials.gov/ct2/show/NCT02704598 (first received 10 March 2016). deAthayde SoaresR , MatieloMF , Brochado NetoFC , AlmeidaRD , SacilottoR . LEV 2. Comparison of the recanalization rate and post-thrombotic syndrome in patients with deep venous thrombosis treated with rivaroxaban or warfarin. Journal of Vascular Surgery2019;70(5):e169-e170. deAthayde SoaresR , MatieloMF , Brochado NetoFC , NogueiraMP , AlmeidaRD , SacilottoR . Comparison of the recanalization rate and postthrombotic syndrome in patients with deep venous thrombosis treated with rivaroxaban or warfarin. Surgery2019;166(6):1076-83. ">de Athayde 2019</a>; <a href="./references#CD010956-bbs2-0006" title="BamberL , WangMY , PrinsMH , CiniglioC , BauersachsR , LensingAW , et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis. Thrombosis and Haemostasis2013;110(4):732-41. BauersachsR , LensingAW , PapA , DecoususH . No need for a rivaroxaban dose reduction in renally impaired patients with symptomatic venous thromboembolism. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):30-1. BistervelsI , GebelM , LensingA , MiddeldorpS , CoppensM . Effect of polypharmacy on bleeding of rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolism. Research and Practice in Thrombosis and Haemostasis2019;3:798‐9. BookhartBK , HaskellL , BamberL , WangM , ScheinJ , ModySH . Length of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial program. Journal of Medical Economics2014;17(10):691-5. BullerHR . Oral rivaroxaban for the acute and continued treatment of symptomatic venous thromboembolism. The Einstein-DVT and Einstein-Extension study. Blood2010;116(21):187. CheungW , MiddeldorpS , PrinsMP , PapAF , LensingAW , Hoek-tenCA , et al. Post thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep vein thrombosis. Journal of Thrombosis and Haemostasis2015;13(S2):219-20. CheungYW , MiddeldorpS , PrinsMH , PapAF , PrandoniP . Post-thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep-vein thrombosis. A post-hoc analysis. Thrombosis and Haemostasis2016;116(4):733-8. EUCTR2004-002171-16-IT. Once-daily oral direct factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis. The EINSTEIN-DVT dose-finding study. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2004%E2%80%90002171%E2%80%9016%E2%80%90IT (first received 15 October 2008). EUCTR2006-004495-13-DK. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep-vein thrombosis or pulmonary embolism. trialsearch.who.int/?TrialID=EUCTR2006-004495-13-DK (first received 29 March 2007). EerenbergES , MiddeldorpS , LeviM , LensingAW , BüllerHR . Clinical impact and course of major bleeding with rivaroxaban and vitamin K antagonists. Journal of Thrombosis and Haemostasis2015;13(9):1590-6. KlineJA , JimenezD , CourtneyDM , IanusJ , CaoL , WellsPS . Use of the Riete 2008 bleeding score to identify patients at low risk for major bleeding in patients treated with rivaroxaban. Academic Emergency Medicine2015;22:S162. NCT00440193. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep vein thrombosis - The EINSTEIN DVT Study. clinicaltrials.gov/ct2/show/NCT00440193 (first received 26 February 2007). PrinsMH , ErkensPG , LensingAW . Incidence of recurrent venous thromboembolism in patients following completion of the EINSTEIN DVT and EINSTEIN PE studies. Journal of Thrombosis and Haemostasis2013;11(Suppl):257. PrinsMH , LensingAW , BauersachsR , Van BellenB , BounameauxH , BrightonTA , et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thrombosis Journal2013;11(1):21. The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. New England Journal of Medicine2010;363(26):2499-510. Van BellenB , PrinsM , BamberL , WangM , LensingAW . Reduction in initial length of stay with rivaroxaban single-drug regimen versus LMWH-VKA standard of care: findings from the EINSTEIN trial program. Blood2012;120(21):3419. Van BellenB , PrinsM , BamberL , WangM , LensingAW . Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism. Current Medical Research and Opinion2014;30(5):829-37. WangY , WangC , ChenZ , ZhangJ , LiuZ , JinB , et al. Rivaroxaban for the treatment of symptomatic deep vein thrombosis and/or pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):694. WangY , WangC , ChenZ , ZhangJ , LiuZ , JinB , et al. Rivaroxaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Thrombosis Journal2013;11(1):25. ">EINSTEIN‐DVT 2010</a>; <a href="./references#CD010956-bbs2-0009" title="PiazzaG , ManiV , GoldhaberSZ , GrossoMA , MercuriM , LanzHJ , et al. Magnetic resonance venography to assess thrombus resolution with edoxaban monotherapy versus parenteral anticoagulation/warfarin for symptomatic deep vein thrombosis: a multicenter feasibility study. Vascular Medicine2016;21(4):361-8. PiazzaG , ManiV , GrossoM , MercuriM , LanzH , SchusslerS , et al. A randomized, open-label, multicenter study of the efficacy and safety of edoxaban monotherapy versus low-molecular weight heparin/warfarin in patients with symptomatic deep vein thrombosis-edoxaban thrombus reduction imaging study (etris). Circulation2014;130:A12074. ">eTRIS 2016</a>; <a href="./references#CD010956-bbs2-0010" title="FarhanA , BukhariM , UmarJ , RazaMA . Oral rivaroxaban in symptomatic deep vein thrombosis. Journal of the College of Physicians and Surgeons Pakistan2019;29(9):814-8. ">Farhan 2019</a>; <a href="./references#CD010956-bbs2-0012" title="AmayaN , UzuiH , HisazakiK , HasegwaK , KasenoK , TadaH . Edoxaban normalizes the elevated D-dimer levels potently and promptly in patients with venous thromboembolisms: a comparison with traditional anticoagulant therapy. European Heart Journal2016;37:278. BoschFT , Van EsN , Di NisioM , CarrierM , SegersA , GrossoMA , et al. The Ottawa score does not predict recurrent venous thromboembolism in cancer patients: results from the Hokusai-VTE cancer study. Research and Practice in Thrombosis and Haemostasis2019;3(S1):717-8. KraaijpoelN , Di NisioM , MulderFI , Van EsN , RaskobGE . Clinical impact of bleeding in cancer-associated venous thromboembolism: results from the Hokusai VTE Cancer randomized trial. Thrombosis Research2018;164(Suppl 1):S223. [DOI: 10.1016/j.thromres.2018.02.094]MulderFI , Di NisioM , AyC , CarrierM , BoschFT , SegersA , et al. Clinical implications of incidental venous thromboembolism in cancer patients. European Respiratory Journal2020;55(2):1901697. [DOI: 10.1183/13993003.01697-2019]MulderFI , Van EsN , KraaijpoelN , Di NisioM , CarrierM , GarciaD , et al. Efficacy and safety of edoxaban in clinically relevant subgroups: results from the Hokusai VTE Cancer randomized trial. Thrombosis Research2018;164:S194. NCT02073682. Cancer venous thromboembolism (VTE). clinicaltrials.gov/ct2/show/NCT02073682 (first received 27 February 2014). RaskobG , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaD , et al. Edoxaban versus dalteparin for treatment of venous thromboembolism (VTE) associated with cancer: Hokusai VTE-cancer randomized trial. Supportive Care in Cancer2018;26(2):S316-S317. RaskobGE , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaD , et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. New England Journal of Medicine2018;378(7):615-24. RaskobGE , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaDA , et al. A randomized, open-label, blinded outcome assessment trial evaluating the efficacy and safety of LMWH/Edoxaban versus dalteparin for venous thromboembolism associated with cancer: Hokusai VTE-cancer study. Blood2017;130(Suppl 1):LBA-6. ">Hokusai VTE Cancer 2018</a>; <a href="./references#CD010956-bbs2-0011" title="BistervelsI , BavaliaR , BoersmaW , MeijerK , VerhammeP , Ten Cate-HoekAJ , et al. Hokusai Post-DVT Study: a follow-up study on long-term outcomes of deep vein thrombosis in patients treated with edoxaban vs warfarin. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):PB2207. BrekelmansMP , AgenoW , BeenenLF , BrennerB , BullerHR , ChenCZ , et al. Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology2016;3(9):e437-45. BrekelmansMP , BlekerSM , BauersachsR , BodaZ , BüllerHR , ChoiY , et al. Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists. Thrombosis and Haemostasis2016;116(1):155-61. Di NisioM , Van EsN , CarrierM , WangTF , GarciaD , SegersA , et al. Extended treatment with edoxaban in cancer patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE Cancer study. Journal of Thrombosis and Haemostasis2019;17:1866–74. EUCTR2009-014290-40-SE. A phase 3, randomized, double-blind, double-dummy, parallel group, multi-center, multi-national study for evaluation of efficacy and safety of DU-176b versus warfarin in subjects with atrial fibrillation - effective anticoagulation with factor Xa next generation in atrial fibrillation (ENGAGE-AF TIMI-48). trialsearch.who.int/?trialid=EUCTR2009-014290-40-SE (first received 30 November 2009). EichingerS , LinM , KyrlePA , GrossoMA . Recurrent venous thromboembolism during anticoagulation: an investigator-initiated post-hoc analysis of the hokusai-VTE trial. Blood2018;132:2539. KlokFA , BarcoS , KonstantinidesSV . External validation of the VTE-BLEED score for predicting major bleeding in stable anticoagulated patients with venous thromboembolism. Thrombosis and Haemostasis2017;117(6):1164-70. KraaijpoelN , Van EsN , RaskobGE , BüllerHR , CarrierM , ZhangG , et al. Risk scores for occult cancer in patients with venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2018;118(7):1270-8. MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMP , ChenCZ , et al. Outpatient management in patients with venous thromboembolism with edoxaban: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2017;117(12):2406-14. MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMP , ChenCZ , et al. Safety and efficacy of edoxaban compared with warfarin for the treatment of acute symptomatic deep-vein thrombosis in the outpatient setting. Research and Practice in Thrombosis and Haemostasis2017;1:913. MulderFI , Van EsN , KraaijpoelN , Di NisioM , CarrierM , DuggalA , et al. Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: results from the Hokusai VTE Cancer study. Thrombosis Research2020;185:13-9. NCT00986154. Comparative investigation of Low Molecular Weight (LMW) heparin/edoxaban tosylate (DU176b) versus (LMW) heparin/warfarin in the treatment of symptomatic deep-vein blood clots and/or lung blood clots. (The Edoxaban Hokusai-VTE Study). clinicaltrials.gov/ct2/show/NCT00986154 (first received 29 September 2009). NakamuraM , WangYQ , WangC , OhD , YinWH , KimuraT , et al. Efficacy and safety of edoxaban for treatment of venous thromboembolism: a subanalysis of East Asian patients in the Hokusai-VTE trial. Journal of Thrombosis and Haemostasis2015;13(9):1606-14. NybergJ , KarlssonKE , JönssonS , YinO , MillerR , KarlssonMO , et al. Edoxaban exposure-response analysis and clinical utility index assessment in patients with symptomatic deep-vein thrombosis or pulmonary embolism. CPT Pharmacometrics and Systems Pharmacology2016;5(4):222-32. RaskobG , AgenoW , CohenAT , BrekelmansMP , GrossoMA , SegersA , et al. Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology2016;3(5):e228-e236. RaskobG , BullerH , PrinsM , SegersA , ShiM , SchwochoL , et al. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study - methodological implications for clinical trials. Journal of Thrombosis and Haemostasis2013;11(7):1287-94. RaskobGE , BullerH , AngchaisuksiriP , OhD , BodaZ , LyonsRM , et al. Edoxaban for long-term treatment of venous thromboembolism in cancer patients. Blood2013;122(21):211. RaskobGE , Van EsN , SegersA , AngchaisuksiriP , OhD , BodaZ , et al. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematology2016;3(8):e379-87. ScheresLJ , BrekelmansMA , WalterA , CihanA , BüllerHR , SabineE , et al. Abnormal vaginal bleeding in women of reproductive age treated with edoxaban or warfarin for venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. British Journal of Obstetrics and Gynaecology2018;125(12):1581-9. The Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. New England Journal of Medicine2013;369(15):1406-15. VanasscheT , VerhammeP , WellsPS , SegersA , AgenoW , BrekelmansMP , et al. Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: an analysis of the randomized, double-blind Hokusai-VTE trial. Thrombosis Research2018;162:7-14. VerhammeP , WellsPS , SegersA , AgenoW , BrekelmansMP , CohenAT , et al. Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial. Thrombosis and Haemostasis2016;116(4):747-53. ">Hokusai‐VTE 2013</a>; <a href="./references#CD010956-bbs2-0014" title="MokademME , HassanA , AlgabyAZ . Efficacy and safety of apixaban in patients with active malignancy and acute deep venous thrombosis. Vascular2021;29(5):745-50. NCT04462003. Efficacy of apixaban in malignancy with deep venous thrombosis (DVT). clinicaltrials.gov/ct2/show/NCT04462003 (first received 3 July 2019). ">Mokadem 2021</a>; <a href="./references#CD010956-bbs2-0016" title="OhmoriH , KadaA , NakamuraM , SaitoAM , SanayamaY , ShinagawaT , et al. Deep vein thrombosis in severe motor and intellectual disabilities patients and its treatment by anticoagulants of warfarin versus edoxaban. Annals of Vascular Diseases2019;12(3):372-8. OhmoriH , NakamuraM , KadaA , SaitoAM , SanayamaY , ShinagawaT , et al. Multicenter, open-label, randomized controlled trial of warfarin and edoxaban tosilate hydrate for the treatment of deep vein thrombosis in persons with severe motor intellectual disabilities. Kurume Medical Journal2018;65(1):11-6. ">Ohmori 2019</a>; <a href="./references#CD010956-bbs2-0017" title="Kang JiM, ParkKH , AhnS , ChoS , MinSK . Rivaroxaban after thrombolysis in acute iliofemoral venous thrombosis: a randomized, open-labeled, multicenter trial. Scientific Reports2019;9(1):20356. MinSK , AhnS , ParkKH , KangJM , KimJY . Prevention of recurrence after thrombolysis in acute iliofemoral venous thrombosis with rivaroxaban (Prais Study): a prospective, randomized, open label, multicenter trial. European Journal of Vascular and Endovascular Surgery2019;58(6):e516. NCT01986192. Prevention of recurrence after thrombolysis in acute iliofemoral venous thrombosis (PRAIS) study. clinicaltrials.gov/show/NCT01986192 (first received 18 November 2013). ">PRAIS 2019</a>; <a href="./references#CD010956-bbs2-0020" title="SukovatykhBS , SereditskiĭAV , MuradianVF , BelikovLN , GerasimovaOF . Results of administering oral anticoagulants for treatment of patients with venous thromboembolic complications. Angiologiia i sosudistaia khirurgiia [Angiology and Vascular Surgery]2017;23(2):82. ">Sukovatykh 2017</a>). The control treatment was heparin combined with VKA in 12 studies (<a href="./references#CD010956-bbs2-0001" title="AgnelliG , BullerH , MasiukiewiczUP . Apixaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism: a randomized, double-blind trial (AMPLIFY). Journal of Thrombosis and Haemostasis2013;11:18. AgnelliG , BullerHR , CohenA , CurtoD , GallusAS , JohnsonM , et al. Oral apixaban for the treatment of acute venous thromboembolism. New England Journal of Medicine2013;369:799-808. AgnelliG , BullerHR , CohenA , CurtoM , GallusAS , PakR , et al. Apixaban for the treatment of venous thromboembolism in cancer patients: data from the AMPLIFY trial. Canadian Journal of Cardiology2014;30(10 Suppl 1):S278. AgnelliG , BullerHR , CohenA , GallusAS , LeeTC , PakR , et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. Journal of Thrombosis and Haemostasis2015;13(12):2187-91. AgnelliG . Apixaban was non-inferior to enoxaparin plus warfarin in patients with acute venous thromboembolism. Annals of Internal Medicine2013;159(8):JC2. BlekerSM , CohenAT , BüllerHR , AgnelliG , GallusAS , RaskobGE , et al. Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Thrombosis and Haemostasis2016;116(6):159-64. BrekelmansM , ScheresL , BlekerS , HuttenB , TimmermansA , BüllerH , et al. Abnormal vaginal bleeding in women with venous thromboembolism treated with apixaban or warfarin. Thrombosis and Haemostasis2017;117(04):809-15. CohenA , AgnelliG , BullerH , GallusA , RaskobG , SandersP , et al. Characteristics and outcomes in patients with venous thromboembolism taking concomitant anti-platelet agents and anticoagulants in the AMPLIFY Trial. Thrombosis and Haemostasis2019;119(3):461-6. CohenA , AgnelliG , BullerHR , ChaudhuriS , GallusAS , RaskobGE , et al. Analysis of the bleeding and thromboembolic risk with concomitant use of antiplatelet treatment in the AMPLIFY trial. Canadian Journal of Cardiology2014;30(10):S272. CohenA , GallusAS , AgnelliG , BullerHR , PakR , PorcariAR , et al. Time in Therapeutic Range (TTR) and relative efficacy and safety of treatment with apixaban or enoxaparin/warfarin for acute symptomatic venous thromboembolism: an analysis of the Amplify trial data. Blood2014;124(21):1543. CohenAT , PanS , ByonW , IlyasBS , LeeTC . Efficacy, safety, and exposure of apixaban in patients with high body weight or obesity and venous thromboembolism: insights from AMPLIFY. Advances in Therapy2021;38(6):3003-18. EUCTR2007-007867-25-PT. A safety and efficacy trial evaluating the use of apixaban in the treatment of symptomatic deep vein thrombosis and pulmonary embolism revised protocol number: 01, incorporates amendment(s) 02 + protocol amendment 01 (version 1.0 dated 21-Apr-08) site-specific - molecular profiling supplement samples for Pfizer’s exploratory research biobank. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2007%E2%80%90007867%E2%80%9025%E2%80%90PT (first received 14 July 2008). GallusAS , AgnelliG , BullerHR , CohenA , LeeTC , PakR , et al. Apixaban for treatment of venous thromboembolism in patients from study centres in Asia: a subgroup analysis of the Amplify trial. Journal of Thrombosis and Haemostasis2015;13:727. LeeT , PanS , ByonW , IlyasBS . Safety and efficacy of apixaban versus enoxaparin/warfarin in patients with extremes of body weight: post-hoc analysis of the AMPLIFY trial. Blood2019;134(Suppl 1):1152. LiuX , JohnsonM , MardekianJ , PhatakH , ThompsonJ , CohenAT . Apixaban reduces hospitalizations in patients with venous thromboembolism: an analysis of the apixaban for the Initial management of pulmonary embolism and deep‐vein thrombosis as first‐line therapy (AMPLIFY) trial. Journal of the American Heart Association2015;4(12):e002340. NCT00633893. Efficacy and safety study of apixaban for extended treatment of deep vein thrombosis or pulmonary embolism. clinicaltrials.gov/ct2/show/NCT00633893?term=ajax&amp;rank=5 (first received 12 March 2008). NCT00643201. Efficacy and safety study of apixaban for the treatment of deep vein thrombosis or pulmonary embolism. clinicaltrials.gov/ct2/show/NCT00643201 (first received 26 March 2008). RaskobGE , GallusAS , SandersP , ThompsonJR , AgnelliG , BullerHR , et al. Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy: a sub-analysis of the AMPLIFY trial. Thrombosis and Haemostasis2016;115(4):809-16. ">AMPLIFY 2013</a>; <a href="./references#CD010956-bbs2-0002" title="NakamuraM , NishikawaM , KomuroI , KitajimaI , UetsukaY , YamagamiT , et al. Apixaban for the treatment of Japanese subjects with acute venous thromboembolism (AMPLIFY-J Study). Circulation2015;79(6):1230–36. ">AMPLIFY‐J 2015</a>; <a href="./references#CD010956-bbs2-0003" title="BarrettYC , WangJ , KnabbR , MohanP . Apixaban decreases coagulation activity in patients with acute deep-vein thrombosis. Thrombosis and Haemostasis2011;105:181-9. Botticelli Investigators Writing Committee, BullerH , DeitchmanD , PrinsM , SegersA . Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. Journal of Thrombosis and Haemostasis2008;6:1313-8. BullerHR . A dose finding study of the oral direct factor Xa inhibitor apixaban in the treatment of patients with acute symptomatic deep vein thrombosis - the Botticelli Investigators. Journal of Thrombosis and Haemostasis2007;5 (Suppl 2):O-S-003. NCT00252005. Oral direct factor Xa-inhibitor apixaban in patients with acute symptomatic deep-vein thrombosis - the Botticelli DVT study. clinicaltrials.gov/ct/show/NCT00252005?order=1 (first received 11 November 2005). ">Botticelli DVT 2008</a>; <a href="./references#CD010956-bbs2-0007" title="BullerH , DariusH . EINSTEIN DVT: oral rivaroxaban versus standard therapy in the initial treatment of symptomatic deep vein thrombosis and long-term prevention of recurrent venous thromboembolism. escardio.org/The-ESC/Press-Office/Press-releases/EINSTEIN-DVT-Oral-rivaroxaban-versus-standard-therapy-in-the-initial-treatment (accessed 19 October 2022). BullerHR , AgnelliG . Once- or twice-daily rivaroxaban for the treatment of proximal deep vein thrombosis: similar efficacy and safety to standard therapy in dose-ranging studies. Blood2006;108(11 Part 1):172-3. BullerHR , LensingAW , PrinsMH , AgnelliG , CohenA , GallusAS , et al. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT dose-ranging study. Blood2008;112(6):2242-7. NCT00395772. Once-daily oral direct factor Xa inhibitor BAY59-7939 in patients with acute symptomatic deep-vein thrombosis. clinicaltrials.gov/ct2/show/NCT00395772?term=einstein-dvt&amp;rank=2 (first received 3 November 2006). ">EINSTEIN‐DVT dose 2008</a>; <a href="./references#CD010956-bbs2-0006" title="BamberL , WangMY , PrinsMH , CiniglioC , BauersachsR , LensingAW , et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis. Thrombosis and Haemostasis2013;110(4):732-41. BauersachsR , LensingAW , PapA , DecoususH . No need for a rivaroxaban dose reduction in renally impaired patients with symptomatic venous thromboembolism. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):30-1. BistervelsI , GebelM , LensingA , MiddeldorpS , CoppensM . Effect of polypharmacy on bleeding of rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolism. Research and Practice in Thrombosis and Haemostasis2019;3:798‐9. BookhartBK , HaskellL , BamberL , WangM , ScheinJ , ModySH . Length of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial program. Journal of Medical Economics2014;17(10):691-5. BullerHR . Oral rivaroxaban for the acute and continued treatment of symptomatic venous thromboembolism. The Einstein-DVT and Einstein-Extension study. Blood2010;116(21):187. CheungW , MiddeldorpS , PrinsMP , PapAF , LensingAW , Hoek-tenCA , et al. Post thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep vein thrombosis. Journal of Thrombosis and Haemostasis2015;13(S2):219-20. CheungYW , MiddeldorpS , PrinsMH , PapAF , PrandoniP . Post-thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep-vein thrombosis. A post-hoc analysis. Thrombosis and Haemostasis2016;116(4):733-8. EUCTR2004-002171-16-IT. Once-daily oral direct factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis. The EINSTEIN-DVT dose-finding study. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2004%E2%80%90002171%E2%80%9016%E2%80%90IT (first received 15 October 2008). EUCTR2006-004495-13-DK. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep-vein thrombosis or pulmonary embolism. trialsearch.who.int/?TrialID=EUCTR2006-004495-13-DK (first received 29 March 2007). EerenbergES , MiddeldorpS , LeviM , LensingAW , BüllerHR . Clinical impact and course of major bleeding with rivaroxaban and vitamin K antagonists. Journal of Thrombosis and Haemostasis2015;13(9):1590-6. KlineJA , JimenezD , CourtneyDM , IanusJ , CaoL , WellsPS . Use of the Riete 2008 bleeding score to identify patients at low risk for major bleeding in patients treated with rivaroxaban. Academic Emergency Medicine2015;22:S162. NCT00440193. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep vein thrombosis - The EINSTEIN DVT Study. clinicaltrials.gov/ct2/show/NCT00440193 (first received 26 February 2007). PrinsMH , ErkensPG , LensingAW . Incidence of recurrent venous thromboembolism in patients following completion of the EINSTEIN DVT and EINSTEIN PE studies. Journal of Thrombosis and Haemostasis2013;11(Suppl):257. PrinsMH , LensingAW , BauersachsR , Van BellenB , BounameauxH , BrightonTA , et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thrombosis Journal2013;11(1):21. The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. New England Journal of Medicine2010;363(26):2499-510. Van BellenB , PrinsM , BamberL , WangM , LensingAW . Reduction in initial length of stay with rivaroxaban single-drug regimen versus LMWH-VKA standard of care: findings from the EINSTEIN trial program. Blood2012;120(21):3419. Van BellenB , PrinsM , BamberL , WangM , LensingAW . Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism. Current Medical Research and Opinion2014;30(5):829-37. WangY , WangC , ChenZ , ZhangJ , LiuZ , JinB , et al. Rivaroxaban for the treatment of symptomatic deep vein thrombosis and/or pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):694. WangY , WangC , ChenZ , ZhangJ , LiuZ , JinB , et al. Rivaroxaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Thrombosis Journal2013;11(1):25. ">EINSTEIN‐DVT 2010</a>; <a href="./references#CD010956-bbs2-0008" title="BullerHR , PrinsMH , LensinAW , DecoususH , JacobsonBF , MinarE , et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. New England Journal of Medicine2012;366:1287-97. FermannGJ , Erkens Pmg, PrinsMH , WellsPS , Pap ÁF, LensingAW , et al. Treatment of pulmonary embolism with rivaroxaban: outcomes by simplified pulmonary embolism severity index score from a post hoc analysis of the EINSTEIN PE study. Academic Emergency Medicine2015;22(3):299-307. NCT00439777. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic pulmonary embolism with or without symptomatic deep-vein thrombosis: Einstein-PE evaluation, 2008. clinicaltrials.gov/ct2/show/NCT00439777?term=NCT00439777&amp;rank=1 (first received 26 February 2007). PrinsM , BamberL , CanoS , WangM , LensingAW , BauersachsR . Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic pulmonary embolism. Blood2012;120(21):1163. PrinsMH , BamberL , CanoSJ , WangMY , ErkensP , BauersachsR , et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial. Thrombosis Research2015;135(2):281-8. ">EINSTEIN‐PE 2012</a>; <a href="./references#CD010956-bbs2-0009" title="PiazzaG , ManiV , GoldhaberSZ , GrossoMA , MercuriM , LanzHJ , et al. Magnetic resonance venography to assess thrombus resolution with edoxaban monotherapy versus parenteral anticoagulation/warfarin for symptomatic deep vein thrombosis: a multicenter feasibility study. Vascular Medicine2016;21(4):361-8. PiazzaG , ManiV , GrossoM , MercuriM , LanzH , SchusslerS , et al. A randomized, open-label, multicenter study of the efficacy and safety of edoxaban monotherapy versus low-molecular weight heparin/warfarin in patients with symptomatic deep vein thrombosis-edoxaban thrombus reduction imaging study (etris). Circulation2014;130:A12074. ">eTRIS 2016</a>; <a href="./references#CD010956-bbs2-0010" title="FarhanA , BukhariM , UmarJ , RazaMA . Oral rivaroxaban in symptomatic deep vein thrombosis. Journal of the College of Physicians and Surgeons Pakistan2019;29(9):814-8. ">Farhan 2019</a>; <a href="./references#CD010956-bbs2-0011" title="BistervelsI , BavaliaR , BoersmaW , MeijerK , VerhammeP , Ten Cate-HoekAJ , et al. Hokusai Post-DVT Study: a follow-up study on long-term outcomes of deep vein thrombosis in patients treated with edoxaban vs warfarin. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):PB2207. BrekelmansMP , AgenoW , BeenenLF , BrennerB , BullerHR , ChenCZ , et al. Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology2016;3(9):e437-45. BrekelmansMP , BlekerSM , BauersachsR , BodaZ , BüllerHR , ChoiY , et al. Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists. Thrombosis and Haemostasis2016;116(1):155-61. Di NisioM , Van EsN , CarrierM , WangTF , GarciaD , SegersA , et al. Extended treatment with edoxaban in cancer patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE Cancer study. Journal of Thrombosis and Haemostasis2019;17:1866–74. EUCTR2009-014290-40-SE. A phase 3, randomized, double-blind, double-dummy, parallel group, multi-center, multi-national study for evaluation of efficacy and safety of DU-176b versus warfarin in subjects with atrial fibrillation - effective anticoagulation with factor Xa next generation in atrial fibrillation (ENGAGE-AF TIMI-48). trialsearch.who.int/?trialid=EUCTR2009-014290-40-SE (first received 30 November 2009). EichingerS , LinM , KyrlePA , GrossoMA . Recurrent venous thromboembolism during anticoagulation: an investigator-initiated post-hoc analysis of the hokusai-VTE trial. Blood2018;132:2539. KlokFA , BarcoS , KonstantinidesSV . External validation of the VTE-BLEED score for predicting major bleeding in stable anticoagulated patients with venous thromboembolism. Thrombosis and Haemostasis2017;117(6):1164-70. KraaijpoelN , Van EsN , RaskobGE , BüllerHR , CarrierM , ZhangG , et al. Risk scores for occult cancer in patients with venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2018;118(7):1270-8. MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMP , ChenCZ , et al. Outpatient management in patients with venous thromboembolism with edoxaban: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2017;117(12):2406-14. MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMP , ChenCZ , et al. Safety and efficacy of edoxaban compared with warfarin for the treatment of acute symptomatic deep-vein thrombosis in the outpatient setting. Research and Practice in Thrombosis and Haemostasis2017;1:913. MulderFI , Van EsN , KraaijpoelN , Di NisioM , CarrierM , DuggalA , et al. Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: results from the Hokusai VTE Cancer study. Thrombosis Research2020;185:13-9. NCT00986154. Comparative investigation of Low Molecular Weight (LMW) heparin/edoxaban tosylate (DU176b) versus (LMW) heparin/warfarin in the treatment of symptomatic deep-vein blood clots and/or lung blood clots. (The Edoxaban Hokusai-VTE Study). clinicaltrials.gov/ct2/show/NCT00986154 (first received 29 September 2009). NakamuraM , WangYQ , WangC , OhD , YinWH , KimuraT , et al. Efficacy and safety of edoxaban for treatment of venous thromboembolism: a subanalysis of East Asian patients in the Hokusai-VTE trial. Journal of Thrombosis and Haemostasis2015;13(9):1606-14. NybergJ , KarlssonKE , JönssonS , YinO , MillerR , KarlssonMO , et al. Edoxaban exposure-response analysis and clinical utility index assessment in patients with symptomatic deep-vein thrombosis or pulmonary embolism. CPT Pharmacometrics and Systems Pharmacology2016;5(4):222-32. RaskobG , AgenoW , CohenAT , BrekelmansMP , GrossoMA , SegersA , et al. Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology2016;3(5):e228-e236. RaskobG , BullerH , PrinsM , SegersA , ShiM , SchwochoL , et al. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study - methodological implications for clinical trials. Journal of Thrombosis and Haemostasis2013;11(7):1287-94. RaskobGE , BullerH , AngchaisuksiriP , OhD , BodaZ , LyonsRM , et al. Edoxaban for long-term treatment of venous thromboembolism in cancer patients. Blood2013;122(21):211. RaskobGE , Van EsN , SegersA , AngchaisuksiriP , OhD , BodaZ , et al. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematology2016;3(8):e379-87. ScheresLJ , BrekelmansMA , WalterA , CihanA , BüllerHR , SabineE , et al. Abnormal vaginal bleeding in women of reproductive age treated with edoxaban or warfarin for venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. British Journal of Obstetrics and Gynaecology2018;125(12):1581-9. The Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. New England Journal of Medicine2013;369(15):1406-15. VanasscheT , VerhammeP , WellsPS , SegersA , AgenoW , BrekelmansMP , et al. Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: an analysis of the randomized, double-blind Hokusai-VTE trial. Thrombosis Research2018;162:7-14. VerhammeP , WellsPS , SegersA , AgenoW , BrekelmansMP , CohenAT , et al. Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial. Thrombosis and Haemostasis2016;116(4):747-53. ">Hokusai‐VTE 2013</a>; <a href="./references#CD010956-bbs2-0013" title="MatsuoH , PrinsM , LensingAW , FujinumaEW , MiyamotoY , KajikawaM . Shortened length of hospital stay with rivaroxaban in patients with symptomatic venous thromboembolism in Japan: the J-EINSTEIN pulmonary embolism and deep vein thrombosis program. Current Medical Research and Opinion2015;31(6):1057-61. NCT01516814. Venous thromboembolism (VTE) treatment study in Japanese pulmonary embolism (PE) patients. clinicaltrials.gov/ct2/show/NCT01516814 (first received 25 January 2012). YamadaN , HirayamaA , MaedaH , SakagamiS , ShikataH , PrinsMH , et al. Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism-the J-EINSTEIN DVT and PE program. Thrombosis Journal2015;13:2. ">J‐EINSTEIN DVT and PE 2015</a>; <a href="./references#CD010956-bbs2-0015" title="AgnelliG , GallusA , GoldhaberSZ , HaasS , HuismanMV , HullRD , et al. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAT 59-7939 in patients with acute symptomatic deep-vein thrombosis) study. Circulation2007;116:180-7. ">ODIXa‐DVT 2007</a>; <a href="./references#CD010956-bbs2-0017" title="Kang JiM, ParkKH , AhnS , ChoS , MinSK . Rivaroxaban after thrombolysis in acute iliofemoral venous thrombosis: a randomized, open-labeled, multicenter trial. Scientific Reports2019;9(1):20356. MinSK , AhnS , ParkKH , KangJM , KimJY . Prevention of recurrence after thrombolysis in acute iliofemoral venous thrombosis with rivaroxaban (Prais Study): a prospective, randomized, open label, multicenter trial. European Journal of Vascular and Endovascular Surgery2019;58(6):e516. NCT01986192. Prevention of recurrence after thrombolysis in acute iliofemoral venous thrombosis (PRAIS) study. clinicaltrials.gov/show/NCT01986192 (first received 18 November 2013). ">PRAIS 2019</a>), LMWH in three studies (<a href="./references#CD010956-bbs2-0004" title="AgenoW , VedovatiMC , CohenA , HuismanM , BauersachsR , GussoniG , et al. Bleeding with apixaban and dalteparin in patients with cancer-associated venous thromboembolism: results from the Caravaggio study. Thrombosis and Haemostasis2021;121(5):616-24. AgnelliG , BecattiniC , BauersachsR , BrennerB , CampaniniM , CohenA , et al. Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the Caravaggio study. Thrombosis and Haemostasis2018;118(9):1668-78. AgnelliG , BecattiniC , MeyerG , MuozA , VersoM . Apixaban for the treatment of venous thromboembolism associated with cancer. New England Journal of Medicine2020;382(17):1599-607. AgnelliG , MuozA , FrancoL , MahéI , BrennerB , ConnorsJM , et al. Apixaban and dalteparin for the treatment of venous thromboembolism in patients with different sites of cancer. Thrombosis and Haemostasis2022;122(5):796-807. BecattiniC , BauersachsR , MarazitiG , BertolettiL , CohenA , ConnorsJM , et al. Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial. Haematologica2021;107(7):1567-76. GiustozziM , ConnorsJM , Ruperez BlancoAB , SzmitS , FalvoN , CohenAT , et al. Clinical characteristics and outcomes of incidental venous thromboembolism in cancer patients: insights from the Caravaggio study. Journal of Thrombosis and Haemostasis2021;19(11):2751-9. NCT03045406. Apixaban for the treatment of venous thromboembolism in patients with cancer (CARAVAGGIO). clinicaltrials.gov/ct2/show/NCT03045406 (first received 7 February 2017). VersoM , MunozA , BauersachsR , HuismanMV , AgnelliG . Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism. European Journal of Cancer2021;148(Suppl C):371-81. ">Caravaggio 2020</a>; <a href="./references#CD010956-bbs2-0012" title="AmayaN , UzuiH , HisazakiK , HasegwaK , KasenoK , TadaH . Edoxaban normalizes the elevated D-dimer levels potently and promptly in patients with venous thromboembolisms: a comparison with traditional anticoagulant therapy. European Heart Journal2016;37:278. BoschFT , Van EsN , Di NisioM , CarrierM , SegersA , GrossoMA , et al. The Ottawa score does not predict recurrent venous thromboembolism in cancer patients: results from the Hokusai-VTE cancer study. Research and Practice in Thrombosis and Haemostasis2019;3(S1):717-8. KraaijpoelN , Di NisioM , MulderFI , Van EsN , RaskobGE . Clinical impact of bleeding in cancer-associated venous thromboembolism: results from the Hokusai VTE Cancer randomized trial. Thrombosis Research2018;164(Suppl 1):S223. [DOI: 10.1016/j.thromres.2018.02.094]MulderFI , Di NisioM , AyC , CarrierM , BoschFT , SegersA , et al. Clinical implications of incidental venous thromboembolism in cancer patients. European Respiratory Journal2020;55(2):1901697. [DOI: 10.1183/13993003.01697-2019]MulderFI , Van EsN , KraaijpoelN , Di NisioM , CarrierM , GarciaD , et al. Efficacy and safety of edoxaban in clinically relevant subgroups: results from the Hokusai VTE Cancer randomized trial. Thrombosis Research2018;164:S194. NCT02073682. Cancer venous thromboembolism (VTE). clinicaltrials.gov/ct2/show/NCT02073682 (first received 27 February 2014). RaskobG , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaD , et al. Edoxaban versus dalteparin for treatment of venous thromboembolism (VTE) associated with cancer: Hokusai VTE-cancer randomized trial. Supportive Care in Cancer2018;26(2):S316-S317. RaskobGE , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaD , et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. New England Journal of Medicine2018;378(7):615-24. RaskobGE , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaDA , et al. A randomized, open-label, blinded outcome assessment trial evaluating the efficacy and safety of LMWH/Edoxaban versus dalteparin for venous thromboembolism associated with cancer: Hokusai VTE-cancer study. Blood2017;130(Suppl 1):LBA-6. ">Hokusai VTE Cancer 2018</a>; <a href="./references#CD010956-bbs2-0014" title="MokademME , HassanA , AlgabyAZ . Efficacy and safety of apixaban in patients with active malignancy and acute deep venous thrombosis. Vascular2021;29(5):745-50. NCT04462003. Efficacy of apixaban in malignancy with deep venous thrombosis (DVT). clinicaltrials.gov/ct2/show/NCT04462003 (first received 3 July 2019). ">Mokadem 2021</a>), and VKA in three studies (<a href="./references#CD010956-bbs2-0005" title="NCT02704598. Comparison between xarelto versus warfarin in the recanalization rate of deep venous thrombosis in patients legs. (DVT). clinicaltrials.gov/ct2/show/NCT02704598 (first received 10 March 2016). deAthayde SoaresR , MatieloMF , Brochado NetoFC , AlmeidaRD , SacilottoR . LEV 2. Comparison of the recanalization rate and post-thrombotic syndrome in patients with deep venous thrombosis treated with rivaroxaban or warfarin. Journal of Vascular Surgery2019;70(5):e169-e170. deAthayde SoaresR , MatieloMF , Brochado NetoFC , NogueiraMP , AlmeidaRD , SacilottoR . Comparison of the recanalization rate and postthrombotic syndrome in patients with deep venous thrombosis treated with rivaroxaban or warfarin. Surgery2019;166(6):1076-83. ">de Athayde 2019</a>; <a href="./references#CD010956-bbs2-0016" title="OhmoriH , KadaA , NakamuraM , SaitoAM , SanayamaY , ShinagawaT , et al. Deep vein thrombosis in severe motor and intellectual disabilities patients and its treatment by anticoagulants of warfarin versus edoxaban. Annals of Vascular Diseases2019;12(3):372-8. OhmoriH , NakamuraM , KadaA , SaitoAM , SanayamaY , ShinagawaT , et al. Multicenter, open-label, randomized controlled trial of warfarin and edoxaban tosilate hydrate for the treatment of deep vein thrombosis in persons with severe motor intellectual disabilities. Kurume Medical Journal2018;65(1):11-6. ">Ohmori 2019</a>; <a href="./references#CD010956-bbs2-0020" title="SukovatykhBS , SereditskiĭAV , MuradianVF , BelikovLN , GerasimovaOF . Results of administering oral anticoagulants for treatment of patients with venous thromboembolic complications. Angiologiia i sosudistaia khirurgiia [Angiology and Vascular Surgery]2017;23(2):82. ">Sukovatykh 2017</a>). <a href="./references#CD010956-bbs2-0020" title="SukovatykhBS , SereditskiĭAV , MuradianVF , BelikovLN , GerasimovaOF . Results of administering oral anticoagulants for treatment of patients with venous thromboembolic complications. Angiologiia i sosudistaia khirurgiia [Angiology and Vascular Surgery]2017;23(2):82. ">Sukovatykh 2017</a> was a three‐arm trial comparing dabigatran, rivaroxaban and warfarin. Duration of treatment was 12 weeks in five studies (<a href="./references#CD010956-bbs2-0003" title="BarrettYC , WangJ , KnabbR , MohanP . Apixaban decreases coagulation activity in patients with acute deep-vein thrombosis. Thrombosis and Haemostasis2011;105:181-9. Botticelli Investigators Writing Committee, BullerH , DeitchmanD , PrinsM , SegersA . Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. Journal of Thrombosis and Haemostasis2008;6:1313-8. BullerHR . A dose finding study of the oral direct factor Xa inhibitor apixaban in the treatment of patients with acute symptomatic deep vein thrombosis - the Botticelli Investigators. Journal of Thrombosis and Haemostasis2007;5 (Suppl 2):O-S-003. NCT00252005. Oral direct factor Xa-inhibitor apixaban in patients with acute symptomatic deep-vein thrombosis - the Botticelli DVT study. clinicaltrials.gov/ct/show/NCT00252005?order=1 (first received 11 November 2005). ">Botticelli DVT 2008</a>; <a href="./references#CD010956-bbs2-0007" title="BullerH , DariusH . EINSTEIN DVT: oral rivaroxaban versus standard therapy in the initial treatment of symptomatic deep vein thrombosis and long-term prevention of recurrent venous thromboembolism. escardio.org/The-ESC/Press-Office/Press-releases/EINSTEIN-DVT-Oral-rivaroxaban-versus-standard-therapy-in-the-initial-treatment (accessed 19 October 2022). BullerHR , AgnelliG . Once- or twice-daily rivaroxaban for the treatment of proximal deep vein thrombosis: similar efficacy and safety to standard therapy in dose-ranging studies. Blood2006;108(11 Part 1):172-3. BullerHR , LensingAW , PrinsMH , AgnelliG , CohenA , GallusAS , et al. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT dose-ranging study. Blood2008;112(6):2242-7. NCT00395772. Once-daily oral direct factor Xa inhibitor BAY59-7939 in patients with acute symptomatic deep-vein thrombosis. clinicaltrials.gov/ct2/show/NCT00395772?term=einstein-dvt&amp;rank=2 (first received 3 November 2006). ">EINSTEIN‐DVT dose 2008</a>; <a href="./references#CD010956-bbs2-0006" title="BamberL , WangMY , PrinsMH , CiniglioC , BauersachsR , LensingAW , et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis. Thrombosis and Haemostasis2013;110(4):732-41. BauersachsR , LensingAW , PapA , DecoususH . No need for a rivaroxaban dose reduction in renally impaired patients with symptomatic venous thromboembolism. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):30-1. BistervelsI , GebelM , LensingA , MiddeldorpS , CoppensM . Effect of polypharmacy on bleeding of rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolism. Research and Practice in Thrombosis and Haemostasis2019;3:798‐9. BookhartBK , HaskellL , BamberL , WangM , ScheinJ , ModySH . Length of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial program. Journal of Medical Economics2014;17(10):691-5. BullerHR . Oral rivaroxaban for the acute and continued treatment of symptomatic venous thromboembolism. The Einstein-DVT and Einstein-Extension study. Blood2010;116(21):187. CheungW , MiddeldorpS , PrinsMP , PapAF , LensingAW , Hoek-tenCA , et al. Post thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep vein thrombosis. Journal of Thrombosis and Haemostasis2015;13(S2):219-20. CheungYW , MiddeldorpS , PrinsMH , PapAF , PrandoniP . Post-thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep-vein thrombosis. A post-hoc analysis. Thrombosis and Haemostasis2016;116(4):733-8. EUCTR2004-002171-16-IT. Once-daily oral direct factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis. The EINSTEIN-DVT dose-finding study. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2004%E2%80%90002171%E2%80%9016%E2%80%90IT (first received 15 October 2008). EUCTR2006-004495-13-DK. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep-vein thrombosis or pulmonary embolism. trialsearch.who.int/?TrialID=EUCTR2006-004495-13-DK (first received 29 March 2007). EerenbergES , MiddeldorpS , LeviM , LensingAW , BüllerHR . Clinical impact and course of major bleeding with rivaroxaban and vitamin K antagonists. Journal of Thrombosis and Haemostasis2015;13(9):1590-6. KlineJA , JimenezD , CourtneyDM , IanusJ , CaoL , WellsPS . Use of the Riete 2008 bleeding score to identify patients at low risk for major bleeding in patients treated with rivaroxaban. Academic Emergency Medicine2015;22:S162. NCT00440193. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep vein thrombosis - The EINSTEIN DVT Study. clinicaltrials.gov/ct2/show/NCT00440193 (first received 26 February 2007). PrinsMH , ErkensPG , LensingAW . Incidence of recurrent venous thromboembolism in patients following completion of the EINSTEIN DVT and EINSTEIN PE studies. Journal of Thrombosis and Haemostasis2013;11(Suppl):257. PrinsMH , LensingAW , BauersachsR , Van BellenB , BounameauxH , BrightonTA , et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thrombosis Journal2013;11(1):21. The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. New England Journal of Medicine2010;363(26):2499-510. Van BellenB , PrinsM , BamberL , WangM , LensingAW . Reduction in initial length of stay with rivaroxaban single-drug regimen versus LMWH-VKA standard of care: findings from the EINSTEIN trial program. Blood2012;120(21):3419. Van BellenB , PrinsM , BamberL , WangM , LensingAW . Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism. Current Medical Research and Opinion2014;30(5):829-37. WangY , WangC , ChenZ , ZhangJ , LiuZ , JinB , et al. Rivaroxaban for the treatment of symptomatic deep vein thrombosis and/or pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):694. WangY , WangC , ChenZ , ZhangJ , LiuZ , JinB , et al. Rivaroxaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Thrombosis Journal2013;11(1):25. ">EINSTEIN‐DVT 2010</a>; <a href="./references#CD010956-bbs2-0009" title="PiazzaG , ManiV , GoldhaberSZ , GrossoMA , MercuriM , LanzHJ , et al. Magnetic resonance venography to assess thrombus resolution with edoxaban monotherapy versus parenteral anticoagulation/warfarin for symptomatic deep vein thrombosis: a multicenter feasibility study. Vascular Medicine2016;21(4):361-8. PiazzaG , ManiV , GrossoM , MercuriM , LanzH , SchusslerS , et al. A randomized, open-label, multicenter study of the efficacy and safety of edoxaban monotherapy versus low-molecular weight heparin/warfarin in patients with symptomatic deep vein thrombosis-edoxaban thrombus reduction imaging study (etris). Circulation2014;130:A12074. ">eTRIS 2016</a>; <a href="./references#CD010956-bbs2-0015" title="AgnelliG , GallusA , GoldhaberSZ , HaasS , HuismanMV , HullRD , et al. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAT 59-7939 in patients with acute symptomatic deep-vein thrombosis) study. Circulation2007;116:180-7. ">ODIXa‐DVT 2007</a>), 5.5 to 6.5 months in 12 studies (<a href="./references#CD010956-bbs2-0001" title="AgnelliG , BullerH , MasiukiewiczUP . Apixaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism: a randomized, double-blind trial (AMPLIFY). Journal of Thrombosis and Haemostasis2013;11:18. AgnelliG , BullerHR , CohenA , CurtoD , GallusAS , JohnsonM , et al. Oral apixaban for the treatment of acute venous thromboembolism. New England Journal of Medicine2013;369:799-808. AgnelliG , BullerHR , CohenA , CurtoM , GallusAS , PakR , et al. Apixaban for the treatment of venous thromboembolism in cancer patients: data from the AMPLIFY trial. Canadian Journal of Cardiology2014;30(10 Suppl 1):S278. AgnelliG , BullerHR , CohenA , GallusAS , LeeTC , PakR , et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. Journal of Thrombosis and Haemostasis2015;13(12):2187-91. AgnelliG . Apixaban was non-inferior to enoxaparin plus warfarin in patients with acute venous thromboembolism. Annals of Internal Medicine2013;159(8):JC2. BlekerSM , CohenAT , BüllerHR , AgnelliG , GallusAS , RaskobGE , et al. Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Thrombosis and Haemostasis2016;116(6):159-64. BrekelmansM , ScheresL , BlekerS , HuttenB , TimmermansA , BüllerH , et al. Abnormal vaginal bleeding in women with venous thromboembolism treated with apixaban or warfarin. Thrombosis and Haemostasis2017;117(04):809-15. CohenA , AgnelliG , BullerH , GallusA , RaskobG , SandersP , et al. Characteristics and outcomes in patients with venous thromboembolism taking concomitant anti-platelet agents and anticoagulants in the AMPLIFY Trial. Thrombosis and Haemostasis2019;119(3):461-6. CohenA , AgnelliG , BullerHR , ChaudhuriS , GallusAS , RaskobGE , et al. Analysis of the bleeding and thromboembolic risk with concomitant use of antiplatelet treatment in the AMPLIFY trial. Canadian Journal of Cardiology2014;30(10):S272. CohenA , GallusAS , AgnelliG , BullerHR , PakR , PorcariAR , et al. Time in Therapeutic Range (TTR) and relative efficacy and safety of treatment with apixaban or enoxaparin/warfarin for acute symptomatic venous thromboembolism: an analysis of the Amplify trial data. Blood2014;124(21):1543. CohenAT , PanS , ByonW , IlyasBS , LeeTC . Efficacy, safety, and exposure of apixaban in patients with high body weight or obesity and venous thromboembolism: insights from AMPLIFY. Advances in Therapy2021;38(6):3003-18. EUCTR2007-007867-25-PT. A safety and efficacy trial evaluating the use of apixaban in the treatment of symptomatic deep vein thrombosis and pulmonary embolism revised protocol number: 01, incorporates amendment(s) 02 + protocol amendment 01 (version 1.0 dated 21-Apr-08) site-specific - molecular profiling supplement samples for Pfizer’s exploratory research biobank. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2007%E2%80%90007867%E2%80%9025%E2%80%90PT (first received 14 July 2008). GallusAS , AgnelliG , BullerHR , CohenA , LeeTC , PakR , et al. Apixaban for treatment of venous thromboembolism in patients from study centres in Asia: a subgroup analysis of the Amplify trial. Journal of Thrombosis and Haemostasis2015;13:727. LeeT , PanS , ByonW , IlyasBS . Safety and efficacy of apixaban versus enoxaparin/warfarin in patients with extremes of body weight: post-hoc analysis of the AMPLIFY trial. Blood2019;134(Suppl 1):1152. LiuX , JohnsonM , MardekianJ , PhatakH , ThompsonJ , CohenAT . Apixaban reduces hospitalizations in patients with venous thromboembolism: an analysis of the apixaban for the Initial management of pulmonary embolism and deep‐vein thrombosis as first‐line therapy (AMPLIFY) trial. Journal of the American Heart Association2015;4(12):e002340. NCT00633893. Efficacy and safety study of apixaban for extended treatment of deep vein thrombosis or pulmonary embolism. clinicaltrials.gov/ct2/show/NCT00633893?term=ajax&amp;rank=5 (first received 12 March 2008). NCT00643201. Efficacy and safety study of apixaban for the treatment of deep vein thrombosis or pulmonary embolism. clinicaltrials.gov/ct2/show/NCT00643201 (first received 26 March 2008). RaskobGE , GallusAS , SandersP , ThompsonJR , AgnelliG , BullerHR , et al. Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy: a sub-analysis of the AMPLIFY trial. Thrombosis and Haemostasis2016;115(4):809-16. ">AMPLIFY 2013</a>; <a href="./references#CD010956-bbs2-0002" title="NakamuraM , NishikawaM , KomuroI , KitajimaI , UetsukaY , YamagamiT , et al. Apixaban for the treatment of Japanese subjects with acute venous thromboembolism (AMPLIFY-J Study). Circulation2015;79(6):1230–36. ">AMPLIFY‐J 2015</a>; <a href="./references#CD010956-bbs2-0004" title="AgenoW , VedovatiMC , CohenA , HuismanM , BauersachsR , GussoniG , et al. Bleeding with apixaban and dalteparin in patients with cancer-associated venous thromboembolism: results from the Caravaggio study. Thrombosis and Haemostasis2021;121(5):616-24. AgnelliG , BecattiniC , BauersachsR , BrennerB , CampaniniM , CohenA , et al. Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the Caravaggio study. Thrombosis and Haemostasis2018;118(9):1668-78. AgnelliG , BecattiniC , MeyerG , MuozA , VersoM . Apixaban for the treatment of venous thromboembolism associated with cancer. New England Journal of Medicine2020;382(17):1599-607. AgnelliG , MuozA , FrancoL , MahéI , BrennerB , ConnorsJM , et al. Apixaban and dalteparin for the treatment of venous thromboembolism in patients with different sites of cancer. Thrombosis and Haemostasis2022;122(5):796-807. BecattiniC , BauersachsR , MarazitiG , BertolettiL , CohenA , ConnorsJM , et al. Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial. Haematologica2021;107(7):1567-76. GiustozziM , ConnorsJM , Ruperez BlancoAB , SzmitS , FalvoN , CohenAT , et al. Clinical characteristics and outcomes of incidental venous thromboembolism in cancer patients: insights from the Caravaggio study. Journal of Thrombosis and Haemostasis2021;19(11):2751-9. NCT03045406. Apixaban for the treatment of venous thromboembolism in patients with cancer (CARAVAGGIO). clinicaltrials.gov/ct2/show/NCT03045406 (first received 7 February 2017). VersoM , MunozA , BauersachsR , HuismanMV , AgnelliG . Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism. European Journal of Cancer2021;148(Suppl C):371-81. ">Caravaggio 2020</a>; <a href="./references#CD010956-bbs2-0005" title="NCT02704598. Comparison between xarelto versus warfarin in the recanalization rate of deep venous thrombosis in patients legs. (DVT). clinicaltrials.gov/ct2/show/NCT02704598 (first received 10 March 2016). deAthayde SoaresR , MatieloMF , Brochado NetoFC , AlmeidaRD , SacilottoR . LEV 2. Comparison of the recanalization rate and post-thrombotic syndrome in patients with deep venous thrombosis treated with rivaroxaban or warfarin. Journal of Vascular Surgery2019;70(5):e169-e170. deAthayde SoaresR , MatieloMF , Brochado NetoFC , NogueiraMP , AlmeidaRD , SacilottoR . Comparison of the recanalization rate and postthrombotic syndrome in patients with deep venous thrombosis treated with rivaroxaban or warfarin. Surgery2019;166(6):1076-83. ">de Athayde 2019</a>; <a href="./references#CD010956-bbs2-0008" title="BullerHR , PrinsMH , LensinAW , DecoususH , JacobsonBF , MinarE , et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. New England Journal of Medicine2012;366:1287-97. FermannGJ , Erkens Pmg, PrinsMH , WellsPS , Pap ÁF, LensingAW , et al. Treatment of pulmonary embolism with rivaroxaban: outcomes by simplified pulmonary embolism severity index score from a post hoc analysis of the EINSTEIN PE study. Academic Emergency Medicine2015;22(3):299-307. NCT00439777. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic pulmonary embolism with or without symptomatic deep-vein thrombosis: Einstein-PE evaluation, 2008. clinicaltrials.gov/ct2/show/NCT00439777?term=NCT00439777&amp;rank=1 (first received 26 February 2007). PrinsM , BamberL , CanoS , WangM , LensingAW , BauersachsR . Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic pulmonary embolism. Blood2012;120(21):1163. PrinsMH , BamberL , CanoSJ , WangMY , ErkensP , BauersachsR , et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial. Thrombosis Research2015;135(2):281-8. ">EINSTEIN‐PE 2012</a>; <a href="./references#CD010956-bbs2-0010" title="FarhanA , BukhariM , UmarJ , RazaMA . Oral rivaroxaban in symptomatic deep vein thrombosis. Journal of the College of Physicians and Surgeons Pakistan2019;29(9):814-8. ">Farhan 2019</a>; <a href="./references#CD010956-bbs2-0011" title="BistervelsI , BavaliaR , BoersmaW , MeijerK , VerhammeP , Ten Cate-HoekAJ , et al. Hokusai Post-DVT Study: a follow-up study on long-term outcomes of deep vein thrombosis in patients treated with edoxaban vs warfarin. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):PB2207. BrekelmansMP , AgenoW , BeenenLF , BrennerB , BullerHR , ChenCZ , et al. Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology2016;3(9):e437-45. BrekelmansMP , BlekerSM , BauersachsR , BodaZ , BüllerHR , ChoiY , et al. Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists. Thrombosis and Haemostasis2016;116(1):155-61. Di NisioM , Van EsN , CarrierM , WangTF , GarciaD , SegersA , et al. Extended treatment with edoxaban in cancer patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE Cancer study. Journal of Thrombosis and Haemostasis2019;17:1866–74. EUCTR2009-014290-40-SE. A phase 3, randomized, double-blind, double-dummy, parallel group, multi-center, multi-national study for evaluation of efficacy and safety of DU-176b versus warfarin in subjects with atrial fibrillation - effective anticoagulation with factor Xa next generation in atrial fibrillation (ENGAGE-AF TIMI-48). trialsearch.who.int/?trialid=EUCTR2009-014290-40-SE (first received 30 November 2009). EichingerS , LinM , KyrlePA , GrossoMA . Recurrent venous thromboembolism during anticoagulation: an investigator-initiated post-hoc analysis of the hokusai-VTE trial. Blood2018;132:2539. KlokFA , BarcoS , KonstantinidesSV . External validation of the VTE-BLEED score for predicting major bleeding in stable anticoagulated patients with venous thromboembolism. Thrombosis and Haemostasis2017;117(6):1164-70. KraaijpoelN , Van EsN , RaskobGE , BüllerHR , CarrierM , ZhangG , et al. Risk scores for occult cancer in patients with venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2018;118(7):1270-8. MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMP , ChenCZ , et al. Outpatient management in patients with venous thromboembolism with edoxaban: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2017;117(12):2406-14. MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMP , ChenCZ , et al. Safety and efficacy of edoxaban compared with warfarin for the treatment of acute symptomatic deep-vein thrombosis in the outpatient setting. Research and Practice in Thrombosis and Haemostasis2017;1:913. MulderFI , Van EsN , KraaijpoelN , Di NisioM , CarrierM , DuggalA , et al. Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: results from the Hokusai VTE Cancer study. Thrombosis Research2020;185:13-9. NCT00986154. Comparative investigation of Low Molecular Weight (LMW) heparin/edoxaban tosylate (DU176b) versus (LMW) heparin/warfarin in the treatment of symptomatic deep-vein blood clots and/or lung blood clots. (The Edoxaban Hokusai-VTE Study). clinicaltrials.gov/ct2/show/NCT00986154 (first received 29 September 2009). NakamuraM , WangYQ , WangC , OhD , YinWH , KimuraT , et al. Efficacy and safety of edoxaban for treatment of venous thromboembolism: a subanalysis of East Asian patients in the Hokusai-VTE trial. Journal of Thrombosis and Haemostasis2015;13(9):1606-14. NybergJ , KarlssonKE , JönssonS , YinO , MillerR , KarlssonMO , et al. Edoxaban exposure-response analysis and clinical utility index assessment in patients with symptomatic deep-vein thrombosis or pulmonary embolism. CPT Pharmacometrics and Systems Pharmacology2016;5(4):222-32. RaskobG , AgenoW , CohenAT , BrekelmansMP , GrossoMA , SegersA , et al. Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology2016;3(5):e228-e236. RaskobG , BullerH , PrinsM , SegersA , ShiM , SchwochoL , et al. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study - methodological implications for clinical trials. Journal of Thrombosis and Haemostasis2013;11(7):1287-94. RaskobGE , BullerH , AngchaisuksiriP , OhD , BodaZ , LyonsRM , et al. Edoxaban for long-term treatment of venous thromboembolism in cancer patients. Blood2013;122(21):211. RaskobGE , Van EsN , SegersA , AngchaisuksiriP , OhD , BodaZ , et al. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematology2016;3(8):e379-87. ScheresLJ , BrekelmansMA , WalterA , CihanA , BüllerHR , SabineE , et al. Abnormal vaginal bleeding in women of reproductive age treated with edoxaban or warfarin for venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. British Journal of Obstetrics and Gynaecology2018;125(12):1581-9. The Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. New England Journal of Medicine2013;369(15):1406-15. VanasscheT , VerhammeP , WellsPS , SegersA , AgenoW , BrekelmansMP , et al. Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: an analysis of the randomized, double-blind Hokusai-VTE trial. Thrombosis Research2018;162:7-14. VerhammeP , WellsPS , SegersA , AgenoW , BrekelmansMP , CohenAT , et al. Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial. Thrombosis and Haemostasis2016;116(4):747-53. ">Hokusai‐VTE 2013</a>; <a href="./references#CD010956-bbs2-0013" title="MatsuoH , PrinsM , LensingAW , FujinumaEW , MiyamotoY , KajikawaM . Shortened length of hospital stay with rivaroxaban in patients with symptomatic venous thromboembolism in Japan: the J-EINSTEIN pulmonary embolism and deep vein thrombosis program. Current Medical Research and Opinion2015;31(6):1057-61. NCT01516814. Venous thromboembolism (VTE) treatment study in Japanese pulmonary embolism (PE) patients. clinicaltrials.gov/ct2/show/NCT01516814 (first received 25 January 2012). YamadaN , HirayamaA , MaedaH , SakagamiS , ShikataH , PrinsMH , et al. Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism-the J-EINSTEIN DVT and PE program. Thrombosis Journal2015;13:2. ">J‐EINSTEIN DVT and PE 2015</a>; <a href="./references#CD010956-bbs2-0014" title="MokademME , HassanA , AlgabyAZ . Efficacy and safety of apixaban in patients with active malignancy and acute deep venous thrombosis. Vascular2021;29(5):745-50. NCT04462003. Efficacy of apixaban in malignancy with deep venous thrombosis (DVT). clinicaltrials.gov/ct2/show/NCT04462003 (first received 3 July 2019). ">Mokadem 2021</a>; <a href="./references#CD010956-bbs2-0016" title="OhmoriH , KadaA , NakamuraM , SaitoAM , SanayamaY , ShinagawaT , et al. Deep vein thrombosis in severe motor and intellectual disabilities patients and its treatment by anticoagulants of warfarin versus edoxaban. Annals of Vascular Diseases2019;12(3):372-8. OhmoriH , NakamuraM , KadaA , SaitoAM , SanayamaY , ShinagawaT , et al. Multicenter, open-label, randomized controlled trial of warfarin and edoxaban tosilate hydrate for the treatment of deep vein thrombosis in persons with severe motor intellectual disabilities. Kurume Medical Journal2018;65(1):11-6. ">Ohmori 2019</a>; <a href="./references#CD010956-bbs2-0017" title="Kang JiM, ParkKH , AhnS , ChoS , MinSK . Rivaroxaban after thrombolysis in acute iliofemoral venous thrombosis: a randomized, open-labeled, multicenter trial. Scientific Reports2019;9(1):20356. MinSK , AhnS , ParkKH , KangJM , KimJY . Prevention of recurrence after thrombolysis in acute iliofemoral venous thrombosis with rivaroxaban (Prais Study): a prospective, randomized, open label, multicenter trial. European Journal of Vascular and Endovascular Surgery2019;58(6):e516. NCT01986192. Prevention of recurrence after thrombolysis in acute iliofemoral venous thrombosis (PRAIS) study. clinicaltrials.gov/show/NCT01986192 (first received 18 November 2013). ">PRAIS 2019</a>; <a href="./references#CD010956-bbs2-0020" title="SukovatykhBS , SereditskiĭAV , MuradianVF , BelikovLN , GerasimovaOF . Results of administering oral anticoagulants for treatment of patients with venous thromboembolic complications. Angiologiia i sosudistaia khirurgiia [Angiology and Vascular Surgery]2017;23(2):82. ">Sukovatykh 2017</a>), 12 months in one study (<a href="./references#CD010956-bbs2-0016" title="OhmoriH , KadaA , NakamuraM , SaitoAM , SanayamaY , ShinagawaT , et al. Deep vein thrombosis in severe motor and intellectual disabilities patients and its treatment by anticoagulants of warfarin versus edoxaban. Annals of Vascular Diseases2019;12(3):372-8. OhmoriH , NakamuraM , KadaA , SaitoAM , SanayamaY , ShinagawaT , et al. Multicenter, open-label, randomized controlled trial of warfarin and edoxaban tosilate hydrate for the treatment of deep vein thrombosis in persons with severe motor intellectual disabilities. Kurume Medical Journal2018;65(1):11-6. ">Ohmori 2019</a>), and six to 12 months in one study (<a href="./references#CD010956-bbs2-0012" title="AmayaN , UzuiH , HisazakiK , HasegwaK , KasenoK , TadaH . Edoxaban normalizes the elevated D-dimer levels potently and promptly in patients with venous thromboembolisms: a comparison with traditional anticoagulant therapy. European Heart Journal2016;37:278. BoschFT , Van EsN , Di NisioM , CarrierM , SegersA , GrossoMA , et al. The Ottawa score does not predict recurrent venous thromboembolism in cancer patients: results from the Hokusai-VTE cancer study. Research and Practice in Thrombosis and Haemostasis2019;3(S1):717-8. KraaijpoelN , Di NisioM , MulderFI , Van EsN , RaskobGE . Clinical impact of bleeding in cancer-associated venous thromboembolism: results from the Hokusai VTE Cancer randomized trial. Thrombosis Research2018;164(Suppl 1):S223. [DOI: 10.1016/j.thromres.2018.02.094]MulderFI , Di NisioM , AyC , CarrierM , BoschFT , SegersA , et al. Clinical implications of incidental venous thromboembolism in cancer patients. European Respiratory Journal2020;55(2):1901697. [DOI: 10.1183/13993003.01697-2019]MulderFI , Van EsN , KraaijpoelN , Di NisioM , CarrierM , GarciaD , et al. Efficacy and safety of edoxaban in clinically relevant subgroups: results from the Hokusai VTE Cancer randomized trial. Thrombosis Research2018;164:S194. NCT02073682. Cancer venous thromboembolism (VTE). clinicaltrials.gov/ct2/show/NCT02073682 (first received 27 February 2014). RaskobG , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaD , et al. Edoxaban versus dalteparin for treatment of venous thromboembolism (VTE) associated with cancer: Hokusai VTE-cancer randomized trial. Supportive Care in Cancer2018;26(2):S316-S317. RaskobGE , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaD , et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. New England Journal of Medicine2018;378(7):615-24. RaskobGE , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaDA , et al. A randomized, open-label, blinded outcome assessment trial evaluating the efficacy and safety of LMWH/Edoxaban versus dalteparin for venous thromboembolism associated with cancer: Hokusai VTE-cancer study. Blood2017;130(Suppl 1):LBA-6. ">Hokusai VTE Cancer 2018</a>). </p> <p>Thirteen oral factor Xa inhibitor studies measured recurrent VTE (<a href="./references#CD010956-bbs2-0001" title="AgnelliG , BullerH , MasiukiewiczUP . Apixaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism: a randomized, double-blind trial (AMPLIFY). Journal of Thrombosis and Haemostasis2013;11:18. AgnelliG , BullerHR , CohenA , CurtoD , GallusAS , JohnsonM , et al. Oral apixaban for the treatment of acute venous thromboembolism. New England Journal of Medicine2013;369:799-808. AgnelliG , BullerHR , CohenA , CurtoM , GallusAS , PakR , et al. Apixaban for the treatment of venous thromboembolism in cancer patients: data from the AMPLIFY trial. Canadian Journal of Cardiology2014;30(10 Suppl 1):S278. AgnelliG , BullerHR , CohenA , GallusAS , LeeTC , PakR , et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. Journal of Thrombosis and Haemostasis2015;13(12):2187-91. AgnelliG . Apixaban was non-inferior to enoxaparin plus warfarin in patients with acute venous thromboembolism. Annals of Internal Medicine2013;159(8):JC2. BlekerSM , CohenAT , BüllerHR , AgnelliG , GallusAS , RaskobGE , et al. Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Thrombosis and Haemostasis2016;116(6):159-64. BrekelmansM , ScheresL , BlekerS , HuttenB , TimmermansA , BüllerH , et al. Abnormal vaginal bleeding in women with venous thromboembolism treated with apixaban or warfarin. Thrombosis and Haemostasis2017;117(04):809-15. CohenA , AgnelliG , BullerH , GallusA , RaskobG , SandersP , et al. Characteristics and outcomes in patients with venous thromboembolism taking concomitant anti-platelet agents and anticoagulants in the AMPLIFY Trial. Thrombosis and Haemostasis2019;119(3):461-6. CohenA , AgnelliG , BullerHR , ChaudhuriS , GallusAS , RaskobGE , et al. Analysis of the bleeding and thromboembolic risk with concomitant use of antiplatelet treatment in the AMPLIFY trial. Canadian Journal of Cardiology2014;30(10):S272. CohenA , GallusAS , AgnelliG , BullerHR , PakR , PorcariAR , et al. Time in Therapeutic Range (TTR) and relative efficacy and safety of treatment with apixaban or enoxaparin/warfarin for acute symptomatic venous thromboembolism: an analysis of the Amplify trial data. Blood2014;124(21):1543. CohenAT , PanS , ByonW , IlyasBS , LeeTC . Efficacy, safety, and exposure of apixaban in patients with high body weight or obesity and venous thromboembolism: insights from AMPLIFY. Advances in Therapy2021;38(6):3003-18. EUCTR2007-007867-25-PT. A safety and efficacy trial evaluating the use of apixaban in the treatment of symptomatic deep vein thrombosis and pulmonary embolism revised protocol number: 01, incorporates amendment(s) 02 + protocol amendment 01 (version 1.0 dated 21-Apr-08) site-specific - molecular profiling supplement samples for Pfizer’s exploratory research biobank. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2007%E2%80%90007867%E2%80%9025%E2%80%90PT (first received 14 July 2008). GallusAS , AgnelliG , BullerHR , CohenA , LeeTC , PakR , et al. Apixaban for treatment of venous thromboembolism in patients from study centres in Asia: a subgroup analysis of the Amplify trial. Journal of Thrombosis and Haemostasis2015;13:727. LeeT , PanS , ByonW , IlyasBS . Safety and efficacy of apixaban versus enoxaparin/warfarin in patients with extremes of body weight: post-hoc analysis of the AMPLIFY trial. Blood2019;134(Suppl 1):1152. LiuX , JohnsonM , MardekianJ , PhatakH , ThompsonJ , CohenAT . Apixaban reduces hospitalizations in patients with venous thromboembolism: an analysis of the apixaban for the Initial management of pulmonary embolism and deep‐vein thrombosis as first‐line therapy (AMPLIFY) trial. Journal of the American Heart Association2015;4(12):e002340. NCT00633893. Efficacy and safety study of apixaban for extended treatment of deep vein thrombosis or pulmonary embolism. clinicaltrials.gov/ct2/show/NCT00633893?term=ajax&amp;rank=5 (first received 12 March 2008). NCT00643201. Efficacy and safety study of apixaban for the treatment of deep vein thrombosis or pulmonary embolism. clinicaltrials.gov/ct2/show/NCT00643201 (first received 26 March 2008). RaskobGE , GallusAS , SandersP , ThompsonJR , AgnelliG , BullerHR , et al. Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy: a sub-analysis of the AMPLIFY trial. Thrombosis and Haemostasis2016;115(4):809-16. ">AMPLIFY 2013</a>; <a href="./references#CD010956-bbs2-0002" title="NakamuraM , NishikawaM , KomuroI , KitajimaI , UetsukaY , YamagamiT , et al. Apixaban for the treatment of Japanese subjects with acute venous thromboembolism (AMPLIFY-J Study). Circulation2015;79(6):1230–36. ">AMPLIFY‐J 2015</a>; <a href="./references#CD010956-bbs2-0003" title="BarrettYC , WangJ , KnabbR , MohanP . Apixaban decreases coagulation activity in patients with acute deep-vein thrombosis. Thrombosis and Haemostasis2011;105:181-9. Botticelli Investigators Writing Committee, BullerH , DeitchmanD , PrinsM , SegersA . Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. Journal of Thrombosis and Haemostasis2008;6:1313-8. BullerHR . A dose finding study of the oral direct factor Xa inhibitor apixaban in the treatment of patients with acute symptomatic deep vein thrombosis - the Botticelli Investigators. Journal of Thrombosis and Haemostasis2007;5 (Suppl 2):O-S-003. NCT00252005. Oral direct factor Xa-inhibitor apixaban in patients with acute symptomatic deep-vein thrombosis - the Botticelli DVT study. clinicaltrials.gov/ct/show/NCT00252005?order=1 (first received 11 November 2005). ">Botticelli DVT 2008</a>; <a href="./references#CD010956-bbs2-0004" title="AgenoW , VedovatiMC , CohenA , HuismanM , BauersachsR , GussoniG , et al. Bleeding with apixaban and dalteparin in patients with cancer-associated venous thromboembolism: results from the Caravaggio study. Thrombosis and Haemostasis2021;121(5):616-24. AgnelliG , BecattiniC , BauersachsR , BrennerB , CampaniniM , CohenA , et al. Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the Caravaggio study. Thrombosis and Haemostasis2018;118(9):1668-78. AgnelliG , BecattiniC , MeyerG , MuozA , VersoM . Apixaban for the treatment of venous thromboembolism associated with cancer. New England Journal of Medicine2020;382(17):1599-607. AgnelliG , MuozA , FrancoL , MahéI , BrennerB , ConnorsJM , et al. Apixaban and dalteparin for the treatment of venous thromboembolism in patients with different sites of cancer. Thrombosis and Haemostasis2022;122(5):796-807. BecattiniC , BauersachsR , MarazitiG , BertolettiL , CohenA , ConnorsJM , et al. Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial. Haematologica2021;107(7):1567-76. GiustozziM , ConnorsJM , Ruperez BlancoAB , SzmitS , FalvoN , CohenAT , et al. Clinical characteristics and outcomes of incidental venous thromboembolism in cancer patients: insights from the Caravaggio study. Journal of Thrombosis and Haemostasis2021;19(11):2751-9. NCT03045406. Apixaban for the treatment of venous thromboembolism in patients with cancer (CARAVAGGIO). clinicaltrials.gov/ct2/show/NCT03045406 (first received 7 February 2017). VersoM , MunozA , BauersachsR , HuismanMV , AgnelliG . Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism. European Journal of Cancer2021;148(Suppl C):371-81. ">Caravaggio 2020</a>; <a href="./references#CD010956-bbs2-0007" title="BullerH , DariusH . EINSTEIN DVT: oral rivaroxaban versus standard therapy in the initial treatment of symptomatic deep vein thrombosis and long-term prevention of recurrent venous thromboembolism. escardio.org/The-ESC/Press-Office/Press-releases/EINSTEIN-DVT-Oral-rivaroxaban-versus-standard-therapy-in-the-initial-treatment (accessed 19 October 2022). BullerHR , AgnelliG . Once- or twice-daily rivaroxaban for the treatment of proximal deep vein thrombosis: similar efficacy and safety to standard therapy in dose-ranging studies. Blood2006;108(11 Part 1):172-3. BullerHR , LensingAW , PrinsMH , AgnelliG , CohenA , GallusAS , et al. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT dose-ranging study. Blood2008;112(6):2242-7. NCT00395772. Once-daily oral direct factor Xa inhibitor BAY59-7939 in patients with acute symptomatic deep-vein thrombosis. clinicaltrials.gov/ct2/show/NCT00395772?term=einstein-dvt&amp;rank=2 (first received 3 November 2006). ">EINSTEIN‐DVT dose 2008</a>; <a href="./references#CD010956-bbs2-0006" title="BamberL , WangMY , PrinsMH , CiniglioC , BauersachsR , LensingAW , et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis. Thrombosis and Haemostasis2013;110(4):732-41. BauersachsR , LensingAW , PapA , DecoususH . No need for a rivaroxaban dose reduction in renally impaired patients with symptomatic venous thromboembolism. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):30-1. BistervelsI , GebelM , LensingA , MiddeldorpS , CoppensM . Effect of polypharmacy on bleeding of rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolism. Research and Practice in Thrombosis and Haemostasis2019;3:798‐9. BookhartBK , HaskellL , BamberL , WangM , ScheinJ , ModySH . Length of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial program. Journal of Medical Economics2014;17(10):691-5. BullerHR . Oral rivaroxaban for the acute and continued treatment of symptomatic venous thromboembolism. The Einstein-DVT and Einstein-Extension study. Blood2010;116(21):187. CheungW , MiddeldorpS , PrinsMP , PapAF , LensingAW , Hoek-tenCA , et al. Post thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep vein thrombosis. Journal of Thrombosis and Haemostasis2015;13(S2):219-20. CheungYW , MiddeldorpS , PrinsMH , PapAF , PrandoniP . Post-thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep-vein thrombosis. A post-hoc analysis. Thrombosis and Haemostasis2016;116(4):733-8. EUCTR2004-002171-16-IT. Once-daily oral direct factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis. The EINSTEIN-DVT dose-finding study. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2004%E2%80%90002171%E2%80%9016%E2%80%90IT (first received 15 October 2008). EUCTR2006-004495-13-DK. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep-vein thrombosis or pulmonary embolism. trialsearch.who.int/?TrialID=EUCTR2006-004495-13-DK (first received 29 March 2007). EerenbergES , MiddeldorpS , LeviM , LensingAW , BüllerHR . Clinical impact and course of major bleeding with rivaroxaban and vitamin K antagonists. Journal of Thrombosis and Haemostasis2015;13(9):1590-6. KlineJA , JimenezD , CourtneyDM , IanusJ , CaoL , WellsPS . Use of the Riete 2008 bleeding score to identify patients at low risk for major bleeding in patients treated with rivaroxaban. Academic Emergency Medicine2015;22:S162. NCT00440193. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep vein thrombosis - The EINSTEIN DVT Study. clinicaltrials.gov/ct2/show/NCT00440193 (first received 26 February 2007). PrinsMH , ErkensPG , LensingAW . Incidence of recurrent venous thromboembolism in patients following completion of the EINSTEIN DVT and EINSTEIN PE studies. Journal of Thrombosis and Haemostasis2013;11(Suppl):257. PrinsMH , LensingAW , BauersachsR , Van BellenB , BounameauxH , BrightonTA , et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thrombosis Journal2013;11(1):21. The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. New England Journal of Medicine2010;363(26):2499-510. Van BellenB , PrinsM , BamberL , WangM , LensingAW . Reduction in initial length of stay with rivaroxaban single-drug regimen versus LMWH-VKA standard of care: findings from the EINSTEIN trial program. Blood2012;120(21):3419. Van BellenB , PrinsM , BamberL , WangM , LensingAW . Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism. Current Medical Research and Opinion2014;30(5):829-37. WangY , WangC , ChenZ , ZhangJ , LiuZ , JinB , et al. Rivaroxaban for the treatment of symptomatic deep vein thrombosis and/or pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):694. WangY , WangC , ChenZ , ZhangJ , LiuZ , JinB , et al. Rivaroxaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Thrombosis Journal2013;11(1):25. ">EINSTEIN‐DVT 2010</a>; <a href="./references#CD010956-bbs2-0008" title="BullerHR , PrinsMH , LensinAW , DecoususH , JacobsonBF , MinarE , et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. New England Journal of Medicine2012;366:1287-97. FermannGJ , Erkens Pmg, PrinsMH , WellsPS , Pap ÁF, LensingAW , et al. Treatment of pulmonary embolism with rivaroxaban: outcomes by simplified pulmonary embolism severity index score from a post hoc analysis of the EINSTEIN PE study. Academic Emergency Medicine2015;22(3):299-307. NCT00439777. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic pulmonary embolism with or without symptomatic deep-vein thrombosis: Einstein-PE evaluation, 2008. clinicaltrials.gov/ct2/show/NCT00439777?term=NCT00439777&amp;rank=1 (first received 26 February 2007). PrinsM , BamberL , CanoS , WangM , LensingAW , BauersachsR . Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic pulmonary embolism. Blood2012;120(21):1163. PrinsMH , BamberL , CanoSJ , WangMY , ErkensP , BauersachsR , et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial. Thrombosis Research2015;135(2):281-8. ">EINSTEIN‐PE 2012</a>; <a href="./references#CD010956-bbs2-0009" title="PiazzaG , ManiV , GoldhaberSZ , GrossoMA , MercuriM , LanzHJ , et al. Magnetic resonance venography to assess thrombus resolution with edoxaban monotherapy versus parenteral anticoagulation/warfarin for symptomatic deep vein thrombosis: a multicenter feasibility study. Vascular Medicine2016;21(4):361-8. PiazzaG , ManiV , GrossoM , MercuriM , LanzH , SchusslerS , et al. A randomized, open-label, multicenter study of the efficacy and safety of edoxaban monotherapy versus low-molecular weight heparin/warfarin in patients with symptomatic deep vein thrombosis-edoxaban thrombus reduction imaging study (etris). Circulation2014;130:A12074. ">eTRIS 2016</a>; <a href="./references#CD010956-bbs2-0012" title="AmayaN , UzuiH , HisazakiK , HasegwaK , KasenoK , TadaH . Edoxaban normalizes the elevated D-dimer levels potently and promptly in patients with venous thromboembolisms: a comparison with traditional anticoagulant therapy. European Heart Journal2016;37:278. BoschFT , Van EsN , Di NisioM , CarrierM , SegersA , GrossoMA , et al. The Ottawa score does not predict recurrent venous thromboembolism in cancer patients: results from the Hokusai-VTE cancer study. Research and Practice in Thrombosis and Haemostasis2019;3(S1):717-8. KraaijpoelN , Di NisioM , MulderFI , Van EsN , RaskobGE . Clinical impact of bleeding in cancer-associated venous thromboembolism: results from the Hokusai VTE Cancer randomized trial. Thrombosis Research2018;164(Suppl 1):S223. [DOI: 10.1016/j.thromres.2018.02.094]MulderFI , Di NisioM , AyC , CarrierM , BoschFT , SegersA , et al. Clinical implications of incidental venous thromboembolism in cancer patients. European Respiratory Journal2020;55(2):1901697. [DOI: 10.1183/13993003.01697-2019]MulderFI , Van EsN , KraaijpoelN , Di NisioM , CarrierM , GarciaD , et al. Efficacy and safety of edoxaban in clinically relevant subgroups: results from the Hokusai VTE Cancer randomized trial. Thrombosis Research2018;164:S194. NCT02073682. Cancer venous thromboembolism (VTE). clinicaltrials.gov/ct2/show/NCT02073682 (first received 27 February 2014). RaskobG , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaD , et al. Edoxaban versus dalteparin for treatment of venous thromboembolism (VTE) associated with cancer: Hokusai VTE-cancer randomized trial. Supportive Care in Cancer2018;26(2):S316-S317. RaskobGE , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaD , et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. New England Journal of Medicine2018;378(7):615-24. RaskobGE , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaDA , et al. A randomized, open-label, blinded outcome assessment trial evaluating the efficacy and safety of LMWH/Edoxaban versus dalteparin for venous thromboembolism associated with cancer: Hokusai VTE-cancer study. Blood2017;130(Suppl 1):LBA-6. ">Hokusai VTE Cancer 2018</a>; <a href="./references#CD010956-bbs2-0011" title="BistervelsI , BavaliaR , BoersmaW , MeijerK , VerhammeP , Ten Cate-HoekAJ , et al. Hokusai Post-DVT Study: a follow-up study on long-term outcomes of deep vein thrombosis in patients treated with edoxaban vs warfarin. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):PB2207. BrekelmansMP , AgenoW , BeenenLF , BrennerB , BullerHR , ChenCZ , et al. Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology2016;3(9):e437-45. BrekelmansMP , BlekerSM , BauersachsR , BodaZ , BüllerHR , ChoiY , et al. Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists. Thrombosis and Haemostasis2016;116(1):155-61. Di NisioM , Van EsN , CarrierM , WangTF , GarciaD , SegersA , et al. Extended treatment with edoxaban in cancer patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE Cancer study. Journal of Thrombosis and Haemostasis2019;17:1866–74. EUCTR2009-014290-40-SE. A phase 3, randomized, double-blind, double-dummy, parallel group, multi-center, multi-national study for evaluation of efficacy and safety of DU-176b versus warfarin in subjects with atrial fibrillation - effective anticoagulation with factor Xa next generation in atrial fibrillation (ENGAGE-AF TIMI-48). trialsearch.who.int/?trialid=EUCTR2009-014290-40-SE (first received 30 November 2009). EichingerS , LinM , KyrlePA , GrossoMA . Recurrent venous thromboembolism during anticoagulation: an investigator-initiated post-hoc analysis of the hokusai-VTE trial. Blood2018;132:2539. KlokFA , BarcoS , KonstantinidesSV . External validation of the VTE-BLEED score for predicting major bleeding in stable anticoagulated patients with venous thromboembolism. Thrombosis and Haemostasis2017;117(6):1164-70. KraaijpoelN , Van EsN , RaskobGE , BüllerHR , CarrierM , ZhangG , et al. Risk scores for occult cancer in patients with venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2018;118(7):1270-8. MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMP , ChenCZ , et al. Outpatient management in patients with venous thromboembolism with edoxaban: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2017;117(12):2406-14. MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMP , ChenCZ , et al. Safety and efficacy of edoxaban compared with warfarin for the treatment of acute symptomatic deep-vein thrombosis in the outpatient setting. Research and Practice in Thrombosis and Haemostasis2017;1:913. MulderFI , Van EsN , KraaijpoelN , Di NisioM , CarrierM , DuggalA , et al. Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: results from the Hokusai VTE Cancer study. Thrombosis Research2020;185:13-9. NCT00986154. Comparative investigation of Low Molecular Weight (LMW) heparin/edoxaban tosylate (DU176b) versus (LMW) heparin/warfarin in the treatment of symptomatic deep-vein blood clots and/or lung blood clots. (The Edoxaban Hokusai-VTE Study). clinicaltrials.gov/ct2/show/NCT00986154 (first received 29 September 2009). NakamuraM , WangYQ , WangC , OhD , YinWH , KimuraT , et al. Efficacy and safety of edoxaban for treatment of venous thromboembolism: a subanalysis of East Asian patients in the Hokusai-VTE trial. Journal of Thrombosis and Haemostasis2015;13(9):1606-14. NybergJ , KarlssonKE , JönssonS , YinO , MillerR , KarlssonMO , et al. Edoxaban exposure-response analysis and clinical utility index assessment in patients with symptomatic deep-vein thrombosis or pulmonary embolism. CPT Pharmacometrics and Systems Pharmacology2016;5(4):222-32. RaskobG , AgenoW , CohenAT , BrekelmansMP , GrossoMA , SegersA , et al. Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology2016;3(5):e228-e236. RaskobG , BullerH , PrinsM , SegersA , ShiM , SchwochoL , et al. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study - methodological implications for clinical trials. Journal of Thrombosis and Haemostasis2013;11(7):1287-94. RaskobGE , BullerH , AngchaisuksiriP , OhD , BodaZ , LyonsRM , et al. Edoxaban for long-term treatment of venous thromboembolism in cancer patients. Blood2013;122(21):211. RaskobGE , Van EsN , SegersA , AngchaisuksiriP , OhD , BodaZ , et al. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematology2016;3(8):e379-87. ScheresLJ , BrekelmansMA , WalterA , CihanA , BüllerHR , SabineE , et al. Abnormal vaginal bleeding in women of reproductive age treated with edoxaban or warfarin for venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. British Journal of Obstetrics and Gynaecology2018;125(12):1581-9. The Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. New England Journal of Medicine2013;369(15):1406-15. VanasscheT , VerhammeP , WellsPS , SegersA , AgenoW , BrekelmansMP , et al. Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: an analysis of the randomized, double-blind Hokusai-VTE trial. Thrombosis Research2018;162:7-14. VerhammeP , WellsPS , SegersA , AgenoW , BrekelmansMP , CohenAT , et al. Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial. Thrombosis and Haemostasis2016;116(4):747-53. ">Hokusai‐VTE 2013</a>; <a href="./references#CD010956-bbs2-0013" title="MatsuoH , PrinsM , LensingAW , FujinumaEW , MiyamotoY , KajikawaM . Shortened length of hospital stay with rivaroxaban in patients with symptomatic venous thromboembolism in Japan: the J-EINSTEIN pulmonary embolism and deep vein thrombosis program. Current Medical Research and Opinion2015;31(6):1057-61. NCT01516814. Venous thromboembolism (VTE) treatment study in Japanese pulmonary embolism (PE) patients. clinicaltrials.gov/ct2/show/NCT01516814 (first received 25 January 2012). YamadaN , HirayamaA , MaedaH , SakagamiS , ShikataH , PrinsMH , et al. Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism-the J-EINSTEIN DVT and PE program. Thrombosis Journal2015;13:2. ">J‐EINSTEIN DVT and PE 2015</a>; <a href="./references#CD010956-bbs2-0014" title="MokademME , HassanA , AlgabyAZ . Efficacy and safety of apixaban in patients with active malignancy and acute deep venous thrombosis. Vascular2021;29(5):745-50. NCT04462003. Efficacy of apixaban in malignancy with deep venous thrombosis (DVT). clinicaltrials.gov/ct2/show/NCT04462003 (first received 3 July 2019). ">Mokadem 2021</a>; <a href="./references#CD010956-bbs2-0015" title="AgnelliG , GallusA , GoldhaberSZ , HaasS , HuismanMV , HullRD , et al. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAT 59-7939 in patients with acute symptomatic deep-vein thrombosis) study. Circulation2007;116:180-7. ">ODIXa‐DVT 2007</a>), nine measured recurrent DVT (<a href="./references#CD010956-bbs2-0001" title="AgnelliG , BullerH , MasiukiewiczUP . Apixaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism: a randomized, double-blind trial (AMPLIFY). Journal of Thrombosis and Haemostasis2013;11:18. AgnelliG , BullerHR , CohenA , CurtoD , GallusAS , JohnsonM , et al. Oral apixaban for the treatment of acute venous thromboembolism. New England Journal of Medicine2013;369:799-808. AgnelliG , BullerHR , CohenA , CurtoM , GallusAS , PakR , et al. Apixaban for the treatment of venous thromboembolism in cancer patients: data from the AMPLIFY trial. Canadian Journal of Cardiology2014;30(10 Suppl 1):S278. AgnelliG , BullerHR , CohenA , GallusAS , LeeTC , PakR , et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. Journal of Thrombosis and Haemostasis2015;13(12):2187-91. AgnelliG . Apixaban was non-inferior to enoxaparin plus warfarin in patients with acute venous thromboembolism. Annals of Internal Medicine2013;159(8):JC2. BlekerSM , CohenAT , BüllerHR , AgnelliG , GallusAS , RaskobGE , et al. Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Thrombosis and Haemostasis2016;116(6):159-64. BrekelmansM , ScheresL , BlekerS , HuttenB , TimmermansA , BüllerH , et al. Abnormal vaginal bleeding in women with venous thromboembolism treated with apixaban or warfarin. Thrombosis and Haemostasis2017;117(04):809-15. CohenA , AgnelliG , BullerH , GallusA , RaskobG , SandersP , et al. Characteristics and outcomes in patients with venous thromboembolism taking concomitant anti-platelet agents and anticoagulants in the AMPLIFY Trial. Thrombosis and Haemostasis2019;119(3):461-6. CohenA , AgnelliG , BullerHR , ChaudhuriS , GallusAS , RaskobGE , et al. Analysis of the bleeding and thromboembolic risk with concomitant use of antiplatelet treatment in the AMPLIFY trial. Canadian Journal of Cardiology2014;30(10):S272. CohenA , GallusAS , AgnelliG , BullerHR , PakR , PorcariAR , et al. Time in Therapeutic Range (TTR) and relative efficacy and safety of treatment with apixaban or enoxaparin/warfarin for acute symptomatic venous thromboembolism: an analysis of the Amplify trial data. Blood2014;124(21):1543. CohenAT , PanS , ByonW , IlyasBS , LeeTC . Efficacy, safety, and exposure of apixaban in patients with high body weight or obesity and venous thromboembolism: insights from AMPLIFY. Advances in Therapy2021;38(6):3003-18. EUCTR2007-007867-25-PT. A safety and efficacy trial evaluating the use of apixaban in the treatment of symptomatic deep vein thrombosis and pulmonary embolism revised protocol number: 01, incorporates amendment(s) 02 + protocol amendment 01 (version 1.0 dated 21-Apr-08) site-specific - molecular profiling supplement samples for Pfizer’s exploratory research biobank. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2007%E2%80%90007867%E2%80%9025%E2%80%90PT (first received 14 July 2008). GallusAS , AgnelliG , BullerHR , CohenA , LeeTC , PakR , et al. Apixaban for treatment of venous thromboembolism in patients from study centres in Asia: a subgroup analysis of the Amplify trial. Journal of Thrombosis and Haemostasis2015;13:727. LeeT , PanS , ByonW , IlyasBS . Safety and efficacy of apixaban versus enoxaparin/warfarin in patients with extremes of body weight: post-hoc analysis of the AMPLIFY trial. Blood2019;134(Suppl 1):1152. LiuX , JohnsonM , MardekianJ , PhatakH , ThompsonJ , CohenAT . Apixaban reduces hospitalizations in patients with venous thromboembolism: an analysis of the apixaban for the Initial management of pulmonary embolism and deep‐vein thrombosis as first‐line therapy (AMPLIFY) trial. Journal of the American Heart Association2015;4(12):e002340. NCT00633893. Efficacy and safety study of apixaban for extended treatment of deep vein thrombosis or pulmonary embolism. clinicaltrials.gov/ct2/show/NCT00633893?term=ajax&amp;rank=5 (first received 12 March 2008). NCT00643201. Efficacy and safety study of apixaban for the treatment of deep vein thrombosis or pulmonary embolism. clinicaltrials.gov/ct2/show/NCT00643201 (first received 26 March 2008). RaskobGE , GallusAS , SandersP , ThompsonJR , AgnelliG , BullerHR , et al. Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy: a sub-analysis of the AMPLIFY trial. Thrombosis and Haemostasis2016;115(4):809-16. ">AMPLIFY 2013</a>; <a href="./references#CD010956-bbs2-0003" title="BarrettYC , WangJ , KnabbR , MohanP . Apixaban decreases coagulation activity in patients with acute deep-vein thrombosis. Thrombosis and Haemostasis2011;105:181-9. Botticelli Investigators Writing Committee, BullerH , DeitchmanD , PrinsM , SegersA . Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. Journal of Thrombosis and Haemostasis2008;6:1313-8. BullerHR . A dose finding study of the oral direct factor Xa inhibitor apixaban in the treatment of patients with acute symptomatic deep vein thrombosis - the Botticelli Investigators. Journal of Thrombosis and Haemostasis2007;5 (Suppl 2):O-S-003. NCT00252005. Oral direct factor Xa-inhibitor apixaban in patients with acute symptomatic deep-vein thrombosis - the Botticelli DVT study. clinicaltrials.gov/ct/show/NCT00252005?order=1 (first received 11 November 2005). ">Botticelli DVT 2008</a>; <a href="./references#CD010956-bbs2-0007" title="BullerH , DariusH . EINSTEIN DVT: oral rivaroxaban versus standard therapy in the initial treatment of symptomatic deep vein thrombosis and long-term prevention of recurrent venous thromboembolism. escardio.org/The-ESC/Press-Office/Press-releases/EINSTEIN-DVT-Oral-rivaroxaban-versus-standard-therapy-in-the-initial-treatment (accessed 19 October 2022). BullerHR , AgnelliG . Once- or twice-daily rivaroxaban for the treatment of proximal deep vein thrombosis: similar efficacy and safety to standard therapy in dose-ranging studies. Blood2006;108(11 Part 1):172-3. BullerHR , LensingAW , PrinsMH , AgnelliG , CohenA , GallusAS , et al. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT dose-ranging study. Blood2008;112(6):2242-7. NCT00395772. Once-daily oral direct factor Xa inhibitor BAY59-7939 in patients with acute symptomatic deep-vein thrombosis. clinicaltrials.gov/ct2/show/NCT00395772?term=einstein-dvt&amp;rank=2 (first received 3 November 2006). ">EINSTEIN‐DVT dose 2008</a>; <a href="./references#CD010956-bbs2-0006" title="BamberL , WangMY , PrinsMH , CiniglioC , BauersachsR , LensingAW , et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis. Thrombosis and Haemostasis2013;110(4):732-41. BauersachsR , LensingAW , PapA , DecoususH . No need for a rivaroxaban dose reduction in renally impaired patients with symptomatic venous thromboembolism. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):30-1. BistervelsI , GebelM , LensingA , MiddeldorpS , CoppensM . Effect of polypharmacy on bleeding of rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolism. Research and Practice in Thrombosis and Haemostasis2019;3:798‐9. BookhartBK , HaskellL , BamberL , WangM , ScheinJ , ModySH . Length of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial program. Journal of Medical Economics2014;17(10):691-5. BullerHR . Oral rivaroxaban for the acute and continued treatment of symptomatic venous thromboembolism. The Einstein-DVT and Einstein-Extension study. Blood2010;116(21):187. CheungW , MiddeldorpS , PrinsMP , PapAF , LensingAW , Hoek-tenCA , et al. Post thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep vein thrombosis. Journal of Thrombosis and Haemostasis2015;13(S2):219-20. CheungYW , MiddeldorpS , PrinsMH , PapAF , PrandoniP . Post-thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep-vein thrombosis. A post-hoc analysis. Thrombosis and Haemostasis2016;116(4):733-8. EUCTR2004-002171-16-IT. Once-daily oral direct factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis. The EINSTEIN-DVT dose-finding study. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2004%E2%80%90002171%E2%80%9016%E2%80%90IT (first received 15 October 2008). EUCTR2006-004495-13-DK. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep-vein thrombosis or pulmonary embolism. trialsearch.who.int/?TrialID=EUCTR2006-004495-13-DK (first received 29 March 2007). EerenbergES , MiddeldorpS , LeviM , LensingAW , BüllerHR . Clinical impact and course of major bleeding with rivaroxaban and vitamin K antagonists. Journal of Thrombosis and Haemostasis2015;13(9):1590-6. KlineJA , JimenezD , CourtneyDM , IanusJ , CaoL , WellsPS . Use of the Riete 2008 bleeding score to identify patients at low risk for major bleeding in patients treated with rivaroxaban. Academic Emergency Medicine2015;22:S162. NCT00440193. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep vein thrombosis - The EINSTEIN DVT Study. clinicaltrials.gov/ct2/show/NCT00440193 (first received 26 February 2007). PrinsMH , ErkensPG , LensingAW . Incidence of recurrent venous thromboembolism in patients following completion of the EINSTEIN DVT and EINSTEIN PE studies. Journal of Thrombosis and Haemostasis2013;11(Suppl):257. PrinsMH , LensingAW , BauersachsR , Van BellenB , BounameauxH , BrightonTA , et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thrombosis Journal2013;11(1):21. The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. New England Journal of Medicine2010;363(26):2499-510. Van BellenB , PrinsM , BamberL , WangM , LensingAW . Reduction in initial length of stay with rivaroxaban single-drug regimen versus LMWH-VKA standard of care: findings from the EINSTEIN trial program. Blood2012;120(21):3419. Van BellenB , PrinsM , BamberL , WangM , LensingAW . Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism. Current Medical Research and Opinion2014;30(5):829-37. WangY , WangC , ChenZ , ZhangJ , LiuZ , JinB , et al. Rivaroxaban for the treatment of symptomatic deep vein thrombosis and/or pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):694. WangY , WangC , ChenZ , ZhangJ , LiuZ , JinB , et al. Rivaroxaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Thrombosis Journal2013;11(1):25. ">EINSTEIN‐DVT 2010</a>; <a href="./references#CD010956-bbs2-0008" title="BullerHR , PrinsMH , LensinAW , DecoususH , JacobsonBF , MinarE , et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. New England Journal of Medicine2012;366:1287-97. FermannGJ , Erkens Pmg, PrinsMH , WellsPS , Pap ÁF, LensingAW , et al. Treatment of pulmonary embolism with rivaroxaban: outcomes by simplified pulmonary embolism severity index score from a post hoc analysis of the EINSTEIN PE study. Academic Emergency Medicine2015;22(3):299-307. NCT00439777. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic pulmonary embolism with or without symptomatic deep-vein thrombosis: Einstein-PE evaluation, 2008. clinicaltrials.gov/ct2/show/NCT00439777?term=NCT00439777&amp;rank=1 (first received 26 February 2007). PrinsM , BamberL , CanoS , WangM , LensingAW , BauersachsR . Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic pulmonary embolism. Blood2012;120(21):1163. PrinsMH , BamberL , CanoSJ , WangMY , ErkensP , BauersachsR , et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial. Thrombosis Research2015;135(2):281-8. ">EINSTEIN‐PE 2012</a>; <a href="./references#CD010956-bbs2-0011" title="BistervelsI , BavaliaR , BoersmaW , MeijerK , VerhammeP , Ten Cate-HoekAJ , et al. Hokusai Post-DVT Study: a follow-up study on long-term outcomes of deep vein thrombosis in patients treated with edoxaban vs warfarin. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):PB2207. BrekelmansMP , AgenoW , BeenenLF , BrennerB , BullerHR , ChenCZ , et al. Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology2016;3(9):e437-45. BrekelmansMP , BlekerSM , BauersachsR , BodaZ , BüllerHR , ChoiY , et al. Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists. Thrombosis and Haemostasis2016;116(1):155-61. Di NisioM , Van EsN , CarrierM , WangTF , GarciaD , SegersA , et al. Extended treatment with edoxaban in cancer patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE Cancer study. Journal of Thrombosis and Haemostasis2019;17:1866–74. EUCTR2009-014290-40-SE. A phase 3, randomized, double-blind, double-dummy, parallel group, multi-center, multi-national study for evaluation of efficacy and safety of DU-176b versus warfarin in subjects with atrial fibrillation - effective anticoagulation with factor Xa next generation in atrial fibrillation (ENGAGE-AF TIMI-48). trialsearch.who.int/?trialid=EUCTR2009-014290-40-SE (first received 30 November 2009). EichingerS , LinM , KyrlePA , GrossoMA . Recurrent venous thromboembolism during anticoagulation: an investigator-initiated post-hoc analysis of the hokusai-VTE trial. Blood2018;132:2539. KlokFA , BarcoS , KonstantinidesSV . External validation of the VTE-BLEED score for predicting major bleeding in stable anticoagulated patients with venous thromboembolism. Thrombosis and Haemostasis2017;117(6):1164-70. KraaijpoelN , Van EsN , RaskobGE , BüllerHR , CarrierM , ZhangG , et al. Risk scores for occult cancer in patients with venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2018;118(7):1270-8. MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMP , ChenCZ , et al. Outpatient management in patients with venous thromboembolism with edoxaban: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2017;117(12):2406-14. MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMP , ChenCZ , et al. Safety and efficacy of edoxaban compared with warfarin for the treatment of acute symptomatic deep-vein thrombosis in the outpatient setting. Research and Practice in Thrombosis and Haemostasis2017;1:913. MulderFI , Van EsN , KraaijpoelN , Di NisioM , CarrierM , DuggalA , et al. Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: results from the Hokusai VTE Cancer study. Thrombosis Research2020;185:13-9. NCT00986154. Comparative investigation of Low Molecular Weight (LMW) heparin/edoxaban tosylate (DU176b) versus (LMW) heparin/warfarin in the treatment of symptomatic deep-vein blood clots and/or lung blood clots. (The Edoxaban Hokusai-VTE Study). clinicaltrials.gov/ct2/show/NCT00986154 (first received 29 September 2009). NakamuraM , WangYQ , WangC , OhD , YinWH , KimuraT , et al. Efficacy and safety of edoxaban for treatment of venous thromboembolism: a subanalysis of East Asian patients in the Hokusai-VTE trial. Journal of Thrombosis and Haemostasis2015;13(9):1606-14. NybergJ , KarlssonKE , JönssonS , YinO , MillerR , KarlssonMO , et al. Edoxaban exposure-response analysis and clinical utility index assessment in patients with symptomatic deep-vein thrombosis or pulmonary embolism. CPT Pharmacometrics and Systems Pharmacology2016;5(4):222-32. RaskobG , AgenoW , CohenAT , BrekelmansMP , GrossoMA , SegersA , et al. Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology2016;3(5):e228-e236. RaskobG , BullerH , PrinsM , SegersA , ShiM , SchwochoL , et al. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study - methodological implications for clinical trials. Journal of Thrombosis and Haemostasis2013;11(7):1287-94. RaskobGE , BullerH , AngchaisuksiriP , OhD , BodaZ , LyonsRM , et al. Edoxaban for long-term treatment of venous thromboembolism in cancer patients. Blood2013;122(21):211. RaskobGE , Van EsN , SegersA , AngchaisuksiriP , OhD , BodaZ , et al. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematology2016;3(8):e379-87. ScheresLJ , BrekelmansMA , WalterA , CihanA , BüllerHR , SabineE , et al. Abnormal vaginal bleeding in women of reproductive age treated with edoxaban or warfarin for venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. British Journal of Obstetrics and Gynaecology2018;125(12):1581-9. The Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. New England Journal of Medicine2013;369(15):1406-15. VanasscheT , VerhammeP , WellsPS , SegersA , AgenoW , BrekelmansMP , et al. Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: an analysis of the randomized, double-blind Hokusai-VTE trial. Thrombosis Research2018;162:7-14. VerhammeP , WellsPS , SegersA , AgenoW , BrekelmansMP , CohenAT , et al. Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial. Thrombosis and Haemostasis2016;116(4):747-53. ">Hokusai‐VTE 2013</a>; <a href="./references#CD010956-bbs2-0014" title="MokademME , HassanA , AlgabyAZ . Efficacy and safety of apixaban in patients with active malignancy and acute deep venous thrombosis. Vascular2021;29(5):745-50. NCT04462003. Efficacy of apixaban in malignancy with deep venous thrombosis (DVT). clinicaltrials.gov/ct2/show/NCT04462003 (first received 3 July 2019). ">Mokadem 2021</a>; <a href="./references#CD010956-bbs2-0015" title="AgnelliG , GallusA , GoldhaberSZ , HaasS , HuismanMV , HullRD , et al. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAT 59-7939 in patients with acute symptomatic deep-vein thrombosis) study. Circulation2007;116:180-7. ">ODIXa‐DVT 2007</a>; <a href="./references#CD010956-bbs2-0017" title="Kang JiM, ParkKH , AhnS , ChoS , MinSK . Rivaroxaban after thrombolysis in acute iliofemoral venous thrombosis: a randomized, open-labeled, multicenter trial. Scientific Reports2019;9(1):20356. MinSK , AhnS , ParkKH , KangJM , KimJY . Prevention of recurrence after thrombolysis in acute iliofemoral venous thrombosis with rivaroxaban (Prais Study): a prospective, randomized, open label, multicenter trial. European Journal of Vascular and Endovascular Surgery2019;58(6):e516. NCT01986192. Prevention of recurrence after thrombolysis in acute iliofemoral venous thrombosis (PRAIS) study. clinicaltrials.gov/show/NCT01986192 (first received 18 November 2013). ">PRAIS 2019</a>), six measured fatal PE (<a href="./references#CD010956-bbs2-0001" title="AgnelliG , BullerH , MasiukiewiczUP . Apixaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism: a randomized, double-blind trial (AMPLIFY). Journal of Thrombosis and Haemostasis2013;11:18. AgnelliG , BullerHR , CohenA , CurtoD , GallusAS , JohnsonM , et al. Oral apixaban for the treatment of acute venous thromboembolism. New England Journal of Medicine2013;369:799-808. AgnelliG , BullerHR , CohenA , CurtoM , GallusAS , PakR , et al. Apixaban for the treatment of venous thromboembolism in cancer patients: data from the AMPLIFY trial. Canadian Journal of Cardiology2014;30(10 Suppl 1):S278. AgnelliG , BullerHR , CohenA , GallusAS , LeeTC , PakR , et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. Journal of Thrombosis and Haemostasis2015;13(12):2187-91. AgnelliG . Apixaban was non-inferior to enoxaparin plus warfarin in patients with acute venous thromboembolism. Annals of Internal Medicine2013;159(8):JC2. BlekerSM , CohenAT , BüllerHR , AgnelliG , GallusAS , RaskobGE , et al. Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Thrombosis and Haemostasis2016;116(6):159-64. BrekelmansM , ScheresL , BlekerS , HuttenB , TimmermansA , BüllerH , et al. Abnormal vaginal bleeding in women with venous thromboembolism treated with apixaban or warfarin. Thrombosis and Haemostasis2017;117(04):809-15. CohenA , AgnelliG , BullerH , GallusA , RaskobG , SandersP , et al. Characteristics and outcomes in patients with venous thromboembolism taking concomitant anti-platelet agents and anticoagulants in the AMPLIFY Trial. Thrombosis and Haemostasis2019;119(3):461-6. CohenA , AgnelliG , BullerHR , ChaudhuriS , GallusAS , RaskobGE , et al. Analysis of the bleeding and thromboembolic risk with concomitant use of antiplatelet treatment in the AMPLIFY trial. Canadian Journal of Cardiology2014;30(10):S272. CohenA , GallusAS , AgnelliG , BullerHR , PakR , PorcariAR , et al. Time in Therapeutic Range (TTR) and relative efficacy and safety of treatment with apixaban or enoxaparin/warfarin for acute symptomatic venous thromboembolism: an analysis of the Amplify trial data. Blood2014;124(21):1543. CohenAT , PanS , ByonW , IlyasBS , LeeTC . Efficacy, safety, and exposure of apixaban in patients with high body weight or obesity and venous thromboembolism: insights from AMPLIFY. Advances in Therapy2021;38(6):3003-18. EUCTR2007-007867-25-PT. A safety and efficacy trial evaluating the use of apixaban in the treatment of symptomatic deep vein thrombosis and pulmonary embolism revised protocol number: 01, incorporates amendment(s) 02 + protocol amendment 01 (version 1.0 dated 21-Apr-08) site-specific - molecular profiling supplement samples for Pfizer’s exploratory research biobank. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2007%E2%80%90007867%E2%80%9025%E2%80%90PT (first received 14 July 2008). GallusAS , AgnelliG , BullerHR , CohenA , LeeTC , PakR , et al. Apixaban for treatment of venous thromboembolism in patients from study centres in Asia: a subgroup analysis of the Amplify trial. Journal of Thrombosis and Haemostasis2015;13:727. LeeT , PanS , ByonW , IlyasBS . Safety and efficacy of apixaban versus enoxaparin/warfarin in patients with extremes of body weight: post-hoc analysis of the AMPLIFY trial. Blood2019;134(Suppl 1):1152. LiuX , JohnsonM , MardekianJ , PhatakH , ThompsonJ , CohenAT . Apixaban reduces hospitalizations in patients with venous thromboembolism: an analysis of the apixaban for the Initial management of pulmonary embolism and deep‐vein thrombosis as first‐line therapy (AMPLIFY) trial. Journal of the American Heart Association2015;4(12):e002340. NCT00633893. Efficacy and safety study of apixaban for extended treatment of deep vein thrombosis or pulmonary embolism. clinicaltrials.gov/ct2/show/NCT00633893?term=ajax&amp;rank=5 (first received 12 March 2008). NCT00643201. Efficacy and safety study of apixaban for the treatment of deep vein thrombosis or pulmonary embolism. clinicaltrials.gov/ct2/show/NCT00643201 (first received 26 March 2008). RaskobGE , GallusAS , SandersP , ThompsonJR , AgnelliG , BullerHR , et al. Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy: a sub-analysis of the AMPLIFY trial. Thrombosis and Haemostasis2016;115(4):809-16. ">AMPLIFY 2013</a>; <a href="./references#CD010956-bbs2-0003" title="BarrettYC , WangJ , KnabbR , MohanP . Apixaban decreases coagulation activity in patients with acute deep-vein thrombosis. Thrombosis and Haemostasis2011;105:181-9. Botticelli Investigators Writing Committee, BullerH , DeitchmanD , PrinsM , SegersA . Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. Journal of Thrombosis and Haemostasis2008;6:1313-8. BullerHR . A dose finding study of the oral direct factor Xa inhibitor apixaban in the treatment of patients with acute symptomatic deep vein thrombosis - the Botticelli Investigators. Journal of Thrombosis and Haemostasis2007;5 (Suppl 2):O-S-003. NCT00252005. Oral direct factor Xa-inhibitor apixaban in patients with acute symptomatic deep-vein thrombosis - the Botticelli DVT study. clinicaltrials.gov/ct/show/NCT00252005?order=1 (first received 11 November 2005). ">Botticelli DVT 2008</a>; <a href="./references#CD010956-bbs2-0007" title="BullerH , DariusH . EINSTEIN DVT: oral rivaroxaban versus standard therapy in the initial treatment of symptomatic deep vein thrombosis and long-term prevention of recurrent venous thromboembolism. escardio.org/The-ESC/Press-Office/Press-releases/EINSTEIN-DVT-Oral-rivaroxaban-versus-standard-therapy-in-the-initial-treatment (accessed 19 October 2022). BullerHR , AgnelliG . Once- or twice-daily rivaroxaban for the treatment of proximal deep vein thrombosis: similar efficacy and safety to standard therapy in dose-ranging studies. Blood2006;108(11 Part 1):172-3. BullerHR , LensingAW , PrinsMH , AgnelliG , CohenA , GallusAS , et al. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT dose-ranging study. Blood2008;112(6):2242-7. NCT00395772. Once-daily oral direct factor Xa inhibitor BAY59-7939 in patients with acute symptomatic deep-vein thrombosis. clinicaltrials.gov/ct2/show/NCT00395772?term=einstein-dvt&amp;rank=2 (first received 3 November 2006). ">EINSTEIN‐DVT dose 2008</a>; <a href="./references#CD010956-bbs2-0006" title="BamberL , WangMY , PrinsMH , CiniglioC , BauersachsR , LensingAW , et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis. Thrombosis and Haemostasis2013;110(4):732-41. BauersachsR , LensingAW , PapA , DecoususH . No need for a rivaroxaban dose reduction in renally impaired patients with symptomatic venous thromboembolism. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):30-1. BistervelsI , GebelM , LensingA , MiddeldorpS , CoppensM . Effect of polypharmacy on bleeding of rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolism. Research and Practice in Thrombosis and Haemostasis2019;3:798‐9. BookhartBK , HaskellL , BamberL , WangM , ScheinJ , ModySH . Length of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial program. Journal of Medical Economics2014;17(10):691-5. BullerHR . Oral rivaroxaban for the acute and continued treatment of symptomatic venous thromboembolism. The Einstein-DVT and Einstein-Extension study. Blood2010;116(21):187. CheungW , MiddeldorpS , PrinsMP , PapAF , LensingAW , Hoek-tenCA , et al. Post thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep vein thrombosis. Journal of Thrombosis and Haemostasis2015;13(S2):219-20. CheungYW , MiddeldorpS , PrinsMH , PapAF , PrandoniP . Post-thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep-vein thrombosis. A post-hoc analysis. Thrombosis and Haemostasis2016;116(4):733-8. EUCTR2004-002171-16-IT. Once-daily oral direct factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis. The EINSTEIN-DVT dose-finding study. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2004%E2%80%90002171%E2%80%9016%E2%80%90IT (first received 15 October 2008). EUCTR2006-004495-13-DK. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep-vein thrombosis or pulmonary embolism. trialsearch.who.int/?TrialID=EUCTR2006-004495-13-DK (first received 29 March 2007). EerenbergES , MiddeldorpS , LeviM , LensingAW , BüllerHR . Clinical impact and course of major bleeding with rivaroxaban and vitamin K antagonists. Journal of Thrombosis and Haemostasis2015;13(9):1590-6. KlineJA , JimenezD , CourtneyDM , IanusJ , CaoL , WellsPS . Use of the Riete 2008 bleeding score to identify patients at low risk for major bleeding in patients treated with rivaroxaban. Academic Emergency Medicine2015;22:S162. NCT00440193. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep vein thrombosis - The EINSTEIN DVT Study. clinicaltrials.gov/ct2/show/NCT00440193 (first received 26 February 2007). PrinsMH , ErkensPG , LensingAW . Incidence of recurrent venous thromboembolism in patients following completion of the EINSTEIN DVT and EINSTEIN PE studies. Journal of Thrombosis and Haemostasis2013;11(Suppl):257. PrinsMH , LensingAW , BauersachsR , Van BellenB , BounameauxH , BrightonTA , et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thrombosis Journal2013;11(1):21. The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. New England Journal of Medicine2010;363(26):2499-510. Van BellenB , PrinsM , BamberL , WangM , LensingAW . Reduction in initial length of stay with rivaroxaban single-drug regimen versus LMWH-VKA standard of care: findings from the EINSTEIN trial program. Blood2012;120(21):3419. Van BellenB , PrinsM , BamberL , WangM , LensingAW . Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism. Current Medical Research and Opinion2014;30(5):829-37. WangY , WangC , ChenZ , ZhangJ , LiuZ , JinB , et al. Rivaroxaban for the treatment of symptomatic deep vein thrombosis and/or pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):694. WangY , WangC , ChenZ , ZhangJ , LiuZ , JinB , et al. Rivaroxaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Thrombosis Journal2013;11(1):25. ">EINSTEIN‐DVT 2010</a>; <a href="./references#CD010956-bbs2-0011" title="BistervelsI , BavaliaR , BoersmaW , MeijerK , VerhammeP , Ten Cate-HoekAJ , et al. Hokusai Post-DVT Study: a follow-up study on long-term outcomes of deep vein thrombosis in patients treated with edoxaban vs warfarin. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):PB2207. BrekelmansMP , AgenoW , BeenenLF , BrennerB , BullerHR , ChenCZ , et al. Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology2016;3(9):e437-45. BrekelmansMP , BlekerSM , BauersachsR , BodaZ , BüllerHR , ChoiY , et al. Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists. Thrombosis and Haemostasis2016;116(1):155-61. Di NisioM , Van EsN , CarrierM , WangTF , GarciaD , SegersA , et al. Extended treatment with edoxaban in cancer patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE Cancer study. Journal of Thrombosis and Haemostasis2019;17:1866–74. EUCTR2009-014290-40-SE. A phase 3, randomized, double-blind, double-dummy, parallel group, multi-center, multi-national study for evaluation of efficacy and safety of DU-176b versus warfarin in subjects with atrial fibrillation - effective anticoagulation with factor Xa next generation in atrial fibrillation (ENGAGE-AF TIMI-48). trialsearch.who.int/?trialid=EUCTR2009-014290-40-SE (first received 30 November 2009). EichingerS , LinM , KyrlePA , GrossoMA . Recurrent venous thromboembolism during anticoagulation: an investigator-initiated post-hoc analysis of the hokusai-VTE trial. Blood2018;132:2539. KlokFA , BarcoS , KonstantinidesSV . External validation of the VTE-BLEED score for predicting major bleeding in stable anticoagulated patients with venous thromboembolism. Thrombosis and Haemostasis2017;117(6):1164-70. KraaijpoelN , Van EsN , RaskobGE , BüllerHR , CarrierM , ZhangG , et al. Risk scores for occult cancer in patients with venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2018;118(7):1270-8. MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMP , ChenCZ , et al. Outpatient management in patients with venous thromboembolism with edoxaban: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2017;117(12):2406-14. MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMP , ChenCZ , et al. Safety and efficacy of edoxaban compared with warfarin for the treatment of acute symptomatic deep-vein thrombosis in the outpatient setting. Research and Practice in Thrombosis and Haemostasis2017;1:913. MulderFI , Van EsN , KraaijpoelN , Di NisioM , CarrierM , DuggalA , et al. Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: results from the Hokusai VTE Cancer study. Thrombosis Research2020;185:13-9. NCT00986154. Comparative investigation of Low Molecular Weight (LMW) heparin/edoxaban tosylate (DU176b) versus (LMW) heparin/warfarin in the treatment of symptomatic deep-vein blood clots and/or lung blood clots. (The Edoxaban Hokusai-VTE Study). clinicaltrials.gov/ct2/show/NCT00986154 (first received 29 September 2009). NakamuraM , WangYQ , WangC , OhD , YinWH , KimuraT , et al. Efficacy and safety of edoxaban for treatment of venous thromboembolism: a subanalysis of East Asian patients in the Hokusai-VTE trial. Journal of Thrombosis and Haemostasis2015;13(9):1606-14. NybergJ , KarlssonKE , JönssonS , YinO , MillerR , KarlssonMO , et al. Edoxaban exposure-response analysis and clinical utility index assessment in patients with symptomatic deep-vein thrombosis or pulmonary embolism. CPT Pharmacometrics and Systems Pharmacology2016;5(4):222-32. RaskobG , AgenoW , CohenAT , BrekelmansMP , GrossoMA , SegersA , et al. Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology2016;3(5):e228-e236. RaskobG , BullerH , PrinsM , SegersA , ShiM , SchwochoL , et al. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study - methodological implications for clinical trials. Journal of Thrombosis and Haemostasis2013;11(7):1287-94. RaskobGE , BullerH , AngchaisuksiriP , OhD , BodaZ , LyonsRM , et al. Edoxaban for long-term treatment of venous thromboembolism in cancer patients. Blood2013;122(21):211. RaskobGE , Van EsN , SegersA , AngchaisuksiriP , OhD , BodaZ , et al. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematology2016;3(8):e379-87. ScheresLJ , BrekelmansMA , WalterA , CihanA , BüllerHR , SabineE , et al. Abnormal vaginal bleeding in women of reproductive age treated with edoxaban or warfarin for venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. British Journal of Obstetrics and Gynaecology2018;125(12):1581-9. The Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. New England Journal of Medicine2013;369(15):1406-15. VanasscheT , VerhammeP , WellsPS , SegersA , AgenoW , BrekelmansMP , et al. Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: an analysis of the randomized, double-blind Hokusai-VTE trial. Thrombosis Research2018;162:7-14. VerhammeP , WellsPS , SegersA , AgenoW , BrekelmansMP , CohenAT , et al. Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial. Thrombosis and Haemostasis2016;116(4):747-53. ">Hokusai‐VTE 2013</a>; <a href="./references#CD010956-bbs2-0015" title="AgnelliG , GallusA , GoldhaberSZ , HaasS , HuismanMV , HullRD , et al. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAT 59-7939 in patients with acute symptomatic deep-vein thrombosis) study. Circulation2007;116:180-7. ">ODIXa‐DVT 2007</a>), seven measured non‐fatal PE (<a href="./references#CD010956-bbs2-0001" title="AgnelliG , BullerH , MasiukiewiczUP . Apixaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism: a randomized, double-blind trial (AMPLIFY). Journal of Thrombosis and Haemostasis2013;11:18. AgnelliG , BullerHR , CohenA , CurtoD , GallusAS , JohnsonM , et al. Oral apixaban for the treatment of acute venous thromboembolism. New England Journal of Medicine2013;369:799-808. AgnelliG , BullerHR , CohenA , CurtoM , GallusAS , PakR , et al. Apixaban for the treatment of venous thromboembolism in cancer patients: data from the AMPLIFY trial. Canadian Journal of Cardiology2014;30(10 Suppl 1):S278. AgnelliG , BullerHR , CohenA , GallusAS , LeeTC , PakR , et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. Journal of Thrombosis and Haemostasis2015;13(12):2187-91. AgnelliG . Apixaban was non-inferior to enoxaparin plus warfarin in patients with acute venous thromboembolism. Annals of Internal Medicine2013;159(8):JC2. BlekerSM , CohenAT , BüllerHR , AgnelliG , GallusAS , RaskobGE , et al. Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Thrombosis and Haemostasis2016;116(6):159-64. BrekelmansM , ScheresL , BlekerS , HuttenB , TimmermansA , BüllerH , et al. Abnormal vaginal bleeding in women with venous thromboembolism treated with apixaban or warfarin. Thrombosis and Haemostasis2017;117(04):809-15. CohenA , AgnelliG , BullerH , GallusA , RaskobG , SandersP , et al. Characteristics and outcomes in patients with venous thromboembolism taking concomitant anti-platelet agents and anticoagulants in the AMPLIFY Trial. Thrombosis and Haemostasis2019;119(3):461-6. CohenA , AgnelliG , BullerHR , ChaudhuriS , GallusAS , RaskobGE , et al. Analysis of the bleeding and thromboembolic risk with concomitant use of antiplatelet treatment in the AMPLIFY trial. Canadian Journal of Cardiology2014;30(10):S272. CohenA , GallusAS , AgnelliG , BullerHR , PakR , PorcariAR , et al. Time in Therapeutic Range (TTR) and relative efficacy and safety of treatment with apixaban or enoxaparin/warfarin for acute symptomatic venous thromboembolism: an analysis of the Amplify trial data. Blood2014;124(21):1543. CohenAT , PanS , ByonW , IlyasBS , LeeTC . Efficacy, safety, and exposure of apixaban in patients with high body weight or obesity and venous thromboembolism: insights from AMPLIFY. Advances in Therapy2021;38(6):3003-18. EUCTR2007-007867-25-PT. A safety and efficacy trial evaluating the use of apixaban in the treatment of symptomatic deep vein thrombosis and pulmonary embolism revised protocol number: 01, incorporates amendment(s) 02 + protocol amendment 01 (version 1.0 dated 21-Apr-08) site-specific - molecular profiling supplement samples for Pfizer’s exploratory research biobank. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2007%E2%80%90007867%E2%80%9025%E2%80%90PT (first received 14 July 2008). GallusAS , AgnelliG , BullerHR , CohenA , LeeTC , PakR , et al. Apixaban for treatment of venous thromboembolism in patients from study centres in Asia: a subgroup analysis of the Amplify trial. Journal of Thrombosis and Haemostasis2015;13:727. LeeT , PanS , ByonW , IlyasBS . Safety and efficacy of apixaban versus enoxaparin/warfarin in patients with extremes of body weight: post-hoc analysis of the AMPLIFY trial. Blood2019;134(Suppl 1):1152. LiuX , JohnsonM , MardekianJ , PhatakH , ThompsonJ , CohenAT . Apixaban reduces hospitalizations in patients with venous thromboembolism: an analysis of the apixaban for the Initial management of pulmonary embolism and deep‐vein thrombosis as first‐line therapy (AMPLIFY) trial. Journal of the American Heart Association2015;4(12):e002340. NCT00633893. Efficacy and safety study of apixaban for extended treatment of deep vein thrombosis or pulmonary embolism. clinicaltrials.gov/ct2/show/NCT00633893?term=ajax&amp;rank=5 (first received 12 March 2008). NCT00643201. Efficacy and safety study of apixaban for the treatment of deep vein thrombosis or pulmonary embolism. clinicaltrials.gov/ct2/show/NCT00643201 (first received 26 March 2008). RaskobGE , GallusAS , SandersP , ThompsonJR , AgnelliG , BullerHR , et al. Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy: a sub-analysis of the AMPLIFY trial. Thrombosis and Haemostasis2016;115(4):809-16. ">AMPLIFY 2013</a>; <a href="./references#CD010956-bbs2-0003" title="BarrettYC , WangJ , KnabbR , MohanP . Apixaban decreases coagulation activity in patients with acute deep-vein thrombosis. Thrombosis and Haemostasis2011;105:181-9. Botticelli Investigators Writing Committee, BullerH , DeitchmanD , PrinsM , SegersA . Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. Journal of Thrombosis and Haemostasis2008;6:1313-8. BullerHR . A dose finding study of the oral direct factor Xa inhibitor apixaban in the treatment of patients with acute symptomatic deep vein thrombosis - the Botticelli Investigators. Journal of Thrombosis and Haemostasis2007;5 (Suppl 2):O-S-003. NCT00252005. Oral direct factor Xa-inhibitor apixaban in patients with acute symptomatic deep-vein thrombosis - the Botticelli DVT study. clinicaltrials.gov/ct/show/NCT00252005?order=1 (first received 11 November 2005). ">Botticelli DVT 2008</a>; <a href="./references#CD010956-bbs2-0007" title="BullerH , DariusH . EINSTEIN DVT: oral rivaroxaban versus standard therapy in the initial treatment of symptomatic deep vein thrombosis and long-term prevention of recurrent venous thromboembolism. escardio.org/The-ESC/Press-Office/Press-releases/EINSTEIN-DVT-Oral-rivaroxaban-versus-standard-therapy-in-the-initial-treatment (accessed 19 October 2022). BullerHR , AgnelliG . Once- or twice-daily rivaroxaban for the treatment of proximal deep vein thrombosis: similar efficacy and safety to standard therapy in dose-ranging studies. Blood2006;108(11 Part 1):172-3. BullerHR , LensingAW , PrinsMH , AgnelliG , CohenA , GallusAS , et al. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT dose-ranging study. Blood2008;112(6):2242-7. NCT00395772. Once-daily oral direct factor Xa inhibitor BAY59-7939 in patients with acute symptomatic deep-vein thrombosis. clinicaltrials.gov/ct2/show/NCT00395772?term=einstein-dvt&amp;rank=2 (first received 3 November 2006). ">EINSTEIN‐DVT dose 2008</a>; <a href="./references#CD010956-bbs2-0006" title="BamberL , WangMY , PrinsMH , CiniglioC , BauersachsR , LensingAW , et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis. Thrombosis and Haemostasis2013;110(4):732-41. BauersachsR , LensingAW , PapA , DecoususH . No need for a rivaroxaban dose reduction in renally impaired patients with symptomatic venous thromboembolism. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):30-1. BistervelsI , GebelM , LensingA , MiddeldorpS , CoppensM . Effect of polypharmacy on bleeding of rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolism. Research and Practice in Thrombosis and Haemostasis2019;3:798‐9. BookhartBK , HaskellL , BamberL , WangM , ScheinJ , ModySH . Length of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial program. Journal of Medical Economics2014;17(10):691-5. BullerHR . Oral rivaroxaban for the acute and continued treatment of symptomatic venous thromboembolism. The Einstein-DVT and Einstein-Extension study. Blood2010;116(21):187. CheungW , MiddeldorpS , PrinsMP , PapAF , LensingAW , Hoek-tenCA , et al. Post thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep vein thrombosis. Journal of Thrombosis and Haemostasis2015;13(S2):219-20. CheungYW , MiddeldorpS , PrinsMH , PapAF , PrandoniP . Post-thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep-vein thrombosis. A post-hoc analysis. Thrombosis and Haemostasis2016;116(4):733-8. EUCTR2004-002171-16-IT. Once-daily oral direct factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis. The EINSTEIN-DVT dose-finding study. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2004%E2%80%90002171%E2%80%9016%E2%80%90IT (first received 15 October 2008). EUCTR2006-004495-13-DK. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep-vein thrombosis or pulmonary embolism. trialsearch.who.int/?TrialID=EUCTR2006-004495-13-DK (first received 29 March 2007). EerenbergES , MiddeldorpS , LeviM , LensingAW , BüllerHR . Clinical impact and course of major bleeding with rivaroxaban and vitamin K antagonists. Journal of Thrombosis and Haemostasis2015;13(9):1590-6. KlineJA , JimenezD , CourtneyDM , IanusJ , CaoL , WellsPS . Use of the Riete 2008 bleeding score to identify patients at low risk for major bleeding in patients treated with rivaroxaban. Academic Emergency Medicine2015;22:S162. NCT00440193. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep vein thrombosis - The EINSTEIN DVT Study. clinicaltrials.gov/ct2/show/NCT00440193 (first received 26 February 2007). PrinsMH , ErkensPG , LensingAW . Incidence of recurrent venous thromboembolism in patients following completion of the EINSTEIN DVT and EINSTEIN PE studies. Journal of Thrombosis and Haemostasis2013;11(Suppl):257. PrinsMH , LensingAW , BauersachsR , Van BellenB , BounameauxH , BrightonTA , et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thrombosis Journal2013;11(1):21. The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. New England Journal of Medicine2010;363(26):2499-510. Van BellenB , PrinsM , BamberL , WangM , LensingAW . Reduction in initial length of stay with rivaroxaban single-drug regimen versus LMWH-VKA standard of care: findings from the EINSTEIN trial program. Blood2012;120(21):3419. Van BellenB , PrinsM , BamberL , WangM , LensingAW . Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism. Current Medical Research and Opinion2014;30(5):829-37. WangY , WangC , ChenZ , ZhangJ , LiuZ , JinB , et al. Rivaroxaban for the treatment of symptomatic deep vein thrombosis and/or pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):694. WangY , WangC , ChenZ , ZhangJ , LiuZ , JinB , et al. Rivaroxaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Thrombosis Journal2013;11(1):25. ">EINSTEIN‐DVT 2010</a>; <a href="./references#CD010956-bbs2-0009" title="PiazzaG , ManiV , GoldhaberSZ , GrossoMA , MercuriM , LanzHJ , et al. Magnetic resonance venography to assess thrombus resolution with edoxaban monotherapy versus parenteral anticoagulation/warfarin for symptomatic deep vein thrombosis: a multicenter feasibility study. Vascular Medicine2016;21(4):361-8. PiazzaG , ManiV , GrossoM , MercuriM , LanzH , SchusslerS , et al. A randomized, open-label, multicenter study of the efficacy and safety of edoxaban monotherapy versus low-molecular weight heparin/warfarin in patients with symptomatic deep vein thrombosis-edoxaban thrombus reduction imaging study (etris). Circulation2014;130:A12074. ">eTRIS 2016</a>; <a href="./references#CD010956-bbs2-0011" title="BistervelsI , BavaliaR , BoersmaW , MeijerK , VerhammeP , Ten Cate-HoekAJ , et al. Hokusai Post-DVT Study: a follow-up study on long-term outcomes of deep vein thrombosis in patients treated with edoxaban vs warfarin. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):PB2207. BrekelmansMP , AgenoW , BeenenLF , BrennerB , BullerHR , ChenCZ , et al. Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology2016;3(9):e437-45. BrekelmansMP , BlekerSM , BauersachsR , BodaZ , BüllerHR , ChoiY , et al. Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists. Thrombosis and Haemostasis2016;116(1):155-61. Di NisioM , Van EsN , CarrierM , WangTF , GarciaD , SegersA , et al. Extended treatment with edoxaban in cancer patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE Cancer study. Journal of Thrombosis and Haemostasis2019;17:1866–74. EUCTR2009-014290-40-SE. A phase 3, randomized, double-blind, double-dummy, parallel group, multi-center, multi-national study for evaluation of efficacy and safety of DU-176b versus warfarin in subjects with atrial fibrillation - effective anticoagulation with factor Xa next generation in atrial fibrillation (ENGAGE-AF TIMI-48). trialsearch.who.int/?trialid=EUCTR2009-014290-40-SE (first received 30 November 2009). EichingerS , LinM , KyrlePA , GrossoMA . Recurrent venous thromboembolism during anticoagulation: an investigator-initiated post-hoc analysis of the hokusai-VTE trial. Blood2018;132:2539. KlokFA , BarcoS , KonstantinidesSV . External validation of the VTE-BLEED score for predicting major bleeding in stable anticoagulated patients with venous thromboembolism. Thrombosis and Haemostasis2017;117(6):1164-70. KraaijpoelN , Van EsN , RaskobGE , BüllerHR , CarrierM , ZhangG , et al. Risk scores for occult cancer in patients with venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2018;118(7):1270-8. MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMP , ChenCZ , et al. Outpatient management in patients with venous thromboembolism with edoxaban: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2017;117(12):2406-14. MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMP , ChenCZ , et al. Safety and efficacy of edoxaban compared with warfarin for the treatment of acute symptomatic deep-vein thrombosis in the outpatient setting. Research and Practice in Thrombosis and Haemostasis2017;1:913. MulderFI , Van EsN , KraaijpoelN , Di NisioM , CarrierM , DuggalA , et al. Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: results from the Hokusai VTE Cancer study. Thrombosis Research2020;185:13-9. NCT00986154. Comparative investigation of Low Molecular Weight (LMW) heparin/edoxaban tosylate (DU176b) versus (LMW) heparin/warfarin in the treatment of symptomatic deep-vein blood clots and/or lung blood clots. (The Edoxaban Hokusai-VTE Study). clinicaltrials.gov/ct2/show/NCT00986154 (first received 29 September 2009). NakamuraM , WangYQ , WangC , OhD , YinWH , KimuraT , et al. Efficacy and safety of edoxaban for treatment of venous thromboembolism: a subanalysis of East Asian patients in the Hokusai-VTE trial. Journal of Thrombosis and Haemostasis2015;13(9):1606-14. NybergJ , KarlssonKE , JönssonS , YinO , MillerR , KarlssonMO , et al. Edoxaban exposure-response analysis and clinical utility index assessment in patients with symptomatic deep-vein thrombosis or pulmonary embolism. CPT Pharmacometrics and Systems Pharmacology2016;5(4):222-32. RaskobG , AgenoW , CohenAT , BrekelmansMP , GrossoMA , SegersA , et al. Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology2016;3(5):e228-e236. RaskobG , BullerH , PrinsM , SegersA , ShiM , SchwochoL , et al. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study - methodological implications for clinical trials. Journal of Thrombosis and Haemostasis2013;11(7):1287-94. RaskobGE , BullerH , AngchaisuksiriP , OhD , BodaZ , LyonsRM , et al. Edoxaban for long-term treatment of venous thromboembolism in cancer patients. Blood2013;122(21):211. RaskobGE , Van EsN , SegersA , AngchaisuksiriP , OhD , BodaZ , et al. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematology2016;3(8):e379-87. ScheresLJ , BrekelmansMA , WalterA , CihanA , BüllerHR , SabineE , et al. Abnormal vaginal bleeding in women of reproductive age treated with edoxaban or warfarin for venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. British Journal of Obstetrics and Gynaecology2018;125(12):1581-9. The Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. New England Journal of Medicine2013;369(15):1406-15. VanasscheT , VerhammeP , WellsPS , SegersA , AgenoW , BrekelmansMP , et al. Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: an analysis of the randomized, double-blind Hokusai-VTE trial. Thrombosis Research2018;162:7-14. VerhammeP , WellsPS , SegersA , AgenoW , BrekelmansMP , CohenAT , et al. Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial. Thrombosis and Haemostasis2016;116(4):747-53. ">Hokusai‐VTE 2013</a>; <a href="./references#CD010956-bbs2-0015" title="AgnelliG , GallusA , GoldhaberSZ , HaasS , HuismanMV , HullRD , et al. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAT 59-7939 in patients with acute symptomatic deep-vein thrombosis) study. Circulation2007;116:180-7. ">ODIXa‐DVT 2007</a>), nine measured all‐cause mortality (<a href="./references#CD010956-bbs2-0001" title="AgnelliG , BullerH , MasiukiewiczUP . Apixaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism: a randomized, double-blind trial (AMPLIFY). Journal of Thrombosis and Haemostasis2013;11:18. AgnelliG , BullerHR , CohenA , CurtoD , GallusAS , JohnsonM , et al. Oral apixaban for the treatment of acute venous thromboembolism. New England Journal of Medicine2013;369:799-808. AgnelliG , BullerHR , CohenA , CurtoM , GallusAS , PakR , et al. Apixaban for the treatment of venous thromboembolism in cancer patients: data from the AMPLIFY trial. Canadian Journal of Cardiology2014;30(10 Suppl 1):S278. AgnelliG , BullerHR , CohenA , GallusAS , LeeTC , PakR , et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. Journal of Thrombosis and Haemostasis2015;13(12):2187-91. AgnelliG . Apixaban was non-inferior to enoxaparin plus warfarin in patients with acute venous thromboembolism. Annals of Internal Medicine2013;159(8):JC2. BlekerSM , CohenAT , BüllerHR , AgnelliG , GallusAS , RaskobGE , et al. Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Thrombosis and Haemostasis2016;116(6):159-64. BrekelmansM , ScheresL , BlekerS , HuttenB , TimmermansA , BüllerH , et al. Abnormal vaginal bleeding in women with venous thromboembolism treated with apixaban or warfarin. Thrombosis and Haemostasis2017;117(04):809-15. CohenA , AgnelliG , BullerH , GallusA , RaskobG , SandersP , et al. Characteristics and outcomes in patients with venous thromboembolism taking concomitant anti-platelet agents and anticoagulants in the AMPLIFY Trial. Thrombosis and Haemostasis2019;119(3):461-6. CohenA , AgnelliG , BullerHR , ChaudhuriS , GallusAS , RaskobGE , et al. Analysis of the bleeding and thromboembolic risk with concomitant use of antiplatelet treatment in the AMPLIFY trial. Canadian Journal of Cardiology2014;30(10):S272. CohenA , GallusAS , AgnelliG , BullerHR , PakR , PorcariAR , et al. Time in Therapeutic Range (TTR) and relative efficacy and safety of treatment with apixaban or enoxaparin/warfarin for acute symptomatic venous thromboembolism: an analysis of the Amplify trial data. Blood2014;124(21):1543. CohenAT , PanS , ByonW , IlyasBS , LeeTC . Efficacy, safety, and exposure of apixaban in patients with high body weight or obesity and venous thromboembolism: insights from AMPLIFY. Advances in Therapy2021;38(6):3003-18. EUCTR2007-007867-25-PT. A safety and efficacy trial evaluating the use of apixaban in the treatment of symptomatic deep vein thrombosis and pulmonary embolism revised protocol number: 01, incorporates amendment(s) 02 + protocol amendment 01 (version 1.0 dated 21-Apr-08) site-specific - molecular profiling supplement samples for Pfizer’s exploratory research biobank. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2007%E2%80%90007867%E2%80%9025%E2%80%90PT (first received 14 July 2008). GallusAS , AgnelliG , BullerHR , CohenA , LeeTC , PakR , et al. Apixaban for treatment of venous thromboembolism in patients from study centres in Asia: a subgroup analysis of the Amplify trial. Journal of Thrombosis and Haemostasis2015;13:727. LeeT , PanS , ByonW , IlyasBS . Safety and efficacy of apixaban versus enoxaparin/warfarin in patients with extremes of body weight: post-hoc analysis of the AMPLIFY trial. Blood2019;134(Suppl 1):1152. LiuX , JohnsonM , MardekianJ , PhatakH , ThompsonJ , CohenAT . Apixaban reduces hospitalizations in patients with venous thromboembolism: an analysis of the apixaban for the Initial management of pulmonary embolism and deep‐vein thrombosis as first‐line therapy (AMPLIFY) trial. Journal of the American Heart Association2015;4(12):e002340. NCT00633893. Efficacy and safety study of apixaban for extended treatment of deep vein thrombosis or pulmonary embolism. clinicaltrials.gov/ct2/show/NCT00633893?term=ajax&amp;rank=5 (first received 12 March 2008). NCT00643201. Efficacy and safety study of apixaban for the treatment of deep vein thrombosis or pulmonary embolism. clinicaltrials.gov/ct2/show/NCT00643201 (first received 26 March 2008). RaskobGE , GallusAS , SandersP , ThompsonJR , AgnelliG , BullerHR , et al. Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy: a sub-analysis of the AMPLIFY trial. Thrombosis and Haemostasis2016;115(4):809-16. ">AMPLIFY 2013</a>; <a href="./references#CD010956-bbs2-0002" title="NakamuraM , NishikawaM , KomuroI , KitajimaI , UetsukaY , YamagamiT , et al. Apixaban for the treatment of Japanese subjects with acute venous thromboembolism (AMPLIFY-J Study). Circulation2015;79(6):1230–36. ">AMPLIFY‐J 2015</a>; <a href="./references#CD010956-bbs2-0003" title="BarrettYC , WangJ , KnabbR , MohanP . Apixaban decreases coagulation activity in patients with acute deep-vein thrombosis. Thrombosis and Haemostasis2011;105:181-9. Botticelli Investigators Writing Committee, BullerH , DeitchmanD , PrinsM , SegersA . Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. Journal of Thrombosis and Haemostasis2008;6:1313-8. BullerHR . A dose finding study of the oral direct factor Xa inhibitor apixaban in the treatment of patients with acute symptomatic deep vein thrombosis - the Botticelli Investigators. Journal of Thrombosis and Haemostasis2007;5 (Suppl 2):O-S-003. NCT00252005. Oral direct factor Xa-inhibitor apixaban in patients with acute symptomatic deep-vein thrombosis - the Botticelli DVT study. clinicaltrials.gov/ct/show/NCT00252005?order=1 (first received 11 November 2005). ">Botticelli DVT 2008</a>; <a href="./references#CD010956-bbs2-0005" title="NCT02704598. Comparison between xarelto versus warfarin in the recanalization rate of deep venous thrombosis in patients legs. (DVT). clinicaltrials.gov/ct2/show/NCT02704598 (first received 10 March 2016). deAthayde SoaresR , MatieloMF , Brochado NetoFC , AlmeidaRD , SacilottoR . LEV 2. Comparison of the recanalization rate and post-thrombotic syndrome in patients with deep venous thrombosis treated with rivaroxaban or warfarin. Journal of Vascular Surgery2019;70(5):e169-e170. deAthayde SoaresR , MatieloMF , Brochado NetoFC , NogueiraMP , AlmeidaRD , SacilottoR . Comparison of the recanalization rate and postthrombotic syndrome in patients with deep venous thrombosis treated with rivaroxaban or warfarin. Surgery2019;166(6):1076-83. ">de Athayde 2019</a>; <a href="./references#CD010956-bbs2-0007" title="BullerH , DariusH . EINSTEIN DVT: oral rivaroxaban versus standard therapy in the initial treatment of symptomatic deep vein thrombosis and long-term prevention of recurrent venous thromboembolism. escardio.org/The-ESC/Press-Office/Press-releases/EINSTEIN-DVT-Oral-rivaroxaban-versus-standard-therapy-in-the-initial-treatment (accessed 19 October 2022). BullerHR , AgnelliG . Once- or twice-daily rivaroxaban for the treatment of proximal deep vein thrombosis: similar efficacy and safety to standard therapy in dose-ranging studies. Blood2006;108(11 Part 1):172-3. BullerHR , LensingAW , PrinsMH , AgnelliG , CohenA , GallusAS , et al. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT dose-ranging study. Blood2008;112(6):2242-7. NCT00395772. Once-daily oral direct factor Xa inhibitor BAY59-7939 in patients with acute symptomatic deep-vein thrombosis. clinicaltrials.gov/ct2/show/NCT00395772?term=einstein-dvt&amp;rank=2 (first received 3 November 2006). ">EINSTEIN‐DVT dose 2008</a>; <a href="./references#CD010956-bbs2-0006" title="BamberL , WangMY , PrinsMH , CiniglioC , BauersachsR , LensingAW , et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis. Thrombosis and Haemostasis2013;110(4):732-41. BauersachsR , LensingAW , PapA , DecoususH . No need for a rivaroxaban dose reduction in renally impaired patients with symptomatic venous thromboembolism. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):30-1. BistervelsI , GebelM , LensingA , MiddeldorpS , CoppensM . Effect of polypharmacy on bleeding of rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolism. Research and Practice in Thrombosis and Haemostasis2019;3:798‐9. BookhartBK , HaskellL , BamberL , WangM , ScheinJ , ModySH . Length of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial program. Journal of Medical Economics2014;17(10):691-5. BullerHR . Oral rivaroxaban for the acute and continued treatment of symptomatic venous thromboembolism. The Einstein-DVT and Einstein-Extension study. Blood2010;116(21):187. CheungW , MiddeldorpS , PrinsMP , PapAF , LensingAW , Hoek-tenCA , et al. Post thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep vein thrombosis. Journal of Thrombosis and Haemostasis2015;13(S2):219-20. CheungYW , MiddeldorpS , PrinsMH , PapAF , PrandoniP . Post-thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep-vein thrombosis. A post-hoc analysis. Thrombosis and Haemostasis2016;116(4):733-8. EUCTR2004-002171-16-IT. Once-daily oral direct factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis. The EINSTEIN-DVT dose-finding study. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2004%E2%80%90002171%E2%80%9016%E2%80%90IT (first received 15 October 2008). EUCTR2006-004495-13-DK. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep-vein thrombosis or pulmonary embolism. trialsearch.who.int/?TrialID=EUCTR2006-004495-13-DK (first received 29 March 2007). EerenbergES , MiddeldorpS , LeviM , LensingAW , BüllerHR . Clinical impact and course of major bleeding with rivaroxaban and vitamin K antagonists. Journal of Thrombosis and Haemostasis2015;13(9):1590-6. KlineJA , JimenezD , CourtneyDM , IanusJ , CaoL , WellsPS . Use of the Riete 2008 bleeding score to identify patients at low risk for major bleeding in patients treated with rivaroxaban. Academic Emergency Medicine2015;22:S162. NCT00440193. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep vein thrombosis - The EINSTEIN DVT Study. clinicaltrials.gov/ct2/show/NCT00440193 (first received 26 February 2007). PrinsMH , ErkensPG , LensingAW . Incidence of recurrent venous thromboembolism in patients following completion of the EINSTEIN DVT and EINSTEIN PE studies. Journal of Thrombosis and Haemostasis2013;11(Suppl):257. PrinsMH , LensingAW , BauersachsR , Van BellenB , BounameauxH , BrightonTA , et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thrombosis Journal2013;11(1):21. The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. New England Journal of Medicine2010;363(26):2499-510. Van BellenB , PrinsM , BamberL , WangM , LensingAW . Reduction in initial length of stay with rivaroxaban single-drug regimen versus LMWH-VKA standard of care: findings from the EINSTEIN trial program. Blood2012;120(21):3419. Van BellenB , PrinsM , BamberL , WangM , LensingAW . Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism. Current Medical Research and Opinion2014;30(5):829-37. WangY , WangC , ChenZ , ZhangJ , LiuZ , JinB , et al. Rivaroxaban for the treatment of symptomatic deep vein thrombosis and/or pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):694. WangY , WangC , ChenZ , ZhangJ , LiuZ , JinB , et al. Rivaroxaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Thrombosis Journal2013;11(1):25. ">EINSTEIN‐DVT 2010</a>; <a href="./references#CD010956-bbs2-0014" title="MokademME , HassanA , AlgabyAZ . Efficacy and safety of apixaban in patients with active malignancy and acute deep venous thrombosis. Vascular2021;29(5):745-50. NCT04462003. Efficacy of apixaban in malignancy with deep venous thrombosis (DVT). clinicaltrials.gov/ct2/show/NCT04462003 (first received 3 July 2019). ">Mokadem 2021</a>; <a href="./references#CD010956-bbs2-0015" title="AgnelliG , GallusA , GoldhaberSZ , HaasS , HuismanMV , HullRD , et al. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAT 59-7939 in patients with acute symptomatic deep-vein thrombosis) study. Circulation2007;116:180-7. ">ODIXa‐DVT 2007</a>; <a href="./references#CD010956-bbs2-0017" title="Kang JiM, ParkKH , AhnS , ChoS , MinSK . Rivaroxaban after thrombolysis in acute iliofemoral venous thrombosis: a randomized, open-labeled, multicenter trial. Scientific Reports2019;9(1):20356. MinSK , AhnS , ParkKH , KangJM , KimJY . Prevention of recurrence after thrombolysis in acute iliofemoral venous thrombosis with rivaroxaban (Prais Study): a prospective, randomized, open label, multicenter trial. European Journal of Vascular and Endovascular Surgery2019;58(6):e516. NCT01986192. Prevention of recurrence after thrombolysis in acute iliofemoral venous thrombosis (PRAIS) study. clinicaltrials.gov/show/NCT01986192 (first received 18 November 2013). ">PRAIS 2019</a>), and 17 measured major bleeding (<a href="./references#CD010956-bbs2-0001" title="AgnelliG , BullerH , MasiukiewiczUP . Apixaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism: a randomized, double-blind trial (AMPLIFY). Journal of Thrombosis and Haemostasis2013;11:18. AgnelliG , BullerHR , CohenA , CurtoD , GallusAS , JohnsonM , et al. Oral apixaban for the treatment of acute venous thromboembolism. New England Journal of Medicine2013;369:799-808. AgnelliG , BullerHR , CohenA , CurtoM , GallusAS , PakR , et al. Apixaban for the treatment of venous thromboembolism in cancer patients: data from the AMPLIFY trial. Canadian Journal of Cardiology2014;30(10 Suppl 1):S278. AgnelliG , BullerHR , CohenA , GallusAS , LeeTC , PakR , et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. Journal of Thrombosis and Haemostasis2015;13(12):2187-91. AgnelliG . Apixaban was non-inferior to enoxaparin plus warfarin in patients with acute venous thromboembolism. Annals of Internal Medicine2013;159(8):JC2. BlekerSM , CohenAT , BüllerHR , AgnelliG , GallusAS , RaskobGE , et al. Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Thrombosis and Haemostasis2016;116(6):159-64. BrekelmansM , ScheresL , BlekerS , HuttenB , TimmermansA , BüllerH , et al. Abnormal vaginal bleeding in women with venous thromboembolism treated with apixaban or warfarin. Thrombosis and Haemostasis2017;117(04):809-15. CohenA , AgnelliG , BullerH , GallusA , RaskobG , SandersP , et al. Characteristics and outcomes in patients with venous thromboembolism taking concomitant anti-platelet agents and anticoagulants in the AMPLIFY Trial. Thrombosis and Haemostasis2019;119(3):461-6. CohenA , AgnelliG , BullerHR , ChaudhuriS , GallusAS , RaskobGE , et al. Analysis of the bleeding and thromboembolic risk with concomitant use of antiplatelet treatment in the AMPLIFY trial. Canadian Journal of Cardiology2014;30(10):S272. CohenA , GallusAS , AgnelliG , BullerHR , PakR , PorcariAR , et al. Time in Therapeutic Range (TTR) and relative efficacy and safety of treatment with apixaban or enoxaparin/warfarin for acute symptomatic venous thromboembolism: an analysis of the Amplify trial data. Blood2014;124(21):1543. CohenAT , PanS , ByonW , IlyasBS , LeeTC . Efficacy, safety, and exposure of apixaban in patients with high body weight or obesity and venous thromboembolism: insights from AMPLIFY. Advances in Therapy2021;38(6):3003-18. EUCTR2007-007867-25-PT. A safety and efficacy trial evaluating the use of apixaban in the treatment of symptomatic deep vein thrombosis and pulmonary embolism revised protocol number: 01, incorporates amendment(s) 02 + protocol amendment 01 (version 1.0 dated 21-Apr-08) site-specific - molecular profiling supplement samples for Pfizer’s exploratory research biobank. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2007%E2%80%90007867%E2%80%9025%E2%80%90PT (first received 14 July 2008). GallusAS , AgnelliG , BullerHR , CohenA , LeeTC , PakR , et al. Apixaban for treatment of venous thromboembolism in patients from study centres in Asia: a subgroup analysis of the Amplify trial. Journal of Thrombosis and Haemostasis2015;13:727. LeeT , PanS , ByonW , IlyasBS . Safety and efficacy of apixaban versus enoxaparin/warfarin in patients with extremes of body weight: post-hoc analysis of the AMPLIFY trial. Blood2019;134(Suppl 1):1152. LiuX , JohnsonM , MardekianJ , PhatakH , ThompsonJ , CohenAT . Apixaban reduces hospitalizations in patients with venous thromboembolism: an analysis of the apixaban for the Initial management of pulmonary embolism and deep‐vein thrombosis as first‐line therapy (AMPLIFY) trial. Journal of the American Heart Association2015;4(12):e002340. NCT00633893. Efficacy and safety study of apixaban for extended treatment of deep vein thrombosis or pulmonary embolism. clinicaltrials.gov/ct2/show/NCT00633893?term=ajax&amp;rank=5 (first received 12 March 2008). NCT00643201. Efficacy and safety study of apixaban for the treatment of deep vein thrombosis or pulmonary embolism. clinicaltrials.gov/ct2/show/NCT00643201 (first received 26 March 2008). RaskobGE , GallusAS , SandersP , ThompsonJR , AgnelliG , BullerHR , et al. Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy: a sub-analysis of the AMPLIFY trial. Thrombosis and Haemostasis2016;115(4):809-16. ">AMPLIFY 2013</a>; <a href="./references#CD010956-bbs2-0002" title="NakamuraM , NishikawaM , KomuroI , KitajimaI , UetsukaY , YamagamiT , et al. Apixaban for the treatment of Japanese subjects with acute venous thromboembolism (AMPLIFY-J Study). Circulation2015;79(6):1230–36. ">AMPLIFY‐J 2015</a>; <a href="./references#CD010956-bbs2-0003" title="BarrettYC , WangJ , KnabbR , MohanP . Apixaban decreases coagulation activity in patients with acute deep-vein thrombosis. Thrombosis and Haemostasis2011;105:181-9. Botticelli Investigators Writing Committee, BullerH , DeitchmanD , PrinsM , SegersA . Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. Journal of Thrombosis and Haemostasis2008;6:1313-8. BullerHR . A dose finding study of the oral direct factor Xa inhibitor apixaban in the treatment of patients with acute symptomatic deep vein thrombosis - the Botticelli Investigators. Journal of Thrombosis and Haemostasis2007;5 (Suppl 2):O-S-003. NCT00252005. Oral direct factor Xa-inhibitor apixaban in patients with acute symptomatic deep-vein thrombosis - the Botticelli DVT study. clinicaltrials.gov/ct/show/NCT00252005?order=1 (first received 11 November 2005). ">Botticelli DVT 2008</a>; <a href="./references#CD010956-bbs2-0004" title="AgenoW , VedovatiMC , CohenA , HuismanM , BauersachsR , GussoniG , et al. Bleeding with apixaban and dalteparin in patients with cancer-associated venous thromboembolism: results from the Caravaggio study. Thrombosis and Haemostasis2021;121(5):616-24. AgnelliG , BecattiniC , BauersachsR , BrennerB , CampaniniM , CohenA , et al. Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the Caravaggio study. Thrombosis and Haemostasis2018;118(9):1668-78. AgnelliG , BecattiniC , MeyerG , MuozA , VersoM . Apixaban for the treatment of venous thromboembolism associated with cancer. New England Journal of Medicine2020;382(17):1599-607. AgnelliG , MuozA , FrancoL , MahéI , BrennerB , ConnorsJM , et al. Apixaban and dalteparin for the treatment of venous thromboembolism in patients with different sites of cancer. Thrombosis and Haemostasis2022;122(5):796-807. BecattiniC , BauersachsR , MarazitiG , BertolettiL , CohenA , ConnorsJM , et al. Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial. Haematologica2021;107(7):1567-76. GiustozziM , ConnorsJM , Ruperez BlancoAB , SzmitS , FalvoN , CohenAT , et al. Clinical characteristics and outcomes of incidental venous thromboembolism in cancer patients: insights from the Caravaggio study. Journal of Thrombosis and Haemostasis2021;19(11):2751-9. NCT03045406. Apixaban for the treatment of venous thromboembolism in patients with cancer (CARAVAGGIO). clinicaltrials.gov/ct2/show/NCT03045406 (first received 7 February 2017). VersoM , MunozA , BauersachsR , HuismanMV , AgnelliG . Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism. European Journal of Cancer2021;148(Suppl C):371-81. ">Caravaggio 2020</a>; <a href="./references#CD010956-bbs2-0005" title="NCT02704598. Comparison between xarelto versus warfarin in the recanalization rate of deep venous thrombosis in patients legs. (DVT). clinicaltrials.gov/ct2/show/NCT02704598 (first received 10 March 2016). deAthayde SoaresR , MatieloMF , Brochado NetoFC , AlmeidaRD , SacilottoR . LEV 2. Comparison of the recanalization rate and post-thrombotic syndrome in patients with deep venous thrombosis treated with rivaroxaban or warfarin. Journal of Vascular Surgery2019;70(5):e169-e170. deAthayde SoaresR , MatieloMF , Brochado NetoFC , NogueiraMP , AlmeidaRD , SacilottoR . Comparison of the recanalization rate and postthrombotic syndrome in patients with deep venous thrombosis treated with rivaroxaban or warfarin. Surgery2019;166(6):1076-83. ">de Athayde 2019</a>; <a href="./references#CD010956-bbs2-0007" title="BullerH , DariusH . EINSTEIN DVT: oral rivaroxaban versus standard therapy in the initial treatment of symptomatic deep vein thrombosis and long-term prevention of recurrent venous thromboembolism. escardio.org/The-ESC/Press-Office/Press-releases/EINSTEIN-DVT-Oral-rivaroxaban-versus-standard-therapy-in-the-initial-treatment (accessed 19 October 2022). BullerHR , AgnelliG . Once- or twice-daily rivaroxaban for the treatment of proximal deep vein thrombosis: similar efficacy and safety to standard therapy in dose-ranging studies. Blood2006;108(11 Part 1):172-3. BullerHR , LensingAW , PrinsMH , AgnelliG , CohenA , GallusAS , et al. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT dose-ranging study. Blood2008;112(6):2242-7. NCT00395772. Once-daily oral direct factor Xa inhibitor BAY59-7939 in patients with acute symptomatic deep-vein thrombosis. clinicaltrials.gov/ct2/show/NCT00395772?term=einstein-dvt&amp;rank=2 (first received 3 November 2006). ">EINSTEIN‐DVT dose 2008</a>; <a href="./references#CD010956-bbs2-0006" title="BamberL , WangMY , PrinsMH , CiniglioC , BauersachsR , LensingAW , et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis. Thrombosis and Haemostasis2013;110(4):732-41. BauersachsR , LensingAW , PapA , DecoususH . No need for a rivaroxaban dose reduction in renally impaired patients with symptomatic venous thromboembolism. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):30-1. BistervelsI , GebelM , LensingA , MiddeldorpS , CoppensM . Effect of polypharmacy on bleeding of rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolism. Research and Practice in Thrombosis and Haemostasis2019;3:798‐9. BookhartBK , HaskellL , BamberL , WangM , ScheinJ , ModySH . Length of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial program. Journal of Medical Economics2014;17(10):691-5. BullerHR . Oral rivaroxaban for the acute and continued treatment of symptomatic venous thromboembolism. The Einstein-DVT and Einstein-Extension study. Blood2010;116(21):187. CheungW , MiddeldorpS , PrinsMP , PapAF , LensingAW , Hoek-tenCA , et al. Post thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep vein thrombosis. Journal of Thrombosis and Haemostasis2015;13(S2):219-20. CheungYW , MiddeldorpS , PrinsMH , PapAF , PrandoniP . Post-thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep-vein thrombosis. A post-hoc analysis. Thrombosis and Haemostasis2016;116(4):733-8. EUCTR2004-002171-16-IT. Once-daily oral direct factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis. The EINSTEIN-DVT dose-finding study. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2004%E2%80%90002171%E2%80%9016%E2%80%90IT (first received 15 October 2008). EUCTR2006-004495-13-DK. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep-vein thrombosis or pulmonary embolism. trialsearch.who.int/?TrialID=EUCTR2006-004495-13-DK (first received 29 March 2007). EerenbergES , MiddeldorpS , LeviM , LensingAW , BüllerHR . Clinical impact and course of major bleeding with rivaroxaban and vitamin K antagonists. Journal of Thrombosis and Haemostasis2015;13(9):1590-6. KlineJA , JimenezD , CourtneyDM , IanusJ , CaoL , WellsPS . Use of the Riete 2008 bleeding score to identify patients at low risk for major bleeding in patients treated with rivaroxaban. Academic Emergency Medicine2015;22:S162. NCT00440193. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep vein thrombosis - The EINSTEIN DVT Study. clinicaltrials.gov/ct2/show/NCT00440193 (first received 26 February 2007). PrinsMH , ErkensPG , LensingAW . Incidence of recurrent venous thromboembolism in patients following completion of the EINSTEIN DVT and EINSTEIN PE studies. Journal of Thrombosis and Haemostasis2013;11(Suppl):257. PrinsMH , LensingAW , BauersachsR , Van BellenB , BounameauxH , BrightonTA , et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thrombosis Journal2013;11(1):21. The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. New England Journal of Medicine2010;363(26):2499-510. Van BellenB , PrinsM , BamberL , WangM , LensingAW . Reduction in initial length of stay with rivaroxaban single-drug regimen versus LMWH-VKA standard of care: findings from the EINSTEIN trial program. Blood2012;120(21):3419. Van BellenB , PrinsM , BamberL , WangM , LensingAW . Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism. Current Medical Research and Opinion2014;30(5):829-37. WangY , WangC , ChenZ , ZhangJ , LiuZ , JinB , et al. Rivaroxaban for the treatment of symptomatic deep vein thrombosis and/or pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):694. WangY , WangC , ChenZ , ZhangJ , LiuZ , JinB , et al. Rivaroxaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Thrombosis Journal2013;11(1):25. ">EINSTEIN‐DVT 2010</a>; <a href="./references#CD010956-bbs2-0008" title="BullerHR , PrinsMH , LensinAW , DecoususH , JacobsonBF , MinarE , et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. New England Journal of Medicine2012;366:1287-97. FermannGJ , Erkens Pmg, PrinsMH , WellsPS , Pap ÁF, LensingAW , et al. Treatment of pulmonary embolism with rivaroxaban: outcomes by simplified pulmonary embolism severity index score from a post hoc analysis of the EINSTEIN PE study. Academic Emergency Medicine2015;22(3):299-307. NCT00439777. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic pulmonary embolism with or without symptomatic deep-vein thrombosis: Einstein-PE evaluation, 2008. clinicaltrials.gov/ct2/show/NCT00439777?term=NCT00439777&amp;rank=1 (first received 26 February 2007). PrinsM , BamberL , CanoS , WangM , LensingAW , BauersachsR . Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic pulmonary embolism. Blood2012;120(21):1163. PrinsMH , BamberL , CanoSJ , WangMY , ErkensP , BauersachsR , et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial. Thrombosis Research2015;135(2):281-8. ">EINSTEIN‐PE 2012</a>; <a href="./references#CD010956-bbs2-0009" title="PiazzaG , ManiV , GoldhaberSZ , GrossoMA , MercuriM , LanzHJ , et al. Magnetic resonance venography to assess thrombus resolution with edoxaban monotherapy versus parenteral anticoagulation/warfarin for symptomatic deep vein thrombosis: a multicenter feasibility study. Vascular Medicine2016;21(4):361-8. PiazzaG , ManiV , GrossoM , MercuriM , LanzH , SchusslerS , et al. A randomized, open-label, multicenter study of the efficacy and safety of edoxaban monotherapy versus low-molecular weight heparin/warfarin in patients with symptomatic deep vein thrombosis-edoxaban thrombus reduction imaging study (etris). Circulation2014;130:A12074. ">eTRIS 2016</a>; <a href="./references#CD010956-bbs2-0010" title="FarhanA , BukhariM , UmarJ , RazaMA . Oral rivaroxaban in symptomatic deep vein thrombosis. Journal of the College of Physicians and Surgeons Pakistan2019;29(9):814-8. ">Farhan 2019</a>; <a href="./references#CD010956-bbs2-0012" title="AmayaN , UzuiH , HisazakiK , HasegwaK , KasenoK , TadaH . Edoxaban normalizes the elevated D-dimer levels potently and promptly in patients with venous thromboembolisms: a comparison with traditional anticoagulant therapy. European Heart Journal2016;37:278. BoschFT , Van EsN , Di NisioM , CarrierM , SegersA , GrossoMA , et al. The Ottawa score does not predict recurrent venous thromboembolism in cancer patients: results from the Hokusai-VTE cancer study. Research and Practice in Thrombosis and Haemostasis2019;3(S1):717-8. KraaijpoelN , Di NisioM , MulderFI , Van EsN , RaskobGE . Clinical impact of bleeding in cancer-associated venous thromboembolism: results from the Hokusai VTE Cancer randomized trial. Thrombosis Research2018;164(Suppl 1):S223. [DOI: 10.1016/j.thromres.2018.02.094]MulderFI , Di NisioM , AyC , CarrierM , BoschFT , SegersA , et al. Clinical implications of incidental venous thromboembolism in cancer patients. European Respiratory Journal2020;55(2):1901697. [DOI: 10.1183/13993003.01697-2019]MulderFI , Van EsN , KraaijpoelN , Di NisioM , CarrierM , GarciaD , et al. Efficacy and safety of edoxaban in clinically relevant subgroups: results from the Hokusai VTE Cancer randomized trial. Thrombosis Research2018;164:S194. NCT02073682. Cancer venous thromboembolism (VTE). clinicaltrials.gov/ct2/show/NCT02073682 (first received 27 February 2014). RaskobG , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaD , et al. Edoxaban versus dalteparin for treatment of venous thromboembolism (VTE) associated with cancer: Hokusai VTE-cancer randomized trial. Supportive Care in Cancer2018;26(2):S316-S317. RaskobGE , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaD , et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. New England Journal of Medicine2018;378(7):615-24. RaskobGE , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaDA , et al. A randomized, open-label, blinded outcome assessment trial evaluating the efficacy and safety of LMWH/Edoxaban versus dalteparin for venous thromboembolism associated with cancer: Hokusai VTE-cancer study. Blood2017;130(Suppl 1):LBA-6. ">Hokusai VTE Cancer 2018</a>; <a href="./references#CD010956-bbs2-0011" title="BistervelsI , BavaliaR , BoersmaW , MeijerK , VerhammeP , Ten Cate-HoekAJ , et al. Hokusai Post-DVT Study: a follow-up study on long-term outcomes of deep vein thrombosis in patients treated with edoxaban vs warfarin. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):PB2207. BrekelmansMP , AgenoW , BeenenLF , BrennerB , BullerHR , ChenCZ , et al. Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology2016;3(9):e437-45. BrekelmansMP , BlekerSM , BauersachsR , BodaZ , BüllerHR , ChoiY , et al. Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists. Thrombosis and Haemostasis2016;116(1):155-61. Di NisioM , Van EsN , CarrierM , WangTF , GarciaD , SegersA , et al. Extended treatment with edoxaban in cancer patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE Cancer study. Journal of Thrombosis and Haemostasis2019;17:1866–74. EUCTR2009-014290-40-SE. A phase 3, randomized, double-blind, double-dummy, parallel group, multi-center, multi-national study for evaluation of efficacy and safety of DU-176b versus warfarin in subjects with atrial fibrillation - effective anticoagulation with factor Xa next generation in atrial fibrillation (ENGAGE-AF TIMI-48). trialsearch.who.int/?trialid=EUCTR2009-014290-40-SE (first received 30 November 2009). EichingerS , LinM , KyrlePA , GrossoMA . Recurrent venous thromboembolism during anticoagulation: an investigator-initiated post-hoc analysis of the hokusai-VTE trial. Blood2018;132:2539. KlokFA , BarcoS , KonstantinidesSV . External validation of the VTE-BLEED score for predicting major bleeding in stable anticoagulated patients with venous thromboembolism. Thrombosis and Haemostasis2017;117(6):1164-70. KraaijpoelN , Van EsN , RaskobGE , BüllerHR , CarrierM , ZhangG , et al. Risk scores for occult cancer in patients with venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2018;118(7):1270-8. MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMP , ChenCZ , et al. Outpatient management in patients with venous thromboembolism with edoxaban: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2017;117(12):2406-14. MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMP , ChenCZ , et al. Safety and efficacy of edoxaban compared with warfarin for the treatment of acute symptomatic deep-vein thrombosis in the outpatient setting. Research and Practice in Thrombosis and Haemostasis2017;1:913. MulderFI , Van EsN , KraaijpoelN , Di NisioM , CarrierM , DuggalA , et al. Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: results from the Hokusai VTE Cancer study. Thrombosis Research2020;185:13-9. NCT00986154. Comparative investigation of Low Molecular Weight (LMW) heparin/edoxaban tosylate (DU176b) versus (LMW) heparin/warfarin in the treatment of symptomatic deep-vein blood clots and/or lung blood clots. (The Edoxaban Hokusai-VTE Study). clinicaltrials.gov/ct2/show/NCT00986154 (first received 29 September 2009). NakamuraM , WangYQ , WangC , OhD , YinWH , KimuraT , et al. Efficacy and safety of edoxaban for treatment of venous thromboembolism: a subanalysis of East Asian patients in the Hokusai-VTE trial. Journal of Thrombosis and Haemostasis2015;13(9):1606-14. NybergJ , KarlssonKE , JönssonS , YinO , MillerR , KarlssonMO , et al. Edoxaban exposure-response analysis and clinical utility index assessment in patients with symptomatic deep-vein thrombosis or pulmonary embolism. CPT Pharmacometrics and Systems Pharmacology2016;5(4):222-32. RaskobG , AgenoW , CohenAT , BrekelmansMP , GrossoMA , SegersA , et al. Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology2016;3(5):e228-e236. RaskobG , BullerH , PrinsM , SegersA , ShiM , SchwochoL , et al. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study - methodological implications for clinical trials. Journal of Thrombosis and Haemostasis2013;11(7):1287-94. RaskobGE , BullerH , AngchaisuksiriP , OhD , BodaZ , LyonsRM , et al. Edoxaban for long-term treatment of venous thromboembolism in cancer patients. Blood2013;122(21):211. RaskobGE , Van EsN , SegersA , AngchaisuksiriP , OhD , BodaZ , et al. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematology2016;3(8):e379-87. ScheresLJ , BrekelmansMA , WalterA , CihanA , BüllerHR , SabineE , et al. Abnormal vaginal bleeding in women of reproductive age treated with edoxaban or warfarin for venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. British Journal of Obstetrics and Gynaecology2018;125(12):1581-9. The Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. New England Journal of Medicine2013;369(15):1406-15. VanasscheT , VerhammeP , WellsPS , SegersA , AgenoW , BrekelmansMP , et al. Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: an analysis of the randomized, double-blind Hokusai-VTE trial. Thrombosis Research2018;162:7-14. VerhammeP , WellsPS , SegersA , AgenoW , BrekelmansMP , CohenAT , et al. Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial. Thrombosis and Haemostasis2016;116(4):747-53. ">Hokusai‐VTE 2013</a>; <a href="./references#CD010956-bbs2-0013" title="MatsuoH , PrinsM , LensingAW , FujinumaEW , MiyamotoY , KajikawaM . Shortened length of hospital stay with rivaroxaban in patients with symptomatic venous thromboembolism in Japan: the J-EINSTEIN pulmonary embolism and deep vein thrombosis program. Current Medical Research and Opinion2015;31(6):1057-61. NCT01516814. Venous thromboembolism (VTE) treatment study in Japanese pulmonary embolism (PE) patients. clinicaltrials.gov/ct2/show/NCT01516814 (first received 25 January 2012). YamadaN , HirayamaA , MaedaH , SakagamiS , ShikataH , PrinsMH , et al. Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism-the J-EINSTEIN DVT and PE program. Thrombosis Journal2015;13:2. ">J‐EINSTEIN DVT and PE 2015</a>; <a href="./references#CD010956-bbs2-0014" title="MokademME , HassanA , AlgabyAZ . Efficacy and safety of apixaban in patients with active malignancy and acute deep venous thrombosis. Vascular2021;29(5):745-50. NCT04462003. Efficacy of apixaban in malignancy with deep venous thrombosis (DVT). clinicaltrials.gov/ct2/show/NCT04462003 (first received 3 July 2019). ">Mokadem 2021</a>; <a href="./references#CD010956-bbs2-0015" title="AgnelliG , GallusA , GoldhaberSZ , HaasS , HuismanMV , HullRD , et al. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAT 59-7939 in patients with acute symptomatic deep-vein thrombosis) study. Circulation2007;116:180-7. ">ODIXa‐DVT 2007</a>; <a href="./references#CD010956-bbs2-0016" title="OhmoriH , KadaA , NakamuraM , SaitoAM , SanayamaY , ShinagawaT , et al. Deep vein thrombosis in severe motor and intellectual disabilities patients and its treatment by anticoagulants of warfarin versus edoxaban. Annals of Vascular Diseases2019;12(3):372-8. OhmoriH , NakamuraM , KadaA , SaitoAM , SanayamaY , ShinagawaT , et al. Multicenter, open-label, randomized controlled trial of warfarin and edoxaban tosilate hydrate for the treatment of deep vein thrombosis in persons with severe motor intellectual disabilities. Kurume Medical Journal2018;65(1):11-6. ">Ohmori 2019</a>; <a href="./references#CD010956-bbs2-0017" title="Kang JiM, ParkKH , AhnS , ChoS , MinSK . Rivaroxaban after thrombolysis in acute iliofemoral venous thrombosis: a randomized, open-labeled, multicenter trial. Scientific Reports2019;9(1):20356. MinSK , AhnS , ParkKH , KangJM , KimJY . Prevention of recurrence after thrombolysis in acute iliofemoral venous thrombosis with rivaroxaban (Prais Study): a prospective, randomized, open label, multicenter trial. European Journal of Vascular and Endovascular Surgery2019;58(6):e516. NCT01986192. Prevention of recurrence after thrombolysis in acute iliofemoral venous thrombosis (PRAIS) study. clinicaltrials.gov/show/NCT01986192 (first received 18 November 2013). ">PRAIS 2019</a>). The <a href="./references#CD010956-bbs2-0020" title="SukovatykhBS , SereditskiĭAV , MuradianVF , BelikovLN , GerasimovaOF . Results of administering oral anticoagulants for treatment of patients with venous thromboembolic complications. Angiologiia i sosudistaia khirurgiia [Angiology and Vascular Surgery]2017;23(2):82. ">Sukovatykh 2017</a> study reported quality of life and <a href="./references#CD010956-bbs2-0005" title="NCT02704598. Comparison between xarelto versus warfarin in the recanalization rate of deep venous thrombosis in patients legs. (DVT). clinicaltrials.gov/ct2/show/NCT02704598 (first received 10 March 2016). deAthayde SoaresR , MatieloMF , Brochado NetoFC , AlmeidaRD , SacilottoR . LEV 2. Comparison of the recanalization rate and post-thrombotic syndrome in patients with deep venous thrombosis treated with rivaroxaban or warfarin. Journal of Vascular Surgery2019;70(5):e169-e170. deAthayde SoaresR , MatieloMF , Brochado NetoFC , NogueiraMP , AlmeidaRD , SacilottoR . Comparison of the recanalization rate and postthrombotic syndrome in patients with deep venous thrombosis treated with rivaroxaban or warfarin. Surgery2019;166(6):1076-83. ">de Athayde 2019</a> reported PTS. </p> <p>We included the <a href="./references#CD010956-bbs2-0008" title="BullerHR , PrinsMH , LensinAW , DecoususH , JacobsonBF , MinarE , et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. New England Journal of Medicine2012;366:1287-97. FermannGJ , Erkens Pmg, PrinsMH , WellsPS , Pap ÁF, LensingAW , et al. Treatment of pulmonary embolism with rivaroxaban: outcomes by simplified pulmonary embolism severity index score from a post hoc analysis of the EINSTEIN PE study. Academic Emergency Medicine2015;22(3):299-307. NCT00439777. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic pulmonary embolism with or without symptomatic deep-vein thrombosis: Einstein-PE evaluation, 2008. clinicaltrials.gov/ct2/show/NCT00439777?term=NCT00439777&amp;rank=1 (first received 26 February 2007). PrinsM , BamberL , CanoS , WangM , LensingAW , BauersachsR . Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic pulmonary embolism. Blood2012;120(21):1163. PrinsMH , BamberL , CanoSJ , WangMY , ErkensP , BauersachsR , et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial. Thrombosis Research2015;135(2):281-8. ">EINSTEIN‐PE 2012</a> study, as 25% of participants had concurrent symptomatic DVT. We contacted the authors of this study, who provided us with the data for the subgroup of people with DVT; however, it was not possible to obtain data on fatal PE, non‐fatal PE and all‐cause mortality from the study authors. We included four studies in participants with either DVT, PE or both (<a href="./references#CD010956-bbs2-0002" title="NakamuraM , NishikawaM , KomuroI , KitajimaI , UetsukaY , YamagamiT , et al. Apixaban for the treatment of Japanese subjects with acute venous thromboembolism (AMPLIFY-J Study). Circulation2015;79(6):1230–36. ">AMPLIFY‐J 2015</a>; <a href="./references#CD010956-bbs2-0004" title="AgenoW , VedovatiMC , CohenA , HuismanM , BauersachsR , GussoniG , et al. Bleeding with apixaban and dalteparin in patients with cancer-associated venous thromboembolism: results from the Caravaggio study. Thrombosis and Haemostasis2021;121(5):616-24. AgnelliG , BecattiniC , BauersachsR , BrennerB , CampaniniM , CohenA , et al. Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the Caravaggio study. Thrombosis and Haemostasis2018;118(9):1668-78. AgnelliG , BecattiniC , MeyerG , MuozA , VersoM . Apixaban for the treatment of venous thromboembolism associated with cancer. New England Journal of Medicine2020;382(17):1599-607. AgnelliG , MuozA , FrancoL , MahéI , BrennerB , ConnorsJM , et al. Apixaban and dalteparin for the treatment of venous thromboembolism in patients with different sites of cancer. Thrombosis and Haemostasis2022;122(5):796-807. BecattiniC , BauersachsR , MarazitiG , BertolettiL , CohenA , ConnorsJM , et al. Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial. Haematologica2021;107(7):1567-76. GiustozziM , ConnorsJM , Ruperez BlancoAB , SzmitS , FalvoN , CohenAT , et al. Clinical characteristics and outcomes of incidental venous thromboembolism in cancer patients: insights from the Caravaggio study. Journal of Thrombosis and Haemostasis2021;19(11):2751-9. NCT03045406. Apixaban for the treatment of venous thromboembolism in patients with cancer (CARAVAGGIO). clinicaltrials.gov/ct2/show/NCT03045406 (first received 7 February 2017). VersoM , MunozA , BauersachsR , HuismanMV , AgnelliG . Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism. European Journal of Cancer2021;148(Suppl C):371-81. ">Caravaggio 2020</a>; <a href="./references#CD010956-bbs2-0012" title="AmayaN , UzuiH , HisazakiK , HasegwaK , KasenoK , TadaH . Edoxaban normalizes the elevated D-dimer levels potently and promptly in patients with venous thromboembolisms: a comparison with traditional anticoagulant therapy. European Heart Journal2016;37:278. BoschFT , Van EsN , Di NisioM , CarrierM , SegersA , GrossoMA , et al. The Ottawa score does not predict recurrent venous thromboembolism in cancer patients: results from the Hokusai-VTE cancer study. Research and Practice in Thrombosis and Haemostasis2019;3(S1):717-8. KraaijpoelN , Di NisioM , MulderFI , Van EsN , RaskobGE . Clinical impact of bleeding in cancer-associated venous thromboembolism: results from the Hokusai VTE Cancer randomized trial. Thrombosis Research2018;164(Suppl 1):S223. [DOI: 10.1016/j.thromres.2018.02.094]MulderFI , Di NisioM , AyC , CarrierM , BoschFT , SegersA , et al. Clinical implications of incidental venous thromboembolism in cancer patients. European Respiratory Journal2020;55(2):1901697. [DOI: 10.1183/13993003.01697-2019]MulderFI , Van EsN , KraaijpoelN , Di NisioM , CarrierM , GarciaD , et al. Efficacy and safety of edoxaban in clinically relevant subgroups: results from the Hokusai VTE Cancer randomized trial. Thrombosis Research2018;164:S194. NCT02073682. Cancer venous thromboembolism (VTE). clinicaltrials.gov/ct2/show/NCT02073682 (first received 27 February 2014). RaskobG , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaD , et al. Edoxaban versus dalteparin for treatment of venous thromboembolism (VTE) associated with cancer: Hokusai VTE-cancer randomized trial. Supportive Care in Cancer2018;26(2):S316-S317. RaskobGE , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaD , et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. New England Journal of Medicine2018;378(7):615-24. RaskobGE , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaDA , et al. A randomized, open-label, blinded outcome assessment trial evaluating the efficacy and safety of LMWH/Edoxaban versus dalteparin for venous thromboembolism associated with cancer: Hokusai VTE-cancer study. Blood2017;130(Suppl 1):LBA-6. ">Hokusai VTE Cancer 2018</a>; <a href="./references#CD010956-bbs2-0011" title="BistervelsI , BavaliaR , BoersmaW , MeijerK , VerhammeP , Ten Cate-HoekAJ , et al. Hokusai Post-DVT Study: a follow-up study on long-term outcomes of deep vein thrombosis in patients treated with edoxaban vs warfarin. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):PB2207. BrekelmansMP , AgenoW , BeenenLF , BrennerB , BullerHR , ChenCZ , et al. Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology2016;3(9):e437-45. BrekelmansMP , BlekerSM , BauersachsR , BodaZ , BüllerHR , ChoiY , et al. Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists. Thrombosis and Haemostasis2016;116(1):155-61. Di NisioM , Van EsN , CarrierM , WangTF , GarciaD , SegersA , et al. Extended treatment with edoxaban in cancer patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE Cancer study. Journal of Thrombosis and Haemostasis2019;17:1866–74. EUCTR2009-014290-40-SE. A phase 3, randomized, double-blind, double-dummy, parallel group, multi-center, multi-national study for evaluation of efficacy and safety of DU-176b versus warfarin in subjects with atrial fibrillation - effective anticoagulation with factor Xa next generation in atrial fibrillation (ENGAGE-AF TIMI-48). trialsearch.who.int/?trialid=EUCTR2009-014290-40-SE (first received 30 November 2009). EichingerS , LinM , KyrlePA , GrossoMA . Recurrent venous thromboembolism during anticoagulation: an investigator-initiated post-hoc analysis of the hokusai-VTE trial. Blood2018;132:2539. KlokFA , BarcoS , KonstantinidesSV . External validation of the VTE-BLEED score for predicting major bleeding in stable anticoagulated patients with venous thromboembolism. Thrombosis and Haemostasis2017;117(6):1164-70. KraaijpoelN , Van EsN , RaskobGE , BüllerHR , CarrierM , ZhangG , et al. Risk scores for occult cancer in patients with venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2018;118(7):1270-8. MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMP , ChenCZ , et al. Outpatient management in patients with venous thromboembolism with edoxaban: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2017;117(12):2406-14. MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMP , ChenCZ , et al. Safety and efficacy of edoxaban compared with warfarin for the treatment of acute symptomatic deep-vein thrombosis in the outpatient setting. Research and Practice in Thrombosis and Haemostasis2017;1:913. MulderFI , Van EsN , KraaijpoelN , Di NisioM , CarrierM , DuggalA , et al. Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: results from the Hokusai VTE Cancer study. Thrombosis Research2020;185:13-9. NCT00986154. Comparative investigation of Low Molecular Weight (LMW) heparin/edoxaban tosylate (DU176b) versus (LMW) heparin/warfarin in the treatment of symptomatic deep-vein blood clots and/or lung blood clots. (The Edoxaban Hokusai-VTE Study). clinicaltrials.gov/ct2/show/NCT00986154 (first received 29 September 2009). NakamuraM , WangYQ , WangC , OhD , YinWH , KimuraT , et al. Efficacy and safety of edoxaban for treatment of venous thromboembolism: a subanalysis of East Asian patients in the Hokusai-VTE trial. Journal of Thrombosis and Haemostasis2015;13(9):1606-14. NybergJ , KarlssonKE , JönssonS , YinO , MillerR , KarlssonMO , et al. Edoxaban exposure-response analysis and clinical utility index assessment in patients with symptomatic deep-vein thrombosis or pulmonary embolism. CPT Pharmacometrics and Systems Pharmacology2016;5(4):222-32. RaskobG , AgenoW , CohenAT , BrekelmansMP , GrossoMA , SegersA , et al. Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology2016;3(5):e228-e236. RaskobG , BullerH , PrinsM , SegersA , ShiM , SchwochoL , et al. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study - methodological implications for clinical trials. Journal of Thrombosis and Haemostasis2013;11(7):1287-94. RaskobGE , BullerH , AngchaisuksiriP , OhD , BodaZ , LyonsRM , et al. Edoxaban for long-term treatment of venous thromboembolism in cancer patients. Blood2013;122(21):211. RaskobGE , Van EsN , SegersA , AngchaisuksiriP , OhD , BodaZ , et al. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematology2016;3(8):e379-87. ScheresLJ , BrekelmansMA , WalterA , CihanA , BüllerHR , SabineE , et al. Abnormal vaginal bleeding in women of reproductive age treated with edoxaban or warfarin for venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. British Journal of Obstetrics and Gynaecology2018;125(12):1581-9. The Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. New England Journal of Medicine2013;369(15):1406-15. VanasscheT , VerhammeP , WellsPS , SegersA , AgenoW , BrekelmansMP , et al. Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: an analysis of the randomized, double-blind Hokusai-VTE trial. Thrombosis Research2018;162:7-14. VerhammeP , WellsPS , SegersA , AgenoW , BrekelmansMP , CohenAT , et al. Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial. Thrombosis and Haemostasis2016;116(4):747-53. ">Hokusai‐VTE 2013</a>). For these studies, we collected reported data from the subgroup of people with an index DVT (44 participants in <a href="./references#CD010956-bbs2-0002" title="NakamuraM , NishikawaM , KomuroI , KitajimaI , UetsukaY , YamagamiT , et al. Apixaban for the treatment of Japanese subjects with acute venous thromboembolism (AMPLIFY-J Study). Circulation2015;79(6):1230–36. ">AMPLIFY‐J 2015</a>, 517 in <a href="./references#CD010956-bbs2-0004" title="AgenoW , VedovatiMC , CohenA , HuismanM , BauersachsR , GussoniG , et al. Bleeding with apixaban and dalteparin in patients with cancer-associated venous thromboembolism: results from the Caravaggio study. Thrombosis and Haemostasis2021;121(5):616-24. AgnelliG , BecattiniC , BauersachsR , BrennerB , CampaniniM , CohenA , et al. Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the Caravaggio study. Thrombosis and Haemostasis2018;118(9):1668-78. AgnelliG , BecattiniC , MeyerG , MuozA , VersoM . Apixaban for the treatment of venous thromboembolism associated with cancer. New England Journal of Medicine2020;382(17):1599-607. AgnelliG , MuozA , FrancoL , MahéI , BrennerB , ConnorsJM , et al. Apixaban and dalteparin for the treatment of venous thromboembolism in patients with different sites of cancer. Thrombosis and Haemostasis2022;122(5):796-807. BecattiniC , BauersachsR , MarazitiG , BertolettiL , CohenA , ConnorsJM , et al. Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial. Haematologica2021;107(7):1567-76. GiustozziM , ConnorsJM , Ruperez BlancoAB , SzmitS , FalvoN , CohenAT , et al. Clinical characteristics and outcomes of incidental venous thromboembolism in cancer patients: insights from the Caravaggio study. Journal of Thrombosis and Haemostasis2021;19(11):2751-9. NCT03045406. Apixaban for the treatment of venous thromboembolism in patients with cancer (CARAVAGGIO). clinicaltrials.gov/ct2/show/NCT03045406 (first received 7 February 2017). VersoM , MunozA , BauersachsR , HuismanMV , AgnelliG . Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism. European Journal of Cancer2021;148(Suppl C):371-81. ">Caravaggio 2020</a>, 4921 in <a href="./references#CD010956-bbs2-0011" title="BistervelsI , BavaliaR , BoersmaW , MeijerK , VerhammeP , Ten Cate-HoekAJ , et al. Hokusai Post-DVT Study: a follow-up study on long-term outcomes of deep vein thrombosis in patients treated with edoxaban vs warfarin. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):PB2207. BrekelmansMP , AgenoW , BeenenLF , BrennerB , BullerHR , ChenCZ , et al. Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology2016;3(9):e437-45. BrekelmansMP , BlekerSM , BauersachsR , BodaZ , BüllerHR , ChoiY , et al. Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists. Thrombosis and Haemostasis2016;116(1):155-61. Di NisioM , Van EsN , CarrierM , WangTF , GarciaD , SegersA , et al. Extended treatment with edoxaban in cancer patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE Cancer study. Journal of Thrombosis and Haemostasis2019;17:1866–74. EUCTR2009-014290-40-SE. A phase 3, randomized, double-blind, double-dummy, parallel group, multi-center, multi-national study for evaluation of efficacy and safety of DU-176b versus warfarin in subjects with atrial fibrillation - effective anticoagulation with factor Xa next generation in atrial fibrillation (ENGAGE-AF TIMI-48). trialsearch.who.int/?trialid=EUCTR2009-014290-40-SE (first received 30 November 2009). EichingerS , LinM , KyrlePA , GrossoMA . Recurrent venous thromboembolism during anticoagulation: an investigator-initiated post-hoc analysis of the hokusai-VTE trial. Blood2018;132:2539. KlokFA , BarcoS , KonstantinidesSV . External validation of the VTE-BLEED score for predicting major bleeding in stable anticoagulated patients with venous thromboembolism. Thrombosis and Haemostasis2017;117(6):1164-70. KraaijpoelN , Van EsN , RaskobGE , BüllerHR , CarrierM , ZhangG , et al. Risk scores for occult cancer in patients with venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2018;118(7):1270-8. MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMP , ChenCZ , et al. Outpatient management in patients with venous thromboembolism with edoxaban: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2017;117(12):2406-14. MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMP , ChenCZ , et al. Safety and efficacy of edoxaban compared with warfarin for the treatment of acute symptomatic deep-vein thrombosis in the outpatient setting. Research and Practice in Thrombosis and Haemostasis2017;1:913. MulderFI , Van EsN , KraaijpoelN , Di NisioM , CarrierM , DuggalA , et al. Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: results from the Hokusai VTE Cancer study. Thrombosis Research2020;185:13-9. NCT00986154. Comparative investigation of Low Molecular Weight (LMW) heparin/edoxaban tosylate (DU176b) versus (LMW) heparin/warfarin in the treatment of symptomatic deep-vein blood clots and/or lung blood clots. (The Edoxaban Hokusai-VTE Study). clinicaltrials.gov/ct2/show/NCT00986154 (first received 29 September 2009). NakamuraM , WangYQ , WangC , OhD , YinWH , KimuraT , et al. Efficacy and safety of edoxaban for treatment of venous thromboembolism: a subanalysis of East Asian patients in the Hokusai-VTE trial. Journal of Thrombosis and Haemostasis2015;13(9):1606-14. NybergJ , KarlssonKE , JönssonS , YinO , MillerR , KarlssonMO , et al. Edoxaban exposure-response analysis and clinical utility index assessment in patients with symptomatic deep-vein thrombosis or pulmonary embolism. CPT Pharmacometrics and Systems Pharmacology2016;5(4):222-32. RaskobG , AgenoW , CohenAT , BrekelmansMP , GrossoMA , SegersA , et al. Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology2016;3(5):e228-e236. RaskobG , BullerH , PrinsM , SegersA , ShiM , SchwochoL , et al. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study - methodological implications for clinical trials. Journal of Thrombosis and Haemostasis2013;11(7):1287-94. RaskobGE , BullerH , AngchaisuksiriP , OhD , BodaZ , LyonsRM , et al. Edoxaban for long-term treatment of venous thromboembolism in cancer patients. Blood2013;122(21):211. RaskobGE , Van EsN , SegersA , AngchaisuksiriP , OhD , BodaZ , et al. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematology2016;3(8):e379-87. ScheresLJ , BrekelmansMA , WalterA , CihanA , BüllerHR , SabineE , et al. Abnormal vaginal bleeding in women of reproductive age treated with edoxaban or warfarin for venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. British Journal of Obstetrics and Gynaecology2018;125(12):1581-9. The Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. New England Journal of Medicine2013;369(15):1406-15. VanasscheT , VerhammeP , WellsPS , SegersA , AgenoW , BrekelmansMP , et al. Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: an analysis of the randomized, double-blind Hokusai-VTE trial. Thrombosis Research2018;162:7-14. VerhammeP , WellsPS , SegersA , AgenoW , BrekelmansMP , CohenAT , et al. Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial. Thrombosis and Haemostasis2016;116(4):747-53. ">Hokusai‐VTE 2013</a>, and 389 in <a href="./references#CD010956-bbs2-0012" title="AmayaN , UzuiH , HisazakiK , HasegwaK , KasenoK , TadaH . Edoxaban normalizes the elevated D-dimer levels potently and promptly in patients with venous thromboembolisms: a comparison with traditional anticoagulant therapy. European Heart Journal2016;37:278. BoschFT , Van EsN , Di NisioM , CarrierM , SegersA , GrossoMA , et al. The Ottawa score does not predict recurrent venous thromboembolism in cancer patients: results from the Hokusai-VTE cancer study. Research and Practice in Thrombosis and Haemostasis2019;3(S1):717-8. KraaijpoelN , Di NisioM , MulderFI , Van EsN , RaskobGE . Clinical impact of bleeding in cancer-associated venous thromboembolism: results from the Hokusai VTE Cancer randomized trial. Thrombosis Research2018;164(Suppl 1):S223. [DOI: 10.1016/j.thromres.2018.02.094]MulderFI , Di NisioM , AyC , CarrierM , BoschFT , SegersA , et al. Clinical implications of incidental venous thromboembolism in cancer patients. European Respiratory Journal2020;55(2):1901697. [DOI: 10.1183/13993003.01697-2019]MulderFI , Van EsN , KraaijpoelN , Di NisioM , CarrierM , GarciaD , et al. Efficacy and safety of edoxaban in clinically relevant subgroups: results from the Hokusai VTE Cancer randomized trial. Thrombosis Research2018;164:S194. NCT02073682. Cancer venous thromboembolism (VTE). clinicaltrials.gov/ct2/show/NCT02073682 (first received 27 February 2014). RaskobG , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaD , et al. Edoxaban versus dalteparin for treatment of venous thromboembolism (VTE) associated with cancer: Hokusai VTE-cancer randomized trial. Supportive Care in Cancer2018;26(2):S316-S317. RaskobGE , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaD , et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. New England Journal of Medicine2018;378(7):615-24. RaskobGE , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaDA , et al. A randomized, open-label, blinded outcome assessment trial evaluating the efficacy and safety of LMWH/Edoxaban versus dalteparin for venous thromboembolism associated with cancer: Hokusai VTE-cancer study. Blood2017;130(Suppl 1):LBA-6. ">Hokusai VTE Cancer 2018</a>). We were unable to obtain outcome data on all‐cause mortality from the authors of the <a href="./references#CD010956-bbs2-0011" title="BistervelsI , BavaliaR , BoersmaW , MeijerK , VerhammeP , Ten Cate-HoekAJ , et al. Hokusai Post-DVT Study: a follow-up study on long-term outcomes of deep vein thrombosis in patients treated with edoxaban vs warfarin. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):PB2207. BrekelmansMP , AgenoW , BeenenLF , BrennerB , BullerHR , ChenCZ , et al. Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology2016;3(9):e437-45. BrekelmansMP , BlekerSM , BauersachsR , BodaZ , BüllerHR , ChoiY , et al. Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists. Thrombosis and Haemostasis2016;116(1):155-61. Di NisioM , Van EsN , CarrierM , WangTF , GarciaD , SegersA , et al. Extended treatment with edoxaban in cancer patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE Cancer study. Journal of Thrombosis and Haemostasis2019;17:1866–74. EUCTR2009-014290-40-SE. A phase 3, randomized, double-blind, double-dummy, parallel group, multi-center, multi-national study for evaluation of efficacy and safety of DU-176b versus warfarin in subjects with atrial fibrillation - effective anticoagulation with factor Xa next generation in atrial fibrillation (ENGAGE-AF TIMI-48). trialsearch.who.int/?trialid=EUCTR2009-014290-40-SE (first received 30 November 2009). EichingerS , LinM , KyrlePA , GrossoMA . Recurrent venous thromboembolism during anticoagulation: an investigator-initiated post-hoc analysis of the hokusai-VTE trial. Blood2018;132:2539. KlokFA , BarcoS , KonstantinidesSV . External validation of the VTE-BLEED score for predicting major bleeding in stable anticoagulated patients with venous thromboembolism. Thrombosis and Haemostasis2017;117(6):1164-70. KraaijpoelN , Van EsN , RaskobGE , BüllerHR , CarrierM , ZhangG , et al. Risk scores for occult cancer in patients with venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2018;118(7):1270-8. MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMP , ChenCZ , et al. Outpatient management in patients with venous thromboembolism with edoxaban: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2017;117(12):2406-14. MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMP , ChenCZ , et al. Safety and efficacy of edoxaban compared with warfarin for the treatment of acute symptomatic deep-vein thrombosis in the outpatient setting. Research and Practice in Thrombosis and Haemostasis2017;1:913. MulderFI , Van EsN , KraaijpoelN , Di NisioM , CarrierM , DuggalA , et al. Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: results from the Hokusai VTE Cancer study. Thrombosis Research2020;185:13-9. NCT00986154. Comparative investigation of Low Molecular Weight (LMW) heparin/edoxaban tosylate (DU176b) versus (LMW) heparin/warfarin in the treatment of symptomatic deep-vein blood clots and/or lung blood clots. (The Edoxaban Hokusai-VTE Study). clinicaltrials.gov/ct2/show/NCT00986154 (first received 29 September 2009). NakamuraM , WangYQ , WangC , OhD , YinWH , KimuraT , et al. Efficacy and safety of edoxaban for treatment of venous thromboembolism: a subanalysis of East Asian patients in the Hokusai-VTE trial. Journal of Thrombosis and Haemostasis2015;13(9):1606-14. NybergJ , KarlssonKE , JönssonS , YinO , MillerR , KarlssonMO , et al. Edoxaban exposure-response analysis and clinical utility index assessment in patients with symptomatic deep-vein thrombosis or pulmonary embolism. CPT Pharmacometrics and Systems Pharmacology2016;5(4):222-32. RaskobG , AgenoW , CohenAT , BrekelmansMP , GrossoMA , SegersA , et al. Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology2016;3(5):e228-e236. RaskobG , BullerH , PrinsM , SegersA , ShiM , SchwochoL , et al. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study - methodological implications for clinical trials. Journal of Thrombosis and Haemostasis2013;11(7):1287-94. RaskobGE , BullerH , AngchaisuksiriP , OhD , BodaZ , LyonsRM , et al. Edoxaban for long-term treatment of venous thromboembolism in cancer patients. Blood2013;122(21):211. RaskobGE , Van EsN , SegersA , AngchaisuksiriP , OhD , BodaZ , et al. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematology2016;3(8):e379-87. ScheresLJ , BrekelmansMA , WalterA , CihanA , BüllerHR , SabineE , et al. Abnormal vaginal bleeding in women of reproductive age treated with edoxaban or warfarin for venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. British Journal of Obstetrics and Gynaecology2018;125(12):1581-9. The Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. New England Journal of Medicine2013;369(15):1406-15. VanasscheT , VerhammeP , WellsPS , SegersA , AgenoW , BrekelmansMP , et al. Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: an analysis of the randomized, double-blind Hokusai-VTE trial. Thrombosis Research2018;162:7-14. VerhammeP , WellsPS , SegersA , AgenoW , BrekelmansMP , CohenAT , et al. Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial. Thrombosis and Haemostasis2016;116(4):747-53. ">Hokusai‐VTE 2013</a> study. </p> </section> <section id="CD010956-sec-0051"> <h4 class="title">Excluded studies</h4> <p>See <a href="./references#CD010956-sec-0118" title="">Characteristics of excluded studies</a>. </p> <p>We excluded 16 studies from this review (<a href="./references#CD010956-bbs2-0022" title="McBane RD 2nd, LoprinziCL , AshraniA , Perez-BoteroJ , FerreRA , HenkinS , et al. Apixaban and dalteparin in active malignancy associated venous thromboembolism. The ADAM VTE trial. Thrombosis and Haemostasis2017;117(10):1952-61. McBane RD 2nd, WysokinskiWE , Le-RademacherJG , ZemlaT , AshraniA , TafurA , et al. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial. Thrombosis and Haemostasis2020;18(2):411-21. NCT02585713. Apixaban or dalteparin in reducing blood clots in patients with cancer related venous thromboembolism. clinicaltrials.gov/ct2/show/NCT02585713 (first received 23 October 2015). ">ADAM VTE trial 2020</a>; <a href="./references#CD010956-bbs2-0023" title="AgnelliG , BullerHR , CohenA , CurtoM , GallusAS , JohnsonM , et al. Apixaban for extended treatment of venous thromboembolism. New England Journal of Medicine2013;368(8):699-708. AgnelliG , BullerHR , CohenA , CurtoM , GallusAS , JohnsonMR , et al. Two doses of apixaban for the extended treatment of venous thromboembolism. Blood2012;120:LBA-1. LiuX , ThompsonJ , PhatakH , MardekianJ , PorcariAR , JohnsonMR . Apixaban reduces hospitalization in patients with venous thromboembolism: an analysis of the AMPLIFY-EXT trial. Blood2013;122(21):3638. [DOI: 10.1182/blood.V122.21.3638.3638]">AMPLIFY Extended Study 2013</a>; <a href="./references#CD010956-bbs2-0024" title="BorsiSH , RajiH , DargahiMM , NokhostinF , KargaranA . Rivaroxaban versus enoxaparin for treatment of patients with nonhematologic cancer with venous thromboembolism: a randomized clinical trial. Tehran University Medical Journal2021;79(4):281-9. ">Borsi 2021</a>; <a href="./references#CD010956-bbs2-0025" title="NCT02746185. Cancer associated thrombosis, a pilot treatment study using rivaroxaban (CASTA-DIVA). clinicaltrials.gov/ct2/show/NCT02746185 (first received 21 April 2016). PlanquetteB , BertolettiL , Charles-NelsonA , LaporteS , GrangeC , MahéI , et al. Rivaroxaban vs dalteparin in cancer-associated thromboembolism: a randomized trial. Chest2022;161(3):781-90. ">CASTA DIVA Trial 2022</a>; <a href="./references#CD010956-bbs2-0026" title="CastellucciLA , HoggK , ChiangP , WuCM , TemplierGL , GalGL , et al. Comparison of bleeding risk between rivaroxaban and apixaban: a pilot feasibility study. Blood2017;130:1108. ">COBRRA 2017</a>; <a href="./references#CD010956-bbs2-0027" title="EUCTR2015-001478-16-DE. The role of rivaroxaban in the treatment of tumor patients with thrombosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2015-001478-16-DE (first received 9 September 2015). NCT02583191. Rivaroxaban in the treatment of venous thromboembolism (VTE) in cancer patients. clinicaltrials.gov/ct2/show/NCT02583191 (first received 22 October 2015). RiessH , SinnM , KreherS . CONKO-011: evaluation of patient satisfaction with the treatment of acute venous thromboembolism with rivaroxaban or low molecular weight heparin in cancer patients. A randomized phase III study. Deutsche Medizinische Wochenschrift2015;140(Suppl 1):S22. RiessH , SinnM , LohneisA , HellmannM , StrieflerJ , SüdhoffT , et al. Improved patient-reported treatment satisfaction with rivaroxaban as compared to low molecular weight heparins for cancer patients with acute venous thromboembolism – results from the CONKO-011 trial. Research and Practice in Thrombosis and Haemostasis2021;5(Suppl 2):LPB0041. SinnM , JuhlingA , HellmannM , OmarM , SudhoffT , StahlM , et al. Patient-reported treatment satisfaction with Rivaroxaban in cancer patients with acute venous thromboembolism - results from the CONKO-011 trial. Oncology Research and Treatment2021;44(Suppl 2):276-7. ">CONKO‐011 study 2015</a>; <a href="./references#CD010956-bbs2-0028" title="AlbisettiM , BissB , BomgaarsL , BrandãoLR , BrueckmannM , ChalmersE , et al. Design and rationale for the DIVERSITY study: an open-label, randomized study of dabigatran etexilate for pediatric venous thromboembolism. Research and Practice in Thrombosis and Haemostasis2018;2(2):347-56. AlbisettiM , BrandãoL , BomgaarsL , ChalmersE , LucianiM , MitchellL , et al. Efficacy and safety of dabigatran etexilate for treatment of venous thromboembolism in paediatric patients - results of the DIVERSITY trial. ISTH Academy2019:OC 57.3. AlbisettiM , TartakovskyI , HaltonJ , BomgaarsL , ChalmersE , MitchellL , et al. Efficacy and safety of dabigatran in the treatment and secondary prevention of venous thromboembolism in children with central line or implantable device–related thrombosis. Research and Practice in Thrombosis and Haemostasis2021;5(Suppl 2):OC 69.2. BrandãoL , TartakovskyI , HaltonJ , BomgaarsL , ChalmersE , MitchellL , et al. Efficacy and safety of dabigatran in the treatment and secondary prevention of venous thromboembolism in children with cerebral venous and sinus thrombosis. Research and Practice in Thrombosis and Haemostasis2021;5(Suppl 2):PB0787. EUCTR2013-002114-12. Open label study comparing efficacy and safety of dabigatran etexilate to standard of care in paediatric patients with VTE. trialsearch.who.int/?TrialID=EUCTR2013%E2%80%90002114%E2%80%9012%E2%80%90Outside%E2%80%90EU/EEA (first received 18 Feburary 2014). HaltonJ , BrandãoL , LucianiM , BomgaarsL , ChalmersE , MitchellL , et al. Efficacy and safety of dabigatran etexilate for treatment of venous thromboembolism in paediatric patients aged from birth to &lt; 2 years - results of the DIVERSITY trial. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):OC 12.1. HaltonJ , BrandãoLR , LucianiM , BomgaarsL , ChalmersE , MitchellLG , et al. Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial. Lancet Haematology2021;8(1):e22-e33. NCT01895777. Open label study comparing efficacy and safety of dabigatran etexilate to standard of care in paediatric patients with venous thromboembolism (VTE). clinicaltrials.gov/ct2/show/NCT01895777 (first received 11 July  2013). NCT01895777. Open label study comparing efficacy and safety of dabigatran etexilate to standard of care in paediatric patients with venous thromboembolism (VTE). clinicaltrials.gov/show/NCT01895777 (first received 25 September 2013). ">DIVERSITY 2021</a>; <a href="./references#CD010956-bbs2-0029" title="PrandoniP , LensingAW , PrinsMH , GebelM , PapAF , HomeringM , et al. Benefits and risks of extended treatment of venous thromboembolism with rivaroxaban or with aspirin. Thrombosis Research2018;168:121-9. WeitzJI , LensingAW , PrinsMH , BauersachsR , Beyer-WestendorfJ , BounameauxH , et al. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. New England Journal of Medicine2017;376(13):1211-22. ">EINSTEIN‐CHOICE 2017</a>; <a href="./references#CD010956-bbs2-0030" title="LensingAW , MaleC , YoungG , KubitzaD , KenetG , MassicotteMP , et al. Rivaroxaban versus standard anticoagulation for acute venous thromboembolism in childhood. Design of the EINSTEIN-Jr phase III study. Thrombosis Journal2018;16:34. MaleC , LensingAW , PalumboJS , KumarR , NurmeevI , HegeK , et al. Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial. Lancet Haematology2020;7(1):e18-e27. NCT01684423. Oral rivaroxaban in children with venous thrombosis (EINSTEIN Junior). clinicaltrials.gov/show/NCT01684423 (first received 13 September 2012). NCT02234843. EINSTEIN Junior: oral rivaroxaban in children with venous thrombosis. clinicaltrials.gov/ct2/show/NCT02234843 (first received 9 September 2014). NCT02309411. EINSTEIN Junior phase II: oral rivaroxaban in young children with venous thrombosis (EINSTEIN Jr). hclinicaltrials.gov/ct2/show/NCT02309411 (first received 5 December 2014). ThomK , LensingAW , NurmeevI , BajolleF , BonnetD , KenetG , et al. Safety and efficacy of anticoagulant therapy in pediatric catheter-related venous thrombosis (EINSTEIN-Jr CVC-VTE). Blood Advances2020;4(19):4632-9. ">EINSTEIN‐Jr 2020</a>; <a href="./references#CD010956-bbs2-0031" title="NCT02584660. A study of rivaroxaban for early discharge of low risk pulmonary embolism from the emergency department. clinicaltrials.gov/ct2/show/NCT02584660 (first received 22 October 2015). PeacockFW , ColemanCI , DiercksDB , FrancisS , KabrhelC , KeayC , et al. Emergency department discharge of pulmonary embolus patients. Academic Emergency Medicine2018;25(9):995-1003. PeacockW , DiercksD , FrancisS , KabrhelC , KeayC , KlineJ , et al. Multicenter trial of rivaroxaban for early discharge of pulmonary embolism from the emergency department. Annals of Emergency Medicine2017;70(4):S29-S30. ">Peacock 2018</a>; <a href="./references#CD010956-bbs2-0032" title="KimJH , YooC , SeoS , JeongJH , RyooBY , KimKP , et al. A phase II study to compare the safety and efficacy of direct oral anticoagulants versus subcutaneous dalteparin for cancer-associated venous thromboembolism in patients with advanced upper gastrointestinal, hepatobiliary and pancreatic cancer: PRIORITY. Cancers2022;14(3):559. NCT03139487. A randomized phase II open label study to compare the safety and efficacy of subcutaneous dalteparin versus direct oral anticoagulants for cancer-associated venous thromboembolism. clinicaltrials.gov/ct2/show/NCT03139487 (first received 4 May 2017). ">PRIORITY 2022</a>; <a href="./references#CD010956-bbs2-0033" title="LiemTK , DeLougheryTG . Randomised controlled trial: extended-duration dabigatran is non-inferior to warfarin and more effective than placebo for symptomatic VTE. Evidence Based Medicine2014;19(1):29. SchulmanS , KearonC , KakkarAK , SchellongS , ErikssonH , BaanstraA , et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. New England Journal of Medicine2013;368:709-18. ">REMEDY 2013</a>; <a href="./references#CD010956-bbs2-0034" title="SchulmanS , BaanstraD , ErikssonH , GoldhaberS , KakkarA , KearonC , et al. Dabigatran vs. placebo for extended maintenance therapy of venous thromboembolism. Journal of Thrombosis and Haemostasis2011;9(Suppl 2):22. SchulmanS , BaanstraD , ErikssonH , GoldhaberSZ , KakkarA , KearonC , et al. Benefit of extended maintenance therapy for venous thromboembolism with dabigatran etexilate is maintained over 1 year of post-treatment follow-up. Blood2012;120(21):Abstract 332. SchulmanS , KearonC , KakkarAK , SchellongS , ErikssonH , BaanstraD , et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. New England Journal of Medicine2013;368(8):709-18. ">RE‐SONATE 2013</a>; <a href="./references#CD010956-bbs2-0035" title="EUCTR2012-005589-37-GB. Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2012-005589-37-GB (first received 18 February 2013). YoungA , DunnJ , ChapmanO , GrumettJ , MarshallA , PhillipsJ , et al. SELECT-D: anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. Journal of Clinical Oncology2014;32(Suppl 15):TPS9661-TPS9661. YoungA , MarshallA , ThirlwallJ , HillC , HaleD , DunnJ , et al. Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism: results of the select-D™ pilot trial. Blood2017;130:625. YoungA , PhillipsJ , HancocksH , HillC , JoshiN , MarshallA , et al. Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism (OC-11). Thrombosis Research2016;140(Suppl 1):S172-3. YoungAM , MarshallA , ThirlwallJ , ChapmanO , LokareA , HillC , et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). Journal of Clinical Oncology2018;36(20):2017-23. ">SELECT‐D 2018</a>; <a href="./references#CD010956-bbs2-0036" title="ErikssonH , WåhlanderK , GustafssonD , WelinLT , FrisonL , SchulmanS , et al. A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I. Journal of Thrombosis and Haemostasis2003;1:41-7. ">THRIVE I 2003</a>; <a href="./references#CD010956-bbs2-0037" title="ErikssonH , LundstromT , WahlanderK , ClasonSB , SchulmanS . Prognostic factors for recurrence of venous thromboembolism (VTE) or bleeding during long-term secondary prevention of VTE with ximelagatran. Thrombosis and Haemostasis2005;94(3):522-7. ErikssonH , WahlanderK , LundstromT , BillingCS , SchulmanS . Extended secondary prevention with the oral direct thrombin inhibitor ximelagatran for 18 months after 6 months of anticoagulation in patients with venous thromboembolism: a randomized, placebo-controlled trial. Blood2002;100(Suppl):81a. SchulmanS , LundstromT , WalanderK , BillingCS , ErikssonH . Ximelagatran for the secondary prevention of venous thromboembolism: a complementary follow-up analysis of the THRIVE III study. Thrombosis and Haemostasis2005;94(4):820-4. SchulmanS , WahlanderK , LundstromT , ClasonSB , ErikssonH , THRIVE III Investigators. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. New England Journal of Medicine2003;349(18):1713-21. ">THRIVE III 2003</a>).  </p> <p>Participants in the <a href="./references#CD010956-bbs2-0023" title="AgnelliG , BullerHR , CohenA , CurtoM , GallusAS , JohnsonM , et al. Apixaban for extended treatment of venous thromboembolism. New England Journal of Medicine2013;368(8):699-708. AgnelliG , BullerHR , CohenA , CurtoM , GallusAS , JohnsonMR , et al. Two doses of apixaban for the extended treatment of venous thromboembolism. Blood2012;120:LBA-1. LiuX , ThompsonJ , PhatakH , MardekianJ , PorcariAR , JohnsonMR . Apixaban reduces hospitalization in patients with venous thromboembolism: an analysis of the AMPLIFY-EXT trial. Blood2013;122(21):3638. [DOI: 10.1182/blood.V122.21.3638.3638]">AMPLIFY Extended Study 2013</a> had already taken part in the included <a href="./references#CD010956-bbs2-0001" title="AgnelliG , BullerH , MasiukiewiczUP . Apixaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism: a randomized, double-blind trial (AMPLIFY). Journal of Thrombosis and Haemostasis2013;11:18. AgnelliG , BullerHR , CohenA , CurtoD , GallusAS , JohnsonM , et al. Oral apixaban for the treatment of acute venous thromboembolism. New England Journal of Medicine2013;369:799-808. AgnelliG , BullerHR , CohenA , CurtoM , GallusAS , PakR , et al. Apixaban for the treatment of venous thromboembolism in cancer patients: data from the AMPLIFY trial. Canadian Journal of Cardiology2014;30(10 Suppl 1):S278. AgnelliG , BullerHR , CohenA , GallusAS , LeeTC , PakR , et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. Journal of Thrombosis and Haemostasis2015;13(12):2187-91. AgnelliG . Apixaban was non-inferior to enoxaparin plus warfarin in patients with acute venous thromboembolism. Annals of Internal Medicine2013;159(8):JC2. BlekerSM , CohenAT , BüllerHR , AgnelliG , GallusAS , RaskobGE , et al. Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Thrombosis and Haemostasis2016;116(6):159-64. BrekelmansM , ScheresL , BlekerS , HuttenB , TimmermansA , BüllerH , et al. Abnormal vaginal bleeding in women with venous thromboembolism treated with apixaban or warfarin. Thrombosis and Haemostasis2017;117(04):809-15. CohenA , AgnelliG , BullerH , GallusA , RaskobG , SandersP , et al. Characteristics and outcomes in patients with venous thromboembolism taking concomitant anti-platelet agents and anticoagulants in the AMPLIFY Trial. Thrombosis and Haemostasis2019;119(3):461-6. CohenA , AgnelliG , BullerHR , ChaudhuriS , GallusAS , RaskobGE , et al. Analysis of the bleeding and thromboembolic risk with concomitant use of antiplatelet treatment in the AMPLIFY trial. Canadian Journal of Cardiology2014;30(10):S272. CohenA , GallusAS , AgnelliG , BullerHR , PakR , PorcariAR , et al. Time in Therapeutic Range (TTR) and relative efficacy and safety of treatment with apixaban or enoxaparin/warfarin for acute symptomatic venous thromboembolism: an analysis of the Amplify trial data. Blood2014;124(21):1543. CohenAT , PanS , ByonW , IlyasBS , LeeTC . Efficacy, safety, and exposure of apixaban in patients with high body weight or obesity and venous thromboembolism: insights from AMPLIFY. Advances in Therapy2021;38(6):3003-18. EUCTR2007-007867-25-PT. A safety and efficacy trial evaluating the use of apixaban in the treatment of symptomatic deep vein thrombosis and pulmonary embolism revised protocol number: 01, incorporates amendment(s) 02 + protocol amendment 01 (version 1.0 dated 21-Apr-08) site-specific - molecular profiling supplement samples for Pfizer’s exploratory research biobank. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2007%E2%80%90007867%E2%80%9025%E2%80%90PT (first received 14 July 2008). GallusAS , AgnelliG , BullerHR , CohenA , LeeTC , PakR , et al. Apixaban for treatment of venous thromboembolism in patients from study centres in Asia: a subgroup analysis of the Amplify trial. Journal of Thrombosis and Haemostasis2015;13:727. LeeT , PanS , ByonW , IlyasBS . Safety and efficacy of apixaban versus enoxaparin/warfarin in patients with extremes of body weight: post-hoc analysis of the AMPLIFY trial. Blood2019;134(Suppl 1):1152. LiuX , JohnsonM , MardekianJ , PhatakH , ThompsonJ , CohenAT . Apixaban reduces hospitalizations in patients with venous thromboembolism: an analysis of the apixaban for the Initial management of pulmonary embolism and deep‐vein thrombosis as first‐line therapy (AMPLIFY) trial. Journal of the American Heart Association2015;4(12):e002340. NCT00633893. Efficacy and safety study of apixaban for extended treatment of deep vein thrombosis or pulmonary embolism. clinicaltrials.gov/ct2/show/NCT00633893?term=ajax&amp;rank=5 (first received 12 March 2008). NCT00643201. Efficacy and safety study of apixaban for the treatment of deep vein thrombosis or pulmonary embolism. clinicaltrials.gov/ct2/show/NCT00643201 (first received 26 March 2008). RaskobGE , GallusAS , SandersP , ThompsonJR , AgnelliG , BullerHR , et al. Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy: a sub-analysis of the AMPLIFY trial. Thrombosis and Haemostasis2016;115(4):809-16. ">AMPLIFY 2013</a> study. Similarly, <a href="./references#CD010956-bbs2-0033" title="LiemTK , DeLougheryTG . Randomised controlled trial: extended-duration dabigatran is non-inferior to warfarin and more effective than placebo for symptomatic VTE. Evidence Based Medicine2014;19(1):29. SchulmanS , KearonC , KakkarAK , SchellongS , ErikssonH , BaanstraA , et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. New England Journal of Medicine2013;368:709-18. ">REMEDY 2013</a> and <a href="./references#CD010956-bbs2-0034" title="SchulmanS , BaanstraD , ErikssonH , GoldhaberS , KakkarA , KearonC , et al. Dabigatran vs. placebo for extended maintenance therapy of venous thromboembolism. Journal of Thrombosis and Haemostasis2011;9(Suppl 2):22. SchulmanS , BaanstraD , ErikssonH , GoldhaberSZ , KakkarA , KearonC , et al. Benefit of extended maintenance therapy for venous thromboembolism with dabigatran etexilate is maintained over 1 year of post-treatment follow-up. Blood2012;120(21):Abstract 332. SchulmanS , KearonC , KakkarAK , SchellongS , ErikssonH , BaanstraD , et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. New England Journal of Medicine2013;368(8):709-18. ">RE‐SONATE 2013</a> were extended treatment studies and participants had already taken part in the <a href="./references#CD010956-bbs2-0018" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00291330. Efficacy and safety of dabigatran compared to warfarin for 6 month treatment of acute symptomatic venous thromboembolism (RE-COVER I). clinicaltrials.gov/ct/show/NCT00291330 (first received 14 February 2006). SchulmanS , ErikssonH , GoldhaberS , KakkarAK , KearonC , KvammeAM , et al. Dabigatran or warfarin for extended maintenance therapy of venous thromboembolism. Journal of Thrombosis and Haemostasis2011;9(Suppl 2):731-2. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-COVER and RE-COVER II. Blood2013;122:2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RECOVER II. Blood2013;122(21):212. SchulmanS , ErikssonH , GoldhaverSZ , KakkarA , KearonC , MismettiP , et al. Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130:A18594. SchulmanS , KearonC , KakkarAK , MismettiP , SchellongS , ErikssonH , et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. New England Journal of Medicine2009;361(24):2342-52. ">RE‐COVER 2009</a> and <a href="./references#CD010956-bbs2-0019" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00680186. Phase III study testing efficacy &amp; safety of oral dabigatran etexilate vs warfarin for 6 m treatment for acute symp venous thromboembolism (VTE) (RE-COVER II). clinicaltrials.gov/ct2/show/NCT00680186 (first received 20 May 2008). SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-COVER and RE-COVER II. Blood2013;122:2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RECOVER II. Blood2013;122(21):212. SchulmanS , ErikssonH , GoldhaverSZ , KakkarA , KearonC , MismettiP , et al. Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130:A18594. SchulmanS , KakkarAK , GoldhaberSZ , SchellongS , ErikssonH , MismettiP , et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation2014;129:764-72. SchulmanS . A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II). Blood2011;118(21):95-6. ">RE‐COVER II 2014</a> studies. We excluded the <a href="./references#CD010956-bbs2-0036" title="ErikssonH , WåhlanderK , GustafssonD , WelinLT , FrisonL , SchulmanS , et al. A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I. Journal of Thrombosis and Haemostasis2003;1:41-7. ">THRIVE I 2003</a> study as treatment was only for four weeks. We excluded <a href="./references#CD010956-bbs2-0037" title="ErikssonH , LundstromT , WahlanderK , ClasonSB , SchulmanS . Prognostic factors for recurrence of venous thromboembolism (VTE) or bleeding during long-term secondary prevention of VTE with ximelagatran. Thrombosis and Haemostasis2005;94(3):522-7. ErikssonH , WahlanderK , LundstromT , BillingCS , SchulmanS . Extended secondary prevention with the oral direct thrombin inhibitor ximelagatran for 18 months after 6 months of anticoagulation in patients with venous thromboembolism: a randomized, placebo-controlled trial. Blood2002;100(Suppl):81a. SchulmanS , LundstromT , WalanderK , BillingCS , ErikssonH . Ximelagatran for the secondary prevention of venous thromboembolism: a complementary follow-up analysis of the THRIVE III study. Thrombosis and Haemostasis2005;94(4):820-4. SchulmanS , WahlanderK , LundstromT , ClasonSB , ErikssonH , THRIVE III Investigators. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. New England Journal of Medicine2003;349(18):1713-21. ">THRIVE III 2003</a> as the control group was administered a placebo, which did not fit as an intervention in this review. We excluded nine studies as, although all participants had venous thromboembolism, specific data on the subgroup with a DVT were not published (<a href="./references#CD010956-bbs2-0022" title="McBane RD 2nd, LoprinziCL , AshraniA , Perez-BoteroJ , FerreRA , HenkinS , et al. Apixaban and dalteparin in active malignancy associated venous thromboembolism. The ADAM VTE trial. Thrombosis and Haemostasis2017;117(10):1952-61. McBane RD 2nd, WysokinskiWE , Le-RademacherJG , ZemlaT , AshraniA , TafurA , et al. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial. Thrombosis and Haemostasis2020;18(2):411-21. NCT02585713. Apixaban or dalteparin in reducing blood clots in patients with cancer related venous thromboembolism. clinicaltrials.gov/ct2/show/NCT02585713 (first received 23 October 2015). ">ADAM VTE trial 2020</a>; <a href="./references#CD010956-bbs2-0024" title="BorsiSH , RajiH , DargahiMM , NokhostinF , KargaranA . Rivaroxaban versus enoxaparin for treatment of patients with nonhematologic cancer with venous thromboembolism: a randomized clinical trial. Tehran University Medical Journal2021;79(4):281-9. ">Borsi 2021</a>; <a href="./references#CD010956-bbs2-0025" title="NCT02746185. Cancer associated thrombosis, a pilot treatment study using rivaroxaban (CASTA-DIVA). clinicaltrials.gov/ct2/show/NCT02746185 (first received 21 April 2016). PlanquetteB , BertolettiL , Charles-NelsonA , LaporteS , GrangeC , MahéI , et al. Rivaroxaban vs dalteparin in cancer-associated thromboembolism: a randomized trial. Chest2022;161(3):781-90. ">CASTA DIVA Trial 2022</a>; <a href="./references#CD010956-bbs2-0026" title="CastellucciLA , HoggK , ChiangP , WuCM , TemplierGL , GalGL , et al. Comparison of bleeding risk between rivaroxaban and apixaban: a pilot feasibility study. Blood2017;130:1108. ">COBRRA 2017</a>; <a href="./references#CD010956-bbs2-0027" title="EUCTR2015-001478-16-DE. The role of rivaroxaban in the treatment of tumor patients with thrombosis. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2015-001478-16-DE (first received 9 September 2015). NCT02583191. Rivaroxaban in the treatment of venous thromboembolism (VTE) in cancer patients. clinicaltrials.gov/ct2/show/NCT02583191 (first received 22 October 2015). RiessH , SinnM , KreherS . CONKO-011: evaluation of patient satisfaction with the treatment of acute venous thromboembolism with rivaroxaban or low molecular weight heparin in cancer patients. A randomized phase III study. Deutsche Medizinische Wochenschrift2015;140(Suppl 1):S22. RiessH , SinnM , LohneisA , HellmannM , StrieflerJ , SüdhoffT , et al. Improved patient-reported treatment satisfaction with rivaroxaban as compared to low molecular weight heparins for cancer patients with acute venous thromboembolism – results from the CONKO-011 trial. Research and Practice in Thrombosis and Haemostasis2021;5(Suppl 2):LPB0041. SinnM , JuhlingA , HellmannM , OmarM , SudhoffT , StahlM , et al. Patient-reported treatment satisfaction with Rivaroxaban in cancer patients with acute venous thromboembolism - results from the CONKO-011 trial. Oncology Research and Treatment2021;44(Suppl 2):276-7. ">CONKO‐011 study 2015</a>; <a href="./references#CD010956-bbs2-0028" title="AlbisettiM , BissB , BomgaarsL , BrandãoLR , BrueckmannM , ChalmersE , et al. Design and rationale for the DIVERSITY study: an open-label, randomized study of dabigatran etexilate for pediatric venous thromboembolism. Research and Practice in Thrombosis and Haemostasis2018;2(2):347-56. AlbisettiM , BrandãoL , BomgaarsL , ChalmersE , LucianiM , MitchellL , et al. Efficacy and safety of dabigatran etexilate for treatment of venous thromboembolism in paediatric patients - results of the DIVERSITY trial. ISTH Academy2019:OC 57.3. AlbisettiM , TartakovskyI , HaltonJ , BomgaarsL , ChalmersE , MitchellL , et al. Efficacy and safety of dabigatran in the treatment and secondary prevention of venous thromboembolism in children with central line or implantable device–related thrombosis. Research and Practice in Thrombosis and Haemostasis2021;5(Suppl 2):OC 69.2. BrandãoL , TartakovskyI , HaltonJ , BomgaarsL , ChalmersE , MitchellL , et al. Efficacy and safety of dabigatran in the treatment and secondary prevention of venous thromboembolism in children with cerebral venous and sinus thrombosis. Research and Practice in Thrombosis and Haemostasis2021;5(Suppl 2):PB0787. EUCTR2013-002114-12. Open label study comparing efficacy and safety of dabigatran etexilate to standard of care in paediatric patients with VTE. trialsearch.who.int/?TrialID=EUCTR2013%E2%80%90002114%E2%80%9012%E2%80%90Outside%E2%80%90EU/EEA (first received 18 Feburary 2014). HaltonJ , BrandãoL , LucianiM , BomgaarsL , ChalmersE , MitchellL , et al. Efficacy and safety of dabigatran etexilate for treatment of venous thromboembolism in paediatric patients aged from birth to &lt; 2 years - results of the DIVERSITY trial. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):OC 12.1. HaltonJ , BrandãoLR , LucianiM , BomgaarsL , ChalmersE , MitchellLG , et al. Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial. Lancet Haematology2021;8(1):e22-e33. NCT01895777. Open label study comparing efficacy and safety of dabigatran etexilate to standard of care in paediatric patients with venous thromboembolism (VTE). clinicaltrials.gov/ct2/show/NCT01895777 (first received 11 July  2013). NCT01895777. Open label study comparing efficacy and safety of dabigatran etexilate to standard of care in paediatric patients with venous thromboembolism (VTE). clinicaltrials.gov/show/NCT01895777 (first received 25 September 2013). ">DIVERSITY 2021</a>; <a href="./references#CD010956-bbs2-0030" title="LensingAW , MaleC , YoungG , KubitzaD , KenetG , MassicotteMP , et al. Rivaroxaban versus standard anticoagulation for acute venous thromboembolism in childhood. Design of the EINSTEIN-Jr phase III study. Thrombosis Journal2018;16:34. MaleC , LensingAW , PalumboJS , KumarR , NurmeevI , HegeK , et al. Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial. Lancet Haematology2020;7(1):e18-e27. NCT01684423. Oral rivaroxaban in children with venous thrombosis (EINSTEIN Junior). clinicaltrials.gov/show/NCT01684423 (first received 13 September 2012). NCT02234843. EINSTEIN Junior: oral rivaroxaban in children with venous thrombosis. clinicaltrials.gov/ct2/show/NCT02234843 (first received 9 September 2014). NCT02309411. EINSTEIN Junior phase II: oral rivaroxaban in young children with venous thrombosis (EINSTEIN Jr). hclinicaltrials.gov/ct2/show/NCT02309411 (first received 5 December 2014). ThomK , LensingAW , NurmeevI , BajolleF , BonnetD , KenetG , et al. Safety and efficacy of anticoagulant therapy in pediatric catheter-related venous thrombosis (EINSTEIN-Jr CVC-VTE). Blood Advances2020;4(19):4632-9. ">EINSTEIN‐Jr 2020</a>; <a href="./references#CD010956-bbs2-0032" title="KimJH , YooC , SeoS , JeongJH , RyooBY , KimKP , et al. A phase II study to compare the safety and efficacy of direct oral anticoagulants versus subcutaneous dalteparin for cancer-associated venous thromboembolism in patients with advanced upper gastrointestinal, hepatobiliary and pancreatic cancer: PRIORITY. Cancers2022;14(3):559. NCT03139487. A randomized phase II open label study to compare the safety and efficacy of subcutaneous dalteparin versus direct oral anticoagulants for cancer-associated venous thromboembolism. clinicaltrials.gov/ct2/show/NCT03139487 (first received 4 May 2017). ">PRIORITY 2022</a>; <a href="./references#CD010956-bbs2-0035" title="EUCTR2012-005589-37-GB. Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2012-005589-37-GB (first received 18 February 2013). YoungA , DunnJ , ChapmanO , GrumettJ , MarshallA , PhillipsJ , et al. SELECT-D: anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. Journal of Clinical Oncology2014;32(Suppl 15):TPS9661-TPS9661. YoungA , MarshallA , ThirlwallJ , HillC , HaleD , DunnJ , et al. Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism: results of the select-D™ pilot trial. Blood2017;130:625. YoungA , PhillipsJ , HancocksH , HillC , JoshiN , MarshallA , et al. Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism (OC-11). Thrombosis Research2016;140(Suppl 1):S172-3. YoungAM , MarshallA , ThirlwallJ , ChapmanO , LokareA , HillC , et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). Journal of Clinical Oncology2018;36(20):2017-23. ">SELECT‐D 2018</a>). We made attempts to contact the authors for these data but were unsuccessful. We excluded <a href="./references#CD010956-bbs2-0029" title="PrandoniP , LensingAW , PrinsMH , GebelM , PapAF , HomeringM , et al. Benefits and risks of extended treatment of venous thromboembolism with rivaroxaban or with aspirin. Thrombosis Research2018;168:121-9. WeitzJI , LensingAW , PrinsMH , BauersachsR , Beyer-WestendorfJ , BounameauxH , et al. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. New England Journal of Medicine2017;376(13):1211-22. ">EINSTEIN‐CHOICE 2017</a> as the comparator was aspirin. We excluded <a href="./references#CD010956-bbs2-0031" title="NCT02584660. A study of rivaroxaban for early discharge of low risk pulmonary embolism from the emergency department. clinicaltrials.gov/ct2/show/NCT02584660 (first received 22 October 2015). PeacockFW , ColemanCI , DiercksDB , FrancisS , KabrhelC , KeayC , et al. Emergency department discharge of pulmonary embolus patients. Academic Emergency Medicine2018;25(9):995-1003. PeacockW , DiercksD , FrancisS , KabrhelC , KeayC , KlineJ , et al. Multicenter trial of rivaroxaban for early discharge of pulmonary embolism from the emergency department. Annals of Emergency Medicine2017;70(4):S29-S30. ">Peacock 2018</a> as participants had PE only. </p> </section> <section id="CD010956-sec-0052"> <h4 class="title">Studies awaiting classification</h4> <p>We assessed one trial as 'awaiting classification'; there are currently insufficient details to assess its eligibility for inclusion (<a href="./references#CD010956-bbs2-0038" title="NCT01780987. A study to evaluate safety and efficacy of apixaban in Japanese acute deep vein thrombosis (DVT) and pulmonary embolism (PE) patients. clinicaltrials.gov/show/NCT01780987 (first received 31 January 2013). ">NCT01780987</a>). </p> </section> <section id="CD010956-sec-0053"> <h4 class="title">Ongoing studies</h4> <p>Eleven trials are ongoing and there are currently no suitable data available for review (<a href="./references#CD010956-bbs2-0039" title="2014-002606-20. A randomized, open-label, active controlled, safety and descriptive efficacy study in pediatric subjects requiring anticoagulation for the treatment of a venous thromboembolic event. clinicaltrialsregister.eu/ctr-search/trial/2014-002606-20/3rd (first received 8 June 2015). ">EudraCT 2014‐002606‐20</a>; <a href="./references#CD010956-bbs2-0040" title="NCT01516840. Venous thromboembolism (VTE) treatment study in Japanese deep vein thrombosis (DVT) patients. clinicaltrials.gov/show/NCT01516840 (first received 25 January 2012). ">NCT01516840</a>; <a href="./references#CD010956-bbs2-0041" title="NCT02464969. Apixaban for the acute treatment of venous thromboembolism in children. clinicaltrials.gov/ct2/show/NCT02464969 (first received 8 June 2015). ">NCT02464969</a>; <a href="./references#CD010956-bbs2-0042" title="NCT02664155. Venous thromboembolism in renally impaired patients and direct oral anticoagulants. clinicaltrials.gov/ct2/show/NCT02664155 (first received 26 January 2016). ">NCT02664155</a>; <a href="./references#CD010956-bbs2-0043" title="NCT02744092. Direct oral anticoagulants (DOACs) versus LMWH +/- warfarin for VTE in cancer. clinicaltrials.gov/ct2/show/NCT02744092 (first received 20 April 2016). ">NCT02744092</a>; <a href="./references#CD010956-bbs2-0044" title="NCT02798471. Hokusai Study in pediatric patients with confirmed venous thromboembolism (VTE). clinicaltrials.gov/ct2/show/NCT02798471 (first received 14 June 2016). ">NCT02798471</a>; <a href="./references#CD010956-bbs2-0045" title="NCT02829957. Rivaroxaban vs. apixaban for heavy menstrual bleeding (RAMBLE). clinicaltrials.gov/ct2/show/study/NCT02829957 (first received 12 July 2016). ">NCT02829957</a>; <a href="./references#CD010956-bbs2-0046" title="NCT03129555. The Danish non-vitamin K antagonist oral anticoagulation study in patients with venous thromboembolism (DANNOAC-VTE). clinicaltrials.gov/ct2/show/NCT03129555 (first received 26 April 2017). ">NCT03129555</a>; <a href="./references#CD010956-bbs2-0047" title="NCT03266783. Comparison of bleeding risk between rivaroxaban and apixaban for the treatment of acute venous thromboembolism (COBRRA). clinicaltrials.gov/ct2/show/NCT03266783 (first received 30 August 2017). ">NCT03266783</a>; <a href="./references#CD010956-bbs2-0048" title="NCT04066764. Rivaroxaban and vitamin K antagonists for the anticoagulation for the implantation of vena cava filters (EPICT). clinicaltrials.gov/ct2/show/NCT04066764 (first received 26 August 2019). ">NCT04066764</a>; <a href="./references#CD010956-bbs2-0049" title="NCT05171049. A study comparing abelacimab to apixaban in the treatment of cancer-associated VTE (ASTER). clinicaltrials.gov/ct2/show/NCT05171049 (first received 28 December 2021). ">NCT05171049</a>). See <a href="./references#CD010956-sec-0120" title="">Characteristics of ongoing studies</a>. </p> </section> </section> <section id="CD010956-sec-0054"> <h3 class="title">Risk of bias in included studies</h3> <p>See <a href="#CD010956-fig-0002">Figure 2</a> and <a href="#CD010956-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD010956-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD010956-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_n/nCD010956-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> </div> <div class="figure" id="CD010956-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD010956-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_n/nCD010956-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> </div> <section id="CD010956-sec-0055"> <h4 class="title">Allocation</h4> <p>Nineteen studies were at low risk of bias for sequence generation as they used a computerised system to generate the randomisation sequence (<a href="./references#CD010956-bbs2-0001" title="AgnelliG , BullerH , MasiukiewiczUP . Apixaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism: a randomized, double-blind trial (AMPLIFY). Journal of Thrombosis and Haemostasis2013;11:18. AgnelliG , BullerHR , CohenA , CurtoD , GallusAS , JohnsonM , et al. Oral apixaban for the treatment of acute venous thromboembolism. New England Journal of Medicine2013;369:799-808. AgnelliG , BullerHR , CohenA , CurtoM , GallusAS , PakR , et al. Apixaban for the treatment of venous thromboembolism in cancer patients: data from the AMPLIFY trial. Canadian Journal of Cardiology2014;30(10 Suppl 1):S278. AgnelliG , BullerHR , CohenA , GallusAS , LeeTC , PakR , et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. Journal of Thrombosis and Haemostasis2015;13(12):2187-91. AgnelliG . Apixaban was non-inferior to enoxaparin plus warfarin in patients with acute venous thromboembolism. Annals of Internal Medicine2013;159(8):JC2. BlekerSM , CohenAT , BüllerHR , AgnelliG , GallusAS , RaskobGE , et al. Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Thrombosis and Haemostasis2016;116(6):159-64. BrekelmansM , ScheresL , BlekerS , HuttenB , TimmermansA , BüllerH , et al. Abnormal vaginal bleeding in women with venous thromboembolism treated with apixaban or warfarin. Thrombosis and Haemostasis2017;117(04):809-15. CohenA , AgnelliG , BullerH , GallusA , RaskobG , SandersP , et al. Characteristics and outcomes in patients with venous thromboembolism taking concomitant anti-platelet agents and anticoagulants in the AMPLIFY Trial. Thrombosis and Haemostasis2019;119(3):461-6. CohenA , AgnelliG , BullerHR , ChaudhuriS , GallusAS , RaskobGE , et al. Analysis of the bleeding and thromboembolic risk with concomitant use of antiplatelet treatment in the AMPLIFY trial. Canadian Journal of Cardiology2014;30(10):S272. CohenA , GallusAS , AgnelliG , BullerHR , PakR , PorcariAR , et al. Time in Therapeutic Range (TTR) and relative efficacy and safety of treatment with apixaban or enoxaparin/warfarin for acute symptomatic venous thromboembolism: an analysis of the Amplify trial data. Blood2014;124(21):1543. CohenAT , PanS , ByonW , IlyasBS , LeeTC . Efficacy, safety, and exposure of apixaban in patients with high body weight or obesity and venous thromboembolism: insights from AMPLIFY. Advances in Therapy2021;38(6):3003-18. EUCTR2007-007867-25-PT. A safety and efficacy trial evaluating the use of apixaban in the treatment of symptomatic deep vein thrombosis and pulmonary embolism revised protocol number: 01, incorporates amendment(s) 02 + protocol amendment 01 (version 1.0 dated 21-Apr-08) site-specific - molecular profiling supplement samples for Pfizer’s exploratory research biobank. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2007%E2%80%90007867%E2%80%9025%E2%80%90PT (first received 14 July 2008). GallusAS , AgnelliG , BullerHR , CohenA , LeeTC , PakR , et al. Apixaban for treatment of venous thromboembolism in patients from study centres in Asia: a subgroup analysis of the Amplify trial. Journal of Thrombosis and Haemostasis2015;13:727. LeeT , PanS , ByonW , IlyasBS . Safety and efficacy of apixaban versus enoxaparin/warfarin in patients with extremes of body weight: post-hoc analysis of the AMPLIFY trial. Blood2019;134(Suppl 1):1152. LiuX , JohnsonM , MardekianJ , PhatakH , ThompsonJ , CohenAT . Apixaban reduces hospitalizations in patients with venous thromboembolism: an analysis of the apixaban for the Initial management of pulmonary embolism and deep‐vein thrombosis as first‐line therapy (AMPLIFY) trial. Journal of the American Heart Association2015;4(12):e002340. NCT00633893. Efficacy and safety study of apixaban for extended treatment of deep vein thrombosis or pulmonary embolism. clinicaltrials.gov/ct2/show/NCT00633893?term=ajax&amp;rank=5 (first received 12 March 2008). NCT00643201. Efficacy and safety study of apixaban for the treatment of deep vein thrombosis or pulmonary embolism. clinicaltrials.gov/ct2/show/NCT00643201 (first received 26 March 2008). RaskobGE , GallusAS , SandersP , ThompsonJR , AgnelliG , BullerHR , et al. Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy: a sub-analysis of the AMPLIFY trial. Thrombosis and Haemostasis2016;115(4):809-16. ">AMPLIFY 2013</a>; <a href="./references#CD010956-bbs2-0002" title="NakamuraM , NishikawaM , KomuroI , KitajimaI , UetsukaY , YamagamiT , et al. Apixaban for the treatment of Japanese subjects with acute venous thromboembolism (AMPLIFY-J Study). Circulation2015;79(6):1230–36. ">AMPLIFY‐J 2015</a>; <a href="./references#CD010956-bbs2-0003" title="BarrettYC , WangJ , KnabbR , MohanP . Apixaban decreases coagulation activity in patients with acute deep-vein thrombosis. Thrombosis and Haemostasis2011;105:181-9. Botticelli Investigators Writing Committee, BullerH , DeitchmanD , PrinsM , SegersA . Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. Journal of Thrombosis and Haemostasis2008;6:1313-8. BullerHR . A dose finding study of the oral direct factor Xa inhibitor apixaban in the treatment of patients with acute symptomatic deep vein thrombosis - the Botticelli Investigators. Journal of Thrombosis and Haemostasis2007;5 (Suppl 2):O-S-003. NCT00252005. Oral direct factor Xa-inhibitor apixaban in patients with acute symptomatic deep-vein thrombosis - the Botticelli DVT study. clinicaltrials.gov/ct/show/NCT00252005?order=1 (first received 11 November 2005). ">Botticelli DVT 2008</a>; <a href="./references#CD010956-bbs2-0004" title="AgenoW , VedovatiMC , CohenA , HuismanM , BauersachsR , GussoniG , et al. Bleeding with apixaban and dalteparin in patients with cancer-associated venous thromboembolism: results from the Caravaggio study. Thrombosis and Haemostasis2021;121(5):616-24. AgnelliG , BecattiniC , BauersachsR , BrennerB , CampaniniM , CohenA , et al. Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the Caravaggio study. Thrombosis and Haemostasis2018;118(9):1668-78. AgnelliG , BecattiniC , MeyerG , MuozA , VersoM . Apixaban for the treatment of venous thromboembolism associated with cancer. New England Journal of Medicine2020;382(17):1599-607. AgnelliG , MuozA , FrancoL , MahéI , BrennerB , ConnorsJM , et al. Apixaban and dalteparin for the treatment of venous thromboembolism in patients with different sites of cancer. Thrombosis and Haemostasis2022;122(5):796-807. BecattiniC , BauersachsR , MarazitiG , BertolettiL , CohenA , ConnorsJM , et al. Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial. Haematologica2021;107(7):1567-76. GiustozziM , ConnorsJM , Ruperez BlancoAB , SzmitS , FalvoN , CohenAT , et al. Clinical characteristics and outcomes of incidental venous thromboembolism in cancer patients: insights from the Caravaggio study. Journal of Thrombosis and Haemostasis2021;19(11):2751-9. NCT03045406. Apixaban for the treatment of venous thromboembolism in patients with cancer (CARAVAGGIO). clinicaltrials.gov/ct2/show/NCT03045406 (first received 7 February 2017). VersoM , MunozA , BauersachsR , HuismanMV , AgnelliG . Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism. European Journal of Cancer2021;148(Suppl C):371-81. ">Caravaggio 2020</a>; <a href="./references#CD010956-bbs2-0005" title="NCT02704598. Comparison between xarelto versus warfarin in the recanalization rate of deep venous thrombosis in patients legs. (DVT). clinicaltrials.gov/ct2/show/NCT02704598 (first received 10 March 2016). deAthayde SoaresR , MatieloMF , Brochado NetoFC , AlmeidaRD , SacilottoR . LEV 2. Comparison of the recanalization rate and post-thrombotic syndrome in patients with deep venous thrombosis treated with rivaroxaban or warfarin. Journal of Vascular Surgery2019;70(5):e169-e170. deAthayde SoaresR , MatieloMF , Brochado NetoFC , NogueiraMP , AlmeidaRD , SacilottoR . Comparison of the recanalization rate and postthrombotic syndrome in patients with deep venous thrombosis treated with rivaroxaban or warfarin. Surgery2019;166(6):1076-83. ">de Athayde 2019</a>; <a href="./references#CD010956-bbs2-0007" title="BullerH , DariusH . EINSTEIN DVT: oral rivaroxaban versus standard therapy in the initial treatment of symptomatic deep vein thrombosis and long-term prevention of recurrent venous thromboembolism. escardio.org/The-ESC/Press-Office/Press-releases/EINSTEIN-DVT-Oral-rivaroxaban-versus-standard-therapy-in-the-initial-treatment (accessed 19 October 2022). BullerHR , AgnelliG . Once- or twice-daily rivaroxaban for the treatment of proximal deep vein thrombosis: similar efficacy and safety to standard therapy in dose-ranging studies. Blood2006;108(11 Part 1):172-3. BullerHR , LensingAW , PrinsMH , AgnelliG , CohenA , GallusAS , et al. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT dose-ranging study. Blood2008;112(6):2242-7. NCT00395772. Once-daily oral direct factor Xa inhibitor BAY59-7939 in patients with acute symptomatic deep-vein thrombosis. clinicaltrials.gov/ct2/show/NCT00395772?term=einstein-dvt&amp;rank=2 (first received 3 November 2006). ">EINSTEIN‐DVT dose 2008</a>; <a href="./references#CD010956-bbs2-0006" title="BamberL , WangMY , PrinsMH , CiniglioC , BauersachsR , LensingAW , et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis. Thrombosis and Haemostasis2013;110(4):732-41. BauersachsR , LensingAW , PapA , DecoususH . No need for a rivaroxaban dose reduction in renally impaired patients with symptomatic venous thromboembolism. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):30-1. BistervelsI , GebelM , LensingA , MiddeldorpS , CoppensM . Effect of polypharmacy on bleeding of rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolism. Research and Practice in Thrombosis and Haemostasis2019;3:798‐9. BookhartBK , HaskellL , BamberL , WangM , ScheinJ , ModySH . Length of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial program. Journal of Medical Economics2014;17(10):691-5. BullerHR . Oral rivaroxaban for the acute and continued treatment of symptomatic venous thromboembolism. The Einstein-DVT and Einstein-Extension study. Blood2010;116(21):187. CheungW , MiddeldorpS , PrinsMP , PapAF , LensingAW , Hoek-tenCA , et al. Post thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep vein thrombosis. Journal of Thrombosis and Haemostasis2015;13(S2):219-20. CheungYW , MiddeldorpS , PrinsMH , PapAF , PrandoniP . Post-thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep-vein thrombosis. A post-hoc analysis. Thrombosis and Haemostasis2016;116(4):733-8. EUCTR2004-002171-16-IT. Once-daily oral direct factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis. The EINSTEIN-DVT dose-finding study. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2004%E2%80%90002171%E2%80%9016%E2%80%90IT (first received 15 October 2008). EUCTR2006-004495-13-DK. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep-vein thrombosis or pulmonary embolism. trialsearch.who.int/?TrialID=EUCTR2006-004495-13-DK (first received 29 March 2007). EerenbergES , MiddeldorpS , LeviM , LensingAW , BüllerHR . Clinical impact and course of major bleeding with rivaroxaban and vitamin K antagonists. Journal of Thrombosis and Haemostasis2015;13(9):1590-6. KlineJA , JimenezD , CourtneyDM , IanusJ , CaoL , WellsPS . Use of the Riete 2008 bleeding score to identify patients at low risk for major bleeding in patients treated with rivaroxaban. Academic Emergency Medicine2015;22:S162. NCT00440193. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep vein thrombosis - The EINSTEIN DVT Study. clinicaltrials.gov/ct2/show/NCT00440193 (first received 26 February 2007). PrinsMH , ErkensPG , LensingAW . Incidence of recurrent venous thromboembolism in patients following completion of the EINSTEIN DVT and EINSTEIN PE studies. Journal of Thrombosis and Haemostasis2013;11(Suppl):257. PrinsMH , LensingAW , BauersachsR , Van BellenB , BounameauxH , BrightonTA , et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thrombosis Journal2013;11(1):21. The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. New England Journal of Medicine2010;363(26):2499-510. Van BellenB , PrinsM , BamberL , WangM , LensingAW . Reduction in initial length of stay with rivaroxaban single-drug regimen versus LMWH-VKA standard of care: findings from the EINSTEIN trial program. Blood2012;120(21):3419. Van BellenB , PrinsM , BamberL , WangM , LensingAW . Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism. Current Medical Research and Opinion2014;30(5):829-37. WangY , WangC , ChenZ , ZhangJ , LiuZ , JinB , et al. Rivaroxaban for the treatment of symptomatic deep vein thrombosis and/or pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):694. WangY , WangC , ChenZ , ZhangJ , LiuZ , JinB , et al. Rivaroxaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Thrombosis Journal2013;11(1):25. ">EINSTEIN‐DVT 2010</a>; <a href="./references#CD010956-bbs2-0008" title="BullerHR , PrinsMH , LensinAW , DecoususH , JacobsonBF , MinarE , et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. New England Journal of Medicine2012;366:1287-97. FermannGJ , Erkens Pmg, PrinsMH , WellsPS , Pap ÁF, LensingAW , et al. Treatment of pulmonary embolism with rivaroxaban: outcomes by simplified pulmonary embolism severity index score from a post hoc analysis of the EINSTEIN PE study. Academic Emergency Medicine2015;22(3):299-307. NCT00439777. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic pulmonary embolism with or without symptomatic deep-vein thrombosis: Einstein-PE evaluation, 2008. clinicaltrials.gov/ct2/show/NCT00439777?term=NCT00439777&amp;rank=1 (first received 26 February 2007). PrinsM , BamberL , CanoS , WangM , LensingAW , BauersachsR . Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic pulmonary embolism. Blood2012;120(21):1163. PrinsMH , BamberL , CanoSJ , WangMY , ErkensP , BauersachsR , et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial. Thrombosis Research2015;135(2):281-8. ">EINSTEIN‐PE 2012</a>; <a href="./references#CD010956-bbs2-0009" title="PiazzaG , ManiV , GoldhaberSZ , GrossoMA , MercuriM , LanzHJ , et al. Magnetic resonance venography to assess thrombus resolution with edoxaban monotherapy versus parenteral anticoagulation/warfarin for symptomatic deep vein thrombosis: a multicenter feasibility study. Vascular Medicine2016;21(4):361-8. PiazzaG , ManiV , GrossoM , MercuriM , LanzH , SchusslerS , et al. A randomized, open-label, multicenter study of the efficacy and safety of edoxaban monotherapy versus low-molecular weight heparin/warfarin in patients with symptomatic deep vein thrombosis-edoxaban thrombus reduction imaging study (etris). Circulation2014;130:A12074. ">eTRIS 2016</a>; <a href="./references#CD010956-bbs2-0010" title="FarhanA , BukhariM , UmarJ , RazaMA . Oral rivaroxaban in symptomatic deep vein thrombosis. Journal of the College of Physicians and Surgeons Pakistan2019;29(9):814-8. ">Farhan 2019</a>; <a href="./references#CD010956-bbs2-0012" title="AmayaN , UzuiH , HisazakiK , HasegwaK , KasenoK , TadaH . Edoxaban normalizes the elevated D-dimer levels potently and promptly in patients with venous thromboembolisms: a comparison with traditional anticoagulant therapy. European Heart Journal2016;37:278. BoschFT , Van EsN , Di NisioM , CarrierM , SegersA , GrossoMA , et al. The Ottawa score does not predict recurrent venous thromboembolism in cancer patients: results from the Hokusai-VTE cancer study. Research and Practice in Thrombosis and Haemostasis2019;3(S1):717-8. KraaijpoelN , Di NisioM , MulderFI , Van EsN , RaskobGE . Clinical impact of bleeding in cancer-associated venous thromboembolism: results from the Hokusai VTE Cancer randomized trial. Thrombosis Research2018;164(Suppl 1):S223. [DOI: 10.1016/j.thromres.2018.02.094]MulderFI , Di NisioM , AyC , CarrierM , BoschFT , SegersA , et al. Clinical implications of incidental venous thromboembolism in cancer patients. European Respiratory Journal2020;55(2):1901697. [DOI: 10.1183/13993003.01697-2019]MulderFI , Van EsN , KraaijpoelN , Di NisioM , CarrierM , GarciaD , et al. Efficacy and safety of edoxaban in clinically relevant subgroups: results from the Hokusai VTE Cancer randomized trial. Thrombosis Research2018;164:S194. NCT02073682. Cancer venous thromboembolism (VTE). clinicaltrials.gov/ct2/show/NCT02073682 (first received 27 February 2014). RaskobG , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaD , et al. Edoxaban versus dalteparin for treatment of venous thromboembolism (VTE) associated with cancer: Hokusai VTE-cancer randomized trial. Supportive Care in Cancer2018;26(2):S316-S317. RaskobGE , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaD , et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. New England Journal of Medicine2018;378(7):615-24. RaskobGE , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaDA , et al. A randomized, open-label, blinded outcome assessment trial evaluating the efficacy and safety of LMWH/Edoxaban versus dalteparin for venous thromboembolism associated with cancer: Hokusai VTE-cancer study. Blood2017;130(Suppl 1):LBA-6. ">Hokusai VTE Cancer 2018</a>; <a href="./references#CD010956-bbs2-0011" title="BistervelsI , BavaliaR , BoersmaW , MeijerK , VerhammeP , Ten Cate-HoekAJ , et al. Hokusai Post-DVT Study: a follow-up study on long-term outcomes of deep vein thrombosis in patients treated with edoxaban vs warfarin. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):PB2207. BrekelmansMP , AgenoW , BeenenLF , BrennerB , BullerHR , ChenCZ , et al. Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology2016;3(9):e437-45. BrekelmansMP , BlekerSM , BauersachsR , BodaZ , BüllerHR , ChoiY , et al. Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists. Thrombosis and Haemostasis2016;116(1):155-61. Di NisioM , Van EsN , CarrierM , WangTF , GarciaD , SegersA , et al. Extended treatment with edoxaban in cancer patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE Cancer study. Journal of Thrombosis and Haemostasis2019;17:1866–74. EUCTR2009-014290-40-SE. A phase 3, randomized, double-blind, double-dummy, parallel group, multi-center, multi-national study for evaluation of efficacy and safety of DU-176b versus warfarin in subjects with atrial fibrillation - effective anticoagulation with factor Xa next generation in atrial fibrillation (ENGAGE-AF TIMI-48). trialsearch.who.int/?trialid=EUCTR2009-014290-40-SE (first received 30 November 2009). EichingerS , LinM , KyrlePA , GrossoMA . Recurrent venous thromboembolism during anticoagulation: an investigator-initiated post-hoc analysis of the hokusai-VTE trial. Blood2018;132:2539. KlokFA , BarcoS , KonstantinidesSV . External validation of the VTE-BLEED score for predicting major bleeding in stable anticoagulated patients with venous thromboembolism. Thrombosis and Haemostasis2017;117(6):1164-70. KraaijpoelN , Van EsN , RaskobGE , BüllerHR , CarrierM , ZhangG , et al. Risk scores for occult cancer in patients with venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2018;118(7):1270-8. MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMP , ChenCZ , et al. Outpatient management in patients with venous thromboembolism with edoxaban: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2017;117(12):2406-14. MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMP , ChenCZ , et al. Safety and efficacy of edoxaban compared with warfarin for the treatment of acute symptomatic deep-vein thrombosis in the outpatient setting. Research and Practice in Thrombosis and Haemostasis2017;1:913. MulderFI , Van EsN , KraaijpoelN , Di NisioM , CarrierM , DuggalA , et al. Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: results from the Hokusai VTE Cancer study. Thrombosis Research2020;185:13-9. NCT00986154. Comparative investigation of Low Molecular Weight (LMW) heparin/edoxaban tosylate (DU176b) versus (LMW) heparin/warfarin in the treatment of symptomatic deep-vein blood clots and/or lung blood clots. (The Edoxaban Hokusai-VTE Study). clinicaltrials.gov/ct2/show/NCT00986154 (first received 29 September 2009). NakamuraM , WangYQ , WangC , OhD , YinWH , KimuraT , et al. Efficacy and safety of edoxaban for treatment of venous thromboembolism: a subanalysis of East Asian patients in the Hokusai-VTE trial. Journal of Thrombosis and Haemostasis2015;13(9):1606-14. NybergJ , KarlssonKE , JönssonS , YinO , MillerR , KarlssonMO , et al. Edoxaban exposure-response analysis and clinical utility index assessment in patients with symptomatic deep-vein thrombosis or pulmonary embolism. CPT Pharmacometrics and Systems Pharmacology2016;5(4):222-32. RaskobG , AgenoW , CohenAT , BrekelmansMP , GrossoMA , SegersA , et al. Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology2016;3(5):e228-e236. RaskobG , BullerH , PrinsM , SegersA , ShiM , SchwochoL , et al. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study - methodological implications for clinical trials. Journal of Thrombosis and Haemostasis2013;11(7):1287-94. RaskobGE , BullerH , AngchaisuksiriP , OhD , BodaZ , LyonsRM , et al. Edoxaban for long-term treatment of venous thromboembolism in cancer patients. Blood2013;122(21):211. RaskobGE , Van EsN , SegersA , AngchaisuksiriP , OhD , BodaZ , et al. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematology2016;3(8):e379-87. ScheresLJ , BrekelmansMA , WalterA , CihanA , BüllerHR , SabineE , et al. Abnormal vaginal bleeding in women of reproductive age treated with edoxaban or warfarin for venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. British Journal of Obstetrics and Gynaecology2018;125(12):1581-9. The Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. New England Journal of Medicine2013;369(15):1406-15. VanasscheT , VerhammeP , WellsPS , SegersA , AgenoW , BrekelmansMP , et al. Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: an analysis of the randomized, double-blind Hokusai-VTE trial. Thrombosis Research2018;162:7-14. VerhammeP , WellsPS , SegersA , AgenoW , BrekelmansMP , CohenAT , et al. Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial. Thrombosis and Haemostasis2016;116(4):747-53. ">Hokusai‐VTE 2013</a>; <a href="./references#CD010956-bbs2-0013" title="MatsuoH , PrinsM , LensingAW , FujinumaEW , MiyamotoY , KajikawaM . Shortened length of hospital stay with rivaroxaban in patients with symptomatic venous thromboembolism in Japan: the J-EINSTEIN pulmonary embolism and deep vein thrombosis program. Current Medical Research and Opinion2015;31(6):1057-61. NCT01516814. Venous thromboembolism (VTE) treatment study in Japanese pulmonary embolism (PE) patients. clinicaltrials.gov/ct2/show/NCT01516814 (first received 25 January 2012). YamadaN , HirayamaA , MaedaH , SakagamiS , ShikataH , PrinsMH , et al. Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism-the J-EINSTEIN DVT and PE program. Thrombosis Journal2015;13:2. ">J‐EINSTEIN DVT and PE 2015</a>; <a href="./references#CD010956-bbs2-0014" title="MokademME , HassanA , AlgabyAZ . Efficacy and safety of apixaban in patients with active malignancy and acute deep venous thrombosis. Vascular2021;29(5):745-50. NCT04462003. Efficacy of apixaban in malignancy with deep venous thrombosis (DVT). clinicaltrials.gov/ct2/show/NCT04462003 (first received 3 July 2019). ">Mokadem 2021</a>; <a href="./references#CD010956-bbs2-0015" title="AgnelliG , GallusA , GoldhaberSZ , HaasS , HuismanMV , HullRD , et al. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAT 59-7939 in patients with acute symptomatic deep-vein thrombosis) study. Circulation2007;116:180-7. ">ODIXa‐DVT 2007</a>; <a href="./references#CD010956-bbs2-0017" title="Kang JiM, ParkKH , AhnS , ChoS , MinSK . Rivaroxaban after thrombolysis in acute iliofemoral venous thrombosis: a randomized, open-labeled, multicenter trial. Scientific Reports2019;9(1):20356. MinSK , AhnS , ParkKH , KangJM , KimJY . Prevention of recurrence after thrombolysis in acute iliofemoral venous thrombosis with rivaroxaban (Prais Study): a prospective, randomized, open label, multicenter trial. European Journal of Vascular and Endovascular Surgery2019;58(6):e516. NCT01986192. Prevention of recurrence after thrombolysis in acute iliofemoral venous thrombosis (PRAIS) study. clinicaltrials.gov/show/NCT01986192 (first received 18 November 2013). ">PRAIS 2019</a>; <a href="./references#CD010956-bbs2-0018" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00291330. Efficacy and safety of dabigatran compared to warfarin for 6 month treatment of acute symptomatic venous thromboembolism (RE-COVER I). clinicaltrials.gov/ct/show/NCT00291330 (first received 14 February 2006). SchulmanS , ErikssonH , GoldhaberS , KakkarAK , KearonC , KvammeAM , et al. Dabigatran or warfarin for extended maintenance therapy of venous thromboembolism. Journal of Thrombosis and Haemostasis2011;9(Suppl 2):731-2. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-COVER and RE-COVER II. Blood2013;122:2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RECOVER II. Blood2013;122(21):212. SchulmanS , ErikssonH , GoldhaverSZ , KakkarA , KearonC , MismettiP , et al. Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130:A18594. SchulmanS , KearonC , KakkarAK , MismettiP , SchellongS , ErikssonH , et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. New England Journal of Medicine2009;361(24):2342-52. ">RE‐COVER 2009</a>; <a href="./references#CD010956-bbs2-0019" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00680186. Phase III study testing efficacy &amp; safety of oral dabigatran etexilate vs warfarin for 6 m treatment for acute symp venous thromboembolism (VTE) (RE-COVER II). clinicaltrials.gov/ct2/show/NCT00680186 (first received 20 May 2008). SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-COVER and RE-COVER II. Blood2013;122:2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RECOVER II. Blood2013;122(21):212. SchulmanS , ErikssonH , GoldhaverSZ , KakkarA , KearonC , MismettiP , et al. Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130:A18594. SchulmanS , KakkarAK , GoldhaberSZ , SchellongS , ErikssonH , MismettiP , et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation2014;129:764-72. SchulmanS . A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II). Blood2011;118(21):95-6. ">RE‐COVER II 2014</a>; <a href="./references#CD010956-bbs2-0021" title="FiessingerJN , HuismanMV , DavidsonBL , BounameauxH , FrancisCW , ErikssonH , et al. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomised trial. JAMA2005;293(6):681-9. FrancisCW , GinsbergJS , BerkowitzSD , BounameauxH , DavidsonBL , ErikssonH , et al. Efficacy and safety of the oral direct thrombin inhibitor ximelagatran compared with current therapy for acute, symptomatic deep vein thrombosis, with or without pulmonary embolus: the THRIVE treatment study. Blood2003;102(11):Abstract 7. HarenbergJ , IngridJ , TivadarF . Treatment of venous thromboembolism with the oral thrombin inhibitor, ximelagatran. Israel Medical Association Journal2002;4(11):1003-5. HarenbergJ , JoergI , WeissC . Incidence of recurrent venous thromboembolism of patients after termination of treatment with ximelagatran. European Journal of Clinical Pharmacology2006;62(3):173-7. HarenbergJ , JorgI , WeissC , HarenbergJ , JorgI , WeissC . Observations of alanine aminotransferase and aspartate aminotransferase in THRIVE studies treated orally with ximelagatran. International Journal of Toxicology2006;25(3):165-9. HuismanMV , The THRIVE Treatment Study Investigators. Efficacy and safety of the oral direct thrombin inhibitor ximelagatran compared with current standard therapy for acute symptomatic deep vein thrombosis, with or without pulmonary embolism: a randomized, double-blind, multinational study. Journal of Thrombosis and Haemostasis2003;1(Suppl 1):Abstract OC003. WimperisJ , FiessingerJN , HuismanMV , DavidsonBL , BounameauxH , FrancisCW , et al. Ximelagatran, an oral direct thrombin inhibitor, compared with current standard therapy for acute, symptomatic deep vein thrombosis, with or without pulmonary embolism: the THRIVE treatment study. British Journal of Haematology2004;125(Suppl 1):66. ">THRIVE 2005</a>). Two studies were at unclear risk of bias: <a href="./references#CD010956-bbs2-0016" title="OhmoriH , KadaA , NakamuraM , SaitoAM , SanayamaY , ShinagawaT , et al. Deep vein thrombosis in severe motor and intellectual disabilities patients and its treatment by anticoagulants of warfarin versus edoxaban. Annals of Vascular Diseases2019;12(3):372-8. OhmoriH , NakamuraM , KadaA , SaitoAM , SanayamaY , ShinagawaT , et al. Multicenter, open-label, randomized controlled trial of warfarin and edoxaban tosilate hydrate for the treatment of deep vein thrombosis in persons with severe motor intellectual disabilities. Kurume Medical Journal2018;65(1):11-6. ">Ohmori 2019</a> used block randomisation (1:1) but did not describe the process in detail, and <a href="./references#CD010956-bbs2-0020" title="SukovatykhBS , SereditskiĭAV , MuradianVF , BelikovLN , GerasimovaOF . Results of administering oral anticoagulants for treatment of patients with venous thromboembolic complications. Angiologiia i sosudistaia khirurgiia [Angiology and Vascular Surgery]2017;23(2):82. ">Sukovatykh 2017</a> did not report information about randomisation. </p> <p>Similarly, 19 studies adequately concealed the treatment allocation with the use of a computerised system and we judged them to be at low risk of selection bias for allocation concealment (<a href="./references#CD010956-bbs2-0001" title="AgnelliG , BullerH , MasiukiewiczUP . Apixaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism: a randomized, double-blind trial (AMPLIFY). Journal of Thrombosis and Haemostasis2013;11:18. AgnelliG , BullerHR , CohenA , CurtoD , GallusAS , JohnsonM , et al. Oral apixaban for the treatment of acute venous thromboembolism. New England Journal of Medicine2013;369:799-808. AgnelliG , BullerHR , CohenA , CurtoM , GallusAS , PakR , et al. Apixaban for the treatment of venous thromboembolism in cancer patients: data from the AMPLIFY trial. Canadian Journal of Cardiology2014;30(10 Suppl 1):S278. AgnelliG , BullerHR , CohenA , GallusAS , LeeTC , PakR , et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. Journal of Thrombosis and Haemostasis2015;13(12):2187-91. AgnelliG . Apixaban was non-inferior to enoxaparin plus warfarin in patients with acute venous thromboembolism. Annals of Internal Medicine2013;159(8):JC2. BlekerSM , CohenAT , BüllerHR , AgnelliG , GallusAS , RaskobGE , et al. Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Thrombosis and Haemostasis2016;116(6):159-64. BrekelmansM , ScheresL , BlekerS , HuttenB , TimmermansA , BüllerH , et al. Abnormal vaginal bleeding in women with venous thromboembolism treated with apixaban or warfarin. Thrombosis and Haemostasis2017;117(04):809-15. CohenA , AgnelliG , BullerH , GallusA , RaskobG , SandersP , et al. Characteristics and outcomes in patients with venous thromboembolism taking concomitant anti-platelet agents and anticoagulants in the AMPLIFY Trial. Thrombosis and Haemostasis2019;119(3):461-6. CohenA , AgnelliG , BullerHR , ChaudhuriS , GallusAS , RaskobGE , et al. Analysis of the bleeding and thromboembolic risk with concomitant use of antiplatelet treatment in the AMPLIFY trial. Canadian Journal of Cardiology2014;30(10):S272. CohenA , GallusAS , AgnelliG , BullerHR , PakR , PorcariAR , et al. Time in Therapeutic Range (TTR) and relative efficacy and safety of treatment with apixaban or enoxaparin/warfarin for acute symptomatic venous thromboembolism: an analysis of the Amplify trial data. Blood2014;124(21):1543. CohenAT , PanS , ByonW , IlyasBS , LeeTC . Efficacy, safety, and exposure of apixaban in patients with high body weight or obesity and venous thromboembolism: insights from AMPLIFY. Advances in Therapy2021;38(6):3003-18. EUCTR2007-007867-25-PT. A safety and efficacy trial evaluating the use of apixaban in the treatment of symptomatic deep vein thrombosis and pulmonary embolism revised protocol number: 01, incorporates amendment(s) 02 + protocol amendment 01 (version 1.0 dated 21-Apr-08) site-specific - molecular profiling supplement samples for Pfizer’s exploratory research biobank. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2007%E2%80%90007867%E2%80%9025%E2%80%90PT (first received 14 July 2008). GallusAS , AgnelliG , BullerHR , CohenA , LeeTC , PakR , et al. Apixaban for treatment of venous thromboembolism in patients from study centres in Asia: a subgroup analysis of the Amplify trial. Journal of Thrombosis and Haemostasis2015;13:727. LeeT , PanS , ByonW , IlyasBS . Safety and efficacy of apixaban versus enoxaparin/warfarin in patients with extremes of body weight: post-hoc analysis of the AMPLIFY trial. Blood2019;134(Suppl 1):1152. LiuX , JohnsonM , MardekianJ , PhatakH , ThompsonJ , CohenAT . Apixaban reduces hospitalizations in patients with venous thromboembolism: an analysis of the apixaban for the Initial management of pulmonary embolism and deep‐vein thrombosis as first‐line therapy (AMPLIFY) trial. Journal of the American Heart Association2015;4(12):e002340. NCT00633893. Efficacy and safety study of apixaban for extended treatment of deep vein thrombosis or pulmonary embolism. clinicaltrials.gov/ct2/show/NCT00633893?term=ajax&amp;rank=5 (first received 12 March 2008). NCT00643201. Efficacy and safety study of apixaban for the treatment of deep vein thrombosis or pulmonary embolism. clinicaltrials.gov/ct2/show/NCT00643201 (first received 26 March 2008). RaskobGE , GallusAS , SandersP , ThompsonJR , AgnelliG , BullerHR , et al. Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy: a sub-analysis of the AMPLIFY trial. Thrombosis and Haemostasis2016;115(4):809-16. ">AMPLIFY 2013</a>; <a href="./references#CD010956-bbs2-0002" title="NakamuraM , NishikawaM , KomuroI , KitajimaI , UetsukaY , YamagamiT , et al. Apixaban for the treatment of Japanese subjects with acute venous thromboembolism (AMPLIFY-J Study). Circulation2015;79(6):1230–36. ">AMPLIFY‐J 2015</a>; <a href="./references#CD010956-bbs2-0003" title="BarrettYC , WangJ , KnabbR , MohanP . Apixaban decreases coagulation activity in patients with acute deep-vein thrombosis. Thrombosis and Haemostasis2011;105:181-9. Botticelli Investigators Writing Committee, BullerH , DeitchmanD , PrinsM , SegersA . Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. Journal of Thrombosis and Haemostasis2008;6:1313-8. BullerHR . A dose finding study of the oral direct factor Xa inhibitor apixaban in the treatment of patients with acute symptomatic deep vein thrombosis - the Botticelli Investigators. Journal of Thrombosis and Haemostasis2007;5 (Suppl 2):O-S-003. NCT00252005. Oral direct factor Xa-inhibitor apixaban in patients with acute symptomatic deep-vein thrombosis - the Botticelli DVT study. clinicaltrials.gov/ct/show/NCT00252005?order=1 (first received 11 November 2005). ">Botticelli DVT 2008</a>; <a href="./references#CD010956-bbs2-0004" title="AgenoW , VedovatiMC , CohenA , HuismanM , BauersachsR , GussoniG , et al. Bleeding with apixaban and dalteparin in patients with cancer-associated venous thromboembolism: results from the Caravaggio study. Thrombosis and Haemostasis2021;121(5):616-24. AgnelliG , BecattiniC , BauersachsR , BrennerB , CampaniniM , CohenA , et al. Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the Caravaggio study. Thrombosis and Haemostasis2018;118(9):1668-78. AgnelliG , BecattiniC , MeyerG , MuozA , VersoM . Apixaban for the treatment of venous thromboembolism associated with cancer. New England Journal of Medicine2020;382(17):1599-607. AgnelliG , MuozA , FrancoL , MahéI , BrennerB , ConnorsJM , et al. Apixaban and dalteparin for the treatment of venous thromboembolism in patients with different sites of cancer. Thrombosis and Haemostasis2022;122(5):796-807. BecattiniC , BauersachsR , MarazitiG , BertolettiL , CohenA , ConnorsJM , et al. Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial. Haematologica2021;107(7):1567-76. GiustozziM , ConnorsJM , Ruperez BlancoAB , SzmitS , FalvoN , CohenAT , et al. Clinical characteristics and outcomes of incidental venous thromboembolism in cancer patients: insights from the Caravaggio study. Journal of Thrombosis and Haemostasis2021;19(11):2751-9. NCT03045406. Apixaban for the treatment of venous thromboembolism in patients with cancer (CARAVAGGIO). clinicaltrials.gov/ct2/show/NCT03045406 (first received 7 February 2017). VersoM , MunozA , BauersachsR , HuismanMV , AgnelliG . Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism. European Journal of Cancer2021;148(Suppl C):371-81. ">Caravaggio 2020</a>; <a href="./references#CD010956-bbs2-0005" title="NCT02704598. Comparison between xarelto versus warfarin in the recanalization rate of deep venous thrombosis in patients legs. (DVT). clinicaltrials.gov/ct2/show/NCT02704598 (first received 10 March 2016). deAthayde SoaresR , MatieloMF , Brochado NetoFC , AlmeidaRD , SacilottoR . LEV 2. Comparison of the recanalization rate and post-thrombotic syndrome in patients with deep venous thrombosis treated with rivaroxaban or warfarin. Journal of Vascular Surgery2019;70(5):e169-e170. deAthayde SoaresR , MatieloMF , Brochado NetoFC , NogueiraMP , AlmeidaRD , SacilottoR . Comparison of the recanalization rate and postthrombotic syndrome in patients with deep venous thrombosis treated with rivaroxaban or warfarin. Surgery2019;166(6):1076-83. ">de Athayde 2019</a>; <a href="./references#CD010956-bbs2-0007" title="BullerH , DariusH . EINSTEIN DVT: oral rivaroxaban versus standard therapy in the initial treatment of symptomatic deep vein thrombosis and long-term prevention of recurrent venous thromboembolism. escardio.org/The-ESC/Press-Office/Press-releases/EINSTEIN-DVT-Oral-rivaroxaban-versus-standard-therapy-in-the-initial-treatment (accessed 19 October 2022). BullerHR , AgnelliG . Once- or twice-daily rivaroxaban for the treatment of proximal deep vein thrombosis: similar efficacy and safety to standard therapy in dose-ranging studies. Blood2006;108(11 Part 1):172-3. BullerHR , LensingAW , PrinsMH , AgnelliG , CohenA , GallusAS , et al. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT dose-ranging study. Blood2008;112(6):2242-7. NCT00395772. Once-daily oral direct factor Xa inhibitor BAY59-7939 in patients with acute symptomatic deep-vein thrombosis. clinicaltrials.gov/ct2/show/NCT00395772?term=einstein-dvt&amp;rank=2 (first received 3 November 2006). ">EINSTEIN‐DVT dose 2008</a>; <a href="./references#CD010956-bbs2-0006" title="BamberL , WangMY , PrinsMH , CiniglioC , BauersachsR , LensingAW , et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis. Thrombosis and Haemostasis2013;110(4):732-41. BauersachsR , LensingAW , PapA , DecoususH . No need for a rivaroxaban dose reduction in renally impaired patients with symptomatic venous thromboembolism. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):30-1. BistervelsI , GebelM , LensingA , MiddeldorpS , CoppensM . Effect of polypharmacy on bleeding of rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolism. Research and Practice in Thrombosis and Haemostasis2019;3:798‐9. BookhartBK , HaskellL , BamberL , WangM , ScheinJ , ModySH . Length of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial program. Journal of Medical Economics2014;17(10):691-5. BullerHR . Oral rivaroxaban for the acute and continued treatment of symptomatic venous thromboembolism. The Einstein-DVT and Einstein-Extension study. Blood2010;116(21):187. CheungW , MiddeldorpS , PrinsMP , PapAF , LensingAW , Hoek-tenCA , et al. Post thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep vein thrombosis. Journal of Thrombosis and Haemostasis2015;13(S2):219-20. CheungYW , MiddeldorpS , PrinsMH , PapAF , PrandoniP . Post-thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep-vein thrombosis. A post-hoc analysis. Thrombosis and Haemostasis2016;116(4):733-8. EUCTR2004-002171-16-IT. Once-daily oral direct factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis. The EINSTEIN-DVT dose-finding study. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2004%E2%80%90002171%E2%80%9016%E2%80%90IT (first received 15 October 2008). EUCTR2006-004495-13-DK. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep-vein thrombosis or pulmonary embolism. trialsearch.who.int/?TrialID=EUCTR2006-004495-13-DK (first received 29 March 2007). EerenbergES , MiddeldorpS , LeviM , LensingAW , BüllerHR . Clinical impact and course of major bleeding with rivaroxaban and vitamin K antagonists. Journal of Thrombosis and Haemostasis2015;13(9):1590-6. KlineJA , JimenezD , CourtneyDM , IanusJ , CaoL , WellsPS . Use of the Riete 2008 bleeding score to identify patients at low risk for major bleeding in patients treated with rivaroxaban. Academic Emergency Medicine2015;22:S162. NCT00440193. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep vein thrombosis - The EINSTEIN DVT Study. clinicaltrials.gov/ct2/show/NCT00440193 (first received 26 February 2007). PrinsMH , ErkensPG , LensingAW . Incidence of recurrent venous thromboembolism in patients following completion of the EINSTEIN DVT and EINSTEIN PE studies. Journal of Thrombosis and Haemostasis2013;11(Suppl):257. PrinsMH , LensingAW , BauersachsR , Van BellenB , BounameauxH , BrightonTA , et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thrombosis Journal2013;11(1):21. The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. New England Journal of Medicine2010;363(26):2499-510. Van BellenB , PrinsM , BamberL , WangM , LensingAW . Reduction in initial length of stay with rivaroxaban single-drug regimen versus LMWH-VKA standard of care: findings from the EINSTEIN trial program. Blood2012;120(21):3419. Van BellenB , PrinsM , BamberL , WangM , LensingAW . Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism. Current Medical Research and Opinion2014;30(5):829-37. WangY , WangC , ChenZ , ZhangJ , LiuZ , JinB , et al. Rivaroxaban for the treatment of symptomatic deep vein thrombosis and/or pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):694. WangY , WangC , ChenZ , ZhangJ , LiuZ , JinB , et al. Rivaroxaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Thrombosis Journal2013;11(1):25. ">EINSTEIN‐DVT 2010</a>; <a href="./references#CD010956-bbs2-0008" title="BullerHR , PrinsMH , LensinAW , DecoususH , JacobsonBF , MinarE , et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. New England Journal of Medicine2012;366:1287-97. FermannGJ , Erkens Pmg, PrinsMH , WellsPS , Pap ÁF, LensingAW , et al. Treatment of pulmonary embolism with rivaroxaban: outcomes by simplified pulmonary embolism severity index score from a post hoc analysis of the EINSTEIN PE study. Academic Emergency Medicine2015;22(3):299-307. NCT00439777. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic pulmonary embolism with or without symptomatic deep-vein thrombosis: Einstein-PE evaluation, 2008. clinicaltrials.gov/ct2/show/NCT00439777?term=NCT00439777&amp;rank=1 (first received 26 February 2007). PrinsM , BamberL , CanoS , WangM , LensingAW , BauersachsR . Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic pulmonary embolism. Blood2012;120(21):1163. PrinsMH , BamberL , CanoSJ , WangMY , ErkensP , BauersachsR , et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial. Thrombosis Research2015;135(2):281-8. ">EINSTEIN‐PE 2012</a>; <a href="./references#CD010956-bbs2-0009" title="PiazzaG , ManiV , GoldhaberSZ , GrossoMA , MercuriM , LanzHJ , et al. Magnetic resonance venography to assess thrombus resolution with edoxaban monotherapy versus parenteral anticoagulation/warfarin for symptomatic deep vein thrombosis: a multicenter feasibility study. Vascular Medicine2016;21(4):361-8. PiazzaG , ManiV , GrossoM , MercuriM , LanzH , SchusslerS , et al. A randomized, open-label, multicenter study of the efficacy and safety of edoxaban monotherapy versus low-molecular weight heparin/warfarin in patients with symptomatic deep vein thrombosis-edoxaban thrombus reduction imaging study (etris). Circulation2014;130:A12074. ">eTRIS 2016</a>; <a href="./references#CD010956-bbs2-0010" title="FarhanA , BukhariM , UmarJ , RazaMA . Oral rivaroxaban in symptomatic deep vein thrombosis. Journal of the College of Physicians and Surgeons Pakistan2019;29(9):814-8. ">Farhan 2019</a>; <a href="./references#CD010956-bbs2-0012" title="AmayaN , UzuiH , HisazakiK , HasegwaK , KasenoK , TadaH . Edoxaban normalizes the elevated D-dimer levels potently and promptly in patients with venous thromboembolisms: a comparison with traditional anticoagulant therapy. European Heart Journal2016;37:278. BoschFT , Van EsN , Di NisioM , CarrierM , SegersA , GrossoMA , et al. The Ottawa score does not predict recurrent venous thromboembolism in cancer patients: results from the Hokusai-VTE cancer study. Research and Practice in Thrombosis and Haemostasis2019;3(S1):717-8. KraaijpoelN , Di NisioM , MulderFI , Van EsN , RaskobGE . Clinical impact of bleeding in cancer-associated venous thromboembolism: results from the Hokusai VTE Cancer randomized trial. Thrombosis Research2018;164(Suppl 1):S223. [DOI: 10.1016/j.thromres.2018.02.094]MulderFI , Di NisioM , AyC , CarrierM , BoschFT , SegersA , et al. Clinical implications of incidental venous thromboembolism in cancer patients. European Respiratory Journal2020;55(2):1901697. [DOI: 10.1183/13993003.01697-2019]MulderFI , Van EsN , KraaijpoelN , Di NisioM , CarrierM , GarciaD , et al. Efficacy and safety of edoxaban in clinically relevant subgroups: results from the Hokusai VTE Cancer randomized trial. Thrombosis Research2018;164:S194. NCT02073682. Cancer venous thromboembolism (VTE). clinicaltrials.gov/ct2/show/NCT02073682 (first received 27 February 2014). RaskobG , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaD , et al. Edoxaban versus dalteparin for treatment of venous thromboembolism (VTE) associated with cancer: Hokusai VTE-cancer randomized trial. Supportive Care in Cancer2018;26(2):S316-S317. RaskobGE , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaD , et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. New England Journal of Medicine2018;378(7):615-24. RaskobGE , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaDA , et al. A randomized, open-label, blinded outcome assessment trial evaluating the efficacy and safety of LMWH/Edoxaban versus dalteparin for venous thromboembolism associated with cancer: Hokusai VTE-cancer study. Blood2017;130(Suppl 1):LBA-6. ">Hokusai VTE Cancer 2018</a>; <a href="./references#CD010956-bbs2-0011" title="BistervelsI , BavaliaR , BoersmaW , MeijerK , VerhammeP , Ten Cate-HoekAJ , et al. Hokusai Post-DVT Study: a follow-up study on long-term outcomes of deep vein thrombosis in patients treated with edoxaban vs warfarin. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):PB2207. BrekelmansMP , AgenoW , BeenenLF , BrennerB , BullerHR , ChenCZ , et al. Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology2016;3(9):e437-45. BrekelmansMP , BlekerSM , BauersachsR , BodaZ , BüllerHR , ChoiY , et al. Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists. Thrombosis and Haemostasis2016;116(1):155-61. Di NisioM , Van EsN , CarrierM , WangTF , GarciaD , SegersA , et al. Extended treatment with edoxaban in cancer patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE Cancer study. Journal of Thrombosis and Haemostasis2019;17:1866–74. EUCTR2009-014290-40-SE. A phase 3, randomized, double-blind, double-dummy, parallel group, multi-center, multi-national study for evaluation of efficacy and safety of DU-176b versus warfarin in subjects with atrial fibrillation - effective anticoagulation with factor Xa next generation in atrial fibrillation (ENGAGE-AF TIMI-48). trialsearch.who.int/?trialid=EUCTR2009-014290-40-SE (first received 30 November 2009). EichingerS , LinM , KyrlePA , GrossoMA . Recurrent venous thromboembolism during anticoagulation: an investigator-initiated post-hoc analysis of the hokusai-VTE trial. Blood2018;132:2539. KlokFA , BarcoS , KonstantinidesSV . External validation of the VTE-BLEED score for predicting major bleeding in stable anticoagulated patients with venous thromboembolism. Thrombosis and Haemostasis2017;117(6):1164-70. KraaijpoelN , Van EsN , RaskobGE , BüllerHR , CarrierM , ZhangG , et al. Risk scores for occult cancer in patients with venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2018;118(7):1270-8. MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMP , ChenCZ , et al. Outpatient management in patients with venous thromboembolism with edoxaban: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2017;117(12):2406-14. MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMP , ChenCZ , et al. Safety and efficacy of edoxaban compared with warfarin for the treatment of acute symptomatic deep-vein thrombosis in the outpatient setting. Research and Practice in Thrombosis and Haemostasis2017;1:913. MulderFI , Van EsN , KraaijpoelN , Di NisioM , CarrierM , DuggalA , et al. Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: results from the Hokusai VTE Cancer study. Thrombosis Research2020;185:13-9. NCT00986154. Comparative investigation of Low Molecular Weight (LMW) heparin/edoxaban tosylate (DU176b) versus (LMW) heparin/warfarin in the treatment of symptomatic deep-vein blood clots and/or lung blood clots. (The Edoxaban Hokusai-VTE Study). clinicaltrials.gov/ct2/show/NCT00986154 (first received 29 September 2009). NakamuraM , WangYQ , WangC , OhD , YinWH , KimuraT , et al. Efficacy and safety of edoxaban for treatment of venous thromboembolism: a subanalysis of East Asian patients in the Hokusai-VTE trial. Journal of Thrombosis and Haemostasis2015;13(9):1606-14. NybergJ , KarlssonKE , JönssonS , YinO , MillerR , KarlssonMO , et al. Edoxaban exposure-response analysis and clinical utility index assessment in patients with symptomatic deep-vein thrombosis or pulmonary embolism. CPT Pharmacometrics and Systems Pharmacology2016;5(4):222-32. RaskobG , AgenoW , CohenAT , BrekelmansMP , GrossoMA , SegersA , et al. Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology2016;3(5):e228-e236. RaskobG , BullerH , PrinsM , SegersA , ShiM , SchwochoL , et al. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study - methodological implications for clinical trials. Journal of Thrombosis and Haemostasis2013;11(7):1287-94. RaskobGE , BullerH , AngchaisuksiriP , OhD , BodaZ , LyonsRM , et al. Edoxaban for long-term treatment of venous thromboembolism in cancer patients. Blood2013;122(21):211. RaskobGE , Van EsN , SegersA , AngchaisuksiriP , OhD , BodaZ , et al. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematology2016;3(8):e379-87. ScheresLJ , BrekelmansMA , WalterA , CihanA , BüllerHR , SabineE , et al. Abnormal vaginal bleeding in women of reproductive age treated with edoxaban or warfarin for venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. British Journal of Obstetrics and Gynaecology2018;125(12):1581-9. The Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. New England Journal of Medicine2013;369(15):1406-15. VanasscheT , VerhammeP , WellsPS , SegersA , AgenoW , BrekelmansMP , et al. Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: an analysis of the randomized, double-blind Hokusai-VTE trial. Thrombosis Research2018;162:7-14. VerhammeP , WellsPS , SegersA , AgenoW , BrekelmansMP , CohenAT , et al. Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial. Thrombosis and Haemostasis2016;116(4):747-53. ">Hokusai‐VTE 2013</a>; <a href="./references#CD010956-bbs2-0013" title="MatsuoH , PrinsM , LensingAW , FujinumaEW , MiyamotoY , KajikawaM . Shortened length of hospital stay with rivaroxaban in patients with symptomatic venous thromboembolism in Japan: the J-EINSTEIN pulmonary embolism and deep vein thrombosis program. Current Medical Research and Opinion2015;31(6):1057-61. NCT01516814. Venous thromboembolism (VTE) treatment study in Japanese pulmonary embolism (PE) patients. clinicaltrials.gov/ct2/show/NCT01516814 (first received 25 January 2012). YamadaN , HirayamaA , MaedaH , SakagamiS , ShikataH , PrinsMH , et al. Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism-the J-EINSTEIN DVT and PE program. Thrombosis Journal2015;13:2. ">J‐EINSTEIN DVT and PE 2015</a>; <a href="./references#CD010956-bbs2-0014" title="MokademME , HassanA , AlgabyAZ . Efficacy and safety of apixaban in patients with active malignancy and acute deep venous thrombosis. Vascular2021;29(5):745-50. NCT04462003. Efficacy of apixaban in malignancy with deep venous thrombosis (DVT). clinicaltrials.gov/ct2/show/NCT04462003 (first received 3 July 2019). ">Mokadem 2021</a>; <a href="./references#CD010956-bbs2-0015" title="AgnelliG , GallusA , GoldhaberSZ , HaasS , HuismanMV , HullRD , et al. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAT 59-7939 in patients with acute symptomatic deep-vein thrombosis) study. Circulation2007;116:180-7. ">ODIXa‐DVT 2007</a>; <a href="./references#CD010956-bbs2-0017" title="Kang JiM, ParkKH , AhnS , ChoS , MinSK . Rivaroxaban after thrombolysis in acute iliofemoral venous thrombosis: a randomized, open-labeled, multicenter trial. Scientific Reports2019;9(1):20356. MinSK , AhnS , ParkKH , KangJM , KimJY . Prevention of recurrence after thrombolysis in acute iliofemoral venous thrombosis with rivaroxaban (Prais Study): a prospective, randomized, open label, multicenter trial. European Journal of Vascular and Endovascular Surgery2019;58(6):e516. NCT01986192. Prevention of recurrence after thrombolysis in acute iliofemoral venous thrombosis (PRAIS) study. clinicaltrials.gov/show/NCT01986192 (first received 18 November 2013). ">PRAIS 2019</a>; <a href="./references#CD010956-bbs2-0018" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00291330. Efficacy and safety of dabigatran compared to warfarin for 6 month treatment of acute symptomatic venous thromboembolism (RE-COVER I). clinicaltrials.gov/ct/show/NCT00291330 (first received 14 February 2006). SchulmanS , ErikssonH , GoldhaberS , KakkarAK , KearonC , KvammeAM , et al. Dabigatran or warfarin for extended maintenance therapy of venous thromboembolism. Journal of Thrombosis and Haemostasis2011;9(Suppl 2):731-2. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-COVER and RE-COVER II. Blood2013;122:2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RECOVER II. Blood2013;122(21):212. SchulmanS , ErikssonH , GoldhaverSZ , KakkarA , KearonC , MismettiP , et al. Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130:A18594. SchulmanS , KearonC , KakkarAK , MismettiP , SchellongS , ErikssonH , et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. New England Journal of Medicine2009;361(24):2342-52. ">RE‐COVER 2009</a>; <a href="./references#CD010956-bbs2-0019" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00680186. Phase III study testing efficacy &amp; safety of oral dabigatran etexilate vs warfarin for 6 m treatment for acute symp venous thromboembolism (VTE) (RE-COVER II). clinicaltrials.gov/ct2/show/NCT00680186 (first received 20 May 2008). SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-COVER and RE-COVER II. Blood2013;122:2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RECOVER II. Blood2013;122(21):212. SchulmanS , ErikssonH , GoldhaverSZ , KakkarA , KearonC , MismettiP , et al. Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130:A18594. SchulmanS , KakkarAK , GoldhaberSZ , SchellongS , ErikssonH , MismettiP , et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation2014;129:764-72. SchulmanS . A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II). Blood2011;118(21):95-6. ">RE‐COVER II 2014</a>; <a href="./references#CD010956-bbs2-0021" title="FiessingerJN , HuismanMV , DavidsonBL , BounameauxH , FrancisCW , ErikssonH , et al. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomised trial. JAMA2005;293(6):681-9. FrancisCW , GinsbergJS , BerkowitzSD , BounameauxH , DavidsonBL , ErikssonH , et al. Efficacy and safety of the oral direct thrombin inhibitor ximelagatran compared with current therapy for acute, symptomatic deep vein thrombosis, with or without pulmonary embolus: the THRIVE treatment study. Blood2003;102(11):Abstract 7. HarenbergJ , IngridJ , TivadarF . Treatment of venous thromboembolism with the oral thrombin inhibitor, ximelagatran. Israel Medical Association Journal2002;4(11):1003-5. HarenbergJ , JoergI , WeissC . Incidence of recurrent venous thromboembolism of patients after termination of treatment with ximelagatran. European Journal of Clinical Pharmacology2006;62(3):173-7. HarenbergJ , JorgI , WeissC , HarenbergJ , JorgI , WeissC . Observations of alanine aminotransferase and aspartate aminotransferase in THRIVE studies treated orally with ximelagatran. International Journal of Toxicology2006;25(3):165-9. HuismanMV , The THRIVE Treatment Study Investigators. Efficacy and safety of the oral direct thrombin inhibitor ximelagatran compared with current standard therapy for acute symptomatic deep vein thrombosis, with or without pulmonary embolism: a randomized, double-blind, multinational study. Journal of Thrombosis and Haemostasis2003;1(Suppl 1):Abstract OC003. WimperisJ , FiessingerJN , HuismanMV , DavidsonBL , BounameauxH , FrancisCW , et al. Ximelagatran, an oral direct thrombin inhibitor, compared with current standard therapy for acute, symptomatic deep vein thrombosis, with or without pulmonary embolism: the THRIVE treatment study. British Journal of Haematology2004;125(Suppl 1):66. ">THRIVE 2005</a>). Two studies were at an unclear risk because of insufficient information (<a href="./references#CD010956-bbs2-0016" title="OhmoriH , KadaA , NakamuraM , SaitoAM , SanayamaY , ShinagawaT , et al. Deep vein thrombosis in severe motor and intellectual disabilities patients and its treatment by anticoagulants of warfarin versus edoxaban. Annals of Vascular Diseases2019;12(3):372-8. OhmoriH , NakamuraM , KadaA , SaitoAM , SanayamaY , ShinagawaT , et al. Multicenter, open-label, randomized controlled trial of warfarin and edoxaban tosilate hydrate for the treatment of deep vein thrombosis in persons with severe motor intellectual disabilities. Kurume Medical Journal2018;65(1):11-6. ">Ohmori 2019</a>; <a href="./references#CD010956-bbs2-0020" title="SukovatykhBS , SereditskiĭAV , MuradianVF , BelikovLN , GerasimovaOF . Results of administering oral anticoagulants for treatment of patients with venous thromboembolic complications. Angiologiia i sosudistaia khirurgiia [Angiology and Vascular Surgery]2017;23(2):82. ">Sukovatykh 2017</a>). The <a href="./references#CD010956-bbs2-0009" title="PiazzaG , ManiV , GoldhaberSZ , GrossoMA , MercuriM , LanzHJ , et al. Magnetic resonance venography to assess thrombus resolution with edoxaban monotherapy versus parenteral anticoagulation/warfarin for symptomatic deep vein thrombosis: a multicenter feasibility study. Vascular Medicine2016;21(4):361-8. PiazzaG , ManiV , GrossoM , MercuriM , LanzH , SchusslerS , et al. A randomized, open-label, multicenter study of the efficacy and safety of edoxaban monotherapy versus low-molecular weight heparin/warfarin in patients with symptomatic deep vein thrombosis-edoxaban thrombus reduction imaging study (etris). Circulation2014;130:A12074. ">eTRIS 2016</a> study was reported as an abstract in the previous version of the review and we have now included the full‐text report. This did not provide clear information regarding allocation concealment. However, personal communication with the study author revealed that treatment allocation was concealed with the use of a computerised system and, therefore, we judged this study to be at low risk of bias.  </p> </section> <section id="CD010956-sec-0056"> <h4 class="title">Blinding</h4> <p>We assessed 14 studies to be at low risk of bias for blinding (<a href="./references#CD010956-bbs2-0002" title="NakamuraM , NishikawaM , KomuroI , KitajimaI , UetsukaY , YamagamiT , et al. Apixaban for the treatment of Japanese subjects with acute venous thromboembolism (AMPLIFY-J Study). Circulation2015;79(6):1230–36. ">AMPLIFY‐J 2015</a>; <a href="./references#CD010956-bbs2-0003" title="BarrettYC , WangJ , KnabbR , MohanP . Apixaban decreases coagulation activity in patients with acute deep-vein thrombosis. Thrombosis and Haemostasis2011;105:181-9. Botticelli Investigators Writing Committee, BullerH , DeitchmanD , PrinsM , SegersA . Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. Journal of Thrombosis and Haemostasis2008;6:1313-8. BullerHR . A dose finding study of the oral direct factor Xa inhibitor apixaban in the treatment of patients with acute symptomatic deep vein thrombosis - the Botticelli Investigators. Journal of Thrombosis and Haemostasis2007;5 (Suppl 2):O-S-003. NCT00252005. Oral direct factor Xa-inhibitor apixaban in patients with acute symptomatic deep-vein thrombosis - the Botticelli DVT study. clinicaltrials.gov/ct/show/NCT00252005?order=1 (first received 11 November 2005). ">Botticelli DVT 2008</a>; <a href="./references#CD010956-bbs2-0004" title="AgenoW , VedovatiMC , CohenA , HuismanM , BauersachsR , GussoniG , et al. Bleeding with apixaban and dalteparin in patients with cancer-associated venous thromboembolism: results from the Caravaggio study. Thrombosis and Haemostasis2021;121(5):616-24. AgnelliG , BecattiniC , BauersachsR , BrennerB , CampaniniM , CohenA , et al. Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the Caravaggio study. Thrombosis and Haemostasis2018;118(9):1668-78. AgnelliG , BecattiniC , MeyerG , MuozA , VersoM . Apixaban for the treatment of venous thromboembolism associated with cancer. New England Journal of Medicine2020;382(17):1599-607. AgnelliG , MuozA , FrancoL , MahéI , BrennerB , ConnorsJM , et al. Apixaban and dalteparin for the treatment of venous thromboembolism in patients with different sites of cancer. Thrombosis and Haemostasis2022;122(5):796-807. BecattiniC , BauersachsR , MarazitiG , BertolettiL , CohenA , ConnorsJM , et al. Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial. Haematologica2021;107(7):1567-76. GiustozziM , ConnorsJM , Ruperez BlancoAB , SzmitS , FalvoN , CohenAT , et al. Clinical characteristics and outcomes of incidental venous thromboembolism in cancer patients: insights from the Caravaggio study. Journal of Thrombosis and Haemostasis2021;19(11):2751-9. NCT03045406. Apixaban for the treatment of venous thromboembolism in patients with cancer (CARAVAGGIO). clinicaltrials.gov/ct2/show/NCT03045406 (first received 7 February 2017). VersoM , MunozA , BauersachsR , HuismanMV , AgnelliG . Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism. European Journal of Cancer2021;148(Suppl C):371-81. ">Caravaggio 2020</a>; <a href="./references#CD010956-bbs2-0007" title="BullerH , DariusH . EINSTEIN DVT: oral rivaroxaban versus standard therapy in the initial treatment of symptomatic deep vein thrombosis and long-term prevention of recurrent venous thromboembolism. escardio.org/The-ESC/Press-Office/Press-releases/EINSTEIN-DVT-Oral-rivaroxaban-versus-standard-therapy-in-the-initial-treatment (accessed 19 October 2022). BullerHR , AgnelliG . Once- or twice-daily rivaroxaban for the treatment of proximal deep vein thrombosis: similar efficacy and safety to standard therapy in dose-ranging studies. Blood2006;108(11 Part 1):172-3. BullerHR , LensingAW , PrinsMH , AgnelliG , CohenA , GallusAS , et al. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT dose-ranging study. Blood2008;112(6):2242-7. NCT00395772. Once-daily oral direct factor Xa inhibitor BAY59-7939 in patients with acute symptomatic deep-vein thrombosis. clinicaltrials.gov/ct2/show/NCT00395772?term=einstein-dvt&amp;rank=2 (first received 3 November 2006). ">EINSTEIN‐DVT dose 2008</a>; <a href="./references#CD010956-bbs2-0006" title="BamberL , WangMY , PrinsMH , CiniglioC , BauersachsR , LensingAW , et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis. Thrombosis and Haemostasis2013;110(4):732-41. BauersachsR , LensingAW , PapA , DecoususH . No need for a rivaroxaban dose reduction in renally impaired patients with symptomatic venous thromboembolism. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):30-1. BistervelsI , GebelM , LensingA , MiddeldorpS , CoppensM . Effect of polypharmacy on bleeding of rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolism. Research and Practice in Thrombosis and Haemostasis2019;3:798‐9. BookhartBK , HaskellL , BamberL , WangM , ScheinJ , ModySH . Length of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial program. Journal of Medical Economics2014;17(10):691-5. BullerHR . Oral rivaroxaban for the acute and continued treatment of symptomatic venous thromboembolism. The Einstein-DVT and Einstein-Extension study. Blood2010;116(21):187. CheungW , MiddeldorpS , PrinsMP , PapAF , LensingAW , Hoek-tenCA , et al. Post thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep vein thrombosis. Journal of Thrombosis and Haemostasis2015;13(S2):219-20. CheungYW , MiddeldorpS , PrinsMH , PapAF , PrandoniP . Post-thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep-vein thrombosis. A post-hoc analysis. Thrombosis and Haemostasis2016;116(4):733-8. EUCTR2004-002171-16-IT. Once-daily oral direct factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis. The EINSTEIN-DVT dose-finding study. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2004%E2%80%90002171%E2%80%9016%E2%80%90IT (first received 15 October 2008). EUCTR2006-004495-13-DK. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep-vein thrombosis or pulmonary embolism. trialsearch.who.int/?TrialID=EUCTR2006-004495-13-DK (first received 29 March 2007). EerenbergES , MiddeldorpS , LeviM , LensingAW , BüllerHR . Clinical impact and course of major bleeding with rivaroxaban and vitamin K antagonists. Journal of Thrombosis and Haemostasis2015;13(9):1590-6. KlineJA , JimenezD , CourtneyDM , IanusJ , CaoL , WellsPS . Use of the Riete 2008 bleeding score to identify patients at low risk for major bleeding in patients treated with rivaroxaban. Academic Emergency Medicine2015;22:S162. NCT00440193. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep vein thrombosis - The EINSTEIN DVT Study. clinicaltrials.gov/ct2/show/NCT00440193 (first received 26 February 2007). PrinsMH , ErkensPG , LensingAW . Incidence of recurrent venous thromboembolism in patients following completion of the EINSTEIN DVT and EINSTEIN PE studies. Journal of Thrombosis and Haemostasis2013;11(Suppl):257. PrinsMH , LensingAW , BauersachsR , Van BellenB , BounameauxH , BrightonTA , et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thrombosis Journal2013;11(1):21. The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. New England Journal of Medicine2010;363(26):2499-510. Van BellenB , PrinsM , BamberL , WangM , LensingAW . Reduction in initial length of stay with rivaroxaban single-drug regimen versus LMWH-VKA standard of care: findings from the EINSTEIN trial program. Blood2012;120(21):3419. Van BellenB , PrinsM , BamberL , WangM , LensingAW . Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism. Current Medical Research and Opinion2014;30(5):829-37. WangY , WangC , ChenZ , ZhangJ , LiuZ , JinB , et al. Rivaroxaban for the treatment of symptomatic deep vein thrombosis and/or pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):694. WangY , WangC , ChenZ , ZhangJ , LiuZ , JinB , et al. Rivaroxaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Thrombosis Journal2013;11(1):25. ">EINSTEIN‐DVT 2010</a>; <a href="./references#CD010956-bbs2-0008" title="BullerHR , PrinsMH , LensinAW , DecoususH , JacobsonBF , MinarE , et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. New England Journal of Medicine2012;366:1287-97. FermannGJ , Erkens Pmg, PrinsMH , WellsPS , Pap ÁF, LensingAW , et al. Treatment of pulmonary embolism with rivaroxaban: outcomes by simplified pulmonary embolism severity index score from a post hoc analysis of the EINSTEIN PE study. Academic Emergency Medicine2015;22(3):299-307. NCT00439777. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic pulmonary embolism with or without symptomatic deep-vein thrombosis: Einstein-PE evaluation, 2008. clinicaltrials.gov/ct2/show/NCT00439777?term=NCT00439777&amp;rank=1 (first received 26 February 2007). PrinsM , BamberL , CanoS , WangM , LensingAW , BauersachsR . Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic pulmonary embolism. Blood2012;120(21):1163. PrinsMH , BamberL , CanoSJ , WangMY , ErkensP , BauersachsR , et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial. Thrombosis Research2015;135(2):281-8. ">EINSTEIN‐PE 2012</a>; <a href="./references#CD010956-bbs2-0009" title="PiazzaG , ManiV , GoldhaberSZ , GrossoMA , MercuriM , LanzHJ , et al. Magnetic resonance venography to assess thrombus resolution with edoxaban monotherapy versus parenteral anticoagulation/warfarin for symptomatic deep vein thrombosis: a multicenter feasibility study. Vascular Medicine2016;21(4):361-8. PiazzaG , ManiV , GrossoM , MercuriM , LanzH , SchusslerS , et al. A randomized, open-label, multicenter study of the efficacy and safety of edoxaban monotherapy versus low-molecular weight heparin/warfarin in patients with symptomatic deep vein thrombosis-edoxaban thrombus reduction imaging study (etris). Circulation2014;130:A12074. ">eTRIS 2016</a>; <a href="./references#CD010956-bbs2-0010" title="FarhanA , BukhariM , UmarJ , RazaMA . Oral rivaroxaban in symptomatic deep vein thrombosis. Journal of the College of Physicians and Surgeons Pakistan2019;29(9):814-8. ">Farhan 2019</a>; <a href="./references#CD010956-bbs2-0012" title="AmayaN , UzuiH , HisazakiK , HasegwaK , KasenoK , TadaH . Edoxaban normalizes the elevated D-dimer levels potently and promptly in patients with venous thromboembolisms: a comparison with traditional anticoagulant therapy. European Heart Journal2016;37:278. BoschFT , Van EsN , Di NisioM , CarrierM , SegersA , GrossoMA , et al. The Ottawa score does not predict recurrent venous thromboembolism in cancer patients: results from the Hokusai-VTE cancer study. Research and Practice in Thrombosis and Haemostasis2019;3(S1):717-8. KraaijpoelN , Di NisioM , MulderFI , Van EsN , RaskobGE . Clinical impact of bleeding in cancer-associated venous thromboembolism: results from the Hokusai VTE Cancer randomized trial. Thrombosis Research2018;164(Suppl 1):S223. [DOI: 10.1016/j.thromres.2018.02.094]MulderFI , Di NisioM , AyC , CarrierM , BoschFT , SegersA , et al. Clinical implications of incidental venous thromboembolism in cancer patients. European Respiratory Journal2020;55(2):1901697. [DOI: 10.1183/13993003.01697-2019]MulderFI , Van EsN , KraaijpoelN , Di NisioM , CarrierM , GarciaD , et al. Efficacy and safety of edoxaban in clinically relevant subgroups: results from the Hokusai VTE Cancer randomized trial. Thrombosis Research2018;164:S194. NCT02073682. Cancer venous thromboembolism (VTE). clinicaltrials.gov/ct2/show/NCT02073682 (first received 27 February 2014). RaskobG , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaD , et al. Edoxaban versus dalteparin for treatment of venous thromboembolism (VTE) associated with cancer: Hokusai VTE-cancer randomized trial. Supportive Care in Cancer2018;26(2):S316-S317. RaskobGE , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaD , et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. New England Journal of Medicine2018;378(7):615-24. RaskobGE , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaDA , et al. A randomized, open-label, blinded outcome assessment trial evaluating the efficacy and safety of LMWH/Edoxaban versus dalteparin for venous thromboembolism associated with cancer: Hokusai VTE-cancer study. Blood2017;130(Suppl 1):LBA-6. ">Hokusai VTE Cancer 2018</a>; <a href="./references#CD010956-bbs2-0013" title="MatsuoH , PrinsM , LensingAW , FujinumaEW , MiyamotoY , KajikawaM . Shortened length of hospital stay with rivaroxaban in patients with symptomatic venous thromboembolism in Japan: the J-EINSTEIN pulmonary embolism and deep vein thrombosis program. Current Medical Research and Opinion2015;31(6):1057-61. NCT01516814. Venous thromboembolism (VTE) treatment study in Japanese pulmonary embolism (PE) patients. clinicaltrials.gov/ct2/show/NCT01516814 (first received 25 January 2012). YamadaN , HirayamaA , MaedaH , SakagamiS , ShikataH , PrinsMH , et al. Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism-the J-EINSTEIN DVT and PE program. Thrombosis Journal2015;13:2. ">J‐EINSTEIN DVT and PE 2015</a>; <a href="./references#CD010956-bbs2-0014" title="MokademME , HassanA , AlgabyAZ . Efficacy and safety of apixaban in patients with active malignancy and acute deep venous thrombosis. Vascular2021;29(5):745-50. NCT04462003. Efficacy of apixaban in malignancy with deep venous thrombosis (DVT). clinicaltrials.gov/ct2/show/NCT04462003 (first received 3 July 2019). ">Mokadem 2021</a>; <a href="./references#CD010956-bbs2-0015" title="AgnelliG , GallusA , GoldhaberSZ , HaasS , HuismanMV , HullRD , et al. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAT 59-7939 in patients with acute symptomatic deep-vein thrombosis) study. Circulation2007;116:180-7. ">ODIXa‐DVT 2007</a>; <a href="./references#CD010956-bbs2-0016" title="OhmoriH , KadaA , NakamuraM , SaitoAM , SanayamaY , ShinagawaT , et al. Deep vein thrombosis in severe motor and intellectual disabilities patients and its treatment by anticoagulants of warfarin versus edoxaban. Annals of Vascular Diseases2019;12(3):372-8. OhmoriH , NakamuraM , KadaA , SaitoAM , SanayamaY , ShinagawaT , et al. Multicenter, open-label, randomized controlled trial of warfarin and edoxaban tosilate hydrate for the treatment of deep vein thrombosis in persons with severe motor intellectual disabilities. Kurume Medical Journal2018;65(1):11-6. ">Ohmori 2019</a>; <a href="./references#CD010956-bbs2-0017" title="Kang JiM, ParkKH , AhnS , ChoS , MinSK . Rivaroxaban after thrombolysis in acute iliofemoral venous thrombosis: a randomized, open-labeled, multicenter trial. Scientific Reports2019;9(1):20356. MinSK , AhnS , ParkKH , KangJM , KimJY . Prevention of recurrence after thrombolysis in acute iliofemoral venous thrombosis with rivaroxaban (Prais Study): a prospective, randomized, open label, multicenter trial. European Journal of Vascular and Endovascular Surgery2019;58(6):e516. NCT01986192. Prevention of recurrence after thrombolysis in acute iliofemoral venous thrombosis (PRAIS) study. clinicaltrials.gov/show/NCT01986192 (first received 18 November 2013). ">PRAIS 2019</a>). They either did not blind participants and personnel to the control treatment or did not report blinding, but we judged that the lack of blinding in the control group was unlikely to have affected the outcomes of this review. A further five studies were double‐blinded and used placebo tablets or injection so were at low risk of bias (<a href="./references#CD010956-bbs2-0001" title="AgnelliG , BullerH , MasiukiewiczUP . Apixaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism: a randomized, double-blind trial (AMPLIFY). Journal of Thrombosis and Haemostasis2013;11:18. AgnelliG , BullerHR , CohenA , CurtoD , GallusAS , JohnsonM , et al. Oral apixaban for the treatment of acute venous thromboembolism. New England Journal of Medicine2013;369:799-808. AgnelliG , BullerHR , CohenA , CurtoM , GallusAS , PakR , et al. Apixaban for the treatment of venous thromboembolism in cancer patients: data from the AMPLIFY trial. Canadian Journal of Cardiology2014;30(10 Suppl 1):S278. AgnelliG , BullerHR , CohenA , GallusAS , LeeTC , PakR , et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. Journal of Thrombosis and Haemostasis2015;13(12):2187-91. AgnelliG . Apixaban was non-inferior to enoxaparin plus warfarin in patients with acute venous thromboembolism. Annals of Internal Medicine2013;159(8):JC2. BlekerSM , CohenAT , BüllerHR , AgnelliG , GallusAS , RaskobGE , et al. Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Thrombosis and Haemostasis2016;116(6):159-64. BrekelmansM , ScheresL , BlekerS , HuttenB , TimmermansA , BüllerH , et al. Abnormal vaginal bleeding in women with venous thromboembolism treated with apixaban or warfarin. Thrombosis and Haemostasis2017;117(04):809-15. CohenA , AgnelliG , BullerH , GallusA , RaskobG , SandersP , et al. Characteristics and outcomes in patients with venous thromboembolism taking concomitant anti-platelet agents and anticoagulants in the AMPLIFY Trial. Thrombosis and Haemostasis2019;119(3):461-6. CohenA , AgnelliG , BullerHR , ChaudhuriS , GallusAS , RaskobGE , et al. Analysis of the bleeding and thromboembolic risk with concomitant use of antiplatelet treatment in the AMPLIFY trial. Canadian Journal of Cardiology2014;30(10):S272. CohenA , GallusAS , AgnelliG , BullerHR , PakR , PorcariAR , et al. Time in Therapeutic Range (TTR) and relative efficacy and safety of treatment with apixaban or enoxaparin/warfarin for acute symptomatic venous thromboembolism: an analysis of the Amplify trial data. Blood2014;124(21):1543. CohenAT , PanS , ByonW , IlyasBS , LeeTC . Efficacy, safety, and exposure of apixaban in patients with high body weight or obesity and venous thromboembolism: insights from AMPLIFY. Advances in Therapy2021;38(6):3003-18. EUCTR2007-007867-25-PT. A safety and efficacy trial evaluating the use of apixaban in the treatment of symptomatic deep vein thrombosis and pulmonary embolism revised protocol number: 01, incorporates amendment(s) 02 + protocol amendment 01 (version 1.0 dated 21-Apr-08) site-specific - molecular profiling supplement samples for Pfizer’s exploratory research biobank. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2007%E2%80%90007867%E2%80%9025%E2%80%90PT (first received 14 July 2008). GallusAS , AgnelliG , BullerHR , CohenA , LeeTC , PakR , et al. Apixaban for treatment of venous thromboembolism in patients from study centres in Asia: a subgroup analysis of the Amplify trial. Journal of Thrombosis and Haemostasis2015;13:727. LeeT , PanS , ByonW , IlyasBS . Safety and efficacy of apixaban versus enoxaparin/warfarin in patients with extremes of body weight: post-hoc analysis of the AMPLIFY trial. Blood2019;134(Suppl 1):1152. LiuX , JohnsonM , MardekianJ , PhatakH , ThompsonJ , CohenAT . Apixaban reduces hospitalizations in patients with venous thromboembolism: an analysis of the apixaban for the Initial management of pulmonary embolism and deep‐vein thrombosis as first‐line therapy (AMPLIFY) trial. Journal of the American Heart Association2015;4(12):e002340. NCT00633893. Efficacy and safety study of apixaban for extended treatment of deep vein thrombosis or pulmonary embolism. clinicaltrials.gov/ct2/show/NCT00633893?term=ajax&amp;rank=5 (first received 12 March 2008). NCT00643201. Efficacy and safety study of apixaban for the treatment of deep vein thrombosis or pulmonary embolism. clinicaltrials.gov/ct2/show/NCT00643201 (first received 26 March 2008). RaskobGE , GallusAS , SandersP , ThompsonJR , AgnelliG , BullerHR , et al. Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy: a sub-analysis of the AMPLIFY trial. Thrombosis and Haemostasis2016;115(4):809-16. ">AMPLIFY 2013</a>; <a href="./references#CD010956-bbs2-0011" title="BistervelsI , BavaliaR , BoersmaW , MeijerK , VerhammeP , Ten Cate-HoekAJ , et al. Hokusai Post-DVT Study: a follow-up study on long-term outcomes of deep vein thrombosis in patients treated with edoxaban vs warfarin. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):PB2207. BrekelmansMP , AgenoW , BeenenLF , BrennerB , BullerHR , ChenCZ , et al. Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology2016;3(9):e437-45. BrekelmansMP , BlekerSM , BauersachsR , BodaZ , BüllerHR , ChoiY , et al. Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists. Thrombosis and Haemostasis2016;116(1):155-61. Di NisioM , Van EsN , CarrierM , WangTF , GarciaD , SegersA , et al. Extended treatment with edoxaban in cancer patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE Cancer study. Journal of Thrombosis and Haemostasis2019;17:1866–74. EUCTR2009-014290-40-SE. A phase 3, randomized, double-blind, double-dummy, parallel group, multi-center, multi-national study for evaluation of efficacy and safety of DU-176b versus warfarin in subjects with atrial fibrillation - effective anticoagulation with factor Xa next generation in atrial fibrillation (ENGAGE-AF TIMI-48). trialsearch.who.int/?trialid=EUCTR2009-014290-40-SE (first received 30 November 2009). EichingerS , LinM , KyrlePA , GrossoMA . Recurrent venous thromboembolism during anticoagulation: an investigator-initiated post-hoc analysis of the hokusai-VTE trial. Blood2018;132:2539. KlokFA , BarcoS , KonstantinidesSV . External validation of the VTE-BLEED score for predicting major bleeding in stable anticoagulated patients with venous thromboembolism. Thrombosis and Haemostasis2017;117(6):1164-70. KraaijpoelN , Van EsN , RaskobGE , BüllerHR , CarrierM , ZhangG , et al. Risk scores for occult cancer in patients with venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2018;118(7):1270-8. MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMP , ChenCZ , et al. Outpatient management in patients with venous thromboembolism with edoxaban: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2017;117(12):2406-14. MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMP , ChenCZ , et al. Safety and efficacy of edoxaban compared with warfarin for the treatment of acute symptomatic deep-vein thrombosis in the outpatient setting. Research and Practice in Thrombosis and Haemostasis2017;1:913. MulderFI , Van EsN , KraaijpoelN , Di NisioM , CarrierM , DuggalA , et al. Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: results from the Hokusai VTE Cancer study. Thrombosis Research2020;185:13-9. NCT00986154. Comparative investigation of Low Molecular Weight (LMW) heparin/edoxaban tosylate (DU176b) versus (LMW) heparin/warfarin in the treatment of symptomatic deep-vein blood clots and/or lung blood clots. (The Edoxaban Hokusai-VTE Study). clinicaltrials.gov/ct2/show/NCT00986154 (first received 29 September 2009). NakamuraM , WangYQ , WangC , OhD , YinWH , KimuraT , et al. Efficacy and safety of edoxaban for treatment of venous thromboembolism: a subanalysis of East Asian patients in the Hokusai-VTE trial. Journal of Thrombosis and Haemostasis2015;13(9):1606-14. NybergJ , KarlssonKE , JönssonS , YinO , MillerR , KarlssonMO , et al. Edoxaban exposure-response analysis and clinical utility index assessment in patients with symptomatic deep-vein thrombosis or pulmonary embolism. CPT Pharmacometrics and Systems Pharmacology2016;5(4):222-32. RaskobG , AgenoW , CohenAT , BrekelmansMP , GrossoMA , SegersA , et al. Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology2016;3(5):e228-e236. RaskobG , BullerH , PrinsM , SegersA , ShiM , SchwochoL , et al. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study - methodological implications for clinical trials. Journal of Thrombosis and Haemostasis2013;11(7):1287-94. RaskobGE , BullerH , AngchaisuksiriP , OhD , BodaZ , LyonsRM , et al. Edoxaban for long-term treatment of venous thromboembolism in cancer patients. Blood2013;122(21):211. RaskobGE , Van EsN , SegersA , AngchaisuksiriP , OhD , BodaZ , et al. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematology2016;3(8):e379-87. ScheresLJ , BrekelmansMA , WalterA , CihanA , BüllerHR , SabineE , et al. Abnormal vaginal bleeding in women of reproductive age treated with edoxaban or warfarin for venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. British Journal of Obstetrics and Gynaecology2018;125(12):1581-9. The Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. New England Journal of Medicine2013;369(15):1406-15. VanasscheT , VerhammeP , WellsPS , SegersA , AgenoW , BrekelmansMP , et al. Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: an analysis of the randomized, double-blind Hokusai-VTE trial. Thrombosis Research2018;162:7-14. VerhammeP , WellsPS , SegersA , AgenoW , BrekelmansMP , CohenAT , et al. Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial. Thrombosis and Haemostasis2016;116(4):747-53. ">Hokusai‐VTE 2013</a>; <a href="./references#CD010956-bbs2-0018" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00291330. Efficacy and safety of dabigatran compared to warfarin for 6 month treatment of acute symptomatic venous thromboembolism (RE-COVER I). clinicaltrials.gov/ct/show/NCT00291330 (first received 14 February 2006). SchulmanS , ErikssonH , GoldhaberS , KakkarAK , KearonC , KvammeAM , et al. Dabigatran or warfarin for extended maintenance therapy of venous thromboembolism. Journal of Thrombosis and Haemostasis2011;9(Suppl 2):731-2. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-COVER and RE-COVER II. Blood2013;122:2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RECOVER II. Blood2013;122(21):212. SchulmanS , ErikssonH , GoldhaverSZ , KakkarA , KearonC , MismettiP , et al. Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130:A18594. SchulmanS , KearonC , KakkarAK , MismettiP , SchellongS , ErikssonH , et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. New England Journal of Medicine2009;361(24):2342-52. ">RE‐COVER 2009</a>; <a href="./references#CD010956-bbs2-0019" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00680186. Phase III study testing efficacy &amp; safety of oral dabigatran etexilate vs warfarin for 6 m treatment for acute symp venous thromboembolism (VTE) (RE-COVER II). clinicaltrials.gov/ct2/show/NCT00680186 (first received 20 May 2008). SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-COVER and RE-COVER II. Blood2013;122:2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RECOVER II. Blood2013;122(21):212. SchulmanS , ErikssonH , GoldhaverSZ , KakkarA , KearonC , MismettiP , et al. Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130:A18594. SchulmanS , KakkarAK , GoldhaberSZ , SchellongS , ErikssonH , MismettiP , et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation2014;129:764-72. SchulmanS . A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II). Blood2011;118(21):95-6. ">RE‐COVER II 2014</a>; <a href="./references#CD010956-bbs2-0021" title="FiessingerJN , HuismanMV , DavidsonBL , BounameauxH , FrancisCW , ErikssonH , et al. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomised trial. JAMA2005;293(6):681-9. FrancisCW , GinsbergJS , BerkowitzSD , BounameauxH , DavidsonBL , ErikssonH , et al. Efficacy and safety of the oral direct thrombin inhibitor ximelagatran compared with current therapy for acute, symptomatic deep vein thrombosis, with or without pulmonary embolus: the THRIVE treatment study. Blood2003;102(11):Abstract 7. HarenbergJ , IngridJ , TivadarF . Treatment of venous thromboembolism with the oral thrombin inhibitor, ximelagatran. Israel Medical Association Journal2002;4(11):1003-5. HarenbergJ , JoergI , WeissC . Incidence of recurrent venous thromboembolism of patients after termination of treatment with ximelagatran. European Journal of Clinical Pharmacology2006;62(3):173-7. HarenbergJ , JorgI , WeissC , HarenbergJ , JorgI , WeissC . Observations of alanine aminotransferase and aspartate aminotransferase in THRIVE studies treated orally with ximelagatran. International Journal of Toxicology2006;25(3):165-9. HuismanMV , The THRIVE Treatment Study Investigators. Efficacy and safety of the oral direct thrombin inhibitor ximelagatran compared with current standard therapy for acute symptomatic deep vein thrombosis, with or without pulmonary embolism: a randomized, double-blind, multinational study. Journal of Thrombosis and Haemostasis2003;1(Suppl 1):Abstract OC003. WimperisJ , FiessingerJN , HuismanMV , DavidsonBL , BounameauxH , FrancisCW , et al. Ximelagatran, an oral direct thrombin inhibitor, compared with current standard therapy for acute, symptomatic deep vein thrombosis, with or without pulmonary embolism: the THRIVE treatment study. British Journal of Haematology2004;125(Suppl 1):66. ">THRIVE 2005</a>). Therefore, we judged 19 studies to be at low risk of performance bias. The <a href="./references#CD010956-bbs2-0005" title="NCT02704598. Comparison between xarelto versus warfarin in the recanalization rate of deep venous thrombosis in patients legs. (DVT). clinicaltrials.gov/ct2/show/NCT02704598 (first received 10 March 2016). deAthayde SoaresR , MatieloMF , Brochado NetoFC , AlmeidaRD , SacilottoR . LEV 2. Comparison of the recanalization rate and post-thrombotic syndrome in patients with deep venous thrombosis treated with rivaroxaban or warfarin. Journal of Vascular Surgery2019;70(5):e169-e170. deAthayde SoaresR , MatieloMF , Brochado NetoFC , NogueiraMP , AlmeidaRD , SacilottoR . Comparison of the recanalization rate and postthrombotic syndrome in patients with deep venous thrombosis treated with rivaroxaban or warfarin. Surgery2019;166(6):1076-83. ">de Athayde 2019</a> study reported PTS but provided no information about blinding for participants. The PTS score included participants' self‐reported domains (such as pain, cramps, heaviness, pruritus and paraesthesia), so we judged the risk of blinding for participants and personnel as high, as knowing what treatment group they were in may have affected the outcome. The <a href="./references#CD010956-bbs2-0020" title="SukovatykhBS , SereditskiĭAV , MuradianVF , BelikovLN , GerasimovaOF . Results of administering oral anticoagulants for treatment of patients with venous thromboembolic complications. Angiologiia i sosudistaia khirurgiia [Angiology and Vascular Surgery]2017;23(2):82. ">Sukovatykh 2017</a> study measured quality of life using SF‐36, which is a participant self‐reported instrument. We judged the risk of blinding for both participants and personnel as unclear as no information was provided, and knowing what treatment group participants were in may have affected the outcome. </p> <p>Fourteen studies blinded outcome assessors to treatment, and we judged them to be at low risk of detection bias (<a href="./references#CD010956-bbs2-0001" title="AgnelliG , BullerH , MasiukiewiczUP . Apixaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism: a randomized, double-blind trial (AMPLIFY). Journal of Thrombosis and Haemostasis2013;11:18. AgnelliG , BullerHR , CohenA , CurtoD , GallusAS , JohnsonM , et al. Oral apixaban for the treatment of acute venous thromboembolism. New England Journal of Medicine2013;369:799-808. AgnelliG , BullerHR , CohenA , CurtoM , GallusAS , PakR , et al. Apixaban for the treatment of venous thromboembolism in cancer patients: data from the AMPLIFY trial. Canadian Journal of Cardiology2014;30(10 Suppl 1):S278. AgnelliG , BullerHR , CohenA , GallusAS , LeeTC , PakR , et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. Journal of Thrombosis and Haemostasis2015;13(12):2187-91. AgnelliG . Apixaban was non-inferior to enoxaparin plus warfarin in patients with acute venous thromboembolism. Annals of Internal Medicine2013;159(8):JC2. BlekerSM , CohenAT , BüllerHR , AgnelliG , GallusAS , RaskobGE , et al. Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Thrombosis and Haemostasis2016;116(6):159-64. BrekelmansM , ScheresL , BlekerS , HuttenB , TimmermansA , BüllerH , et al. Abnormal vaginal bleeding in women with venous thromboembolism treated with apixaban or warfarin. Thrombosis and Haemostasis2017;117(04):809-15. CohenA , AgnelliG , BullerH , GallusA , RaskobG , SandersP , et al. Characteristics and outcomes in patients with venous thromboembolism taking concomitant anti-platelet agents and anticoagulants in the AMPLIFY Trial. Thrombosis and Haemostasis2019;119(3):461-6. CohenA , AgnelliG , BullerHR , ChaudhuriS , GallusAS , RaskobGE , et al. Analysis of the bleeding and thromboembolic risk with concomitant use of antiplatelet treatment in the AMPLIFY trial. Canadian Journal of Cardiology2014;30(10):S272. CohenA , GallusAS , AgnelliG , BullerHR , PakR , PorcariAR , et al. Time in Therapeutic Range (TTR) and relative efficacy and safety of treatment with apixaban or enoxaparin/warfarin for acute symptomatic venous thromboembolism: an analysis of the Amplify trial data. Blood2014;124(21):1543. CohenAT , PanS , ByonW , IlyasBS , LeeTC . Efficacy, safety, and exposure of apixaban in patients with high body weight or obesity and venous thromboembolism: insights from AMPLIFY. Advances in Therapy2021;38(6):3003-18. EUCTR2007-007867-25-PT. A safety and efficacy trial evaluating the use of apixaban in the treatment of symptomatic deep vein thrombosis and pulmonary embolism revised protocol number: 01, incorporates amendment(s) 02 + protocol amendment 01 (version 1.0 dated 21-Apr-08) site-specific - molecular profiling supplement samples for Pfizer’s exploratory research biobank. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2007%E2%80%90007867%E2%80%9025%E2%80%90PT (first received 14 July 2008). GallusAS , AgnelliG , BullerHR , CohenA , LeeTC , PakR , et al. Apixaban for treatment of venous thromboembolism in patients from study centres in Asia: a subgroup analysis of the Amplify trial. Journal of Thrombosis and Haemostasis2015;13:727. LeeT , PanS , ByonW , IlyasBS . Safety and efficacy of apixaban versus enoxaparin/warfarin in patients with extremes of body weight: post-hoc analysis of the AMPLIFY trial. Blood2019;134(Suppl 1):1152. LiuX , JohnsonM , MardekianJ , PhatakH , ThompsonJ , CohenAT . Apixaban reduces hospitalizations in patients with venous thromboembolism: an analysis of the apixaban for the Initial management of pulmonary embolism and deep‐vein thrombosis as first‐line therapy (AMPLIFY) trial. Journal of the American Heart Association2015;4(12):e002340. NCT00633893. Efficacy and safety study of apixaban for extended treatment of deep vein thrombosis or pulmonary embolism. clinicaltrials.gov/ct2/show/NCT00633893?term=ajax&amp;rank=5 (first received 12 March 2008). NCT00643201. Efficacy and safety study of apixaban for the treatment of deep vein thrombosis or pulmonary embolism. clinicaltrials.gov/ct2/show/NCT00643201 (first received 26 March 2008). RaskobGE , GallusAS , SandersP , ThompsonJR , AgnelliG , BullerHR , et al. Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy: a sub-analysis of the AMPLIFY trial. Thrombosis and Haemostasis2016;115(4):809-16. ">AMPLIFY 2013</a>; <a href="./references#CD010956-bbs2-0002" title="NakamuraM , NishikawaM , KomuroI , KitajimaI , UetsukaY , YamagamiT , et al. Apixaban for the treatment of Japanese subjects with acute venous thromboembolism (AMPLIFY-J Study). Circulation2015;79(6):1230–36. ">AMPLIFY‐J 2015</a>; <a href="./references#CD010956-bbs2-0003" title="BarrettYC , WangJ , KnabbR , MohanP . Apixaban decreases coagulation activity in patients with acute deep-vein thrombosis. Thrombosis and Haemostasis2011;105:181-9. Botticelli Investigators Writing Committee, BullerH , DeitchmanD , PrinsM , SegersA . Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. Journal of Thrombosis and Haemostasis2008;6:1313-8. BullerHR . A dose finding study of the oral direct factor Xa inhibitor apixaban in the treatment of patients with acute symptomatic deep vein thrombosis - the Botticelli Investigators. Journal of Thrombosis and Haemostasis2007;5 (Suppl 2):O-S-003. NCT00252005. Oral direct factor Xa-inhibitor apixaban in patients with acute symptomatic deep-vein thrombosis - the Botticelli DVT study. clinicaltrials.gov/ct/show/NCT00252005?order=1 (first received 11 November 2005). ">Botticelli DVT 2008</a>; <a href="./references#CD010956-bbs2-0004" title="AgenoW , VedovatiMC , CohenA , HuismanM , BauersachsR , GussoniG , et al. Bleeding with apixaban and dalteparin in patients with cancer-associated venous thromboembolism: results from the Caravaggio study. Thrombosis and Haemostasis2021;121(5):616-24. AgnelliG , BecattiniC , BauersachsR , BrennerB , CampaniniM , CohenA , et al. Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the Caravaggio study. Thrombosis and Haemostasis2018;118(9):1668-78. AgnelliG , BecattiniC , MeyerG , MuozA , VersoM . Apixaban for the treatment of venous thromboembolism associated with cancer. New England Journal of Medicine2020;382(17):1599-607. AgnelliG , MuozA , FrancoL , MahéI , BrennerB , ConnorsJM , et al. Apixaban and dalteparin for the treatment of venous thromboembolism in patients with different sites of cancer. Thrombosis and Haemostasis2022;122(5):796-807. BecattiniC , BauersachsR , MarazitiG , BertolettiL , CohenA , ConnorsJM , et al. Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial. Haematologica2021;107(7):1567-76. GiustozziM , ConnorsJM , Ruperez BlancoAB , SzmitS , FalvoN , CohenAT , et al. Clinical characteristics and outcomes of incidental venous thromboembolism in cancer patients: insights from the Caravaggio study. Journal of Thrombosis and Haemostasis2021;19(11):2751-9. NCT03045406. Apixaban for the treatment of venous thromboembolism in patients with cancer (CARAVAGGIO). clinicaltrials.gov/ct2/show/NCT03045406 (first received 7 February 2017). VersoM , MunozA , BauersachsR , HuismanMV , AgnelliG . Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism. European Journal of Cancer2021;148(Suppl C):371-81. ">Caravaggio 2020</a>; <a href="./references#CD010956-bbs2-0007" title="BullerH , DariusH . EINSTEIN DVT: oral rivaroxaban versus standard therapy in the initial treatment of symptomatic deep vein thrombosis and long-term prevention of recurrent venous thromboembolism. escardio.org/The-ESC/Press-Office/Press-releases/EINSTEIN-DVT-Oral-rivaroxaban-versus-standard-therapy-in-the-initial-treatment (accessed 19 October 2022). BullerHR , AgnelliG . Once- or twice-daily rivaroxaban for the treatment of proximal deep vein thrombosis: similar efficacy and safety to standard therapy in dose-ranging studies. Blood2006;108(11 Part 1):172-3. BullerHR , LensingAW , PrinsMH , AgnelliG , CohenA , GallusAS , et al. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT dose-ranging study. Blood2008;112(6):2242-7. NCT00395772. Once-daily oral direct factor Xa inhibitor BAY59-7939 in patients with acute symptomatic deep-vein thrombosis. clinicaltrials.gov/ct2/show/NCT00395772?term=einstein-dvt&amp;rank=2 (first received 3 November 2006). ">EINSTEIN‐DVT dose 2008</a>; <a href="./references#CD010956-bbs2-0006" title="BamberL , WangMY , PrinsMH , CiniglioC , BauersachsR , LensingAW , et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis. Thrombosis and Haemostasis2013;110(4):732-41. BauersachsR , LensingAW , PapA , DecoususH . No need for a rivaroxaban dose reduction in renally impaired patients with symptomatic venous thromboembolism. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):30-1. BistervelsI , GebelM , LensingA , MiddeldorpS , CoppensM . Effect of polypharmacy on bleeding of rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolism. Research and Practice in Thrombosis and Haemostasis2019;3:798‐9. BookhartBK , HaskellL , BamberL , WangM , ScheinJ , ModySH . Length of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial program. Journal of Medical Economics2014;17(10):691-5. BullerHR . Oral rivaroxaban for the acute and continued treatment of symptomatic venous thromboembolism. The Einstein-DVT and Einstein-Extension study. Blood2010;116(21):187. CheungW , MiddeldorpS , PrinsMP , PapAF , LensingAW , Hoek-tenCA , et al. Post thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep vein thrombosis. Journal of Thrombosis and Haemostasis2015;13(S2):219-20. CheungYW , MiddeldorpS , PrinsMH , PapAF , PrandoniP . Post-thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep-vein thrombosis. A post-hoc analysis. Thrombosis and Haemostasis2016;116(4):733-8. EUCTR2004-002171-16-IT. Once-daily oral direct factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis. The EINSTEIN-DVT dose-finding study. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2004%E2%80%90002171%E2%80%9016%E2%80%90IT (first received 15 October 2008). EUCTR2006-004495-13-DK. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep-vein thrombosis or pulmonary embolism. trialsearch.who.int/?TrialID=EUCTR2006-004495-13-DK (first received 29 March 2007). EerenbergES , MiddeldorpS , LeviM , LensingAW , BüllerHR . Clinical impact and course of major bleeding with rivaroxaban and vitamin K antagonists. Journal of Thrombosis and Haemostasis2015;13(9):1590-6. KlineJA , JimenezD , CourtneyDM , IanusJ , CaoL , WellsPS . Use of the Riete 2008 bleeding score to identify patients at low risk for major bleeding in patients treated with rivaroxaban. Academic Emergency Medicine2015;22:S162. NCT00440193. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep vein thrombosis - The EINSTEIN DVT Study. clinicaltrials.gov/ct2/show/NCT00440193 (first received 26 February 2007). PrinsMH , ErkensPG , LensingAW . Incidence of recurrent venous thromboembolism in patients following completion of the EINSTEIN DVT and EINSTEIN PE studies. Journal of Thrombosis and Haemostasis2013;11(Suppl):257. PrinsMH , LensingAW , BauersachsR , Van BellenB , BounameauxH , BrightonTA , et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thrombosis Journal2013;11(1):21. The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. New England Journal of Medicine2010;363(26):2499-510. Van BellenB , PrinsM , BamberL , WangM , LensingAW . Reduction in initial length of stay with rivaroxaban single-drug regimen versus LMWH-VKA standard of care: findings from the EINSTEIN trial program. Blood2012;120(21):3419. Van BellenB , PrinsM , BamberL , WangM , LensingAW . Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism. Current Medical Research and Opinion2014;30(5):829-37. WangY , WangC , ChenZ , ZhangJ , LiuZ , JinB , et al. Rivaroxaban for the treatment of symptomatic deep vein thrombosis and/or pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):694. WangY , WangC , ChenZ , ZhangJ , LiuZ , JinB , et al. Rivaroxaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Thrombosis Journal2013;11(1):25. ">EINSTEIN‐DVT 2010</a>; <a href="./references#CD010956-bbs2-0008" title="BullerHR , PrinsMH , LensinAW , DecoususH , JacobsonBF , MinarE , et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. New England Journal of Medicine2012;366:1287-97. FermannGJ , Erkens Pmg, PrinsMH , WellsPS , Pap ÁF, LensingAW , et al. Treatment of pulmonary embolism with rivaroxaban: outcomes by simplified pulmonary embolism severity index score from a post hoc analysis of the EINSTEIN PE study. Academic Emergency Medicine2015;22(3):299-307. NCT00439777. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic pulmonary embolism with or without symptomatic deep-vein thrombosis: Einstein-PE evaluation, 2008. clinicaltrials.gov/ct2/show/NCT00439777?term=NCT00439777&amp;rank=1 (first received 26 February 2007). PrinsM , BamberL , CanoS , WangM , LensingAW , BauersachsR . Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic pulmonary embolism. Blood2012;120(21):1163. PrinsMH , BamberL , CanoSJ , WangMY , ErkensP , BauersachsR , et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial. Thrombosis Research2015;135(2):281-8. ">EINSTEIN‐PE 2012</a>; <a href="./references#CD010956-bbs2-0012" title="AmayaN , UzuiH , HisazakiK , HasegwaK , KasenoK , TadaH . Edoxaban normalizes the elevated D-dimer levels potently and promptly in patients with venous thromboembolisms: a comparison with traditional anticoagulant therapy. European Heart Journal2016;37:278. BoschFT , Van EsN , Di NisioM , CarrierM , SegersA , GrossoMA , et al. The Ottawa score does not predict recurrent venous thromboembolism in cancer patients: results from the Hokusai-VTE cancer study. Research and Practice in Thrombosis and Haemostasis2019;3(S1):717-8. KraaijpoelN , Di NisioM , MulderFI , Van EsN , RaskobGE . Clinical impact of bleeding in cancer-associated venous thromboembolism: results from the Hokusai VTE Cancer randomized trial. Thrombosis Research2018;164(Suppl 1):S223. [DOI: 10.1016/j.thromres.2018.02.094]MulderFI , Di NisioM , AyC , CarrierM , BoschFT , SegersA , et al. Clinical implications of incidental venous thromboembolism in cancer patients. European Respiratory Journal2020;55(2):1901697. [DOI: 10.1183/13993003.01697-2019]MulderFI , Van EsN , KraaijpoelN , Di NisioM , CarrierM , GarciaD , et al. Efficacy and safety of edoxaban in clinically relevant subgroups: results from the Hokusai VTE Cancer randomized trial. Thrombosis Research2018;164:S194. NCT02073682. Cancer venous thromboembolism (VTE). clinicaltrials.gov/ct2/show/NCT02073682 (first received 27 February 2014). RaskobG , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaD , et al. Edoxaban versus dalteparin for treatment of venous thromboembolism (VTE) associated with cancer: Hokusai VTE-cancer randomized trial. Supportive Care in Cancer2018;26(2):S316-S317. RaskobGE , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaD , et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. New England Journal of Medicine2018;378(7):615-24. RaskobGE , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaDA , et al. A randomized, open-label, blinded outcome assessment trial evaluating the efficacy and safety of LMWH/Edoxaban versus dalteparin for venous thromboembolism associated with cancer: Hokusai VTE-cancer study. Blood2017;130(Suppl 1):LBA-6. ">Hokusai VTE Cancer 2018</a>; <a href="./references#CD010956-bbs2-0011" title="BistervelsI , BavaliaR , BoersmaW , MeijerK , VerhammeP , Ten Cate-HoekAJ , et al. Hokusai Post-DVT Study: a follow-up study on long-term outcomes of deep vein thrombosis in patients treated with edoxaban vs warfarin. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):PB2207. BrekelmansMP , AgenoW , BeenenLF , BrennerB , BullerHR , ChenCZ , et al. Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology2016;3(9):e437-45. BrekelmansMP , BlekerSM , BauersachsR , BodaZ , BüllerHR , ChoiY , et al. Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists. Thrombosis and Haemostasis2016;116(1):155-61. Di NisioM , Van EsN , CarrierM , WangTF , GarciaD , SegersA , et al. Extended treatment with edoxaban in cancer patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE Cancer study. Journal of Thrombosis and Haemostasis2019;17:1866–74. EUCTR2009-014290-40-SE. A phase 3, randomized, double-blind, double-dummy, parallel group, multi-center, multi-national study for evaluation of efficacy and safety of DU-176b versus warfarin in subjects with atrial fibrillation - effective anticoagulation with factor Xa next generation in atrial fibrillation (ENGAGE-AF TIMI-48). trialsearch.who.int/?trialid=EUCTR2009-014290-40-SE (first received 30 November 2009). EichingerS , LinM , KyrlePA , GrossoMA . Recurrent venous thromboembolism during anticoagulation: an investigator-initiated post-hoc analysis of the hokusai-VTE trial. Blood2018;132:2539. KlokFA , BarcoS , KonstantinidesSV . External validation of the VTE-BLEED score for predicting major bleeding in stable anticoagulated patients with venous thromboembolism. Thrombosis and Haemostasis2017;117(6):1164-70. KraaijpoelN , Van EsN , RaskobGE , BüllerHR , CarrierM , ZhangG , et al. Risk scores for occult cancer in patients with venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2018;118(7):1270-8. MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMP , ChenCZ , et al. Outpatient management in patients with venous thromboembolism with edoxaban: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2017;117(12):2406-14. MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMP , ChenCZ , et al. Safety and efficacy of edoxaban compared with warfarin for the treatment of acute symptomatic deep-vein thrombosis in the outpatient setting. Research and Practice in Thrombosis and Haemostasis2017;1:913. MulderFI , Van EsN , KraaijpoelN , Di NisioM , CarrierM , DuggalA , et al. Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: results from the Hokusai VTE Cancer study. Thrombosis Research2020;185:13-9. NCT00986154. Comparative investigation of Low Molecular Weight (LMW) heparin/edoxaban tosylate (DU176b) versus (LMW) heparin/warfarin in the treatment of symptomatic deep-vein blood clots and/or lung blood clots. (The Edoxaban Hokusai-VTE Study). clinicaltrials.gov/ct2/show/NCT00986154 (first received 29 September 2009). NakamuraM , WangYQ , WangC , OhD , YinWH , KimuraT , et al. Efficacy and safety of edoxaban for treatment of venous thromboembolism: a subanalysis of East Asian patients in the Hokusai-VTE trial. Journal of Thrombosis and Haemostasis2015;13(9):1606-14. NybergJ , KarlssonKE , JönssonS , YinO , MillerR , KarlssonMO , et al. Edoxaban exposure-response analysis and clinical utility index assessment in patients with symptomatic deep-vein thrombosis or pulmonary embolism. CPT Pharmacometrics and Systems Pharmacology2016;5(4):222-32. RaskobG , AgenoW , CohenAT , BrekelmansMP , GrossoMA , SegersA , et al. Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology2016;3(5):e228-e236. RaskobG , BullerH , PrinsM , SegersA , ShiM , SchwochoL , et al. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study - methodological implications for clinical trials. Journal of Thrombosis and Haemostasis2013;11(7):1287-94. RaskobGE , BullerH , AngchaisuksiriP , OhD , BodaZ , LyonsRM , et al. Edoxaban for long-term treatment of venous thromboembolism in cancer patients. Blood2013;122(21):211. RaskobGE , Van EsN , SegersA , AngchaisuksiriP , OhD , BodaZ , et al. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematology2016;3(8):e379-87. ScheresLJ , BrekelmansMA , WalterA , CihanA , BüllerHR , SabineE , et al. Abnormal vaginal bleeding in women of reproductive age treated with edoxaban or warfarin for venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. British Journal of Obstetrics and Gynaecology2018;125(12):1581-9. The Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. New England Journal of Medicine2013;369(15):1406-15. VanasscheT , VerhammeP , WellsPS , SegersA , AgenoW , BrekelmansMP , et al. Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: an analysis of the randomized, double-blind Hokusai-VTE trial. Thrombosis Research2018;162:7-14. VerhammeP , WellsPS , SegersA , AgenoW , BrekelmansMP , CohenAT , et al. Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial. Thrombosis and Haemostasis2016;116(4):747-53. ">Hokusai‐VTE 2013</a>; <a href="./references#CD010956-bbs2-0013" title="MatsuoH , PrinsM , LensingAW , FujinumaEW , MiyamotoY , KajikawaM . Shortened length of hospital stay with rivaroxaban in patients with symptomatic venous thromboembolism in Japan: the J-EINSTEIN pulmonary embolism and deep vein thrombosis program. Current Medical Research and Opinion2015;31(6):1057-61. NCT01516814. Venous thromboembolism (VTE) treatment study in Japanese pulmonary embolism (PE) patients. clinicaltrials.gov/ct2/show/NCT01516814 (first received 25 January 2012). YamadaN , HirayamaA , MaedaH , SakagamiS , ShikataH , PrinsMH , et al. Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism-the J-EINSTEIN DVT and PE program. Thrombosis Journal2015;13:2. ">J‐EINSTEIN DVT and PE 2015</a>; <a href="./references#CD010956-bbs2-0015" title="AgnelliG , GallusA , GoldhaberSZ , HaasS , HuismanMV , HullRD , et al. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAT 59-7939 in patients with acute symptomatic deep-vein thrombosis) study. Circulation2007;116:180-7. ">ODIXa‐DVT 2007</a>; <a href="./references#CD010956-bbs2-0018" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00291330. Efficacy and safety of dabigatran compared to warfarin for 6 month treatment of acute symptomatic venous thromboembolism (RE-COVER I). clinicaltrials.gov/ct/show/NCT00291330 (first received 14 February 2006). SchulmanS , ErikssonH , GoldhaberS , KakkarAK , KearonC , KvammeAM , et al. Dabigatran or warfarin for extended maintenance therapy of venous thromboembolism. Journal of Thrombosis and Haemostasis2011;9(Suppl 2):731-2. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-COVER and RE-COVER II. Blood2013;122:2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RECOVER II. Blood2013;122(21):212. SchulmanS , ErikssonH , GoldhaverSZ , KakkarA , KearonC , MismettiP , et al. Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130:A18594. SchulmanS , KearonC , KakkarAK , MismettiP , SchellongS , ErikssonH , et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. New England Journal of Medicine2009;361(24):2342-52. ">RE‐COVER 2009</a>; <a href="./references#CD010956-bbs2-0019" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00680186. Phase III study testing efficacy &amp; safety of oral dabigatran etexilate vs warfarin for 6 m treatment for acute symp venous thromboembolism (VTE) (RE-COVER II). clinicaltrials.gov/ct2/show/NCT00680186 (first received 20 May 2008). SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-COVER and RE-COVER II. Blood2013;122:2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RECOVER II. Blood2013;122(21):212. SchulmanS , ErikssonH , GoldhaverSZ , KakkarA , KearonC , MismettiP , et al. Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130:A18594. SchulmanS , KakkarAK , GoldhaberSZ , SchellongS , ErikssonH , MismettiP , et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation2014;129:764-72. SchulmanS . A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II). Blood2011;118(21):95-6. ">RE‐COVER II 2014</a>; <a href="./references#CD010956-bbs2-0021" title="FiessingerJN , HuismanMV , DavidsonBL , BounameauxH , FrancisCW , ErikssonH , et al. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomised trial. JAMA2005;293(6):681-9. FrancisCW , GinsbergJS , BerkowitzSD , BounameauxH , DavidsonBL , ErikssonH , et al. Efficacy and safety of the oral direct thrombin inhibitor ximelagatran compared with current therapy for acute, symptomatic deep vein thrombosis, with or without pulmonary embolus: the THRIVE treatment study. Blood2003;102(11):Abstract 7. HarenbergJ , IngridJ , TivadarF . Treatment of venous thromboembolism with the oral thrombin inhibitor, ximelagatran. Israel Medical Association Journal2002;4(11):1003-5. HarenbergJ , JoergI , WeissC . Incidence of recurrent venous thromboembolism of patients after termination of treatment with ximelagatran. European Journal of Clinical Pharmacology2006;62(3):173-7. HarenbergJ , JorgI , WeissC , HarenbergJ , JorgI , WeissC . Observations of alanine aminotransferase and aspartate aminotransferase in THRIVE studies treated orally with ximelagatran. International Journal of Toxicology2006;25(3):165-9. HuismanMV , The THRIVE Treatment Study Investigators. Efficacy and safety of the oral direct thrombin inhibitor ximelagatran compared with current standard therapy for acute symptomatic deep vein thrombosis, with or without pulmonary embolism: a randomized, double-blind, multinational study. Journal of Thrombosis and Haemostasis2003;1(Suppl 1):Abstract OC003. WimperisJ , FiessingerJN , HuismanMV , DavidsonBL , BounameauxH , FrancisCW , et al. Ximelagatran, an oral direct thrombin inhibitor, compared with current standard therapy for acute, symptomatic deep vein thrombosis, with or without pulmonary embolism: the THRIVE treatment study. British Journal of Haematology2004;125(Suppl 1):66. ">THRIVE 2005</a>). We rated a further five studies that either did not blind outcome assessors or reported insufficient information on this to be at low risk of detection bias, as a lack of blinding was unlikely to have affected the objective outcome (<a href="./references#CD010956-bbs2-0009" title="PiazzaG , ManiV , GoldhaberSZ , GrossoMA , MercuriM , LanzHJ , et al. Magnetic resonance venography to assess thrombus resolution with edoxaban monotherapy versus parenteral anticoagulation/warfarin for symptomatic deep vein thrombosis: a multicenter feasibility study. Vascular Medicine2016;21(4):361-8. PiazzaG , ManiV , GrossoM , MercuriM , LanzH , SchusslerS , et al. A randomized, open-label, multicenter study of the efficacy and safety of edoxaban monotherapy versus low-molecular weight heparin/warfarin in patients with symptomatic deep vein thrombosis-edoxaban thrombus reduction imaging study (etris). Circulation2014;130:A12074. ">eTRIS 2016</a>; <a href="./references#CD010956-bbs2-0010" title="FarhanA , BukhariM , UmarJ , RazaMA . Oral rivaroxaban in symptomatic deep vein thrombosis. Journal of the College of Physicians and Surgeons Pakistan2019;29(9):814-8. ">Farhan 2019</a>; <a href="./references#CD010956-bbs2-0017" title="Kang JiM, ParkKH , AhnS , ChoS , MinSK . Rivaroxaban after thrombolysis in acute iliofemoral venous thrombosis: a randomized, open-labeled, multicenter trial. Scientific Reports2019;9(1):20356. MinSK , AhnS , ParkKH , KangJM , KimJY . Prevention of recurrence after thrombolysis in acute iliofemoral venous thrombosis with rivaroxaban (Prais Study): a prospective, randomized, open label, multicenter trial. European Journal of Vascular and Endovascular Surgery2019;58(6):e516. NCT01986192. Prevention of recurrence after thrombolysis in acute iliofemoral venous thrombosis (PRAIS) study. clinicaltrials.gov/show/NCT01986192 (first received 18 November 2013). ">PRAIS 2019</a>; <a href="./references#CD010956-bbs2-0014" title="MokademME , HassanA , AlgabyAZ . Efficacy and safety of apixaban in patients with active malignancy and acute deep venous thrombosis. Vascular2021;29(5):745-50. NCT04462003. Efficacy of apixaban in malignancy with deep venous thrombosis (DVT). clinicaltrials.gov/ct2/show/NCT04462003 (first received 3 July 2019). ">Mokadem 2021</a>; <a href="./references#CD010956-bbs2-0016" title="OhmoriH , KadaA , NakamuraM , SaitoAM , SanayamaY , ShinagawaT , et al. Deep vein thrombosis in severe motor and intellectual disabilities patients and its treatment by anticoagulants of warfarin versus edoxaban. Annals of Vascular Diseases2019;12(3):372-8. OhmoriH , NakamuraM , KadaA , SaitoAM , SanayamaY , ShinagawaT , et al. Multicenter, open-label, randomized controlled trial of warfarin and edoxaban tosilate hydrate for the treatment of deep vein thrombosis in persons with severe motor intellectual disabilities. Kurume Medical Journal2018;65(1):11-6. ">Ohmori 2019</a>). The <a href="./references#CD010956-bbs2-0005" title="NCT02704598. Comparison between xarelto versus warfarin in the recanalization rate of deep venous thrombosis in patients legs. (DVT). clinicaltrials.gov/ct2/show/NCT02704598 (first received 10 March 2016). deAthayde SoaresR , MatieloMF , Brochado NetoFC , AlmeidaRD , SacilottoR . LEV 2. Comparison of the recanalization rate and post-thrombotic syndrome in patients with deep venous thrombosis treated with rivaroxaban or warfarin. Journal of Vascular Surgery2019;70(5):e169-e170. deAthayde SoaresR , MatieloMF , Brochado NetoFC , NogueiraMP , AlmeidaRD , SacilottoR . Comparison of the recanalization rate and postthrombotic syndrome in patients with deep venous thrombosis treated with rivaroxaban or warfarin. Surgery2019;166(6):1076-83. ">de Athayde 2019</a> study blinded the physician responsible for data assessment; however, the PTS score included participants' self‐reported domains, so we judged this study to have an unclear risk of detection bias. The <a href="./references#CD010956-bbs2-0020" title="SukovatykhBS , SereditskiĭAV , MuradianVF , BelikovLN , GerasimovaOF . Results of administering oral anticoagulants for treatment of patients with venous thromboembolic complications. Angiologiia i sosudistaia khirurgiia [Angiology and Vascular Surgery]2017;23(2):82. ">Sukovatykh 2017</a> study did not provide enough information for an assessment of detection bias to be made so we also judged it to be at an unclear risk of detection bias. </p> </section> <section id="CD010956-sec-0057"> <h4 class="title">Incomplete outcome data</h4> <p>Seventeen studies sufficiently reported missing outcome data and were balanced across treatment groups. Therefore, we judged these studies to be at low risk of attrition bias (<a href="./references#CD010956-bbs2-0002" title="NakamuraM , NishikawaM , KomuroI , KitajimaI , UetsukaY , YamagamiT , et al. Apixaban for the treatment of Japanese subjects with acute venous thromboembolism (AMPLIFY-J Study). Circulation2015;79(6):1230–36. ">AMPLIFY‐J 2015</a>; <a href="./references#CD010956-bbs2-0003" title="BarrettYC , WangJ , KnabbR , MohanP . Apixaban decreases coagulation activity in patients with acute deep-vein thrombosis. Thrombosis and Haemostasis2011;105:181-9. Botticelli Investigators Writing Committee, BullerH , DeitchmanD , PrinsM , SegersA . Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. Journal of Thrombosis and Haemostasis2008;6:1313-8. BullerHR . A dose finding study of the oral direct factor Xa inhibitor apixaban in the treatment of patients with acute symptomatic deep vein thrombosis - the Botticelli Investigators. Journal of Thrombosis and Haemostasis2007;5 (Suppl 2):O-S-003. NCT00252005. Oral direct factor Xa-inhibitor apixaban in patients with acute symptomatic deep-vein thrombosis - the Botticelli DVT study. clinicaltrials.gov/ct/show/NCT00252005?order=1 (first received 11 November 2005). ">Botticelli DVT 2008</a>; <a href="./references#CD010956-bbs2-0004" title="AgenoW , VedovatiMC , CohenA , HuismanM , BauersachsR , GussoniG , et al. Bleeding with apixaban and dalteparin in patients with cancer-associated venous thromboembolism: results from the Caravaggio study. Thrombosis and Haemostasis2021;121(5):616-24. AgnelliG , BecattiniC , BauersachsR , BrennerB , CampaniniM , CohenA , et al. Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the Caravaggio study. Thrombosis and Haemostasis2018;118(9):1668-78. AgnelliG , BecattiniC , MeyerG , MuozA , VersoM . Apixaban for the treatment of venous thromboembolism associated with cancer. New England Journal of Medicine2020;382(17):1599-607. AgnelliG , MuozA , FrancoL , MahéI , BrennerB , ConnorsJM , et al. Apixaban and dalteparin for the treatment of venous thromboembolism in patients with different sites of cancer. Thrombosis and Haemostasis2022;122(5):796-807. BecattiniC , BauersachsR , MarazitiG , BertolettiL , CohenA , ConnorsJM , et al. Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial. Haematologica2021;107(7):1567-76. GiustozziM , ConnorsJM , Ruperez BlancoAB , SzmitS , FalvoN , CohenAT , et al. Clinical characteristics and outcomes of incidental venous thromboembolism in cancer patients: insights from the Caravaggio study. Journal of Thrombosis and Haemostasis2021;19(11):2751-9. NCT03045406. Apixaban for the treatment of venous thromboembolism in patients with cancer (CARAVAGGIO). clinicaltrials.gov/ct2/show/NCT03045406 (first received 7 February 2017). VersoM , MunozA , BauersachsR , HuismanMV , AgnelliG . Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism. European Journal of Cancer2021;148(Suppl C):371-81. ">Caravaggio 2020</a>; <a href="./references#CD010956-bbs2-0005" title="NCT02704598. Comparison between xarelto versus warfarin in the recanalization rate of deep venous thrombosis in patients legs. (DVT). clinicaltrials.gov/ct2/show/NCT02704598 (first received 10 March 2016). deAthayde SoaresR , MatieloMF , Brochado NetoFC , AlmeidaRD , SacilottoR . LEV 2. Comparison of the recanalization rate and post-thrombotic syndrome in patients with deep venous thrombosis treated with rivaroxaban or warfarin. Journal of Vascular Surgery2019;70(5):e169-e170. deAthayde SoaresR , MatieloMF , Brochado NetoFC , NogueiraMP , AlmeidaRD , SacilottoR . Comparison of the recanalization rate and postthrombotic syndrome in patients with deep venous thrombosis treated with rivaroxaban or warfarin. Surgery2019;166(6):1076-83. ">de Athayde 2019</a>; <a href="./references#CD010956-bbs2-0007" title="BullerH , DariusH . EINSTEIN DVT: oral rivaroxaban versus standard therapy in the initial treatment of symptomatic deep vein thrombosis and long-term prevention of recurrent venous thromboembolism. escardio.org/The-ESC/Press-Office/Press-releases/EINSTEIN-DVT-Oral-rivaroxaban-versus-standard-therapy-in-the-initial-treatment (accessed 19 October 2022). BullerHR , AgnelliG . Once- or twice-daily rivaroxaban for the treatment of proximal deep vein thrombosis: similar efficacy and safety to standard therapy in dose-ranging studies. Blood2006;108(11 Part 1):172-3. BullerHR , LensingAW , PrinsMH , AgnelliG , CohenA , GallusAS , et al. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT dose-ranging study. Blood2008;112(6):2242-7. NCT00395772. Once-daily oral direct factor Xa inhibitor BAY59-7939 in patients with acute symptomatic deep-vein thrombosis. clinicaltrials.gov/ct2/show/NCT00395772?term=einstein-dvt&amp;rank=2 (first received 3 November 2006). ">EINSTEIN‐DVT dose 2008</a>; <a href="./references#CD010956-bbs2-0006" title="BamberL , WangMY , PrinsMH , CiniglioC , BauersachsR , LensingAW , et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis. Thrombosis and Haemostasis2013;110(4):732-41. BauersachsR , LensingAW , PapA , DecoususH . No need for a rivaroxaban dose reduction in renally impaired patients with symptomatic venous thromboembolism. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):30-1. BistervelsI , GebelM , LensingA , MiddeldorpS , CoppensM . Effect of polypharmacy on bleeding of rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolism. Research and Practice in Thrombosis and Haemostasis2019;3:798‐9. BookhartBK , HaskellL , BamberL , WangM , ScheinJ , ModySH . Length of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial program. Journal of Medical Economics2014;17(10):691-5. BullerHR . Oral rivaroxaban for the acute and continued treatment of symptomatic venous thromboembolism. The Einstein-DVT and Einstein-Extension study. Blood2010;116(21):187. CheungW , MiddeldorpS , PrinsMP , PapAF , LensingAW , Hoek-tenCA , et al. Post thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep vein thrombosis. Journal of Thrombosis and Haemostasis2015;13(S2):219-20. CheungYW , MiddeldorpS , PrinsMH , PapAF , PrandoniP . Post-thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep-vein thrombosis. A post-hoc analysis. Thrombosis and Haemostasis2016;116(4):733-8. EUCTR2004-002171-16-IT. Once-daily oral direct factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis. The EINSTEIN-DVT dose-finding study. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2004%E2%80%90002171%E2%80%9016%E2%80%90IT (first received 15 October 2008). EUCTR2006-004495-13-DK. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep-vein thrombosis or pulmonary embolism. trialsearch.who.int/?TrialID=EUCTR2006-004495-13-DK (first received 29 March 2007). EerenbergES , MiddeldorpS , LeviM , LensingAW , BüllerHR . Clinical impact and course of major bleeding with rivaroxaban and vitamin K antagonists. Journal of Thrombosis and Haemostasis2015;13(9):1590-6. KlineJA , JimenezD , CourtneyDM , IanusJ , CaoL , WellsPS . Use of the Riete 2008 bleeding score to identify patients at low risk for major bleeding in patients treated with rivaroxaban. Academic Emergency Medicine2015;22:S162. NCT00440193. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep vein thrombosis - The EINSTEIN DVT Study. clinicaltrials.gov/ct2/show/NCT00440193 (first received 26 February 2007). PrinsMH , ErkensPG , LensingAW . Incidence of recurrent venous thromboembolism in patients following completion of the EINSTEIN DVT and EINSTEIN PE studies. Journal of Thrombosis and Haemostasis2013;11(Suppl):257. PrinsMH , LensingAW , BauersachsR , Van BellenB , BounameauxH , BrightonTA , et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thrombosis Journal2013;11(1):21. The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. New England Journal of Medicine2010;363(26):2499-510. Van BellenB , PrinsM , BamberL , WangM , LensingAW . Reduction in initial length of stay with rivaroxaban single-drug regimen versus LMWH-VKA standard of care: findings from the EINSTEIN trial program. Blood2012;120(21):3419. Van BellenB , PrinsM , BamberL , WangM , LensingAW . Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism. Current Medical Research and Opinion2014;30(5):829-37. WangY , WangC , ChenZ , ZhangJ , LiuZ , JinB , et al. Rivaroxaban for the treatment of symptomatic deep vein thrombosis and/or pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):694. WangY , WangC , ChenZ , ZhangJ , LiuZ , JinB , et al. Rivaroxaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Thrombosis Journal2013;11(1):25. ">EINSTEIN‐DVT 2010</a>; <a href="./references#CD010956-bbs2-0008" title="BullerHR , PrinsMH , LensinAW , DecoususH , JacobsonBF , MinarE , et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. New England Journal of Medicine2012;366:1287-97. FermannGJ , Erkens Pmg, PrinsMH , WellsPS , Pap ÁF, LensingAW , et al. Treatment of pulmonary embolism with rivaroxaban: outcomes by simplified pulmonary embolism severity index score from a post hoc analysis of the EINSTEIN PE study. Academic Emergency Medicine2015;22(3):299-307. NCT00439777. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic pulmonary embolism with or without symptomatic deep-vein thrombosis: Einstein-PE evaluation, 2008. clinicaltrials.gov/ct2/show/NCT00439777?term=NCT00439777&amp;rank=1 (first received 26 February 2007). PrinsM , BamberL , CanoS , WangM , LensingAW , BauersachsR . Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic pulmonary embolism. Blood2012;120(21):1163. PrinsMH , BamberL , CanoSJ , WangMY , ErkensP , BauersachsR , et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial. Thrombosis Research2015;135(2):281-8. ">EINSTEIN‐PE 2012</a>; <a href="./references#CD010956-bbs2-0012" title="AmayaN , UzuiH , HisazakiK , HasegwaK , KasenoK , TadaH . Edoxaban normalizes the elevated D-dimer levels potently and promptly in patients with venous thromboembolisms: a comparison with traditional anticoagulant therapy. European Heart Journal2016;37:278. BoschFT , Van EsN , Di NisioM , CarrierM , SegersA , GrossoMA , et al. The Ottawa score does not predict recurrent venous thromboembolism in cancer patients: results from the Hokusai-VTE cancer study. Research and Practice in Thrombosis and Haemostasis2019;3(S1):717-8. KraaijpoelN , Di NisioM , MulderFI , Van EsN , RaskobGE . Clinical impact of bleeding in cancer-associated venous thromboembolism: results from the Hokusai VTE Cancer randomized trial. Thrombosis Research2018;164(Suppl 1):S223. [DOI: 10.1016/j.thromres.2018.02.094]MulderFI , Di NisioM , AyC , CarrierM , BoschFT , SegersA , et al. Clinical implications of incidental venous thromboembolism in cancer patients. European Respiratory Journal2020;55(2):1901697. [DOI: 10.1183/13993003.01697-2019]MulderFI , Van EsN , KraaijpoelN , Di NisioM , CarrierM , GarciaD , et al. Efficacy and safety of edoxaban in clinically relevant subgroups: results from the Hokusai VTE Cancer randomized trial. Thrombosis Research2018;164:S194. NCT02073682. Cancer venous thromboembolism (VTE). clinicaltrials.gov/ct2/show/NCT02073682 (first received 27 February 2014). RaskobG , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaD , et al. Edoxaban versus dalteparin for treatment of venous thromboembolism (VTE) associated with cancer: Hokusai VTE-cancer randomized trial. Supportive Care in Cancer2018;26(2):S316-S317. RaskobGE , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaD , et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. New England Journal of Medicine2018;378(7):615-24. RaskobGE , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaDA , et al. A randomized, open-label, blinded outcome assessment trial evaluating the efficacy and safety of LMWH/Edoxaban versus dalteparin for venous thromboembolism associated with cancer: Hokusai VTE-cancer study. Blood2017;130(Suppl 1):LBA-6. ">Hokusai VTE Cancer 2018</a>; <a href="./references#CD010956-bbs2-0011" title="BistervelsI , BavaliaR , BoersmaW , MeijerK , VerhammeP , Ten Cate-HoekAJ , et al. Hokusai Post-DVT Study: a follow-up study on long-term outcomes of deep vein thrombosis in patients treated with edoxaban vs warfarin. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):PB2207. BrekelmansMP , AgenoW , BeenenLF , BrennerB , BullerHR , ChenCZ , et al. Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology2016;3(9):e437-45. BrekelmansMP , BlekerSM , BauersachsR , BodaZ , BüllerHR , ChoiY , et al. Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists. Thrombosis and Haemostasis2016;116(1):155-61. Di NisioM , Van EsN , CarrierM , WangTF , GarciaD , SegersA , et al. Extended treatment with edoxaban in cancer patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE Cancer study. Journal of Thrombosis and Haemostasis2019;17:1866–74. EUCTR2009-014290-40-SE. A phase 3, randomized, double-blind, double-dummy, parallel group, multi-center, multi-national study for evaluation of efficacy and safety of DU-176b versus warfarin in subjects with atrial fibrillation - effective anticoagulation with factor Xa next generation in atrial fibrillation (ENGAGE-AF TIMI-48). trialsearch.who.int/?trialid=EUCTR2009-014290-40-SE (first received 30 November 2009). EichingerS , LinM , KyrlePA , GrossoMA . Recurrent venous thromboembolism during anticoagulation: an investigator-initiated post-hoc analysis of the hokusai-VTE trial. Blood2018;132:2539. KlokFA , BarcoS , KonstantinidesSV . External validation of the VTE-BLEED score for predicting major bleeding in stable anticoagulated patients with venous thromboembolism. Thrombosis and Haemostasis2017;117(6):1164-70. KraaijpoelN , Van EsN , RaskobGE , BüllerHR , CarrierM , ZhangG , et al. Risk scores for occult cancer in patients with venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2018;118(7):1270-8. MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMP , ChenCZ , et al. Outpatient management in patients with venous thromboembolism with edoxaban: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2017;117(12):2406-14. MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMP , ChenCZ , et al. Safety and efficacy of edoxaban compared with warfarin for the treatment of acute symptomatic deep-vein thrombosis in the outpatient setting. Research and Practice in Thrombosis and Haemostasis2017;1:913. MulderFI , Van EsN , KraaijpoelN , Di NisioM , CarrierM , DuggalA , et al. Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: results from the Hokusai VTE Cancer study. Thrombosis Research2020;185:13-9. NCT00986154. Comparative investigation of Low Molecular Weight (LMW) heparin/edoxaban tosylate (DU176b) versus (LMW) heparin/warfarin in the treatment of symptomatic deep-vein blood clots and/or lung blood clots. (The Edoxaban Hokusai-VTE Study). clinicaltrials.gov/ct2/show/NCT00986154 (first received 29 September 2009). NakamuraM , WangYQ , WangC , OhD , YinWH , KimuraT , et al. Efficacy and safety of edoxaban for treatment of venous thromboembolism: a subanalysis of East Asian patients in the Hokusai-VTE trial. Journal of Thrombosis and Haemostasis2015;13(9):1606-14. NybergJ , KarlssonKE , JönssonS , YinO , MillerR , KarlssonMO , et al. Edoxaban exposure-response analysis and clinical utility index assessment in patients with symptomatic deep-vein thrombosis or pulmonary embolism. CPT Pharmacometrics and Systems Pharmacology2016;5(4):222-32. RaskobG , AgenoW , CohenAT , BrekelmansMP , GrossoMA , SegersA , et al. Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology2016;3(5):e228-e236. RaskobG , BullerH , PrinsM , SegersA , ShiM , SchwochoL , et al. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study - methodological implications for clinical trials. Journal of Thrombosis and Haemostasis2013;11(7):1287-94. RaskobGE , BullerH , AngchaisuksiriP , OhD , BodaZ , LyonsRM , et al. Edoxaban for long-term treatment of venous thromboembolism in cancer patients. Blood2013;122(21):211. RaskobGE , Van EsN , SegersA , AngchaisuksiriP , OhD , BodaZ , et al. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematology2016;3(8):e379-87. ScheresLJ , BrekelmansMA , WalterA , CihanA , BüllerHR , SabineE , et al. Abnormal vaginal bleeding in women of reproductive age treated with edoxaban or warfarin for venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. British Journal of Obstetrics and Gynaecology2018;125(12):1581-9. The Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. New England Journal of Medicine2013;369(15):1406-15. VanasscheT , VerhammeP , WellsPS , SegersA , AgenoW , BrekelmansMP , et al. Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: an analysis of the randomized, double-blind Hokusai-VTE trial. Thrombosis Research2018;162:7-14. VerhammeP , WellsPS , SegersA , AgenoW , BrekelmansMP , CohenAT , et al. Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial. Thrombosis and Haemostasis2016;116(4):747-53. ">Hokusai‐VTE 2013</a>; <a href="./references#CD010956-bbs2-0013" title="MatsuoH , PrinsM , LensingAW , FujinumaEW , MiyamotoY , KajikawaM . Shortened length of hospital stay with rivaroxaban in patients with symptomatic venous thromboembolism in Japan: the J-EINSTEIN pulmonary embolism and deep vein thrombosis program. Current Medical Research and Opinion2015;31(6):1057-61. NCT01516814. Venous thromboembolism (VTE) treatment study in Japanese pulmonary embolism (PE) patients. clinicaltrials.gov/ct2/show/NCT01516814 (first received 25 January 2012). YamadaN , HirayamaA , MaedaH , SakagamiS , ShikataH , PrinsMH , et al. Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism-the J-EINSTEIN DVT and PE program. Thrombosis Journal2015;13:2. ">J‐EINSTEIN DVT and PE 2015</a>; <a href="./references#CD010956-bbs2-0014" title="MokademME , HassanA , AlgabyAZ . Efficacy and safety of apixaban in patients with active malignancy and acute deep venous thrombosis. Vascular2021;29(5):745-50. NCT04462003. Efficacy of apixaban in malignancy with deep venous thrombosis (DVT). clinicaltrials.gov/ct2/show/NCT04462003 (first received 3 July 2019). ">Mokadem 2021</a>; <a href="./references#CD010956-bbs2-0015" title="AgnelliG , GallusA , GoldhaberSZ , HaasS , HuismanMV , HullRD , et al. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAT 59-7939 in patients with acute symptomatic deep-vein thrombosis) study. Circulation2007;116:180-7. ">ODIXa‐DVT 2007</a>; <a href="./references#CD010956-bbs2-0017" title="Kang JiM, ParkKH , AhnS , ChoS , MinSK . Rivaroxaban after thrombolysis in acute iliofemoral venous thrombosis: a randomized, open-labeled, multicenter trial. Scientific Reports2019;9(1):20356. MinSK , AhnS , ParkKH , KangJM , KimJY . Prevention of recurrence after thrombolysis in acute iliofemoral venous thrombosis with rivaroxaban (Prais Study): a prospective, randomized, open label, multicenter trial. European Journal of Vascular and Endovascular Surgery2019;58(6):e516. NCT01986192. Prevention of recurrence after thrombolysis in acute iliofemoral venous thrombosis (PRAIS) study. clinicaltrials.gov/show/NCT01986192 (first received 18 November 2013). ">PRAIS 2019</a>; <a href="./references#CD010956-bbs2-0018" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00291330. Efficacy and safety of dabigatran compared to warfarin for 6 month treatment of acute symptomatic venous thromboembolism (RE-COVER I). clinicaltrials.gov/ct/show/NCT00291330 (first received 14 February 2006). SchulmanS , ErikssonH , GoldhaberS , KakkarAK , KearonC , KvammeAM , et al. Dabigatran or warfarin for extended maintenance therapy of venous thromboembolism. Journal of Thrombosis and Haemostasis2011;9(Suppl 2):731-2. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-COVER and RE-COVER II. Blood2013;122:2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RECOVER II. Blood2013;122(21):212. SchulmanS , ErikssonH , GoldhaverSZ , KakkarA , KearonC , MismettiP , et al. Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130:A18594. SchulmanS , KearonC , KakkarAK , MismettiP , SchellongS , ErikssonH , et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. New England Journal of Medicine2009;361(24):2342-52. ">RE‐COVER 2009</a>; <a href="./references#CD010956-bbs2-0019" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00680186. Phase III study testing efficacy &amp; safety of oral dabigatran etexilate vs warfarin for 6 m treatment for acute symp venous thromboembolism (VTE) (RE-COVER II). clinicaltrials.gov/ct2/show/NCT00680186 (first received 20 May 2008). SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-COVER and RE-COVER II. Blood2013;122:2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RECOVER II. Blood2013;122(21):212. SchulmanS , ErikssonH , GoldhaverSZ , KakkarA , KearonC , MismettiP , et al. Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130:A18594. SchulmanS , KakkarAK , GoldhaberSZ , SchellongS , ErikssonH , MismettiP , et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation2014;129:764-72. SchulmanS . A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II). Blood2011;118(21):95-6. ">RE‐COVER II 2014</a>; <a href="./references#CD010956-bbs2-0020" title="SukovatykhBS , SereditskiĭAV , MuradianVF , BelikovLN , GerasimovaOF . Results of administering oral anticoagulants for treatment of patients with venous thromboembolic complications. Angiologiia i sosudistaia khirurgiia [Angiology and Vascular Surgery]2017;23(2):82. ">Sukovatykh 2017</a>; <a href="./references#CD010956-bbs2-0021" title="FiessingerJN , HuismanMV , DavidsonBL , BounameauxH , FrancisCW , ErikssonH , et al. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomised trial. JAMA2005;293(6):681-9. FrancisCW , GinsbergJS , BerkowitzSD , BounameauxH , DavidsonBL , ErikssonH , et al. Efficacy and safety of the oral direct thrombin inhibitor ximelagatran compared with current therapy for acute, symptomatic deep vein thrombosis, with or without pulmonary embolus: the THRIVE treatment study. Blood2003;102(11):Abstract 7. HarenbergJ , IngridJ , TivadarF . Treatment of venous thromboembolism with the oral thrombin inhibitor, ximelagatran. Israel Medical Association Journal2002;4(11):1003-5. HarenbergJ , JoergI , WeissC . Incidence of recurrent venous thromboembolism of patients after termination of treatment with ximelagatran. European Journal of Clinical Pharmacology2006;62(3):173-7. HarenbergJ , JorgI , WeissC , HarenbergJ , JorgI , WeissC . Observations of alanine aminotransferase and aspartate aminotransferase in THRIVE studies treated orally with ximelagatran. International Journal of Toxicology2006;25(3):165-9. HuismanMV , The THRIVE Treatment Study Investigators. Efficacy and safety of the oral direct thrombin inhibitor ximelagatran compared with current standard therapy for acute symptomatic deep vein thrombosis, with or without pulmonary embolism: a randomized, double-blind, multinational study. Journal of Thrombosis and Haemostasis2003;1(Suppl 1):Abstract OC003. WimperisJ , FiessingerJN , HuismanMV , DavidsonBL , BounameauxH , FrancisCW , et al. Ximelagatran, an oral direct thrombin inhibitor, compared with current standard therapy for acute, symptomatic deep vein thrombosis, with or without pulmonary embolism: the THRIVE treatment study. British Journal of Haematology2004;125(Suppl 1):66. ">THRIVE 2005</a>). The <a href="./references#CD010956-bbs2-0001" title="AgnelliG , BullerH , MasiukiewiczUP . Apixaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism: a randomized, double-blind trial (AMPLIFY). Journal of Thrombosis and Haemostasis2013;11:18. AgnelliG , BullerHR , CohenA , CurtoD , GallusAS , JohnsonM , et al. Oral apixaban for the treatment of acute venous thromboembolism. New England Journal of Medicine2013;369:799-808. AgnelliG , BullerHR , CohenA , CurtoM , GallusAS , PakR , et al. Apixaban for the treatment of venous thromboembolism in cancer patients: data from the AMPLIFY trial. Canadian Journal of Cardiology2014;30(10 Suppl 1):S278. AgnelliG , BullerHR , CohenA , GallusAS , LeeTC , PakR , et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. Journal of Thrombosis and Haemostasis2015;13(12):2187-91. AgnelliG . Apixaban was non-inferior to enoxaparin plus warfarin in patients with acute venous thromboembolism. Annals of Internal Medicine2013;159(8):JC2. BlekerSM , CohenAT , BüllerHR , AgnelliG , GallusAS , RaskobGE , et al. Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Thrombosis and Haemostasis2016;116(6):159-64. BrekelmansM , ScheresL , BlekerS , HuttenB , TimmermansA , BüllerH , et al. Abnormal vaginal bleeding in women with venous thromboembolism treated with apixaban or warfarin. Thrombosis and Haemostasis2017;117(04):809-15. CohenA , AgnelliG , BullerH , GallusA , RaskobG , SandersP , et al. Characteristics and outcomes in patients with venous thromboembolism taking concomitant anti-platelet agents and anticoagulants in the AMPLIFY Trial. Thrombosis and Haemostasis2019;119(3):461-6. CohenA , AgnelliG , BullerHR , ChaudhuriS , GallusAS , RaskobGE , et al. Analysis of the bleeding and thromboembolic risk with concomitant use of antiplatelet treatment in the AMPLIFY trial. Canadian Journal of Cardiology2014;30(10):S272. CohenA , GallusAS , AgnelliG , BullerHR , PakR , PorcariAR , et al. Time in Therapeutic Range (TTR) and relative efficacy and safety of treatment with apixaban or enoxaparin/warfarin for acute symptomatic venous thromboembolism: an analysis of the Amplify trial data. Blood2014;124(21):1543. CohenAT , PanS , ByonW , IlyasBS , LeeTC . Efficacy, safety, and exposure of apixaban in patients with high body weight or obesity and venous thromboembolism: insights from AMPLIFY. Advances in Therapy2021;38(6):3003-18. EUCTR2007-007867-25-PT. A safety and efficacy trial evaluating the use of apixaban in the treatment of symptomatic deep vein thrombosis and pulmonary embolism revised protocol number: 01, incorporates amendment(s) 02 + protocol amendment 01 (version 1.0 dated 21-Apr-08) site-specific - molecular profiling supplement samples for Pfizer’s exploratory research biobank. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2007%E2%80%90007867%E2%80%9025%E2%80%90PT (first received 14 July 2008). GallusAS , AgnelliG , BullerHR , CohenA , LeeTC , PakR , et al. Apixaban for treatment of venous thromboembolism in patients from study centres in Asia: a subgroup analysis of the Amplify trial. Journal of Thrombosis and Haemostasis2015;13:727. LeeT , PanS , ByonW , IlyasBS . Safety and efficacy of apixaban versus enoxaparin/warfarin in patients with extremes of body weight: post-hoc analysis of the AMPLIFY trial. Blood2019;134(Suppl 1):1152. LiuX , JohnsonM , MardekianJ , PhatakH , ThompsonJ , CohenAT . Apixaban reduces hospitalizations in patients with venous thromboembolism: an analysis of the apixaban for the Initial management of pulmonary embolism and deep‐vein thrombosis as first‐line therapy (AMPLIFY) trial. Journal of the American Heart Association2015;4(12):e002340. NCT00633893. Efficacy and safety study of apixaban for extended treatment of deep vein thrombosis or pulmonary embolism. clinicaltrials.gov/ct2/show/NCT00633893?term=ajax&amp;rank=5 (first received 12 March 2008). NCT00643201. Efficacy and safety study of apixaban for the treatment of deep vein thrombosis or pulmonary embolism. clinicaltrials.gov/ct2/show/NCT00643201 (first received 26 March 2008). RaskobGE , GallusAS , SandersP , ThompsonJR , AgnelliG , BullerHR , et al. Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy: a sub-analysis of the AMPLIFY trial. Thrombosis and Haemostasis2016;115(4):809-16. ">AMPLIFY 2013</a> inappropriately excluded a number of randomised participants from the intention‐to‐treat analysis. Furthermore, a large number of participants within each treatment group were classified as discontinuing the study for "other reasons" with no explanation given. We therefore deemed this study to be at high risk of attrition bias. We also judged the risk of attrition bias as high for the <a href="./references#CD010956-bbs2-0009" title="PiazzaG , ManiV , GoldhaberSZ , GrossoMA , MercuriM , LanzHJ , et al. Magnetic resonance venography to assess thrombus resolution with edoxaban monotherapy versus parenteral anticoagulation/warfarin for symptomatic deep vein thrombosis: a multicenter feasibility study. Vascular Medicine2016;21(4):361-8. PiazzaG , ManiV , GrossoM , MercuriM , LanzH , SchusslerS , et al. A randomized, open-label, multicenter study of the efficacy and safety of edoxaban monotherapy versus low-molecular weight heparin/warfarin in patients with symptomatic deep vein thrombosis-edoxaban thrombus reduction imaging study (etris). Circulation2014;130:A12074. ">eTRIS 2016</a>, <a href="./references#CD010956-bbs2-0010" title="FarhanA , BukhariM , UmarJ , RazaMA . Oral rivaroxaban in symptomatic deep vein thrombosis. Journal of the College of Physicians and Surgeons Pakistan2019;29(9):814-8. ">Farhan 2019</a> and <a href="./references#CD010956-bbs2-0016" title="OhmoriH , KadaA , NakamuraM , SaitoAM , SanayamaY , ShinagawaT , et al. Deep vein thrombosis in severe motor and intellectual disabilities patients and its treatment by anticoagulants of warfarin versus edoxaban. Annals of Vascular Diseases2019;12(3):372-8. OhmoriH , NakamuraM , KadaA , SaitoAM , SanayamaY , ShinagawaT , et al. Multicenter, open-label, randomized controlled trial of warfarin and edoxaban tosilate hydrate for the treatment of deep vein thrombosis in persons with severe motor intellectual disabilities. Kurume Medical Journal2018;65(1):11-6. ">Ohmori 2019</a> studies, as they all lost more than 20% of participants and did not clarify if the loss was balanced across groups. </p> </section> <section id="CD010956-sec-0058"> <h4 class="title">Selective reporting</h4> <p>Sixteen studies clearly stated and reported their pre‐specified outcomes and, therefore, we judged these to be at low risk of reporting bias (<a href="./references#CD010956-bbs2-0002" title="NakamuraM , NishikawaM , KomuroI , KitajimaI , UetsukaY , YamagamiT , et al. Apixaban for the treatment of Japanese subjects with acute venous thromboembolism (AMPLIFY-J Study). Circulation2015;79(6):1230–36. ">AMPLIFY‐J 2015</a>; <a href="./references#CD010956-bbs2-0003" title="BarrettYC , WangJ , KnabbR , MohanP . Apixaban decreases coagulation activity in patients with acute deep-vein thrombosis. Thrombosis and Haemostasis2011;105:181-9. Botticelli Investigators Writing Committee, BullerH , DeitchmanD , PrinsM , SegersA . Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. Journal of Thrombosis and Haemostasis2008;6:1313-8. BullerHR . A dose finding study of the oral direct factor Xa inhibitor apixaban in the treatment of patients with acute symptomatic deep vein thrombosis - the Botticelli Investigators. Journal of Thrombosis and Haemostasis2007;5 (Suppl 2):O-S-003. NCT00252005. Oral direct factor Xa-inhibitor apixaban in patients with acute symptomatic deep-vein thrombosis - the Botticelli DVT study. clinicaltrials.gov/ct/show/NCT00252005?order=1 (first received 11 November 2005). ">Botticelli DVT 2008</a>; <a href="./references#CD010956-bbs2-0007" title="BullerH , DariusH . EINSTEIN DVT: oral rivaroxaban versus standard therapy in the initial treatment of symptomatic deep vein thrombosis and long-term prevention of recurrent venous thromboembolism. escardio.org/The-ESC/Press-Office/Press-releases/EINSTEIN-DVT-Oral-rivaroxaban-versus-standard-therapy-in-the-initial-treatment (accessed 19 October 2022). BullerHR , AgnelliG . Once- or twice-daily rivaroxaban for the treatment of proximal deep vein thrombosis: similar efficacy and safety to standard therapy in dose-ranging studies. Blood2006;108(11 Part 1):172-3. BullerHR , LensingAW , PrinsMH , AgnelliG , CohenA , GallusAS , et al. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT dose-ranging study. Blood2008;112(6):2242-7. NCT00395772. Once-daily oral direct factor Xa inhibitor BAY59-7939 in patients with acute symptomatic deep-vein thrombosis. clinicaltrials.gov/ct2/show/NCT00395772?term=einstein-dvt&amp;rank=2 (first received 3 November 2006). ">EINSTEIN‐DVT dose 2008</a>; <a href="./references#CD010956-bbs2-0006" title="BamberL , WangMY , PrinsMH , CiniglioC , BauersachsR , LensingAW , et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis. Thrombosis and Haemostasis2013;110(4):732-41. BauersachsR , LensingAW , PapA , DecoususH . No need for a rivaroxaban dose reduction in renally impaired patients with symptomatic venous thromboembolism. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):30-1. BistervelsI , GebelM , LensingA , MiddeldorpS , CoppensM . Effect of polypharmacy on bleeding of rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolism. Research and Practice in Thrombosis and Haemostasis2019;3:798‐9. BookhartBK , HaskellL , BamberL , WangM , ScheinJ , ModySH . Length of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial program. Journal of Medical Economics2014;17(10):691-5. BullerHR . Oral rivaroxaban for the acute and continued treatment of symptomatic venous thromboembolism. The Einstein-DVT and Einstein-Extension study. Blood2010;116(21):187. CheungW , MiddeldorpS , PrinsMP , PapAF , LensingAW , Hoek-tenCA , et al. Post thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep vein thrombosis. Journal of Thrombosis and Haemostasis2015;13(S2):219-20. CheungYW , MiddeldorpS , PrinsMH , PapAF , PrandoniP . Post-thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep-vein thrombosis. A post-hoc analysis. Thrombosis and Haemostasis2016;116(4):733-8. EUCTR2004-002171-16-IT. Once-daily oral direct factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis. The EINSTEIN-DVT dose-finding study. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2004%E2%80%90002171%E2%80%9016%E2%80%90IT (first received 15 October 2008). EUCTR2006-004495-13-DK. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep-vein thrombosis or pulmonary embolism. trialsearch.who.int/?TrialID=EUCTR2006-004495-13-DK (first received 29 March 2007). EerenbergES , MiddeldorpS , LeviM , LensingAW , BüllerHR . Clinical impact and course of major bleeding with rivaroxaban and vitamin K antagonists. Journal of Thrombosis and Haemostasis2015;13(9):1590-6. KlineJA , JimenezD , CourtneyDM , IanusJ , CaoL , WellsPS . Use of the Riete 2008 bleeding score to identify patients at low risk for major bleeding in patients treated with rivaroxaban. Academic Emergency Medicine2015;22:S162. NCT00440193. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep vein thrombosis - The EINSTEIN DVT Study. clinicaltrials.gov/ct2/show/NCT00440193 (first received 26 February 2007). PrinsMH , ErkensPG , LensingAW . Incidence of recurrent venous thromboembolism in patients following completion of the EINSTEIN DVT and EINSTEIN PE studies. Journal of Thrombosis and Haemostasis2013;11(Suppl):257. PrinsMH , LensingAW , BauersachsR , Van BellenB , BounameauxH , BrightonTA , et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thrombosis Journal2013;11(1):21. The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. New England Journal of Medicine2010;363(26):2499-510. Van BellenB , PrinsM , BamberL , WangM , LensingAW . Reduction in initial length of stay with rivaroxaban single-drug regimen versus LMWH-VKA standard of care: findings from the EINSTEIN trial program. Blood2012;120(21):3419. Van BellenB , PrinsM , BamberL , WangM , LensingAW . Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism. Current Medical Research and Opinion2014;30(5):829-37. WangY , WangC , ChenZ , ZhangJ , LiuZ , JinB , et al. Rivaroxaban for the treatment of symptomatic deep vein thrombosis and/or pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):694. WangY , WangC , ChenZ , ZhangJ , LiuZ , JinB , et al. Rivaroxaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Thrombosis Journal2013;11(1):25. ">EINSTEIN‐DVT 2010</a>; <a href="./references#CD010956-bbs2-0008" title="BullerHR , PrinsMH , LensinAW , DecoususH , JacobsonBF , MinarE , et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. New England Journal of Medicine2012;366:1287-97. FermannGJ , Erkens Pmg, PrinsMH , WellsPS , Pap ÁF, LensingAW , et al. Treatment of pulmonary embolism with rivaroxaban: outcomes by simplified pulmonary embolism severity index score from a post hoc analysis of the EINSTEIN PE study. Academic Emergency Medicine2015;22(3):299-307. NCT00439777. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic pulmonary embolism with or without symptomatic deep-vein thrombosis: Einstein-PE evaluation, 2008. clinicaltrials.gov/ct2/show/NCT00439777?term=NCT00439777&amp;rank=1 (first received 26 February 2007). PrinsM , BamberL , CanoS , WangM , LensingAW , BauersachsR . Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic pulmonary embolism. Blood2012;120(21):1163. PrinsMH , BamberL , CanoSJ , WangMY , ErkensP , BauersachsR , et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial. Thrombosis Research2015;135(2):281-8. ">EINSTEIN‐PE 2012</a>; <a href="./references#CD010956-bbs2-0010" title="FarhanA , BukhariM , UmarJ , RazaMA . Oral rivaroxaban in symptomatic deep vein thrombosis. Journal of the College of Physicians and Surgeons Pakistan2019;29(9):814-8. ">Farhan 2019</a>; <a href="./references#CD010956-bbs2-0012" title="AmayaN , UzuiH , HisazakiK , HasegwaK , KasenoK , TadaH . Edoxaban normalizes the elevated D-dimer levels potently and promptly in patients with venous thromboembolisms: a comparison with traditional anticoagulant therapy. European Heart Journal2016;37:278. BoschFT , Van EsN , Di NisioM , CarrierM , SegersA , GrossoMA , et al. The Ottawa score does not predict recurrent venous thromboembolism in cancer patients: results from the Hokusai-VTE cancer study. Research and Practice in Thrombosis and Haemostasis2019;3(S1):717-8. KraaijpoelN , Di NisioM , MulderFI , Van EsN , RaskobGE . Clinical impact of bleeding in cancer-associated venous thromboembolism: results from the Hokusai VTE Cancer randomized trial. Thrombosis Research2018;164(Suppl 1):S223. [DOI: 10.1016/j.thromres.2018.02.094]MulderFI , Di NisioM , AyC , CarrierM , BoschFT , SegersA , et al. Clinical implications of incidental venous thromboembolism in cancer patients. European Respiratory Journal2020;55(2):1901697. [DOI: 10.1183/13993003.01697-2019]MulderFI , Van EsN , KraaijpoelN , Di NisioM , CarrierM , GarciaD , et al. Efficacy and safety of edoxaban in clinically relevant subgroups: results from the Hokusai VTE Cancer randomized trial. Thrombosis Research2018;164:S194. NCT02073682. Cancer venous thromboembolism (VTE). clinicaltrials.gov/ct2/show/NCT02073682 (first received 27 February 2014). RaskobG , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaD , et al. Edoxaban versus dalteparin for treatment of venous thromboembolism (VTE) associated with cancer: Hokusai VTE-cancer randomized trial. Supportive Care in Cancer2018;26(2):S316-S317. RaskobGE , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaD , et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. New England Journal of Medicine2018;378(7):615-24. RaskobGE , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaDA , et al. A randomized, open-label, blinded outcome assessment trial evaluating the efficacy and safety of LMWH/Edoxaban versus dalteparin for venous thromboembolism associated with cancer: Hokusai VTE-cancer study. Blood2017;130(Suppl 1):LBA-6. ">Hokusai VTE Cancer 2018</a>; <a href="./references#CD010956-bbs2-0011" title="BistervelsI , BavaliaR , BoersmaW , MeijerK , VerhammeP , Ten Cate-HoekAJ , et al. Hokusai Post-DVT Study: a follow-up study on long-term outcomes of deep vein thrombosis in patients treated with edoxaban vs warfarin. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):PB2207. BrekelmansMP , AgenoW , BeenenLF , BrennerB , BullerHR , ChenCZ , et al. Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology2016;3(9):e437-45. BrekelmansMP , BlekerSM , BauersachsR , BodaZ , BüllerHR , ChoiY , et al. Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists. Thrombosis and Haemostasis2016;116(1):155-61. Di NisioM , Van EsN , CarrierM , WangTF , GarciaD , SegersA , et al. Extended treatment with edoxaban in cancer patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE Cancer study. Journal of Thrombosis and Haemostasis2019;17:1866–74. EUCTR2009-014290-40-SE. A phase 3, randomized, double-blind, double-dummy, parallel group, multi-center, multi-national study for evaluation of efficacy and safety of DU-176b versus warfarin in subjects with atrial fibrillation - effective anticoagulation with factor Xa next generation in atrial fibrillation (ENGAGE-AF TIMI-48). trialsearch.who.int/?trialid=EUCTR2009-014290-40-SE (first received 30 November 2009). EichingerS , LinM , KyrlePA , GrossoMA . Recurrent venous thromboembolism during anticoagulation: an investigator-initiated post-hoc analysis of the hokusai-VTE trial. Blood2018;132:2539. KlokFA , BarcoS , KonstantinidesSV . External validation of the VTE-BLEED score for predicting major bleeding in stable anticoagulated patients with venous thromboembolism. Thrombosis and Haemostasis2017;117(6):1164-70. KraaijpoelN , Van EsN , RaskobGE , BüllerHR , CarrierM , ZhangG , et al. Risk scores for occult cancer in patients with venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2018;118(7):1270-8. MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMP , ChenCZ , et al. Outpatient management in patients with venous thromboembolism with edoxaban: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2017;117(12):2406-14. MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMP , ChenCZ , et al. Safety and efficacy of edoxaban compared with warfarin for the treatment of acute symptomatic deep-vein thrombosis in the outpatient setting. Research and Practice in Thrombosis and Haemostasis2017;1:913. MulderFI , Van EsN , KraaijpoelN , Di NisioM , CarrierM , DuggalA , et al. Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: results from the Hokusai VTE Cancer study. Thrombosis Research2020;185:13-9. NCT00986154. Comparative investigation of Low Molecular Weight (LMW) heparin/edoxaban tosylate (DU176b) versus (LMW) heparin/warfarin in the treatment of symptomatic deep-vein blood clots and/or lung blood clots. (The Edoxaban Hokusai-VTE Study). clinicaltrials.gov/ct2/show/NCT00986154 (first received 29 September 2009). NakamuraM , WangYQ , WangC , OhD , YinWH , KimuraT , et al. Efficacy and safety of edoxaban for treatment of venous thromboembolism: a subanalysis of East Asian patients in the Hokusai-VTE trial. Journal of Thrombosis and Haemostasis2015;13(9):1606-14. NybergJ , KarlssonKE , JönssonS , YinO , MillerR , KarlssonMO , et al. Edoxaban exposure-response analysis and clinical utility index assessment in patients with symptomatic deep-vein thrombosis or pulmonary embolism. CPT Pharmacometrics and Systems Pharmacology2016;5(4):222-32. RaskobG , AgenoW , CohenAT , BrekelmansMP , GrossoMA , SegersA , et al. Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology2016;3(5):e228-e236. RaskobG , BullerH , PrinsM , SegersA , ShiM , SchwochoL , et al. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study - methodological implications for clinical trials. Journal of Thrombosis and Haemostasis2013;11(7):1287-94. RaskobGE , BullerH , AngchaisuksiriP , OhD , BodaZ , LyonsRM , et al. Edoxaban for long-term treatment of venous thromboembolism in cancer patients. Blood2013;122(21):211. RaskobGE , Van EsN , SegersA , AngchaisuksiriP , OhD , BodaZ , et al. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematology2016;3(8):e379-87. ScheresLJ , BrekelmansMA , WalterA , CihanA , BüllerHR , SabineE , et al. Abnormal vaginal bleeding in women of reproductive age treated with edoxaban or warfarin for venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. British Journal of Obstetrics and Gynaecology2018;125(12):1581-9. The Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. New England Journal of Medicine2013;369(15):1406-15. VanasscheT , VerhammeP , WellsPS , SegersA , AgenoW , BrekelmansMP , et al. Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: an analysis of the randomized, double-blind Hokusai-VTE trial. Thrombosis Research2018;162:7-14. VerhammeP , WellsPS , SegersA , AgenoW , BrekelmansMP , CohenAT , et al. Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial. Thrombosis and Haemostasis2016;116(4):747-53. ">Hokusai‐VTE 2013</a>; <a href="./references#CD010956-bbs2-0013" title="MatsuoH , PrinsM , LensingAW , FujinumaEW , MiyamotoY , KajikawaM . Shortened length of hospital stay with rivaroxaban in patients with symptomatic venous thromboembolism in Japan: the J-EINSTEIN pulmonary embolism and deep vein thrombosis program. Current Medical Research and Opinion2015;31(6):1057-61. NCT01516814. Venous thromboembolism (VTE) treatment study in Japanese pulmonary embolism (PE) patients. clinicaltrials.gov/ct2/show/NCT01516814 (first received 25 January 2012). YamadaN , HirayamaA , MaedaH , SakagamiS , ShikataH , PrinsMH , et al. Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism-the J-EINSTEIN DVT and PE program. Thrombosis Journal2015;13:2. ">J‐EINSTEIN DVT and PE 2015</a>; <a href="./references#CD010956-bbs2-0014" title="MokademME , HassanA , AlgabyAZ . Efficacy and safety of apixaban in patients with active malignancy and acute deep venous thrombosis. Vascular2021;29(5):745-50. NCT04462003. Efficacy of apixaban in malignancy with deep venous thrombosis (DVT). clinicaltrials.gov/ct2/show/NCT04462003 (first received 3 July 2019). ">Mokadem 2021</a>; <a href="./references#CD010956-bbs2-0015" title="AgnelliG , GallusA , GoldhaberSZ , HaasS , HuismanMV , HullRD , et al. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAT 59-7939 in patients with acute symptomatic deep-vein thrombosis) study. Circulation2007;116:180-7. ">ODIXa‐DVT 2007</a>; <a href="./references#CD010956-bbs2-0017" title="Kang JiM, ParkKH , AhnS , ChoS , MinSK . Rivaroxaban after thrombolysis in acute iliofemoral venous thrombosis: a randomized, open-labeled, multicenter trial. Scientific Reports2019;9(1):20356. MinSK , AhnS , ParkKH , KangJM , KimJY . Prevention of recurrence after thrombolysis in acute iliofemoral venous thrombosis with rivaroxaban (Prais Study): a prospective, randomized, open label, multicenter trial. European Journal of Vascular and Endovascular Surgery2019;58(6):e516. NCT01986192. Prevention of recurrence after thrombolysis in acute iliofemoral venous thrombosis (PRAIS) study. clinicaltrials.gov/show/NCT01986192 (first received 18 November 2013). ">PRAIS 2019</a>; <a href="./references#CD010956-bbs2-0018" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00291330. Efficacy and safety of dabigatran compared to warfarin for 6 month treatment of acute symptomatic venous thromboembolism (RE-COVER I). clinicaltrials.gov/ct/show/NCT00291330 (first received 14 February 2006). SchulmanS , ErikssonH , GoldhaberS , KakkarAK , KearonC , KvammeAM , et al. Dabigatran or warfarin for extended maintenance therapy of venous thromboembolism. Journal of Thrombosis and Haemostasis2011;9(Suppl 2):731-2. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-COVER and RE-COVER II. Blood2013;122:2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RECOVER II. Blood2013;122(21):212. SchulmanS , ErikssonH , GoldhaverSZ , KakkarA , KearonC , MismettiP , et al. Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130:A18594. SchulmanS , KearonC , KakkarAK , MismettiP , SchellongS , ErikssonH , et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. New England Journal of Medicine2009;361(24):2342-52. ">RE‐COVER 2009</a>; <a href="./references#CD010956-bbs2-0019" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00680186. Phase III study testing efficacy &amp; safety of oral dabigatran etexilate vs warfarin for 6 m treatment for acute symp venous thromboembolism (VTE) (RE-COVER II). clinicaltrials.gov/ct2/show/NCT00680186 (first received 20 May 2008). SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-COVER and RE-COVER II. Blood2013;122:2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RECOVER II. Blood2013;122(21):212. SchulmanS , ErikssonH , GoldhaverSZ , KakkarA , KearonC , MismettiP , et al. Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130:A18594. SchulmanS , KakkarAK , GoldhaberSZ , SchellongS , ErikssonH , MismettiP , et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation2014;129:764-72. SchulmanS . A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II). Blood2011;118(21):95-6. ">RE‐COVER II 2014</a>; <a href="./references#CD010956-bbs2-0020" title="SukovatykhBS , SereditskiĭAV , MuradianVF , BelikovLN , GerasimovaOF . Results of administering oral anticoagulants for treatment of patients with venous thromboembolic complications. Angiologiia i sosudistaia khirurgiia [Angiology and Vascular Surgery]2017;23(2):82. ">Sukovatykh 2017</a>; <a href="./references#CD010956-bbs2-0021" title="FiessingerJN , HuismanMV , DavidsonBL , BounameauxH , FrancisCW , ErikssonH , et al. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomised trial. JAMA2005;293(6):681-9. FrancisCW , GinsbergJS , BerkowitzSD , BounameauxH , DavidsonBL , ErikssonH , et al. Efficacy and safety of the oral direct thrombin inhibitor ximelagatran compared with current therapy for acute, symptomatic deep vein thrombosis, with or without pulmonary embolus: the THRIVE treatment study. Blood2003;102(11):Abstract 7. HarenbergJ , IngridJ , TivadarF . Treatment of venous thromboembolism with the oral thrombin inhibitor, ximelagatran. Israel Medical Association Journal2002;4(11):1003-5. HarenbergJ , JoergI , WeissC . Incidence of recurrent venous thromboembolism of patients after termination of treatment with ximelagatran. European Journal of Clinical Pharmacology2006;62(3):173-7. HarenbergJ , JorgI , WeissC , HarenbergJ , JorgI , WeissC . Observations of alanine aminotransferase and aspartate aminotransferase in THRIVE studies treated orally with ximelagatran. International Journal of Toxicology2006;25(3):165-9. HuismanMV , The THRIVE Treatment Study Investigators. Efficacy and safety of the oral direct thrombin inhibitor ximelagatran compared with current standard therapy for acute symptomatic deep vein thrombosis, with or without pulmonary embolism: a randomized, double-blind, multinational study. Journal of Thrombosis and Haemostasis2003;1(Suppl 1):Abstract OC003. WimperisJ , FiessingerJN , HuismanMV , DavidsonBL , BounameauxH , FrancisCW , et al. Ximelagatran, an oral direct thrombin inhibitor, compared with current standard therapy for acute, symptomatic deep vein thrombosis, with or without pulmonary embolism: the THRIVE treatment study. British Journal of Haematology2004;125(Suppl 1):66. ">THRIVE 2005</a>). We judged five studies to be at high risk of reporting bias (<a href="./references#CD010956-bbs2-0001" title="AgnelliG , BullerH , MasiukiewiczUP . Apixaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism: a randomized, double-blind trial (AMPLIFY). Journal of Thrombosis and Haemostasis2013;11:18. AgnelliG , BullerHR , CohenA , CurtoD , GallusAS , JohnsonM , et al. Oral apixaban for the treatment of acute venous thromboembolism. New England Journal of Medicine2013;369:799-808. AgnelliG , BullerHR , CohenA , CurtoM , GallusAS , PakR , et al. Apixaban for the treatment of venous thromboembolism in cancer patients: data from the AMPLIFY trial. Canadian Journal of Cardiology2014;30(10 Suppl 1):S278. AgnelliG , BullerHR , CohenA , GallusAS , LeeTC , PakR , et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. Journal of Thrombosis and Haemostasis2015;13(12):2187-91. AgnelliG . Apixaban was non-inferior to enoxaparin plus warfarin in patients with acute venous thromboembolism. Annals of Internal Medicine2013;159(8):JC2. BlekerSM , CohenAT , BüllerHR , AgnelliG , GallusAS , RaskobGE , et al. Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Thrombosis and Haemostasis2016;116(6):159-64. BrekelmansM , ScheresL , BlekerS , HuttenB , TimmermansA , BüllerH , et al. Abnormal vaginal bleeding in women with venous thromboembolism treated with apixaban or warfarin. Thrombosis and Haemostasis2017;117(04):809-15. CohenA , AgnelliG , BullerH , GallusA , RaskobG , SandersP , et al. Characteristics and outcomes in patients with venous thromboembolism taking concomitant anti-platelet agents and anticoagulants in the AMPLIFY Trial. Thrombosis and Haemostasis2019;119(3):461-6. CohenA , AgnelliG , BullerHR , ChaudhuriS , GallusAS , RaskobGE , et al. Analysis of the bleeding and thromboembolic risk with concomitant use of antiplatelet treatment in the AMPLIFY trial. Canadian Journal of Cardiology2014;30(10):S272. CohenA , GallusAS , AgnelliG , BullerHR , PakR , PorcariAR , et al. Time in Therapeutic Range (TTR) and relative efficacy and safety of treatment with apixaban or enoxaparin/warfarin for acute symptomatic venous thromboembolism: an analysis of the Amplify trial data. Blood2014;124(21):1543. CohenAT , PanS , ByonW , IlyasBS , LeeTC . Efficacy, safety, and exposure of apixaban in patients with high body weight or obesity and venous thromboembolism: insights from AMPLIFY. Advances in Therapy2021;38(6):3003-18. EUCTR2007-007867-25-PT. A safety and efficacy trial evaluating the use of apixaban in the treatment of symptomatic deep vein thrombosis and pulmonary embolism revised protocol number: 01, incorporates amendment(s) 02 + protocol amendment 01 (version 1.0 dated 21-Apr-08) site-specific - molecular profiling supplement samples for Pfizer’s exploratory research biobank. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2007%E2%80%90007867%E2%80%9025%E2%80%90PT (first received 14 July 2008). GallusAS , AgnelliG , BullerHR , CohenA , LeeTC , PakR , et al. Apixaban for treatment of venous thromboembolism in patients from study centres in Asia: a subgroup analysis of the Amplify trial. Journal of Thrombosis and Haemostasis2015;13:727. LeeT , PanS , ByonW , IlyasBS . Safety and efficacy of apixaban versus enoxaparin/warfarin in patients with extremes of body weight: post-hoc analysis of the AMPLIFY trial. Blood2019;134(Suppl 1):1152. LiuX , JohnsonM , MardekianJ , PhatakH , ThompsonJ , CohenAT . Apixaban reduces hospitalizations in patients with venous thromboembolism: an analysis of the apixaban for the Initial management of pulmonary embolism and deep‐vein thrombosis as first‐line therapy (AMPLIFY) trial. Journal of the American Heart Association2015;4(12):e002340. NCT00633893. Efficacy and safety study of apixaban for extended treatment of deep vein thrombosis or pulmonary embolism. clinicaltrials.gov/ct2/show/NCT00633893?term=ajax&amp;rank=5 (first received 12 March 2008). NCT00643201. Efficacy and safety study of apixaban for the treatment of deep vein thrombosis or pulmonary embolism. clinicaltrials.gov/ct2/show/NCT00643201 (first received 26 March 2008). RaskobGE , GallusAS , SandersP , ThompsonJR , AgnelliG , BullerHR , et al. Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy: a sub-analysis of the AMPLIFY trial. Thrombosis and Haemostasis2016;115(4):809-16. ">AMPLIFY 2013</a>; <a href="./references#CD010956-bbs2-0004" title="AgenoW , VedovatiMC , CohenA , HuismanM , BauersachsR , GussoniG , et al. Bleeding with apixaban and dalteparin in patients with cancer-associated venous thromboembolism: results from the Caravaggio study. Thrombosis and Haemostasis2021;121(5):616-24. AgnelliG , BecattiniC , BauersachsR , BrennerB , CampaniniM , CohenA , et al. Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the Caravaggio study. Thrombosis and Haemostasis2018;118(9):1668-78. AgnelliG , BecattiniC , MeyerG , MuozA , VersoM . Apixaban for the treatment of venous thromboembolism associated with cancer. New England Journal of Medicine2020;382(17):1599-607. AgnelliG , MuozA , FrancoL , MahéI , BrennerB , ConnorsJM , et al. Apixaban and dalteparin for the treatment of venous thromboembolism in patients with different sites of cancer. Thrombosis and Haemostasis2022;122(5):796-807. BecattiniC , BauersachsR , MarazitiG , BertolettiL , CohenA , ConnorsJM , et al. Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial. Haematologica2021;107(7):1567-76. GiustozziM , ConnorsJM , Ruperez BlancoAB , SzmitS , FalvoN , CohenAT , et al. Clinical characteristics and outcomes of incidental venous thromboembolism in cancer patients: insights from the Caravaggio study. Journal of Thrombosis and Haemostasis2021;19(11):2751-9. NCT03045406. Apixaban for the treatment of venous thromboembolism in patients with cancer (CARAVAGGIO). clinicaltrials.gov/ct2/show/NCT03045406 (first received 7 February 2017). VersoM , MunozA , BauersachsR , HuismanMV , AgnelliG . Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism. European Journal of Cancer2021;148(Suppl C):371-81. ">Caravaggio 2020</a>; <a href="./references#CD010956-bbs2-0005" title="NCT02704598. Comparison between xarelto versus warfarin in the recanalization rate of deep venous thrombosis in patients legs. (DVT). clinicaltrials.gov/ct2/show/NCT02704598 (first received 10 March 2016). deAthayde SoaresR , MatieloMF , Brochado NetoFC , AlmeidaRD , SacilottoR . LEV 2. Comparison of the recanalization rate and post-thrombotic syndrome in patients with deep venous thrombosis treated with rivaroxaban or warfarin. Journal of Vascular Surgery2019;70(5):e169-e170. deAthayde SoaresR , MatieloMF , Brochado NetoFC , NogueiraMP , AlmeidaRD , SacilottoR . Comparison of the recanalization rate and postthrombotic syndrome in patients with deep venous thrombosis treated with rivaroxaban or warfarin. Surgery2019;166(6):1076-83. ">de Athayde 2019</a>; <a href="./references#CD010956-bbs2-0009" title="PiazzaG , ManiV , GoldhaberSZ , GrossoMA , MercuriM , LanzHJ , et al. Magnetic resonance venography to assess thrombus resolution with edoxaban monotherapy versus parenteral anticoagulation/warfarin for symptomatic deep vein thrombosis: a multicenter feasibility study. Vascular Medicine2016;21(4):361-8. PiazzaG , ManiV , GrossoM , MercuriM , LanzH , SchusslerS , et al. A randomized, open-label, multicenter study of the efficacy and safety of edoxaban monotherapy versus low-molecular weight heparin/warfarin in patients with symptomatic deep vein thrombosis-edoxaban thrombus reduction imaging study (etris). Circulation2014;130:A12074. ">eTRIS 2016</a>; <a href="./references#CD010956-bbs2-0016" title="OhmoriH , KadaA , NakamuraM , SaitoAM , SanayamaY , ShinagawaT , et al. Deep vein thrombosis in severe motor and intellectual disabilities patients and its treatment by anticoagulants of warfarin versus edoxaban. Annals of Vascular Diseases2019;12(3):372-8. OhmoriH , NakamuraM , KadaA , SaitoAM , SanayamaY , ShinagawaT , et al. Multicenter, open-label, randomized controlled trial of warfarin and edoxaban tosilate hydrate for the treatment of deep vein thrombosis in persons with severe motor intellectual disabilities. Kurume Medical Journal2018;65(1):11-6. ">Ohmori 2019</a>). The <a href="./references#CD010956-bbs2-0001" title="AgnelliG , BullerH , MasiukiewiczUP . Apixaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism: a randomized, double-blind trial (AMPLIFY). Journal of Thrombosis and Haemostasis2013;11:18. AgnelliG , BullerHR , CohenA , CurtoD , GallusAS , JohnsonM , et al. Oral apixaban for the treatment of acute venous thromboembolism. New England Journal of Medicine2013;369:799-808. AgnelliG , BullerHR , CohenA , CurtoM , GallusAS , PakR , et al. Apixaban for the treatment of venous thromboembolism in cancer patients: data from the AMPLIFY trial. Canadian Journal of Cardiology2014;30(10 Suppl 1):S278. AgnelliG , BullerHR , CohenA , GallusAS , LeeTC , PakR , et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. Journal of Thrombosis and Haemostasis2015;13(12):2187-91. AgnelliG . Apixaban was non-inferior to enoxaparin plus warfarin in patients with acute venous thromboembolism. Annals of Internal Medicine2013;159(8):JC2. BlekerSM , CohenAT , BüllerHR , AgnelliG , GallusAS , RaskobGE , et al. Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Thrombosis and Haemostasis2016;116(6):159-64. BrekelmansM , ScheresL , BlekerS , HuttenB , TimmermansA , BüllerH , et al. Abnormal vaginal bleeding in women with venous thromboembolism treated with apixaban or warfarin. Thrombosis and Haemostasis2017;117(04):809-15. CohenA , AgnelliG , BullerH , GallusA , RaskobG , SandersP , et al. Characteristics and outcomes in patients with venous thromboembolism taking concomitant anti-platelet agents and anticoagulants in the AMPLIFY Trial. Thrombosis and Haemostasis2019;119(3):461-6. CohenA , AgnelliG , BullerHR , ChaudhuriS , GallusAS , RaskobGE , et al. Analysis of the bleeding and thromboembolic risk with concomitant use of antiplatelet treatment in the AMPLIFY trial. Canadian Journal of Cardiology2014;30(10):S272. CohenA , GallusAS , AgnelliG , BullerHR , PakR , PorcariAR , et al. Time in Therapeutic Range (TTR) and relative efficacy and safety of treatment with apixaban or enoxaparin/warfarin for acute symptomatic venous thromboembolism: an analysis of the Amplify trial data. Blood2014;124(21):1543. CohenAT , PanS , ByonW , IlyasBS , LeeTC . Efficacy, safety, and exposure of apixaban in patients with high body weight or obesity and venous thromboembolism: insights from AMPLIFY. Advances in Therapy2021;38(6):3003-18. EUCTR2007-007867-25-PT. A safety and efficacy trial evaluating the use of apixaban in the treatment of symptomatic deep vein thrombosis and pulmonary embolism revised protocol number: 01, incorporates amendment(s) 02 + protocol amendment 01 (version 1.0 dated 21-Apr-08) site-specific - molecular profiling supplement samples for Pfizer’s exploratory research biobank. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2007%E2%80%90007867%E2%80%9025%E2%80%90PT (first received 14 July 2008). GallusAS , AgnelliG , BullerHR , CohenA , LeeTC , PakR , et al. Apixaban for treatment of venous thromboembolism in patients from study centres in Asia: a subgroup analysis of the Amplify trial. Journal of Thrombosis and Haemostasis2015;13:727. LeeT , PanS , ByonW , IlyasBS . Safety and efficacy of apixaban versus enoxaparin/warfarin in patients with extremes of body weight: post-hoc analysis of the AMPLIFY trial. Blood2019;134(Suppl 1):1152. LiuX , JohnsonM , MardekianJ , PhatakH , ThompsonJ , CohenAT . Apixaban reduces hospitalizations in patients with venous thromboembolism: an analysis of the apixaban for the Initial management of pulmonary embolism and deep‐vein thrombosis as first‐line therapy (AMPLIFY) trial. Journal of the American Heart Association2015;4(12):e002340. NCT00633893. Efficacy and safety study of apixaban for extended treatment of deep vein thrombosis or pulmonary embolism. clinicaltrials.gov/ct2/show/NCT00633893?term=ajax&amp;rank=5 (first received 12 March 2008). NCT00643201. Efficacy and safety study of apixaban for the treatment of deep vein thrombosis or pulmonary embolism. clinicaltrials.gov/ct2/show/NCT00643201 (first received 26 March 2008). RaskobGE , GallusAS , SandersP , ThompsonJR , AgnelliG , BullerHR , et al. Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy: a sub-analysis of the AMPLIFY trial. Thrombosis and Haemostasis2016;115(4):809-16. ">AMPLIFY 2013</a> study pre‐defined minor bleeding as a secondary outcome but data were not reported in the paper. In addition, this study analysed non‐inferiority using an ITT analysis. When compared with the per‐protocol analysis, ITT favoured the finding of non‐inferior results. This may have skewed the result in favour of increased efficacy of apixaban. The <a href="./references#CD010956-bbs2-0004" title="AgenoW , VedovatiMC , CohenA , HuismanM , BauersachsR , GussoniG , et al. Bleeding with apixaban and dalteparin in patients with cancer-associated venous thromboembolism: results from the Caravaggio study. Thrombosis and Haemostasis2021;121(5):616-24. AgnelliG , BecattiniC , BauersachsR , BrennerB , CampaniniM , CohenA , et al. Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the Caravaggio study. Thrombosis and Haemostasis2018;118(9):1668-78. AgnelliG , BecattiniC , MeyerG , MuozA , VersoM . Apixaban for the treatment of venous thromboembolism associated with cancer. New England Journal of Medicine2020;382(17):1599-607. AgnelliG , MuozA , FrancoL , MahéI , BrennerB , ConnorsJM , et al. Apixaban and dalteparin for the treatment of venous thromboembolism in patients with different sites of cancer. Thrombosis and Haemostasis2022;122(5):796-807. BecattiniC , BauersachsR , MarazitiG , BertolettiL , CohenA , ConnorsJM , et al. Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial. Haematologica2021;107(7):1567-76. GiustozziM , ConnorsJM , Ruperez BlancoAB , SzmitS , FalvoN , CohenAT , et al. Clinical characteristics and outcomes of incidental venous thromboembolism in cancer patients: insights from the Caravaggio study. Journal of Thrombosis and Haemostasis2021;19(11):2751-9. NCT03045406. Apixaban for the treatment of venous thromboembolism in patients with cancer (CARAVAGGIO). clinicaltrials.gov/ct2/show/NCT03045406 (first received 7 February 2017). VersoM , MunozA , BauersachsR , HuismanMV , AgnelliG . Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism. European Journal of Cancer2021;148(Suppl C):371-81. ">Caravaggio 2020</a> study defined quality of life as a secondary outcome in its protocol but no information was reported in the full text. This study also stated that a "significant interaction was noted between age subgroups and treatment for recurrent venous thromboembolism", but no result was found in the paper and appendix. Both the <a href="./references#CD010956-bbs2-0005" title="NCT02704598. Comparison between xarelto versus warfarin in the recanalization rate of deep venous thrombosis in patients legs. (DVT). clinicaltrials.gov/ct2/show/NCT02704598 (first received 10 March 2016). deAthayde SoaresR , MatieloMF , Brochado NetoFC , AlmeidaRD , SacilottoR . LEV 2. Comparison of the recanalization rate and post-thrombotic syndrome in patients with deep venous thrombosis treated with rivaroxaban or warfarin. Journal of Vascular Surgery2019;70(5):e169-e170. deAthayde SoaresR , MatieloMF , Brochado NetoFC , NogueiraMP , AlmeidaRD , SacilottoR . Comparison of the recanalization rate and postthrombotic syndrome in patients with deep venous thrombosis treated with rivaroxaban or warfarin. Surgery2019;166(6):1076-83. ">de Athayde 2019</a> and <a href="./references#CD010956-bbs2-0016" title="OhmoriH , KadaA , NakamuraM , SaitoAM , SanayamaY , ShinagawaT , et al. Deep vein thrombosis in severe motor and intellectual disabilities patients and its treatment by anticoagulants of warfarin versus edoxaban. Annals of Vascular Diseases2019;12(3):372-8. OhmoriH , NakamuraM , KadaA , SaitoAM , SanayamaY , ShinagawaT , et al. Multicenter, open-label, randomized controlled trial of warfarin and edoxaban tosilate hydrate for the treatment of deep vein thrombosis in persons with severe motor intellectual disabilities. Kurume Medical Journal2018;65(1):11-6. ">Ohmori 2019</a> studies failed to report the pre‐defined secondary outcome complications in their full report. The <a href="./references#CD010956-bbs2-0009" title="PiazzaG , ManiV , GoldhaberSZ , GrossoMA , MercuriM , LanzHJ , et al. Magnetic resonance venography to assess thrombus resolution with edoxaban monotherapy versus parenteral anticoagulation/warfarin for symptomatic deep vein thrombosis: a multicenter feasibility study. Vascular Medicine2016;21(4):361-8. PiazzaG , ManiV , GrossoM , MercuriM , LanzH , SchusslerS , et al. A randomized, open-label, multicenter study of the efficacy and safety of edoxaban monotherapy versus low-molecular weight heparin/warfarin in patients with symptomatic deep vein thrombosis-edoxaban thrombus reduction imaging study (etris). Circulation2014;130:A12074. ">eTRIS 2016</a> study planned to report the number of participants with major adverse cardiovascular events (MACE) when registered; however, this outcome was not provided in the full text. Protocols were available for eight studies (<a href="./references#CD010956-bbs2-0001" title="AgnelliG , BullerH , MasiukiewiczUP . Apixaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism: a randomized, double-blind trial (AMPLIFY). Journal of Thrombosis and Haemostasis2013;11:18. AgnelliG , BullerHR , CohenA , CurtoD , GallusAS , JohnsonM , et al. Oral apixaban for the treatment of acute venous thromboembolism. New England Journal of Medicine2013;369:799-808. AgnelliG , BullerHR , CohenA , CurtoM , GallusAS , PakR , et al. Apixaban for the treatment of venous thromboembolism in cancer patients: data from the AMPLIFY trial. Canadian Journal of Cardiology2014;30(10 Suppl 1):S278. AgnelliG , BullerHR , CohenA , GallusAS , LeeTC , PakR , et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. Journal of Thrombosis and Haemostasis2015;13(12):2187-91. AgnelliG . Apixaban was non-inferior to enoxaparin plus warfarin in patients with acute venous thromboembolism. Annals of Internal Medicine2013;159(8):JC2. BlekerSM , CohenAT , BüllerHR , AgnelliG , GallusAS , RaskobGE , et al. Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Thrombosis and Haemostasis2016;116(6):159-64. BrekelmansM , ScheresL , BlekerS , HuttenB , TimmermansA , BüllerH , et al. Abnormal vaginal bleeding in women with venous thromboembolism treated with apixaban or warfarin. Thrombosis and Haemostasis2017;117(04):809-15. CohenA , AgnelliG , BullerH , GallusA , RaskobG , SandersP , et al. Characteristics and outcomes in patients with venous thromboembolism taking concomitant anti-platelet agents and anticoagulants in the AMPLIFY Trial. Thrombosis and Haemostasis2019;119(3):461-6. CohenA , AgnelliG , BullerHR , ChaudhuriS , GallusAS , RaskobGE , et al. Analysis of the bleeding and thromboembolic risk with concomitant use of antiplatelet treatment in the AMPLIFY trial. Canadian Journal of Cardiology2014;30(10):S272. CohenA , GallusAS , AgnelliG , BullerHR , PakR , PorcariAR , et al. Time in Therapeutic Range (TTR) and relative efficacy and safety of treatment with apixaban or enoxaparin/warfarin for acute symptomatic venous thromboembolism: an analysis of the Amplify trial data. Blood2014;124(21):1543. CohenAT , PanS , ByonW , IlyasBS , LeeTC . Efficacy, safety, and exposure of apixaban in patients with high body weight or obesity and venous thromboembolism: insights from AMPLIFY. Advances in Therapy2021;38(6):3003-18. EUCTR2007-007867-25-PT. A safety and efficacy trial evaluating the use of apixaban in the treatment of symptomatic deep vein thrombosis and pulmonary embolism revised protocol number: 01, incorporates amendment(s) 02 + protocol amendment 01 (version 1.0 dated 21-Apr-08) site-specific - molecular profiling supplement samples for Pfizer’s exploratory research biobank. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2007%E2%80%90007867%E2%80%9025%E2%80%90PT (first received 14 July 2008). GallusAS , AgnelliG , BullerHR , CohenA , LeeTC , PakR , et al. Apixaban for treatment of venous thromboembolism in patients from study centres in Asia: a subgroup analysis of the Amplify trial. Journal of Thrombosis and Haemostasis2015;13:727. LeeT , PanS , ByonW , IlyasBS . Safety and efficacy of apixaban versus enoxaparin/warfarin in patients with extremes of body weight: post-hoc analysis of the AMPLIFY trial. Blood2019;134(Suppl 1):1152. LiuX , JohnsonM , MardekianJ , PhatakH , ThompsonJ , CohenAT . Apixaban reduces hospitalizations in patients with venous thromboembolism: an analysis of the apixaban for the Initial management of pulmonary embolism and deep‐vein thrombosis as first‐line therapy (AMPLIFY) trial. Journal of the American Heart Association2015;4(12):e002340. NCT00633893. Efficacy and safety study of apixaban for extended treatment of deep vein thrombosis or pulmonary embolism. clinicaltrials.gov/ct2/show/NCT00633893?term=ajax&amp;rank=5 (first received 12 March 2008). NCT00643201. Efficacy and safety study of apixaban for the treatment of deep vein thrombosis or pulmonary embolism. clinicaltrials.gov/ct2/show/NCT00643201 (first received 26 March 2008). RaskobGE , GallusAS , SandersP , ThompsonJR , AgnelliG , BullerHR , et al. Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy: a sub-analysis of the AMPLIFY trial. Thrombosis and Haemostasis2016;115(4):809-16. ">AMPLIFY 2013</a>; <a href="./references#CD010956-bbs2-0004" title="AgenoW , VedovatiMC , CohenA , HuismanM , BauersachsR , GussoniG , et al. Bleeding with apixaban and dalteparin in patients with cancer-associated venous thromboembolism: results from the Caravaggio study. Thrombosis and Haemostasis2021;121(5):616-24. AgnelliG , BecattiniC , BauersachsR , BrennerB , CampaniniM , CohenA , et al. Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the Caravaggio study. Thrombosis and Haemostasis2018;118(9):1668-78. AgnelliG , BecattiniC , MeyerG , MuozA , VersoM . Apixaban for the treatment of venous thromboembolism associated with cancer. New England Journal of Medicine2020;382(17):1599-607. AgnelliG , MuozA , FrancoL , MahéI , BrennerB , ConnorsJM , et al. Apixaban and dalteparin for the treatment of venous thromboembolism in patients with different sites of cancer. Thrombosis and Haemostasis2022;122(5):796-807. BecattiniC , BauersachsR , MarazitiG , BertolettiL , CohenA , ConnorsJM , et al. Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial. Haematologica2021;107(7):1567-76. GiustozziM , ConnorsJM , Ruperez BlancoAB , SzmitS , FalvoN , CohenAT , et al. Clinical characteristics and outcomes of incidental venous thromboembolism in cancer patients: insights from the Caravaggio study. Journal of Thrombosis and Haemostasis2021;19(11):2751-9. NCT03045406. Apixaban for the treatment of venous thromboembolism in patients with cancer (CARAVAGGIO). clinicaltrials.gov/ct2/show/NCT03045406 (first received 7 February 2017). VersoM , MunozA , BauersachsR , HuismanMV , AgnelliG . Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism. European Journal of Cancer2021;148(Suppl C):371-81. ">Caravaggio 2020</a>; <a href="./references#CD010956-bbs2-0007" title="BullerH , DariusH . EINSTEIN DVT: oral rivaroxaban versus standard therapy in the initial treatment of symptomatic deep vein thrombosis and long-term prevention of recurrent venous thromboembolism. escardio.org/The-ESC/Press-Office/Press-releases/EINSTEIN-DVT-Oral-rivaroxaban-versus-standard-therapy-in-the-initial-treatment (accessed 19 October 2022). BullerHR , AgnelliG . Once- or twice-daily rivaroxaban for the treatment of proximal deep vein thrombosis: similar efficacy and safety to standard therapy in dose-ranging studies. Blood2006;108(11 Part 1):172-3. BullerHR , LensingAW , PrinsMH , AgnelliG , CohenA , GallusAS , et al. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT dose-ranging study. Blood2008;112(6):2242-7. NCT00395772. Once-daily oral direct factor Xa inhibitor BAY59-7939 in patients with acute symptomatic deep-vein thrombosis. clinicaltrials.gov/ct2/show/NCT00395772?term=einstein-dvt&amp;rank=2 (first received 3 November 2006). ">EINSTEIN‐DVT dose 2008</a>; <a href="./references#CD010956-bbs2-0006" title="BamberL , WangMY , PrinsMH , CiniglioC , BauersachsR , LensingAW , et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis. Thrombosis and Haemostasis2013;110(4):732-41. BauersachsR , LensingAW , PapA , DecoususH . No need for a rivaroxaban dose reduction in renally impaired patients with symptomatic venous thromboembolism. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):30-1. BistervelsI , GebelM , LensingA , MiddeldorpS , CoppensM . Effect of polypharmacy on bleeding of rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolism. Research and Practice in Thrombosis and Haemostasis2019;3:798‐9. BookhartBK , HaskellL , BamberL , WangM , ScheinJ , ModySH . Length of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial program. Journal of Medical Economics2014;17(10):691-5. BullerHR . Oral rivaroxaban for the acute and continued treatment of symptomatic venous thromboembolism. The Einstein-DVT and Einstein-Extension study. Blood2010;116(21):187. CheungW , MiddeldorpS , PrinsMP , PapAF , LensingAW , Hoek-tenCA , et al. Post thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep vein thrombosis. Journal of Thrombosis and Haemostasis2015;13(S2):219-20. CheungYW , MiddeldorpS , PrinsMH , PapAF , PrandoniP . Post-thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep-vein thrombosis. A post-hoc analysis. Thrombosis and Haemostasis2016;116(4):733-8. EUCTR2004-002171-16-IT. Once-daily oral direct factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis. The EINSTEIN-DVT dose-finding study. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2004%E2%80%90002171%E2%80%9016%E2%80%90IT (first received 15 October 2008). EUCTR2006-004495-13-DK. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep-vein thrombosis or pulmonary embolism. trialsearch.who.int/?TrialID=EUCTR2006-004495-13-DK (first received 29 March 2007). EerenbergES , MiddeldorpS , LeviM , LensingAW , BüllerHR . Clinical impact and course of major bleeding with rivaroxaban and vitamin K antagonists. Journal of Thrombosis and Haemostasis2015;13(9):1590-6. KlineJA , JimenezD , CourtneyDM , IanusJ , CaoL , WellsPS . Use of the Riete 2008 bleeding score to identify patients at low risk for major bleeding in patients treated with rivaroxaban. Academic Emergency Medicine2015;22:S162. NCT00440193. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep vein thrombosis - The EINSTEIN DVT Study. clinicaltrials.gov/ct2/show/NCT00440193 (first received 26 February 2007). PrinsMH , ErkensPG , LensingAW . Incidence of recurrent venous thromboembolism in patients following completion of the EINSTEIN DVT and EINSTEIN PE studies. Journal of Thrombosis and Haemostasis2013;11(Suppl):257. PrinsMH , LensingAW , BauersachsR , Van BellenB , BounameauxH , BrightonTA , et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thrombosis Journal2013;11(1):21. The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. New England Journal of Medicine2010;363(26):2499-510. Van BellenB , PrinsM , BamberL , WangM , LensingAW . Reduction in initial length of stay with rivaroxaban single-drug regimen versus LMWH-VKA standard of care: findings from the EINSTEIN trial program. Blood2012;120(21):3419. Van BellenB , PrinsM , BamberL , WangM , LensingAW . Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism. Current Medical Research and Opinion2014;30(5):829-37. WangY , WangC , ChenZ , ZhangJ , LiuZ , JinB , et al. Rivaroxaban for the treatment of symptomatic deep vein thrombosis and/or pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):694. WangY , WangC , ChenZ , ZhangJ , LiuZ , JinB , et al. Rivaroxaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Thrombosis Journal2013;11(1):25. ">EINSTEIN‐DVT 2010</a>; <a href="./references#CD010956-bbs2-0008" title="BullerHR , PrinsMH , LensinAW , DecoususH , JacobsonBF , MinarE , et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. New England Journal of Medicine2012;366:1287-97. FermannGJ , Erkens Pmg, PrinsMH , WellsPS , Pap ÁF, LensingAW , et al. Treatment of pulmonary embolism with rivaroxaban: outcomes by simplified pulmonary embolism severity index score from a post hoc analysis of the EINSTEIN PE study. Academic Emergency Medicine2015;22(3):299-307. NCT00439777. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic pulmonary embolism with or without symptomatic deep-vein thrombosis: Einstein-PE evaluation, 2008. clinicaltrials.gov/ct2/show/NCT00439777?term=NCT00439777&amp;rank=1 (first received 26 February 2007). PrinsM , BamberL , CanoS , WangM , LensingAW , BauersachsR . Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic pulmonary embolism. Blood2012;120(21):1163. PrinsMH , BamberL , CanoSJ , WangMY , ErkensP , BauersachsR , et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial. Thrombosis Research2015;135(2):281-8. ">EINSTEIN‐PE 2012</a>; <a href="./references#CD010956-bbs2-0012" title="AmayaN , UzuiH , HisazakiK , HasegwaK , KasenoK , TadaH . Edoxaban normalizes the elevated D-dimer levels potently and promptly in patients with venous thromboembolisms: a comparison with traditional anticoagulant therapy. European Heart Journal2016;37:278. BoschFT , Van EsN , Di NisioM , CarrierM , SegersA , GrossoMA , et al. The Ottawa score does not predict recurrent venous thromboembolism in cancer patients: results from the Hokusai-VTE cancer study. Research and Practice in Thrombosis and Haemostasis2019;3(S1):717-8. KraaijpoelN , Di NisioM , MulderFI , Van EsN , RaskobGE . Clinical impact of bleeding in cancer-associated venous thromboembolism: results from the Hokusai VTE Cancer randomized trial. Thrombosis Research2018;164(Suppl 1):S223. [DOI: 10.1016/j.thromres.2018.02.094]MulderFI , Di NisioM , AyC , CarrierM , BoschFT , SegersA , et al. Clinical implications of incidental venous thromboembolism in cancer patients. European Respiratory Journal2020;55(2):1901697. [DOI: 10.1183/13993003.01697-2019]MulderFI , Van EsN , KraaijpoelN , Di NisioM , CarrierM , GarciaD , et al. Efficacy and safety of edoxaban in clinically relevant subgroups: results from the Hokusai VTE Cancer randomized trial. Thrombosis Research2018;164:S194. NCT02073682. Cancer venous thromboembolism (VTE). clinicaltrials.gov/ct2/show/NCT02073682 (first received 27 February 2014). RaskobG , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaD , et al. Edoxaban versus dalteparin for treatment of venous thromboembolism (VTE) associated with cancer: Hokusai VTE-cancer randomized trial. Supportive Care in Cancer2018;26(2):S316-S317. RaskobGE , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaD , et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. New England Journal of Medicine2018;378(7):615-24. RaskobGE , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaDA , et al. A randomized, open-label, blinded outcome assessment trial evaluating the efficacy and safety of LMWH/Edoxaban versus dalteparin for venous thromboembolism associated with cancer: Hokusai VTE-cancer study. Blood2017;130(Suppl 1):LBA-6. ">Hokusai VTE Cancer 2018</a>; <a href="./references#CD010956-bbs2-0011" title="BistervelsI , BavaliaR , BoersmaW , MeijerK , VerhammeP , Ten Cate-HoekAJ , et al. Hokusai Post-DVT Study: a follow-up study on long-term outcomes of deep vein thrombosis in patients treated with edoxaban vs warfarin. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):PB2207. BrekelmansMP , AgenoW , BeenenLF , BrennerB , BullerHR , ChenCZ , et al. Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology2016;3(9):e437-45. BrekelmansMP , BlekerSM , BauersachsR , BodaZ , BüllerHR , ChoiY , et al. Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists. Thrombosis and Haemostasis2016;116(1):155-61. Di NisioM , Van EsN , CarrierM , WangTF , GarciaD , SegersA , et al. Extended treatment with edoxaban in cancer patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE Cancer study. Journal of Thrombosis and Haemostasis2019;17:1866–74. EUCTR2009-014290-40-SE. A phase 3, randomized, double-blind, double-dummy, parallel group, multi-center, multi-national study for evaluation of efficacy and safety of DU-176b versus warfarin in subjects with atrial fibrillation - effective anticoagulation with factor Xa next generation in atrial fibrillation (ENGAGE-AF TIMI-48). trialsearch.who.int/?trialid=EUCTR2009-014290-40-SE (first received 30 November 2009). EichingerS , LinM , KyrlePA , GrossoMA . Recurrent venous thromboembolism during anticoagulation: an investigator-initiated post-hoc analysis of the hokusai-VTE trial. Blood2018;132:2539. KlokFA , BarcoS , KonstantinidesSV . External validation of the VTE-BLEED score for predicting major bleeding in stable anticoagulated patients with venous thromboembolism. Thrombosis and Haemostasis2017;117(6):1164-70. KraaijpoelN , Van EsN , RaskobGE , BüllerHR , CarrierM , ZhangG , et al. Risk scores for occult cancer in patients with venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2018;118(7):1270-8. MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMP , ChenCZ , et al. Outpatient management in patients with venous thromboembolism with edoxaban: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2017;117(12):2406-14. MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMP , ChenCZ , et al. Safety and efficacy of edoxaban compared with warfarin for the treatment of acute symptomatic deep-vein thrombosis in the outpatient setting. Research and Practice in Thrombosis and Haemostasis2017;1:913. MulderFI , Van EsN , KraaijpoelN , Di NisioM , CarrierM , DuggalA , et al. Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: results from the Hokusai VTE Cancer study. Thrombosis Research2020;185:13-9. NCT00986154. Comparative investigation of Low Molecular Weight (LMW) heparin/edoxaban tosylate (DU176b) versus (LMW) heparin/warfarin in the treatment of symptomatic deep-vein blood clots and/or lung blood clots. (The Edoxaban Hokusai-VTE Study). clinicaltrials.gov/ct2/show/NCT00986154 (first received 29 September 2009). NakamuraM , WangYQ , WangC , OhD , YinWH , KimuraT , et al. Efficacy and safety of edoxaban for treatment of venous thromboembolism: a subanalysis of East Asian patients in the Hokusai-VTE trial. Journal of Thrombosis and Haemostasis2015;13(9):1606-14. NybergJ , KarlssonKE , JönssonS , YinO , MillerR , KarlssonMO , et al. Edoxaban exposure-response analysis and clinical utility index assessment in patients with symptomatic deep-vein thrombosis or pulmonary embolism. CPT Pharmacometrics and Systems Pharmacology2016;5(4):222-32. RaskobG , AgenoW , CohenAT , BrekelmansMP , GrossoMA , SegersA , et al. Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology2016;3(5):e228-e236. RaskobG , BullerH , PrinsM , SegersA , ShiM , SchwochoL , et al. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study - methodological implications for clinical trials. Journal of Thrombosis and Haemostasis2013;11(7):1287-94. RaskobGE , BullerH , AngchaisuksiriP , OhD , BodaZ , LyonsRM , et al. Edoxaban for long-term treatment of venous thromboembolism in cancer patients. Blood2013;122(21):211. RaskobGE , Van EsN , SegersA , AngchaisuksiriP , OhD , BodaZ , et al. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematology2016;3(8):e379-87. ScheresLJ , BrekelmansMA , WalterA , CihanA , BüllerHR , SabineE , et al. Abnormal vaginal bleeding in women of reproductive age treated with edoxaban or warfarin for venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. British Journal of Obstetrics and Gynaecology2018;125(12):1581-9. The Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. New England Journal of Medicine2013;369(15):1406-15. VanasscheT , VerhammeP , WellsPS , SegersA , AgenoW , BrekelmansMP , et al. Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: an analysis of the randomized, double-blind Hokusai-VTE trial. Thrombosis Research2018;162:7-14. VerhammeP , WellsPS , SegersA , AgenoW , BrekelmansMP , CohenAT , et al. Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial. Thrombosis and Haemostasis2016;116(4):747-53. ">Hokusai‐VTE 2013</a>; <a href="./references#CD010956-bbs2-0016" title="OhmoriH , KadaA , NakamuraM , SaitoAM , SanayamaY , ShinagawaT , et al. Deep vein thrombosis in severe motor and intellectual disabilities patients and its treatment by anticoagulants of warfarin versus edoxaban. Annals of Vascular Diseases2019;12(3):372-8. OhmoriH , NakamuraM , KadaA , SaitoAM , SanayamaY , ShinagawaT , et al. Multicenter, open-label, randomized controlled trial of warfarin and edoxaban tosilate hydrate for the treatment of deep vein thrombosis in persons with severe motor intellectual disabilities. Kurume Medical Journal2018;65(1):11-6. ">Ohmori 2019</a>).  </p> </section> <section id="CD010956-sec-0059"> <h4 class="title">Other potential sources of bias</h4> <p>We judged the other risk of bias for all included studies as low as no potential risks were detected. </p> </section> </section> <section id="CD010956-sec-0060"> <h3 class="title" id="CD010956-sec-0060">Effects of interventions</h3> <p>See: <a href="./full#CD010956-tbl-0001"><b>Summary of findings 1</b> Oral DTIs versus conventional anticoagulation for participants with diagnosed DVT</a>; <a href="./full#CD010956-tbl-0002"><b>Summary of findings 2</b> Oral factor Xa inhibitors compared to conventional anticoagulation for participants with diagnosed DVT</a> </p> <section id="CD010956-sec-0061"> <h4 class="title">Oral direct thrombin inhibitors (DTIs) versus conventional anticoagulation</h4> <p>In the meta‐analysis of oral DTIs versus conventional anticoagulation, we used data from <a href="./references#CD010956-bbs2-0079" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21.">Goldhaber 2016</a>, as it reported the separate deep vein thrombosis (DVT) data for <a href="./references#CD010956-bbs2-0018" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00291330. Efficacy and safety of dabigatran compared to warfarin for 6 month treatment of acute symptomatic venous thromboembolism (RE-COVER I). clinicaltrials.gov/ct/show/NCT00291330 (first received 14 February 2006). SchulmanS , ErikssonH , GoldhaberS , KakkarAK , KearonC , KvammeAM , et al. Dabigatran or warfarin for extended maintenance therapy of venous thromboembolism. Journal of Thrombosis and Haemostasis2011;9(Suppl 2):731-2. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-COVER and RE-COVER II. Blood2013;122:2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RECOVER II. Blood2013;122(21):212. SchulmanS , ErikssonH , GoldhaverSZ , KakkarA , KearonC , MismettiP , et al. Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130:A18594. SchulmanS , KearonC , KakkarAK , MismettiP , SchellongS , ErikssonH , et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. New England Journal of Medicine2009;361(24):2342-52. ">RE‐COVER 2009</a> and <a href="./references#CD010956-bbs2-0019" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00680186. Phase III study testing efficacy &amp; safety of oral dabigatran etexilate vs warfarin for 6 m treatment for acute symp venous thromboembolism (VTE) (RE-COVER II). clinicaltrials.gov/ct2/show/NCT00680186 (first received 20 May 2008). SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-COVER and RE-COVER II. Blood2013;122:2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RECOVER II. Blood2013;122(21):212. SchulmanS , ErikssonH , GoldhaverSZ , KakkarA , KearonC , MismettiP , et al. Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130:A18594. SchulmanS , KakkarAK , GoldhaberSZ , SchellongS , ErikssonH , MismettiP , et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation2014;129:764-72. SchulmanS . A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II). Blood2011;118(21):95-6. ">RE‐COVER II 2014</a>. It combined these studies, which is reflected in the data analysis tables and <a href="./full#CD010956-tbl-0001">summary of findings Table 1</a> by showing only one study for this comparison. </p> <section id="CD010956-sec-0062"> <h5 class="title">Recurrent venous thromboembolism (VTE)</h5> <p>Meta‐analysis of three studies (5994 participants) showed no clear difference in the rate of recurrent VTE between the groups treated with a DTI and conventional anticoagulation with heparin and a VKA (<a href="./references#CD010956-bbs2-0018" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00291330. Efficacy and safety of dabigatran compared to warfarin for 6 month treatment of acute symptomatic venous thromboembolism (RE-COVER I). clinicaltrials.gov/ct/show/NCT00291330 (first received 14 February 2006). SchulmanS , ErikssonH , GoldhaberS , KakkarAK , KearonC , KvammeAM , et al. Dabigatran or warfarin for extended maintenance therapy of venous thromboembolism. Journal of Thrombosis and Haemostasis2011;9(Suppl 2):731-2. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-COVER and RE-COVER II. Blood2013;122:2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RECOVER II. Blood2013;122(21):212. SchulmanS , ErikssonH , GoldhaverSZ , KakkarA , KearonC , MismettiP , et al. Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130:A18594. SchulmanS , KearonC , KakkarAK , MismettiP , SchellongS , ErikssonH , et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. New England Journal of Medicine2009;361(24):2342-52. ">RE‐COVER 2009</a>; <a href="./references#CD010956-bbs2-0019" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00680186. Phase III study testing efficacy &amp; safety of oral dabigatran etexilate vs warfarin for 6 m treatment for acute symp venous thromboembolism (VTE) (RE-COVER II). clinicaltrials.gov/ct2/show/NCT00680186 (first received 20 May 2008). SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-COVER and RE-COVER II. Blood2013;122:2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RECOVER II. Blood2013;122(21):212. SchulmanS , ErikssonH , GoldhaverSZ , KakkarA , KearonC , MismettiP , et al. Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130:A18594. SchulmanS , KakkarAK , GoldhaberSZ , SchellongS , ErikssonH , MismettiP , et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation2014;129:764-72. SchulmanS . A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II). Blood2011;118(21):95-6. ">RE‐COVER II 2014</a>; <a href="./references#CD010956-bbs2-0021" title="FiessingerJN , HuismanMV , DavidsonBL , BounameauxH , FrancisCW , ErikssonH , et al. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomised trial. JAMA2005;293(6):681-9. FrancisCW , GinsbergJS , BerkowitzSD , BounameauxH , DavidsonBL , ErikssonH , et al. Efficacy and safety of the oral direct thrombin inhibitor ximelagatran compared with current therapy for acute, symptomatic deep vein thrombosis, with or without pulmonary embolus: the THRIVE treatment study. Blood2003;102(11):Abstract 7. HarenbergJ , IngridJ , TivadarF . Treatment of venous thromboembolism with the oral thrombin inhibitor, ximelagatran. Israel Medical Association Journal2002;4(11):1003-5. HarenbergJ , JoergI , WeissC . Incidence of recurrent venous thromboembolism of patients after termination of treatment with ximelagatran. European Journal of Clinical Pharmacology2006;62(3):173-7. HarenbergJ , JorgI , WeissC , HarenbergJ , JorgI , WeissC . Observations of alanine aminotransferase and aspartate aminotransferase in THRIVE studies treated orally with ximelagatran. International Journal of Toxicology2006;25(3):165-9. HuismanMV , The THRIVE Treatment Study Investigators. Efficacy and safety of the oral direct thrombin inhibitor ximelagatran compared with current standard therapy for acute symptomatic deep vein thrombosis, with or without pulmonary embolism: a randomized, double-blind, multinational study. Journal of Thrombosis and Haemostasis2003;1(Suppl 1):Abstract OC003. WimperisJ , FiessingerJN , HuismanMV , DavidsonBL , BounameauxH , FrancisCW , et al. Ximelagatran, an oral direct thrombin inhibitor, compared with current standard therapy for acute, symptomatic deep vein thrombosis, with or without pulmonary embolism: the THRIVE treatment study. British Journal of Haematology2004;125(Suppl 1):66. ">THRIVE 2005</a>). The incidence was 2.37% (71 events/2998 participants) in the DTI group and 2.04% (61 events/2996 participants) in the conventional anticoagulation group, leading to an odds ratio (OR) of 1.17 (95% confidence interval (CI) 0.83 to 1.65; 3 studies, 5994 participants; I<sup>2</sup> = 0%; moderate‐certainty evidence; <a href="./references#CD010956-fig-0006" title="">Analysis 1.1</a>).  </p> </section> <section id="CD010956-sec-0063"> <h5 class="title">Recurrent deep vein thrombosis</h5> <p>Three studies reported recurrent DVT (<a href="./references#CD010956-bbs2-0018" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00291330. Efficacy and safety of dabigatran compared to warfarin for 6 month treatment of acute symptomatic venous thromboembolism (RE-COVER I). clinicaltrials.gov/ct/show/NCT00291330 (first received 14 February 2006). SchulmanS , ErikssonH , GoldhaberS , KakkarAK , KearonC , KvammeAM , et al. Dabigatran or warfarin for extended maintenance therapy of venous thromboembolism. Journal of Thrombosis and Haemostasis2011;9(Suppl 2):731-2. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-COVER and RE-COVER II. Blood2013;122:2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RECOVER II. Blood2013;122(21):212. SchulmanS , ErikssonH , GoldhaverSZ , KakkarA , KearonC , MismettiP , et al. Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130:A18594. SchulmanS , KearonC , KakkarAK , MismettiP , SchellongS , ErikssonH , et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. New England Journal of Medicine2009;361(24):2342-52. ">RE‐COVER 2009</a>; <a href="./references#CD010956-bbs2-0019" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00680186. Phase III study testing efficacy &amp; safety of oral dabigatran etexilate vs warfarin for 6 m treatment for acute symp venous thromboembolism (VTE) (RE-COVER II). clinicaltrials.gov/ct2/show/NCT00680186 (first received 20 May 2008). SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-COVER and RE-COVER II. Blood2013;122:2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RECOVER II. Blood2013;122(21):212. SchulmanS , ErikssonH , GoldhaverSZ , KakkarA , KearonC , MismettiP , et al. Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130:A18594. SchulmanS , KakkarAK , GoldhaberSZ , SchellongS , ErikssonH , MismettiP , et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation2014;129:764-72. SchulmanS . A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II). Blood2011;118(21):95-6. ">RE‐COVER II 2014</a>; <a href="./references#CD010956-bbs2-0021" title="FiessingerJN , HuismanMV , DavidsonBL , BounameauxH , FrancisCW , ErikssonH , et al. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomised trial. JAMA2005;293(6):681-9. FrancisCW , GinsbergJS , BerkowitzSD , BounameauxH , DavidsonBL , ErikssonH , et al. Efficacy and safety of the oral direct thrombin inhibitor ximelagatran compared with current therapy for acute, symptomatic deep vein thrombosis, with or without pulmonary embolus: the THRIVE treatment study. Blood2003;102(11):Abstract 7. HarenbergJ , IngridJ , TivadarF . Treatment of venous thromboembolism with the oral thrombin inhibitor, ximelagatran. Israel Medical Association Journal2002;4(11):1003-5. HarenbergJ , JoergI , WeissC . Incidence of recurrent venous thromboembolism of patients after termination of treatment with ximelagatran. European Journal of Clinical Pharmacology2006;62(3):173-7. HarenbergJ , JorgI , WeissC , HarenbergJ , JorgI , WeissC . Observations of alanine aminotransferase and aspartate aminotransferase in THRIVE studies treated orally with ximelagatran. International Journal of Toxicology2006;25(3):165-9. HuismanMV , The THRIVE Treatment Study Investigators. Efficacy and safety of the oral direct thrombin inhibitor ximelagatran compared with current standard therapy for acute symptomatic deep vein thrombosis, with or without pulmonary embolism: a randomized, double-blind, multinational study. Journal of Thrombosis and Haemostasis2003;1(Suppl 1):Abstract OC003. WimperisJ , FiessingerJN , HuismanMV , DavidsonBL , BounameauxH , FrancisCW , et al. Ximelagatran, an oral direct thrombin inhibitor, compared with current standard therapy for acute, symptomatic deep vein thrombosis, with or without pulmonary embolism: the THRIVE treatment study. British Journal of Haematology2004;125(Suppl 1):66. ">THRIVE 2005</a>). The incidence was 1.70% (51 events/2998 participants) in the DTI group and 1.54% (46 events/2996 participants) in the conventional anticoagulation group, leading to an OR of 1.11 (95% CI 0.74 to 1.66; 3 studies, 5994 participants; I<sup>2</sup> = 0%; moderate‐certainty evidence; <a href="./references#CD010956-fig-0007" title="">Analysis 1.2</a>).  </p> </section> <section id="CD010956-sec-0064"> <h5 class="title">Fatal pulmonary embolism</h5> <p>The same three studies reported fatal PE. The incidence of fatal PE was 0.13% (4 events/2998 participants) in the DTI group compared with 0.10% (3 events/2996 participants) in the conventional anticoagulation group (OR 1.32, 95% CI 0.29 to 6.02; 3 studies, 5994 participants; I<sup>2</sup> = 0%; moderate‐certainty evidence; <a href="./references#CD010956-fig-0008" title="">Analysis 1.3</a>). </p> </section> <section id="CD010956-sec-0065"> <h5 class="title">Non‐fatal pulmonary embolism</h5> <p>The same three studies reported non‐fatal PE, which occurred in 0.60% (18 events/2998 participants) of DTI participants and 0.47% (14 events/2996 participants) of conventional anticoagulation participants (OR 1.29, 95% CI 0.64 to 2.59; 3 studies, 5994 participants; I<sup>2</sup> = 0%; moderate‐certainty evidence; <a href="./references#CD010956-fig-0009" title="">Analysis 1.4</a>).  </p> </section> <section id="CD010956-sec-0066"> <h5 class="title">All‐cause mortality</h5> <p>We could not obtain the all‐cause mortality data from <a href="./references#CD010956-bbs2-0018" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00291330. Efficacy and safety of dabigatran compared to warfarin for 6 month treatment of acute symptomatic venous thromboembolism (RE-COVER I). clinicaltrials.gov/ct/show/NCT00291330 (first received 14 February 2006). SchulmanS , ErikssonH , GoldhaberS , KakkarAK , KearonC , KvammeAM , et al. Dabigatran or warfarin for extended maintenance therapy of venous thromboembolism. Journal of Thrombosis and Haemostasis2011;9(Suppl 2):731-2. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-COVER and RE-COVER II. Blood2013;122:2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RECOVER II. Blood2013;122(21):212. SchulmanS , ErikssonH , GoldhaverSZ , KakkarA , KearonC , MismettiP , et al. Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130:A18594. SchulmanS , KearonC , KakkarAK , MismettiP , SchellongS , ErikssonH , et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. New England Journal of Medicine2009;361(24):2342-52. ">RE‐COVER 2009</a> and <a href="./references#CD010956-bbs2-0019" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00680186. Phase III study testing efficacy &amp; safety of oral dabigatran etexilate vs warfarin for 6 m treatment for acute symp venous thromboembolism (VTE) (RE-COVER II). clinicaltrials.gov/ct2/show/NCT00680186 (first received 20 May 2008). SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-COVER and RE-COVER II. Blood2013;122:2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RECOVER II. Blood2013;122(21):212. SchulmanS , ErikssonH , GoldhaverSZ , KakkarA , KearonC , MismettiP , et al. Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130:A18594. SchulmanS , KakkarAK , GoldhaberSZ , SchellongS , ErikssonH , MismettiP , et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation2014;129:764-72. SchulmanS . A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II). Blood2011;118(21):95-6. ">RE‐COVER II 2014</a> from any report or by contacting authors. There was no difference in the rate of all‐cause mortality between the two treatment groups based on data from <a href="./references#CD010956-bbs2-0021" title="FiessingerJN , HuismanMV , DavidsonBL , BounameauxH , FrancisCW , ErikssonH , et al. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomised trial. JAMA2005;293(6):681-9. FrancisCW , GinsbergJS , BerkowitzSD , BounameauxH , DavidsonBL , ErikssonH , et al. Efficacy and safety of the oral direct thrombin inhibitor ximelagatran compared with current therapy for acute, symptomatic deep vein thrombosis, with or without pulmonary embolus: the THRIVE treatment study. Blood2003;102(11):Abstract 7. HarenbergJ , IngridJ , TivadarF . Treatment of venous thromboembolism with the oral thrombin inhibitor, ximelagatran. Israel Medical Association Journal2002;4(11):1003-5. HarenbergJ , JoergI , WeissC . Incidence of recurrent venous thromboembolism of patients after termination of treatment with ximelagatran. European Journal of Clinical Pharmacology2006;62(3):173-7. HarenbergJ , JorgI , WeissC , HarenbergJ , JorgI , WeissC . Observations of alanine aminotransferase and aspartate aminotransferase in THRIVE studies treated orally with ximelagatran. International Journal of Toxicology2006;25(3):165-9. HuismanMV , The THRIVE Treatment Study Investigators. Efficacy and safety of the oral direct thrombin inhibitor ximelagatran compared with current standard therapy for acute symptomatic deep vein thrombosis, with or without pulmonary embolism: a randomized, double-blind, multinational study. Journal of Thrombosis and Haemostasis2003;1(Suppl 1):Abstract OC003. WimperisJ , FiessingerJN , HuismanMV , DavidsonBL , BounameauxH , FrancisCW , et al. Ximelagatran, an oral direct thrombin inhibitor, compared with current standard therapy for acute, symptomatic deep vein thrombosis, with or without pulmonary embolism: the THRIVE treatment study. British Journal of Haematology2004;125(Suppl 1):66. ">THRIVE 2005</a>. The incidence was 2.26% (28 events/1240 participants) in the DTI (ximelagatran) group and 3.36% (42 events/1249 participants) in the conventional anticoagulation group, with an OR of 0.66 (95% CI 0.41 to 1.08; 1 study, 2489 participants; moderate‐certainty evidence; <a href="./references#CD010956-fig-0010" title="">Analysis 1.5</a>).  </p> </section> <section id="CD010956-sec-0067"> <h5 class="title">Major bleeding</h5> <p>Meta‐analysis showed that DTIs were associated with fewer major bleeding episodes than conventional anticoagulation therapy. Of the DTI participants, 1.13% (34 events/2998 participants) had a major clinically relevant bleeding episode compared with 1.94% (58 events/2996 participants) of conventional anticoagulation participants, resulting in an OR of 0.58 (95% CI 0.38 to 0.89; 3 studies, 5994 participants; I<sup>2</sup> = 0%; high‐certainty evidence; <a href="./references#CD010956-fig-0011" title="">Analysis 1.6</a>).  </p> </section> <section id="CD010956-sec-0068"> <h5 class="title">Post‐thrombotic syndrome</h5> <p>None of the included studies measured PTS as an outcome.</p> </section> <section id="CD010956-sec-0069"> <h5 class="title">Health‐related quality of life</h5> <p><a href="./references#CD010956-bbs2-0020" title="SukovatykhBS , SereditskiĭAV , MuradianVF , BelikovLN , GerasimovaOF . Results of administering oral anticoagulants for treatment of patients with venous thromboembolic complications. Angiologiia i sosudistaia khirurgiia [Angiology and Vascular Surgery]2017;23(2):82. ">Sukovatykh 2017</a> used SF‐36 scales to measure the quality of life (0 to 100 mm scales where a higher score indicates better health). The study authors did not report the overall score and baseline data, so we collected data as physical component of health and psychological component of health at 12 months as these were reported. Both indices appeared to be higher in the dabigatran group compared to the warfarin group: physical component: mean difference (MD) 6.75 (95% CI 2.37 to 11.13; 1 study, 75 participants; <a href="./references#CD010956-fig-0012" title="">Analysis 1.7</a>) and psychological component: MD 6.45 (95% CI 3.24 to 9.66; 1 study, 75 participants; <a href="./references#CD010956-fig-0013" title="">Analysis 1.8</a>). </p> </section> <section id="CD010956-sec-0070"> <h5 class="title">Sensitivity analyses</h5> <p>As part of the planned sensitivity analysis, we removed the <a href="./references#CD010956-bbs2-0021" title="FiessingerJN , HuismanMV , DavidsonBL , BounameauxH , FrancisCW , ErikssonH , et al. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomised trial. JAMA2005;293(6):681-9. FrancisCW , GinsbergJS , BerkowitzSD , BounameauxH , DavidsonBL , ErikssonH , et al. Efficacy and safety of the oral direct thrombin inhibitor ximelagatran compared with current therapy for acute, symptomatic deep vein thrombosis, with or without pulmonary embolus: the THRIVE treatment study. Blood2003;102(11):Abstract 7. HarenbergJ , IngridJ , TivadarF . Treatment of venous thromboembolism with the oral thrombin inhibitor, ximelagatran. Israel Medical Association Journal2002;4(11):1003-5. HarenbergJ , JoergI , WeissC . Incidence of recurrent venous thromboembolism of patients after termination of treatment with ximelagatran. European Journal of Clinical Pharmacology2006;62(3):173-7. HarenbergJ , JorgI , WeissC , HarenbergJ , JorgI , WeissC . Observations of alanine aminotransferase and aspartate aminotransferase in THRIVE studies treated orally with ximelagatran. International Journal of Toxicology2006;25(3):165-9. HuismanMV , The THRIVE Treatment Study Investigators. Efficacy and safety of the oral direct thrombin inhibitor ximelagatran compared with current standard therapy for acute symptomatic deep vein thrombosis, with or without pulmonary embolism: a randomized, double-blind, multinational study. Journal of Thrombosis and Haemostasis2003;1(Suppl 1):Abstract OC003. WimperisJ , FiessingerJN , HuismanMV , DavidsonBL , BounameauxH , FrancisCW , et al. Ximelagatran, an oral direct thrombin inhibitor, compared with current standard therapy for acute, symptomatic deep vein thrombosis, with or without pulmonary embolism: the THRIVE treatment study. British Journal of Haematology2004;125(Suppl 1):66. ">THRIVE 2005</a> study testing ximelagatran from the meta‐analyses since the drug is no longer available (<a href="./references#CD010956-fig-0014" title="">Analysis 2.1</a>; <a href="./references#CD010956-fig-0015" title="">Analysis 2.2</a>; <a href="./references#CD010956-fig-0016" title="">Analysis 2.3</a>; <a href="./references#CD010956-fig-0017" title="">Analysis 2.4</a>; <a href="./references#CD010956-fig-0018" title="">Analysis 2.5</a>). Excluding these results had little effect on the outcomes. The rate of recurrent VTE (OR 1.21, 95% CI 0.78 to 1.89), recurrent DVT (OR 1.24, 95% CI 0.76 to 2.03), fatal PE (OR 0.66, 95% CI 0.11 to 3.97) and non‐fatal PE (OR 1.12, 95% CI 0.43 to 2.91) remained similar between participants treated with dabigatran and participants treated with a VKA. However, excluding the ximelagatran study resulted in a similar point estimate for major bleeding but was no longer statistically significant (OR 0.62, 95% CI 0.35 to 1.08) due to insufficient statistical power. </p> <p>We deemed no studies to be at high risk of bias, therefore, we did not perform a sensitivity analysis excluding studies judged to be of high risk of bias. </p> </section> </section> <section id="CD010956-sec-0071"> <h4 class="title">Oral factor Xa inhibitors versus conventional anticoagulation</h4> <section id="CD010956-sec-0072"> <h5 class="title">Recurrent venous thromboembolism</h5> <p>Meta‐analysis of 13 studies (17,505 participants) demonstrated that there was no clear difference in the rate of recurrent VTE in participants treated with an oral factor Xa inhibitor compared with conventional anticoagulation (<a href="./references#CD010956-bbs2-0001" title="AgnelliG , BullerH , MasiukiewiczUP . Apixaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism: a randomized, double-blind trial (AMPLIFY). Journal of Thrombosis and Haemostasis2013;11:18. AgnelliG , BullerHR , CohenA , CurtoD , GallusAS , JohnsonM , et al. Oral apixaban for the treatment of acute venous thromboembolism. New England Journal of Medicine2013;369:799-808. AgnelliG , BullerHR , CohenA , CurtoM , GallusAS , PakR , et al. Apixaban for the treatment of venous thromboembolism in cancer patients: data from the AMPLIFY trial. Canadian Journal of Cardiology2014;30(10 Suppl 1):S278. AgnelliG , BullerHR , CohenA , GallusAS , LeeTC , PakR , et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. Journal of Thrombosis and Haemostasis2015;13(12):2187-91. AgnelliG . Apixaban was non-inferior to enoxaparin plus warfarin in patients with acute venous thromboembolism. Annals of Internal Medicine2013;159(8):JC2. BlekerSM , CohenAT , BüllerHR , AgnelliG , GallusAS , RaskobGE , et al. Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Thrombosis and Haemostasis2016;116(6):159-64. BrekelmansM , ScheresL , BlekerS , HuttenB , TimmermansA , BüllerH , et al. Abnormal vaginal bleeding in women with venous thromboembolism treated with apixaban or warfarin. Thrombosis and Haemostasis2017;117(04):809-15. CohenA , AgnelliG , BullerH , GallusA , RaskobG , SandersP , et al. Characteristics and outcomes in patients with venous thromboembolism taking concomitant anti-platelet agents and anticoagulants in the AMPLIFY Trial. Thrombosis and Haemostasis2019;119(3):461-6. CohenA , AgnelliG , BullerHR , ChaudhuriS , GallusAS , RaskobGE , et al. Analysis of the bleeding and thromboembolic risk with concomitant use of antiplatelet treatment in the AMPLIFY trial. Canadian Journal of Cardiology2014;30(10):S272. CohenA , GallusAS , AgnelliG , BullerHR , PakR , PorcariAR , et al. Time in Therapeutic Range (TTR) and relative efficacy and safety of treatment with apixaban or enoxaparin/warfarin for acute symptomatic venous thromboembolism: an analysis of the Amplify trial data. Blood2014;124(21):1543. CohenAT , PanS , ByonW , IlyasBS , LeeTC . Efficacy, safety, and exposure of apixaban in patients with high body weight or obesity and venous thromboembolism: insights from AMPLIFY. Advances in Therapy2021;38(6):3003-18. EUCTR2007-007867-25-PT. A safety and efficacy trial evaluating the use of apixaban in the treatment of symptomatic deep vein thrombosis and pulmonary embolism revised protocol number: 01, incorporates amendment(s) 02 + protocol amendment 01 (version 1.0 dated 21-Apr-08) site-specific - molecular profiling supplement samples for Pfizer’s exploratory research biobank. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2007%E2%80%90007867%E2%80%9025%E2%80%90PT (first received 14 July 2008). GallusAS , AgnelliG , BullerHR , CohenA , LeeTC , PakR , et al. Apixaban for treatment of venous thromboembolism in patients from study centres in Asia: a subgroup analysis of the Amplify trial. Journal of Thrombosis and Haemostasis2015;13:727. LeeT , PanS , ByonW , IlyasBS . Safety and efficacy of apixaban versus enoxaparin/warfarin in patients with extremes of body weight: post-hoc analysis of the AMPLIFY trial. Blood2019;134(Suppl 1):1152. LiuX , JohnsonM , MardekianJ , PhatakH , ThompsonJ , CohenAT . Apixaban reduces hospitalizations in patients with venous thromboembolism: an analysis of the apixaban for the Initial management of pulmonary embolism and deep‐vein thrombosis as first‐line therapy (AMPLIFY) trial. Journal of the American Heart Association2015;4(12):e002340. NCT00633893. Efficacy and safety study of apixaban for extended treatment of deep vein thrombosis or pulmonary embolism. clinicaltrials.gov/ct2/show/NCT00633893?term=ajax&amp;rank=5 (first received 12 March 2008). NCT00643201. Efficacy and safety study of apixaban for the treatment of deep vein thrombosis or pulmonary embolism. clinicaltrials.gov/ct2/show/NCT00643201 (first received 26 March 2008). RaskobGE , GallusAS , SandersP , ThompsonJR , AgnelliG , BullerHR , et al. Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy: a sub-analysis of the AMPLIFY trial. Thrombosis and Haemostasis2016;115(4):809-16. ">AMPLIFY 2013</a>; <a href="./references#CD010956-bbs2-0002" title="NakamuraM , NishikawaM , KomuroI , KitajimaI , UetsukaY , YamagamiT , et al. Apixaban for the treatment of Japanese subjects with acute venous thromboembolism (AMPLIFY-J Study). Circulation2015;79(6):1230–36. ">AMPLIFY‐J 2015</a>; <a href="./references#CD010956-bbs2-0003" title="BarrettYC , WangJ , KnabbR , MohanP . Apixaban decreases coagulation activity in patients with acute deep-vein thrombosis. Thrombosis and Haemostasis2011;105:181-9. Botticelli Investigators Writing Committee, BullerH , DeitchmanD , PrinsM , SegersA . Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. Journal of Thrombosis and Haemostasis2008;6:1313-8. BullerHR . A dose finding study of the oral direct factor Xa inhibitor apixaban in the treatment of patients with acute symptomatic deep vein thrombosis - the Botticelli Investigators. Journal of Thrombosis and Haemostasis2007;5 (Suppl 2):O-S-003. NCT00252005. Oral direct factor Xa-inhibitor apixaban in patients with acute symptomatic deep-vein thrombosis - the Botticelli DVT study. clinicaltrials.gov/ct/show/NCT00252005?order=1 (first received 11 November 2005). ">Botticelli DVT 2008</a>; <a href="./references#CD010956-bbs2-0004" title="AgenoW , VedovatiMC , CohenA , HuismanM , BauersachsR , GussoniG , et al. Bleeding with apixaban and dalteparin in patients with cancer-associated venous thromboembolism: results from the Caravaggio study. Thrombosis and Haemostasis2021;121(5):616-24. AgnelliG , BecattiniC , BauersachsR , BrennerB , CampaniniM , CohenA , et al. Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the Caravaggio study. Thrombosis and Haemostasis2018;118(9):1668-78. AgnelliG , BecattiniC , MeyerG , MuozA , VersoM . Apixaban for the treatment of venous thromboembolism associated with cancer. New England Journal of Medicine2020;382(17):1599-607. AgnelliG , MuozA , FrancoL , MahéI , BrennerB , ConnorsJM , et al. Apixaban and dalteparin for the treatment of venous thromboembolism in patients with different sites of cancer. Thrombosis and Haemostasis2022;122(5):796-807. BecattiniC , BauersachsR , MarazitiG , BertolettiL , CohenA , ConnorsJM , et al. Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial. Haematologica2021;107(7):1567-76. GiustozziM , ConnorsJM , Ruperez BlancoAB , SzmitS , FalvoN , CohenAT , et al. Clinical characteristics and outcomes of incidental venous thromboembolism in cancer patients: insights from the Caravaggio study. Journal of Thrombosis and Haemostasis2021;19(11):2751-9. NCT03045406. Apixaban for the treatment of venous thromboembolism in patients with cancer (CARAVAGGIO). clinicaltrials.gov/ct2/show/NCT03045406 (first received 7 February 2017). VersoM , MunozA , BauersachsR , HuismanMV , AgnelliG . Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism. European Journal of Cancer2021;148(Suppl C):371-81. ">Caravaggio 2020</a>; <a href="./references#CD010956-bbs2-0007" title="BullerH , DariusH . EINSTEIN DVT: oral rivaroxaban versus standard therapy in the initial treatment of symptomatic deep vein thrombosis and long-term prevention of recurrent venous thromboembolism. escardio.org/The-ESC/Press-Office/Press-releases/EINSTEIN-DVT-Oral-rivaroxaban-versus-standard-therapy-in-the-initial-treatment (accessed 19 October 2022). BullerHR , AgnelliG . Once- or twice-daily rivaroxaban for the treatment of proximal deep vein thrombosis: similar efficacy and safety to standard therapy in dose-ranging studies. Blood2006;108(11 Part 1):172-3. BullerHR , LensingAW , PrinsMH , AgnelliG , CohenA , GallusAS , et al. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT dose-ranging study. Blood2008;112(6):2242-7. NCT00395772. Once-daily oral direct factor Xa inhibitor BAY59-7939 in patients with acute symptomatic deep-vein thrombosis. clinicaltrials.gov/ct2/show/NCT00395772?term=einstein-dvt&amp;rank=2 (first received 3 November 2006). ">EINSTEIN‐DVT dose 2008</a>; <a href="./references#CD010956-bbs2-0006" title="BamberL , WangMY , PrinsMH , CiniglioC , BauersachsR , LensingAW , et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis. Thrombosis and Haemostasis2013;110(4):732-41. BauersachsR , LensingAW , PapA , DecoususH . No need for a rivaroxaban dose reduction in renally impaired patients with symptomatic venous thromboembolism. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):30-1. BistervelsI , GebelM , LensingA , MiddeldorpS , CoppensM . Effect of polypharmacy on bleeding of rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolism. Research and Practice in Thrombosis and Haemostasis2019;3:798‐9. BookhartBK , HaskellL , BamberL , WangM , ScheinJ , ModySH . Length of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial program. Journal of Medical Economics2014;17(10):691-5. BullerHR . Oral rivaroxaban for the acute and continued treatment of symptomatic venous thromboembolism. The Einstein-DVT and Einstein-Extension study. Blood2010;116(21):187. CheungW , MiddeldorpS , PrinsMP , PapAF , LensingAW , Hoek-tenCA , et al. Post thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep vein thrombosis. Journal of Thrombosis and Haemostasis2015;13(S2):219-20. CheungYW , MiddeldorpS , PrinsMH , PapAF , PrandoniP . Post-thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep-vein thrombosis. A post-hoc analysis. Thrombosis and Haemostasis2016;116(4):733-8. EUCTR2004-002171-16-IT. Once-daily oral direct factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis. The EINSTEIN-DVT dose-finding study. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2004%E2%80%90002171%E2%80%9016%E2%80%90IT (first received 15 October 2008). EUCTR2006-004495-13-DK. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep-vein thrombosis or pulmonary embolism. trialsearch.who.int/?TrialID=EUCTR2006-004495-13-DK (first received 29 March 2007). EerenbergES , MiddeldorpS , LeviM , LensingAW , BüllerHR . Clinical impact and course of major bleeding with rivaroxaban and vitamin K antagonists. Journal of Thrombosis and Haemostasis2015;13(9):1590-6. KlineJA , JimenezD , CourtneyDM , IanusJ , CaoL , WellsPS . Use of the Riete 2008 bleeding score to identify patients at low risk for major bleeding in patients treated with rivaroxaban. Academic Emergency Medicine2015;22:S162. NCT00440193. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep vein thrombosis - The EINSTEIN DVT Study. clinicaltrials.gov/ct2/show/NCT00440193 (first received 26 February 2007). PrinsMH , ErkensPG , LensingAW . Incidence of recurrent venous thromboembolism in patients following completion of the EINSTEIN DVT and EINSTEIN PE studies. Journal of Thrombosis and Haemostasis2013;11(Suppl):257. PrinsMH , LensingAW , BauersachsR , Van BellenB , BounameauxH , BrightonTA , et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thrombosis Journal2013;11(1):21. The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. New England Journal of Medicine2010;363(26):2499-510. Van BellenB , PrinsM , BamberL , WangM , LensingAW . Reduction in initial length of stay with rivaroxaban single-drug regimen versus LMWH-VKA standard of care: findings from the EINSTEIN trial program. Blood2012;120(21):3419. Van BellenB , PrinsM , BamberL , WangM , LensingAW . Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism. Current Medical Research and Opinion2014;30(5):829-37. WangY , WangC , ChenZ , ZhangJ , LiuZ , JinB , et al. Rivaroxaban for the treatment of symptomatic deep vein thrombosis and/or pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):694. WangY , WangC , ChenZ , ZhangJ , LiuZ , JinB , et al. Rivaroxaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Thrombosis Journal2013;11(1):25. ">EINSTEIN‐DVT 2010</a>; <a href="./references#CD010956-bbs2-0008" title="BullerHR , PrinsMH , LensinAW , DecoususH , JacobsonBF , MinarE , et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. New England Journal of Medicine2012;366:1287-97. FermannGJ , Erkens Pmg, PrinsMH , WellsPS , Pap ÁF, LensingAW , et al. Treatment of pulmonary embolism with rivaroxaban: outcomes by simplified pulmonary embolism severity index score from a post hoc analysis of the EINSTEIN PE study. Academic Emergency Medicine2015;22(3):299-307. NCT00439777. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic pulmonary embolism with or without symptomatic deep-vein thrombosis: Einstein-PE evaluation, 2008. clinicaltrials.gov/ct2/show/NCT00439777?term=NCT00439777&amp;rank=1 (first received 26 February 2007). PrinsM , BamberL , CanoS , WangM , LensingAW , BauersachsR . Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic pulmonary embolism. Blood2012;120(21):1163. PrinsMH , BamberL , CanoSJ , WangMY , ErkensP , BauersachsR , et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial. Thrombosis Research2015;135(2):281-8. ">EINSTEIN‐PE 2012</a>; <a href="./references#CD010956-bbs2-0009" title="PiazzaG , ManiV , GoldhaberSZ , GrossoMA , MercuriM , LanzHJ , et al. Magnetic resonance venography to assess thrombus resolution with edoxaban monotherapy versus parenteral anticoagulation/warfarin for symptomatic deep vein thrombosis: a multicenter feasibility study. Vascular Medicine2016;21(4):361-8. PiazzaG , ManiV , GrossoM , MercuriM , LanzH , SchusslerS , et al. A randomized, open-label, multicenter study of the efficacy and safety of edoxaban monotherapy versus low-molecular weight heparin/warfarin in patients with symptomatic deep vein thrombosis-edoxaban thrombus reduction imaging study (etris). Circulation2014;130:A12074. ">eTRIS 2016</a>; <a href="./references#CD010956-bbs2-0012" title="AmayaN , UzuiH , HisazakiK , HasegwaK , KasenoK , TadaH . Edoxaban normalizes the elevated D-dimer levels potently and promptly in patients with venous thromboembolisms: a comparison with traditional anticoagulant therapy. European Heart Journal2016;37:278. BoschFT , Van EsN , Di NisioM , CarrierM , SegersA , GrossoMA , et al. The Ottawa score does not predict recurrent venous thromboembolism in cancer patients: results from the Hokusai-VTE cancer study. Research and Practice in Thrombosis and Haemostasis2019;3(S1):717-8. KraaijpoelN , Di NisioM , MulderFI , Van EsN , RaskobGE . Clinical impact of bleeding in cancer-associated venous thromboembolism: results from the Hokusai VTE Cancer randomized trial. Thrombosis Research2018;164(Suppl 1):S223. [DOI: 10.1016/j.thromres.2018.02.094]MulderFI , Di NisioM , AyC , CarrierM , BoschFT , SegersA , et al. Clinical implications of incidental venous thromboembolism in cancer patients. European Respiratory Journal2020;55(2):1901697. [DOI: 10.1183/13993003.01697-2019]MulderFI , Van EsN , KraaijpoelN , Di NisioM , CarrierM , GarciaD , et al. Efficacy and safety of edoxaban in clinically relevant subgroups: results from the Hokusai VTE Cancer randomized trial. Thrombosis Research2018;164:S194. NCT02073682. Cancer venous thromboembolism (VTE). clinicaltrials.gov/ct2/show/NCT02073682 (first received 27 February 2014). RaskobG , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaD , et al. Edoxaban versus dalteparin for treatment of venous thromboembolism (VTE) associated with cancer: Hokusai VTE-cancer randomized trial. Supportive Care in Cancer2018;26(2):S316-S317. RaskobGE , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaD , et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. New England Journal of Medicine2018;378(7):615-24. RaskobGE , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaDA , et al. A randomized, open-label, blinded outcome assessment trial evaluating the efficacy and safety of LMWH/Edoxaban versus dalteparin for venous thromboembolism associated with cancer: Hokusai VTE-cancer study. Blood2017;130(Suppl 1):LBA-6. ">Hokusai VTE Cancer 2018</a>; <a href="./references#CD010956-bbs2-0011" title="BistervelsI , BavaliaR , BoersmaW , MeijerK , VerhammeP , Ten Cate-HoekAJ , et al. Hokusai Post-DVT Study: a follow-up study on long-term outcomes of deep vein thrombosis in patients treated with edoxaban vs warfarin. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):PB2207. BrekelmansMP , AgenoW , BeenenLF , BrennerB , BullerHR , ChenCZ , et al. Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology2016;3(9):e437-45. BrekelmansMP , BlekerSM , BauersachsR , BodaZ , BüllerHR , ChoiY , et al. Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists. Thrombosis and Haemostasis2016;116(1):155-61. Di NisioM , Van EsN , CarrierM , WangTF , GarciaD , SegersA , et al. Extended treatment with edoxaban in cancer patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE Cancer study. Journal of Thrombosis and Haemostasis2019;17:1866–74. EUCTR2009-014290-40-SE. A phase 3, randomized, double-blind, double-dummy, parallel group, multi-center, multi-national study for evaluation of efficacy and safety of DU-176b versus warfarin in subjects with atrial fibrillation - effective anticoagulation with factor Xa next generation in atrial fibrillation (ENGAGE-AF TIMI-48). trialsearch.who.int/?trialid=EUCTR2009-014290-40-SE (first received 30 November 2009). EichingerS , LinM , KyrlePA , GrossoMA . Recurrent venous thromboembolism during anticoagulation: an investigator-initiated post-hoc analysis of the hokusai-VTE trial. Blood2018;132:2539. KlokFA , BarcoS , KonstantinidesSV . External validation of the VTE-BLEED score for predicting major bleeding in stable anticoagulated patients with venous thromboembolism. Thrombosis and Haemostasis2017;117(6):1164-70. KraaijpoelN , Van EsN , RaskobGE , BüllerHR , CarrierM , ZhangG , et al. Risk scores for occult cancer in patients with venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2018;118(7):1270-8. MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMP , ChenCZ , et al. Outpatient management in patients with venous thromboembolism with edoxaban: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2017;117(12):2406-14. MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMP , ChenCZ , et al. Safety and efficacy of edoxaban compared with warfarin for the treatment of acute symptomatic deep-vein thrombosis in the outpatient setting. Research and Practice in Thrombosis and Haemostasis2017;1:913. MulderFI , Van EsN , KraaijpoelN , Di NisioM , CarrierM , DuggalA , et al. Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: results from the Hokusai VTE Cancer study. Thrombosis Research2020;185:13-9. NCT00986154. Comparative investigation of Low Molecular Weight (LMW) heparin/edoxaban tosylate (DU176b) versus (LMW) heparin/warfarin in the treatment of symptomatic deep-vein blood clots and/or lung blood clots. (The Edoxaban Hokusai-VTE Study). clinicaltrials.gov/ct2/show/NCT00986154 (first received 29 September 2009). NakamuraM , WangYQ , WangC , OhD , YinWH , KimuraT , et al. Efficacy and safety of edoxaban for treatment of venous thromboembolism: a subanalysis of East Asian patients in the Hokusai-VTE trial. Journal of Thrombosis and Haemostasis2015;13(9):1606-14. NybergJ , KarlssonKE , JönssonS , YinO , MillerR , KarlssonMO , et al. Edoxaban exposure-response analysis and clinical utility index assessment in patients with symptomatic deep-vein thrombosis or pulmonary embolism. CPT Pharmacometrics and Systems Pharmacology2016;5(4):222-32. RaskobG , AgenoW , CohenAT , BrekelmansMP , GrossoMA , SegersA , et al. Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology2016;3(5):e228-e236. RaskobG , BullerH , PrinsM , SegersA , ShiM , SchwochoL , et al. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study - methodological implications for clinical trials. Journal of Thrombosis and Haemostasis2013;11(7):1287-94. RaskobGE , BullerH , AngchaisuksiriP , OhD , BodaZ , LyonsRM , et al. Edoxaban for long-term treatment of venous thromboembolism in cancer patients. Blood2013;122(21):211. RaskobGE , Van EsN , SegersA , AngchaisuksiriP , OhD , BodaZ , et al. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematology2016;3(8):e379-87. ScheresLJ , BrekelmansMA , WalterA , CihanA , BüllerHR , SabineE , et al. Abnormal vaginal bleeding in women of reproductive age treated with edoxaban or warfarin for venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. British Journal of Obstetrics and Gynaecology2018;125(12):1581-9. The Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. New England Journal of Medicine2013;369(15):1406-15. VanasscheT , VerhammeP , WellsPS , SegersA , AgenoW , BrekelmansMP , et al. Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: an analysis of the randomized, double-blind Hokusai-VTE trial. Thrombosis Research2018;162:7-14. VerhammeP , WellsPS , SegersA , AgenoW , BrekelmansMP , CohenAT , et al. Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial. Thrombosis and Haemostasis2016;116(4):747-53. ">Hokusai‐VTE 2013</a>; <a href="./references#CD010956-bbs2-0013" title="MatsuoH , PrinsM , LensingAW , FujinumaEW , MiyamotoY , KajikawaM . Shortened length of hospital stay with rivaroxaban in patients with symptomatic venous thromboembolism in Japan: the J-EINSTEIN pulmonary embolism and deep vein thrombosis program. Current Medical Research and Opinion2015;31(6):1057-61. NCT01516814. Venous thromboembolism (VTE) treatment study in Japanese pulmonary embolism (PE) patients. clinicaltrials.gov/ct2/show/NCT01516814 (first received 25 January 2012). YamadaN , HirayamaA , MaedaH , SakagamiS , ShikataH , PrinsMH , et al. Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism-the J-EINSTEIN DVT and PE program. Thrombosis Journal2015;13:2. ">J‐EINSTEIN DVT and PE 2015</a>; <a href="./references#CD010956-bbs2-0014" title="MokademME , HassanA , AlgabyAZ . Efficacy and safety of apixaban in patients with active malignancy and acute deep venous thrombosis. Vascular2021;29(5):745-50. NCT04462003. Efficacy of apixaban in malignancy with deep venous thrombosis (DVT). clinicaltrials.gov/ct2/show/NCT04462003 (first received 3 July 2019). ">Mokadem 2021</a>; <a href="./references#CD010956-bbs2-0015" title="AgnelliG , GallusA , GoldhaberSZ , HaasS , HuismanMV , HullRD , et al. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAT 59-7939 in patients with acute symptomatic deep-vein thrombosis) study. Circulation2007;116:180-7. ">ODIXa‐DVT 2007</a>). The <a href="./references#CD010956-bbs2-0002" title="NakamuraM , NishikawaM , KomuroI , KitajimaI , UetsukaY , YamagamiT , et al. Apixaban for the treatment of Japanese subjects with acute venous thromboembolism (AMPLIFY-J Study). Circulation2015;79(6):1230–36. ">AMPLIFY‐J 2015</a> study had no events in either group and so did not contribute to the analysis (not estimable). The incidence was 2.90% (267 events/9207 participants) in the factor Xa inhibitor group and 3.42% (283 events/8298 participants) in the conventional anticoagulation group, leading to an OR of 0.85 (95% CI 0.71 to 1.01; 13 studies, 17,505 participants; I<sup>2</sup> = 0%; moderate‐certainty evidence; <a href="./references#CD010956-fig-0019" title="">Analysis 3.1</a>). When analysed according to duration of treatment, the incidence of recurrent VTE was slightly lower in participants treated with factor Xa inhibitors for three months compared with participants treated with conventional anticoagulation (OR 0.68, 95% CI 0.47 to 0.99; 5 studies, 5001 participants). There was no clear difference in the incidence between the two groups when duration of treatment was for longer than three months (OR 0.90, 95% CI 0.74 to 1.10; 8 studies, 12,460 participants) (test for subgroup differences: P = 0.20). Further, subgroup analysis of people experiencing DVT with cancer (OR 0.69, 95% CI 0.51 to 0.94; 4 studies, 4248 participants) versus without cancer (OR 0.82, 95% CI 0.59 to 1.15; 4 studies, 5579 participants) suggested no subgroup difference (test for subgroup differences: P = 0.45, <a href="./references#CD010956-fig-0028" title="">Analysis 4.1</a>). We produced a funnel plot and found no indication of publication bias (<a href="#CD010956-fig-0004">Figure 4</a>). No subgroup effect was indicated when analysed by the three oral factor Xa inhibitors (apixaban, edoxaban, rivaroxaban) (test for subgroup differences: P = 0.48, <a href="./references#CD010956-fig-0030" title="">Analysis 5.1</a>). </p> <div class="figure" id="CD010956-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Funnel plot of oral factor Xa inhibitors versus conventional anticoagulants for recurrent VTE " data-id="CD010956-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_n/nCD010956-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of oral factor Xa inhibitors versus conventional anticoagulants for recurrent VTE  </p> </div> </div> </div> </section> <section id="CD010956-sec-0073"> <h5 class="title">Recurrent deep vein thrombosis</h5> <p>Data on recurrent DVT was available in nine studies (16,439 participants) (<a href="./references#CD010956-bbs2-0001" title="AgnelliG , BullerH , MasiukiewiczUP . Apixaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism: a randomized, double-blind trial (AMPLIFY). Journal of Thrombosis and Haemostasis2013;11:18. AgnelliG , BullerHR , CohenA , CurtoD , GallusAS , JohnsonM , et al. Oral apixaban for the treatment of acute venous thromboembolism. New England Journal of Medicine2013;369:799-808. AgnelliG , BullerHR , CohenA , CurtoM , GallusAS , PakR , et al. Apixaban for the treatment of venous thromboembolism in cancer patients: data from the AMPLIFY trial. Canadian Journal of Cardiology2014;30(10 Suppl 1):S278. AgnelliG , BullerHR , CohenA , GallusAS , LeeTC , PakR , et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. Journal of Thrombosis and Haemostasis2015;13(12):2187-91. AgnelliG . Apixaban was non-inferior to enoxaparin plus warfarin in patients with acute venous thromboembolism. Annals of Internal Medicine2013;159(8):JC2. BlekerSM , CohenAT , BüllerHR , AgnelliG , GallusAS , RaskobGE , et al. Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Thrombosis and Haemostasis2016;116(6):159-64. BrekelmansM , ScheresL , BlekerS , HuttenB , TimmermansA , BüllerH , et al. Abnormal vaginal bleeding in women with venous thromboembolism treated with apixaban or warfarin. Thrombosis and Haemostasis2017;117(04):809-15. CohenA , AgnelliG , BullerH , GallusA , RaskobG , SandersP , et al. Characteristics and outcomes in patients with venous thromboembolism taking concomitant anti-platelet agents and anticoagulants in the AMPLIFY Trial. Thrombosis and Haemostasis2019;119(3):461-6. CohenA , AgnelliG , BullerHR , ChaudhuriS , GallusAS , RaskobGE , et al. Analysis of the bleeding and thromboembolic risk with concomitant use of antiplatelet treatment in the AMPLIFY trial. Canadian Journal of Cardiology2014;30(10):S272. CohenA , GallusAS , AgnelliG , BullerHR , PakR , PorcariAR , et al. Time in Therapeutic Range (TTR) and relative efficacy and safety of treatment with apixaban or enoxaparin/warfarin for acute symptomatic venous thromboembolism: an analysis of the Amplify trial data. Blood2014;124(21):1543. CohenAT , PanS , ByonW , IlyasBS , LeeTC . Efficacy, safety, and exposure of apixaban in patients with high body weight or obesity and venous thromboembolism: insights from AMPLIFY. Advances in Therapy2021;38(6):3003-18. EUCTR2007-007867-25-PT. A safety and efficacy trial evaluating the use of apixaban in the treatment of symptomatic deep vein thrombosis and pulmonary embolism revised protocol number: 01, incorporates amendment(s) 02 + protocol amendment 01 (version 1.0 dated 21-Apr-08) site-specific - molecular profiling supplement samples for Pfizer’s exploratory research biobank. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2007%E2%80%90007867%E2%80%9025%E2%80%90PT (first received 14 July 2008). GallusAS , AgnelliG , BullerHR , CohenA , LeeTC , PakR , et al. Apixaban for treatment of venous thromboembolism in patients from study centres in Asia: a subgroup analysis of the Amplify trial. Journal of Thrombosis and Haemostasis2015;13:727. LeeT , PanS , ByonW , IlyasBS . Safety and efficacy of apixaban versus enoxaparin/warfarin in patients with extremes of body weight: post-hoc analysis of the AMPLIFY trial. Blood2019;134(Suppl 1):1152. LiuX , JohnsonM , MardekianJ , PhatakH , ThompsonJ , CohenAT . Apixaban reduces hospitalizations in patients with venous thromboembolism: an analysis of the apixaban for the Initial management of pulmonary embolism and deep‐vein thrombosis as first‐line therapy (AMPLIFY) trial. Journal of the American Heart Association2015;4(12):e002340. NCT00633893. Efficacy and safety study of apixaban for extended treatment of deep vein thrombosis or pulmonary embolism. clinicaltrials.gov/ct2/show/NCT00633893?term=ajax&amp;rank=5 (first received 12 March 2008). NCT00643201. Efficacy and safety study of apixaban for the treatment of deep vein thrombosis or pulmonary embolism. clinicaltrials.gov/ct2/show/NCT00643201 (first received 26 March 2008). RaskobGE , GallusAS , SandersP , ThompsonJR , AgnelliG , BullerHR , et al. Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy: a sub-analysis of the AMPLIFY trial. Thrombosis and Haemostasis2016;115(4):809-16. ">AMPLIFY 2013</a>; <a href="./references#CD010956-bbs2-0003" title="BarrettYC , WangJ , KnabbR , MohanP . Apixaban decreases coagulation activity in patients with acute deep-vein thrombosis. Thrombosis and Haemostasis2011;105:181-9. Botticelli Investigators Writing Committee, BullerH , DeitchmanD , PrinsM , SegersA . Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. Journal of Thrombosis and Haemostasis2008;6:1313-8. BullerHR . A dose finding study of the oral direct factor Xa inhibitor apixaban in the treatment of patients with acute symptomatic deep vein thrombosis - the Botticelli Investigators. Journal of Thrombosis and Haemostasis2007;5 (Suppl 2):O-S-003. NCT00252005. Oral direct factor Xa-inhibitor apixaban in patients with acute symptomatic deep-vein thrombosis - the Botticelli DVT study. clinicaltrials.gov/ct/show/NCT00252005?order=1 (first received 11 November 2005). ">Botticelli DVT 2008</a>; <a href="./references#CD010956-bbs2-0007" title="BullerH , DariusH . EINSTEIN DVT: oral rivaroxaban versus standard therapy in the initial treatment of symptomatic deep vein thrombosis and long-term prevention of recurrent venous thromboembolism. escardio.org/The-ESC/Press-Office/Press-releases/EINSTEIN-DVT-Oral-rivaroxaban-versus-standard-therapy-in-the-initial-treatment (accessed 19 October 2022). BullerHR , AgnelliG . Once- or twice-daily rivaroxaban for the treatment of proximal deep vein thrombosis: similar efficacy and safety to standard therapy in dose-ranging studies. Blood2006;108(11 Part 1):172-3. BullerHR , LensingAW , PrinsMH , AgnelliG , CohenA , GallusAS , et al. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT dose-ranging study. Blood2008;112(6):2242-7. NCT00395772. Once-daily oral direct factor Xa inhibitor BAY59-7939 in patients with acute symptomatic deep-vein thrombosis. clinicaltrials.gov/ct2/show/NCT00395772?term=einstein-dvt&amp;rank=2 (first received 3 November 2006). ">EINSTEIN‐DVT dose 2008</a>; <a href="./references#CD010956-bbs2-0006" title="BamberL , WangMY , PrinsMH , CiniglioC , BauersachsR , LensingAW , et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis. Thrombosis and Haemostasis2013;110(4):732-41. BauersachsR , LensingAW , PapA , DecoususH . No need for a rivaroxaban dose reduction in renally impaired patients with symptomatic venous thromboembolism. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):30-1. BistervelsI , GebelM , LensingA , MiddeldorpS , CoppensM . Effect of polypharmacy on bleeding of rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolism. Research and Practice in Thrombosis and Haemostasis2019;3:798‐9. BookhartBK , HaskellL , BamberL , WangM , ScheinJ , ModySH . Length of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial program. Journal of Medical Economics2014;17(10):691-5. BullerHR . Oral rivaroxaban for the acute and continued treatment of symptomatic venous thromboembolism. The Einstein-DVT and Einstein-Extension study. Blood2010;116(21):187. CheungW , MiddeldorpS , PrinsMP , PapAF , LensingAW , Hoek-tenCA , et al. Post thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep vein thrombosis. Journal of Thrombosis and Haemostasis2015;13(S2):219-20. CheungYW , MiddeldorpS , PrinsMH , PapAF , PrandoniP . Post-thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep-vein thrombosis. A post-hoc analysis. Thrombosis and Haemostasis2016;116(4):733-8. EUCTR2004-002171-16-IT. Once-daily oral direct factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis. The EINSTEIN-DVT dose-finding study. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2004%E2%80%90002171%E2%80%9016%E2%80%90IT (first received 15 October 2008). EUCTR2006-004495-13-DK. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep-vein thrombosis or pulmonary embolism. trialsearch.who.int/?TrialID=EUCTR2006-004495-13-DK (first received 29 March 2007). EerenbergES , MiddeldorpS , LeviM , LensingAW , BüllerHR . Clinical impact and course of major bleeding with rivaroxaban and vitamin K antagonists. Journal of Thrombosis and Haemostasis2015;13(9):1590-6. KlineJA , JimenezD , CourtneyDM , IanusJ , CaoL , WellsPS . Use of the Riete 2008 bleeding score to identify patients at low risk for major bleeding in patients treated with rivaroxaban. Academic Emergency Medicine2015;22:S162. NCT00440193. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep vein thrombosis - The EINSTEIN DVT Study. clinicaltrials.gov/ct2/show/NCT00440193 (first received 26 February 2007). PrinsMH , ErkensPG , LensingAW . Incidence of recurrent venous thromboembolism in patients following completion of the EINSTEIN DVT and EINSTEIN PE studies. Journal of Thrombosis and Haemostasis2013;11(Suppl):257. PrinsMH , LensingAW , BauersachsR , Van BellenB , BounameauxH , BrightonTA , et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thrombosis Journal2013;11(1):21. The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. New England Journal of Medicine2010;363(26):2499-510. Van BellenB , PrinsM , BamberL , WangM , LensingAW . Reduction in initial length of stay with rivaroxaban single-drug regimen versus LMWH-VKA standard of care: findings from the EINSTEIN trial program. Blood2012;120(21):3419. Van BellenB , PrinsM , BamberL , WangM , LensingAW . Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism. Current Medical Research and Opinion2014;30(5):829-37. WangY , WangC , ChenZ , ZhangJ , LiuZ , JinB , et al. Rivaroxaban for the treatment of symptomatic deep vein thrombosis and/or pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):694. WangY , WangC , ChenZ , ZhangJ , LiuZ , JinB , et al. Rivaroxaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Thrombosis Journal2013;11(1):25. ">EINSTEIN‐DVT 2010</a>; <a href="./references#CD010956-bbs2-0008" title="BullerHR , PrinsMH , LensinAW , DecoususH , JacobsonBF , MinarE , et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. New England Journal of Medicine2012;366:1287-97. FermannGJ , Erkens Pmg, PrinsMH , WellsPS , Pap ÁF, LensingAW , et al. Treatment of pulmonary embolism with rivaroxaban: outcomes by simplified pulmonary embolism severity index score from a post hoc analysis of the EINSTEIN PE study. Academic Emergency Medicine2015;22(3):299-307. NCT00439777. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic pulmonary embolism with or without symptomatic deep-vein thrombosis: Einstein-PE evaluation, 2008. clinicaltrials.gov/ct2/show/NCT00439777?term=NCT00439777&amp;rank=1 (first received 26 February 2007). PrinsM , BamberL , CanoS , WangM , LensingAW , BauersachsR . Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic pulmonary embolism. Blood2012;120(21):1163. PrinsMH , BamberL , CanoSJ , WangMY , ErkensP , BauersachsR , et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial. Thrombosis Research2015;135(2):281-8. ">EINSTEIN‐PE 2012</a>; <a href="./references#CD010956-bbs2-0011" title="BistervelsI , BavaliaR , BoersmaW , MeijerK , VerhammeP , Ten Cate-HoekAJ , et al. Hokusai Post-DVT Study: a follow-up study on long-term outcomes of deep vein thrombosis in patients treated with edoxaban vs warfarin. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):PB2207. BrekelmansMP , AgenoW , BeenenLF , BrennerB , BullerHR , ChenCZ , et al. Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology2016;3(9):e437-45. BrekelmansMP , BlekerSM , BauersachsR , BodaZ , BüllerHR , ChoiY , et al. Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists. Thrombosis and Haemostasis2016;116(1):155-61. Di NisioM , Van EsN , CarrierM , WangTF , GarciaD , SegersA , et al. Extended treatment with edoxaban in cancer patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE Cancer study. Journal of Thrombosis and Haemostasis2019;17:1866–74. EUCTR2009-014290-40-SE. A phase 3, randomized, double-blind, double-dummy, parallel group, multi-center, multi-national study for evaluation of efficacy and safety of DU-176b versus warfarin in subjects with atrial fibrillation - effective anticoagulation with factor Xa next generation in atrial fibrillation (ENGAGE-AF TIMI-48). trialsearch.who.int/?trialid=EUCTR2009-014290-40-SE (first received 30 November 2009). EichingerS , LinM , KyrlePA , GrossoMA . Recurrent venous thromboembolism during anticoagulation: an investigator-initiated post-hoc analysis of the hokusai-VTE trial. Blood2018;132:2539. KlokFA , BarcoS , KonstantinidesSV . External validation of the VTE-BLEED score for predicting major bleeding in stable anticoagulated patients with venous thromboembolism. Thrombosis and Haemostasis2017;117(6):1164-70. KraaijpoelN , Van EsN , RaskobGE , BüllerHR , CarrierM , ZhangG , et al. Risk scores for occult cancer in patients with venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2018;118(7):1270-8. MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMP , ChenCZ , et al. Outpatient management in patients with venous thromboembolism with edoxaban: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2017;117(12):2406-14. MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMP , ChenCZ , et al. Safety and efficacy of edoxaban compared with warfarin for the treatment of acute symptomatic deep-vein thrombosis in the outpatient setting. Research and Practice in Thrombosis and Haemostasis2017;1:913. MulderFI , Van EsN , KraaijpoelN , Di NisioM , CarrierM , DuggalA , et al. Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: results from the Hokusai VTE Cancer study. Thrombosis Research2020;185:13-9. NCT00986154. Comparative investigation of Low Molecular Weight (LMW) heparin/edoxaban tosylate (DU176b) versus (LMW) heparin/warfarin in the treatment of symptomatic deep-vein blood clots and/or lung blood clots. (The Edoxaban Hokusai-VTE Study). clinicaltrials.gov/ct2/show/NCT00986154 (first received 29 September 2009). NakamuraM , WangYQ , WangC , OhD , YinWH , KimuraT , et al. Efficacy and safety of edoxaban for treatment of venous thromboembolism: a subanalysis of East Asian patients in the Hokusai-VTE trial. Journal of Thrombosis and Haemostasis2015;13(9):1606-14. NybergJ , KarlssonKE , JönssonS , YinO , MillerR , KarlssonMO , et al. Edoxaban exposure-response analysis and clinical utility index assessment in patients with symptomatic deep-vein thrombosis or pulmonary embolism. CPT Pharmacometrics and Systems Pharmacology2016;5(4):222-32. RaskobG , AgenoW , CohenAT , BrekelmansMP , GrossoMA , SegersA , et al. Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology2016;3(5):e228-e236. RaskobG , BullerH , PrinsM , SegersA , ShiM , SchwochoL , et al. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study - methodological implications for clinical trials. Journal of Thrombosis and Haemostasis2013;11(7):1287-94. RaskobGE , BullerH , AngchaisuksiriP , OhD , BodaZ , LyonsRM , et al. Edoxaban for long-term treatment of venous thromboembolism in cancer patients. Blood2013;122(21):211. RaskobGE , Van EsN , SegersA , AngchaisuksiriP , OhD , BodaZ , et al. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematology2016;3(8):e379-87. ScheresLJ , BrekelmansMA , WalterA , CihanA , BüllerHR , SabineE , et al. Abnormal vaginal bleeding in women of reproductive age treated with edoxaban or warfarin for venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. British Journal of Obstetrics and Gynaecology2018;125(12):1581-9. The Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. New England Journal of Medicine2013;369(15):1406-15. VanasscheT , VerhammeP , WellsPS , SegersA , AgenoW , BrekelmansMP , et al. Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: an analysis of the randomized, double-blind Hokusai-VTE trial. Thrombosis Research2018;162:7-14. VerhammeP , WellsPS , SegersA , AgenoW , BrekelmansMP , CohenAT , et al. Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial. Thrombosis and Haemostasis2016;116(4):747-53. ">Hokusai‐VTE 2013</a>; <a href="./references#CD010956-bbs2-0014" title="MokademME , HassanA , AlgabyAZ . Efficacy and safety of apixaban in patients with active malignancy and acute deep venous thrombosis. Vascular2021;29(5):745-50. NCT04462003. Efficacy of apixaban in malignancy with deep venous thrombosis (DVT). clinicaltrials.gov/ct2/show/NCT04462003 (first received 3 July 2019). ">Mokadem 2021</a>; <a href="./references#CD010956-bbs2-0015" title="AgnelliG , GallusA , GoldhaberSZ , HaasS , HuismanMV , HullRD , et al. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAT 59-7939 in patients with acute symptomatic deep-vein thrombosis) study. Circulation2007;116:180-7. ">ODIXa‐DVT 2007</a>; <a href="./references#CD010956-bbs2-0017" title="Kang JiM, ParkKH , AhnS , ChoS , MinSK . Rivaroxaban after thrombolysis in acute iliofemoral venous thrombosis: a randomized, open-labeled, multicenter trial. Scientific Reports2019;9(1):20356. MinSK , AhnS , ParkKH , KangJM , KimJY . Prevention of recurrence after thrombolysis in acute iliofemoral venous thrombosis with rivaroxaban (Prais Study): a prospective, randomized, open label, multicenter trial. European Journal of Vascular and Endovascular Surgery2019;58(6):e516. NCT01986192. Prevention of recurrence after thrombolysis in acute iliofemoral venous thrombosis (PRAIS) study. clinicaltrials.gov/show/NCT01986192 (first received 18 November 2013). ">PRAIS 2019</a>). The authors of <a href="./references#CD010956-bbs2-0011" title="BistervelsI , BavaliaR , BoersmaW , MeijerK , VerhammeP , Ten Cate-HoekAJ , et al. Hokusai Post-DVT Study: a follow-up study on long-term outcomes of deep vein thrombosis in patients treated with edoxaban vs warfarin. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):PB2207. BrekelmansMP , AgenoW , BeenenLF , BrennerB , BullerHR , ChenCZ , et al. Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology2016;3(9):e437-45. BrekelmansMP , BlekerSM , BauersachsR , BodaZ , BüllerHR , ChoiY , et al. Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists. Thrombosis and Haemostasis2016;116(1):155-61. Di NisioM , Van EsN , CarrierM , WangTF , GarciaD , SegersA , et al. Extended treatment with edoxaban in cancer patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE Cancer study. Journal of Thrombosis and Haemostasis2019;17:1866–74. EUCTR2009-014290-40-SE. A phase 3, randomized, double-blind, double-dummy, parallel group, multi-center, multi-national study for evaluation of efficacy and safety of DU-176b versus warfarin in subjects with atrial fibrillation - effective anticoagulation with factor Xa next generation in atrial fibrillation (ENGAGE-AF TIMI-48). trialsearch.who.int/?trialid=EUCTR2009-014290-40-SE (first received 30 November 2009). EichingerS , LinM , KyrlePA , GrossoMA . Recurrent venous thromboembolism during anticoagulation: an investigator-initiated post-hoc analysis of the hokusai-VTE trial. Blood2018;132:2539. KlokFA , BarcoS , KonstantinidesSV . External validation of the VTE-BLEED score for predicting major bleeding in stable anticoagulated patients with venous thromboembolism. Thrombosis and Haemostasis2017;117(6):1164-70. KraaijpoelN , Van EsN , RaskobGE , BüllerHR , CarrierM , ZhangG , et al. Risk scores for occult cancer in patients with venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2018;118(7):1270-8. MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMP , ChenCZ , et al. Outpatient management in patients with venous thromboembolism with edoxaban: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2017;117(12):2406-14. MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMP , ChenCZ , et al. Safety and efficacy of edoxaban compared with warfarin for the treatment of acute symptomatic deep-vein thrombosis in the outpatient setting. Research and Practice in Thrombosis and Haemostasis2017;1:913. MulderFI , Van EsN , KraaijpoelN , Di NisioM , CarrierM , DuggalA , et al. Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: results from the Hokusai VTE Cancer study. Thrombosis Research2020;185:13-9. NCT00986154. Comparative investigation of Low Molecular Weight (LMW) heparin/edoxaban tosylate (DU176b) versus (LMW) heparin/warfarin in the treatment of symptomatic deep-vein blood clots and/or lung blood clots. (The Edoxaban Hokusai-VTE Study). clinicaltrials.gov/ct2/show/NCT00986154 (first received 29 September 2009). NakamuraM , WangYQ , WangC , OhD , YinWH , KimuraT , et al. Efficacy and safety of edoxaban for treatment of venous thromboembolism: a subanalysis of East Asian patients in the Hokusai-VTE trial. Journal of Thrombosis and Haemostasis2015;13(9):1606-14. NybergJ , KarlssonKE , JönssonS , YinO , MillerR , KarlssonMO , et al. Edoxaban exposure-response analysis and clinical utility index assessment in patients with symptomatic deep-vein thrombosis or pulmonary embolism. CPT Pharmacometrics and Systems Pharmacology2016;5(4):222-32. RaskobG , AgenoW , CohenAT , BrekelmansMP , GrossoMA , SegersA , et al. Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology2016;3(5):e228-e236. RaskobG , BullerH , PrinsM , SegersA , ShiM , SchwochoL , et al. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study - methodological implications for clinical trials. Journal of Thrombosis and Haemostasis2013;11(7):1287-94. RaskobGE , BullerH , AngchaisuksiriP , OhD , BodaZ , LyonsRM , et al. Edoxaban for long-term treatment of venous thromboembolism in cancer patients. Blood2013;122(21):211. RaskobGE , Van EsN , SegersA , AngchaisuksiriP , OhD , BodaZ , et al. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematology2016;3(8):e379-87. ScheresLJ , BrekelmansMA , WalterA , CihanA , BüllerHR , SabineE , et al. Abnormal vaginal bleeding in women of reproductive age treated with edoxaban or warfarin for venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. British Journal of Obstetrics and Gynaecology2018;125(12):1581-9. The Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. New England Journal of Medicine2013;369(15):1406-15. VanasscheT , VerhammeP , WellsPS , SegersA , AgenoW , BrekelmansMP , et al. Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: an analysis of the randomized, double-blind Hokusai-VTE trial. Thrombosis Research2018;162:7-14. VerhammeP , WellsPS , SegersA , AgenoW , BrekelmansMP , CohenAT , et al. Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial. Thrombosis and Haemostasis2016;116(4):747-53. ">Hokusai‐VTE 2013</a> kindly provided us with separate data on recurrent DVT and fatal and non‐fatal PE. There was no clear difference in rate of recurrent DVT between oral factor Xa inhibitors (1.26%, 109 events/8633 participants) and conventional anticoagulation (1.64%, 128 events/7806 participants), leading to an OR of 0.70 (95% CI 0.49 to 1.01; 9 studies, 16,439 participants; I<sup>2</sup> = 30%; moderate‐certainty evidence; <a href="./references#CD010956-fig-0020" title="">Analysis 3.2</a>). When analysed according to treatment duration, there were no clear differences in the incidence of recurrent DVT between participants treated with factor Xa inhibitors and participants treated with conventional anticoagulation for either three months (OR 0.50, 95% CI 0.22 to 1.15; 4 studies, 4917 participants) or more than three months (OR 0.86, 95% CI 0.63 to 1.17; 5 studies, 11,522 participants). No subgroup differences were indicated (test for subgroup differences: P = 0.23). As a limited number of studies reporting on this outcome provided separate data for participants with or without cancer, we were not able to undertake subgroup analysis on this characteristic. No subgroup effect was indicated when analysed by the three oral factor Xa inhibitors (apixaban, edoxaban, rivaroxaban) (test for subgroup differences: P = 0.20, <a href="./references#CD010956-fig-0031" title="">Analysis 5.2</a>). </p> </section> <section id="CD010956-sec-0074"> <h5 class="title">Fatal pulmonary embolism</h5> <p>Six studies (15,082 participants) reported fatal PE (<a href="./references#CD010956-bbs2-0001" title="AgnelliG , BullerH , MasiukiewiczUP . Apixaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism: a randomized, double-blind trial (AMPLIFY). Journal of Thrombosis and Haemostasis2013;11:18. AgnelliG , BullerHR , CohenA , CurtoD , GallusAS , JohnsonM , et al. Oral apixaban for the treatment of acute venous thromboembolism. New England Journal of Medicine2013;369:799-808. AgnelliG , BullerHR , CohenA , CurtoM , GallusAS , PakR , et al. Apixaban for the treatment of venous thromboembolism in cancer patients: data from the AMPLIFY trial. Canadian Journal of Cardiology2014;30(10 Suppl 1):S278. AgnelliG , BullerHR , CohenA , GallusAS , LeeTC , PakR , et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. Journal of Thrombosis and Haemostasis2015;13(12):2187-91. AgnelliG . Apixaban was non-inferior to enoxaparin plus warfarin in patients with acute venous thromboembolism. Annals of Internal Medicine2013;159(8):JC2. BlekerSM , CohenAT , BüllerHR , AgnelliG , GallusAS , RaskobGE , et al. Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Thrombosis and Haemostasis2016;116(6):159-64. BrekelmansM , ScheresL , BlekerS , HuttenB , TimmermansA , BüllerH , et al. Abnormal vaginal bleeding in women with venous thromboembolism treated with apixaban or warfarin. Thrombosis and Haemostasis2017;117(04):809-15. CohenA , AgnelliG , BullerH , GallusA , RaskobG , SandersP , et al. Characteristics and outcomes in patients with venous thromboembolism taking concomitant anti-platelet agents and anticoagulants in the AMPLIFY Trial. Thrombosis and Haemostasis2019;119(3):461-6. CohenA , AgnelliG , BullerHR , ChaudhuriS , GallusAS , RaskobGE , et al. Analysis of the bleeding and thromboembolic risk with concomitant use of antiplatelet treatment in the AMPLIFY trial. Canadian Journal of Cardiology2014;30(10):S272. CohenA , GallusAS , AgnelliG , BullerHR , PakR , PorcariAR , et al. Time in Therapeutic Range (TTR) and relative efficacy and safety of treatment with apixaban or enoxaparin/warfarin for acute symptomatic venous thromboembolism: an analysis of the Amplify trial data. Blood2014;124(21):1543. CohenAT , PanS , ByonW , IlyasBS , LeeTC . Efficacy, safety, and exposure of apixaban in patients with high body weight or obesity and venous thromboembolism: insights from AMPLIFY. Advances in Therapy2021;38(6):3003-18. EUCTR2007-007867-25-PT. A safety and efficacy trial evaluating the use of apixaban in the treatment of symptomatic deep vein thrombosis and pulmonary embolism revised protocol number: 01, incorporates amendment(s) 02 + protocol amendment 01 (version 1.0 dated 21-Apr-08) site-specific - molecular profiling supplement samples for Pfizer’s exploratory research biobank. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2007%E2%80%90007867%E2%80%9025%E2%80%90PT (first received 14 July 2008). GallusAS , AgnelliG , BullerHR , CohenA , LeeTC , PakR , et al. Apixaban for treatment of venous thromboembolism in patients from study centres in Asia: a subgroup analysis of the Amplify trial. Journal of Thrombosis and Haemostasis2015;13:727. LeeT , PanS , ByonW , IlyasBS . Safety and efficacy of apixaban versus enoxaparin/warfarin in patients with extremes of body weight: post-hoc analysis of the AMPLIFY trial. Blood2019;134(Suppl 1):1152. LiuX , JohnsonM , MardekianJ , PhatakH , ThompsonJ , CohenAT . Apixaban reduces hospitalizations in patients with venous thromboembolism: an analysis of the apixaban for the Initial management of pulmonary embolism and deep‐vein thrombosis as first‐line therapy (AMPLIFY) trial. Journal of the American Heart Association2015;4(12):e002340. NCT00633893. Efficacy and safety study of apixaban for extended treatment of deep vein thrombosis or pulmonary embolism. clinicaltrials.gov/ct2/show/NCT00633893?term=ajax&amp;rank=5 (first received 12 March 2008). NCT00643201. Efficacy and safety study of apixaban for the treatment of deep vein thrombosis or pulmonary embolism. clinicaltrials.gov/ct2/show/NCT00643201 (first received 26 March 2008). RaskobGE , GallusAS , SandersP , ThompsonJR , AgnelliG , BullerHR , et al. Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy: a sub-analysis of the AMPLIFY trial. Thrombosis and Haemostasis2016;115(4):809-16. ">AMPLIFY 2013</a>; <a href="./references#CD010956-bbs2-0003" title="BarrettYC , WangJ , KnabbR , MohanP . Apixaban decreases coagulation activity in patients with acute deep-vein thrombosis. Thrombosis and Haemostasis2011;105:181-9. Botticelli Investigators Writing Committee, BullerH , DeitchmanD , PrinsM , SegersA . Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. Journal of Thrombosis and Haemostasis2008;6:1313-8. BullerHR . A dose finding study of the oral direct factor Xa inhibitor apixaban in the treatment of patients with acute symptomatic deep vein thrombosis - the Botticelli Investigators. Journal of Thrombosis and Haemostasis2007;5 (Suppl 2):O-S-003. NCT00252005. Oral direct factor Xa-inhibitor apixaban in patients with acute symptomatic deep-vein thrombosis - the Botticelli DVT study. clinicaltrials.gov/ct/show/NCT00252005?order=1 (first received 11 November 2005). ">Botticelli DVT 2008</a>; <a href="./references#CD010956-bbs2-0007" title="BullerH , DariusH . EINSTEIN DVT: oral rivaroxaban versus standard therapy in the initial treatment of symptomatic deep vein thrombosis and long-term prevention of recurrent venous thromboembolism. escardio.org/The-ESC/Press-Office/Press-releases/EINSTEIN-DVT-Oral-rivaroxaban-versus-standard-therapy-in-the-initial-treatment (accessed 19 October 2022). BullerHR , AgnelliG . Once- or twice-daily rivaroxaban for the treatment of proximal deep vein thrombosis: similar efficacy and safety to standard therapy in dose-ranging studies. Blood2006;108(11 Part 1):172-3. BullerHR , LensingAW , PrinsMH , AgnelliG , CohenA , GallusAS , et al. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT dose-ranging study. Blood2008;112(6):2242-7. NCT00395772. Once-daily oral direct factor Xa inhibitor BAY59-7939 in patients with acute symptomatic deep-vein thrombosis. clinicaltrials.gov/ct2/show/NCT00395772?term=einstein-dvt&amp;rank=2 (first received 3 November 2006). ">EINSTEIN‐DVT dose 2008</a>; <a href="./references#CD010956-bbs2-0006" title="BamberL , WangMY , PrinsMH , CiniglioC , BauersachsR , LensingAW , et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis. Thrombosis and Haemostasis2013;110(4):732-41. BauersachsR , LensingAW , PapA , DecoususH . No need for a rivaroxaban dose reduction in renally impaired patients with symptomatic venous thromboembolism. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):30-1. BistervelsI , GebelM , LensingA , MiddeldorpS , CoppensM . Effect of polypharmacy on bleeding of rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolism. Research and Practice in Thrombosis and Haemostasis2019;3:798‐9. BookhartBK , HaskellL , BamberL , WangM , ScheinJ , ModySH . Length of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial program. Journal of Medical Economics2014;17(10):691-5. BullerHR . Oral rivaroxaban for the acute and continued treatment of symptomatic venous thromboembolism. The Einstein-DVT and Einstein-Extension study. Blood2010;116(21):187. CheungW , MiddeldorpS , PrinsMP , PapAF , LensingAW , Hoek-tenCA , et al. Post thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep vein thrombosis. Journal of Thrombosis and Haemostasis2015;13(S2):219-20. CheungYW , MiddeldorpS , PrinsMH , PapAF , PrandoniP . Post-thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep-vein thrombosis. A post-hoc analysis. Thrombosis and Haemostasis2016;116(4):733-8. EUCTR2004-002171-16-IT. Once-daily oral direct factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis. The EINSTEIN-DVT dose-finding study. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2004%E2%80%90002171%E2%80%9016%E2%80%90IT (first received 15 October 2008). EUCTR2006-004495-13-DK. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep-vein thrombosis or pulmonary embolism. trialsearch.who.int/?TrialID=EUCTR2006-004495-13-DK (first received 29 March 2007). EerenbergES , MiddeldorpS , LeviM , LensingAW , BüllerHR . Clinical impact and course of major bleeding with rivaroxaban and vitamin K antagonists. Journal of Thrombosis and Haemostasis2015;13(9):1590-6. KlineJA , JimenezD , CourtneyDM , IanusJ , CaoL , WellsPS . Use of the Riete 2008 bleeding score to identify patients at low risk for major bleeding in patients treated with rivaroxaban. Academic Emergency Medicine2015;22:S162. NCT00440193. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep vein thrombosis - The EINSTEIN DVT Study. clinicaltrials.gov/ct2/show/NCT00440193 (first received 26 February 2007). PrinsMH , ErkensPG , LensingAW . Incidence of recurrent venous thromboembolism in patients following completion of the EINSTEIN DVT and EINSTEIN PE studies. Journal of Thrombosis and Haemostasis2013;11(Suppl):257. PrinsMH , LensingAW , BauersachsR , Van BellenB , BounameauxH , BrightonTA , et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thrombosis Journal2013;11(1):21. The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. New England Journal of Medicine2010;363(26):2499-510. Van BellenB , PrinsM , BamberL , WangM , LensingAW . Reduction in initial length of stay with rivaroxaban single-drug regimen versus LMWH-VKA standard of care: findings from the EINSTEIN trial program. Blood2012;120(21):3419. Van BellenB , PrinsM , BamberL , WangM , LensingAW . Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism. Current Medical Research and Opinion2014;30(5):829-37. WangY , WangC , ChenZ , ZhangJ , LiuZ , JinB , et al. Rivaroxaban for the treatment of symptomatic deep vein thrombosis and/or pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):694. WangY , WangC , ChenZ , ZhangJ , LiuZ , JinB , et al. Rivaroxaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Thrombosis Journal2013;11(1):25. ">EINSTEIN‐DVT 2010</a>; <a href="./references#CD010956-bbs2-0011" title="BistervelsI , BavaliaR , BoersmaW , MeijerK , VerhammeP , Ten Cate-HoekAJ , et al. Hokusai Post-DVT Study: a follow-up study on long-term outcomes of deep vein thrombosis in patients treated with edoxaban vs warfarin. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):PB2207. BrekelmansMP , AgenoW , BeenenLF , BrennerB , BullerHR , ChenCZ , et al. Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology2016;3(9):e437-45. BrekelmansMP , BlekerSM , BauersachsR , BodaZ , BüllerHR , ChoiY , et al. Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists. Thrombosis and Haemostasis2016;116(1):155-61. Di NisioM , Van EsN , CarrierM , WangTF , GarciaD , SegersA , et al. Extended treatment with edoxaban in cancer patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE Cancer study. Journal of Thrombosis and Haemostasis2019;17:1866–74. EUCTR2009-014290-40-SE. A phase 3, randomized, double-blind, double-dummy, parallel group, multi-center, multi-national study for evaluation of efficacy and safety of DU-176b versus warfarin in subjects with atrial fibrillation - effective anticoagulation with factor Xa next generation in atrial fibrillation (ENGAGE-AF TIMI-48). trialsearch.who.int/?trialid=EUCTR2009-014290-40-SE (first received 30 November 2009). EichingerS , LinM , KyrlePA , GrossoMA . Recurrent venous thromboembolism during anticoagulation: an investigator-initiated post-hoc analysis of the hokusai-VTE trial. Blood2018;132:2539. KlokFA , BarcoS , KonstantinidesSV . External validation of the VTE-BLEED score for predicting major bleeding in stable anticoagulated patients with venous thromboembolism. Thrombosis and Haemostasis2017;117(6):1164-70. KraaijpoelN , Van EsN , RaskobGE , BüllerHR , CarrierM , ZhangG , et al. Risk scores for occult cancer in patients with venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2018;118(7):1270-8. MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMP , ChenCZ , et al. Outpatient management in patients with venous thromboembolism with edoxaban: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2017;117(12):2406-14. MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMP , ChenCZ , et al. Safety and efficacy of edoxaban compared with warfarin for the treatment of acute symptomatic deep-vein thrombosis in the outpatient setting. Research and Practice in Thrombosis and Haemostasis2017;1:913. MulderFI , Van EsN , KraaijpoelN , Di NisioM , CarrierM , DuggalA , et al. Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: results from the Hokusai VTE Cancer study. Thrombosis Research2020;185:13-9. NCT00986154. Comparative investigation of Low Molecular Weight (LMW) heparin/edoxaban tosylate (DU176b) versus (LMW) heparin/warfarin in the treatment of symptomatic deep-vein blood clots and/or lung blood clots. (The Edoxaban Hokusai-VTE Study). clinicaltrials.gov/ct2/show/NCT00986154 (first received 29 September 2009). NakamuraM , WangYQ , WangC , OhD , YinWH , KimuraT , et al. Efficacy and safety of edoxaban for treatment of venous thromboembolism: a subanalysis of East Asian patients in the Hokusai-VTE trial. Journal of Thrombosis and Haemostasis2015;13(9):1606-14. NybergJ , KarlssonKE , JönssonS , YinO , MillerR , KarlssonMO , et al. Edoxaban exposure-response analysis and clinical utility index assessment in patients with symptomatic deep-vein thrombosis or pulmonary embolism. CPT Pharmacometrics and Systems Pharmacology2016;5(4):222-32. RaskobG , AgenoW , CohenAT , BrekelmansMP , GrossoMA , SegersA , et al. Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology2016;3(5):e228-e236. RaskobG , BullerH , PrinsM , SegersA , ShiM , SchwochoL , et al. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study - methodological implications for clinical trials. Journal of Thrombosis and Haemostasis2013;11(7):1287-94. RaskobGE , BullerH , AngchaisuksiriP , OhD , BodaZ , LyonsRM , et al. Edoxaban for long-term treatment of venous thromboembolism in cancer patients. Blood2013;122(21):211. RaskobGE , Van EsN , SegersA , AngchaisuksiriP , OhD , BodaZ , et al. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematology2016;3(8):e379-87. ScheresLJ , BrekelmansMA , WalterA , CihanA , BüllerHR , SabineE , et al. Abnormal vaginal bleeding in women of reproductive age treated with edoxaban or warfarin for venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. British Journal of Obstetrics and Gynaecology2018;125(12):1581-9. The Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. New England Journal of Medicine2013;369(15):1406-15. VanasscheT , VerhammeP , WellsPS , SegersA , AgenoW , BrekelmansMP , et al. Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: an analysis of the randomized, double-blind Hokusai-VTE trial. Thrombosis Research2018;162:7-14. VerhammeP , WellsPS , SegersA , AgenoW , BrekelmansMP , CohenAT , et al. Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial. Thrombosis and Haemostasis2016;116(4):747-53. ">Hokusai‐VTE 2013</a>; <a href="./references#CD010956-bbs2-0015" title="AgnelliG , GallusA , GoldhaberSZ , HaasS , HuismanMV , HullRD , et al. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAT 59-7939 in patients with acute symptomatic deep-vein thrombosis) study. Circulation2007;116:180-7. ">ODIXa‐DVT 2007</a>). There was no clear difference in the rate of fatal PE between the two treatment groups. Meta‐analysis showed that fatal PE occurred in 0.42% (33 events/7945 participants) in the factor Xa inhibitor group versus 0.32% (23 events/7137 participants) in the conventional anticoagulation group (OR 1.18, 95% CI 0.69 to 2.02; 6 studies, 15,082 participants; I<sup>2</sup> = 0%; moderate‐certainty evidence; <a href="./references#CD010956-fig-0021" title="">Analysis 3.3</a>). We found no clear difference in the incidence of fatal PE between participants treated with factor Xa inhibitors and conventional anticoagulation when treatment was for three months (OR 1.68, 95% CI 0.36 to 7.94; 4 studies, 4917 participants) and for more than three months (OR 1.15, 95% CI 0.54 to 2.44; 2 studies, 10,165 participants). No subgroup differences were indicated (test for subgroup differences: P = 0.67). As a limited number of studies reporting on this outcome provided separate data for participants with or without cancer, we were not able to undertake subgroup analysis on this characteristic. No subgroup effect was indicated when analysed by the three oral factor Xa inhibitors (apixaban, edoxaban, rivaroxaban) (test for subgroup differences: P = 0.36, <a href="./references#CD010956-fig-0032" title="">Analysis 5.3</a>). </p> </section> <section id="CD010956-sec-0075"> <h5 class="title">Non‐fatal pulmonary embolism</h5> <p>Seven studies (15,166 participants) reported non‐fatal PE (<a href="./references#CD010956-bbs2-0001" title="AgnelliG , BullerH , MasiukiewiczUP . Apixaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism: a randomized, double-blind trial (AMPLIFY). Journal of Thrombosis and Haemostasis2013;11:18. AgnelliG , BullerHR , CohenA , CurtoD , GallusAS , JohnsonM , et al. Oral apixaban for the treatment of acute venous thromboembolism. New England Journal of Medicine2013;369:799-808. AgnelliG , BullerHR , CohenA , CurtoM , GallusAS , PakR , et al. Apixaban for the treatment of venous thromboembolism in cancer patients: data from the AMPLIFY trial. Canadian Journal of Cardiology2014;30(10 Suppl 1):S278. AgnelliG , BullerHR , CohenA , GallusAS , LeeTC , PakR , et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. Journal of Thrombosis and Haemostasis2015;13(12):2187-91. AgnelliG . Apixaban was non-inferior to enoxaparin plus warfarin in patients with acute venous thromboembolism. Annals of Internal Medicine2013;159(8):JC2. BlekerSM , CohenAT , BüllerHR , AgnelliG , GallusAS , RaskobGE , et al. Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Thrombosis and Haemostasis2016;116(6):159-64. BrekelmansM , ScheresL , BlekerS , HuttenB , TimmermansA , BüllerH , et al. Abnormal vaginal bleeding in women with venous thromboembolism treated with apixaban or warfarin. Thrombosis and Haemostasis2017;117(04):809-15. CohenA , AgnelliG , BullerH , GallusA , RaskobG , SandersP , et al. Characteristics and outcomes in patients with venous thromboembolism taking concomitant anti-platelet agents and anticoagulants in the AMPLIFY Trial. Thrombosis and Haemostasis2019;119(3):461-6. CohenA , AgnelliG , BullerHR , ChaudhuriS , GallusAS , RaskobGE , et al. Analysis of the bleeding and thromboembolic risk with concomitant use of antiplatelet treatment in the AMPLIFY trial. Canadian Journal of Cardiology2014;30(10):S272. CohenA , GallusAS , AgnelliG , BullerHR , PakR , PorcariAR , et al. Time in Therapeutic Range (TTR) and relative efficacy and safety of treatment with apixaban or enoxaparin/warfarin for acute symptomatic venous thromboembolism: an analysis of the Amplify trial data. Blood2014;124(21):1543. CohenAT , PanS , ByonW , IlyasBS , LeeTC . Efficacy, safety, and exposure of apixaban in patients with high body weight or obesity and venous thromboembolism: insights from AMPLIFY. Advances in Therapy2021;38(6):3003-18. EUCTR2007-007867-25-PT. A safety and efficacy trial evaluating the use of apixaban in the treatment of symptomatic deep vein thrombosis and pulmonary embolism revised protocol number: 01, incorporates amendment(s) 02 + protocol amendment 01 (version 1.0 dated 21-Apr-08) site-specific - molecular profiling supplement samples for Pfizer’s exploratory research biobank. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2007%E2%80%90007867%E2%80%9025%E2%80%90PT (first received 14 July 2008). GallusAS , AgnelliG , BullerHR , CohenA , LeeTC , PakR , et al. Apixaban for treatment of venous thromboembolism in patients from study centres in Asia: a subgroup analysis of the Amplify trial. Journal of Thrombosis and Haemostasis2015;13:727. LeeT , PanS , ByonW , IlyasBS . Safety and efficacy of apixaban versus enoxaparin/warfarin in patients with extremes of body weight: post-hoc analysis of the AMPLIFY trial. Blood2019;134(Suppl 1):1152. LiuX , JohnsonM , MardekianJ , PhatakH , ThompsonJ , CohenAT . Apixaban reduces hospitalizations in patients with venous thromboembolism: an analysis of the apixaban for the Initial management of pulmonary embolism and deep‐vein thrombosis as first‐line therapy (AMPLIFY) trial. Journal of the American Heart Association2015;4(12):e002340. NCT00633893. Efficacy and safety study of apixaban for extended treatment of deep vein thrombosis or pulmonary embolism. clinicaltrials.gov/ct2/show/NCT00633893?term=ajax&amp;rank=5 (first received 12 March 2008). NCT00643201. Efficacy and safety study of apixaban for the treatment of deep vein thrombosis or pulmonary embolism. clinicaltrials.gov/ct2/show/NCT00643201 (first received 26 March 2008). RaskobGE , GallusAS , SandersP , ThompsonJR , AgnelliG , BullerHR , et al. Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy: a sub-analysis of the AMPLIFY trial. Thrombosis and Haemostasis2016;115(4):809-16. ">AMPLIFY 2013</a>; <a href="./references#CD010956-bbs2-0003" title="BarrettYC , WangJ , KnabbR , MohanP . Apixaban decreases coagulation activity in patients with acute deep-vein thrombosis. Thrombosis and Haemostasis2011;105:181-9. Botticelli Investigators Writing Committee, BullerH , DeitchmanD , PrinsM , SegersA . Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. Journal of Thrombosis and Haemostasis2008;6:1313-8. BullerHR . A dose finding study of the oral direct factor Xa inhibitor apixaban in the treatment of patients with acute symptomatic deep vein thrombosis - the Botticelli Investigators. Journal of Thrombosis and Haemostasis2007;5 (Suppl 2):O-S-003. NCT00252005. Oral direct factor Xa-inhibitor apixaban in patients with acute symptomatic deep-vein thrombosis - the Botticelli DVT study. clinicaltrials.gov/ct/show/NCT00252005?order=1 (first received 11 November 2005). ">Botticelli DVT 2008</a>; <a href="./references#CD010956-bbs2-0007" title="BullerH , DariusH . EINSTEIN DVT: oral rivaroxaban versus standard therapy in the initial treatment of symptomatic deep vein thrombosis and long-term prevention of recurrent venous thromboembolism. escardio.org/The-ESC/Press-Office/Press-releases/EINSTEIN-DVT-Oral-rivaroxaban-versus-standard-therapy-in-the-initial-treatment (accessed 19 October 2022). BullerHR , AgnelliG . Once- or twice-daily rivaroxaban for the treatment of proximal deep vein thrombosis: similar efficacy and safety to standard therapy in dose-ranging studies. Blood2006;108(11 Part 1):172-3. BullerHR , LensingAW , PrinsMH , AgnelliG , CohenA , GallusAS , et al. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT dose-ranging study. Blood2008;112(6):2242-7. NCT00395772. Once-daily oral direct factor Xa inhibitor BAY59-7939 in patients with acute symptomatic deep-vein thrombosis. clinicaltrials.gov/ct2/show/NCT00395772?term=einstein-dvt&amp;rank=2 (first received 3 November 2006). ">EINSTEIN‐DVT dose 2008</a>; <a href="./references#CD010956-bbs2-0006" title="BamberL , WangMY , PrinsMH , CiniglioC , BauersachsR , LensingAW , et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis. Thrombosis and Haemostasis2013;110(4):732-41. BauersachsR , LensingAW , PapA , DecoususH . No need for a rivaroxaban dose reduction in renally impaired patients with symptomatic venous thromboembolism. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):30-1. BistervelsI , GebelM , LensingA , MiddeldorpS , CoppensM . Effect of polypharmacy on bleeding of rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolism. Research and Practice in Thrombosis and Haemostasis2019;3:798‐9. BookhartBK , HaskellL , BamberL , WangM , ScheinJ , ModySH . Length of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial program. Journal of Medical Economics2014;17(10):691-5. BullerHR . Oral rivaroxaban for the acute and continued treatment of symptomatic venous thromboembolism. The Einstein-DVT and Einstein-Extension study. Blood2010;116(21):187. CheungW , MiddeldorpS , PrinsMP , PapAF , LensingAW , Hoek-tenCA , et al. Post thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep vein thrombosis. Journal of Thrombosis and Haemostasis2015;13(S2):219-20. CheungYW , MiddeldorpS , PrinsMH , PapAF , PrandoniP . Post-thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep-vein thrombosis. A post-hoc analysis. Thrombosis and Haemostasis2016;116(4):733-8. EUCTR2004-002171-16-IT. Once-daily oral direct factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis. The EINSTEIN-DVT dose-finding study. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2004%E2%80%90002171%E2%80%9016%E2%80%90IT (first received 15 October 2008). EUCTR2006-004495-13-DK. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep-vein thrombosis or pulmonary embolism. trialsearch.who.int/?TrialID=EUCTR2006-004495-13-DK (first received 29 March 2007). EerenbergES , MiddeldorpS , LeviM , LensingAW , BüllerHR . Clinical impact and course of major bleeding with rivaroxaban and vitamin K antagonists. Journal of Thrombosis and Haemostasis2015;13(9):1590-6. KlineJA , JimenezD , CourtneyDM , IanusJ , CaoL , WellsPS . Use of the Riete 2008 bleeding score to identify patients at low risk for major bleeding in patients treated with rivaroxaban. Academic Emergency Medicine2015;22:S162. NCT00440193. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep vein thrombosis - The EINSTEIN DVT Study. clinicaltrials.gov/ct2/show/NCT00440193 (first received 26 February 2007). PrinsMH , ErkensPG , LensingAW . Incidence of recurrent venous thromboembolism in patients following completion of the EINSTEIN DVT and EINSTEIN PE studies. Journal of Thrombosis and Haemostasis2013;11(Suppl):257. PrinsMH , LensingAW , BauersachsR , Van BellenB , BounameauxH , BrightonTA , et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thrombosis Journal2013;11(1):21. The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. New England Journal of Medicine2010;363(26):2499-510. Van BellenB , PrinsM , BamberL , WangM , LensingAW . Reduction in initial length of stay with rivaroxaban single-drug regimen versus LMWH-VKA standard of care: findings from the EINSTEIN trial program. Blood2012;120(21):3419. Van BellenB , PrinsM , BamberL , WangM , LensingAW . Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism. Current Medical Research and Opinion2014;30(5):829-37. WangY , WangC , ChenZ , ZhangJ , LiuZ , JinB , et al. Rivaroxaban for the treatment of symptomatic deep vein thrombosis and/or pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):694. WangY , WangC , ChenZ , ZhangJ , LiuZ , JinB , et al. Rivaroxaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Thrombosis Journal2013;11(1):25. ">EINSTEIN‐DVT 2010</a>; <a href="./references#CD010956-bbs2-0009" title="PiazzaG , ManiV , GoldhaberSZ , GrossoMA , MercuriM , LanzHJ , et al. Magnetic resonance venography to assess thrombus resolution with edoxaban monotherapy versus parenteral anticoagulation/warfarin for symptomatic deep vein thrombosis: a multicenter feasibility study. Vascular Medicine2016;21(4):361-8. PiazzaG , ManiV , GrossoM , MercuriM , LanzH , SchusslerS , et al. A randomized, open-label, multicenter study of the efficacy and safety of edoxaban monotherapy versus low-molecular weight heparin/warfarin in patients with symptomatic deep vein thrombosis-edoxaban thrombus reduction imaging study (etris). Circulation2014;130:A12074. ">eTRIS 2016</a>; <a href="./references#CD010956-bbs2-0011" title="BistervelsI , BavaliaR , BoersmaW , MeijerK , VerhammeP , Ten Cate-HoekAJ , et al. Hokusai Post-DVT Study: a follow-up study on long-term outcomes of deep vein thrombosis in patients treated with edoxaban vs warfarin. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):PB2207. BrekelmansMP , AgenoW , BeenenLF , BrennerB , BullerHR , ChenCZ , et al. Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology2016;3(9):e437-45. BrekelmansMP , BlekerSM , BauersachsR , BodaZ , BüllerHR , ChoiY , et al. Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists. Thrombosis and Haemostasis2016;116(1):155-61. Di NisioM , Van EsN , CarrierM , WangTF , GarciaD , SegersA , et al. Extended treatment with edoxaban in cancer patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE Cancer study. Journal of Thrombosis and Haemostasis2019;17:1866–74. EUCTR2009-014290-40-SE. A phase 3, randomized, double-blind, double-dummy, parallel group, multi-center, multi-national study for evaluation of efficacy and safety of DU-176b versus warfarin in subjects with atrial fibrillation - effective anticoagulation with factor Xa next generation in atrial fibrillation (ENGAGE-AF TIMI-48). trialsearch.who.int/?trialid=EUCTR2009-014290-40-SE (first received 30 November 2009). EichingerS , LinM , KyrlePA , GrossoMA . Recurrent venous thromboembolism during anticoagulation: an investigator-initiated post-hoc analysis of the hokusai-VTE trial. Blood2018;132:2539. KlokFA , BarcoS , KonstantinidesSV . External validation of the VTE-BLEED score for predicting major bleeding in stable anticoagulated patients with venous thromboembolism. Thrombosis and Haemostasis2017;117(6):1164-70. KraaijpoelN , Van EsN , RaskobGE , BüllerHR , CarrierM , ZhangG , et al. Risk scores for occult cancer in patients with venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2018;118(7):1270-8. MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMP , ChenCZ , et al. Outpatient management in patients with venous thromboembolism with edoxaban: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2017;117(12):2406-14. MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMP , ChenCZ , et al. Safety and efficacy of edoxaban compared with warfarin for the treatment of acute symptomatic deep-vein thrombosis in the outpatient setting. Research and Practice in Thrombosis and Haemostasis2017;1:913. MulderFI , Van EsN , KraaijpoelN , Di NisioM , CarrierM , DuggalA , et al. Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: results from the Hokusai VTE Cancer study. Thrombosis Research2020;185:13-9. NCT00986154. Comparative investigation of Low Molecular Weight (LMW) heparin/edoxaban tosylate (DU176b) versus (LMW) heparin/warfarin in the treatment of symptomatic deep-vein blood clots and/or lung blood clots. (The Edoxaban Hokusai-VTE Study). clinicaltrials.gov/ct2/show/NCT00986154 (first received 29 September 2009). NakamuraM , WangYQ , WangC , OhD , YinWH , KimuraT , et al. Efficacy and safety of edoxaban for treatment of venous thromboembolism: a subanalysis of East Asian patients in the Hokusai-VTE trial. Journal of Thrombosis and Haemostasis2015;13(9):1606-14. NybergJ , KarlssonKE , JönssonS , YinO , MillerR , KarlssonMO , et al. Edoxaban exposure-response analysis and clinical utility index assessment in patients with symptomatic deep-vein thrombosis or pulmonary embolism. CPT Pharmacometrics and Systems Pharmacology2016;5(4):222-32. RaskobG , AgenoW , CohenAT , BrekelmansMP , GrossoMA , SegersA , et al. Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology2016;3(5):e228-e236. RaskobG , BullerH , PrinsM , SegersA , ShiM , SchwochoL , et al. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study - methodological implications for clinical trials. Journal of Thrombosis and Haemostasis2013;11(7):1287-94. RaskobGE , BullerH , AngchaisuksiriP , OhD , BodaZ , LyonsRM , et al. Edoxaban for long-term treatment of venous thromboembolism in cancer patients. Blood2013;122(21):211. RaskobGE , Van EsN , SegersA , AngchaisuksiriP , OhD , BodaZ , et al. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematology2016;3(8):e379-87. ScheresLJ , BrekelmansMA , WalterA , CihanA , BüllerHR , SabineE , et al. Abnormal vaginal bleeding in women of reproductive age treated with edoxaban or warfarin for venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. British Journal of Obstetrics and Gynaecology2018;125(12):1581-9. The Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. New England Journal of Medicine2013;369(15):1406-15. VanasscheT , VerhammeP , WellsPS , SegersA , AgenoW , BrekelmansMP , et al. Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: an analysis of the randomized, double-blind Hokusai-VTE trial. Thrombosis Research2018;162:7-14. VerhammeP , WellsPS , SegersA , AgenoW , BrekelmansMP , CohenAT , et al. Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial. Thrombosis and Haemostasis2016;116(4):747-53. ">Hokusai‐VTE 2013</a>; <a href="./references#CD010956-bbs2-0015" title="AgnelliG , GallusA , GoldhaberSZ , HaasS , HuismanMV , HullRD , et al. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAT 59-7939 in patients with acute symptomatic deep-vein thrombosis) study. Circulation2007;116:180-7. ">ODIXa‐DVT 2007</a>). The incidence was 1.00% (80 events/8001 participants) in the factor Xa inhibitor group versus 1.11% (80 events/7165 participants) in the conventional anticoagulation group (OR 0.93, 95% CI 0.68 to 1.27; 7 studies, 15,166 participants; I<sup>2</sup> = 0%; moderate‐certainty evidence; <a href="./references#CD010956-fig-0022" title="">Analysis 3.4</a>). There was no clear difference in incidence of non‐fatal PE between factor Xa inhibitors and conventional anticoagulation when treatment was for three months (OR 0.87, 95% CI 0.51 to 1.48; 5 studies, 5001 participants) and for more than three months (OR 0.96, 95% CI 0.65 to 1.43; 2 studies, 10,165 participants). No subgroup differences were indicated (test for subgroup differences: P = 0.77). As a limited number of studies reporting on this outcome provided separate data for participants with or without cancer, we were not able to undertake subgroup analysis on this characteristic. No subgroup effect was indicated when analysed by the three oral factor Xa inhibitors (apixaban, edoxaban, rivaroxaban) (test for subgroup differences: P = 0.84, <a href="./references#CD010956-fig-0033" title="">Analysis 5.4</a>). </p> </section> <section id="CD010956-sec-0076"> <h5 class="title">All‐cause mortality</h5> <p>Nine studies (10,770 participants) reported all‐cause mortality (<a href="./references#CD010956-bbs2-0001" title="AgnelliG , BullerH , MasiukiewiczUP . Apixaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism: a randomized, double-blind trial (AMPLIFY). Journal of Thrombosis and Haemostasis2013;11:18. AgnelliG , BullerHR , CohenA , CurtoD , GallusAS , JohnsonM , et al. Oral apixaban for the treatment of acute venous thromboembolism. New England Journal of Medicine2013;369:799-808. AgnelliG , BullerHR , CohenA , CurtoM , GallusAS , PakR , et al. Apixaban for the treatment of venous thromboembolism in cancer patients: data from the AMPLIFY trial. Canadian Journal of Cardiology2014;30(10 Suppl 1):S278. AgnelliG , BullerHR , CohenA , GallusAS , LeeTC , PakR , et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. Journal of Thrombosis and Haemostasis2015;13(12):2187-91. AgnelliG . Apixaban was non-inferior to enoxaparin plus warfarin in patients with acute venous thromboembolism. Annals of Internal Medicine2013;159(8):JC2. BlekerSM , CohenAT , BüllerHR , AgnelliG , GallusAS , RaskobGE , et al. Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Thrombosis and Haemostasis2016;116(6):159-64. BrekelmansM , ScheresL , BlekerS , HuttenB , TimmermansA , BüllerH , et al. Abnormal vaginal bleeding in women with venous thromboembolism treated with apixaban or warfarin. Thrombosis and Haemostasis2017;117(04):809-15. CohenA , AgnelliG , BullerH , GallusA , RaskobG , SandersP , et al. Characteristics and outcomes in patients with venous thromboembolism taking concomitant anti-platelet agents and anticoagulants in the AMPLIFY Trial. Thrombosis and Haemostasis2019;119(3):461-6. CohenA , AgnelliG , BullerHR , ChaudhuriS , GallusAS , RaskobGE , et al. Analysis of the bleeding and thromboembolic risk with concomitant use of antiplatelet treatment in the AMPLIFY trial. Canadian Journal of Cardiology2014;30(10):S272. CohenA , GallusAS , AgnelliG , BullerHR , PakR , PorcariAR , et al. Time in Therapeutic Range (TTR) and relative efficacy and safety of treatment with apixaban or enoxaparin/warfarin for acute symptomatic venous thromboembolism: an analysis of the Amplify trial data. Blood2014;124(21):1543. CohenAT , PanS , ByonW , IlyasBS , LeeTC . Efficacy, safety, and exposure of apixaban in patients with high body weight or obesity and venous thromboembolism: insights from AMPLIFY. Advances in Therapy2021;38(6):3003-18. EUCTR2007-007867-25-PT. A safety and efficacy trial evaluating the use of apixaban in the treatment of symptomatic deep vein thrombosis and pulmonary embolism revised protocol number: 01, incorporates amendment(s) 02 + protocol amendment 01 (version 1.0 dated 21-Apr-08) site-specific - molecular profiling supplement samples for Pfizer’s exploratory research biobank. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2007%E2%80%90007867%E2%80%9025%E2%80%90PT (first received 14 July 2008). GallusAS , AgnelliG , BullerHR , CohenA , LeeTC , PakR , et al. Apixaban for treatment of venous thromboembolism in patients from study centres in Asia: a subgroup analysis of the Amplify trial. Journal of Thrombosis and Haemostasis2015;13:727. LeeT , PanS , ByonW , IlyasBS . Safety and efficacy of apixaban versus enoxaparin/warfarin in patients with extremes of body weight: post-hoc analysis of the AMPLIFY trial. Blood2019;134(Suppl 1):1152. LiuX , JohnsonM , MardekianJ , PhatakH , ThompsonJ , CohenAT . Apixaban reduces hospitalizations in patients with venous thromboembolism: an analysis of the apixaban for the Initial management of pulmonary embolism and deep‐vein thrombosis as first‐line therapy (AMPLIFY) trial. Journal of the American Heart Association2015;4(12):e002340. NCT00633893. Efficacy and safety study of apixaban for extended treatment of deep vein thrombosis or pulmonary embolism. clinicaltrials.gov/ct2/show/NCT00633893?term=ajax&amp;rank=5 (first received 12 March 2008). NCT00643201. Efficacy and safety study of apixaban for the treatment of deep vein thrombosis or pulmonary embolism. clinicaltrials.gov/ct2/show/NCT00643201 (first received 26 March 2008). RaskobGE , GallusAS , SandersP , ThompsonJR , AgnelliG , BullerHR , et al. Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy: a sub-analysis of the AMPLIFY trial. Thrombosis and Haemostasis2016;115(4):809-16. ">AMPLIFY 2013</a>; <a href="./references#CD010956-bbs2-0002" title="NakamuraM , NishikawaM , KomuroI , KitajimaI , UetsukaY , YamagamiT , et al. Apixaban for the treatment of Japanese subjects with acute venous thromboembolism (AMPLIFY-J Study). Circulation2015;79(6):1230–36. ">AMPLIFY‐J 2015</a>; <a href="./references#CD010956-bbs2-0003" title="BarrettYC , WangJ , KnabbR , MohanP . Apixaban decreases coagulation activity in patients with acute deep-vein thrombosis. Thrombosis and Haemostasis2011;105:181-9. Botticelli Investigators Writing Committee, BullerH , DeitchmanD , PrinsM , SegersA . Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. Journal of Thrombosis and Haemostasis2008;6:1313-8. BullerHR . A dose finding study of the oral direct factor Xa inhibitor apixaban in the treatment of patients with acute symptomatic deep vein thrombosis - the Botticelli Investigators. Journal of Thrombosis and Haemostasis2007;5 (Suppl 2):O-S-003. NCT00252005. Oral direct factor Xa-inhibitor apixaban in patients with acute symptomatic deep-vein thrombosis - the Botticelli DVT study. clinicaltrials.gov/ct/show/NCT00252005?order=1 (first received 11 November 2005). ">Botticelli DVT 2008</a>; <a href="./references#CD010956-bbs2-0005" title="NCT02704598. Comparison between xarelto versus warfarin in the recanalization rate of deep venous thrombosis in patients legs. (DVT). clinicaltrials.gov/ct2/show/NCT02704598 (first received 10 March 2016). deAthayde SoaresR , MatieloMF , Brochado NetoFC , AlmeidaRD , SacilottoR . LEV 2. Comparison of the recanalization rate and post-thrombotic syndrome in patients with deep venous thrombosis treated with rivaroxaban or warfarin. Journal of Vascular Surgery2019;70(5):e169-e170. deAthayde SoaresR , MatieloMF , Brochado NetoFC , NogueiraMP , AlmeidaRD , SacilottoR . Comparison of the recanalization rate and postthrombotic syndrome in patients with deep venous thrombosis treated with rivaroxaban or warfarin. Surgery2019;166(6):1076-83. ">de Athayde 2019</a>; <a href="./references#CD010956-bbs2-0007" title="BullerH , DariusH . EINSTEIN DVT: oral rivaroxaban versus standard therapy in the initial treatment of symptomatic deep vein thrombosis and long-term prevention of recurrent venous thromboembolism. escardio.org/The-ESC/Press-Office/Press-releases/EINSTEIN-DVT-Oral-rivaroxaban-versus-standard-therapy-in-the-initial-treatment (accessed 19 October 2022). BullerHR , AgnelliG . Once- or twice-daily rivaroxaban for the treatment of proximal deep vein thrombosis: similar efficacy and safety to standard therapy in dose-ranging studies. Blood2006;108(11 Part 1):172-3. BullerHR , LensingAW , PrinsMH , AgnelliG , CohenA , GallusAS , et al. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT dose-ranging study. Blood2008;112(6):2242-7. NCT00395772. Once-daily oral direct factor Xa inhibitor BAY59-7939 in patients with acute symptomatic deep-vein thrombosis. clinicaltrials.gov/ct2/show/NCT00395772?term=einstein-dvt&amp;rank=2 (first received 3 November 2006). ">EINSTEIN‐DVT dose 2008</a>; <a href="./references#CD010956-bbs2-0006" title="BamberL , WangMY , PrinsMH , CiniglioC , BauersachsR , LensingAW , et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis. Thrombosis and Haemostasis2013;110(4):732-41. BauersachsR , LensingAW , PapA , DecoususH . No need for a rivaroxaban dose reduction in renally impaired patients with symptomatic venous thromboembolism. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):30-1. BistervelsI , GebelM , LensingA , MiddeldorpS , CoppensM . Effect of polypharmacy on bleeding of rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolism. Research and Practice in Thrombosis and Haemostasis2019;3:798‐9. BookhartBK , HaskellL , BamberL , WangM , ScheinJ , ModySH . Length of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial program. Journal of Medical Economics2014;17(10):691-5. BullerHR . Oral rivaroxaban for the acute and continued treatment of symptomatic venous thromboembolism. The Einstein-DVT and Einstein-Extension study. Blood2010;116(21):187. CheungW , MiddeldorpS , PrinsMP , PapAF , LensingAW , Hoek-tenCA , et al. Post thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep vein thrombosis. Journal of Thrombosis and Haemostasis2015;13(S2):219-20. CheungYW , MiddeldorpS , PrinsMH , PapAF , PrandoniP . Post-thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep-vein thrombosis. A post-hoc analysis. Thrombosis and Haemostasis2016;116(4):733-8. EUCTR2004-002171-16-IT. Once-daily oral direct factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis. The EINSTEIN-DVT dose-finding study. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2004%E2%80%90002171%E2%80%9016%E2%80%90IT (first received 15 October 2008). EUCTR2006-004495-13-DK. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep-vein thrombosis or pulmonary embolism. trialsearch.who.int/?TrialID=EUCTR2006-004495-13-DK (first received 29 March 2007). EerenbergES , MiddeldorpS , LeviM , LensingAW , BüllerHR . Clinical impact and course of major bleeding with rivaroxaban and vitamin K antagonists. Journal of Thrombosis and Haemostasis2015;13(9):1590-6. KlineJA , JimenezD , CourtneyDM , IanusJ , CaoL , WellsPS . Use of the Riete 2008 bleeding score to identify patients at low risk for major bleeding in patients treated with rivaroxaban. Academic Emergency Medicine2015;22:S162. NCT00440193. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep vein thrombosis - The EINSTEIN DVT Study. clinicaltrials.gov/ct2/show/NCT00440193 (first received 26 February 2007). PrinsMH , ErkensPG , LensingAW . Incidence of recurrent venous thromboembolism in patients following completion of the EINSTEIN DVT and EINSTEIN PE studies. Journal of Thrombosis and Haemostasis2013;11(Suppl):257. PrinsMH , LensingAW , BauersachsR , Van BellenB , BounameauxH , BrightonTA , et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thrombosis Journal2013;11(1):21. The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. New England Journal of Medicine2010;363(26):2499-510. Van BellenB , PrinsM , BamberL , WangM , LensingAW . Reduction in initial length of stay with rivaroxaban single-drug regimen versus LMWH-VKA standard of care: findings from the EINSTEIN trial program. Blood2012;120(21):3419. Van BellenB , PrinsM , BamberL , WangM , LensingAW . Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism. Current Medical Research and Opinion2014;30(5):829-37. WangY , WangC , ChenZ , ZhangJ , LiuZ , JinB , et al. Rivaroxaban for the treatment of symptomatic deep vein thrombosis and/or pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):694. WangY , WangC , ChenZ , ZhangJ , LiuZ , JinB , et al. Rivaroxaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Thrombosis Journal2013;11(1):25. ">EINSTEIN‐DVT 2010</a>; <a href="./references#CD010956-bbs2-0014" title="MokademME , HassanA , AlgabyAZ . Efficacy and safety of apixaban in patients with active malignancy and acute deep venous thrombosis. Vascular2021;29(5):745-50. NCT04462003. Efficacy of apixaban in malignancy with deep venous thrombosis (DVT). clinicaltrials.gov/ct2/show/NCT04462003 (first received 3 July 2019). ">Mokadem 2021</a>; <a href="./references#CD010956-bbs2-0015" title="AgnelliG , GallusA , GoldhaberSZ , HaasS , HuismanMV , HullRD , et al. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAT 59-7939 in patients with acute symptomatic deep-vein thrombosis) study. Circulation2007;116:180-7. ">ODIXa‐DVT 2007</a>; <a href="./references#CD010956-bbs2-0017" title="Kang JiM, ParkKH , AhnS , ChoS , MinSK . Rivaroxaban after thrombolysis in acute iliofemoral venous thrombosis: a randomized, open-labeled, multicenter trial. Scientific Reports2019;9(1):20356. MinSK , AhnS , ParkKH , KangJM , KimJY . Prevention of recurrence after thrombolysis in acute iliofemoral venous thrombosis with rivaroxaban (Prais Study): a prospective, randomized, open label, multicenter trial. European Journal of Vascular and Endovascular Surgery2019;58(6):e516. NCT01986192. Prevention of recurrence after thrombolysis in acute iliofemoral venous thrombosis (PRAIS) study. clinicaltrials.gov/show/NCT01986192 (first received 18 November 2013). ">PRAIS 2019</a>). We did not include the <a href="./references#CD010956-bbs2-0008" title="BullerHR , PrinsMH , LensinAW , DecoususH , JacobsonBF , MinarE , et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. New England Journal of Medicine2012;366:1287-97. FermannGJ , Erkens Pmg, PrinsMH , WellsPS , Pap ÁF, LensingAW , et al. Treatment of pulmonary embolism with rivaroxaban: outcomes by simplified pulmonary embolism severity index score from a post hoc analysis of the EINSTEIN PE study. Academic Emergency Medicine2015;22(3):299-307. NCT00439777. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic pulmonary embolism with or without symptomatic deep-vein thrombosis: Einstein-PE evaluation, 2008. clinicaltrials.gov/ct2/show/NCT00439777?term=NCT00439777&amp;rank=1 (first received 26 February 2007). PrinsM , BamberL , CanoS , WangM , LensingAW , BauersachsR . Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic pulmonary embolism. Blood2012;120(21):1163. PrinsMH , BamberL , CanoSJ , WangMY , ErkensP , BauersachsR , et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial. Thrombosis Research2015;135(2):281-8. ">EINSTEIN‐PE 2012</a> as it was not possible to obtain the specific all‐cause mortality data on participants with an index DVT. The <a href="./references#CD010956-bbs2-0002" title="NakamuraM , NishikawaM , KomuroI , KitajimaI , UetsukaY , YamagamiT , et al. Apixaban for the treatment of Japanese subjects with acute venous thromboembolism (AMPLIFY-J Study). Circulation2015;79(6):1230–36. ">AMPLIFY‐J 2015</a>, <a href="./references#CD010956-bbs2-0005" title="NCT02704598. Comparison between xarelto versus warfarin in the recanalization rate of deep venous thrombosis in patients legs. (DVT). clinicaltrials.gov/ct2/show/NCT02704598 (first received 10 March 2016). deAthayde SoaresR , MatieloMF , Brochado NetoFC , AlmeidaRD , SacilottoR . LEV 2. Comparison of the recanalization rate and post-thrombotic syndrome in patients with deep venous thrombosis treated with rivaroxaban or warfarin. Journal of Vascular Surgery2019;70(5):e169-e170. deAthayde SoaresR , MatieloMF , Brochado NetoFC , NogueiraMP , AlmeidaRD , SacilottoR . Comparison of the recanalization rate and postthrombotic syndrome in patients with deep venous thrombosis treated with rivaroxaban or warfarin. Surgery2019;166(6):1076-83. ">de Athayde 2019</a> and <a href="./references#CD010956-bbs2-0017" title="Kang JiM, ParkKH , AhnS , ChoS , MinSK . Rivaroxaban after thrombolysis in acute iliofemoral venous thrombosis: a randomized, open-labeled, multicenter trial. Scientific Reports2019;9(1):20356. MinSK , AhnS , ParkKH , KangJM , KimJY . Prevention of recurrence after thrombolysis in acute iliofemoral venous thrombosis with rivaroxaban (Prais Study): a prospective, randomized, open label, multicenter trial. European Journal of Vascular and Endovascular Surgery2019;58(6):e516. NCT01986192. Prevention of recurrence after thrombolysis in acute iliofemoral venous thrombosis (PRAIS) study. clinicaltrials.gov/show/NCT01986192 (first received 18 November 2013). ">PRAIS 2019</a> studies had no events in either group and contributed no estimate in the forest plot. Meta‐analysis showed no clear difference in the rate of all‐cause mortality between the two treatment groups (OR 0.87, 95% CI 0.67 to 1.14; 9 studies, 10,770 participants; I<sup>2</sup> = 0%; moderate‐certainty evidence; <a href="./references#CD010956-fig-0023" title="">Analysis 3.5</a>). The incidence was 2.12% (126 events/5834 participants) in the factor Xa inhibitor group and 2.35% (118 events/4936 participants) in the conventional anticoagulation group. Furthermore, there was no difference in the incidence of all‐cause mortality between participants treated with factor Xa inhibitors and conventional anticoagulation when treatment was three months (OR 0.85, 95% CI 0.58 to 1.25; 4 studies, 5072 participants) or more than three months (OR 0.95, 95% CI 0.55 to 1.67; 5 studies, 5698 participants). No subgroup differences were indicated (test for subgroup differences: P = 0.75). As a limited number of studies reporting on this outcome provided separate data for participants with or without cancer, we were not able to undertake subgroup analysis on this characteristic. No subgroup effect was indicated when analysed by different oral factor Xa inhibitors (apixaban and rivaroxaban) (test for subgroup differences: P = 0.61, <a href="./references#CD010956-fig-0034" title="">Analysis 5.5</a>). </p> </section> <section id="CD010956-sec-0077"> <h5 class="title">Major bleeding</h5> <p>We included 17 studies (18,066 participants) in the meta‐analysis of major bleeding (<a href="./references#CD010956-bbs2-0001" title="AgnelliG , BullerH , MasiukiewiczUP . Apixaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism: a randomized, double-blind trial (AMPLIFY). Journal of Thrombosis and Haemostasis2013;11:18. AgnelliG , BullerHR , CohenA , CurtoD , GallusAS , JohnsonM , et al. Oral apixaban for the treatment of acute venous thromboembolism. New England Journal of Medicine2013;369:799-808. AgnelliG , BullerHR , CohenA , CurtoM , GallusAS , PakR , et al. Apixaban for the treatment of venous thromboembolism in cancer patients: data from the AMPLIFY trial. Canadian Journal of Cardiology2014;30(10 Suppl 1):S278. AgnelliG , BullerHR , CohenA , GallusAS , LeeTC , PakR , et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. Journal of Thrombosis and Haemostasis2015;13(12):2187-91. AgnelliG . Apixaban was non-inferior to enoxaparin plus warfarin in patients with acute venous thromboembolism. Annals of Internal Medicine2013;159(8):JC2. BlekerSM , CohenAT , BüllerHR , AgnelliG , GallusAS , RaskobGE , et al. Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Thrombosis and Haemostasis2016;116(6):159-64. BrekelmansM , ScheresL , BlekerS , HuttenB , TimmermansA , BüllerH , et al. Abnormal vaginal bleeding in women with venous thromboembolism treated with apixaban or warfarin. Thrombosis and Haemostasis2017;117(04):809-15. CohenA , AgnelliG , BullerH , GallusA , RaskobG , SandersP , et al. Characteristics and outcomes in patients with venous thromboembolism taking concomitant anti-platelet agents and anticoagulants in the AMPLIFY Trial. Thrombosis and Haemostasis2019;119(3):461-6. CohenA , AgnelliG , BullerHR , ChaudhuriS , GallusAS , RaskobGE , et al. Analysis of the bleeding and thromboembolic risk with concomitant use of antiplatelet treatment in the AMPLIFY trial. Canadian Journal of Cardiology2014;30(10):S272. CohenA , GallusAS , AgnelliG , BullerHR , PakR , PorcariAR , et al. Time in Therapeutic Range (TTR) and relative efficacy and safety of treatment with apixaban or enoxaparin/warfarin for acute symptomatic venous thromboembolism: an analysis of the Amplify trial data. Blood2014;124(21):1543. CohenAT , PanS , ByonW , IlyasBS , LeeTC . Efficacy, safety, and exposure of apixaban in patients with high body weight or obesity and venous thromboembolism: insights from AMPLIFY. Advances in Therapy2021;38(6):3003-18. EUCTR2007-007867-25-PT. A safety and efficacy trial evaluating the use of apixaban in the treatment of symptomatic deep vein thrombosis and pulmonary embolism revised protocol number: 01, incorporates amendment(s) 02 + protocol amendment 01 (version 1.0 dated 21-Apr-08) site-specific - molecular profiling supplement samples for Pfizer’s exploratory research biobank. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2007%E2%80%90007867%E2%80%9025%E2%80%90PT (first received 14 July 2008). GallusAS , AgnelliG , BullerHR , CohenA , LeeTC , PakR , et al. Apixaban for treatment of venous thromboembolism in patients from study centres in Asia: a subgroup analysis of the Amplify trial. Journal of Thrombosis and Haemostasis2015;13:727. LeeT , PanS , ByonW , IlyasBS . Safety and efficacy of apixaban versus enoxaparin/warfarin in patients with extremes of body weight: post-hoc analysis of the AMPLIFY trial. Blood2019;134(Suppl 1):1152. LiuX , JohnsonM , MardekianJ , PhatakH , ThompsonJ , CohenAT . Apixaban reduces hospitalizations in patients with venous thromboembolism: an analysis of the apixaban for the Initial management of pulmonary embolism and deep‐vein thrombosis as first‐line therapy (AMPLIFY) trial. Journal of the American Heart Association2015;4(12):e002340. NCT00633893. Efficacy and safety study of apixaban for extended treatment of deep vein thrombosis or pulmonary embolism. clinicaltrials.gov/ct2/show/NCT00633893?term=ajax&amp;rank=5 (first received 12 March 2008). NCT00643201. Efficacy and safety study of apixaban for the treatment of deep vein thrombosis or pulmonary embolism. clinicaltrials.gov/ct2/show/NCT00643201 (first received 26 March 2008). RaskobGE , GallusAS , SandersP , ThompsonJR , AgnelliG , BullerHR , et al. Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy: a sub-analysis of the AMPLIFY trial. Thrombosis and Haemostasis2016;115(4):809-16. ">AMPLIFY 2013</a>; <a href="./references#CD010956-bbs2-0002" title="NakamuraM , NishikawaM , KomuroI , KitajimaI , UetsukaY , YamagamiT , et al. Apixaban for the treatment of Japanese subjects with acute venous thromboembolism (AMPLIFY-J Study). Circulation2015;79(6):1230–36. ">AMPLIFY‐J 2015</a>; <a href="./references#CD010956-bbs2-0003" title="BarrettYC , WangJ , KnabbR , MohanP . Apixaban decreases coagulation activity in patients with acute deep-vein thrombosis. Thrombosis and Haemostasis2011;105:181-9. Botticelli Investigators Writing Committee, BullerH , DeitchmanD , PrinsM , SegersA . Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. Journal of Thrombosis and Haemostasis2008;6:1313-8. BullerHR . A dose finding study of the oral direct factor Xa inhibitor apixaban in the treatment of patients with acute symptomatic deep vein thrombosis - the Botticelli Investigators. Journal of Thrombosis and Haemostasis2007;5 (Suppl 2):O-S-003. NCT00252005. Oral direct factor Xa-inhibitor apixaban in patients with acute symptomatic deep-vein thrombosis - the Botticelli DVT study. clinicaltrials.gov/ct/show/NCT00252005?order=1 (first received 11 November 2005). ">Botticelli DVT 2008</a>; <a href="./references#CD010956-bbs2-0004" title="AgenoW , VedovatiMC , CohenA , HuismanM , BauersachsR , GussoniG , et al. Bleeding with apixaban and dalteparin in patients with cancer-associated venous thromboembolism: results from the Caravaggio study. Thrombosis and Haemostasis2021;121(5):616-24. AgnelliG , BecattiniC , BauersachsR , BrennerB , CampaniniM , CohenA , et al. Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the Caravaggio study. Thrombosis and Haemostasis2018;118(9):1668-78. AgnelliG , BecattiniC , MeyerG , MuozA , VersoM . Apixaban for the treatment of venous thromboembolism associated with cancer. New England Journal of Medicine2020;382(17):1599-607. AgnelliG , MuozA , FrancoL , MahéI , BrennerB , ConnorsJM , et al. Apixaban and dalteparin for the treatment of venous thromboembolism in patients with different sites of cancer. Thrombosis and Haemostasis2022;122(5):796-807. BecattiniC , BauersachsR , MarazitiG , BertolettiL , CohenA , ConnorsJM , et al. Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial. Haematologica2021;107(7):1567-76. GiustozziM , ConnorsJM , Ruperez BlancoAB , SzmitS , FalvoN , CohenAT , et al. Clinical characteristics and outcomes of incidental venous thromboembolism in cancer patients: insights from the Caravaggio study. Journal of Thrombosis and Haemostasis2021;19(11):2751-9. NCT03045406. Apixaban for the treatment of venous thromboembolism in patients with cancer (CARAVAGGIO). clinicaltrials.gov/ct2/show/NCT03045406 (first received 7 February 2017). VersoM , MunozA , BauersachsR , HuismanMV , AgnelliG . Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism. European Journal of Cancer2021;148(Suppl C):371-81. ">Caravaggio 2020</a>; <a href="./references#CD010956-bbs2-0005" title="NCT02704598. Comparison between xarelto versus warfarin in the recanalization rate of deep venous thrombosis in patients legs. (DVT). clinicaltrials.gov/ct2/show/NCT02704598 (first received 10 March 2016). deAthayde SoaresR , MatieloMF , Brochado NetoFC , AlmeidaRD , SacilottoR . LEV 2. Comparison of the recanalization rate and post-thrombotic syndrome in patients with deep venous thrombosis treated with rivaroxaban or warfarin. Journal of Vascular Surgery2019;70(5):e169-e170. deAthayde SoaresR , MatieloMF , Brochado NetoFC , NogueiraMP , AlmeidaRD , SacilottoR . Comparison of the recanalization rate and postthrombotic syndrome in patients with deep venous thrombosis treated with rivaroxaban or warfarin. Surgery2019;166(6):1076-83. ">de Athayde 2019</a>; <a href="./references#CD010956-bbs2-0007" title="BullerH , DariusH . EINSTEIN DVT: oral rivaroxaban versus standard therapy in the initial treatment of symptomatic deep vein thrombosis and long-term prevention of recurrent venous thromboembolism. escardio.org/The-ESC/Press-Office/Press-releases/EINSTEIN-DVT-Oral-rivaroxaban-versus-standard-therapy-in-the-initial-treatment (accessed 19 October 2022). BullerHR , AgnelliG . Once- or twice-daily rivaroxaban for the treatment of proximal deep vein thrombosis: similar efficacy and safety to standard therapy in dose-ranging studies. Blood2006;108(11 Part 1):172-3. BullerHR , LensingAW , PrinsMH , AgnelliG , CohenA , GallusAS , et al. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT dose-ranging study. Blood2008;112(6):2242-7. NCT00395772. Once-daily oral direct factor Xa inhibitor BAY59-7939 in patients with acute symptomatic deep-vein thrombosis. clinicaltrials.gov/ct2/show/NCT00395772?term=einstein-dvt&amp;rank=2 (first received 3 November 2006). ">EINSTEIN‐DVT dose 2008</a>; <a href="./references#CD010956-bbs2-0006" title="BamberL , WangMY , PrinsMH , CiniglioC , BauersachsR , LensingAW , et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis. Thrombosis and Haemostasis2013;110(4):732-41. BauersachsR , LensingAW , PapA , DecoususH . No need for a rivaroxaban dose reduction in renally impaired patients with symptomatic venous thromboembolism. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):30-1. BistervelsI , GebelM , LensingA , MiddeldorpS , CoppensM . Effect of polypharmacy on bleeding of rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolism. Research and Practice in Thrombosis and Haemostasis2019;3:798‐9. BookhartBK , HaskellL , BamberL , WangM , ScheinJ , ModySH . Length of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial program. Journal of Medical Economics2014;17(10):691-5. BullerHR . Oral rivaroxaban for the acute and continued treatment of symptomatic venous thromboembolism. The Einstein-DVT and Einstein-Extension study. Blood2010;116(21):187. CheungW , MiddeldorpS , PrinsMP , PapAF , LensingAW , Hoek-tenCA , et al. Post thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep vein thrombosis. Journal of Thrombosis and Haemostasis2015;13(S2):219-20. CheungYW , MiddeldorpS , PrinsMH , PapAF , PrandoniP . Post-thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep-vein thrombosis. A post-hoc analysis. Thrombosis and Haemostasis2016;116(4):733-8. EUCTR2004-002171-16-IT. Once-daily oral direct factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis. The EINSTEIN-DVT dose-finding study. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2004%E2%80%90002171%E2%80%9016%E2%80%90IT (first received 15 October 2008). EUCTR2006-004495-13-DK. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep-vein thrombosis or pulmonary embolism. trialsearch.who.int/?TrialID=EUCTR2006-004495-13-DK (first received 29 March 2007). EerenbergES , MiddeldorpS , LeviM , LensingAW , BüllerHR . Clinical impact and course of major bleeding with rivaroxaban and vitamin K antagonists. Journal of Thrombosis and Haemostasis2015;13(9):1590-6. KlineJA , JimenezD , CourtneyDM , IanusJ , CaoL , WellsPS . Use of the Riete 2008 bleeding score to identify patients at low risk for major bleeding in patients treated with rivaroxaban. Academic Emergency Medicine2015;22:S162. NCT00440193. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep vein thrombosis - The EINSTEIN DVT Study. clinicaltrials.gov/ct2/show/NCT00440193 (first received 26 February 2007). PrinsMH , ErkensPG , LensingAW . Incidence of recurrent venous thromboembolism in patients following completion of the EINSTEIN DVT and EINSTEIN PE studies. Journal of Thrombosis and Haemostasis2013;11(Suppl):257. PrinsMH , LensingAW , BauersachsR , Van BellenB , BounameauxH , BrightonTA , et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thrombosis Journal2013;11(1):21. The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. New England Journal of Medicine2010;363(26):2499-510. Van BellenB , PrinsM , BamberL , WangM , LensingAW . Reduction in initial length of stay with rivaroxaban single-drug regimen versus LMWH-VKA standard of care: findings from the EINSTEIN trial program. Blood2012;120(21):3419. Van BellenB , PrinsM , BamberL , WangM , LensingAW . Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism. Current Medical Research and Opinion2014;30(5):829-37. WangY , WangC , ChenZ , ZhangJ , LiuZ , JinB , et al. Rivaroxaban for the treatment of symptomatic deep vein thrombosis and/or pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):694. WangY , WangC , ChenZ , ZhangJ , LiuZ , JinB , et al. Rivaroxaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Thrombosis Journal2013;11(1):25. ">EINSTEIN‐DVT 2010</a>; <a href="./references#CD010956-bbs2-0008" title="BullerHR , PrinsMH , LensinAW , DecoususH , JacobsonBF , MinarE , et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. New England Journal of Medicine2012;366:1287-97. FermannGJ , Erkens Pmg, PrinsMH , WellsPS , Pap ÁF, LensingAW , et al. Treatment of pulmonary embolism with rivaroxaban: outcomes by simplified pulmonary embolism severity index score from a post hoc analysis of the EINSTEIN PE study. Academic Emergency Medicine2015;22(3):299-307. NCT00439777. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic pulmonary embolism with or without symptomatic deep-vein thrombosis: Einstein-PE evaluation, 2008. clinicaltrials.gov/ct2/show/NCT00439777?term=NCT00439777&amp;rank=1 (first received 26 February 2007). PrinsM , BamberL , CanoS , WangM , LensingAW , BauersachsR . Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic pulmonary embolism. Blood2012;120(21):1163. PrinsMH , BamberL , CanoSJ , WangMY , ErkensP , BauersachsR , et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial. Thrombosis Research2015;135(2):281-8. ">EINSTEIN‐PE 2012</a>; <a href="./references#CD010956-bbs2-0009" title="PiazzaG , ManiV , GoldhaberSZ , GrossoMA , MercuriM , LanzHJ , et al. Magnetic resonance venography to assess thrombus resolution with edoxaban monotherapy versus parenteral anticoagulation/warfarin for symptomatic deep vein thrombosis: a multicenter feasibility study. Vascular Medicine2016;21(4):361-8. PiazzaG , ManiV , GrossoM , MercuriM , LanzH , SchusslerS , et al. A randomized, open-label, multicenter study of the efficacy and safety of edoxaban monotherapy versus low-molecular weight heparin/warfarin in patients with symptomatic deep vein thrombosis-edoxaban thrombus reduction imaging study (etris). Circulation2014;130:A12074. ">eTRIS 2016</a>; <a href="./references#CD010956-bbs2-0010" title="FarhanA , BukhariM , UmarJ , RazaMA . Oral rivaroxaban in symptomatic deep vein thrombosis. Journal of the College of Physicians and Surgeons Pakistan2019;29(9):814-8. ">Farhan 2019</a>; <a href="./references#CD010956-bbs2-0012" title="AmayaN , UzuiH , HisazakiK , HasegwaK , KasenoK , TadaH . Edoxaban normalizes the elevated D-dimer levels potently and promptly in patients with venous thromboembolisms: a comparison with traditional anticoagulant therapy. European Heart Journal2016;37:278. BoschFT , Van EsN , Di NisioM , CarrierM , SegersA , GrossoMA , et al. The Ottawa score does not predict recurrent venous thromboembolism in cancer patients: results from the Hokusai-VTE cancer study. Research and Practice in Thrombosis and Haemostasis2019;3(S1):717-8. KraaijpoelN , Di NisioM , MulderFI , Van EsN , RaskobGE . Clinical impact of bleeding in cancer-associated venous thromboembolism: results from the Hokusai VTE Cancer randomized trial. Thrombosis Research2018;164(Suppl 1):S223. [DOI: 10.1016/j.thromres.2018.02.094]MulderFI , Di NisioM , AyC , CarrierM , BoschFT , SegersA , et al. Clinical implications of incidental venous thromboembolism in cancer patients. European Respiratory Journal2020;55(2):1901697. [DOI: 10.1183/13993003.01697-2019]MulderFI , Van EsN , KraaijpoelN , Di NisioM , CarrierM , GarciaD , et al. Efficacy and safety of edoxaban in clinically relevant subgroups: results from the Hokusai VTE Cancer randomized trial. Thrombosis Research2018;164:S194. NCT02073682. Cancer venous thromboembolism (VTE). clinicaltrials.gov/ct2/show/NCT02073682 (first received 27 February 2014). RaskobG , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaD , et al. Edoxaban versus dalteparin for treatment of venous thromboembolism (VTE) associated with cancer: Hokusai VTE-cancer randomized trial. Supportive Care in Cancer2018;26(2):S316-S317. RaskobGE , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaD , et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. New England Journal of Medicine2018;378(7):615-24. RaskobGE , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaDA , et al. A randomized, open-label, blinded outcome assessment trial evaluating the efficacy and safety of LMWH/Edoxaban versus dalteparin for venous thromboembolism associated with cancer: Hokusai VTE-cancer study. Blood2017;130(Suppl 1):LBA-6. ">Hokusai VTE Cancer 2018</a>; <a href="./references#CD010956-bbs2-0011" title="BistervelsI , BavaliaR , BoersmaW , MeijerK , VerhammeP , Ten Cate-HoekAJ , et al. Hokusai Post-DVT Study: a follow-up study on long-term outcomes of deep vein thrombosis in patients treated with edoxaban vs warfarin. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):PB2207. BrekelmansMP , AgenoW , BeenenLF , BrennerB , BullerHR , ChenCZ , et al. Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology2016;3(9):e437-45. BrekelmansMP , BlekerSM , BauersachsR , BodaZ , BüllerHR , ChoiY , et al. Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists. Thrombosis and Haemostasis2016;116(1):155-61. Di NisioM , Van EsN , CarrierM , WangTF , GarciaD , SegersA , et al. Extended treatment with edoxaban in cancer patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE Cancer study. Journal of Thrombosis and Haemostasis2019;17:1866–74. EUCTR2009-014290-40-SE. A phase 3, randomized, double-blind, double-dummy, parallel group, multi-center, multi-national study for evaluation of efficacy and safety of DU-176b versus warfarin in subjects with atrial fibrillation - effective anticoagulation with factor Xa next generation in atrial fibrillation (ENGAGE-AF TIMI-48). trialsearch.who.int/?trialid=EUCTR2009-014290-40-SE (first received 30 November 2009). EichingerS , LinM , KyrlePA , GrossoMA . Recurrent venous thromboembolism during anticoagulation: an investigator-initiated post-hoc analysis of the hokusai-VTE trial. Blood2018;132:2539. KlokFA , BarcoS , KonstantinidesSV . External validation of the VTE-BLEED score for predicting major bleeding in stable anticoagulated patients with venous thromboembolism. Thrombosis and Haemostasis2017;117(6):1164-70. KraaijpoelN , Van EsN , RaskobGE , BüllerHR , CarrierM , ZhangG , et al. Risk scores for occult cancer in patients with venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2018;118(7):1270-8. MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMP , ChenCZ , et al. Outpatient management in patients with venous thromboembolism with edoxaban: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2017;117(12):2406-14. MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMP , ChenCZ , et al. Safety and efficacy of edoxaban compared with warfarin for the treatment of acute symptomatic deep-vein thrombosis in the outpatient setting. Research and Practice in Thrombosis and Haemostasis2017;1:913. MulderFI , Van EsN , KraaijpoelN , Di NisioM , CarrierM , DuggalA , et al. Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: results from the Hokusai VTE Cancer study. Thrombosis Research2020;185:13-9. NCT00986154. Comparative investigation of Low Molecular Weight (LMW) heparin/edoxaban tosylate (DU176b) versus (LMW) heparin/warfarin in the treatment of symptomatic deep-vein blood clots and/or lung blood clots. (The Edoxaban Hokusai-VTE Study). clinicaltrials.gov/ct2/show/NCT00986154 (first received 29 September 2009). NakamuraM , WangYQ , WangC , OhD , YinWH , KimuraT , et al. Efficacy and safety of edoxaban for treatment of venous thromboembolism: a subanalysis of East Asian patients in the Hokusai-VTE trial. Journal of Thrombosis and Haemostasis2015;13(9):1606-14. NybergJ , KarlssonKE , JönssonS , YinO , MillerR , KarlssonMO , et al. Edoxaban exposure-response analysis and clinical utility index assessment in patients with symptomatic deep-vein thrombosis or pulmonary embolism. CPT Pharmacometrics and Systems Pharmacology2016;5(4):222-32. RaskobG , AgenoW , CohenAT , BrekelmansMP , GrossoMA , SegersA , et al. Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology2016;3(5):e228-e236. RaskobG , BullerH , PrinsM , SegersA , ShiM , SchwochoL , et al. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study - methodological implications for clinical trials. Journal of Thrombosis and Haemostasis2013;11(7):1287-94. RaskobGE , BullerH , AngchaisuksiriP , OhD , BodaZ , LyonsRM , et al. Edoxaban for long-term treatment of venous thromboembolism in cancer patients. Blood2013;122(21):211. RaskobGE , Van EsN , SegersA , AngchaisuksiriP , OhD , BodaZ , et al. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematology2016;3(8):e379-87. ScheresLJ , BrekelmansMA , WalterA , CihanA , BüllerHR , SabineE , et al. Abnormal vaginal bleeding in women of reproductive age treated with edoxaban or warfarin for venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. British Journal of Obstetrics and Gynaecology2018;125(12):1581-9. The Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. New England Journal of Medicine2013;369(15):1406-15. VanasscheT , VerhammeP , WellsPS , SegersA , AgenoW , BrekelmansMP , et al. Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: an analysis of the randomized, double-blind Hokusai-VTE trial. Thrombosis Research2018;162:7-14. VerhammeP , WellsPS , SegersA , AgenoW , BrekelmansMP , CohenAT , et al. Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial. Thrombosis and Haemostasis2016;116(4):747-53. ">Hokusai‐VTE 2013</a>; <a href="./references#CD010956-bbs2-0013" title="MatsuoH , PrinsM , LensingAW , FujinumaEW , MiyamotoY , KajikawaM . Shortened length of hospital stay with rivaroxaban in patients with symptomatic venous thromboembolism in Japan: the J-EINSTEIN pulmonary embolism and deep vein thrombosis program. Current Medical Research and Opinion2015;31(6):1057-61. NCT01516814. Venous thromboembolism (VTE) treatment study in Japanese pulmonary embolism (PE) patients. clinicaltrials.gov/ct2/show/NCT01516814 (first received 25 January 2012). YamadaN , HirayamaA , MaedaH , SakagamiS , ShikataH , PrinsMH , et al. Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism-the J-EINSTEIN DVT and PE program. Thrombosis Journal2015;13:2. ">J‐EINSTEIN DVT and PE 2015</a>; <a href="./references#CD010956-bbs2-0014" title="MokademME , HassanA , AlgabyAZ . Efficacy and safety of apixaban in patients with active malignancy and acute deep venous thrombosis. Vascular2021;29(5):745-50. NCT04462003. Efficacy of apixaban in malignancy with deep venous thrombosis (DVT). clinicaltrials.gov/ct2/show/NCT04462003 (first received 3 July 2019). ">Mokadem 2021</a>; <a href="./references#CD010956-bbs2-0015" title="AgnelliG , GallusA , GoldhaberSZ , HaasS , HuismanMV , HullRD , et al. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAT 59-7939 in patients with acute symptomatic deep-vein thrombosis) study. Circulation2007;116:180-7. ">ODIXa‐DVT 2007</a>; <a href="./references#CD010956-bbs2-0016" title="OhmoriH , KadaA , NakamuraM , SaitoAM , SanayamaY , ShinagawaT , et al. Deep vein thrombosis in severe motor and intellectual disabilities patients and its treatment by anticoagulants of warfarin versus edoxaban. Annals of Vascular Diseases2019;12(3):372-8. OhmoriH , NakamuraM , KadaA , SaitoAM , SanayamaY , ShinagawaT , et al. Multicenter, open-label, randomized controlled trial of warfarin and edoxaban tosilate hydrate for the treatment of deep vein thrombosis in persons with severe motor intellectual disabilities. Kurume Medical Journal2018;65(1):11-6. ">Ohmori 2019</a>; <a href="./references#CD010956-bbs2-0017" title="Kang JiM, ParkKH , AhnS , ChoS , MinSK . Rivaroxaban after thrombolysis in acute iliofemoral venous thrombosis: a randomized, open-labeled, multicenter trial. Scientific Reports2019;9(1):20356. MinSK , AhnS , ParkKH , KangJM , KimJY . Prevention of recurrence after thrombolysis in acute iliofemoral venous thrombosis with rivaroxaban (Prais Study): a prospective, randomized, open label, multicenter trial. European Journal of Vascular and Endovascular Surgery2019;58(6):e516. NCT01986192. Prevention of recurrence after thrombolysis in acute iliofemoral venous thrombosis (PRAIS) study. clinicaltrials.gov/show/NCT01986192 (first received 18 November 2013). ">PRAIS 2019</a>). Five studies reported zero events in both experimental and control groups and contributed no estimate to the pooled result (<a href="./references#CD010956-bbs2-0002" title="NakamuraM , NishikawaM , KomuroI , KitajimaI , UetsukaY , YamagamiT , et al. Apixaban for the treatment of Japanese subjects with acute venous thromboembolism (AMPLIFY-J Study). Circulation2015;79(6):1230–36. ">AMPLIFY‐J 2015</a>; <a href="./references#CD010956-bbs2-0005" title="NCT02704598. Comparison between xarelto versus warfarin in the recanalization rate of deep venous thrombosis in patients legs. (DVT). clinicaltrials.gov/ct2/show/NCT02704598 (first received 10 March 2016). deAthayde SoaresR , MatieloMF , Brochado NetoFC , AlmeidaRD , SacilottoR . LEV 2. Comparison of the recanalization rate and post-thrombotic syndrome in patients with deep venous thrombosis treated with rivaroxaban or warfarin. Journal of Vascular Surgery2019;70(5):e169-e170. deAthayde SoaresR , MatieloMF , Brochado NetoFC , NogueiraMP , AlmeidaRD , SacilottoR . Comparison of the recanalization rate and postthrombotic syndrome in patients with deep venous thrombosis treated with rivaroxaban or warfarin. Surgery2019;166(6):1076-83. ">de Athayde 2019</a>; <a href="./references#CD010956-bbs2-0009" title="PiazzaG , ManiV , GoldhaberSZ , GrossoMA , MercuriM , LanzHJ , et al. Magnetic resonance venography to assess thrombus resolution with edoxaban monotherapy versus parenteral anticoagulation/warfarin for symptomatic deep vein thrombosis: a multicenter feasibility study. Vascular Medicine2016;21(4):361-8. PiazzaG , ManiV , GrossoM , MercuriM , LanzH , SchusslerS , et al. A randomized, open-label, multicenter study of the efficacy and safety of edoxaban monotherapy versus low-molecular weight heparin/warfarin in patients with symptomatic deep vein thrombosis-edoxaban thrombus reduction imaging study (etris). Circulation2014;130:A12074. ">eTRIS 2016</a>; <a href="./references#CD010956-bbs2-0013" title="MatsuoH , PrinsM , LensingAW , FujinumaEW , MiyamotoY , KajikawaM . Shortened length of hospital stay with rivaroxaban in patients with symptomatic venous thromboembolism in Japan: the J-EINSTEIN pulmonary embolism and deep vein thrombosis program. Current Medical Research and Opinion2015;31(6):1057-61. NCT01516814. Venous thromboembolism (VTE) treatment study in Japanese pulmonary embolism (PE) patients. clinicaltrials.gov/ct2/show/NCT01516814 (first received 25 January 2012). YamadaN , HirayamaA , MaedaH , SakagamiS , ShikataH , PrinsMH , et al. Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism-the J-EINSTEIN DVT and PE program. Thrombosis Journal2015;13:2. ">J‐EINSTEIN DVT and PE 2015</a>; <a href="./references#CD010956-bbs2-0016" title="OhmoriH , KadaA , NakamuraM , SaitoAM , SanayamaY , ShinagawaT , et al. Deep vein thrombosis in severe motor and intellectual disabilities patients and its treatment by anticoagulants of warfarin versus edoxaban. Annals of Vascular Diseases2019;12(3):372-8. OhmoriH , NakamuraM , KadaA , SaitoAM , SanayamaY , ShinagawaT , et al. Multicenter, open-label, randomized controlled trial of warfarin and edoxaban tosilate hydrate for the treatment of deep vein thrombosis in persons with severe motor intellectual disabilities. Kurume Medical Journal2018;65(1):11-6. ">Ohmori 2019</a>). The incidence was 1.04% (101 events/9536 participants) in the factor Xa inhibitor group and 1.68% (145 events/8530 participants) in the conventional anticoagulation group. This led to an OR of 0.63 (95% CI 0.45 to 0.89; 17 studies, 18,066 participants; I<sup>2</sup> = 18%; high‐certainty evidence; <a href="./references#CD010956-fig-0024" title="">Analysis 3.6</a>), indicating that factor Xa inhibitors reduced the risk of major bleeding compared with conventional anticoagulation. We produced a funnel plot and found no indication of publication bias (<a href="#CD010956-fig-0005">Figure 5</a>). </p> <div class="figure" id="CD010956-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Funnel plot of oral factor Xa inhibitors versus conventional anticoagulants for major bleeding" data-id="CD010956-fig-0005" src="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_n/nCD010956-FIG-05.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of oral factor Xa inhibitors versus conventional anticoagulants for major bleeding </p> </div> </div> </div> <p>When analysed according to treatment duration, no subgroup differences were indicated (test for subgroup differences: P = 0.48) between treatment for three months (OR 0.78, 95% CI 0.42 to 1.43; 5 studies, 5170 participants) or for more than three months (OR 0.60, 95% CI 0.39 to 0.91; 12 studies, 12,986 participants).   </p> <p>Additional analysis indicated a possible subgroup difference between people with cancer (OR 0.93, 95% CI 0.49 to 1.76; 3 studies, 1006 participants) and people without cancer (OR 0.30, 95% CI 0.17 to 0.52; 6 studies, 5795 participants) (test for subgroup differences: P = 0.009, <a href="./references#CD010956-fig-0029" title="">Analysis 4.2</a>). No subgroup effect was indicated when analysed by the three oral factor Xa inhibitors (apixaban, edoxaban, rivaroxaban) (test for subgroup differences: P = 0.65, <a href="./references#CD010956-fig-0035" title="">Analysis 5.6</a>). </p> </section> <section id="CD010956-sec-0078"> <h5 class="title">Post‐thrombotic syndrome</h5> <p>The <a href="./references#CD010956-bbs2-0005" title="NCT02704598. Comparison between xarelto versus warfarin in the recanalization rate of deep venous thrombosis in patients legs. (DVT). clinicaltrials.gov/ct2/show/NCT02704598 (first received 10 March 2016). deAthayde SoaresR , MatieloMF , Brochado NetoFC , AlmeidaRD , SacilottoR . LEV 2. Comparison of the recanalization rate and post-thrombotic syndrome in patients with deep venous thrombosis treated with rivaroxaban or warfarin. Journal of Vascular Surgery2019;70(5):e169-e170. deAthayde SoaresR , MatieloMF , Brochado NetoFC , NogueiraMP , AlmeidaRD , SacilottoR . Comparison of the recanalization rate and postthrombotic syndrome in patients with deep venous thrombosis treated with rivaroxaban or warfarin. Surgery2019;166(6):1076-83. ">de Athayde 2019</a> study reported PTS as an outcome, and the results indicated that oral factor Xa inhibitor (rivaroxaban) had a lower rate of PTS events compared with warfarin. The incidence for rivaroxaban was 8.70% (4 events/46 participants) for both six months and 12 months; for warfarin, the incidence was 36.84% (14 events /38 participants) at six months, and 28.95% (11 events/38 participants) at 12 months. This led to an OR of 0.16 (95% CI 0.05 to 0.55; 1 study, 84 participants) and 0.23 (95% CI 0.08 to 0.46; 1 study, 84 participants; <a href="./references#CD010956-fig-0025" title="">Analysis 3.7</a>) at six months and 12 months, respectively.  </p> </section> <section id="CD010956-sec-0079"> <h5 class="title">Health‐related quality of life</h5> <p><a href="./references#CD010956-bbs2-0020" title="SukovatykhBS , SereditskiĭAV , MuradianVF , BelikovLN , GerasimovaOF . Results of administering oral anticoagulants for treatment of patients with venous thromboembolic complications. Angiologiia i sosudistaia khirurgiia [Angiology and Vascular Surgery]2017;23(2):82. ">Sukovatykh 2017</a> used SF‐36 scales (described above) to measure the quality of life of 65 participants. The factor Xa inhibitors group had a better score on the physical component of health (MD 5.55, 95% CI 1.18 to 9.92) and a similar score on the psychological component (MD 1.41, 95% CI ‐2.61 to 5.43) when compared with the warfarin group (<a href="./references#CD010956-fig-0026" title="">Analysis 3.8</a>; <a href="./references#CD010956-fig-0027" title="">Analysis 3.9</a>). </p> </section> <section id="CD010956-sec-0080"> <h5 class="title">Sensitivity analyses</h5> <p>As planned, we excluded studies with a high risk of bias in sensitivity analysis (<a href="./references#CD010956-fig-0036" title="">Analysis 6.1</a>; <a href="./references#CD010956-fig-0037" title="">Analysis 6.2</a>; <a href="./references#CD010956-fig-0038" title="">Analysis 6.3</a>; <a href="./references#CD010956-fig-0039" title="">Analysis 6.4</a>; <a href="./references#CD010956-fig-0040" title="">Analysis 6.5</a>; <a href="./references#CD010956-fig-0041" title="">Analysis 6.6</a>). The rate of recurrent VTE (OR 0.89, 95% CI 0.70 to 1.13), recurrent DVT (OR 0.72, 95% CI 0.45 to 1.13), fatal PE (OR 1.73, 95% CI 0.81 to 3.69), non‐fatal PE (OR 0.84, 95% CI 0.57 to 1.23) and all‐cause mortality (OR 0.94, 95%CI 0.66 to 1.35) remained similar when excluding high risk studies. However, excluding these studies did alter the result for major bleeding to no difference between oral factor Xa inhibitors versus conventional anticoagulation (OR 0.76, 95% CI 0.55 to 1.05).   </p> </section> </section> <section id="CD010956-sec-0081"> <h4 class="title">Oral direct thrombin inhibitor versus oral factor Xa inhibitor</h4> <p><a href="./references#CD010956-bbs2-0020" title="SukovatykhBS , SereditskiĭAV , MuradianVF , BelikovLN , GerasimovaOF . Results of administering oral anticoagulants for treatment of patients with venous thromboembolic complications. Angiologiia i sosudistaia khirurgiia [Angiology and Vascular Surgery]2017;23(2):82. ">Sukovatykh 2017</a> was the only study to compare an oral DTI with an oral factor Xa inhibitor, and the only outcome of interest reported was quality of life. <a href="./references#CD010956-bbs2-0020" title="SukovatykhBS , SereditskiĭAV , MuradianVF , BelikovLN , GerasimovaOF . Results of administering oral anticoagulants for treatment of patients with venous thromboembolic complications. Angiologiia i sosudistaia khirurgiia [Angiology and Vascular Surgery]2017;23(2):82. ">Sukovatykh 2017</a> compared oral dabigatran to oral rivaroxaban for quality of life using SF‐36 scales. The DTI group had a similar score on the physical component of health (MD 1.20, 95% CI ‐2.89 to 5.29; 1 study, 60 participants) and a higher score on the psychological component (MD 5.04, 95% CI 1.24 to 8.84; 1 study, 60 participants) compared to the factor Xa inhibitor group (<a href="./references#CD010956-fig-0042" title="">Analysis 7.1</a>; <a href="./references#CD010956-fig-0043" title="">Analysis 7.2</a>). </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD010956-sec-0082" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD010956-sec-0082"></div> <section id="CD010956-sec-0083"> <h3 class="title" id="CD010956-sec-0083">Summary of main results</h3> <p>We included an additional ten studies for this update, bringing the total to 21 included studies involving 30,895 participants. Compared with conventional anticoagulation, three studies investigated oral direct thrombin inhibitors (DTIs) (two dabigatran and one ximelagatran), 17 studies investigated oral factor Xa inhibitors (eight rivaroxaban, five apixaban and four edoxaban) and one study with three arms investigated both a DTI (dabigatran) and a factor Xa inhibitor (rivaroxaban). </p> <section id="CD010956-sec-0084"> <h4 class="title">Recurrent venous thromboembolism</h4> <p>Meta‐analyses showed no clear difference between direct oral anticoagulants (DOACs) and conventional anticoagulation in the prevention of recurrent VTE during treatment. This is unsurprising as the incidence of recurrent events during treatment with vitamin K antagonists (VKAs) is low and often only occurs in people with an aggressive thrombotic tendency, such as people with metastatic malignancy. </p> <p>The duration of treatment in the included studies varied, from three months (<a href="./references#CD010956-bbs2-0003" title="BarrettYC , WangJ , KnabbR , MohanP . Apixaban decreases coagulation activity in patients with acute deep-vein thrombosis. Thrombosis and Haemostasis2011;105:181-9. Botticelli Investigators Writing Committee, BullerH , DeitchmanD , PrinsM , SegersA . Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. Journal of Thrombosis and Haemostasis2008;6:1313-8. BullerHR . A dose finding study of the oral direct factor Xa inhibitor apixaban in the treatment of patients with acute symptomatic deep vein thrombosis - the Botticelli Investigators. Journal of Thrombosis and Haemostasis2007;5 (Suppl 2):O-S-003. NCT00252005. Oral direct factor Xa-inhibitor apixaban in patients with acute symptomatic deep-vein thrombosis - the Botticelli DVT study. clinicaltrials.gov/ct/show/NCT00252005?order=1 (first received 11 November 2005). ">Botticelli DVT 2008</a>; <a href="./references#CD010956-bbs2-0007" title="BullerH , DariusH . EINSTEIN DVT: oral rivaroxaban versus standard therapy in the initial treatment of symptomatic deep vein thrombosis and long-term prevention of recurrent venous thromboembolism. escardio.org/The-ESC/Press-Office/Press-releases/EINSTEIN-DVT-Oral-rivaroxaban-versus-standard-therapy-in-the-initial-treatment (accessed 19 October 2022). BullerHR , AgnelliG . Once- or twice-daily rivaroxaban for the treatment of proximal deep vein thrombosis: similar efficacy and safety to standard therapy in dose-ranging studies. Blood2006;108(11 Part 1):172-3. BullerHR , LensingAW , PrinsMH , AgnelliG , CohenA , GallusAS , et al. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT dose-ranging study. Blood2008;112(6):2242-7. NCT00395772. Once-daily oral direct factor Xa inhibitor BAY59-7939 in patients with acute symptomatic deep-vein thrombosis. clinicaltrials.gov/ct2/show/NCT00395772?term=einstein-dvt&amp;rank=2 (first received 3 November 2006). ">EINSTEIN‐DVT dose 2008</a>; <a href="./references#CD010956-bbs2-0009" title="PiazzaG , ManiV , GoldhaberSZ , GrossoMA , MercuriM , LanzHJ , et al. Magnetic resonance venography to assess thrombus resolution with edoxaban monotherapy versus parenteral anticoagulation/warfarin for symptomatic deep vein thrombosis: a multicenter feasibility study. Vascular Medicine2016;21(4):361-8. PiazzaG , ManiV , GrossoM , MercuriM , LanzH , SchusslerS , et al. A randomized, open-label, multicenter study of the efficacy and safety of edoxaban monotherapy versus low-molecular weight heparin/warfarin in patients with symptomatic deep vein thrombosis-edoxaban thrombus reduction imaging study (etris). Circulation2014;130:A12074. ">eTRIS 2016</a>; <a href="./references#CD010956-bbs2-0015" title="AgnelliG , GallusA , GoldhaberSZ , HaasS , HuismanMV , HullRD , et al. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAT 59-7939 in patients with acute symptomatic deep-vein thrombosis) study. Circulation2007;116:180-7. ">ODIXa‐DVT 2007</a>), four months (<a href="./references#CD010956-bbs2-0006" title="BamberL , WangMY , PrinsMH , CiniglioC , BauersachsR , LensingAW , et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis. Thrombosis and Haemostasis2013;110(4):732-41. BauersachsR , LensingAW , PapA , DecoususH . No need for a rivaroxaban dose reduction in renally impaired patients with symptomatic venous thromboembolism. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):30-1. BistervelsI , GebelM , LensingA , MiddeldorpS , CoppensM . Effect of polypharmacy on bleeding of rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolism. Research and Practice in Thrombosis and Haemostasis2019;3:798‐9. BookhartBK , HaskellL , BamberL , WangM , ScheinJ , ModySH . Length of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial program. Journal of Medical Economics2014;17(10):691-5. BullerHR . Oral rivaroxaban for the acute and continued treatment of symptomatic venous thromboembolism. The Einstein-DVT and Einstein-Extension study. Blood2010;116(21):187. CheungW , MiddeldorpS , PrinsMP , PapAF , LensingAW , Hoek-tenCA , et al. Post thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep vein thrombosis. Journal of Thrombosis and Haemostasis2015;13(S2):219-20. CheungYW , MiddeldorpS , PrinsMH , PapAF , PrandoniP . Post-thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep-vein thrombosis. A post-hoc analysis. Thrombosis and Haemostasis2016;116(4):733-8. EUCTR2004-002171-16-IT. Once-daily oral direct factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis. The EINSTEIN-DVT dose-finding study. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2004%E2%80%90002171%E2%80%9016%E2%80%90IT (first received 15 October 2008). EUCTR2006-004495-13-DK. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep-vein thrombosis or pulmonary embolism. trialsearch.who.int/?TrialID=EUCTR2006-004495-13-DK (first received 29 March 2007). EerenbergES , MiddeldorpS , LeviM , LensingAW , BüllerHR . Clinical impact and course of major bleeding with rivaroxaban and vitamin K antagonists. Journal of Thrombosis and Haemostasis2015;13(9):1590-6. KlineJA , JimenezD , CourtneyDM , IanusJ , CaoL , WellsPS . Use of the Riete 2008 bleeding score to identify patients at low risk for major bleeding in patients treated with rivaroxaban. Academic Emergency Medicine2015;22:S162. NCT00440193. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep vein thrombosis - The EINSTEIN DVT Study. clinicaltrials.gov/ct2/show/NCT00440193 (first received 26 February 2007). PrinsMH , ErkensPG , LensingAW . Incidence of recurrent venous thromboembolism in patients following completion of the EINSTEIN DVT and EINSTEIN PE studies. Journal of Thrombosis and Haemostasis2013;11(Suppl):257. PrinsMH , LensingAW , BauersachsR , Van BellenB , BounameauxH , BrightonTA , et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thrombosis Journal2013;11(1):21. The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. New England Journal of Medicine2010;363(26):2499-510. Van BellenB , PrinsM , BamberL , WangM , LensingAW . Reduction in initial length of stay with rivaroxaban single-drug regimen versus LMWH-VKA standard of care: findings from the EINSTEIN trial program. Blood2012;120(21):3419. Van BellenB , PrinsM , BamberL , WangM , LensingAW . Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism. Current Medical Research and Opinion2014;30(5):829-37. WangY , WangC , ChenZ , ZhangJ , LiuZ , JinB , et al. Rivaroxaban for the treatment of symptomatic deep vein thrombosis and/or pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):694. WangY , WangC , ChenZ , ZhangJ , LiuZ , JinB , et al. Rivaroxaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Thrombosis Journal2013;11(1):25. ">EINSTEIN‐DVT 2010</a>), six months (<a href="./references#CD010956-bbs2-0001" title="AgnelliG , BullerH , MasiukiewiczUP . Apixaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism: a randomized, double-blind trial (AMPLIFY). Journal of Thrombosis and Haemostasis2013;11:18. AgnelliG , BullerHR , CohenA , CurtoD , GallusAS , JohnsonM , et al. Oral apixaban for the treatment of acute venous thromboembolism. New England Journal of Medicine2013;369:799-808. AgnelliG , BullerHR , CohenA , CurtoM , GallusAS , PakR , et al. Apixaban for the treatment of venous thromboembolism in cancer patients: data from the AMPLIFY trial. Canadian Journal of Cardiology2014;30(10 Suppl 1):S278. AgnelliG , BullerHR , CohenA , GallusAS , LeeTC , PakR , et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. Journal of Thrombosis and Haemostasis2015;13(12):2187-91. AgnelliG . Apixaban was non-inferior to enoxaparin plus warfarin in patients with acute venous thromboembolism. Annals of Internal Medicine2013;159(8):JC2. BlekerSM , CohenAT , BüllerHR , AgnelliG , GallusAS , RaskobGE , et al. Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Thrombosis and Haemostasis2016;116(6):159-64. BrekelmansM , ScheresL , BlekerS , HuttenB , TimmermansA , BüllerH , et al. Abnormal vaginal bleeding in women with venous thromboembolism treated with apixaban or warfarin. Thrombosis and Haemostasis2017;117(04):809-15. CohenA , AgnelliG , BullerH , GallusA , RaskobG , SandersP , et al. Characteristics and outcomes in patients with venous thromboembolism taking concomitant anti-platelet agents and anticoagulants in the AMPLIFY Trial. Thrombosis and Haemostasis2019;119(3):461-6. CohenA , AgnelliG , BullerHR , ChaudhuriS , GallusAS , RaskobGE , et al. Analysis of the bleeding and thromboembolic risk with concomitant use of antiplatelet treatment in the AMPLIFY trial. Canadian Journal of Cardiology2014;30(10):S272. CohenA , GallusAS , AgnelliG , BullerHR , PakR , PorcariAR , et al. Time in Therapeutic Range (TTR) and relative efficacy and safety of treatment with apixaban or enoxaparin/warfarin for acute symptomatic venous thromboembolism: an analysis of the Amplify trial data. Blood2014;124(21):1543. CohenAT , PanS , ByonW , IlyasBS , LeeTC . Efficacy, safety, and exposure of apixaban in patients with high body weight or obesity and venous thromboembolism: insights from AMPLIFY. Advances in Therapy2021;38(6):3003-18. EUCTR2007-007867-25-PT. A safety and efficacy trial evaluating the use of apixaban in the treatment of symptomatic deep vein thrombosis and pulmonary embolism revised protocol number: 01, incorporates amendment(s) 02 + protocol amendment 01 (version 1.0 dated 21-Apr-08) site-specific - molecular profiling supplement samples for Pfizer’s exploratory research biobank. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2007%E2%80%90007867%E2%80%9025%E2%80%90PT (first received 14 July 2008). GallusAS , AgnelliG , BullerHR , CohenA , LeeTC , PakR , et al. Apixaban for treatment of venous thromboembolism in patients from study centres in Asia: a subgroup analysis of the Amplify trial. Journal of Thrombosis and Haemostasis2015;13:727. LeeT , PanS , ByonW , IlyasBS . Safety and efficacy of apixaban versus enoxaparin/warfarin in patients with extremes of body weight: post-hoc analysis of the AMPLIFY trial. Blood2019;134(Suppl 1):1152. LiuX , JohnsonM , MardekianJ , PhatakH , ThompsonJ , CohenAT . Apixaban reduces hospitalizations in patients with venous thromboembolism: an analysis of the apixaban for the Initial management of pulmonary embolism and deep‐vein thrombosis as first‐line therapy (AMPLIFY) trial. Journal of the American Heart Association2015;4(12):e002340. NCT00633893. Efficacy and safety study of apixaban for extended treatment of deep vein thrombosis or pulmonary embolism. clinicaltrials.gov/ct2/show/NCT00633893?term=ajax&amp;rank=5 (first received 12 March 2008). NCT00643201. Efficacy and safety study of apixaban for the treatment of deep vein thrombosis or pulmonary embolism. clinicaltrials.gov/ct2/show/NCT00643201 (first received 26 March 2008). RaskobGE , GallusAS , SandersP , ThompsonJR , AgnelliG , BullerHR , et al. Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy: a sub-analysis of the AMPLIFY trial. Thrombosis and Haemostasis2016;115(4):809-16. ">AMPLIFY 2013</a>; <a href="./references#CD010956-bbs2-0002" title="NakamuraM , NishikawaM , KomuroI , KitajimaI , UetsukaY , YamagamiT , et al. Apixaban for the treatment of Japanese subjects with acute venous thromboembolism (AMPLIFY-J Study). Circulation2015;79(6):1230–36. ">AMPLIFY‐J 2015</a>; <a href="./references#CD010956-bbs2-0004" title="AgenoW , VedovatiMC , CohenA , HuismanM , BauersachsR , GussoniG , et al. Bleeding with apixaban and dalteparin in patients with cancer-associated venous thromboembolism: results from the Caravaggio study. Thrombosis and Haemostasis2021;121(5):616-24. AgnelliG , BecattiniC , BauersachsR , BrennerB , CampaniniM , CohenA , et al. Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the Caravaggio study. Thrombosis and Haemostasis2018;118(9):1668-78. AgnelliG , BecattiniC , MeyerG , MuozA , VersoM . Apixaban for the treatment of venous thromboembolism associated with cancer. New England Journal of Medicine2020;382(17):1599-607. AgnelliG , MuozA , FrancoL , MahéI , BrennerB , ConnorsJM , et al. Apixaban and dalteparin for the treatment of venous thromboembolism in patients with different sites of cancer. Thrombosis and Haemostasis2022;122(5):796-807. BecattiniC , BauersachsR , MarazitiG , BertolettiL , CohenA , ConnorsJM , et al. Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial. Haematologica2021;107(7):1567-76. GiustozziM , ConnorsJM , Ruperez BlancoAB , SzmitS , FalvoN , CohenAT , et al. Clinical characteristics and outcomes of incidental venous thromboembolism in cancer patients: insights from the Caravaggio study. Journal of Thrombosis and Haemostasis2021;19(11):2751-9. NCT03045406. Apixaban for the treatment of venous thromboembolism in patients with cancer (CARAVAGGIO). clinicaltrials.gov/ct2/show/NCT03045406 (first received 7 February 2017). VersoM , MunozA , BauersachsR , HuismanMV , AgnelliG . Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism. European Journal of Cancer2021;148(Suppl C):371-81. ">Caravaggio 2020</a>; <a href="./references#CD010956-bbs2-0005" title="NCT02704598. Comparison between xarelto versus warfarin in the recanalization rate of deep venous thrombosis in patients legs. (DVT). clinicaltrials.gov/ct2/show/NCT02704598 (first received 10 March 2016). deAthayde SoaresR , MatieloMF , Brochado NetoFC , AlmeidaRD , SacilottoR . LEV 2. Comparison of the recanalization rate and post-thrombotic syndrome in patients with deep venous thrombosis treated with rivaroxaban or warfarin. Journal of Vascular Surgery2019;70(5):e169-e170. deAthayde SoaresR , MatieloMF , Brochado NetoFC , NogueiraMP , AlmeidaRD , SacilottoR . Comparison of the recanalization rate and postthrombotic syndrome in patients with deep venous thrombosis treated with rivaroxaban or warfarin. Surgery2019;166(6):1076-83. ">de Athayde 2019</a>; <a href="./references#CD010956-bbs2-0010" title="FarhanA , BukhariM , UmarJ , RazaMA . Oral rivaroxaban in symptomatic deep vein thrombosis. Journal of the College of Physicians and Surgeons Pakistan2019;29(9):814-8. ">Farhan 2019</a>; <a href="./references#CD010956-bbs2-0013" title="MatsuoH , PrinsM , LensingAW , FujinumaEW , MiyamotoY , KajikawaM . Shortened length of hospital stay with rivaroxaban in patients with symptomatic venous thromboembolism in Japan: the J-EINSTEIN pulmonary embolism and deep vein thrombosis program. Current Medical Research and Opinion2015;31(6):1057-61. NCT01516814. Venous thromboembolism (VTE) treatment study in Japanese pulmonary embolism (PE) patients. clinicaltrials.gov/ct2/show/NCT01516814 (first received 25 January 2012). YamadaN , HirayamaA , MaedaH , SakagamiS , ShikataH , PrinsMH , et al. Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism-the J-EINSTEIN DVT and PE program. Thrombosis Journal2015;13:2. ">J‐EINSTEIN DVT and PE 2015</a>; <a href="./references#CD010956-bbs2-0014" title="MokademME , HassanA , AlgabyAZ . Efficacy and safety of apixaban in patients with active malignancy and acute deep venous thrombosis. Vascular2021;29(5):745-50. NCT04462003. Efficacy of apixaban in malignancy with deep venous thrombosis (DVT). clinicaltrials.gov/ct2/show/NCT04462003 (first received 3 July 2019). ">Mokadem 2021</a>; <a href="./references#CD010956-bbs2-0017" title="Kang JiM, ParkKH , AhnS , ChoS , MinSK . Rivaroxaban after thrombolysis in acute iliofemoral venous thrombosis: a randomized, open-labeled, multicenter trial. Scientific Reports2019;9(1):20356. MinSK , AhnS , ParkKH , KangJM , KimJY . Prevention of recurrence after thrombolysis in acute iliofemoral venous thrombosis with rivaroxaban (Prais Study): a prospective, randomized, open label, multicenter trial. European Journal of Vascular and Endovascular Surgery2019;58(6):e516. NCT01986192. Prevention of recurrence after thrombolysis in acute iliofemoral venous thrombosis (PRAIS) study. clinicaltrials.gov/show/NCT01986192 (first received 18 November 2013). ">PRAIS 2019</a>; <a href="./references#CD010956-bbs2-0018" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00291330. Efficacy and safety of dabigatran compared to warfarin for 6 month treatment of acute symptomatic venous thromboembolism (RE-COVER I). clinicaltrials.gov/ct/show/NCT00291330 (first received 14 February 2006). SchulmanS , ErikssonH , GoldhaberS , KakkarAK , KearonC , KvammeAM , et al. Dabigatran or warfarin for extended maintenance therapy of venous thromboembolism. Journal of Thrombosis and Haemostasis2011;9(Suppl 2):731-2. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-COVER and RE-COVER II. Blood2013;122:2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RECOVER II. Blood2013;122(21):212. SchulmanS , ErikssonH , GoldhaverSZ , KakkarA , KearonC , MismettiP , et al. Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130:A18594. SchulmanS , KearonC , KakkarAK , MismettiP , SchellongS , ErikssonH , et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. New England Journal of Medicine2009;361(24):2342-52. ">RE‐COVER 2009</a>; <a href="./references#CD010956-bbs2-0019" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00680186. Phase III study testing efficacy &amp; safety of oral dabigatran etexilate vs warfarin for 6 m treatment for acute symp venous thromboembolism (VTE) (RE-COVER II). clinicaltrials.gov/ct2/show/NCT00680186 (first received 20 May 2008). SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-COVER and RE-COVER II. Blood2013;122:2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RECOVER II. Blood2013;122(21):212. SchulmanS , ErikssonH , GoldhaverSZ , KakkarA , KearonC , MismettiP , et al. Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130:A18594. SchulmanS , KakkarAK , GoldhaberSZ , SchellongS , ErikssonH , MismettiP , et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation2014;129:764-72. SchulmanS . A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II). Blood2011;118(21):95-6. ">RE‐COVER II 2014</a>; <a href="./references#CD010956-bbs2-0020" title="SukovatykhBS , SereditskiĭAV , MuradianVF , BelikovLN , GerasimovaOF . Results of administering oral anticoagulants for treatment of patients with venous thromboembolic complications. Angiologiia i sosudistaia khirurgiia [Angiology and Vascular Surgery]2017;23(2):82. ">Sukovatykh 2017</a>; <a href="./references#CD010956-bbs2-0021" title="FiessingerJN , HuismanMV , DavidsonBL , BounameauxH , FrancisCW , ErikssonH , et al. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomised trial. JAMA2005;293(6):681-9. FrancisCW , GinsbergJS , BerkowitzSD , BounameauxH , DavidsonBL , ErikssonH , et al. Efficacy and safety of the oral direct thrombin inhibitor ximelagatran compared with current therapy for acute, symptomatic deep vein thrombosis, with or without pulmonary embolus: the THRIVE treatment study. Blood2003;102(11):Abstract 7. HarenbergJ , IngridJ , TivadarF . Treatment of venous thromboembolism with the oral thrombin inhibitor, ximelagatran. Israel Medical Association Journal2002;4(11):1003-5. HarenbergJ , JoergI , WeissC . Incidence of recurrent venous thromboembolism of patients after termination of treatment with ximelagatran. European Journal of Clinical Pharmacology2006;62(3):173-7. HarenbergJ , JorgI , WeissC , HarenbergJ , JorgI , WeissC . Observations of alanine aminotransferase and aspartate aminotransferase in THRIVE studies treated orally with ximelagatran. International Journal of Toxicology2006;25(3):165-9. HuismanMV , The THRIVE Treatment Study Investigators. Efficacy and safety of the oral direct thrombin inhibitor ximelagatran compared with current standard therapy for acute symptomatic deep vein thrombosis, with or without pulmonary embolism: a randomized, double-blind, multinational study. Journal of Thrombosis and Haemostasis2003;1(Suppl 1):Abstract OC003. WimperisJ , FiessingerJN , HuismanMV , DavidsonBL , BounameauxH , FrancisCW , et al. Ximelagatran, an oral direct thrombin inhibitor, compared with current standard therapy for acute, symptomatic deep vein thrombosis, with or without pulmonary embolism: the THRIVE treatment study. British Journal of Haematology2004;125(Suppl 1):66. ">THRIVE 2005</a>), six to 12 months (<a href="./references#CD010956-bbs2-0012" title="AmayaN , UzuiH , HisazakiK , HasegwaK , KasenoK , TadaH . Edoxaban normalizes the elevated D-dimer levels potently and promptly in patients with venous thromboembolisms: a comparison with traditional anticoagulant therapy. European Heart Journal2016;37:278. BoschFT , Van EsN , Di NisioM , CarrierM , SegersA , GrossoMA , et al. The Ottawa score does not predict recurrent venous thromboembolism in cancer patients: results from the Hokusai-VTE cancer study. Research and Practice in Thrombosis and Haemostasis2019;3(S1):717-8. KraaijpoelN , Di NisioM , MulderFI , Van EsN , RaskobGE . Clinical impact of bleeding in cancer-associated venous thromboembolism: results from the Hokusai VTE Cancer randomized trial. Thrombosis Research2018;164(Suppl 1):S223. [DOI: 10.1016/j.thromres.2018.02.094]MulderFI , Di NisioM , AyC , CarrierM , BoschFT , SegersA , et al. Clinical implications of incidental venous thromboembolism in cancer patients. European Respiratory Journal2020;55(2):1901697. [DOI: 10.1183/13993003.01697-2019]MulderFI , Van EsN , KraaijpoelN , Di NisioM , CarrierM , GarciaD , et al. Efficacy and safety of edoxaban in clinically relevant subgroups: results from the Hokusai VTE Cancer randomized trial. Thrombosis Research2018;164:S194. NCT02073682. Cancer venous thromboembolism (VTE). clinicaltrials.gov/ct2/show/NCT02073682 (first received 27 February 2014). RaskobG , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaD , et al. Edoxaban versus dalteparin for treatment of venous thromboembolism (VTE) associated with cancer: Hokusai VTE-cancer randomized trial. Supportive Care in Cancer2018;26(2):S316-S317. RaskobGE , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaD , et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. New England Journal of Medicine2018;378(7):615-24. RaskobGE , Van EsN , VerhammeP , CarrierM , Di NisioM , GarciaDA , et al. A randomized, open-label, blinded outcome assessment trial evaluating the efficacy and safety of LMWH/Edoxaban versus dalteparin for venous thromboembolism associated with cancer: Hokusai VTE-cancer study. Blood2017;130(Suppl 1):LBA-6. ">Hokusai VTE Cancer 2018</a>), and 12 months (<a href="./references#CD010956-bbs2-0008" title="BullerHR , PrinsMH , LensinAW , DecoususH , JacobsonBF , MinarE , et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. New England Journal of Medicine2012;366:1287-97. FermannGJ , Erkens Pmg, PrinsMH , WellsPS , Pap ÁF, LensingAW , et al. Treatment of pulmonary embolism with rivaroxaban: outcomes by simplified pulmonary embolism severity index score from a post hoc analysis of the EINSTEIN PE study. Academic Emergency Medicine2015;22(3):299-307. NCT00439777. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic pulmonary embolism with or without symptomatic deep-vein thrombosis: Einstein-PE evaluation, 2008. clinicaltrials.gov/ct2/show/NCT00439777?term=NCT00439777&amp;rank=1 (first received 26 February 2007). PrinsM , BamberL , CanoS , WangM , LensingAW , BauersachsR . Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic pulmonary embolism. Blood2012;120(21):1163. PrinsMH , BamberL , CanoSJ , WangMY , ErkensP , BauersachsR , et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial. Thrombosis Research2015;135(2):281-8. ">EINSTEIN‐PE 2012</a>; <a href="./references#CD010956-bbs2-0011" title="BistervelsI , BavaliaR , BoersmaW , MeijerK , VerhammeP , Ten Cate-HoekAJ , et al. Hokusai Post-DVT Study: a follow-up study on long-term outcomes of deep vein thrombosis in patients treated with edoxaban vs warfarin. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):PB2207. BrekelmansMP , AgenoW , BeenenLF , BrennerB , BullerHR , ChenCZ , et al. Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology2016;3(9):e437-45. BrekelmansMP , BlekerSM , BauersachsR , BodaZ , BüllerHR , ChoiY , et al. Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists. Thrombosis and Haemostasis2016;116(1):155-61. Di NisioM , Van EsN , CarrierM , WangTF , GarciaD , SegersA , et al. Extended treatment with edoxaban in cancer patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE Cancer study. Journal of Thrombosis and Haemostasis2019;17:1866–74. EUCTR2009-014290-40-SE. A phase 3, randomized, double-blind, double-dummy, parallel group, multi-center, multi-national study for evaluation of efficacy and safety of DU-176b versus warfarin in subjects with atrial fibrillation - effective anticoagulation with factor Xa next generation in atrial fibrillation (ENGAGE-AF TIMI-48). trialsearch.who.int/?trialid=EUCTR2009-014290-40-SE (first received 30 November 2009). EichingerS , LinM , KyrlePA , GrossoMA . Recurrent venous thromboembolism during anticoagulation: an investigator-initiated post-hoc analysis of the hokusai-VTE trial. Blood2018;132:2539. KlokFA , BarcoS , KonstantinidesSV . External validation of the VTE-BLEED score for predicting major bleeding in stable anticoagulated patients with venous thromboembolism. Thrombosis and Haemostasis2017;117(6):1164-70. KraaijpoelN , Van EsN , RaskobGE , BüllerHR , CarrierM , ZhangG , et al. Risk scores for occult cancer in patients with venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2018;118(7):1270-8. MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMP , ChenCZ , et al. Outpatient management in patients with venous thromboembolism with edoxaban: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2017;117(12):2406-14. MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMP , ChenCZ , et al. Safety and efficacy of edoxaban compared with warfarin for the treatment of acute symptomatic deep-vein thrombosis in the outpatient setting. Research and Practice in Thrombosis and Haemostasis2017;1:913. MulderFI , Van EsN , KraaijpoelN , Di NisioM , CarrierM , DuggalA , et al. Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: results from the Hokusai VTE Cancer study. Thrombosis Research2020;185:13-9. NCT00986154. Comparative investigation of Low Molecular Weight (LMW) heparin/edoxaban tosylate (DU176b) versus (LMW) heparin/warfarin in the treatment of symptomatic deep-vein blood clots and/or lung blood clots. (The Edoxaban Hokusai-VTE Study). clinicaltrials.gov/ct2/show/NCT00986154 (first received 29 September 2009). NakamuraM , WangYQ , WangC , OhD , YinWH , KimuraT , et al. Efficacy and safety of edoxaban for treatment of venous thromboembolism: a subanalysis of East Asian patients in the Hokusai-VTE trial. Journal of Thrombosis and Haemostasis2015;13(9):1606-14. NybergJ , KarlssonKE , JönssonS , YinO , MillerR , KarlssonMO , et al. Edoxaban exposure-response analysis and clinical utility index assessment in patients with symptomatic deep-vein thrombosis or pulmonary embolism. CPT Pharmacometrics and Systems Pharmacology2016;5(4):222-32. RaskobG , AgenoW , CohenAT , BrekelmansMP , GrossoMA , SegersA , et al. Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology2016;3(5):e228-e236. RaskobG , BullerH , PrinsM , SegersA , ShiM , SchwochoL , et al. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study - methodological implications for clinical trials. Journal of Thrombosis and Haemostasis2013;11(7):1287-94. RaskobGE , BullerH , AngchaisuksiriP , OhD , BodaZ , LyonsRM , et al. Edoxaban for long-term treatment of venous thromboembolism in cancer patients. Blood2013;122(21):211. RaskobGE , Van EsN , SegersA , AngchaisuksiriP , OhD , BodaZ , et al. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematology2016;3(8):e379-87. ScheresLJ , BrekelmansMA , WalterA , CihanA , BüllerHR , SabineE , et al. Abnormal vaginal bleeding in women of reproductive age treated with edoxaban or warfarin for venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. British Journal of Obstetrics and Gynaecology2018;125(12):1581-9. The Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. New England Journal of Medicine2013;369(15):1406-15. VanasscheT , VerhammeP , WellsPS , SegersA , AgenoW , BrekelmansMP , et al. Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: an analysis of the randomized, double-blind Hokusai-VTE trial. Thrombosis Research2018;162:7-14. VerhammeP , WellsPS , SegersA , AgenoW , BrekelmansMP , CohenAT , et al. Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial. Thrombosis and Haemostasis2016;116(4):747-53. ">Hokusai‐VTE 2013</a>; <a href="./references#CD010956-bbs2-0016" title="OhmoriH , KadaA , NakamuraM , SaitoAM , SanayamaY , ShinagawaT , et al. Deep vein thrombosis in severe motor and intellectual disabilities patients and its treatment by anticoagulants of warfarin versus edoxaban. Annals of Vascular Diseases2019;12(3):372-8. OhmoriH , NakamuraM , KadaA , SaitoAM , SanayamaY , ShinagawaT , et al. Multicenter, open-label, randomized controlled trial of warfarin and edoxaban tosilate hydrate for the treatment of deep vein thrombosis in persons with severe motor intellectual disabilities. Kurume Medical Journal2018;65(1):11-6. ">Ohmori 2019</a>). Our analyses showed little or no statistical heterogeneity amongst the included studies. We performed subgroup analyses by grouping studies where treatment was for three months only and for longer than three months. No differences were observed for oral factor Xa versus conventional anticoagulation. This is consistent with findings from previous studies, which have also indicated that there is little difference in outcomes between three, six and 12 months' treatment, although recurrence rates after treatment rose if anticoagulated for less than three months (<a href="./references#CD010956-bbs2-0060" title="BoutitieF , PinedeL , SchulmanS , AgnelliG , RaskobG , JulianJ , et al. Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants' data from seven trials. BMJ2011;342:d3036.">Boutitie 2011</a>).  </p> <p>We did not detect any subgroup differences between DVT associated with cancer versus without cancer. A review by <a href="./references#CD010956-bbs2-0084" title="KahaleLA , HakoumMB , TsolakianIG , MatarCF , TerrenatoI , SperatiF , et al. Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer. Cochrane Database of Systematic Reviews2018, Issue 6. Art. No: CD006650. [DOI: 10.1002/14651858.CD006650.pub5]">Kahale 2018</a> found that compared to low molecular weight heparin (LMWH), DOACs may reduce VTE but may increase risk of major bleeding in people with cancer. However, the <a href="./references#CD010956-bbs2-0103" title="MulderFI , BoschFT , YoungAM , MarshallA , McBaneRD , ZemlaTJ , et al. Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis. Blood2020;136(12):1433-41.">Mulder 2020</a> review did not find a difference in these outcomes in cancer‐associated venous thromboembolism (<a href="./references#CD010956-bbs2-0103" title="MulderFI , BoschFT , YoungAM , MarshallA , McBaneRD , ZemlaTJ , et al. Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis. Blood2020;136(12):1433-41.">Mulder 2020</a>).  </p> </section> <section id="CD010956-sec-0085"> <h4 class="title">Recurrent deep vein thrombosis</h4> <p>There is no clear difference between DOACs and conventional anticoagulation in the prevention of recurrent DVT.  </p> </section> <section id="CD010956-sec-0086"> <h4 class="title">Fatal pulmonary embolism</h4> <p>Meta‐analyses showed no clear difference in the rate of fatal pulmonary embolism (PE) between DOACs and conventional anticoagulation, indicating that neither was more or less effective. This association was unaffected by the length of treatment. However, it is important to note that the confidence intervals (CIs) were wide for both DTIs and factor Xa inhibitors due to the small number of events overall. </p> </section> <section id="CD010956-sec-0087"> <h4 class="title">Non‐fatal pulmonary embolism</h4> <p>Meta‐analyses also showed no clear difference in the rate of non‐fatal PE between DOACs and conventional anticoagulation regardless of treatment duration, indicating that neither was more or less effective. However, it is important to note that the CIs were wide due to the small number of non‐fatal PE events overall. </p> </section> <section id="CD010956-sec-0088"> <h4 class="title">All‐cause mortality</h4> <p>There is no clear difference in preventing all‐cause mortality between the DOACs tested in this review (apixaban, rivaroxaban and ximelagatran) and conventional anticoagulants; no clear difference was observed between treatment durations of three months and longer. This result is unsurprising as current treatment with heparin and VKAs is associated with very low mortality. </p> </section> <section id="CD010956-sec-0089"> <h4 class="title">Major bleeding</h4> <p>Results of our meta‐analysis indicated that DOACs were associated with a reduction in major bleeding compared with conventional anticoagulation. This appears to be a class effect and may be due to the different mechanisms of action. The included studies all used the strict definition of major bleeding provided by the International Society on Thrombosis and Haemostasis (ISTH) (<a href="./references#CD010956-bbs2-0111" title="SchulmanS , KearonC , Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. Journal of Thrombosis and Haemostasis2005;3(4):692-4.">Schulman 2005</a>), except for the <a href="./references#CD010956-bbs2-0005" title="NCT02704598. Comparison between xarelto versus warfarin in the recanalization rate of deep venous thrombosis in patients legs. (DVT). clinicaltrials.gov/ct2/show/NCT02704598 (first received 10 March 2016). deAthayde SoaresR , MatieloMF , Brochado NetoFC , AlmeidaRD , SacilottoR . LEV 2. Comparison of the recanalization rate and post-thrombotic syndrome in patients with deep venous thrombosis treated with rivaroxaban or warfarin. Journal of Vascular Surgery2019;70(5):e169-e170. deAthayde SoaresR , MatieloMF , Brochado NetoFC , NogueiraMP , AlmeidaRD , SacilottoR . Comparison of the recanalization rate and postthrombotic syndrome in patients with deep venous thrombosis treated with rivaroxaban or warfarin. Surgery2019;166(6):1076-83. ">de Athayde 2019</a> study, which did not report the definition. For factor Xa inhibitors compared with conventional anticoagulation, no subgroup difference was indicated by treatment duration, but there may be a difference between participants with cancer and those without. We cannot draw conclusions from these subgroup analyses as both were heavily dependent on one trial with a high risk of bias in selective reporting and missing data. In addition, research from observational studies showed that apixaban decreased risk of major and minor bleeding events compared with rivaroxaban in VTE patients (<a href="./references#CD010956-bbs2-0054" title="AryalMR , GosainR , DonatoA , YuH , KatelA , BhandariY , et al. Systematic review and meta-analysis of the efficacy and safety of apixaban compared to rivaroxaban in acute VTE in the real world. Blood Advances2019;3(15):2381-7.">Aryal 2019</a>; <a href="./references#CD010956-bbs2-0056" title="BallestriS , RomagnoliE , ArioliD , ColuccioV , MarrazzoA , AthanasiouA , et al. Risk and management of bleeding complications with direct oral anticoagulants in patients with atrial fibrillation and venous thromboembolism: a narrative review. Advances in Therapy2023;40(1):41-66.">Ballestri 2023</a>; <a href="./references#CD010956-bbs2-0100" title="LiuZY , ZhangHX , MaLY , MuGY , XieQF , ZhouS , et al. Non-vitamin K antagonist oral anticoagulants in venous thromboembolism patients: a meta-analysis of real-world studies. BMC Cardiovascular Disorders2022;22(1):105.">Liu 2022</a>), while the subgroup analysis based on randomised controlled trials (RCTs) included in this review did not show a difference.  </p> </section> <section id="CD010956-sec-0090"> <h4 class="title">Post‐thrombotic syndrome</h4> <p>Only one small study comparing oral factor Xa inhibitor (rivaroxaban) with conventional anticoagulation measured post‐thrombotic syndrome (PTS). The incidence was lower in the oral factor Xa inhibitor group versus the warfarin group; however, the PTS score was partially self‐reported by participants, who were not blinded in this study. This prevents us from drawing any strong conclusions on this outcome. </p> </section> <section id="CD010956-sec-0091"> <h4 class="title">Health‐related quality of life</h4> <p>Only one small study measured participants' quality of life. It did not report baseline data so we could not conclude whether DOACs improved quality of life versus conventional anticoagulation. This was also the only study we found that compared a DTI (dabigatran) with a factor Xa inhibitor (rivaroxaban). </p> </section> </section> <section id="CD010956-sec-0092"> <h3 class="title" id="CD010956-sec-0092">Overall completeness and applicability of evidence</h3> <p>This review assessed whether DOACs, such as DTIs and factor Xa inhibitors, reduced the rate of recurrent VTE, recurrent DVT, fatal PE, non‐fatal PE, all‐cause mortality, major bleeding and PTS, and whether DOACs improved quality of life in people with a DVT. Three studies explored DTIs, 17 studies explored factor Xa inhibitors, and one explored both. All studies included similar study populations, with three focused on cancer‐associated DVT. The trials analysed and reported all of the addressed outcomes, with PTS and health‐related quality of life reported in only one study with a small sample size. Statistical heterogeneity was low for all outcomes. This was expected as each individual study had strict inclusion criteria, which resulted in the overall participant population of this review having almost identical conditions. Furthermore, for each particular drug, the concentrations used across studies were similar. </p> <p>We could not perform subgroup analyses according to history of VTE, age, pregnancy, major surgery requiring general or regional anaesthesia in the previous 12 weeks, recent period of immobility, and thrombophilia because of the lack of participant‐level data. Additionally, the treatment effect may differ between DVT in unusual sites (e.g. upper limbs) and lower limbs, considering different clinical symptoms and risk (<a href="./references#CD010956-bbs2-0051" title="AgenoW , HaasS , WeitzJI , GoldhaberSZ , TurpieAG , GotoS , et al. Upper extremity DVT versus lower extremity DVT: perspectives from the GARFIELD-VTE registry. Thrombosis and Haemostasis2019;119(8):1365-72.">Ageno 2019</a>; <a href="./references#CD010956-bbs2-0067" title="CoteLP , GreenbergS , CapriniJA , TafurA , ChoiC , MuñozFJ , et al. Comparisons between upper and lower extremity deep vein thrombosis: a review of the RIETE registry. Clinical and Applied Thrombosis/Hemostasis2017;23(7):748-54.">Cote 2017</a>); however, almost all the participants from included studies had been diagnosed with DVT in lower limbs. Thus, we could not address this issue in this review. These analyses might be important to guide the clinical management of people with different risk factors for DVT.   </p> <p>In the subgroup analysis based on participants with cancer versus without cancer, most included trials for DOACs included only small numbers of participants with cancer, and likely included those with only lower‐risk malignancies. Dedicated cancer‐associated DVT trials have not been performed for DTIs, and results in this review relating to their use in cancer‐associated thrombosis should therefore be interpreted with caution. </p> <p>Although many researchers consider DVT and PE to be manifestations of the same disorder, we elected to study these two conditions separately as there is evidence of clinically significant differences between them. The majority of recurrent events occur at the same site as the original thrombosis (in other words, in a person presenting with a PE, a recurrent event after treatment is much more likely to be another PE); both oral contraceptive use and Factor V Leiden mutation are more likely to be associated with DVT than PE; and, for example, lung disease is much more likely to be associated with PE. An update of the review on the effectiveness of oral DTIs and factor Xa inhibitors for the treatment of PE is ongoing (<a href="./references#CD010956-bbs2-0099" title="LiM , LiJ , WangX , HuiX , WangQ , XieS , et al. Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of pulmonary embolism. Cochrane Database of Systematic Reviews2023, Issue 4. Art. No: CD010957. [DOI: 10.1002/14651858.CD010957.pub3]">Li 2023</a>).  </p> <p>We found no studies comparing:</p> <p> <ul id="CD010956-list-0009"> <li> <p>one oral DTI versus another oral DTI;</p> </li> <li> <p>one oral factor Xa inhibitor versus another oral factor Xa inhibitor.</p> </li> </ul> </p> <p>While DOACs are more expensive than VKAs, these costs are offset by reduced bleeding and laboratory monitoring costs (<a href="./references#CD010956-bbs2-0065" title="ChenA , SteckerE , WardenBA . Direct oral anticoagulant use: a practical guide to common clinical challenges. Journal of the American Heart Association2020;9(13):e017559.">Chen 2020</a>). The UK's National Institute for Health and Care Excellence (NICE) conducted a recent cost‐effectiveness analysis of DOACs versus conventional anticoagulation for the treatment of DVT and PE (<a href="./references#CD010956-bbs2-0104" title="National Institute for Health and Care Excellence. Venous thromboembolic diseases: diagnosis, management and thrombophilia testing. NG158: 26 March 2020. Available at: nice.org.uk/guidance/ng158 (accessed 16 August 2022).">NICE 2020</a>). Within the DOACs, apixaban appeared to be the most cost‐effective, both in people with a DVT and people with a PE. Rivaroxaban had the next most favourable effect on major bleeding and generated the second highest total quality‐adjusted life years (QALYs). The cost of the two drugs was similar and the difference in total costs was mainly led by differences in the number of bleeding events.  </p> </section> <section id="CD010956-sec-0093"> <h3 class="title" id="CD010956-sec-0093">Certainty of the evidence</h3> <p>We created summary of findings tables for both our main comparisons and reported recurrent VTE, recurrent DVT, fatal PE, non‐fatal PE, all‐cause mortality and major bleeding. We assessed the certainty of the evidence using GRADE criteria (<a href="./references#CD010956-bbs2-0113" title="SchünemannHJ , VistGE , HigginsJP , SantessoN , DeeksJJ , GlasziouP , et al. Chapter 15: Interpreting results and drawing conclusions. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook.">Schünemann 2022</a>). </p> <p><a href="./full#CD010956-tbl-0001">summary of findings Table 1</a> presented the result of oral DTIs versus conventional anticoagulation used for the treatment of DVT. We found moderate‐certainty evidence suggesting that DTIs were not inferior to conventional anticoagulation for reducing recurrent VTE, recurrent DVT, fatal PE, non‐fatal PE, and all‐cause mortality when used for treating DVT. We downgraded the certainty by one level for all of these outcomes because of imprecision due to the low number of events. High‐certainty evidence indicated that DTIs had a lower rate of major bleeding. This difference became unclear when we excluded the study on ximelagatran in sensitivity analysis. Ximelagatran was not approved and not used in practice. </p> <p><a href="./full#CD010956-tbl-0002">summary of findings Table 2</a> presented the result of oral factor Xa inhibitors versus conventional anticoagulation used for the treatment of DVT. We found moderate‐certainty evidence indicating no clear difference between oral factor Xa inhibitors and conventional anticoagulation in preventing recurrent VTE, recurrent DVT, fatal PE, non‐fatal PE and all‐cause mortality. We downgraded the certainty by one level for all of these outcomes because of imprecision due to small sample size or the low number of events. High‐certainty evidence indicated that oral factor Xa inhibitors had a lower rate of major bleeding. </p> </section> <section id="CD010956-sec-0094"> <h3 class="title" id="CD010956-sec-0094">Potential biases in the review process</h3> <p>The search was as comprehensive as possible and we are confident that we have included all relevant studies. However, the possibility remains that some relevant trials, particularly in the 'grey' literature (e.g. conference proceedings), have been missed. Pairs of review authors independently performed study selection and data extraction in duplicate in order to minimise bias in the review process. The inclusion and exclusion criteria set out in the protocol were strictly adhered to in order to limit subjectivity (<a href="./references#CD010956-bbs2-0133" title="RobertsonL , KestevenP . Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of deep vein thrombosis. Cochrane Database of Systematic Reviews2014, Issue 2. Art. No: CD010956. [DOI: 10.1002/14651858.CD010956]">Robertson 2014</a>). We performed data collection according to the process suggested by Cochrane. We also followed Cochrane processes as described by <a href="./references#CD010956-bbs2-0082" title="HigginsJP , AltmanDG , SterneJA , editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.2.0 (updated June 2017). The Cochrane Colllaboration, 2017. Available from training.cochrane.org/handbook/archive/v5.2.">Higgins 2017</a> for assessing the risk of bias. Furthermore, we used the GRADE approach, which enabled us to rate the certainty of evidence systematically and interpret the data appropriately. For two of the included studies, <a href="./references#CD010956-bbs2-0018" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00291330. Efficacy and safety of dabigatran compared to warfarin for 6 month treatment of acute symptomatic venous thromboembolism (RE-COVER I). clinicaltrials.gov/ct/show/NCT00291330 (first received 14 February 2006). SchulmanS , ErikssonH , GoldhaberS , KakkarAK , KearonC , KvammeAM , et al. Dabigatran or warfarin for extended maintenance therapy of venous thromboembolism. Journal of Thrombosis and Haemostasis2011;9(Suppl 2):731-2. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-COVER and RE-COVER II. Blood2013;122:2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RECOVER II. Blood2013;122(21):212. SchulmanS , ErikssonH , GoldhaverSZ , KakkarA , KearonC , MismettiP , et al. Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130:A18594. SchulmanS , KearonC , KakkarAK , MismettiP , SchellongS , ErikssonH , et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. New England Journal of Medicine2009;361(24):2342-52. ">RE‐COVER 2009</a> and <a href="./references#CD010956-bbs2-0019" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00680186. Phase III study testing efficacy &amp; safety of oral dabigatran etexilate vs warfarin for 6 m treatment for acute symp venous thromboembolism (VTE) (RE-COVER II). clinicaltrials.gov/ct2/show/NCT00680186 (first received 20 May 2008). SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-COVER and RE-COVER II. Blood2013;122:2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RECOVER II. Blood2013;122(21):212. SchulmanS , ErikssonH , GoldhaverSZ , KakkarA , KearonC , MismettiP , et al. Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130:A18594. SchulmanS , KakkarAK , GoldhaberSZ , SchellongS , ErikssonH , MismettiP , et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation2014;129:764-72. SchulmanS . A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II). Blood2011;118(21):95-6. ">RE‐COVER II 2014</a>, we could only obtain data for DVT participants from a pooled analysis from <a href="./references#CD010956-bbs2-0079" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21.">Goldhaber 2016</a>. We were able to obtain all outcomes, except all‐cause mortality, from both trials. Evidence regarding all‐cause mortality of DTIs versus control is therefore supported by only one study. </p> </section> <section id="CD010956-sec-0095"> <h3 class="title" id="CD010956-sec-0095">Agreements and disagreements with other studies or reviews</h3> <p>To our knowledge, this is the first systematic review of RCTs, now updated, to measure the efficacy and safety of oral anticoagulants in people with a DVT. We found 12 other systematic reviews that assessed the same oral anticoagulants but in people with a VTE (<a href="./references#CD010956-bbs2-0053" title="AntoniazziS , BerdaiD , ContiV , ClementiE , SalvoF . Risk of major bleeding and the standard doses of dabigatran. European Journal of Internal Medicine2014;25(6):e73-5. [DOI: 10.1016/j.ejim.2014.02.005]">Antoniazzi 2014</a>; <a href="./references#CD010956-bbs2-0064" title="CastellucciLA , CameronC , Le GalG , RodgerMA , CoyleD , WellsPS , et al. Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis. BMJ2013;347:f5133.">Castellucci 2013</a>; <a href="./references#CD010956-bbs2-0071" title="Di MinnoMN , AmbrosinoP , LupoliR , Di MinnoA , DentaliF . Direct oral anticoagulants for the treatment of unprovoked venous thromboembolism: a meta-analysis of randomised controlled trials. Blood Transfusion2015;13(3):391-5.">Di Minno 2015</a>; <a href="./references#CD010956-bbs2-0078" title="FoxBD , KahnSR , LanglebenD , EisenbergMJ , ShimonyA . Efficacy and safety of novel oral anticoagulants for treatment of acute venous thromboembolism: direct and adjusted indirect meta-analysis of randomised controlled trials. BMJ2012;345:e7498.">Fox 2012</a>; <a href="./references#CD010956-bbs2-0080" title="Gomez-OutesA , Terleira-FernandezAI , LecumberriR , Suarez-GeaML , Vargas-CastrillonE . Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis. Thrombosis Research2014;134(4):774-82.">Gomez‐Outes 2014</a>; <a href="./references#CD010956-bbs2-0083" title="HirschlM , KundiM . New oral anticoagulants in the treatment of acute venous thromboembolism - a systematic review with indirect comparisons. Vasa2014;43(5):353-64.">Hirschl 2014</a>; <a href="./references#CD010956-bbs2-0088" title="KakkosSK , KirkilesisGI , TsolakisIA . Editor's Choice - efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials. European Journal of Vascular and Endovascular Surgery2014;48(5):565-75.">Kakkos 2014</a>; <a href="./references#CD010956-bbs2-0090" title="KangN , SobierajDM . Indirect treatment comparison of new oral anticoagulants for the treatment of acute venous thromboembolism. Thrombosis Research2014;133:1145-51.">Kang 2014</a>; <a href="./references#CD010956-bbs2-0101" title="LoffredoL , PerriL , Del BenM , AngelicoF , VioliF . New oral anticoagulants for the treatment of acute venous thromboembolism: are they safer than vitamin K antagonists? A meta-analysis of the interventional trials. Internal Emergency Medicine2015;10(4):499-506.">Loffredo 2015</a>; <a href="./references#CD010956-bbs2-0110" title="SardarP , ChatterjeeS , MukherjeeD . Efficacy and safety or new oral anticoagulants for extended treatment of venous thromboembolism: systematic review and meta-analyses of randomised controlled trials. Drugs2013;73:1171-82.">Sardar 2013</a>; <a href="./references#CD010956-bbs2-0114" title="SenooK , KondoY , MiyazawaK , IsogaiT , ChunYH , KobayashiY . Safety and efficacy of direct oral anticoagulants over warfarin in Japanese patients with acute venous thromboembolism: a meta-analysis. Journal of Cardiology2017;69(5):763-8.">Senoo 2017</a>; <a href="./references#CD010956-bbs2-0125" title="Van der HuilleT , Den ExterPL , DekkersOM , KlokFA . Effectiveness and safety of novel anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. Journal of Thrombosis and Haemostasis2014;12:320-8.">Van der Huille 2014</a>). Five reviews found similar results to this review: that DOACs are associated with less bleeding than conventional treatment (<a href="./references#CD010956-bbs2-0053" title="AntoniazziS , BerdaiD , ContiV , ClementiE , SalvoF . Risk of major bleeding and the standard doses of dabigatran. European Journal of Internal Medicine2014;25(6):e73-5. [DOI: 10.1016/j.ejim.2014.02.005]">Antoniazzi 2014</a>; <a href="./references#CD010956-bbs2-0078" title="FoxBD , KahnSR , LanglebenD , EisenbergMJ , ShimonyA . Efficacy and safety of novel oral anticoagulants for treatment of acute venous thromboembolism: direct and adjusted indirect meta-analysis of randomised controlled trials. BMJ2012;345:e7498.">Fox 2012</a>; <a href="./references#CD010956-bbs2-0080" title="Gomez-OutesA , Terleira-FernandezAI , LecumberriR , Suarez-GeaML , Vargas-CastrillonE . Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis. Thrombosis Research2014;134(4):774-82.">Gomez‐Outes 2014</a>; <a href="./references#CD010956-bbs2-0083" title="HirschlM , KundiM . New oral anticoagulants in the treatment of acute venous thromboembolism - a systematic review with indirect comparisons. Vasa2014;43(5):353-64.">Hirschl 2014</a>; <a href="./references#CD010956-bbs2-0088" title="KakkosSK , KirkilesisGI , TsolakisIA . Editor's Choice - efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials. European Journal of Vascular and Endovascular Surgery2014;48(5):565-75.">Kakkos 2014</a>; <a href="./references#CD010956-bbs2-0101" title="LoffredoL , PerriL , Del BenM , AngelicoF , VioliF . New oral anticoagulants for the treatment of acute venous thromboembolism: are they safer than vitamin K antagonists? A meta-analysis of the interventional trials. Internal Emergency Medicine2015;10(4):499-506.">Loffredo 2015</a>; <a href="./references#CD010956-bbs2-0114" title="SenooK , KondoY , MiyazawaK , IsogaiT , ChunYH , KobayashiY . Safety and efficacy of direct oral anticoagulants over warfarin in Japanese patients with acute venous thromboembolism: a meta-analysis. Journal of Cardiology2017;69(5):763-8.">Senoo 2017</a>; <a href="./references#CD010956-bbs2-0125" title="Van der HuilleT , Den ExterPL , DekkersOM , KlokFA . Effectiveness and safety of novel anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. Journal of Thrombosis and Haemostasis2014;12:320-8.">Van der Huille 2014</a>). </p> <p>The review by <a href="./references#CD010956-bbs2-0078" title="FoxBD , KahnSR , LanglebenD , EisenbergMJ , ShimonyA . Efficacy and safety of novel oral anticoagulants for treatment of acute venous thromboembolism: direct and adjusted indirect meta-analysis of randomised controlled trials. BMJ2012;345:e7498.">Fox 2012</a> included eight of the 11 studies that we included in the 2015 version of this review. The <a href="./references#CD010956-bbs2-0078" title="FoxBD , KahnSR , LanglebenD , EisenbergMJ , ShimonyA . Efficacy and safety of novel oral anticoagulants for treatment of acute venous thromboembolism: direct and adjusted indirect meta-analysis of randomised controlled trials. BMJ2012;345:e7498.">Fox 2012</a> review did not include the remaining studies (<a href="./references#CD010956-bbs2-0001" title="AgnelliG , BullerH , MasiukiewiczUP . Apixaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism: a randomized, double-blind trial (AMPLIFY). Journal of Thrombosis and Haemostasis2013;11:18. AgnelliG , BullerHR , CohenA , CurtoD , GallusAS , JohnsonM , et al. Oral apixaban for the treatment of acute venous thromboembolism. New England Journal of Medicine2013;369:799-808. AgnelliG , BullerHR , CohenA , CurtoM , GallusAS , PakR , et al. Apixaban for the treatment of venous thromboembolism in cancer patients: data from the AMPLIFY trial. Canadian Journal of Cardiology2014;30(10 Suppl 1):S278. AgnelliG , BullerHR , CohenA , GallusAS , LeeTC , PakR , et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. Journal of Thrombosis and Haemostasis2015;13(12):2187-91. AgnelliG . Apixaban was non-inferior to enoxaparin plus warfarin in patients with acute venous thromboembolism. Annals of Internal Medicine2013;159(8):JC2. BlekerSM , CohenAT , BüllerHR , AgnelliG , GallusAS , RaskobGE , et al. Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Thrombosis and Haemostasis2016;116(6):159-64. BrekelmansM , ScheresL , BlekerS , HuttenB , TimmermansA , BüllerH , et al. Abnormal vaginal bleeding in women with venous thromboembolism treated with apixaban or warfarin. Thrombosis and Haemostasis2017;117(04):809-15. CohenA , AgnelliG , BullerH , GallusA , RaskobG , SandersP , et al. Characteristics and outcomes in patients with venous thromboembolism taking concomitant anti-platelet agents and anticoagulants in the AMPLIFY Trial. Thrombosis and Haemostasis2019;119(3):461-6. CohenA , AgnelliG , BullerHR , ChaudhuriS , GallusAS , RaskobGE , et al. Analysis of the bleeding and thromboembolic risk with concomitant use of antiplatelet treatment in the AMPLIFY trial. Canadian Journal of Cardiology2014;30(10):S272. CohenA , GallusAS , AgnelliG , BullerHR , PakR , PorcariAR , et al. Time in Therapeutic Range (TTR) and relative efficacy and safety of treatment with apixaban or enoxaparin/warfarin for acute symptomatic venous thromboembolism: an analysis of the Amplify trial data. Blood2014;124(21):1543. CohenAT , PanS , ByonW , IlyasBS , LeeTC . Efficacy, safety, and exposure of apixaban in patients with high body weight or obesity and venous thromboembolism: insights from AMPLIFY. Advances in Therapy2021;38(6):3003-18. EUCTR2007-007867-25-PT. A safety and efficacy trial evaluating the use of apixaban in the treatment of symptomatic deep vein thrombosis and pulmonary embolism revised protocol number: 01, incorporates amendment(s) 02 + protocol amendment 01 (version 1.0 dated 21-Apr-08) site-specific - molecular profiling supplement samples for Pfizer’s exploratory research biobank. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2007%E2%80%90007867%E2%80%9025%E2%80%90PT (first received 14 July 2008). GallusAS , AgnelliG , BullerHR , CohenA , LeeTC , PakR , et al. Apixaban for treatment of venous thromboembolism in patients from study centres in Asia: a subgroup analysis of the Amplify trial. Journal of Thrombosis and Haemostasis2015;13:727. LeeT , PanS , ByonW , IlyasBS . Safety and efficacy of apixaban versus enoxaparin/warfarin in patients with extremes of body weight: post-hoc analysis of the AMPLIFY trial. Blood2019;134(Suppl 1):1152. LiuX , JohnsonM , MardekianJ , PhatakH , ThompsonJ , CohenAT . Apixaban reduces hospitalizations in patients with venous thromboembolism: an analysis of the apixaban for the Initial management of pulmonary embolism and deep‐vein thrombosis as first‐line therapy (AMPLIFY) trial. Journal of the American Heart Association2015;4(12):e002340. NCT00633893. Efficacy and safety study of apixaban for extended treatment of deep vein thrombosis or pulmonary embolism. clinicaltrials.gov/ct2/show/NCT00633893?term=ajax&amp;rank=5 (first received 12 March 2008). NCT00643201. Efficacy and safety study of apixaban for the treatment of deep vein thrombosis or pulmonary embolism. clinicaltrials.gov/ct2/show/NCT00643201 (first received 26 March 2008). RaskobGE , GallusAS , SandersP , ThompsonJR , AgnelliG , BullerHR , et al. Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy: a sub-analysis of the AMPLIFY trial. Thrombosis and Haemostasis2016;115(4):809-16. ">AMPLIFY 2013</a>; <a href="./references#CD010956-bbs2-0011" title="BistervelsI , BavaliaR , BoersmaW , MeijerK , VerhammeP , Ten Cate-HoekAJ , et al. Hokusai Post-DVT Study: a follow-up study on long-term outcomes of deep vein thrombosis in patients treated with edoxaban vs warfarin. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):PB2207. BrekelmansMP , AgenoW , BeenenLF , BrennerB , BullerHR , ChenCZ , et al. Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology2016;3(9):e437-45. BrekelmansMP , BlekerSM , BauersachsR , BodaZ , BüllerHR , ChoiY , et al. Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists. Thrombosis and Haemostasis2016;116(1):155-61. Di NisioM , Van EsN , CarrierM , WangTF , GarciaD , SegersA , et al. Extended treatment with edoxaban in cancer patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE Cancer study. Journal of Thrombosis and Haemostasis2019;17:1866–74. EUCTR2009-014290-40-SE. A phase 3, randomized, double-blind, double-dummy, parallel group, multi-center, multi-national study for evaluation of efficacy and safety of DU-176b versus warfarin in subjects with atrial fibrillation - effective anticoagulation with factor Xa next generation in atrial fibrillation (ENGAGE-AF TIMI-48). trialsearch.who.int/?trialid=EUCTR2009-014290-40-SE (first received 30 November 2009). EichingerS , LinM , KyrlePA , GrossoMA . Recurrent venous thromboembolism during anticoagulation: an investigator-initiated post-hoc analysis of the hokusai-VTE trial. Blood2018;132:2539. KlokFA , BarcoS , KonstantinidesSV . External validation of the VTE-BLEED score for predicting major bleeding in stable anticoagulated patients with venous thromboembolism. Thrombosis and Haemostasis2017;117(6):1164-70. KraaijpoelN , Van EsN , RaskobGE , BüllerHR , CarrierM , ZhangG , et al. Risk scores for occult cancer in patients with venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2018;118(7):1270-8. MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMP , ChenCZ , et al. Outpatient management in patients with venous thromboembolism with edoxaban: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2017;117(12):2406-14. MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMP , ChenCZ , et al. Safety and efficacy of edoxaban compared with warfarin for the treatment of acute symptomatic deep-vein thrombosis in the outpatient setting. Research and Practice in Thrombosis and Haemostasis2017;1:913. MulderFI , Van EsN , KraaijpoelN , Di NisioM , CarrierM , DuggalA , et al. Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: results from the Hokusai VTE Cancer study. Thrombosis Research2020;185:13-9. NCT00986154. Comparative investigation of Low Molecular Weight (LMW) heparin/edoxaban tosylate (DU176b) versus (LMW) heparin/warfarin in the treatment of symptomatic deep-vein blood clots and/or lung blood clots. (The Edoxaban Hokusai-VTE Study). clinicaltrials.gov/ct2/show/NCT00986154 (first received 29 September 2009). NakamuraM , WangYQ , WangC , OhD , YinWH , KimuraT , et al. Efficacy and safety of edoxaban for treatment of venous thromboembolism: a subanalysis of East Asian patients in the Hokusai-VTE trial. Journal of Thrombosis and Haemostasis2015;13(9):1606-14. NybergJ , KarlssonKE , JönssonS , YinO , MillerR , KarlssonMO , et al. Edoxaban exposure-response analysis and clinical utility index assessment in patients with symptomatic deep-vein thrombosis or pulmonary embolism. CPT Pharmacometrics and Systems Pharmacology2016;5(4):222-32. RaskobG , AgenoW , CohenAT , BrekelmansMP , GrossoMA , SegersA , et al. Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology2016;3(5):e228-e236. RaskobG , BullerH , PrinsM , SegersA , ShiM , SchwochoL , et al. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study - methodological implications for clinical trials. Journal of Thrombosis and Haemostasis2013;11(7):1287-94. RaskobGE , BullerH , AngchaisuksiriP , OhD , BodaZ , LyonsRM , et al. Edoxaban for long-term treatment of venous thromboembolism in cancer patients. Blood2013;122(21):211. RaskobGE , Van EsN , SegersA , AngchaisuksiriP , OhD , BodaZ , et al. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematology2016;3(8):e379-87. ScheresLJ , BrekelmansMA , WalterA , CihanA , BüllerHR , SabineE , et al. Abnormal vaginal bleeding in women of reproductive age treated with edoxaban or warfarin for venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. British Journal of Obstetrics and Gynaecology2018;125(12):1581-9. The Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. New England Journal of Medicine2013;369(15):1406-15. VanasscheT , VerhammeP , WellsPS , SegersA , AgenoW , BrekelmansMP , et al. Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: an analysis of the randomized, double-blind Hokusai-VTE trial. Thrombosis Research2018;162:7-14. VerhammeP , WellsPS , SegersA , AgenoW , BrekelmansMP , CohenAT , et al. Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial. Thrombosis and Haemostasis2016;116(4):747-53. ">Hokusai‐VTE 2013</a>), but did not state the reasons for this in the review. Meta‐analysis was done by brand rather than class of drug. <a href="./references#CD010956-bbs2-0078" title="FoxBD , KahnSR , LanglebenD , EisenbergMJ , ShimonyA . Efficacy and safety of novel oral anticoagulants for treatment of acute venous thromboembolism: direct and adjusted indirect meta-analysis of randomised controlled trials. BMJ2012;345:e7498.">Fox 2012</a> found no difference in recurrent VTE between the two treatment groups. Rivaroxaban was the only drug found to be significantly associated with fewer major bleeding episodes (OR 0.57, 95% CI 0.39 to 0.84). All‐cause mortality did not differ between the two treatment groups. </p> <p>The review by <a href="./references#CD010956-bbs2-0125" title="Van der HuilleT , Den ExterPL , DekkersOM , KlokFA . Effectiveness and safety of novel anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. Journal of Thrombosis and Haemostasis2014;12:320-8.">Van der Huille 2014</a> excluded four studies that were included in our review. They excluded three as they were phase II trials (<a href="./references#CD010956-bbs2-0003" title="BarrettYC , WangJ , KnabbR , MohanP . Apixaban decreases coagulation activity in patients with acute deep-vein thrombosis. Thrombosis and Haemostasis2011;105:181-9. Botticelli Investigators Writing Committee, BullerH , DeitchmanD , PrinsM , SegersA . Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. Journal of Thrombosis and Haemostasis2008;6:1313-8. BullerHR . A dose finding study of the oral direct factor Xa inhibitor apixaban in the treatment of patients with acute symptomatic deep vein thrombosis - the Botticelli Investigators. Journal of Thrombosis and Haemostasis2007;5 (Suppl 2):O-S-003. NCT00252005. Oral direct factor Xa-inhibitor apixaban in patients with acute symptomatic deep-vein thrombosis - the Botticelli DVT study. clinicaltrials.gov/ct/show/NCT00252005?order=1 (first received 11 November 2005). ">Botticelli DVT 2008</a>; <a href="./references#CD010956-bbs2-0015" title="AgnelliG , GallusA , GoldhaberSZ , HaasS , HuismanMV , HullRD , et al. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAT 59-7939 in patients with acute symptomatic deep-vein thrombosis) study. Circulation2007;116:180-7. ">ODIXa‐DVT 2007</a>; <a href="./references#CD010956-bbs2-0021" title="FiessingerJN , HuismanMV , DavidsonBL , BounameauxH , FrancisCW , ErikssonH , et al. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomised trial. JAMA2005;293(6):681-9. FrancisCW , GinsbergJS , BerkowitzSD , BounameauxH , DavidsonBL , ErikssonH , et al. Efficacy and safety of the oral direct thrombin inhibitor ximelagatran compared with current therapy for acute, symptomatic deep vein thrombosis, with or without pulmonary embolus: the THRIVE treatment study. Blood2003;102(11):Abstract 7. HarenbergJ , IngridJ , TivadarF . Treatment of venous thromboembolism with the oral thrombin inhibitor, ximelagatran. Israel Medical Association Journal2002;4(11):1003-5. HarenbergJ , JoergI , WeissC . Incidence of recurrent venous thromboembolism of patients after termination of treatment with ximelagatran. European Journal of Clinical Pharmacology2006;62(3):173-7. HarenbergJ , JorgI , WeissC , HarenbergJ , JorgI , WeissC . Observations of alanine aminotransferase and aspartate aminotransferase in THRIVE studies treated orally with ximelagatran. International Journal of Toxicology2006;25(3):165-9. HuismanMV , The THRIVE Treatment Study Investigators. Efficacy and safety of the oral direct thrombin inhibitor ximelagatran compared with current standard therapy for acute symptomatic deep vein thrombosis, with or without pulmonary embolism: a randomized, double-blind, multinational study. Journal of Thrombosis and Haemostasis2003;1(Suppl 1):Abstract OC003. WimperisJ , FiessingerJN , HuismanMV , DavidsonBL , BounameauxH , FrancisCW , et al. Ximelagatran, an oral direct thrombin inhibitor, compared with current standard therapy for acute, symptomatic deep vein thrombosis, with or without pulmonary embolism: the THRIVE treatment study. British Journal of Haematology2004;125(Suppl 1):66. ">THRIVE 2005</a>), and one as it had not been published in a peer‐reviewed journal at the time of the review (<a href="./references#CD010956-bbs2-0019" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00680186. Phase III study testing efficacy &amp; safety of oral dabigatran etexilate vs warfarin for 6 m treatment for acute symp venous thromboembolism (VTE) (RE-COVER II). clinicaltrials.gov/ct2/show/NCT00680186 (first received 20 May 2008). SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-COVER and RE-COVER II. Blood2013;122:2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RECOVER II. Blood2013;122(21):212. SchulmanS , ErikssonH , GoldhaverSZ , KakkarA , KearonC , MismettiP , et al. Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130:A18594. SchulmanS , KakkarAK , GoldhaberSZ , SchellongS , ErikssonH , MismettiP , et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation2014;129:764-72. SchulmanS . A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II). Blood2011;118(21):95-6. ">RE‐COVER II 2014</a>). Therefore, only five studies were included in the review (<a href="./references#CD010956-bbs2-0001" title="AgnelliG , BullerH , MasiukiewiczUP . Apixaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism: a randomized, double-blind trial (AMPLIFY). Journal of Thrombosis and Haemostasis2013;11:18. AgnelliG , BullerHR , CohenA , CurtoD , GallusAS , JohnsonM , et al. Oral apixaban for the treatment of acute venous thromboembolism. New England Journal of Medicine2013;369:799-808. AgnelliG , BullerHR , CohenA , CurtoM , GallusAS , PakR , et al. Apixaban for the treatment of venous thromboembolism in cancer patients: data from the AMPLIFY trial. Canadian Journal of Cardiology2014;30(10 Suppl 1):S278. AgnelliG , BullerHR , CohenA , GallusAS , LeeTC , PakR , et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. Journal of Thrombosis and Haemostasis2015;13(12):2187-91. AgnelliG . Apixaban was non-inferior to enoxaparin plus warfarin in patients with acute venous thromboembolism. Annals of Internal Medicine2013;159(8):JC2. BlekerSM , CohenAT , BüllerHR , AgnelliG , GallusAS , RaskobGE , et al. Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Thrombosis and Haemostasis2016;116(6):159-64. BrekelmansM , ScheresL , BlekerS , HuttenB , TimmermansA , BüllerH , et al. Abnormal vaginal bleeding in women with venous thromboembolism treated with apixaban or warfarin. Thrombosis and Haemostasis2017;117(04):809-15. CohenA , AgnelliG , BullerH , GallusA , RaskobG , SandersP , et al. Characteristics and outcomes in patients with venous thromboembolism taking concomitant anti-platelet agents and anticoagulants in the AMPLIFY Trial. Thrombosis and Haemostasis2019;119(3):461-6. CohenA , AgnelliG , BullerHR , ChaudhuriS , GallusAS , RaskobGE , et al. Analysis of the bleeding and thromboembolic risk with concomitant use of antiplatelet treatment in the AMPLIFY trial. Canadian Journal of Cardiology2014;30(10):S272. CohenA , GallusAS , AgnelliG , BullerHR , PakR , PorcariAR , et al. Time in Therapeutic Range (TTR) and relative efficacy and safety of treatment with apixaban or enoxaparin/warfarin for acute symptomatic venous thromboembolism: an analysis of the Amplify trial data. Blood2014;124(21):1543. CohenAT , PanS , ByonW , IlyasBS , LeeTC . Efficacy, safety, and exposure of apixaban in patients with high body weight or obesity and venous thromboembolism: insights from AMPLIFY. Advances in Therapy2021;38(6):3003-18. EUCTR2007-007867-25-PT. A safety and efficacy trial evaluating the use of apixaban in the treatment of symptomatic deep vein thrombosis and pulmonary embolism revised protocol number: 01, incorporates amendment(s) 02 + protocol amendment 01 (version 1.0 dated 21-Apr-08) site-specific - molecular profiling supplement samples for Pfizer’s exploratory research biobank. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2007%E2%80%90007867%E2%80%9025%E2%80%90PT (first received 14 July 2008). GallusAS , AgnelliG , BullerHR , CohenA , LeeTC , PakR , et al. Apixaban for treatment of venous thromboembolism in patients from study centres in Asia: a subgroup analysis of the Amplify trial. Journal of Thrombosis and Haemostasis2015;13:727. LeeT , PanS , ByonW , IlyasBS . Safety and efficacy of apixaban versus enoxaparin/warfarin in patients with extremes of body weight: post-hoc analysis of the AMPLIFY trial. Blood2019;134(Suppl 1):1152. LiuX , JohnsonM , MardekianJ , PhatakH , ThompsonJ , CohenAT . Apixaban reduces hospitalizations in patients with venous thromboembolism: an analysis of the apixaban for the Initial management of pulmonary embolism and deep‐vein thrombosis as first‐line therapy (AMPLIFY) trial. Journal of the American Heart Association2015;4(12):e002340. NCT00633893. Efficacy and safety study of apixaban for extended treatment of deep vein thrombosis or pulmonary embolism. clinicaltrials.gov/ct2/show/NCT00633893?term=ajax&amp;rank=5 (first received 12 March 2008). NCT00643201. Efficacy and safety study of apixaban for the treatment of deep vein thrombosis or pulmonary embolism. clinicaltrials.gov/ct2/show/NCT00643201 (first received 26 March 2008). RaskobGE , GallusAS , SandersP , ThompsonJR , AgnelliG , BullerHR , et al. Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy: a sub-analysis of the AMPLIFY trial. Thrombosis and Haemostasis2016;115(4):809-16. ">AMPLIFY 2013</a>; <a href="./references#CD010956-bbs2-0006" title="BamberL , WangMY , PrinsMH , CiniglioC , BauersachsR , LensingAW , et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis. Thrombosis and Haemostasis2013;110(4):732-41. BauersachsR , LensingAW , PapA , DecoususH . No need for a rivaroxaban dose reduction in renally impaired patients with symptomatic venous thromboembolism. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):30-1. BistervelsI , GebelM , LensingA , MiddeldorpS , CoppensM . Effect of polypharmacy on bleeding of rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolism. Research and Practice in Thrombosis and Haemostasis2019;3:798‐9. BookhartBK , HaskellL , BamberL , WangM , ScheinJ , ModySH . Length of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial program. Journal of Medical Economics2014;17(10):691-5. BullerHR . Oral rivaroxaban for the acute and continued treatment of symptomatic venous thromboembolism. The Einstein-DVT and Einstein-Extension study. Blood2010;116(21):187. CheungW , MiddeldorpS , PrinsMP , PapAF , LensingAW , Hoek-tenCA , et al. Post thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep vein thrombosis. Journal of Thrombosis and Haemostasis2015;13(S2):219-20. CheungYW , MiddeldorpS , PrinsMH , PapAF , PrandoniP . Post-thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep-vein thrombosis. A post-hoc analysis. Thrombosis and Haemostasis2016;116(4):733-8. EUCTR2004-002171-16-IT. Once-daily oral direct factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis. The EINSTEIN-DVT dose-finding study. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2004%E2%80%90002171%E2%80%9016%E2%80%90IT (first received 15 October 2008). EUCTR2006-004495-13-DK. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep-vein thrombosis or pulmonary embolism. trialsearch.who.int/?TrialID=EUCTR2006-004495-13-DK (first received 29 March 2007). EerenbergES , MiddeldorpS , LeviM , LensingAW , BüllerHR . Clinical impact and course of major bleeding with rivaroxaban and vitamin K antagonists. Journal of Thrombosis and Haemostasis2015;13(9):1590-6. KlineJA , JimenezD , CourtneyDM , IanusJ , CaoL , WellsPS . Use of the Riete 2008 bleeding score to identify patients at low risk for major bleeding in patients treated with rivaroxaban. Academic Emergency Medicine2015;22:S162. NCT00440193. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep vein thrombosis - The EINSTEIN DVT Study. clinicaltrials.gov/ct2/show/NCT00440193 (first received 26 February 2007). PrinsMH , ErkensPG , LensingAW . Incidence of recurrent venous thromboembolism in patients following completion of the EINSTEIN DVT and EINSTEIN PE studies. Journal of Thrombosis and Haemostasis2013;11(Suppl):257. PrinsMH , LensingAW , BauersachsR , Van BellenB , BounameauxH , BrightonTA , et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thrombosis Journal2013;11(1):21. The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. New England Journal of Medicine2010;363(26):2499-510. Van BellenB , PrinsM , BamberL , WangM , LensingAW . Reduction in initial length of stay with rivaroxaban single-drug regimen versus LMWH-VKA standard of care: findings from the EINSTEIN trial program. Blood2012;120(21):3419. Van BellenB , PrinsM , BamberL , WangM , LensingAW . Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism. Current Medical Research and Opinion2014;30(5):829-37. WangY , WangC , ChenZ , ZhangJ , LiuZ , JinB , et al. Rivaroxaban for the treatment of symptomatic deep vein thrombosis and/or pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):694. WangY , WangC , ChenZ , ZhangJ , LiuZ , JinB , et al. Rivaroxaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Thrombosis Journal2013;11(1):25. ">EINSTEIN‐DVT 2010</a>; <a href="./references#CD010956-bbs2-0008" title="BullerHR , PrinsMH , LensinAW , DecoususH , JacobsonBF , MinarE , et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. New England Journal of Medicine2012;366:1287-97. FermannGJ , Erkens Pmg, PrinsMH , WellsPS , Pap ÁF, LensingAW , et al. Treatment of pulmonary embolism with rivaroxaban: outcomes by simplified pulmonary embolism severity index score from a post hoc analysis of the EINSTEIN PE study. Academic Emergency Medicine2015;22(3):299-307. NCT00439777. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic pulmonary embolism with or without symptomatic deep-vein thrombosis: Einstein-PE evaluation, 2008. clinicaltrials.gov/ct2/show/NCT00439777?term=NCT00439777&amp;rank=1 (first received 26 February 2007). PrinsM , BamberL , CanoS , WangM , LensingAW , BauersachsR . Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic pulmonary embolism. Blood2012;120(21):1163. PrinsMH , BamberL , CanoSJ , WangMY , ErkensP , BauersachsR , et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial. Thrombosis Research2015;135(2):281-8. ">EINSTEIN‐PE 2012</a>; <a href="./references#CD010956-bbs2-0011" title="BistervelsI , BavaliaR , BoersmaW , MeijerK , VerhammeP , Ten Cate-HoekAJ , et al. Hokusai Post-DVT Study: a follow-up study on long-term outcomes of deep vein thrombosis in patients treated with edoxaban vs warfarin. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):PB2207. BrekelmansMP , AgenoW , BeenenLF , BrennerB , BullerHR , ChenCZ , et al. Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology2016;3(9):e437-45. BrekelmansMP , BlekerSM , BauersachsR , BodaZ , BüllerHR , ChoiY , et al. Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists. Thrombosis and Haemostasis2016;116(1):155-61. Di NisioM , Van EsN , CarrierM , WangTF , GarciaD , SegersA , et al. Extended treatment with edoxaban in cancer patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE Cancer study. Journal of Thrombosis and Haemostasis2019;17:1866–74. EUCTR2009-014290-40-SE. A phase 3, randomized, double-blind, double-dummy, parallel group, multi-center, multi-national study for evaluation of efficacy and safety of DU-176b versus warfarin in subjects with atrial fibrillation - effective anticoagulation with factor Xa next generation in atrial fibrillation (ENGAGE-AF TIMI-48). trialsearch.who.int/?trialid=EUCTR2009-014290-40-SE (first received 30 November 2009). EichingerS , LinM , KyrlePA , GrossoMA . Recurrent venous thromboembolism during anticoagulation: an investigator-initiated post-hoc analysis of the hokusai-VTE trial. Blood2018;132:2539. KlokFA , BarcoS , KonstantinidesSV . External validation of the VTE-BLEED score for predicting major bleeding in stable anticoagulated patients with venous thromboembolism. Thrombosis and Haemostasis2017;117(6):1164-70. KraaijpoelN , Van EsN , RaskobGE , BüllerHR , CarrierM , ZhangG , et al. Risk scores for occult cancer in patients with venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2018;118(7):1270-8. MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMP , ChenCZ , et al. Outpatient management in patients with venous thromboembolism with edoxaban: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2017;117(12):2406-14. MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMP , ChenCZ , et al. Safety and efficacy of edoxaban compared with warfarin for the treatment of acute symptomatic deep-vein thrombosis in the outpatient setting. Research and Practice in Thrombosis and Haemostasis2017;1:913. MulderFI , Van EsN , KraaijpoelN , Di NisioM , CarrierM , DuggalA , et al. Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: results from the Hokusai VTE Cancer study. Thrombosis Research2020;185:13-9. NCT00986154. Comparative investigation of Low Molecular Weight (LMW) heparin/edoxaban tosylate (DU176b) versus (LMW) heparin/warfarin in the treatment of symptomatic deep-vein blood clots and/or lung blood clots. (The Edoxaban Hokusai-VTE Study). clinicaltrials.gov/ct2/show/NCT00986154 (first received 29 September 2009). NakamuraM , WangYQ , WangC , OhD , YinWH , KimuraT , et al. Efficacy and safety of edoxaban for treatment of venous thromboembolism: a subanalysis of East Asian patients in the Hokusai-VTE trial. Journal of Thrombosis and Haemostasis2015;13(9):1606-14. NybergJ , KarlssonKE , JönssonS , YinO , MillerR , KarlssonMO , et al. Edoxaban exposure-response analysis and clinical utility index assessment in patients with symptomatic deep-vein thrombosis or pulmonary embolism. CPT Pharmacometrics and Systems Pharmacology2016;5(4):222-32. RaskobG , AgenoW , CohenAT , BrekelmansMP , GrossoMA , SegersA , et al. Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology2016;3(5):e228-e236. RaskobG , BullerH , PrinsM , SegersA , ShiM , SchwochoL , et al. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study - methodological implications for clinical trials. Journal of Thrombosis and Haemostasis2013;11(7):1287-94. RaskobGE , BullerH , AngchaisuksiriP , OhD , BodaZ , LyonsRM , et al. Edoxaban for long-term treatment of venous thromboembolism in cancer patients. Blood2013;122(21):211. RaskobGE , Van EsN , SegersA , AngchaisuksiriP , OhD , BodaZ , et al. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematology2016;3(8):e379-87. ScheresLJ , BrekelmansMA , WalterA , CihanA , BüllerHR , SabineE , et al. Abnormal vaginal bleeding in women of reproductive age treated with edoxaban or warfarin for venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. British Journal of Obstetrics and Gynaecology2018;125(12):1581-9. The Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. New England Journal of Medicine2013;369(15):1406-15. VanasscheT , VerhammeP , WellsPS , SegersA , AgenoW , BrekelmansMP , et al. Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: an analysis of the randomized, double-blind Hokusai-VTE trial. Thrombosis Research2018;162:7-14. VerhammeP , WellsPS , SegersA , AgenoW , BrekelmansMP , CohenAT , et al. Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial. Thrombosis and Haemostasis2016;116(4):747-53. ">Hokusai‐VTE 2013</a>; <a href="./references#CD010956-bbs2-0018" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00291330. Efficacy and safety of dabigatran compared to warfarin for 6 month treatment of acute symptomatic venous thromboembolism (RE-COVER I). clinicaltrials.gov/ct/show/NCT00291330 (first received 14 February 2006). SchulmanS , ErikssonH , GoldhaberS , KakkarAK , KearonC , KvammeAM , et al. Dabigatran or warfarin for extended maintenance therapy of venous thromboembolism. Journal of Thrombosis and Haemostasis2011;9(Suppl 2):731-2. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-COVER and RE-COVER II. Blood2013;122:2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RECOVER II. Blood2013;122(21):212. SchulmanS , ErikssonH , GoldhaverSZ , KakkarA , KearonC , MismettiP , et al. Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130:A18594. SchulmanS , KearonC , KakkarAK , MismettiP , SchellongS , ErikssonH , et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. New England Journal of Medicine2009;361(24):2342-52. ">RE‐COVER 2009</a>). Meta‐analysis showed no difference between the two treatment groups in terms of recurrent VTE, fatal PE and all‐cause mortality. However, the DOACs were associated with a reduced risk of major bleeding (risk ratio (RR) 0.60, 95% CI 0.41 to 0.88) and fatal bleeding (RR 0.36, 95% CI 0.15 to 0.87). </p> <p><a href="./references#CD010956-bbs2-0083" title="HirschlM , KundiM . New oral anticoagulants in the treatment of acute venous thromboembolism - a systematic review with indirect comparisons. Vasa2014;43(5):353-64.">Hirschl 2014</a> included six studies and found no differences between DOACs and conventional treatment regarding recurrent VTE and mortality (<a href="./references#CD010956-bbs2-0001" title="AgnelliG , BullerH , MasiukiewiczUP . Apixaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism: a randomized, double-blind trial (AMPLIFY). Journal of Thrombosis and Haemostasis2013;11:18. AgnelliG , BullerHR , CohenA , CurtoD , GallusAS , JohnsonM , et al. Oral apixaban for the treatment of acute venous thromboembolism. New England Journal of Medicine2013;369:799-808. AgnelliG , BullerHR , CohenA , CurtoM , GallusAS , PakR , et al. Apixaban for the treatment of venous thromboembolism in cancer patients: data from the AMPLIFY trial. Canadian Journal of Cardiology2014;30(10 Suppl 1):S278. AgnelliG , BullerHR , CohenA , GallusAS , LeeTC , PakR , et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. Journal of Thrombosis and Haemostasis2015;13(12):2187-91. AgnelliG . Apixaban was non-inferior to enoxaparin plus warfarin in patients with acute venous thromboembolism. Annals of Internal Medicine2013;159(8):JC2. BlekerSM , CohenAT , BüllerHR , AgnelliG , GallusAS , RaskobGE , et al. Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Thrombosis and Haemostasis2016;116(6):159-64. BrekelmansM , ScheresL , BlekerS , HuttenB , TimmermansA , BüllerH , et al. Abnormal vaginal bleeding in women with venous thromboembolism treated with apixaban or warfarin. Thrombosis and Haemostasis2017;117(04):809-15. CohenA , AgnelliG , BullerH , GallusA , RaskobG , SandersP , et al. Characteristics and outcomes in patients with venous thromboembolism taking concomitant anti-platelet agents and anticoagulants in the AMPLIFY Trial. Thrombosis and Haemostasis2019;119(3):461-6. CohenA , AgnelliG , BullerHR , ChaudhuriS , GallusAS , RaskobGE , et al. Analysis of the bleeding and thromboembolic risk with concomitant use of antiplatelet treatment in the AMPLIFY trial. Canadian Journal of Cardiology2014;30(10):S272. CohenA , GallusAS , AgnelliG , BullerHR , PakR , PorcariAR , et al. Time in Therapeutic Range (TTR) and relative efficacy and safety of treatment with apixaban or enoxaparin/warfarin for acute symptomatic venous thromboembolism: an analysis of the Amplify trial data. Blood2014;124(21):1543. CohenAT , PanS , ByonW , IlyasBS , LeeTC . Efficacy, safety, and exposure of apixaban in patients with high body weight or obesity and venous thromboembolism: insights from AMPLIFY. Advances in Therapy2021;38(6):3003-18. EUCTR2007-007867-25-PT. A safety and efficacy trial evaluating the use of apixaban in the treatment of symptomatic deep vein thrombosis and pulmonary embolism revised protocol number: 01, incorporates amendment(s) 02 + protocol amendment 01 (version 1.0 dated 21-Apr-08) site-specific - molecular profiling supplement samples for Pfizer’s exploratory research biobank. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2007%E2%80%90007867%E2%80%9025%E2%80%90PT (first received 14 July 2008). GallusAS , AgnelliG , BullerHR , CohenA , LeeTC , PakR , et al. Apixaban for treatment of venous thromboembolism in patients from study centres in Asia: a subgroup analysis of the Amplify trial. Journal of Thrombosis and Haemostasis2015;13:727. LeeT , PanS , ByonW , IlyasBS . Safety and efficacy of apixaban versus enoxaparin/warfarin in patients with extremes of body weight: post-hoc analysis of the AMPLIFY trial. Blood2019;134(Suppl 1):1152. LiuX , JohnsonM , MardekianJ , PhatakH , ThompsonJ , CohenAT . Apixaban reduces hospitalizations in patients with venous thromboembolism: an analysis of the apixaban for the Initial management of pulmonary embolism and deep‐vein thrombosis as first‐line therapy (AMPLIFY) trial. Journal of the American Heart Association2015;4(12):e002340. NCT00633893. Efficacy and safety study of apixaban for extended treatment of deep vein thrombosis or pulmonary embolism. clinicaltrials.gov/ct2/show/NCT00633893?term=ajax&amp;rank=5 (first received 12 March 2008). NCT00643201. Efficacy and safety study of apixaban for the treatment of deep vein thrombosis or pulmonary embolism. clinicaltrials.gov/ct2/show/NCT00643201 (first received 26 March 2008). RaskobGE , GallusAS , SandersP , ThompsonJR , AgnelliG , BullerHR , et al. Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy: a sub-analysis of the AMPLIFY trial. Thrombosis and Haemostasis2016;115(4):809-16. ">AMPLIFY 2013</a>; <a href="./references#CD010956-bbs2-0006" title="BamberL , WangMY , PrinsMH , CiniglioC , BauersachsR , LensingAW , et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis. Thrombosis and Haemostasis2013;110(4):732-41. BauersachsR , LensingAW , PapA , DecoususH . No need for a rivaroxaban dose reduction in renally impaired patients with symptomatic venous thromboembolism. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):30-1. BistervelsI , GebelM , LensingA , MiddeldorpS , CoppensM . Effect of polypharmacy on bleeding of rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolism. Research and Practice in Thrombosis and Haemostasis2019;3:798‐9. BookhartBK , HaskellL , BamberL , WangM , ScheinJ , ModySH . Length of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial program. Journal of Medical Economics2014;17(10):691-5. BullerHR . Oral rivaroxaban for the acute and continued treatment of symptomatic venous thromboembolism. The Einstein-DVT and Einstein-Extension study. Blood2010;116(21):187. CheungW , MiddeldorpS , PrinsMP , PapAF , LensingAW , Hoek-tenCA , et al. Post thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep vein thrombosis. Journal of Thrombosis and Haemostasis2015;13(S2):219-20. CheungYW , MiddeldorpS , PrinsMH , PapAF , PrandoniP . Post-thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep-vein thrombosis. A post-hoc analysis. Thrombosis and Haemostasis2016;116(4):733-8. EUCTR2004-002171-16-IT. Once-daily oral direct factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis. The EINSTEIN-DVT dose-finding study. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2004%E2%80%90002171%E2%80%9016%E2%80%90IT (first received 15 October 2008). EUCTR2006-004495-13-DK. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep-vein thrombosis or pulmonary embolism. trialsearch.who.int/?TrialID=EUCTR2006-004495-13-DK (first received 29 March 2007). EerenbergES , MiddeldorpS , LeviM , LensingAW , BüllerHR . Clinical impact and course of major bleeding with rivaroxaban and vitamin K antagonists. Journal of Thrombosis and Haemostasis2015;13(9):1590-6. KlineJA , JimenezD , CourtneyDM , IanusJ , CaoL , WellsPS . Use of the Riete 2008 bleeding score to identify patients at low risk for major bleeding in patients treated with rivaroxaban. Academic Emergency Medicine2015;22:S162. NCT00440193. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep vein thrombosis - The EINSTEIN DVT Study. clinicaltrials.gov/ct2/show/NCT00440193 (first received 26 February 2007). PrinsMH , ErkensPG , LensingAW . Incidence of recurrent venous thromboembolism in patients following completion of the EINSTEIN DVT and EINSTEIN PE studies. Journal of Thrombosis and Haemostasis2013;11(Suppl):257. PrinsMH , LensingAW , BauersachsR , Van BellenB , BounameauxH , BrightonTA , et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thrombosis Journal2013;11(1):21. The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. New England Journal of Medicine2010;363(26):2499-510. Van BellenB , PrinsM , BamberL , WangM , LensingAW . Reduction in initial length of stay with rivaroxaban single-drug regimen versus LMWH-VKA standard of care: findings from the EINSTEIN trial program. Blood2012;120(21):3419. Van BellenB , PrinsM , BamberL , WangM , LensingAW . Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism. Current Medical Research and Opinion2014;30(5):829-37. WangY , WangC , ChenZ , ZhangJ , LiuZ , JinB , et al. Rivaroxaban for the treatment of symptomatic deep vein thrombosis and/or pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):694. WangY , WangC , ChenZ , ZhangJ , LiuZ , JinB , et al. Rivaroxaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Thrombosis Journal2013;11(1):25. ">EINSTEIN‐DVT 2010</a>; <a href="./references#CD010956-bbs2-0008" title="BullerHR , PrinsMH , LensinAW , DecoususH , JacobsonBF , MinarE , et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. New England Journal of Medicine2012;366:1287-97. FermannGJ , Erkens Pmg, PrinsMH , WellsPS , Pap ÁF, LensingAW , et al. Treatment of pulmonary embolism with rivaroxaban: outcomes by simplified pulmonary embolism severity index score from a post hoc analysis of the EINSTEIN PE study. Academic Emergency Medicine2015;22(3):299-307. NCT00439777. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic pulmonary embolism with or without symptomatic deep-vein thrombosis: Einstein-PE evaluation, 2008. clinicaltrials.gov/ct2/show/NCT00439777?term=NCT00439777&amp;rank=1 (first received 26 February 2007). PrinsM , BamberL , CanoS , WangM , LensingAW , BauersachsR . Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic pulmonary embolism. Blood2012;120(21):1163. PrinsMH , BamberL , CanoSJ , WangMY , ErkensP , BauersachsR , et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial. Thrombosis Research2015;135(2):281-8. ">EINSTEIN‐PE 2012</a>; <a href="./references#CD010956-bbs2-0011" title="BistervelsI , BavaliaR , BoersmaW , MeijerK , VerhammeP , Ten Cate-HoekAJ , et al. Hokusai Post-DVT Study: a follow-up study on long-term outcomes of deep vein thrombosis in patients treated with edoxaban vs warfarin. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):PB2207. BrekelmansMP , AgenoW , BeenenLF , BrennerB , BullerHR , ChenCZ , et al. Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology2016;3(9):e437-45. BrekelmansMP , BlekerSM , BauersachsR , BodaZ , BüllerHR , ChoiY , et al. Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists. Thrombosis and Haemostasis2016;116(1):155-61. Di NisioM , Van EsN , CarrierM , WangTF , GarciaD , SegersA , et al. Extended treatment with edoxaban in cancer patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE Cancer study. Journal of Thrombosis and Haemostasis2019;17:1866–74. EUCTR2009-014290-40-SE. A phase 3, randomized, double-blind, double-dummy, parallel group, multi-center, multi-national study for evaluation of efficacy and safety of DU-176b versus warfarin in subjects with atrial fibrillation - effective anticoagulation with factor Xa next generation in atrial fibrillation (ENGAGE-AF TIMI-48). trialsearch.who.int/?trialid=EUCTR2009-014290-40-SE (first received 30 November 2009). EichingerS , LinM , KyrlePA , GrossoMA . Recurrent venous thromboembolism during anticoagulation: an investigator-initiated post-hoc analysis of the hokusai-VTE trial. Blood2018;132:2539. KlokFA , BarcoS , KonstantinidesSV . External validation of the VTE-BLEED score for predicting major bleeding in stable anticoagulated patients with venous thromboembolism. Thrombosis and Haemostasis2017;117(6):1164-70. KraaijpoelN , Van EsN , RaskobGE , BüllerHR , CarrierM , ZhangG , et al. Risk scores for occult cancer in patients with venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2018;118(7):1270-8. MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMP , ChenCZ , et al. Outpatient management in patients with venous thromboembolism with edoxaban: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2017;117(12):2406-14. MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMP , ChenCZ , et al. Safety and efficacy of edoxaban compared with warfarin for the treatment of acute symptomatic deep-vein thrombosis in the outpatient setting. Research and Practice in Thrombosis and Haemostasis2017;1:913. MulderFI , Van EsN , KraaijpoelN , Di NisioM , CarrierM , DuggalA , et al. Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: results from the Hokusai VTE Cancer study. Thrombosis Research2020;185:13-9. NCT00986154. Comparative investigation of Low Molecular Weight (LMW) heparin/edoxaban tosylate (DU176b) versus (LMW) heparin/warfarin in the treatment of symptomatic deep-vein blood clots and/or lung blood clots. (The Edoxaban Hokusai-VTE Study). clinicaltrials.gov/ct2/show/NCT00986154 (first received 29 September 2009). NakamuraM , WangYQ , WangC , OhD , YinWH , KimuraT , et al. Efficacy and safety of edoxaban for treatment of venous thromboembolism: a subanalysis of East Asian patients in the Hokusai-VTE trial. Journal of Thrombosis and Haemostasis2015;13(9):1606-14. NybergJ , KarlssonKE , JönssonS , YinO , MillerR , KarlssonMO , et al. Edoxaban exposure-response analysis and clinical utility index assessment in patients with symptomatic deep-vein thrombosis or pulmonary embolism. CPT Pharmacometrics and Systems Pharmacology2016;5(4):222-32. RaskobG , AgenoW , CohenAT , BrekelmansMP , GrossoMA , SegersA , et al. Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology2016;3(5):e228-e236. RaskobG , BullerH , PrinsM , SegersA , ShiM , SchwochoL , et al. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study - methodological implications for clinical trials. Journal of Thrombosis and Haemostasis2013;11(7):1287-94. RaskobGE , BullerH , AngchaisuksiriP , OhD , BodaZ , LyonsRM , et al. Edoxaban for long-term treatment of venous thromboembolism in cancer patients. Blood2013;122(21):211. RaskobGE , Van EsN , SegersA , AngchaisuksiriP , OhD , BodaZ , et al. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematology2016;3(8):e379-87. ScheresLJ , BrekelmansMA , WalterA , CihanA , BüllerHR , SabineE , et al. Abnormal vaginal bleeding in women of reproductive age treated with edoxaban or warfarin for venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. British Journal of Obstetrics and Gynaecology2018;125(12):1581-9. The Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. New England Journal of Medicine2013;369(15):1406-15. VanasscheT , VerhammeP , WellsPS , SegersA , AgenoW , BrekelmansMP , et al. Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: an analysis of the randomized, double-blind Hokusai-VTE trial. Thrombosis Research2018;162:7-14. VerhammeP , WellsPS , SegersA , AgenoW , BrekelmansMP , CohenAT , et al. Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial. Thrombosis and Haemostasis2016;116(4):747-53. ">Hokusai‐VTE 2013</a>; <a href="./references#CD010956-bbs2-0018" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00291330. Efficacy and safety of dabigatran compared to warfarin for 6 month treatment of acute symptomatic venous thromboembolism (RE-COVER I). clinicaltrials.gov/ct/show/NCT00291330 (first received 14 February 2006). SchulmanS , ErikssonH , GoldhaberS , KakkarAK , KearonC , KvammeAM , et al. Dabigatran or warfarin for extended maintenance therapy of venous thromboembolism. Journal of Thrombosis and Haemostasis2011;9(Suppl 2):731-2. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-COVER and RE-COVER II. Blood2013;122:2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RECOVER II. Blood2013;122(21):212. SchulmanS , ErikssonH , GoldhaverSZ , KakkarA , KearonC , MismettiP , et al. Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130:A18594. SchulmanS , KearonC , KakkarAK , MismettiP , SchellongS , ErikssonH , et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. New England Journal of Medicine2009;361(24):2342-52. ">RE‐COVER 2009</a>; <a href="./references#CD010956-bbs2-0019" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00680186. Phase III study testing efficacy &amp; safety of oral dabigatran etexilate vs warfarin for 6 m treatment for acute symp venous thromboembolism (VTE) (RE-COVER II). clinicaltrials.gov/ct2/show/NCT00680186 (first received 20 May 2008). SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-COVER and RE-COVER II. Blood2013;122:2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RECOVER II. Blood2013;122(21):212. SchulmanS , ErikssonH , GoldhaverSZ , KakkarA , KearonC , MismettiP , et al. Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130:A18594. SchulmanS , KakkarAK , GoldhaberSZ , SchellongS , ErikssonH , MismettiP , et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation2014;129:764-72. SchulmanS . A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II). Blood2011;118(21):95-6. ">RE‐COVER II 2014</a>). However, they reported bleeding was reduced by rivaroxaban (RR 0.55, 95% CI 0.38 to 0.81), apixaban (RR 0.31, 95% CI 0.17 to 0.55) and edoxaban (RR 0.81, 95% CI 0.71 to 0.93). The reviews by <a href="./references#CD010956-bbs2-0080" title="Gomez-OutesA , Terleira-FernandezAI , LecumberriR , Suarez-GeaML , Vargas-CastrillonE . Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis. Thrombosis Research2014;134(4):774-82.">Gomez‐Outes 2014</a> and <a href="./references#CD010956-bbs2-0090" title="KangN , SobierajDM . Indirect treatment comparison of new oral anticoagulants for the treatment of acute venous thromboembolism. Thrombosis Research2014;133:1145-51.">Kang 2014</a> included the same six studies as <a href="./references#CD010956-bbs2-0083" title="HirschlM , KundiM . New oral anticoagulants in the treatment of acute venous thromboembolism - a systematic review with indirect comparisons. Vasa2014;43(5):353-64.">Hirschl 2014</a>. <a href="./references#CD010956-bbs2-0080" title="Gomez-OutesA , Terleira-FernandezAI , LecumberriR , Suarez-GeaML , Vargas-CastrillonE . Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis. Thrombosis Research2014;134(4):774-82.">Gomez‐Outes 2014</a> found no difference in the risk of recurrent VTE between the two treatment groups (RR 0.91, 95% CI 0.79 to 1.06) and DOACs were associated with reduced major bleeding (absolute risk difference ‐0.6%, 95% CI ‐1.0% to ‐0.3%). <a href="./references#CD010956-bbs2-0090" title="KangN , SobierajDM . Indirect treatment comparison of new oral anticoagulants for the treatment of acute venous thromboembolism. Thrombosis Research2014;133:1145-51.">Kang 2014</a> reported that DOACs did not differ in the risk of mortality or recurrent VTE. However, an indirect comparison suggested that dabigatran was associated with increased major bleeding compared to apixaban (RR 2.69, 95% CI 1.19 to 6.07) and edoxaban also had a higher bleeding rate compared with apixaban (RR 2.74, 95% CI 1.40 to 5.39). The review from <a href="./references#CD010956-bbs2-0088" title="KakkosSK , KirkilesisGI , TsolakisIA . Editor's Choice - efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials. European Journal of Vascular and Endovascular Surgery2014;48(5):565-75.">Kakkos 2014</a> also included these six studies on treatment for VTE and reached similar conclusions. </p> <p><a href="./references#CD010956-bbs2-0071" title="Di MinnoMN , AmbrosinoP , LupoliR , Di MinnoA , DentaliF . Direct oral anticoagulants for the treatment of unprovoked venous thromboembolism: a meta-analysis of randomised controlled trials. Blood Transfusion2015;13(3):391-5.">Di Minno 2015</a> focused on the treatment of unprovoked or provoked VTE and included five studies (<a href="./references#CD010956-bbs2-0006" title="BamberL , WangMY , PrinsMH , CiniglioC , BauersachsR , LensingAW , et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis. Thrombosis and Haemostasis2013;110(4):732-41. BauersachsR , LensingAW , PapA , DecoususH . No need for a rivaroxaban dose reduction in renally impaired patients with symptomatic venous thromboembolism. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):30-1. BistervelsI , GebelM , LensingA , MiddeldorpS , CoppensM . Effect of polypharmacy on bleeding of rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolism. Research and Practice in Thrombosis and Haemostasis2019;3:798‐9. BookhartBK , HaskellL , BamberL , WangM , ScheinJ , ModySH . Length of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial program. Journal of Medical Economics2014;17(10):691-5. BullerHR . Oral rivaroxaban for the acute and continued treatment of symptomatic venous thromboembolism. The Einstein-DVT and Einstein-Extension study. Blood2010;116(21):187. CheungW , MiddeldorpS , PrinsMP , PapAF , LensingAW , Hoek-tenCA , et al. Post thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep vein thrombosis. Journal of Thrombosis and Haemostasis2015;13(S2):219-20. CheungYW , MiddeldorpS , PrinsMH , PapAF , PrandoniP . Post-thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep-vein thrombosis. A post-hoc analysis. Thrombosis and Haemostasis2016;116(4):733-8. EUCTR2004-002171-16-IT. Once-daily oral direct factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis. The EINSTEIN-DVT dose-finding study. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2004%E2%80%90002171%E2%80%9016%E2%80%90IT (first received 15 October 2008). EUCTR2006-004495-13-DK. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep-vein thrombosis or pulmonary embolism. trialsearch.who.int/?TrialID=EUCTR2006-004495-13-DK (first received 29 March 2007). EerenbergES , MiddeldorpS , LeviM , LensingAW , BüllerHR . Clinical impact and course of major bleeding with rivaroxaban and vitamin K antagonists. Journal of Thrombosis and Haemostasis2015;13(9):1590-6. KlineJA , JimenezD , CourtneyDM , IanusJ , CaoL , WellsPS . Use of the Riete 2008 bleeding score to identify patients at low risk for major bleeding in patients treated with rivaroxaban. Academic Emergency Medicine2015;22:S162. NCT00440193. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep vein thrombosis - The EINSTEIN DVT Study. clinicaltrials.gov/ct2/show/NCT00440193 (first received 26 February 2007). PrinsMH , ErkensPG , LensingAW . Incidence of recurrent venous thromboembolism in patients following completion of the EINSTEIN DVT and EINSTEIN PE studies. Journal of Thrombosis and Haemostasis2013;11(Suppl):257. PrinsMH , LensingAW , BauersachsR , Van BellenB , BounameauxH , BrightonTA , et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thrombosis Journal2013;11(1):21. The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. New England Journal of Medicine2010;363(26):2499-510. Van BellenB , PrinsM , BamberL , WangM , LensingAW . Reduction in initial length of stay with rivaroxaban single-drug regimen versus LMWH-VKA standard of care: findings from the EINSTEIN trial program. Blood2012;120(21):3419. Van BellenB , PrinsM , BamberL , WangM , LensingAW . Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism. Current Medical Research and Opinion2014;30(5):829-37. WangY , WangC , ChenZ , ZhangJ , LiuZ , JinB , et al. Rivaroxaban for the treatment of symptomatic deep vein thrombosis and/or pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):694. WangY , WangC , ChenZ , ZhangJ , LiuZ , JinB , et al. Rivaroxaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Thrombosis Journal2013;11(1):25. ">EINSTEIN‐DVT 2010</a>; <a href="./references#CD010956-bbs2-0008" title="BullerHR , PrinsMH , LensinAW , DecoususH , JacobsonBF , MinarE , et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. New England Journal of Medicine2012;366:1287-97. FermannGJ , Erkens Pmg, PrinsMH , WellsPS , Pap ÁF, LensingAW , et al. Treatment of pulmonary embolism with rivaroxaban: outcomes by simplified pulmonary embolism severity index score from a post hoc analysis of the EINSTEIN PE study. Academic Emergency Medicine2015;22(3):299-307. NCT00439777. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic pulmonary embolism with or without symptomatic deep-vein thrombosis: Einstein-PE evaluation, 2008. clinicaltrials.gov/ct2/show/NCT00439777?term=NCT00439777&amp;rank=1 (first received 26 February 2007). PrinsM , BamberL , CanoS , WangM , LensingAW , BauersachsR . Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic pulmonary embolism. Blood2012;120(21):1163. PrinsMH , BamberL , CanoSJ , WangMY , ErkensP , BauersachsR , et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial. Thrombosis Research2015;135(2):281-8. ">EINSTEIN‐PE 2012</a>; <a href="./references#CD010956-bbs2-0011" title="BistervelsI , BavaliaR , BoersmaW , MeijerK , VerhammeP , Ten Cate-HoekAJ , et al. Hokusai Post-DVT Study: a follow-up study on long-term outcomes of deep vein thrombosis in patients treated with edoxaban vs warfarin. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):PB2207. BrekelmansMP , AgenoW , BeenenLF , BrennerB , BullerHR , ChenCZ , et al. Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology2016;3(9):e437-45. BrekelmansMP , BlekerSM , BauersachsR , BodaZ , BüllerHR , ChoiY , et al. Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists. Thrombosis and Haemostasis2016;116(1):155-61. Di NisioM , Van EsN , CarrierM , WangTF , GarciaD , SegersA , et al. Extended treatment with edoxaban in cancer patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE Cancer study. Journal of Thrombosis and Haemostasis2019;17:1866–74. EUCTR2009-014290-40-SE. A phase 3, randomized, double-blind, double-dummy, parallel group, multi-center, multi-national study for evaluation of efficacy and safety of DU-176b versus warfarin in subjects with atrial fibrillation - effective anticoagulation with factor Xa next generation in atrial fibrillation (ENGAGE-AF TIMI-48). trialsearch.who.int/?trialid=EUCTR2009-014290-40-SE (first received 30 November 2009). EichingerS , LinM , KyrlePA , GrossoMA . Recurrent venous thromboembolism during anticoagulation: an investigator-initiated post-hoc analysis of the hokusai-VTE trial. Blood2018;132:2539. KlokFA , BarcoS , KonstantinidesSV . External validation of the VTE-BLEED score for predicting major bleeding in stable anticoagulated patients with venous thromboembolism. Thrombosis and Haemostasis2017;117(6):1164-70. KraaijpoelN , Van EsN , RaskobGE , BüllerHR , CarrierM , ZhangG , et al. Risk scores for occult cancer in patients with venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2018;118(7):1270-8. MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMP , ChenCZ , et al. Outpatient management in patients with venous thromboembolism with edoxaban: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2017;117(12):2406-14. MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMP , ChenCZ , et al. Safety and efficacy of edoxaban compared with warfarin for the treatment of acute symptomatic deep-vein thrombosis in the outpatient setting. Research and Practice in Thrombosis and Haemostasis2017;1:913. MulderFI , Van EsN , KraaijpoelN , Di NisioM , CarrierM , DuggalA , et al. Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: results from the Hokusai VTE Cancer study. Thrombosis Research2020;185:13-9. NCT00986154. Comparative investigation of Low Molecular Weight (LMW) heparin/edoxaban tosylate (DU176b) versus (LMW) heparin/warfarin in the treatment of symptomatic deep-vein blood clots and/or lung blood clots. (The Edoxaban Hokusai-VTE Study). clinicaltrials.gov/ct2/show/NCT00986154 (first received 29 September 2009). NakamuraM , WangYQ , WangC , OhD , YinWH , KimuraT , et al. Efficacy and safety of edoxaban for treatment of venous thromboembolism: a subanalysis of East Asian patients in the Hokusai-VTE trial. Journal of Thrombosis and Haemostasis2015;13(9):1606-14. NybergJ , KarlssonKE , JönssonS , YinO , MillerR , KarlssonMO , et al. Edoxaban exposure-response analysis and clinical utility index assessment in patients with symptomatic deep-vein thrombosis or pulmonary embolism. CPT Pharmacometrics and Systems Pharmacology2016;5(4):222-32. RaskobG , AgenoW , CohenAT , BrekelmansMP , GrossoMA , SegersA , et al. Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology2016;3(5):e228-e236. RaskobG , BullerH , PrinsM , SegersA , ShiM , SchwochoL , et al. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study - methodological implications for clinical trials. Journal of Thrombosis and Haemostasis2013;11(7):1287-94. RaskobGE , BullerH , AngchaisuksiriP , OhD , BodaZ , LyonsRM , et al. Edoxaban for long-term treatment of venous thromboembolism in cancer patients. Blood2013;122(21):211. RaskobGE , Van EsN , SegersA , AngchaisuksiriP , OhD , BodaZ , et al. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematology2016;3(8):e379-87. ScheresLJ , BrekelmansMA , WalterA , CihanA , BüllerHR , SabineE , et al. Abnormal vaginal bleeding in women of reproductive age treated with edoxaban or warfarin for venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. British Journal of Obstetrics and Gynaecology2018;125(12):1581-9. The Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. New England Journal of Medicine2013;369(15):1406-15. VanasscheT , VerhammeP , WellsPS , SegersA , AgenoW , BrekelmansMP , et al. Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: an analysis of the randomized, double-blind Hokusai-VTE trial. Thrombosis Research2018;162:7-14. VerhammeP , WellsPS , SegersA , AgenoW , BrekelmansMP , CohenAT , et al. Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial. Thrombosis and Haemostasis2016;116(4):747-53. ">Hokusai‐VTE 2013</a>; <a href="./references#CD010956-bbs2-0018" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00291330. Efficacy and safety of dabigatran compared to warfarin for 6 month treatment of acute symptomatic venous thromboembolism (RE-COVER I). clinicaltrials.gov/ct/show/NCT00291330 (first received 14 February 2006). SchulmanS , ErikssonH , GoldhaberS , KakkarAK , KearonC , KvammeAM , et al. Dabigatran or warfarin for extended maintenance therapy of venous thromboembolism. Journal of Thrombosis and Haemostasis2011;9(Suppl 2):731-2. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-COVER and RE-COVER II. Blood2013;122:2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RECOVER II. Blood2013;122(21):212. SchulmanS , ErikssonH , GoldhaverSZ , KakkarA , KearonC , MismettiP , et al. Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130:A18594. SchulmanS , KearonC , KakkarAK , MismettiP , SchellongS , ErikssonH , et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. New England Journal of Medicine2009;361(24):2342-52. ">RE‐COVER 2009</a>; <a href="./references#CD010956-bbs2-0019" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00680186. Phase III study testing efficacy &amp; safety of oral dabigatran etexilate vs warfarin for 6 m treatment for acute symp venous thromboembolism (VTE) (RE-COVER II). clinicaltrials.gov/ct2/show/NCT00680186 (first received 20 May 2008). SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-COVER and RE-COVER II. Blood2013;122:2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RECOVER II. Blood2013;122(21):212. SchulmanS , ErikssonH , GoldhaverSZ , KakkarA , KearonC , MismettiP , et al. Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130:A18594. SchulmanS , KakkarAK , GoldhaberSZ , SchellongS , ErikssonH , MismettiP , et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation2014;129:764-72. SchulmanS . A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II). Blood2011;118(21):95-6. ">RE‐COVER II 2014</a>). This review found that DOACs and VKAs had equal efficacy in treating VTE. </p> <p>The <a href="./references#CD010956-bbs2-0101" title="LoffredoL , PerriL , Del BenM , AngelicoF , VioliF . New oral anticoagulants for the treatment of acute venous thromboembolism: are they safer than vitamin K antagonists? A meta-analysis of the interventional trials. Internal Emergency Medicine2015;10(4):499-506.">Loffredo 2015</a> review included seven studies (<a href="./references#CD010956-bbs2-0001" title="AgnelliG , BullerH , MasiukiewiczUP . Apixaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism: a randomized, double-blind trial (AMPLIFY). Journal of Thrombosis and Haemostasis2013;11:18. AgnelliG , BullerHR , CohenA , CurtoD , GallusAS , JohnsonM , et al. Oral apixaban for the treatment of acute venous thromboembolism. New England Journal of Medicine2013;369:799-808. AgnelliG , BullerHR , CohenA , CurtoM , GallusAS , PakR , et al. Apixaban for the treatment of venous thromboembolism in cancer patients: data from the AMPLIFY trial. Canadian Journal of Cardiology2014;30(10 Suppl 1):S278. AgnelliG , BullerHR , CohenA , GallusAS , LeeTC , PakR , et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. Journal of Thrombosis and Haemostasis2015;13(12):2187-91. AgnelliG . Apixaban was non-inferior to enoxaparin plus warfarin in patients with acute venous thromboembolism. Annals of Internal Medicine2013;159(8):JC2. BlekerSM , CohenAT , BüllerHR , AgnelliG , GallusAS , RaskobGE , et al. Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Thrombosis and Haemostasis2016;116(6):159-64. BrekelmansM , ScheresL , BlekerS , HuttenB , TimmermansA , BüllerH , et al. Abnormal vaginal bleeding in women with venous thromboembolism treated with apixaban or warfarin. Thrombosis and Haemostasis2017;117(04):809-15. CohenA , AgnelliG , BullerH , GallusA , RaskobG , SandersP , et al. Characteristics and outcomes in patients with venous thromboembolism taking concomitant anti-platelet agents and anticoagulants in the AMPLIFY Trial. Thrombosis and Haemostasis2019;119(3):461-6. CohenA , AgnelliG , BullerHR , ChaudhuriS , GallusAS , RaskobGE , et al. Analysis of the bleeding and thromboembolic risk with concomitant use of antiplatelet treatment in the AMPLIFY trial. Canadian Journal of Cardiology2014;30(10):S272. CohenA , GallusAS , AgnelliG , BullerHR , PakR , PorcariAR , et al. Time in Therapeutic Range (TTR) and relative efficacy and safety of treatment with apixaban or enoxaparin/warfarin for acute symptomatic venous thromboembolism: an analysis of the Amplify trial data. Blood2014;124(21):1543. CohenAT , PanS , ByonW , IlyasBS , LeeTC . Efficacy, safety, and exposure of apixaban in patients with high body weight or obesity and venous thromboembolism: insights from AMPLIFY. Advances in Therapy2021;38(6):3003-18. EUCTR2007-007867-25-PT. A safety and efficacy trial evaluating the use of apixaban in the treatment of symptomatic deep vein thrombosis and pulmonary embolism revised protocol number: 01, incorporates amendment(s) 02 + protocol amendment 01 (version 1.0 dated 21-Apr-08) site-specific - molecular profiling supplement samples for Pfizer’s exploratory research biobank. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2007%E2%80%90007867%E2%80%9025%E2%80%90PT (first received 14 July 2008). GallusAS , AgnelliG , BullerHR , CohenA , LeeTC , PakR , et al. Apixaban for treatment of venous thromboembolism in patients from study centres in Asia: a subgroup analysis of the Amplify trial. Journal of Thrombosis and Haemostasis2015;13:727. LeeT , PanS , ByonW , IlyasBS . Safety and efficacy of apixaban versus enoxaparin/warfarin in patients with extremes of body weight: post-hoc analysis of the AMPLIFY trial. Blood2019;134(Suppl 1):1152. LiuX , JohnsonM , MardekianJ , PhatakH , ThompsonJ , CohenAT . Apixaban reduces hospitalizations in patients with venous thromboembolism: an analysis of the apixaban for the Initial management of pulmonary embolism and deep‐vein thrombosis as first‐line therapy (AMPLIFY) trial. Journal of the American Heart Association2015;4(12):e002340. NCT00633893. Efficacy and safety study of apixaban for extended treatment of deep vein thrombosis or pulmonary embolism. clinicaltrials.gov/ct2/show/NCT00633893?term=ajax&amp;rank=5 (first received 12 March 2008). NCT00643201. Efficacy and safety study of apixaban for the treatment of deep vein thrombosis or pulmonary embolism. clinicaltrials.gov/ct2/show/NCT00643201 (first received 26 March 2008). RaskobGE , GallusAS , SandersP , ThompsonJR , AgnelliG , BullerHR , et al. Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy: a sub-analysis of the AMPLIFY trial. Thrombosis and Haemostasis2016;115(4):809-16. ">AMPLIFY 2013</a>; <a href="./references#CD010956-bbs2-0006" title="BamberL , WangMY , PrinsMH , CiniglioC , BauersachsR , LensingAW , et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis. Thrombosis and Haemostasis2013;110(4):732-41. BauersachsR , LensingAW , PapA , DecoususH . No need for a rivaroxaban dose reduction in renally impaired patients with symptomatic venous thromboembolism. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):30-1. BistervelsI , GebelM , LensingA , MiddeldorpS , CoppensM . Effect of polypharmacy on bleeding of rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolism. Research and Practice in Thrombosis and Haemostasis2019;3:798‐9. BookhartBK , HaskellL , BamberL , WangM , ScheinJ , ModySH . Length of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial program. Journal of Medical Economics2014;17(10):691-5. BullerHR . Oral rivaroxaban for the acute and continued treatment of symptomatic venous thromboembolism. The Einstein-DVT and Einstein-Extension study. Blood2010;116(21):187. CheungW , MiddeldorpS , PrinsMP , PapAF , LensingAW , Hoek-tenCA , et al. Post thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep vein thrombosis. Journal of Thrombosis and Haemostasis2015;13(S2):219-20. CheungYW , MiddeldorpS , PrinsMH , PapAF , PrandoniP . Post-thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep-vein thrombosis. A post-hoc analysis. Thrombosis and Haemostasis2016;116(4):733-8. EUCTR2004-002171-16-IT. Once-daily oral direct factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis. The EINSTEIN-DVT dose-finding study. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2004%E2%80%90002171%E2%80%9016%E2%80%90IT (first received 15 October 2008). EUCTR2006-004495-13-DK. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep-vein thrombosis or pulmonary embolism. trialsearch.who.int/?TrialID=EUCTR2006-004495-13-DK (first received 29 March 2007). EerenbergES , MiddeldorpS , LeviM , LensingAW , BüllerHR . Clinical impact and course of major bleeding with rivaroxaban and vitamin K antagonists. Journal of Thrombosis and Haemostasis2015;13(9):1590-6. KlineJA , JimenezD , CourtneyDM , IanusJ , CaoL , WellsPS . Use of the Riete 2008 bleeding score to identify patients at low risk for major bleeding in patients treated with rivaroxaban. Academic Emergency Medicine2015;22:S162. NCT00440193. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep vein thrombosis - The EINSTEIN DVT Study. clinicaltrials.gov/ct2/show/NCT00440193 (first received 26 February 2007). PrinsMH , ErkensPG , LensingAW . Incidence of recurrent venous thromboembolism in patients following completion of the EINSTEIN DVT and EINSTEIN PE studies. Journal of Thrombosis and Haemostasis2013;11(Suppl):257. PrinsMH , LensingAW , BauersachsR , Van BellenB , BounameauxH , BrightonTA , et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thrombosis Journal2013;11(1):21. The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. New England Journal of Medicine2010;363(26):2499-510. Van BellenB , PrinsM , BamberL , WangM , LensingAW . Reduction in initial length of stay with rivaroxaban single-drug regimen versus LMWH-VKA standard of care: findings from the EINSTEIN trial program. Blood2012;120(21):3419. Van BellenB , PrinsM , BamberL , WangM , LensingAW . Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism. Current Medical Research and Opinion2014;30(5):829-37. WangY , WangC , ChenZ , ZhangJ , LiuZ , JinB , et al. Rivaroxaban for the treatment of symptomatic deep vein thrombosis and/or pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Journal of Thrombosis and Haemostasis2013;11(Suppl 2):694. WangY , WangC , ChenZ , ZhangJ , LiuZ , JinB , et al. Rivaroxaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Thrombosis Journal2013;11(1):25. ">EINSTEIN‐DVT 2010</a>; <a href="./references#CD010956-bbs2-0008" title="BullerHR , PrinsMH , LensinAW , DecoususH , JacobsonBF , MinarE , et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. New England Journal of Medicine2012;366:1287-97. FermannGJ , Erkens Pmg, PrinsMH , WellsPS , Pap ÁF, LensingAW , et al. Treatment of pulmonary embolism with rivaroxaban: outcomes by simplified pulmonary embolism severity index score from a post hoc analysis of the EINSTEIN PE study. Academic Emergency Medicine2015;22(3):299-307. NCT00439777. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic pulmonary embolism with or without symptomatic deep-vein thrombosis: Einstein-PE evaluation, 2008. clinicaltrials.gov/ct2/show/NCT00439777?term=NCT00439777&amp;rank=1 (first received 26 February 2007). PrinsM , BamberL , CanoS , WangM , LensingAW , BauersachsR . Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic pulmonary embolism. Blood2012;120(21):1163. PrinsMH , BamberL , CanoSJ , WangMY , ErkensP , BauersachsR , et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial. Thrombosis Research2015;135(2):281-8. ">EINSTEIN‐PE 2012</a>; <a href="./references#CD010956-bbs2-0011" title="BistervelsI , BavaliaR , BoersmaW , MeijerK , VerhammeP , Ten Cate-HoekAJ , et al. Hokusai Post-DVT Study: a follow-up study on long-term outcomes of deep vein thrombosis in patients treated with edoxaban vs warfarin. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):PB2207. BrekelmansMP , AgenoW , BeenenLF , BrennerB , BullerHR , ChenCZ , et al. Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology2016;3(9):e437-45. BrekelmansMP , BlekerSM , BauersachsR , BodaZ , BüllerHR , ChoiY , et al. Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists. Thrombosis and Haemostasis2016;116(1):155-61. Di NisioM , Van EsN , CarrierM , WangTF , GarciaD , SegersA , et al. Extended treatment with edoxaban in cancer patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE Cancer study. Journal of Thrombosis and Haemostasis2019;17:1866–74. EUCTR2009-014290-40-SE. A phase 3, randomized, double-blind, double-dummy, parallel group, multi-center, multi-national study for evaluation of efficacy and safety of DU-176b versus warfarin in subjects with atrial fibrillation - effective anticoagulation with factor Xa next generation in atrial fibrillation (ENGAGE-AF TIMI-48). trialsearch.who.int/?trialid=EUCTR2009-014290-40-SE (first received 30 November 2009). EichingerS , LinM , KyrlePA , GrossoMA . Recurrent venous thromboembolism during anticoagulation: an investigator-initiated post-hoc analysis of the hokusai-VTE trial. Blood2018;132:2539. KlokFA , BarcoS , KonstantinidesSV . External validation of the VTE-BLEED score for predicting major bleeding in stable anticoagulated patients with venous thromboembolism. Thrombosis and Haemostasis2017;117(6):1164-70. KraaijpoelN , Van EsN , RaskobGE , BüllerHR , CarrierM , ZhangG , et al. Risk scores for occult cancer in patients with venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2018;118(7):1270-8. MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMP , ChenCZ , et al. Outpatient management in patients with venous thromboembolism with edoxaban: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2017;117(12):2406-14. MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMP , ChenCZ , et al. Safety and efficacy of edoxaban compared with warfarin for the treatment of acute symptomatic deep-vein thrombosis in the outpatient setting. Research and Practice in Thrombosis and Haemostasis2017;1:913. MulderFI , Van EsN , KraaijpoelN , Di NisioM , CarrierM , DuggalA , et al. Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: results from the Hokusai VTE Cancer study. Thrombosis Research2020;185:13-9. NCT00986154. Comparative investigation of Low Molecular Weight (LMW) heparin/edoxaban tosylate (DU176b) versus (LMW) heparin/warfarin in the treatment of symptomatic deep-vein blood clots and/or lung blood clots. (The Edoxaban Hokusai-VTE Study). clinicaltrials.gov/ct2/show/NCT00986154 (first received 29 September 2009). NakamuraM , WangYQ , WangC , OhD , YinWH , KimuraT , et al. Efficacy and safety of edoxaban for treatment of venous thromboembolism: a subanalysis of East Asian patients in the Hokusai-VTE trial. Journal of Thrombosis and Haemostasis2015;13(9):1606-14. NybergJ , KarlssonKE , JönssonS , YinO , MillerR , KarlssonMO , et al. Edoxaban exposure-response analysis and clinical utility index assessment in patients with symptomatic deep-vein thrombosis or pulmonary embolism. CPT Pharmacometrics and Systems Pharmacology2016;5(4):222-32. RaskobG , AgenoW , CohenAT , BrekelmansMP , GrossoMA , SegersA , et al. Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology2016;3(5):e228-e236. RaskobG , BullerH , PrinsM , SegersA , ShiM , SchwochoL , et al. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study - methodological implications for clinical trials. Journal of Thrombosis and Haemostasis2013;11(7):1287-94. RaskobGE , BullerH , AngchaisuksiriP , OhD , BodaZ , LyonsRM , et al. Edoxaban for long-term treatment of venous thromboembolism in cancer patients. Blood2013;122(21):211. RaskobGE , Van EsN , SegersA , AngchaisuksiriP , OhD , BodaZ , et al. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematology2016;3(8):e379-87. ScheresLJ , BrekelmansMA , WalterA , CihanA , BüllerHR , SabineE , et al. Abnormal vaginal bleeding in women of reproductive age treated with edoxaban or warfarin for venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. British Journal of Obstetrics and Gynaecology2018;125(12):1581-9. The Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. New England Journal of Medicine2013;369(15):1406-15. VanasscheT , VerhammeP , WellsPS , SegersA , AgenoW , BrekelmansMP , et al. Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: an analysis of the randomized, double-blind Hokusai-VTE trial. Thrombosis Research2018;162:7-14. VerhammeP , WellsPS , SegersA , AgenoW , BrekelmansMP , CohenAT , et al. Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial. Thrombosis and Haemostasis2016;116(4):747-53. ">Hokusai‐VTE 2013</a>; <a href="./references#CD010956-bbs2-0018" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00291330. Efficacy and safety of dabigatran compared to warfarin for 6 month treatment of acute symptomatic venous thromboembolism (RE-COVER I). clinicaltrials.gov/ct/show/NCT00291330 (first received 14 February 2006). SchulmanS , ErikssonH , GoldhaberS , KakkarAK , KearonC , KvammeAM , et al. Dabigatran or warfarin for extended maintenance therapy of venous thromboembolism. Journal of Thrombosis and Haemostasis2011;9(Suppl 2):731-2. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-COVER and RE-COVER II. Blood2013;122:2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RECOVER II. Blood2013;122(21):212. SchulmanS , ErikssonH , GoldhaverSZ , KakkarA , KearonC , MismettiP , et al. Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130:A18594. SchulmanS , KearonC , KakkarAK , MismettiP , SchellongS , ErikssonH , et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. New England Journal of Medicine2009;361(24):2342-52. ">RE‐COVER 2009</a>; <a href="./references#CD010956-bbs2-0019" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00680186. Phase III study testing efficacy &amp; safety of oral dabigatran etexilate vs warfarin for 6 m treatment for acute symp venous thromboembolism (VTE) (RE-COVER II). clinicaltrials.gov/ct2/show/NCT00680186 (first received 20 May 2008). SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-COVER and RE-COVER II. Blood2013;122:2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RECOVER II. Blood2013;122(21):212. SchulmanS , ErikssonH , GoldhaverSZ , KakkarA , KearonC , MismettiP , et al. Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130:A18594. SchulmanS , KakkarAK , GoldhaberSZ , SchellongS , ErikssonH , MismettiP , et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation2014;129:764-72. SchulmanS . A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II). Blood2011;118(21):95-6. ">RE‐COVER II 2014</a>; <a href="./references#CD010956-bbs2-0021" title="FiessingerJN , HuismanMV , DavidsonBL , BounameauxH , FrancisCW , ErikssonH , et al. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomised trial. JAMA2005;293(6):681-9. FrancisCW , GinsbergJS , BerkowitzSD , BounameauxH , DavidsonBL , ErikssonH , et al. Efficacy and safety of the oral direct thrombin inhibitor ximelagatran compared with current therapy for acute, symptomatic deep vein thrombosis, with or without pulmonary embolus: the THRIVE treatment study. Blood2003;102(11):Abstract 7. HarenbergJ , IngridJ , TivadarF . Treatment of venous thromboembolism with the oral thrombin inhibitor, ximelagatran. Israel Medical Association Journal2002;4(11):1003-5. HarenbergJ , JoergI , WeissC . Incidence of recurrent venous thromboembolism of patients after termination of treatment with ximelagatran. European Journal of Clinical Pharmacology2006;62(3):173-7. HarenbergJ , JorgI , WeissC , HarenbergJ , JorgI , WeissC . Observations of alanine aminotransferase and aspartate aminotransferase in THRIVE studies treated orally with ximelagatran. International Journal of Toxicology2006;25(3):165-9. HuismanMV , The THRIVE Treatment Study Investigators. Efficacy and safety of the oral direct thrombin inhibitor ximelagatran compared with current standard therapy for acute symptomatic deep vein thrombosis, with or without pulmonary embolism: a randomized, double-blind, multinational study. Journal of Thrombosis and Haemostasis2003;1(Suppl 1):Abstract OC003. WimperisJ , FiessingerJN , HuismanMV , DavidsonBL , BounameauxH , FrancisCW , et al. Ximelagatran, an oral direct thrombin inhibitor, compared with current standard therapy for acute, symptomatic deep vein thrombosis, with or without pulmonary embolism: the THRIVE treatment study. British Journal of Haematology2004;125(Suppl 1):66. ">THRIVE 2005</a>). The results suggested that DOACs for participants with acute VTE are not inferior to conventional therapy for recurrent VTE and all‐cause mortality, and reduced major bleeding (RR 0.63, 95% CI 0.47 to 0.83). However, there might be an increased incidence of myocardial infarction. </p> <p><a href="./references#CD010956-bbs2-0114" title="SenooK , KondoY , MiyazawaK , IsogaiT , ChunYH , KobayashiY . Safety and efficacy of direct oral anticoagulants over warfarin in Japanese patients with acute venous thromboembolism: a meta-analysis. Journal of Cardiology2017;69(5):763-8.">Senoo 2017</a> focused on Japanese participants only and included three studies (<a href="./references#CD010956-bbs2-0002" title="NakamuraM , NishikawaM , KomuroI , KitajimaI , UetsukaY , YamagamiT , et al. Apixaban for the treatment of Japanese subjects with acute venous thromboembolism (AMPLIFY-J Study). Circulation2015;79(6):1230–36. ">AMPLIFY‐J 2015</a>; <a href="./references#CD010956-bbs2-0011" title="BistervelsI , BavaliaR , BoersmaW , MeijerK , VerhammeP , Ten Cate-HoekAJ , et al. Hokusai Post-DVT Study: a follow-up study on long-term outcomes of deep vein thrombosis in patients treated with edoxaban vs warfarin. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):PB2207. BrekelmansMP , AgenoW , BeenenLF , BrennerB , BullerHR , ChenCZ , et al. Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology2016;3(9):e437-45. BrekelmansMP , BlekerSM , BauersachsR , BodaZ , BüllerHR , ChoiY , et al. Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists. Thrombosis and Haemostasis2016;116(1):155-61. Di NisioM , Van EsN , CarrierM , WangTF , GarciaD , SegersA , et al. Extended treatment with edoxaban in cancer patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE Cancer study. Journal of Thrombosis and Haemostasis2019;17:1866–74. EUCTR2009-014290-40-SE. A phase 3, randomized, double-blind, double-dummy, parallel group, multi-center, multi-national study for evaluation of efficacy and safety of DU-176b versus warfarin in subjects with atrial fibrillation - effective anticoagulation with factor Xa next generation in atrial fibrillation (ENGAGE-AF TIMI-48). trialsearch.who.int/?trialid=EUCTR2009-014290-40-SE (first received 30 November 2009). EichingerS , LinM , KyrlePA , GrossoMA . Recurrent venous thromboembolism during anticoagulation: an investigator-initiated post-hoc analysis of the hokusai-VTE trial. Blood2018;132:2539. KlokFA , BarcoS , KonstantinidesSV . External validation of the VTE-BLEED score for predicting major bleeding in stable anticoagulated patients with venous thromboembolism. Thrombosis and Haemostasis2017;117(6):1164-70. KraaijpoelN , Van EsN , RaskobGE , BüllerHR , CarrierM , ZhangG , et al. Risk scores for occult cancer in patients with venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2018;118(7):1270-8. MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMP , ChenCZ , et al. Outpatient management in patients with venous thromboembolism with edoxaban: a post hoc analysis of the Hokusai-VTE study. Thrombosis and Haemostasis2017;117(12):2406-14. MedinaA , RaskobG , AgenoW , CohenAT , BrekelmansMP , ChenCZ , et al. Safety and efficacy of edoxaban compared with warfarin for the treatment of acute symptomatic deep-vein thrombosis in the outpatient setting. Research and Practice in Thrombosis and Haemostasis2017;1:913. MulderFI , Van EsN , KraaijpoelN , Di NisioM , CarrierM , DuggalA , et al. Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: results from the Hokusai VTE Cancer study. Thrombosis Research2020;185:13-9. NCT00986154. Comparative investigation of Low Molecular Weight (LMW) heparin/edoxaban tosylate (DU176b) versus (LMW) heparin/warfarin in the treatment of symptomatic deep-vein blood clots and/or lung blood clots. (The Edoxaban Hokusai-VTE Study). clinicaltrials.gov/ct2/show/NCT00986154 (first received 29 September 2009). NakamuraM , WangYQ , WangC , OhD , YinWH , KimuraT , et al. Efficacy and safety of edoxaban for treatment of venous thromboembolism: a subanalysis of East Asian patients in the Hokusai-VTE trial. Journal of Thrombosis and Haemostasis2015;13(9):1606-14. NybergJ , KarlssonKE , JönssonS , YinO , MillerR , KarlssonMO , et al. Edoxaban exposure-response analysis and clinical utility index assessment in patients with symptomatic deep-vein thrombosis or pulmonary embolism. CPT Pharmacometrics and Systems Pharmacology2016;5(4):222-32. RaskobG , AgenoW , CohenAT , BrekelmansMP , GrossoMA , SegersA , et al. Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology2016;3(5):e228-e236. RaskobG , BullerH , PrinsM , SegersA , ShiM , SchwochoL , et al. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study - methodological implications for clinical trials. Journal of Thrombosis and Haemostasis2013;11(7):1287-94. RaskobGE , BullerH , AngchaisuksiriP , OhD , BodaZ , LyonsRM , et al. Edoxaban for long-term treatment of venous thromboembolism in cancer patients. Blood2013;122(21):211. RaskobGE , Van EsN , SegersA , AngchaisuksiriP , OhD , BodaZ , et al. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematology2016;3(8):e379-87. ScheresLJ , BrekelmansMA , WalterA , CihanA , BüllerHR , SabineE , et al. Abnormal vaginal bleeding in women of reproductive age treated with edoxaban or warfarin for venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. British Journal of Obstetrics and Gynaecology2018;125(12):1581-9. The Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. New England Journal of Medicine2013;369(15):1406-15. VanasscheT , VerhammeP , WellsPS , SegersA , AgenoW , BrekelmansMP , et al. Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: an analysis of the randomized, double-blind Hokusai-VTE trial. Thrombosis Research2018;162:7-14. VerhammeP , WellsPS , SegersA , AgenoW , BrekelmansMP , CohenAT , et al. Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial. Thrombosis and Haemostasis2016;116(4):747-53. ">Hokusai‐VTE 2013</a>; <a href="./references#CD010956-bbs2-0013" title="MatsuoH , PrinsM , LensingAW , FujinumaEW , MiyamotoY , KajikawaM . Shortened length of hospital stay with rivaroxaban in patients with symptomatic venous thromboembolism in Japan: the J-EINSTEIN pulmonary embolism and deep vein thrombosis program. Current Medical Research and Opinion2015;31(6):1057-61. NCT01516814. Venous thromboembolism (VTE) treatment study in Japanese pulmonary embolism (PE) patients. clinicaltrials.gov/ct2/show/NCT01516814 (first received 25 January 2012). YamadaN , HirayamaA , MaedaH , SakagamiS , ShikataH , PrinsMH , et al. Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism-the J-EINSTEIN DVT and PE program. Thrombosis Journal2015;13:2. ">J‐EINSTEIN DVT and PE 2015</a>). This review found that DOACs had a decreased risk for all bleeding (RR 0.69, 95% CI 0.50 to 0.95), without any significant differences in recurrent VTE (RR 0.84, 95% CI 0.29 to 2.43). </p> <p>The review by <a href="./references#CD010956-bbs2-0053" title="AntoniazziS , BerdaiD , ContiV , ClementiE , SalvoF . Risk of major bleeding and the standard doses of dabigatran. European Journal of Internal Medicine2014;25(6):e73-5. [DOI: 10.1016/j.ejim.2014.02.005]">Antoniazzi 2014</a> included people with VTE and atrial fibrillation. The review was only available as an abstract report and included eight studies. Its results showed that the risk of major bleeding was lower in people treated with dabigatran (RR 0.83, 95% CI 0.78 to 0.97). </p> <p>The reviews by <a href="./references#CD010956-bbs2-0064" title="CastellucciLA , CameronC , Le GalG , RodgerMA , CoyleD , WellsPS , et al. Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis. BMJ2013;347:f5133.">Castellucci 2013</a> and <a href="./references#CD010956-bbs2-0110" title="SardarP , ChatterjeeS , MukherjeeD . Efficacy and safety or new oral anticoagulants for extended treatment of venous thromboembolism: systematic review and meta-analyses of randomised controlled trials. Drugs2013;73:1171-82.">Sardar 2013</a> compared oral anticoagulants with antiplatelet drugs but the focus was on the secondary prevention of VTE rather than treatment. </p> <p>Several systematic reviews focused on cancer‐associated VTE have been published in recent years, but these made no separate results for DVT available (<a href="./references#CD010956-bbs2-0070" title="DesaiA , GyawaliB . Assessing the benefits and harms of direct oral anticoagulants in patients with cancer for the prophylaxis and treatment of venous thromboembolism: a systematic review and meta-analysis. Ecancermedicalscience2020;14:1091. [DOI: 10.3332/ecancer.2020.1091]">Desai 2020</a>; <a href="./references#CD010956-bbs2-0084" title="KahaleLA , HakoumMB , TsolakianIG , MatarCF , TerrenatoI , SperatiF , et al. Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer. Cochrane Database of Systematic Reviews2018, Issue 6. Art. No: CD006650. [DOI: 10.1002/14651858.CD006650.pub5]">Kahale 2018</a>; <a href="./references#CD010956-bbs2-0098" title="LiA , GarciaDA , LymanGH , CarrierM . Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): a systematic review and meta-analysis. Thrombosis Research2019;173:158-63.">Li 2019</a>; <a href="./references#CD010956-bbs2-0103" title="MulderFI , BoschFT , YoungAM , MarshallA , McBaneRD , ZemlaTJ , et al. Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis. Blood2020;136(12):1433-41.">Mulder 2020</a>; <a href="./references#CD010956-bbs2-0132" title="YangM , LiJ , SunR , WangY , XuH , YangB , et al. Comparison between direct factor Xa inhibitors and low-molecular-weight heparin for efficacy and safety in the treatment of cancer-associated venous thromboembolism: a meta-analysis. Journal of Cancer Research and Therapeutics2019;15(7):1541-6.">Yang 2019</a>). The results differed slightly among these reviews, but all suggested a similar trend: that DOACs likely reduce recurrent VTE but may increase the risk of major bleeding in participants with cancer‐associated VTE. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD010956-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/urn:x-wiley:14651858:media:CD010956:CD010956-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram" data-id="CD010956-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_n/nCD010956-FIG-01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_t/tCD010956-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/full#CD010956-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_n/nCD010956-FIG-01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010956-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/urn:x-wiley:14651858:media:CD010956:CD010956-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD010956-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_n/nCD010956-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_t/tCD010956-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/full#CD010956-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_n/nCD010956-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010956-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/urn:x-wiley:14651858:media:CD010956:CD010956-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD010956-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_n/nCD010956-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_t/tCD010956-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/full#CD010956-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_n/nCD010956-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010956-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/urn:x-wiley:14651858:media:CD010956:CD010956-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of oral factor Xa inhibitors versus conventional anticoagulants for recurrent VTE " data-id="CD010956-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_n/nCD010956-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_t/tCD010956-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Funnel plot of oral factor Xa inhibitors versus conventional anticoagulants for recurrent VTE  </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/full#CD010956-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_n/nCD010956-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010956-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/urn:x-wiley:14651858:media:CD010956:CD010956-FIG-05" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of oral factor Xa inhibitors versus conventional anticoagulants for major bleeding" data-id="CD010956-fig-0005" src="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_n/nCD010956-FIG-05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_t/tCD010956-FIG-05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Funnel plot of oral factor Xa inhibitors versus conventional anticoagulants for major bleeding </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/full#CD010956-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_n/nCD010956-FIG-05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010956-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/urn:x-wiley:14651858:media:CD010956:CD010956-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Oral direct thrombin inhibitors (DTIs) versus conventional anticoagulation, Outcome 1: Recurrent venous thromboembolism" data-id="CD010956-fig-0006" src="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_n/nCD010956-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_t/tCD010956-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Oral direct thrombin inhibitors (DTIs) versus conventional anticoagulation, Outcome 1: Recurrent venous thromboembolism </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/references#CD010956-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_n/nCD010956-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010956-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/urn:x-wiley:14651858:media:CD010956:CD010956-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Oral direct thrombin inhibitors (DTIs) versus conventional anticoagulation, Outcome 2: Recurrent deep vein thrombosis" data-id="CD010956-fig-0007" src="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_n/nCD010956-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_t/tCD010956-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Oral direct thrombin inhibitors (DTIs) versus conventional anticoagulation, Outcome 2: Recurrent deep vein thrombosis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/references#CD010956-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_n/nCD010956-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010956-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/urn:x-wiley:14651858:media:CD010956:CD010956-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Oral direct thrombin inhibitors (DTIs) versus conventional anticoagulation, Outcome 3: Fatal pulmonary embolism" data-id="CD010956-fig-0008" src="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_n/nCD010956-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_t/tCD010956-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Oral direct thrombin inhibitors (DTIs) versus conventional anticoagulation, Outcome 3: Fatal pulmonary embolism </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/references#CD010956-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_n/nCD010956-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010956-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/urn:x-wiley:14651858:media:CD010956:CD010956-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Oral direct thrombin inhibitors (DTIs) versus conventional anticoagulation, Outcome 4: Non‐fatal pulmonary embolism" data-id="CD010956-fig-0009" src="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_n/nCD010956-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_t/tCD010956-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Oral direct thrombin inhibitors (DTIs) versus conventional anticoagulation, Outcome 4: Non‐fatal pulmonary embolism </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/references#CD010956-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_n/nCD010956-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010956-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/urn:x-wiley:14651858:media:CD010956:CD010956-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Oral direct thrombin inhibitors (DTIs) versus conventional anticoagulation, Outcome 5: All‐cause mortality" data-id="CD010956-fig-0010" src="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_n/nCD010956-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_t/tCD010956-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Oral direct thrombin inhibitors (DTIs) versus conventional anticoagulation, Outcome 5: All‐cause mortality </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/references#CD010956-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_n/nCD010956-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010956-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/urn:x-wiley:14651858:media:CD010956:CD010956-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Oral direct thrombin inhibitors (DTIs) versus conventional anticoagulation, Outcome 6: Major bleeding" data-id="CD010956-fig-0011" src="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_n/nCD010956-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_t/tCD010956-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Oral direct thrombin inhibitors (DTIs) versus conventional anticoagulation, Outcome 6: Major bleeding </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/references#CD010956-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_n/nCD010956-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010956-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/urn:x-wiley:14651858:media:CD010956:CD010956-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Oral direct thrombin inhibitors (DTIs) versus conventional anticoagulation, Outcome 7: Health‐related quality of life: SF‐36 physical component" data-id="CD010956-fig-0012" src="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_n/nCD010956-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_t/tCD010956-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Oral direct thrombin inhibitors (DTIs) versus conventional anticoagulation, Outcome 7: Health‐related quality of life: SF‐36 physical component </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/references#CD010956-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_n/nCD010956-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010956-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/urn:x-wiley:14651858:media:CD010956:CD010956-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Oral direct thrombin inhibitors (DTIs) versus conventional anticoagulation, Outcome 8: Health‐related quality of life: SF‐36 psychological component" data-id="CD010956-fig-0013" src="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_n/nCD010956-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_t/tCD010956-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Oral direct thrombin inhibitors (DTIs) versus conventional anticoagulation, Outcome 8: Health‐related quality of life: SF‐36 psychological component </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/references#CD010956-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_n/nCD010956-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010956-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/urn:x-wiley:14651858:media:CD010956:CD010956-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Oral direct thrombin inhibitors (DTIs) versus conventional anticoagulation (sensitivity analysis excluding ximelagatran), Outcome 1: Recurrent venous thromboembolism" data-id="CD010956-fig-0014" src="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_n/nCD010956-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_t/tCD010956-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Oral direct thrombin inhibitors (DTIs) versus conventional anticoagulation (sensitivity analysis excluding ximelagatran), Outcome 1: Recurrent venous thromboembolism </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/references#CD010956-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_n/nCD010956-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010956-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/urn:x-wiley:14651858:media:CD010956:CD010956-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Oral direct thrombin inhibitors (DTIs) versus conventional anticoagulation (sensitivity analysis excluding ximelagatran), Outcome 2: Recurrent deep vein thrombosis" data-id="CD010956-fig-0015" src="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_n/nCD010956-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_t/tCD010956-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Oral direct thrombin inhibitors (DTIs) versus conventional anticoagulation (sensitivity analysis excluding ximelagatran), Outcome 2: Recurrent deep vein thrombosis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/references#CD010956-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_n/nCD010956-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010956-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/urn:x-wiley:14651858:media:CD010956:CD010956-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Oral direct thrombin inhibitors (DTIs) versus conventional anticoagulation (sensitivity analysis excluding ximelagatran), Outcome 3: Fatal pulmonary embolism" data-id="CD010956-fig-0016" src="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_n/nCD010956-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_t/tCD010956-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Oral direct thrombin inhibitors (DTIs) versus conventional anticoagulation (sensitivity analysis excluding ximelagatran), Outcome 3: Fatal pulmonary embolism </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/references#CD010956-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_n/nCD010956-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010956-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/urn:x-wiley:14651858:media:CD010956:CD010956-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Oral direct thrombin inhibitors (DTIs) versus conventional anticoagulation (sensitivity analysis excluding ximelagatran), Outcome 4: Non‐fatal pulmonary embolism" data-id="CD010956-fig-0017" src="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_n/nCD010956-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_t/tCD010956-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Oral direct thrombin inhibitors (DTIs) versus conventional anticoagulation (sensitivity analysis excluding ximelagatran), Outcome 4: Non‐fatal pulmonary embolism </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/references#CD010956-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_n/nCD010956-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010956-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/urn:x-wiley:14651858:media:CD010956:CD010956-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Oral direct thrombin inhibitors (DTIs) versus conventional anticoagulation (sensitivity analysis excluding ximelagatran), Outcome 5: Major bleeding" data-id="CD010956-fig-0018" src="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_n/nCD010956-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_t/tCD010956-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Oral direct thrombin inhibitors (DTIs) versus conventional anticoagulation (sensitivity analysis excluding ximelagatran), Outcome 5: Major bleeding </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/references#CD010956-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_n/nCD010956-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010956-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/urn:x-wiley:14651858:media:CD010956:CD010956-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Oral factor Xa inhibitors versus conventional anticoagulation, Outcome 1: Recurrent venous thromboembolism" data-id="CD010956-fig-0019" src="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_n/nCD010956-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_t/tCD010956-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Oral factor Xa inhibitors versus conventional anticoagulation, Outcome 1: Recurrent venous thromboembolism </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/references#CD010956-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_n/nCD010956-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010956-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/urn:x-wiley:14651858:media:CD010956:CD010956-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Oral factor Xa inhibitors versus conventional anticoagulation, Outcome 2: Recurrent deep vein thrombosis" data-id="CD010956-fig-0020" src="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_n/nCD010956-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_t/tCD010956-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Oral factor Xa inhibitors versus conventional anticoagulation, Outcome 2: Recurrent deep vein thrombosis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/references#CD010956-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_n/nCD010956-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010956-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/urn:x-wiley:14651858:media:CD010956:CD010956-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Oral factor Xa inhibitors versus conventional anticoagulation, Outcome 3: Fatal pulmonary embolism" data-id="CD010956-fig-0021" src="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_n/nCD010956-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_t/tCD010956-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Oral factor Xa inhibitors versus conventional anticoagulation, Outcome 3: Fatal pulmonary embolism </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/references#CD010956-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_n/nCD010956-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010956-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/urn:x-wiley:14651858:media:CD010956:CD010956-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Oral factor Xa inhibitors versus conventional anticoagulation, Outcome 4: Non‐fatal pulmonary embolism" data-id="CD010956-fig-0022" src="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_n/nCD010956-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_t/tCD010956-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: Oral factor Xa inhibitors versus conventional anticoagulation, Outcome 4: Non‐fatal pulmonary embolism </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/references#CD010956-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_n/nCD010956-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010956-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/urn:x-wiley:14651858:media:CD010956:CD010956-CMP-003.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Oral factor Xa inhibitors versus conventional anticoagulation, Outcome 5: All‐cause mortality" data-id="CD010956-fig-0023" src="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_n/nCD010956-CMP-003.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_t/tCD010956-CMP-003.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3: Oral factor Xa inhibitors versus conventional anticoagulation, Outcome 5: All‐cause mortality </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/references#CD010956-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_n/nCD010956-CMP-003.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010956-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/urn:x-wiley:14651858:media:CD010956:CD010956-CMP-003.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Oral factor Xa inhibitors versus conventional anticoagulation, Outcome 6: Major bleeding" data-id="CD010956-fig-0024" src="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_n/nCD010956-CMP-003.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_t/tCD010956-CMP-003.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3: Oral factor Xa inhibitors versus conventional anticoagulation, Outcome 6: Major bleeding </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/references#CD010956-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_n/nCD010956-CMP-003.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010956-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/urn:x-wiley:14651858:media:CD010956:CD010956-CMP-003.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Oral factor Xa inhibitors versus conventional anticoagulation, Outcome 7: Post‐thrombotic syndrome" data-id="CD010956-fig-0025" src="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_n/nCD010956-CMP-003.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_t/tCD010956-CMP-003.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3: Oral factor Xa inhibitors versus conventional anticoagulation, Outcome 7: Post‐thrombotic syndrome </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/references#CD010956-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_n/nCD010956-CMP-003.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010956-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/urn:x-wiley:14651858:media:CD010956:CD010956-CMP-003.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Oral factor Xa inhibitors versus conventional anticoagulation, Outcome 8: Health‐related quality of life: SF‐36 physical component" data-id="CD010956-fig-0026" src="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_n/nCD010956-CMP-003.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_t/tCD010956-CMP-003.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3: Oral factor Xa inhibitors versus conventional anticoagulation, Outcome 8: Health‐related quality of life: SF‐36 physical component </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/references#CD010956-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_n/nCD010956-CMP-003.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010956-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/urn:x-wiley:14651858:media:CD010956:CD010956-CMP-003.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Oral factor Xa inhibitors versus conventional anticoagulation, Outcome 9: Health‐related quality of life: SF‐36 psychological component" data-id="CD010956-fig-0027" src="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_n/nCD010956-CMP-003.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_t/tCD010956-CMP-003.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3: Oral factor Xa inhibitors versus conventional anticoagulation, Outcome 9: Health‐related quality of life: SF‐36 psychological component </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/references#CD010956-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_n/nCD010956-CMP-003.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010956-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/urn:x-wiley:14651858:media:CD010956:CD010956-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Oral factor Xa inhibitors versus conventional anticoagulation: subgroup analysis of participants with versus without active cancer, Outcome 1: Recurrent VTE" data-id="CD010956-fig-0028" src="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_n/nCD010956-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_t/tCD010956-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Oral factor Xa inhibitors versus conventional anticoagulation: subgroup analysis of participants with versus without active cancer, Outcome 1: Recurrent VTE </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/references#CD010956-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_n/nCD010956-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010956-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/urn:x-wiley:14651858:media:CD010956:CD010956-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Oral factor Xa inhibitors versus conventional anticoagulation: subgroup analysis of participants with versus without active cancer, Outcome 2: Major bleeding" data-id="CD010956-fig-0029" src="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_n/nCD010956-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_t/tCD010956-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: Oral factor Xa inhibitors versus conventional anticoagulation: subgroup analysis of participants with versus without active cancer, Outcome 2: Major bleeding </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/references#CD010956-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_n/nCD010956-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010956-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/urn:x-wiley:14651858:media:CD010956:CD010956-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Oral factor Xa inhibitors versus conventional anticoagulation: subgroup analysis by different oral factor Xa inhibitors, Outcome 1: Recurrent venous thromboembolism" data-id="CD010956-fig-0030" src="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_n/nCD010956-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_t/tCD010956-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: Oral factor Xa inhibitors versus conventional anticoagulation: subgroup analysis by different oral factor Xa inhibitors, Outcome 1: Recurrent venous thromboembolism </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/references#CD010956-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_n/nCD010956-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010956-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/urn:x-wiley:14651858:media:CD010956:CD010956-CMP-005.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Oral factor Xa inhibitors versus conventional anticoagulation: subgroup analysis by different oral factor Xa inhibitors, Outcome 2: Recurrent deep vein thrombosis" data-id="CD010956-fig-0031" src="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_n/nCD010956-CMP-005.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_t/tCD010956-CMP-005.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5: Oral factor Xa inhibitors versus conventional anticoagulation: subgroup analysis by different oral factor Xa inhibitors, Outcome 2: Recurrent deep vein thrombosis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/references#CD010956-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_n/nCD010956-CMP-005.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010956-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/urn:x-wiley:14651858:media:CD010956:CD010956-CMP-005.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Oral factor Xa inhibitors versus conventional anticoagulation: subgroup analysis by different oral factor Xa inhibitors, Outcome 3: Fatal pulmonary embolism" data-id="CD010956-fig-0032" src="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_n/nCD010956-CMP-005.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_t/tCD010956-CMP-005.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5: Oral factor Xa inhibitors versus conventional anticoagulation: subgroup analysis by different oral factor Xa inhibitors, Outcome 3: Fatal pulmonary embolism </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/references#CD010956-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_n/nCD010956-CMP-005.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010956-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/urn:x-wiley:14651858:media:CD010956:CD010956-CMP-005.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Oral factor Xa inhibitors versus conventional anticoagulation: subgroup analysis by different oral factor Xa inhibitors, Outcome 4: Non‐fatal pulmonary embolism" data-id="CD010956-fig-0033" src="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_n/nCD010956-CMP-005.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_t/tCD010956-CMP-005.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5: Oral factor Xa inhibitors versus conventional anticoagulation: subgroup analysis by different oral factor Xa inhibitors, Outcome 4: Non‐fatal pulmonary embolism </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/references#CD010956-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_n/nCD010956-CMP-005.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010956-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/urn:x-wiley:14651858:media:CD010956:CD010956-CMP-005.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Oral factor Xa inhibitors versus conventional anticoagulation: subgroup analysis by different oral factor Xa inhibitors, Outcome 5: All‐cause mortality" data-id="CD010956-fig-0034" src="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_n/nCD010956-CMP-005.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_t/tCD010956-CMP-005.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5: Oral factor Xa inhibitors versus conventional anticoagulation: subgroup analysis by different oral factor Xa inhibitors, Outcome 5: All‐cause mortality </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/references#CD010956-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_n/nCD010956-CMP-005.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010956-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/urn:x-wiley:14651858:media:CD010956:CD010956-CMP-005.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Oral factor Xa inhibitors versus conventional anticoagulation: subgroup analysis by different oral factor Xa inhibitors, Outcome 6: Major bleeding" data-id="CD010956-fig-0035" src="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_n/nCD010956-CMP-005.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_t/tCD010956-CMP-005.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.6</div> <div class="figure-caption"> <p>Comparison 5: Oral factor Xa inhibitors versus conventional anticoagulation: subgroup analysis by different oral factor Xa inhibitors, Outcome 6: Major bleeding </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/references#CD010956-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_n/nCD010956-CMP-005.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010956-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/urn:x-wiley:14651858:media:CD010956:CD010956-CMP-006.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Oral factor Xa inhibitors versus conventional anticoagulation (sensitivity analysis excluding high risk of bias studies), Outcome 1: Recurrent venous thromboembolism" data-id="CD010956-fig-0036" src="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_n/nCD010956-CMP-006.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_t/tCD010956-CMP-006.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6: Oral factor Xa inhibitors versus conventional anticoagulation (sensitivity analysis excluding high risk of bias studies), Outcome 1: Recurrent venous thromboembolism </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/references#CD010956-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_n/nCD010956-CMP-006.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010956-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/urn:x-wiley:14651858:media:CD010956:CD010956-CMP-006.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Oral factor Xa inhibitors versus conventional anticoagulation (sensitivity analysis excluding high risk of bias studies), Outcome 2: Recurrent deep vein thrombosis" data-id="CD010956-fig-0037" src="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_n/nCD010956-CMP-006.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_t/tCD010956-CMP-006.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6: Oral factor Xa inhibitors versus conventional anticoagulation (sensitivity analysis excluding high risk of bias studies), Outcome 2: Recurrent deep vein thrombosis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/references#CD010956-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_n/nCD010956-CMP-006.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010956-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/urn:x-wiley:14651858:media:CD010956:CD010956-CMP-006.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Oral factor Xa inhibitors versus conventional anticoagulation (sensitivity analysis excluding high risk of bias studies), Outcome 3: Fatal pulmonary embolism" data-id="CD010956-fig-0038" src="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_n/nCD010956-CMP-006.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_t/tCD010956-CMP-006.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6: Oral factor Xa inhibitors versus conventional anticoagulation (sensitivity analysis excluding high risk of bias studies), Outcome 3: Fatal pulmonary embolism </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/references#CD010956-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_n/nCD010956-CMP-006.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010956-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/urn:x-wiley:14651858:media:CD010956:CD010956-CMP-006.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Oral factor Xa inhibitors versus conventional anticoagulation (sensitivity analysis excluding high risk of bias studies), Outcome 4: Non‐fatal pulmonary embolism" data-id="CD010956-fig-0039" src="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_n/nCD010956-CMP-006.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_t/tCD010956-CMP-006.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6: Oral factor Xa inhibitors versus conventional anticoagulation (sensitivity analysis excluding high risk of bias studies), Outcome 4: Non‐fatal pulmonary embolism </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/references#CD010956-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_n/nCD010956-CMP-006.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010956-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/urn:x-wiley:14651858:media:CD010956:CD010956-CMP-006.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Oral factor Xa inhibitors versus conventional anticoagulation (sensitivity analysis excluding high risk of bias studies), Outcome 5: All‐cause mortality" data-id="CD010956-fig-0040" src="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_n/nCD010956-CMP-006.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_t/tCD010956-CMP-006.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.5</div> <div class="figure-caption"> <p>Comparison 6: Oral factor Xa inhibitors versus conventional anticoagulation (sensitivity analysis excluding high risk of bias studies), Outcome 5: All‐cause mortality </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/references#CD010956-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_n/nCD010956-CMP-006.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010956-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/urn:x-wiley:14651858:media:CD010956:CD010956-CMP-006.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Oral factor Xa inhibitors versus conventional anticoagulation (sensitivity analysis excluding high risk of bias studies), Outcome 6: Major bleeding" data-id="CD010956-fig-0041" src="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_n/nCD010956-CMP-006.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_t/tCD010956-CMP-006.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.6</div> <div class="figure-caption"> <p>Comparison 6: Oral factor Xa inhibitors versus conventional anticoagulation (sensitivity analysis excluding high risk of bias studies), Outcome 6: Major bleeding </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/references#CD010956-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_n/nCD010956-CMP-006.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010956-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/urn:x-wiley:14651858:media:CD010956:CD010956-CMP-007.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Oral direct thrombin inhibitor (DTI) versus oral factor Xa inhibitor, Outcome 1: Health‐related quality of life: SF‐36 physical component" data-id="CD010956-fig-0042" src="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_n/nCD010956-CMP-007.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_t/tCD010956-CMP-007.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7: Oral direct thrombin inhibitor (DTI) versus oral factor Xa inhibitor, Outcome 1: Health‐related quality of life: SF‐36 physical component </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/references#CD010956-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_n/nCD010956-CMP-007.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010956-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/urn:x-wiley:14651858:media:CD010956:CD010956-CMP-007.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Oral direct thrombin inhibitor (DTI) versus oral factor Xa inhibitor, Outcome 2: Health‐related quality of life: SF‐36 psychological component" data-id="CD010956-fig-0043" src="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_n/nCD010956-CMP-007.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_t/tCD010956-CMP-007.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7: Oral direct thrombin inhibitor (DTI) versus oral factor Xa inhibitor, Outcome 2: Health‐related quality of life: SF‐36 psychological component </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/references#CD010956-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/media/CDSR/CD010956/image_n/nCD010956-CMP-007.02.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD010956-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Oral DTIs versus conventional anticoagulation for participants with diagnosed DVT</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Oral DTIs versus conventional anticoagulation for participants with diagnosed DVT</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> participants with diagnosed DVT <br/><b>Setting: </b> hospital<b> </b> <br/><b>Intervention:</b> oral DTIs <br/><b>Comparison:</b> conventional anticoagulation </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with conventional anticoagulation</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with oral DTIs</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Recurrent VTE</b> </p> <p> </p> <p>(7 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 1.17</b> <br/><b>(0.83 to 1.65)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>5994<br/>(3 RCTs<sup>a</sup>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>21 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>25 per 1000<br/>(18 to 35) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Recurrent DVT</b> </p> <p> </p> <p>(7 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 1.11</b> <br/><b>(0.74 to 1.66)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>5994<br/>(3 RCTs<sup>a</sup>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>15 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>17 per 1000<br/>(11 to 25) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Fatal PE</b> </p> <p> </p> <p>(7 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 1.32</b> <br/><b>(0.29 to 6.02)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>5994<br/>(3 RCTs<sup>a</sup>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 per 1000<br/>(0 to 6) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Non‐fatal PE</b> </p> <p> </p> <p>(7 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 1.29</b> <br/><b>(0.64 to 2.59)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>5994<br/>(3 RCTs<sup>a</sup>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 per 1000<br/>(3 to 12) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>All‐cause mortality</b> </p> <p> </p> <p>(7 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 0.66</b> <br/><b>(0.41 to 1.08)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2489<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>34 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>22 per 1000<br/>(14 to 36) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Major bleeding</b> </p> <p> </p> <p>(7 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 0.58</b> <br/><b>(0.38 to 0.89)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>5994<br/>(3 RCTs<sup>a</sup>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>19 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11 per 1000<br/>(7 to 17) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <br/><b>CI:</b> confidence interval; <b>DTIs:</b> direct thrombin inhibitors; <b>DVT</b> : deep vein thrombosis; <b>OR:</b> odds ratio; <b>PE</b> : pulmonary embolism; <b>RCT</b> : randomised controlled trial; <b>VTE</b>: venous thromboembolism </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>The data from <a href="./references#CD010956-bbs2-0018" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00291330. Efficacy and safety of dabigatran compared to warfarin for 6 month treatment of acute symptomatic venous thromboembolism (RE-COVER I). clinicaltrials.gov/ct/show/NCT00291330 (first received 14 February 2006). SchulmanS , ErikssonH , GoldhaberS , KakkarAK , KearonC , KvammeAM , et al. Dabigatran or warfarin for extended maintenance therapy of venous thromboembolism. Journal of Thrombosis and Haemostasis2011;9(Suppl 2):731-2. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-COVER and RE-COVER II. Blood2013;122:2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RECOVER II. Blood2013;122(21):212. SchulmanS , ErikssonH , GoldhaverSZ , KakkarA , KearonC , MismettiP , et al. Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130:A18594. SchulmanS , KearonC , KakkarAK , MismettiP , SchellongS , ErikssonH , et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. New England Journal of Medicine2009;361(24):2342-52. ">RE‐COVER 2009</a> and <a href="./references#CD010956-bbs2-0019" title="GoldhaberSZ , SchellongS , KakkarA , ErikssonH , FeuringM , KreuzerJ , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and Haemostasis2016;116(4):714-21. NCT00680186. Phase III study testing efficacy &amp; safety of oral dabigatran etexilate vs warfarin for 6 m treatment for acute symp venous thromboembolism (VTE) (RE-COVER II). clinicaltrials.gov/ct2/show/NCT00680186 (first received 20 May 2008). SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , MismettiP , et al. Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II. Journal of Thrombosis and Haemostasis2013;11:225-6. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-COVER and RE-COVER II. Blood2013;122:2375. SchulmanS , ErikssonH , GoldhaberSZ , KakkarA , KearonC , SchellongSM , et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RECOVER II. Blood2013;122(21):212. SchulmanS , ErikssonH , GoldhaverSZ , KakkarA , KearonC , MismettiP , et al. Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II. Circulation2014;130:A18594. SchulmanS , KakkarAK , GoldhaberSZ , SchellongS , ErikssonH , MismettiP , et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation2014;129:764-72. SchulmanS . A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II). Blood2011;118(21):95-6. ">RE‐COVER II 2014</a> were taken from one pooled analysis and are therefore shown as one study in our analyses<br/><sup>b</sup>We downgraded one level for imprecision due to the low number of events and a small sample size; the possibility of publication bias is not excluded but we did not consider it sufficient to downgrade the certainty of evidence. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Oral DTIs versus conventional anticoagulation for participants with diagnosed DVT</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/full#CD010956-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010956-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Oral factor Xa inhibitors compared to conventional anticoagulation for participants with diagnosed DVT</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Oral factor Xa inhibitors versus conventional anticoagulation for participants with diagnosed DVT</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> participants with diagnosed DVT <br/><b>Setting: </b> hospital<br/><b>Intervention:</b> oral factor Xa inhibitors<br/><b>Comparison:</b> conventional anticoagulation </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with conventional anticoagulation</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with oral factor Xa</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Recurrent VTE</b> </p> <p> </p> <p>(3 to 12 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 0.85</b> <br/><b>(0.71 to 1.01)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>17,505<br/>(13 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>One of the 13 studies reported no events</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>34 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>29 per 1000<br/>(24 to 34) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Recurrent DVT</b> </p> <p> </p> <p>(3 to 12 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 0.70</b> <br/><b>(0.49 to 1.01)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>16,439<br/>(9 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>16 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>12 per 1000<br/>(8 to 17) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Fatal PE</b> </p> <p> </p> <p>(3 to 12 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 1.18</b> <br/><b>(0.69 to 2.02)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>15,082<br/>(6 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 per 1000<br/>(2 to 6) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Non‐fatal PE</b> </p> <p> </p> <p>(3 to 12 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 0.93</b> <br/><b>(0.68 to 1.27)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>15,166<br/>(7 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 per 1000<br/>(8 to 14) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>All‐cause mortality</b> </p> <p> </p> <p>(3 to 6 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 0.87</b> <br/><b>(0.67 to 1.14)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>10,770<br/>(9 RCTs) </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Three of the nine studies reported no events</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>23 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1000<br/>(16 to 27) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Major bleeding</b> </p> <p> </p> <p>(3 to 12 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>OR 0.63</b> <br/><b>(0.45 to 0.89)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>18,066<br/>(17 RCTs) </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Five of 17 studies reported no events</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>17 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11 per 1000<br/>(8 to 15) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).  </p> <p><b>CI:</b> confidence interval; <b>DVT</b> : deep vein thrombosis; <b>OR:</b> odds ratio; <b>PE</b> : pulmonary embolism; <b>RCT</b> : randomised controlled trial; <b>VTE</b>: venous thromboembolism </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>We downgraded one level for imprecision due to the low number of events and a small sample size; the possibility of publication bias is not excluded but we did not consider it sufficient to downgrade the quality of evidence. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Oral factor Xa inhibitors compared to conventional anticoagulation for participants with diagnosed DVT</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/full#CD010956-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010956-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Oral direct thrombin inhibitors (DTIs) versus conventional anticoagulation</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Recurrent venous thromboembolism <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5994</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.83, 1.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Recurrent deep vein thrombosis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5994</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.74, 1.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Fatal pulmonary embolism <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5994</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [0.29, 6.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Non‐fatal pulmonary embolism <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5994</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [0.64, 2.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2489</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.41, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Major bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5994</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.38, 0.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Health‐related quality of life: SF‐36 physical component <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.75 [2.37, 11.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Health‐related quality of life: SF‐36 psychological component <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.45 [3.24, 9.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Oral direct thrombin inhibitors (DTIs) versus conventional anticoagulation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/references#CD010956-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010956-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Oral direct thrombin inhibitors (DTIs) versus conventional anticoagulation (sensitivity analysis excluding ximelagatran)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Recurrent venous thromboembolism <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3505</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.78, 1.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Recurrent deep vein thrombosis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3505</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [0.76, 2.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Fatal pulmonary embolism <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3505</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.11, 3.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Non‐fatal pulmonary embolism <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3505</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.43, 2.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Major bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3505</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.35, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Oral direct thrombin inhibitors (DTIs) versus conventional anticoagulation (sensitivity analysis excluding ximelagatran)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/references#CD010956-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010956-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Oral factor Xa inhibitors versus conventional anticoagulation</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Recurrent venous thromboembolism <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17461</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.71, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.1 Treatment duration 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.47, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.2 Treatment duration &gt; 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12460</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.74, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Recurrent deep vein thrombosis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16439</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.49, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.1 Treatment duration 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4917</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.22, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.2 Treatment duration &gt; 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11522</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.63, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Fatal pulmonary embolism <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15082</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.69, 2.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.1 Treatment duration 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4917</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.68 [0.36, 7.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.2 Treatment duration &gt; 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10165</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.54, 2.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Non‐fatal pulmonary embolism <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.68, 1.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.1 Treatment duration 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.51, 1.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.2 Treatment duration &gt; 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10165</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.65, 1.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.5 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10770</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.67, 1.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.1 Treatment duration 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5072</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.58, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.2 Treatment duration &gt; 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5698</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.55, 1.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.6 Major bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18066</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.45, 0.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6.1 Treatment duration 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5170</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.42, 1.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6.2 Treatment duration &gt; 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12896</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.39, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.7 Post‐thrombotic syndrome <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7.1 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7.2 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.8 Health‐related quality of life: SF‐36 physical component <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.55 [1.18, 9.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.9 Health‐related quality of life: SF‐36 psychological component <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.41 [‐2.61, 5.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Oral factor Xa inhibitors versus conventional anticoagulation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/references#CD010956-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010956-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Oral factor Xa inhibitors versus conventional anticoagulation: subgroup analysis of participants with versus without active cancer</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Recurrent VTE <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9827</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.59, 0.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.1 Participants without cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5579</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.59, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.2 Participant with Cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4248</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.51, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Major bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6801</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.27, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.1 Participants without cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5795</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.17, 0.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.2 Participant with Cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.49, 1.76]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Oral factor Xa inhibitors versus conventional anticoagulation: subgroup analysis of participants with versus without active cancer</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/references#CD010956-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010956-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Oral factor Xa inhibitors versus conventional anticoagulation: subgroup analysis by different oral factor Xa inhibitors</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Recurrent venous thromboembolism <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17461</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.71, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.1 Apixaban</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6381</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.57, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.2 Edoxaban</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5394</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.74, 1.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.3 Rivaroxaban</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5686</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.45, 1.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.2 Recurrent deep vein thrombosis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16439</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.49, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.1 Apixaban</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5820</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.40, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.2 Edoxaban</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4921</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.68, 1.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.3 Rivaroxaban </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5698</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.29, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.3 Fatal pulmonary embolism <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15082</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.69, 2.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3.1 Apixaban</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5720</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.39, 1.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3.2 Edoxaban</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4921</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.74 [0.73, 4.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3.3 Rivaroxaban</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4441</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.98 [0.34, 11.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.4 Non‐fatal pulmonary embolism <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.68, 1.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4.1 Apixaban</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5720</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.08, 4.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4.2 Edoxaban</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.46, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4.3 Rivaroxaban</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4441</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.55, 1.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.5 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10770</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.67, 1.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5.1 Apixaban</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6058</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.59, 1.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5.2 Rivaroxaban</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4712</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.56, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.6 Major bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18066</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.45, 0.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.6.1 Apixaban</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7141</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.27, 1.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.6.2 Edoxaban</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5405</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.48, 1.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.6.3 Rivaroxaban</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5520</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.36, 1.05]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Oral factor Xa inhibitors versus conventional anticoagulation: subgroup analysis by different oral factor Xa inhibitors</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/references#CD010956-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010956-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Oral factor Xa inhibitors versus conventional anticoagulation (sensitivity analysis excluding high risk of bias studies)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.1 Recurrent venous thromboembolism <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11616</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.70, 1.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.2 Recurrent deep vein thrombosis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11195</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.45, 1.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.3 Fatal pulmonary embolism <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9838</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.73 [0.81, 3.69]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.4 Non‐fatal pulmonary embolism <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9838</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.57, 1.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.5 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5321</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.66, 1.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.6 Major bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11855</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.55, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Oral factor Xa inhibitors versus conventional anticoagulation (sensitivity analysis excluding high risk of bias studies)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/references#CD010956-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010956-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Oral direct thrombin inhibitor (DTI) versus oral factor Xa inhibitor</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.1 Health‐related quality of life: SF‐36 physical component <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [‐2.89, 5.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.2 Health‐related quality of life: SF‐36 psychological component <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.04 [1.24, 8.84]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Oral direct thrombin inhibitor (DTI) versus oral factor Xa inhibitor</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010956.pub3/references#CD010956-tbl-0009">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD010956.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD010956-note-0021">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD010956-note-0017">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD010956-note-0019">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD010956-note-0015">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD010956-note-0014">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pt#CD010956-note-0012">Português</a> </li> <li class="section-language"> <a class="" href="ru#CD010956-note-0011">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD010956-note-0009">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010956\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010956\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010956\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010956\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010956\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010956\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010956\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010956\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010956\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010956\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010956\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010956\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010956\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010956\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010956\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010956\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010956\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010956\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Xx9QLps0&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010956.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010956.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD010956.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD010956.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010956.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740715521339"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010956.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740715521343"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010956.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d891b2b4d9374',t:'MTc0MDcxNTUyMi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 